<SEC-DOCUMENT>0001628280-23-015990.txt : 20230505
<SEC-HEADER>0001628280-23-015990.hdr.sgml : 20230505
<ACCEPTANCE-DATETIME>20230505073941
ACCESSION NUMBER:		0001628280-23-015990
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		82
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230505
DATE AS OF CHANGE:		20230505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Merck & Co., Inc.
		CENTRAL INDEX KEY:			0000310158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221918501
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-06571
		FILM NUMBER:		23891254

	BUSINESS ADDRESS:	
		STREET 1:		2000 GALLOPING HILL ROAD
		CITY:			KENILWORTH
		STATE:			NJ
		ZIP:			07033
		BUSINESS PHONE:		908-740-4000

	MAIL ADDRESS:	
		STREET 1:		2000 GALLOPING HILL ROAD
		CITY:			KENILWORTH
		STATE:			NJ
		ZIP:			07033

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Merck & Co. Inc.
		DATE OF NAME CHANGE:	20091103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SCHERING PLOUGH CORP
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mrk-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:f17f1926-1a01-4baa-a406-054ce45079f2,g:c6b1c5ce-74aa-44b6-956b-90e243d128be,d:3ccccf37677d43f88002f8d995e2fd3c--><html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:mrk="http://www.merck.com/20230331" xmlns:srt="http://fasb.org/srt/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mrk-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180L2ZyYWc6NzkwZWFkN2ZmZjcwNGFiZmE0MDM2OTAwY2ZlZjU1ZGQvdGFibGU6MWEwNjBiM2QyNGJiNDBmNWE3YzM3NGY1ODhiNDk4MTkvdGFibGVyYW5nZToxYTA2MGIzZDI0YmI0MGY1YTdjMzc0ZjU4OGI0OTgxOV8zLTEtMS0xLTEzMTYxOA_94f05150-b88c-4ff4-8cf1-abf185b903a9">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180L2ZyYWc6NzkwZWFkN2ZmZjcwNGFiZmE0MDM2OTAwY2ZlZjU1ZGQvdGFibGU6MWEwNjBiM2QyNGJiNDBmNWE3YzM3NGY1ODhiNDk4MTkvdGFibGVyYW5nZToxYTA2MGIzZDI0YmI0MGY1YTdjMzc0ZjU4OGI0OTgxOV80LTEtMS0xLTEzMTYxOA_0cd28e01-cb5b-450b-aa36-533d28feb38d">2023</ix:nonNumeric><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180L2ZyYWc6NzkwZWFkN2ZmZjcwNGFiZmE0MDM2OTAwY2ZlZjU1ZGQvdGFibGU6MWEwNjBiM2QyNGJiNDBmNWE3YzM3NGY1ODhiNDk4MTkvdGFibGVyYW5nZToxYTA2MGIzZDI0YmI0MGY1YTdjMzc0ZjU4OGI0OTgxOV81LTEtMS0xLTEzMTYxOA_c83e06f5-8eac-446a-97f6-959481ba41d2">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180L2ZyYWc6NzkwZWFkN2ZmZjcwNGFiZmE0MDM2OTAwY2ZlZjU1ZGQvdGFibGU6MWEwNjBiM2QyNGJiNDBmNWE3YzM3NGY1ODhiNDk4MTkvdGFibGVyYW5nZToxYTA2MGIzZDI0YmI0MGY1YTdjMzc0ZjU4OGI0OTgxOV82LTEtMS0xLTEzMTYxOA_f5002049-7d3b-417a-bc70-5f00636437ad">0000310158</ix:nonNumeric><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180L2ZyYWc6NzkwZWFkN2ZmZjcwNGFiZmE0MDM2OTAwY2ZlZjU1ZGQvdGFibGU6MWEwNjBiM2QyNGJiNDBmNWE3YzM3NGY1ODhiNDk4MTkvdGFibGVyYW5nZToxYTA2MGIzZDI0YmI0MGY1YTdjMzc0ZjU4OGI0OTgxOV83LTEtMS0xLTEzMTYxOA_1b036b4b-2009-4f50-b3d1-dee18ebbdf1d">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ifbdf486ae9934cc9a2a5283fa0638116_I20221231" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0xLTEtMS0xMzE2MTg_cdf39073-c7a9-42f3-a873-70852c2d806a">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i548bda88a4fe4bd5bffaa38757444dad_I20230331" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0xLTEtMS0xMzE2MTg_eaa07838-14e0-4387-8b95-9bb43c3d8ff8">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i548bda88a4fe4bd5bffaa38757444dad_I20230331" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xNDUxMzg_9df5cddc-66b1-4a33-8e29-a18d74bcc019">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ifbdf486ae9934cc9a2a5283fa0638116_I20221231" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xNDUxMzg_f3c8a52d-a48a-4e54-b19b-78f16a11f45d">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ifaac2668425b4eb4bfaea2c9834fd061_I20221231" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xMzE2MTg_408692a5-0d77-4a04-a36c-28872dc58415">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i6cd028c906f84a42bf0bf29e3a3a9fcb_I20230331" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xMzE2MTg_4a4e35a6-2d31-4c12-be2f-2f5f0ad91a6c">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i03be4f41b99a4232bdc4d5da0449f285_I20221231" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0xLTEtMS0xMzE2MTg_81797372-b85c-4d09-ac25-516d3f440479">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i2e8fab7c6eb24761b65cc3256e0b926b_I20230331" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0xLTEtMS0xMzE2MTg_ab1b0a2e-c0bf-439c-9322-21e04e73f4f5">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i50b43bd94e56461888fca904c9a7ca24_I20230331" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xLTEtMS0xMzE2MTg_3132afe6-dbe8-4b79-81d1-621892c284e2">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i143c9f2549384565bcdcfdd243771159_I20221231" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xLTEtMS0xMzE2MTg_99d4d534-f137-4781-a93f-a2c418043a22">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="icdf30ba2b8b34d4e8df46f5379e5e821_I20230331" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xLTEtMS0xMzE2MTg_11e2508b-56af-4ce8-a9f2-c0ca375d810e">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ice27572fdfbf445cabdf5a62a7d76022_I20221231" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xLTEtMS0xMzE2MTg_c087e16f-89b4-40c0-959b-f2b2cdd6e23c">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="iac10665025d84f23872225d16c92ffed_I20230331" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMS0xLTEtMTMxNjE4_05e962d8-08ac-4061-91f8-80526dc22b48">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i45afba88d4004605825fe82844d7a4a7_I20221231" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMS0xLTEtMTMxNjE4_c1218d47-d091-44ba-967a-61df1ed0b192">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i5a23903b67354e33a6fc1a8676a4b984_I20221231" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMS0xLTEtMTQ1MTQy_1096f2ac-e5f3-4efe-9d17-7ead4689602e">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="iaf2336f30cc046a28a77fd6f2dc4b465_I20230331" name="us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMS0xLTEtMTQ1MTQy_c4114de6-2d78-4e8c-8218-b4ecfaa65a61">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i3a542fc8b3854857bda9666e66bd056e_I20230331" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMS0xLTEtMTMxNjE4_8e46edaf-73d3-4fb2-a39e-a898b16444e0">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="if4fad0e8da324f249b5dc3a9f01637f7_I20221231" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMS0xLTEtMTMxNjE4_a38bf2e0-7e23-4be7-a57d-412372f2f6e0">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ie091883aa8d84ebf868769397c540276_I20230331" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMS0xLTEtMTQ1MTQ3_0f134479-ab12-4419-8818-0dec3ce2d2eb">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ib057b0780b1b420d824cb8350acd5ba2_I20221231" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMS0xLTEtMTQ1MTQ3_8586bfb3-f29a-42c6-a48d-599f102341da">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mrk-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i135ab11fbbba4bcfa384c862b2035ddd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i147620f1bebe45a09eb1c534137133ec_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrk:A0.500Notesdue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2d8e55f082b4b91b405cb32c49e17e5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrk:A1.875Notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59b625119501404d81b378dc2da40e6e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrk:A2.500Notesdue2034Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0a22a157b7c4d9491fb9c5367a1371b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrk:A1.375Notesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f9aa917fb244d03ab52c4fcb13190ea_I20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i5c3c68968d5a49b98049b259f527466f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2cb2241175c4c8c8fd5daf0a86385e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ff3b595ae954906bf225b8a7cc58b69_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1302ee97335a4b8a864d880d15a75ffd_I20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PrometheusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c03ed79efac404d85fb217647f60f9e_D20230401-20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PrometheusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id017497421574c008e33bacea591637e_D20230701-20230930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PrometheusBiosciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e8e4ea1abaf40778222b2bb6dcfb639_D20230201-20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9dedd741503427183ecc62df92f5085_I20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c175c60a55e4c3eb9ac840966e13ebf_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i609e1582535d4dfb834b95904e849c27_D20230101-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:ImagoBioSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f3adb7e1a4d42dd925db11dbf71eac5_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:ImagoBioSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58a876d3681e4986805915e1bac18ff1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c3d2c4bb8cc45efb4e93d046dd6a753_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a91adde5a68413fbc1cfab655dbcbe6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i350e44c40f67467ba477b370f98d41fc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6b1412b32dd45bf9b2dc2c9740d6c6f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71ce1d5e1bd141539620a96cb8b2ec10_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf9cd10c9efe4059a13ad6f64f232a85_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i654e8b5924d8442fa9eb55859bbc8647_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib681c644ca864f3286e965d6d7324aa4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide79c33fd45c49b19bce108416c71788_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i525916f3d1464ab9b6f291401c761233_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e95ebf7c1884a0396c7c91a0e223ee6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c6d877e0a5147208fe56690fbb929b0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cdf23392f5642ba818b20d852b014a9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46e9161a43a44a2fa59e52960034468a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71ffa17774c44d2287fe9111206866c3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba6c247720a049d28349afa51cec42a7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id22834ff470f4f1aa7da131a94ad1d29_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6500964c8d3f4d06b28f3f23cada56e5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc2de578164e434980f14d63a2153220_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5973fb4a5d684bcca7a62270623ac406_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb9ff33d56484784be92a715ee774c2d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife24131bdfa1419d8d2708d8b616e5b9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaae108da197453bb8b3b58a2cd21d7c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i492255c072c74c9f8a70fdd6212cfe65_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie92cc5b201cf42e9a6a395bf77ad597c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00731f51ddd64c099bf1f3a866d6e0ff_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8a01e007c934b3285178dc642a890ea_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcf5abe1e04c438f81048ecae5f02ed4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i364cafd01c114c558bf6c571df9b34b1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d145059533c4960b5fc110813a1fdbf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief58ac433ad9415a802f0001cc903fa8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifde6e88a8c324b84b8e1ac90ed088a69_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e956d6285d1456abb720e32551e7288_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3779054dfc7a4a51b4e90d43a5ac3684_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7eff0028e2f4952bfe2bb459510ff9f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia56fd7048ad14abf96162c372b142909_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iace54ff30d73465189a461975d7b6b99_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1e72c11f4d449889cefb13617918cd0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d825d4c2aa44c79bf5a2366a7a86a9b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6c9458bb97f476b867db620d779e5fb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie01022120e7d4f7cb61fb037b2355db5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if29e83faad31423b801afdcfcba98e44_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a73485be36248258f5601b826d7bfed_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d20b318541f4dd2831d35fd11a17b0f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3399af7b61814371b4415a2165606deb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80a8ac9e73b64ff18bab741a42d8fdcd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i260c8037bbf543e0aa66e359ab18b50f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ea6ddc3ada9445c95b033d7e07dd561_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaa0511b79e949c7a6547505b9ae5551_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e52ba3989df4480ab8a8c4136af64aa_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68f851c07e23480aa9ff233e42d37d7a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6191c4207cdc459d90d7c79d3e4e64e5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbe1869e706149f48a2091f4b9534dd9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ef0c87d5feb45e381dc0a07c2d16382_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63cb28ee8d6845b3bc89ee74ee01ff67_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58e10bfa620942c4bcb811e0f171d36b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e3019b3c61c4b70a15610624c8a4983_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i650127b972c04c1cbed3bec6d5fdfa9b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2ae3db4c9364ff8843c87c364bab42b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9056f175eca54119943d05559433e20d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib66da4be09b7447ab23b1c1811b5724d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36c8f57b20ce4f26a522df11b2be6320_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i644d973253b54d3e94a4aa3644bbe995_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2a085dfeaeb40a083f13e8a59287e8c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5173a42466784ad9a8ffe86302cb3b87_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebdfd787169843bcaba790e915fc305b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd3bb7ee67904313b2975cfef294c50b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice904109d2ef48fd8e8ed1324f5c2c59_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic51d50d985d84a3f8f588fda28be3ce3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25207351676d4c9e9e6961bf25936afd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d5dff37e3ab4823ab8be6c8611cc6d4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2404a6eca015453d8c2bb0e08613ae7b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec1c506714374a9baa8471e96e643d5b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc4d047e87e6460984a1241620741fc2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i386e5b3e2b1d4771ae602c8544c7de85_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i402d58f25e9e45a68055eb38b7d1d4ab_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0175444d0549416fb305c38749b41b24_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i245cacaf455e42329f9ae587d1a10cad_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dba74425a51433497fa7e5529627e25_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cff7fdd9228489e9a08ae8b3a149a6e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id17be879320f41af82dedebba088c13f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3d1e57b1dd24ae193bd71c6385b8769_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:TransitionServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-02</xbrli:startDate><xbrli:endDate>2021-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4eb1aad4f8349af99fa7c51391e5966_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:TransitionServicesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-02</xbrli:startDate><xbrli:endDate>2021-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7ee924f05bc48c787f3fd1d8f6303b6_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-02</xbrli:startDate><xbrli:endDate>2021-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fd80dbdbfb341a2a9372748079c59e5_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-02</xbrli:startDate><xbrli:endDate>2021-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad59a4cb91a64620bac9b9c19d9f7cc5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i185eb227b4104468b3c29dc49352d43a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60b11c4ee8724493ae377bee597f7db8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i834db89c47b44369b713641fdff58447_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7966ec436ac148489c841a585ea76477_I20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i870f46cf31cd4dd99b24227fb3adf06f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibde26f5431b54da79586ebd96e74a36d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6616b6afece4195a3a8c81945ca5296_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i111e37e345c242418c65ff71f8df4aa4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia85fb7ebe86e48688eaa6cca6140b251_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7968694bdd844dcb91cdee1fa81b0c2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c124834ee87435999488308f1f35177_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie333238530bd43c2ac7bdbedf60929b5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39ffed41bf6448378d17f953bc0cc54b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8831ff53ddb4e9384dd1c730f73c0d1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92816509cf8240d2ab4f3e2c2a61c6b0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfa73697ee0a454c9ad0fdef7eff7f65_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d8c3e3d493941b186866861d3cad3af_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaaa6e70cf90547429286cee866cabd66_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifef7767f302e4418af53b34093c57a9d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i620edf85a16d4e4880ceb84b22f3cfab_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bc8fc361d904fbeb6492f5e521452f8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bf782824e144ac698d3c52441494fa9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie23cb3149ce14b15a9a4f74c76232a80_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb61832d74f44b15bb6f7e1e80aefe10_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd263f21d9824f4d88448a933573382e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7916bd167a5949cf9496c5497260c4da_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59bdd8e429324f6985da2aa4f9cee50f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia26db14d5dfb4db6936c0133c122c21a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb9eb1916f044d189f47e32c6cf11a65_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bd41c6996df44f5ad0c156034845a9e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45f7c7de6a3b4eb69f814c83aa49e79c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f8fc3f059d944d8ad12e7fed7bcc36b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53768e8ff51d41dabfcdf8423e6ee2fa_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46e4f372c2f54684954722f000f9b4fb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72738ef779d443e9ae3f451aa08e9bd5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dbe9c123ccc49ce80d7ee4225c7c4d8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09b391351ac84dc89ccba17bcc925ec9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80771ba562bd4e098155333659c919c8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i735d6ae1f2044389b4cd1ff056ef3646_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cce1bf91c214333b3b50c15e3d7461c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40da318aa247452bac9b3018762feece_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i993831891ccf428592c3e2f850548d44_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5739c18be2b4077ac27f27ef7c6e9f6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb4e20bd4ba34d448a2f3a3397c0d521_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e6cc36740bb4d71a793d4cb817b4486_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44fa00da50de4c2abe7a97b20631529f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ade1a511bd04605a075fd4b05ec6eca_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54ec372484874e4680d7e4b7645c44f7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i313438c53a3745f5a9c308e10580003d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13663e430fa9440c8b9b613386d03310_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3459fac4643e42e29a49394546d2d3b7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9f85f59e99b4ea189c2a085734df397_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c1922ae96df4166a7397fffeb3375e7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b9f469b4df444f7b96723d7a5c8b223_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="interest_rate_swap"><xbrli:measure>mrk:interest_rate_swap</xbrli:measure></xbrli:unit><xbrli:context id="i336c99147cdf41e191d86c13d2a751dc_I20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7029fd7c7a6f43aca68f42e012aec70b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95f9d19ca7854b0288a0454768961670_I20230430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbdf486ae9934cc9a2a5283fa0638116_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i548bda88a4fe4bd5bffaa38757444dad_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bdddb9610a348a48e757c57cc1a2387_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic70cbdc57c9f458abe55135c7b061c1d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i425bb66138fc4a51933c6b6df28796a6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i294f553218424e8cb257f3d9f97e01a5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaac2668425b4eb4bfaea2c9834fd061_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cd028c906f84a42bf0bf29e3a3a9fcb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03be4f41b99a4232bdc4d5da0449f285_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e8fab7c6eb24761b65cc3256e0b926b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50b43bd94e56461888fca904c9a7ca24_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i143c9f2549384565bcdcfdd243771159_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdf30ba2b8b34d4e8df46f5379e5e821_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice27572fdfbf445cabdf5a62a7d76022_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a06f418da43474f9f2f260add8790b3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf11d32e52ad425f979acb12dcd9aaac_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac10665025d84f23872225d16c92ffed_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45afba88d4004605825fe82844d7a4a7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a23903b67354e33a6fc1a8676a4b984_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf2336f30cc046a28a77fd6f2dc4b465_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a542fc8b3854857bda9666e66bd056e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4fad0e8da324f249b5dc3a9f01637f7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie091883aa8d84ebf868769397c540276_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib057b0780b1b420d824cb8350acd5ba2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaadad87b63f48448ddf5360530646a9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7161bc9f4ef34d54a1dd7e0b07640a30_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86b17d802f304918b52da353344f6ac4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i028e5b27f0e04f339d7c2f519b8ae259_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9ff469b241a4cd5972223863bfda226_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96b677da60364882b5bc1b825a50fabe_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i330867f88a774fb08f247e81d478866e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8118cf7c392f4ea598bfcb18b7bbd4d2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if03eefb0e5be4080ba5289591b557e4d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b6b9e2b940749269dcc355aa0ed57d7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc7fb1fb9fd543aba08f396008a05eb0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeFutureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3fb850e1f5f434f8e8a95228021a73d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeFutureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i776fb83d7a1241a0826d11f6ebe76e81_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a3f219a7d404a31bf65ab7515e23942_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e566c5f87a6490788ae30ee3d6f3b50_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92a140256baa4686a25015671d14aa5b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93df6ced8a7748a4abd5d6c32906498c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5aa6408da9024f3ea458c3189fa1916d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1f2bc401a074570afe7c168856f7ee2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85028f8c5acd441497714b4e936b0ece_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17a0e0f674094afda5f097dcbf70b93d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cda95f4db4a4d1e892c7b8b8c2bdd34_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i020b0ff9857f4f16af9e432e1869c1f7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07c700750162434c9390aee0f12c47d9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if47442341eb14e6e97a2cc3f6b5bba11_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bffc0a6380440728c91dc8b47e0f31e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a8f3e37e4904159af4dd090e1bc5731_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a49b37db2544c739f3f57a6c315a232_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66cafb3d313644a3b3ba17dc3c1b05da_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a99f61d5d9c4df5b63c5274b8898116_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f9e79091e5045c68d0f830e6ac4c990_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2795fcc4916b4738ba959e843ff69ec3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96de2214f40e4ba59e7b629d43ba4d91_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i451160fbee604ab990070211ebeba8de_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46d67fffc7944fb8af71441dc67f9462_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb8445329cbd40e38c431a9cab4cb4d6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3beec2a915ab4328b794d0b11fbc0788_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i814823701512438f9446387df4b6adcf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d93e6ac796f4cc0a31cd2625e3240a0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idef3c5cc57074bf7bab4f63f14c711d4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia38b8466a7354dcfb672c615593eeffb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i743f68c0230549c8bfbd0ad0a8901f37_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d3fb0c5d5a24db099308a75d6d48348_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4232e5688d9417880fdb23acd1671dc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c5ea1c804e54b9da2cfa1e35191be79_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31c000934f3b49b4a1049b7c5825c3d0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i012d7bd208a247b4b543d54583a218ef_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07338fb5662b49d5bc2528a3307c626b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic115d2d37fd44d80b15e651843a0417f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8d827d1b17a45afbc3e288430a5dc82_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bb17c88faa0435c933b88267089cb0f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib04f9b00c03c4e4ea6423dcfad58d6b3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie908803a7baf418983f47014731e40ea_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1db38063fdeb45aaa60b2e97a4474133_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idebf467c560c4d1d9245b765b6e590d9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89142ce181ae48e3a2d77a9f72861963_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57ae55075eed47cdb14839b87c57acd5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f4032436bb84e00a3478c08a4a4bac8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bd81adc1667472a96ce3692b39fdda2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i871a358ebbbd48f496202064b0918f47_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e90f41ec72b4d99ab066bfbad83afec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a48a4589b004511be5ec5ad70c7e2da_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c30409b333846a0b003f5261f708353_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d1c02180ad34f3e83fbb3df043ae3f5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6288684e9335426a899ee4586882280c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i305ac9c4908a4bffa1b9ce0a56239183_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eaafa1e0ba64836a551188797cd7c7c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic36ef238f34c4ab180d3b3a52624eb9d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib784c86ce67446f7940a517458674fd1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i004682e5e94d4b12b9f2913eefd3a7fb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34260a2a17d947768f68d2798eb0f8c1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b068359fb3948a182327c67ab308fb4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8f7806f9be14762977b7e08e79e4daf_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a2e484401b24c479443887a01bf805c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b1b40aabc7a4eedbc4ba7ac12424d0c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5265c6f93c7f46d1ab829156c30fdf74_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic497e29b39d04693be035586e02049ba_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i970e6180f53c4baeb53fdd14d90061da_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i075080b8fa0045b6adf42ad9d680a586_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if826811b47d7448eb6e1f3d6c36b5841_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96e781b662154001934e50bb59beb7cd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibffb1c0f1856491795524f9ede8241fc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ba1c7342bdd4e82a5d14645ae050399_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i294603384e1e48b1b1962054c70f8781_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2707a83a0684b81b3f82c21c1a7d1e9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia524db85b9fb4e5faaed403cdac7f778_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4b65ea8a7a94fb5acbe089d34abecfd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefe9381ed615477a8d395b385d4bfc96_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec2a2a2cde214dcf9145e7fed863dfaf_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0fdebb01cd44ff4b7dd90a3757e19a8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92b2724f66144388bc9d877014d99971_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i402e5d3ff33d4949b0046490210e38a1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4a496ea51974c41968d7d7ece436a35_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04e31d8852884bf89e5bcb8b4f124896_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dcc8586471c42e6a0ee92dda4a6bd01_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f39864d8e8e466da61d331c664f14db_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ae2044462124fec8e736b9c160ff048_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fbdfdee6afe4e74be18dd0c62050372_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf5ff6cbdf22489b9efa70ffb318b8aa_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2fc780817394ba39db27d26c677ae95_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49dd486feefe4b749fbe2cca62e80318_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e717c1f26e14e87978e3de102e7c698_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie81327a316a94b36974954a7e8642bc5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="case"><xbrli:measure>mrk:case</xbrli:measure></xbrli:unit><xbrli:context id="ide0712a78628418ab61bbe9bb313aae7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7358a61460544d15a70b0957807efa73_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CO</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i674ee2f2e244467391945b56813ef740_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:ZetiaantitrustlitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="direct_purchaser"><xbrli:measure>mrk:direct_purchaser</xbrli:measure></xbrli:unit><xbrli:context id="i486acde0965b4e4fa567b783874fdd1b_D20220630-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:ZetiaantitrustlitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>mrk:claim</xbrli:measure></xbrli:unit><xbrli:context id="i07e39fac74fc4d08a501e1e14a991816_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:ZetiaantitrustlitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88f1868d275a4b89ac8e4f956b24ddc5_I20230303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:RotaTeqAntitrustLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="state"><xbrli:measure>mrk:state</xbrli:measure></xbrli:unit><xbrli:context id="i4305661e65274f559b5b59766d3c5cc3_D20221219-20221219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-19</xbrli:startDate><xbrli:endDate>2022-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bd3fe27e3bf4036897cd39ae0448f14_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="company"><xbrli:measure>mrk:company</xbrli:measure></xbrli:unit><xbrli:context id="i79aeb0bcc641443b80308ef30bbad1d3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8407355ea334e558a58d39cf813e848_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaAndJanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i270837c6ca8b41c49574b8b379172454_D20230413-20230413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:ComplaintAgainstTheJohnsHopkinsUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-13</xbrli:startDate><xbrli:endDate>2023-04-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>mrk:patent</xbrli:measure></xbrli:unit><xbrli:context id="i5913ce6cd24f4f45a393b8a13ce74d4d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica1e472338aa4a5298e4b867322ded49_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia75c3b66a14446a7b7855544f19742bf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice6bdceaee0c415785e978b1546e824f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f9c7cab12f84742bc529ca888140834_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c01235f9a47471bbfd246c179b8ec70_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa0666b9b0854af18214a4de1da949d6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i957a5e7283804544961eeffd229d90ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieba2932606cf4136b76cf64715d17f5c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifce529878ee94fbc97ff3cdc8e49ccb4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i918170e5b2fc416bb5213a74ad72646f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6faee1c09a204c63baa2f8635ef78da4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4725be788d3c4f1f966fba475c841405_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e2497db5f4b4eda93858dd1c188cfb5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08889407a4ca4fa69735b8332945794b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcc9c8d75d064da9855b8d3b37c02b10_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42da78b36e31450dab3194041180b0ee_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id895bb14f7154486a761071e11a287ca_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4350e7d8d13e45848709eed82cdba738_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15d6c8aebc384e4b973cac8799704239_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb5a854388ff4957836b5593bd4f37e4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7b73a7dc82c4055afd7242f0e94f662_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b21fb880d134a06abed66e7d998914f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i796d55aed90341e6a68727c28ffcab70_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bc10dff04eb494ba85791126e4db053_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87e04afadbc24d00bf0c906ad452972e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe63a010ec0a40ed91fe4b6b16e51a63_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic41cc6c0be824cbeb1598b4ddbddb1ed_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied44c0afd9384c30953e94941daa0cb0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65afee1f42ae486f84514163f3843f68_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1742aab8c35467db6f531e481322561_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b3b6bd9f9044238b1478ab578648204_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18372378d12a4968ac3f82433fa9ffdd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60e7a6142fec4b32aa305b679a0d9a87_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4437cb5ce2e4c6cb15d052910fc825b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aa514bfad3f4f6883b1d3d93683f530_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id12f95a53e9f4822b4ac3324b1225c13_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6ae890426d14159b7b476af5430efdb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fc54055a2e1411986ddfe6f5fa717bb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfb8b583363441eba27b2030dcb092df_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c9f187d5e3f441eacceb4c421ba47e0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48e93ba87cab4afc961e66db38e74311_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ae10b4b780a435b8e0e8fa9ac83e826_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i041db7ac9be74d218c0c23a960fc9a27_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33af4ad78921440a981af5aa4715c88a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad527aecfb724bf3b4777b628fefa6b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d1fa90756944324a7e1f45d9b688361_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74c46eee324f4931a0808813b06bc0f2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39397ad3a95445e39f9ab9b845a9867d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2319d946cd342759a8f984524b58ad8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95a7d6e4f3b642ac849cb5b1af84aca1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8a93158890945a9aa15c60a05506723_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31f76fe0b880480684d05d01c6f398ff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b83eed87b2d41c1a8c610f98765bba3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d63d8c8b08843008160820a9757c059_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d68872fd99d4719972b30864e232d1d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad583d8b44fc49feb98cc9caf016d5a4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife1d684ce4c949b38894572598414983_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7af996fcfb0942ebab3aa1e8cea2e1a4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e5c54f51e5440dd9db7d51479f49629_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44331becfc824debbd8e96c96c590f56_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>mrk:segment</xbrli:measure></xbrli:unit><xbrli:context id="i8df183ec48194fc4a2c6f8e8d986193f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf2b65d0efcd4588b8eaf74e00590ea7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie772b761081d4a3f88dd5b139a18cde5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id23605aa21764c15b522d6ea781638b6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b1fe39c7ec246f0a53097e0b00b0803_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7caeaf606112447a8aa0d87b20c8f163_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if193ecf6603e436e9bc55f3e4f86a576_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b3b69956cc9411da3f54f428aeeeb42_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ef00ecad3374cfaa1259915898dc915_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0d6b8513dcd4021a200090641fe0bff_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0666b87a008d48918f71fa4e40a3259d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied5a517f75814ffdacb6613032349a19_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bdd7b02457a4826aeec0e25dbfa4df0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i373f00d87cd7457d9b079c9415e0c4ad_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic416d710ef924adc9df8131effd1c200_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i421974800c0844798343dd8cfc3f3a20_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26f185cbe1da4f4e89a1e2093171e27b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7706e3163ae4d58a5f8660cb640d5ba_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf21fc9f03d342bbbd66be0123de6225_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i943ebcf31d20440ea90b753cb238fe02_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia13e94e1a90043bcaea2ffba6d27061a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f73d3370a5348dda651da8166f72bfc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie40a08ab45e2491eaad9788d31bc031d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:WeliregMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98d5687c5bca4aa0ae8be180444502a5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:WeliregMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i148665041c5d4969a1b7468fc0b3306f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:WeliregMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i245f27c3d3884d16886e2a02a3bea2be_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:WeliregMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i683c95eda6cc4e83a3f200cd8c1ae979_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:WeliregMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabc5de1d9ad9496abbed9093f2560c7e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:WeliregMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d15bac232384d3d9b567829ed8b4e4c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0eb110c2888a401a99ce08584a59ae29_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0622fda057824fe2acccd535fdedb1c4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1317f96f8242416cb217168b296ac180_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15590b4a502a4441b2031cb5e67c164c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0272e13e3911432484c3574c4d88dea4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1dd61290d2e4c28bdc142b28449b630_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0676bda79d3444beb30669ea1761cefa_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92cf8249b51045fc9f74f556cbb77945_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd868d1665e843e8ba8e68820863660a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85dada8cd49f441ca2211b4790538075_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e7b43ab9aca461cbd07c3408576229d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i502537b5bd3244cba8148fdcded195c1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd1279562a9049789bcf67e36e1345e6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if12d006ccf6947e59b7e26e27405537e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2caa7eb6734e47f694c35387f0b24c5e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefe80ade170b452d810ea857bfb36486_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i168a16270ba04bf5bd0a98c57f6e7453_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38f3c51ed3c142088d512d3cf86a4e85_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaxneuvanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5facb3a2afd54e37a08fcb30616f2d40_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaxneuvanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71c307b84c814567af562b778b4c1b53_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaxneuvanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8a9542dc59a4777a668cd31211b6c7a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaxneuvanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa6e384e748d4e74833d7c8bd58e5051_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaxneuvanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a9cd1b2796b45cd823635c3a4ca1ec1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaxneuvanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc1f221331e847f78e9890ad89af8d80_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iced6646c844d4419a1591abce5241bc1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d46a1bed5b64222a563d18e9091ab03_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee7d83d494044d17ac974c40323b8bfa_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf3bf82a5181435e9e26d6dfe9ccb7a1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83f5ca79492e42dba088722bf7ae9575_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i556f1c52ae734ae6910cf6d6b9d26d16_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie70b1f6ac9824c5c9604f2e6cda7b721_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13c7df0a730141689941ffc740882c67_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie19b5dd8e1da4e7ca8d5114cd25d465e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8845bbae207945c29f58ed0faa7c916d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ce84ce5bc4d4fd09f2f2edef567c63f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3307d951777433f9183e38cea7b0eee_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie514f725ab204576a9d82e520a0747cc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3c351d397e549f08a5550b64c7bd217_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia85cef5855f74b3aa28b80d7e773c5e5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d745b43d42740a2a636f93305a10162_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idffa9ebb25b04dc3ab346d0e2525d0f5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81842dbc49284aeb8c307b130fc51daf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ae5e82b75cb428f864e7695e7ca9c03_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c5c36e08c35436d890e3cc5e49a26b5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63dd5e6b38074752a8397afebca2f449_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6a6d9596af343fe9fbfaadc1d8d3d34_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cb822f6f0d24e56b21b1ba8cf3c5144_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1a2a61f6cc34473ab9936b7066ad51b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6b9400d903e47749af467e683ebf4b8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e28d66cb4d143f5b15da4ce16a7ff80_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83dc7aa4430a4932893b4dc1505dc632_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd11a9dea94b46ed9112ffcc77e533a5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa49ff54d4904fb783f4f755bf9c4739_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16385f11510546058467040c76602eda_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97cacd287b274b7283ca51aef88bed26_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied566206459a4f21bda9d764fbd67597_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c13b48a7232487dade4344d3bd6fef4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36f1883cf7ee41de9a38e097ff1eebdc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1f696b0a7e848ffa8cd28bc5f62be74_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33013fc5c1544b508c1f023d7e114799_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8189ab3ff1aa4b3fac07ab4d084ef309_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0934dfe57f25400aabf7629e013bf2d9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia482068e1c6841608dd3a6fc8530cff5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36f337569e6e4b90b6c49162eccc9245_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i370790356a1f4d0f910d0150c46829ba_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3ad548049e7437392c37716ac4a83fb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3025f3862fa34281bb1ddc0c23288056_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadcf254d19a94241a8a193b57dc553f7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1be1a7ec6a2548d4861b2e925582acb3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ece7f9fc39047fbaf47a27cce6b32ab_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c4d7a0899854fe795ccaec1a0161a84_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01970431619244f9a83fb73990c5cf14_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i958da05d9055499a88d25a539d74f6b9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82a61880f039405d9d8e1832fd26a2d0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06d3dc01e4cd4880b999376bd99d6191_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7414168e369644d7a58d58414fbde705_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d7e8ff816e241f199e0011935427e7a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad4d2d0ea13747a1b99b669cf7ce5f36_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01c8b28beea44e9998a1034bce51e508_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc25085e4f3246fcbff1828176d06cb2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42b4b84e15304e879f573aebe7198888_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1abbf56d966442aea56ac371531ef7d4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46444b1898a945a692f90d2a907898a2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i745ba7617eb74e15ad18bf9b1bb5709e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d35a8760f2f49e89952d761b1399baf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i185e17abc9a24ea38c9ca4921fa60212_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69279d4f3a814a78996b4c54c84aba07_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if658e80c557842d4a20c5570140db4b6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0feca83d79141c7aa9f2bbb6f89ece9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9ab213a9fd74c98afcb44eb19dbc18a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b3ad2cd408f4af38f724dabed4a97ef_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d330794d9a24933add16f9c3e14c0e6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90f3bbf8132048e7a806ef1c700bcb02_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c033c7782a84654914962664067c0b5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic44db3f3e64b400fbb66bf36b4d59948_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0f47191ae984e44a0ea39f24de59ca8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica88e8e09cf5471f8ec81237bf2424e8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf3db16464a242348f5f5ec6b303e8e8_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5dcef3812b24f21b01ed1f074b5e48e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie078fe8aa4b049019f87a49fe7163a94_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic81d4335a8564f6893a52c09eee896bb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38f8338e607f4961b4e06e5ad59f06d1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i481c25e1dc4042e583fd9ae56af1ea83_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ab42425f0e84d0fa9cc1faa24e50ad9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f1f69903f024330aa3cd5f89dfe4aef_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f18afff1f924a87aca15181db888f45_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f2b65669412421487fc5a293c2d0226_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i252bf97a988d4ca089b4880ef38b9f6f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ac3b496e9b7497bbd0a8568c2c05058_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ba905ef97ef4ea2a2b74f044e828215_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i341c1828f974489ca631fd2f6fd5de33_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91767bfb04eb4bad8b4c74cc699c4f11_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i078db72152b7433b892f65578b578811_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d3ed97dcb1048b9b00df266e47fef85_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf7f29b275f343aeb93a10d0bc96a43a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c5a4e651d8048d0bb7be915788d3451_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfe3cd40147f4e2bbdcc6daea5c4f648_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc375c5fb83442ce960061c4c1e7d3d2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1068453fd58a43ed853c52e49d369635_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a170523e4784bd68826594b94740470_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd460b0376004e6c9a2f91d187784dc9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5c0d77138754544a2110eafaf9ef1de_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie30c6b82c81544b2a213a66f88a666e6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i944297bc97294b85b64026a5234105db_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6714caf41ce2406282b4c22d36869265_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib880b79c41404a7f9ccb683284f4a657_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7242924d01844781882444c559d8edd7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b5149a7a9724ba099430ae94f3eb7f9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f44546bfba04d3182b566c995d1d6a5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea28f75c29f9495d97b2490ad495e473_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c30e990884c453a8e86bf31356441ab_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1de53f2d14549978ff86137b26acfdf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea0edbdebc194dbda6f583be24a5f5be_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff180f6730404c2fb6244e53cad88916_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc67e8a229ad434b9d2759887e18dcff_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ecc10254bda49bf803e6b76575554b2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia58fab4c69fb453394fb53a0a9cb3d93_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08f54d2fb7c74345a43dd8eb5652ccb9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia99f107296c340309c3405bc2810419c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied991033c3cc4ae8b1774bcbdfbc6a61_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48ac0207dbb24fba961de45411f8f863_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83d344caa1af4fadaeddfdde40462eb2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c73bc1480c5460787fa096cbca3e186_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4136a4c6588c473b8dbc29bd43446a8c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if77a7432ec784877b792884b4331e9ee_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id486cc4b73964a048598ee4145a36f51_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i260d3e7cbd5a4346b6de45c5013de1eb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2913a3930e88428aacc1ff729877e753_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if553fafbad26405cad25ce4550638d3f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i660405fd34d447fbac3495f01c37c868_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic90971f816384ed793878fbed1daf9b9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i904e8e179a1a49698833ce1b0110d5b4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a26625eb0434b3aa7c78f6443da31d6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7dcf8dd27b941e6a6224761d29aa39d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83fa1e7afed046c4a90965eb45e55ef4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i296f4d5ae9ac48818a1c814d83edd6c5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i541f7bde3cb144d6a1a06f324c128077_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8c4caa074434a8c891a4dbc9477a1df_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2171622cc8164fae9f90806cca105ee4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0201d118d8574b6db54cf6f7f5bb5c3e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc177dc034fa4f9ca0cad6e36eb33f5d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfa83b7726804a0da22e28fcde9c5ed2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70a11b67918c44d3bfc01126c08b9fc2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf8c3545f0134eebae2941403b2e022b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f24746bebef41f9a462c02b830d6110_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i307318101eaf48d785d4b776c386341a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if69fe081e83e44b89e1642cb41b84015_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e9cb136461a4e8aa85239cb391d845b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a97503f4be84d46bdeff57349e01c23_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i809f9ceab45b4cc88ceaa644a4ed41d8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic58118074eba4189a105e403b1233b58_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i679d69340bf54bb4a090a15b7ce9076e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4067fe86262c405cb2919284c7e1f31c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib86ae90471ee4ab18226e2683b749444_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b6b67a7073245c79ad8b17846729383_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee1279d9656246229165b6071a908fe4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1eaefd10a6d4f75bc5b01e6fd6e7612_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice769ebe11cd4873b0e7fae638d4de55_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77d9b85158ec4e37be193731477b820f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83848e68f3b04891aad523922cca52c7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9bae06748084a678545ae2a472fc025_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49396c3fa3284569b4be0611825c2214_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i492a23d281624d04895b84c347c42464_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i158cbb622490428d9efea6420c58fc6b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bc970a022044625a53b9bc92456c9d4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:219.75pt"><tr><td style="width:1.0pt"></td><td style="width:217.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xODk2_a9e6369c-c0b8-4841-a5ee-7c14e8dd6782">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:219.75pt"><tr><td style="width:1.0pt"></td><td style="width:217.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:112.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:396.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;text-align:center"><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6MDMzMjlmNDhhYmRkNDA3NzlmNjA4MmI2NWEwZmZhN2UvdGFibGVyYW5nZTowMzMyOWY0OGFiZGQ0MDc3OWY2MDgyYjY1YTBmZmE3ZV8wLTAtMS0xLTEzMTYxOA_0ef2aa1d-3429-466e-8929-bae9e29f2bb7">&#9746;</ix:nonNumeric> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;padding-left:90pt;padding-right:90pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xNDA_6902a18f-1936-4fec-aebd-32023db37c09">March 31, 2023</ix:nonNumeric> </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:112.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:396.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;text-align:center"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6N2RiYzZmMTY4MWRmNDk2ZjgyZjY1OTcxMWM4ODFlYzAvdGFibGVyYW5nZTo3ZGJjNmYxNjgxZGY0OTZmODJmNjU5NzExYzg4MWVjMF8wLTAtMS0xLTEzMTYxOA_9af3a534-f334-4a7b-b454-43742bae66d1">&#9744;</ix:nonNumeric> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;padding-left:90pt;padding-right:90pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the transition period from ______ to ______</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File No.&#160;<ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xODk3_dd294642-03ce-4af2-8918-b34a07f25457">1-6571</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xODkw_dc1063ad-9eec-447d-823c-ae774448e00f">Merck&#160;&amp; Co., Inc.</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.545%"><tr><td style="width:1.0%"></td><td style="width:41.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6Y2NmNGMxYjJhYzM4NDU0OWJjODQwZmM1NjljNTU0N2YvdGFibGVyYW5nZTpjY2Y0YzFiMmFjMzg0NTQ5YmM4NDBmYzU2OWM1NTQ3Zl8wLTAtMS0xLTEzMTYxOA_9bb8fa4e-1002-45db-a077-cccf42037241">New Jersey</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6Y2NmNGMxYjJhYzM4NDU0OWJjODQwZmM1NjljNTU0N2YvdGFibGVyYW5nZTpjY2Y0YzFiMmFjMzg0NTQ5YmM4NDBmYzU2OWM1NTQ3Zl8wLTEtMS0xLTEzMTYxOA_9f7f5728-1bb4-430c-af20-07b38d74e7af">22-1918501</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6Y2NmNGMxYjJhYzM4NDU0OWJjODQwZmM1NjljNTU0N2YvdGFibGVyYW5nZTpjY2Y0YzFiMmFjMzg0NTQ5YmM4NDBmYzU2OWM1NTQ3Zl8zLTAtMS0xLTEzMTYxOA_3f5e467f-2196-45a5-8801-7d2c70f7f450">126 East Lincoln Avenue</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6Y2NmNGMxYjJhYzM4NDU0OWJjODQwZmM1NjljNTU0N2YvdGFibGVyYW5nZTpjY2Y0YzFiMmFjMzg0NTQ5YmM4NDBmYzU2OWM1NTQ3Zl80LTAtMS0xLTEzMTYxOA_429e5483-903d-4535-b74c-4061620deaf4">Rahway</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6Y2NmNGMxYjJhYzM4NDU0OWJjODQwZmM1NjljNTU0N2YvdGFibGVyYW5nZTpjY2Y0YzFiMmFjMzg0NTQ5YmM4NDBmYzU2OWM1NTQ3Zl80LTEtMS0xLTEzMTYxOA_5aacc37d-44a6-44c1-b167-8b7d85b4d95e">New Jersey</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6Y2NmNGMxYjJhYzM4NDU0OWJjODQwZmM1NjljNTU0N2YvdGFibGVyYW5nZTpjY2Y0YzFiMmFjMzg0NTQ5YmM4NDBmYzU2OWM1NTQ3Zl80LTItMS0xLTEzMTYxOA_1d1bc586-43b1-40c6-8229-d3cbbab81031">07065</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Address of principal executive offices) (zip code)</span></td></tr></table></div><div style="margin-bottom:2pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xODkx_74fcea6c-72d1-4893-9a90-52788148ab69">(908)</ix:nonNumeric>&#160;<ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xODky_8e211ce9-d277-4cb2-9f22-437ed660eab7">740-4000</ix:nonNumeric> </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tr><td style="width:1.0%"></td><td style="width:20.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.011%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Not Applicable</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Former name, former address and former fiscal year, if changed since last report.)</span></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.557%"><tr><td style="width:1.0%"></td><td style="width:35.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Securities Registered pursuant to Section&#160;12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i135ab11fbbba4bcfa384c862b2035ddd_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF8yLTAtMS0xLTEzMTYxOA_d86ab289-5682-4ffd-9727-c903224b6c36">Common Stock ($0.50&#160;par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i135ab11fbbba4bcfa384c862b2035ddd_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF8yLTEtMS0xLTEzMTYxOA_cb529e27-e822-4f40-9a67-0df5922dd889">MRK</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i135ab11fbbba4bcfa384c862b2035ddd_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF8yLTItMS0xLTEzMTYxOA_915a08cf-0363-472b-9dac-0542e7996f24">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i147620f1bebe45a09eb1c534137133ec_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF8zLTAtMS0xLTEzMTYxOA_ebbedc1f-6993-4f83-ab14-e95e629529ff">0.500% Notes due 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i147620f1bebe45a09eb1c534137133ec_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF8zLTEtMS0xLTEzMTYxOA_56bb0e3e-0444-4162-8be4-1c7109b59cf0">MRK 24</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i147620f1bebe45a09eb1c534137133ec_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF8zLTItMS0xLTEzMTYxOA_ea5e4e7d-270b-4a9b-b9a9-73deeed066f5">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2d8e55f082b4b91b405cb32c49e17e5_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF80LTAtMS0xLTEzMTYxOA_6d86a2a0-32e6-448f-a0c3-b4fc636b4f63">1.875% Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2d8e55f082b4b91b405cb32c49e17e5_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF80LTEtMS0xLTEzMTYxOA_beab5f44-7c3d-4a1f-a36b-0d0bd8642fce">MRK/26</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if2d8e55f082b4b91b405cb32c49e17e5_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF80LTItMS0xLTEzMTYxOA_162bc9cc-debd-4b7b-bdf1-c27dddd141f7">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i59b625119501404d81b378dc2da40e6e_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF81LTAtMS0xLTEzMTYxOA_f098378b-1e96-480a-b131-48c625e0dfe4">2.500% Notes due 2034</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i59b625119501404d81b378dc2da40e6e_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF81LTEtMS0xLTEzMTYxOA_92b385d4-56d2-4911-b640-8a9f1955a841">MRK/34</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i59b625119501404d81b378dc2da40e6e_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF81LTItMS0xLTEzMTYxOA_e720995f-3865-48f1-952f-28f02cc7a222">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia0a22a157b7c4d9491fb9c5367a1371b_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF82LTAtMS0xLTEzMTYxOA_a40291b0-c7b2-4a39-8a5a-b26d611d5a23">1.375% Notes due 2036</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia0a22a157b7c4d9491fb9c5367a1371b_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF82LTEtMS0xLTEzMTYxOA_147790df-f046-41f1-93d7-65cb2f92f1b3">MRK 36A</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia0a22a157b7c4d9491fb9c5367a1371b_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF82LTItMS0xLTEzMTYxOA_83d99553-a0ce-41ea-b684-09cdc75ae00d">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;<ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xODkz_b1c24cde-b7b0-4fbc-97f0-841c8f340cb4">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#9744;</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required&#160;to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xODk0_67742bb5-0278-4da9-8e98-562369793366">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"></td><td style="width:17.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6MjgzMTAwZjAyMTE0NDc2NTg4NmQxZDBkMjkwZGQyYzMvdGFibGVyYW5nZToyODMxMDBmMDIxMTQ0NzY1ODg2ZDFkMGQyOTBkZDJjM18wLTAtMS0xLTEzMTYxOA_23cc4da8-c656-4389-ab13-fa260094c00e">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#9744; </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6MjgzMTAwZjAyMTE0NDc2NTg4NmQxZDBkMjkwZGQyYzMvdGFibGVyYW5nZToyODMxMDBmMDIxMTQ0NzY1ODg2ZDFkMGQyOTBkZDJjM18yLTMtMS0xLTEzMTYxOA_3803a375-2884-4e3c-885f-a8d6276073ed">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6MjgzMTAwZjAyMTE0NDc2NTg4NmQxZDBkMjkwZGQyYzMvdGFibGVyYW5nZToyODMxMDBmMDIxMTQ0NzY1ODg2ZDFkMGQyOTBkZDJjM180LTMtMS0xLTEzMTYxOA_eadaf207-a492-4b84-85ce-c008f43988a1">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;Yes&#160;</span><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#333333;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xODk1_b1dd325d-1306-4e45-bead-28f343ff608e">&#9746;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The number of shares of common stock outstanding as of the close of business on April&#160;30, 2023: <ix:nonFraction unitRef="shares" contextRef="i6f9aa917fb244d03ab52c4fcb13190ea_I20230430" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xODg3_be69b0d3-66c6-439c-b4a8-5f68956b99c4">2,537,435,954</ix:nonFraction></span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:9.959%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Page No.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART I</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_10">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_10">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_13">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_16">Condensed Consolidated Statement of Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_19">Condensed Consolidated Statement of Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_22">Condensed Consolidated Balance Sheet</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_25">Condensed Consolidated Statement of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_31">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_31">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_82">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_82">27</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_115">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_115">39</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_118">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_118">39</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_121">Cautionary Factors That May Affect Future Results</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_121">39</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART II</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_124">OTHER INFORMATION </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_124">40</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_127">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_127">40</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_133">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_133">40</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_136">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_136">41</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_139">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i3ccccf37677d43f88002f8d995e2fd3c_139">42</a></span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Part I - Financial Information</span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_13"></div><div style="margin-top:5pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;1. Financial Statements</span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_16"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">MERCK&#160;&amp; CO., INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENT OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited, $ in millions except per share amounts)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.428%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMi0xLTEtMS0xMzE2MTg_22a948dc-764f-4b1e-bd35-1d8c5714fc99">14,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMi0zLTEtMS0xMzE2MTg_bce1380b-87c8-407a-9c79-f8ebd0e11ede">15,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Costs, Expenses and Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfNC0xLTEtMS0xMzE2MTg_0188d0d0-f266-40a6-aa92-9c61754cf8cd">3,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfNC0zLTEtMS0xMzE2MTg_2180f02d-8ce8-437f-a4ea-95b8792af6fa">5,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfNS0xLTEtMS0xMzE2MTg_a4ac50f0-1dea-41f4-b71a-2a24673df9a2">2,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfNS0zLTEtMS0xMzE2MTg_d408b7de-2761-4d61-ad78-59cbcefdfb94">2,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfNi0xLTEtMS0xMzE2MTg_9f820cd5-8bcf-49cc-97b7-b6385fd4b003">4,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfNi0zLTEtMS0xMzE2MTg_756f3780-1e8c-4b78-885d-84bda4f33475">2,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfNy0xLTEtMS0xMzE2MTg_44827c4c-7eba-4264-80bc-1dd8dfe84c88">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfNy0zLTEtMS0xMzE2MTg_6b97c534-fe69-4c7d-aa8f-84c89af6340e">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfOC0xLTEtMS0xMzE2MTg_179cbe9b-cbaf-4611-ab53-9332ca253bc5">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfOC0zLTEtMS0xMzE2MTg_1b228471-d719-454e-9351-e1fae4b738aa">708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="mrk:CostsExpensesAndOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfOS0xLTEtMS0xMzE2MTg_c5123e2e-a3c4-40cf-8372-89e9fbab2ae2">10,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="mrk:CostsExpensesAndOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfOS0zLTEtMS0xMzE2MTg_0fac0ed5-3cb8-4d9a-8ba9-8bfc51189375">11,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income Before Taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTAtMS0xLTEtMTMxNjE4_c02f2f04-f0c9-4239-95ea-5a79557a3f84">3,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTAtMy0xLTEtMTMxNjE4_371e37d2-281a-4235-a5a7-2f9333970a21">4,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes on Income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTEtMS0xLTEtMTMxNjE4_a240005f-5659-4544-bfbf-fb2bb8f88da4">825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTEtMy0xLTEtMTMxNjE4_af2b2bd1-b7c0-43cd-bb39-01398ec1029f">554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTItMS0xLTEtMTMxNjE4_6ca2d321-3ded-41ea-9897-2efa2c811ccb">2,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTItMy0xLTEtMTMxNjE4_e0f721ab-c987-4e71-a1aa-486327058661">4,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net Income (Loss) Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTMtMS0xLTEtMTMxNjE4_1649114a-5201-4188-8214-62f6970413b9">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTMtMy0xLTEtMTMxNjE4_7fad438f-474a-456b-a99b-7c86a6265a87">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income Attributable to Merck &amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTYtMS0xLTEtMTMxNjE4_43492766-3d70-4de9-80c0-fe2e21a3502c">2,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTYtMy0xLTEtMTMxNjE4_56c8a1aa-d900-49af-892d-b9852e0de55b">4,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMjAtMS0xLTEtMTMxNjE4_e06ecac2-0828-4ce4-9b20-1e44c477d8fc">1.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMjAtMy0xLTEtMTMxNjE4_2fd6ca77-c5f7-4bb2-a4e8-670358fdd45e">1.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMjQtMS0xLTEtMTMxNjE4_0ba68e04-477d-4410-a877-9e2049b1916b">1.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMjQtMy0xLTEtMTMxNjE4_613a5df7-687d-42a0-974e-e501b8140487">1.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">MERCK&#160;&amp; CO., INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited, $ in millions)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:78.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.767%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.769%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income Attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfMi0xLTEtMS0xMzE2MTg_9d53d2c2-5134-41e9-9d8d-821d9fe93af3">2,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfMi0zLTEtMS0xMzE2MTg_6e1f75f4-5afd-48c6-af9c-cbf68de94662">4,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Comprehensive (Loss) Income Net of Taxes:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net unrealized (loss) gain on derivatives, net of reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfNC0xLTEtMS0xMzE2MTg_5a7677b3-7232-48b9-a7f4-08a44a47e840">133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfNC0zLTEtMS0xMzE2MTg_9a51891c-672a-4ff0-be38-247e3c6c0521">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit plan net (loss) gain and prior service (cost) credit, net of amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfNS0xLTEtMS0xMzE2MTg_8afa93a5-1374-4939-aac2-b70a3df0387a">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfNS0zLTEtMS0xMzE2MTg_2fb4cc0c-9b00-4f76-bec4-0de35149ff75">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cumulative translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfNi0xLTEtMS0xMzE2MTg_68db319a-f0ba-4a40-bd7d-b928d5f6b5c1">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfNi0zLTEtMS0xMzE2MTg_cb304264-9240-44f2-90ec-ed5bec455ceb">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfNy0xLTEtMS0xMzE2MTg_bd932dc9-79a6-48a5-8035-e1ec438564a5">115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfNy0zLTEtMS0xMzE2MTg_7861fdb2-ca43-4fc1-b735-949b79991b43">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive Income Attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfOC0xLTEtMS0xMzE2MTg_dc01a782-40da-4aa7-8075-ee8dfa630e14">2,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfOC0zLTEtMS0xMzE2MTg_f20970f2-647b-4a21-8e84-be3796791313">4,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 3 -</span></div></div></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">MERCK&#160;&amp; CO., INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEET</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited, $ in millions except per share amounts)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMy0xLTEtMS0xMzE2MTg_967daee1-ff2a-4951-bc69-ef80e6c538bc">9,707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMy0zLTEtMS0xMzE2MTg_cf16b07d-b043-475c-8128-383bd4d4a8d8">12,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNC0xLTEtMS0xMzE2MTg_222f313d-ef29-4b3c-96cc-9f6b9a4a4310">680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNC0zLTEtMS0xMzE2MTg_6b79232d-6853-4540-a628-11657f6e55d1">498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable (net of allowance for doubtful accounts of $<ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNS0wLTEtMS0xMzE2MTgvdGV4dHJlZ2lvbjo0OGFhZGQxM2Y1YWY0YTdiOTY2NGU4M2M5MDYxODI2NF82Nw_822fc7ba-dbd7-4ca1-9492-6374e8145232">76</ix:nonFraction> in 2023</span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;and $<ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNS0wLTEtMS0xMzE2MTgvdGV4dHJlZ2lvbjo0OGFhZGQxM2Y1YWY0YTdiOTY2NGU4M2M5MDYxODI2NF84MQ_6f908c8f-6c0a-48ea-9592-adb4ff628a9f">72</ix:nonFraction> in 2022) </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNS0xLTEtMS0xMzE2MTg_1222faae-5699-4374-906d-dbbcd43c9e18">10,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNS0zLTEtMS0xMzE2MTg_2632de83-4d07-44bb-b75e-8cc7340640b2">9,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories (excludes inventories of $<ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNi0wLTEtMS0xMzE2MTgvdGV4dHJlZ2lvbjowY2FmNDMwOTI0YzM0ZmZjOWFjMmVhMjcyNWRkNGE5M180Mg_c907277a-5910-4e63-8412-acc88ddbd2f2">3,284</ix:nonFraction> in 2023 and $<ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNi0wLTEtMS0xMzE2MTgvdGV4dHJlZ2lvbjowY2FmNDMwOTI0YzM0ZmZjOWFjMmVhMjcyNWRkNGE5M181NQ_44add83a-9702-4bc1-9816-2f6bfc0a2114">2,938</ix:nonFraction> in 2022</span></div><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">classified in Other assets - see Note&#160;7)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNi0xLTEtMS0xMzE2MTg_3f76f305-e2cc-479b-8fb7-8cc02bdfac01">5,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNi0zLTEtMS0xMzE2MTg_3d3b9b26-6181-4b32-9195-a9aa050fd839">5,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNy0xLTEtMS0xMzE2MTg_68f303a5-a8cf-43f1-8d28-342523a8aead">6,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNy0zLTEtMS0xMzE2MTg_5b39bf45-6ea2-46c6-b9f1-3af22664561d">7,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfOC0xLTEtMS0xMzE2MTg_1ca0e339-2d4b-47fe-b39d-6d57bf6bc74b">33,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfOC0zLTEtMS0xMzE2MTg_88756b45-3286-4a3b-81e1-f3a360f3d9fc">35,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfOS0xLTEtMS0xMzE2MTg_191b18c6-fc96-4880-8ded-9c835b314eb5">1,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfOS0zLTEtMS0xMzE2MTg_b252f003-c2a5-48fd-87d8-75270eb6d5df">1,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, Plant and Equipment, at cost, net of accumulated depreciation of $<ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTAtMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NGNjNzRkM2RmNmMyNDVjMmEwOGYwODg5NmNmNjFkZWNfNzk_45b9288c-51fb-4214-8763-27e6779afff4">18,256</ix:nonFraction> </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">in 2023 and $<ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTAtMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NGNjNzRkM2RmNmMyNDVjMmEwOGYwODg5NmNmNjFkZWNfOTI_e9f6ca0c-9ee9-4abb-b0e1-9239835657f8">17,985</ix:nonFraction> in 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTAtMS0xLTEtMTMxNjE4_1902832c-043f-456e-9b28-17abf435c562">21,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTAtMy0xLTEtMTMxNjE4_b3f2922d-1a77-495f-bd89-b28214766485">21,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTEtMS0xLTEtMTMxNjE4_4562c099-5b86-4fc2-a7d5-d3f25188e55b">21,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTEtMy0xLTEtMTMxNjE4_3c100ee6-afa8-4491-ae7e-905b4718a6f1">21,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Intangibles, Net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTItMS0xLTEtMTMxNjE4_7787aa44-dccd-4963-95c4-6b8884765d64">19,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTItMy0xLTEtMTMxNjE4_9987f72b-9b7a-46b2-b5e6-3c6844a32e71">20,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTMtMS0xLTEtMTMxNjE4_e0cb0b02-4494-4513-bbb2-59c39256d635">10,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTMtMy0xLTEtMTMxNjE4_b41112bc-0d60-4e46-9eb8-9baefef41f5b">9,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTQtMS0xLTEtMTMxNjE4_0df0d197-c2c8-4ced-b066-1f734f6fd62d">107,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTQtMy0xLTEtMTMxNjE4_555c1f83-c6ba-4b93-bd57-2375723dd275">109,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTctMS0xLTEtMTMxNjE4_96023f21-9b9f-4413-a412-3cf6d8317a09">2,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTctMy0xLTEtMTMxNjE4_23570947-3333-4116-872a-27e71fb6fada">1,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTgtMS0xLTEtMTMxNjE4_30919281-ef34-4152-86a0-6130039359d2">3,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTgtMy0xLTEtMTMxNjE4_de982a18-bde9-4a2f-8703-5aa1e4467f8e">4,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTktMS0xLTEtMTMxNjE4_5c75670e-171d-4642-809e-b2629b0a969e">13,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTktMy0xLTEtMTMxNjE4_941ff79c-e2eb-44b7-98cd-aabe27fb1454">14,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjAtMS0xLTEtMTMxNjE4_8d3cb187-9ac4-4ea7-9401-18e573106cf0">1,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjAtMy0xLTEtMTMxNjE4_83596902-72c3-4b8a-9664-ac7d0752b626">1,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjEtMS0xLTEtMTMxNjE4_a730ca51-dd3b-4e99-960b-f32420625ed9">1,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjEtMy0xLTEtMTMxNjE4_bb244e75-0734-4718-a367-5934625c9927">1,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjItMS0xLTEtMTMxNjE4_3d9d8385-c265-4769-8757-ac8133ea94d5">23,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjItMy0xLTEtMTMxNjE4_b9c1605e-67f6-4b9d-9fbe-313dce0ab1be">24,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-Term Debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjMtMS0xLTEtMTMxNjE4_7e905a0e-7f44-487a-a3aa-fe584eacf25d">28,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjMtMy0xLTEtMTMxNjE4_f846fcd2-b793-4a77-9d0f-945e2daa5251">28,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred Income Taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjQtMS0xLTEtMTMxNjE4_e559db80-b288-453f-b0dd-14928d9eb67d">1,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjQtMy0xLTEtMTMxNjE4_da5652c4-91bd-4a1b-8b13-03f6c5c5f9ef">1,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjUtMS0xLTEtMTMxNjE4_759565f5-2ba5-4057-ac81-f8818f03e6d0">8,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjUtMy0xLTEtMTMxNjE4_246b808e-19fc-45ce-8028-70f9bc85e926">8,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merck&#160;&amp; Co., Inc. Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjctMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NmYwYjdmMjdjZGM3NGNjMjhlMTM3YTM2YmEwNDkzY2NfMTk_128e47ea-16fc-48b1-a3d1-a39408894e0c"><ix:nonFraction unitRef="usdPerShare" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjctMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NmYwYjdmMjdjZGM3NGNjMjhlMTM3YTM2YmEwNDkzY2NfMTk_504cabe0-2ba9-4258-9d7f-3be08ef9fb82">0.50</ix:nonFraction></ix:nonFraction> par value</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Authorized - <ix:nonFraction unitRef="shares" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjctMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NmYwYjdmMjdjZGM3NGNjMjhlMTM3YTM2YmEwNDkzY2NfNDU_5388a816-78d9-49f3-bcbb-4ece1514df88"><ix:nonFraction unitRef="shares" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjctMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NmYwYjdmMjdjZGM3NGNjMjhlMTM3YTM2YmEwNDkzY2NfNDU_a3209d0f-d4dc-4731-b6a7-7268823b40b6">6,500,000,000</ix:nonFraction></ix:nonFraction> shares</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued - <ix:nonFraction unitRef="shares" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjctMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NmYwYjdmMjdjZGM3NGNjMjhlMTM3YTM2YmEwNDkzY2NfNjQ_341472b4-707a-4453-ab41-60dfa82eaa9b"><ix:nonFraction unitRef="shares" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjctMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NmYwYjdmMjdjZGM3NGNjMjhlMTM3YTM2YmEwNDkzY2NfNjQ_993b83ae-b115-4843-a85c-55f40f10efe8">3,577,103,522</ix:nonFraction></ix:nonFraction> shares in 2023 and 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjctMS0xLTEtMTMxNjE4_79fb7564-56ee-4d60-986f-f2042d770186">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjctMy0xLTEtMTMxNjE4_7b227f27-ff2b-469a-9e6d-18d2de2a2ec3">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjgtMS0xLTEtMTMxNjE4_da6468c1-42c2-46fa-99f8-5e51d9f1c397">44,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjgtMy0xLTEtMTMxNjE4_70bb3dbd-e09a-4850-88ea-f4844bd6a1d2">44,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjktMS0xLTEtMTMxNjE4_cca8165e-e648-4706-bbb1-f09f38f5a380">62,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjktMy0xLTEtMTMxNjE4_3bd92cbf-1e13-437b-a6bd-77c654470344">61,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzAtMS0xLTEtMTMxNjE4_b12dd89a-1d1c-47e7-ad14-8c5484cb4f6f">4,883</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzAtMy0xLTEtMTMxNjE4_aa72c78d-ec8d-4799-8c47-978ea8205ec5">4,768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:StockholdersEquityBeforeTreasuryStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzEtMS0xLTEtMTMxNjE4_3d85a20a-fe4f-4877-adb6-379299a33c60">103,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:StockholdersEquityBeforeTreasuryStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzEtMy0xLTEtMTMxNjE4_66806729-0f43-42d4-9a45-d7ac807dbed8">102,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less treasury stock, at cost:</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzItMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NGQxMGIwNzYwNTM1NDlmMmFjZDZmNjgyMTEyODZkZTVfMzU_4156c5c2-2f3b-4715-8897-8ac783d34baf">1,039,651,210</ix:nonFraction> shares in 2023 and <ix:nonFraction unitRef="shares" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzItMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NGQxMGIwNzYwNTM1NDlmMmFjZDZmNjgyMTEyODZkZTVfNTU_b610ec30-f8ec-4c4f-9476-dbf7523bb992">1,039,269,638</ix:nonFraction> shares in 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzItMS0xLTEtMTMxNjE4_461a7221-c005-40d5-906e-a0ced02e8a6c">56,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzItMy0xLTEtMTMxNjE4_a783c954-4094-44da-afd5-b3063453d865">56,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Merck&#160;&amp; Co., Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzMtMS0xLTEtMTMxNjE4_5d07777d-2ea2-4207-81ce-86b701e6e164">46,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzMtMy0xLTEtMTMxNjE4_424582a5-e3c9-4ebf-9c9a-8325609abc41">45,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzQtMS0xLTEtMTMxNjE4_f8989083-de67-4ad3-bf49-2871f5d529e2">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzQtMy0xLTEtMTMxNjE4_859d6f87-7d8d-4a30-b9e1-e33e12ca7467">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzUtMS0xLTEtMTMxNjE4_09113873-7a8f-4863-868e-d7c1db560549">46,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzUtMy0xLTEtMTMxNjE4_fbdb4efa-b44f-467c-9479-6f8dc058ec69">46,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzYtMS0xLTEtMTMxNjE4_986ca522-42af-495a-8d5c-73ec54bd96fe">107,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzYtMy0xLTEtMTMxNjE4_0dd841fe-3632-4023-8da8-907dd5c192a4">109,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of this condensed consolidated financial statement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 4 -</span></div></div></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">MERCK&#160;&amp; CO., INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Unaudited, $ in millions)</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.575%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMy0xLTEtMS0xMzE2MTg_96df26bc-b065-421d-9b4b-f29e1526bc5e">2,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMy0zLTEtMS0xMzE2MTg_d973dad5-1be3-4ae4-976a-1698ee71f3ea">4,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfNS0xLTEtMS0xMzE2MTg_d90c522f-6883-4fb5-bf24-932945d33689">543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfNS0zLTEtMS0xMzE2MTg_dec9ed94-267c-42fc-8d0e-ee1e62a82fc3">699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfNi0xLTEtMS0xMzE2MTg_b5531913-afe0-4a79-aaea-92497ee62209">448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfNi0zLTEtMS0xMzE2MTg_979a722b-8726-47dd-ae20-57e44456acf2">421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Income) loss from investments in equity securities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfOC0xLTEtMS0xMzE2MTg_f770899b-d54c-4209-9c23-6d6e75dccda4">450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfOC0zLTEtMS0xMzE2MTg_16542396-21c6-4733-a312-03bcbd4a33f1">708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charge for the acquisition of Imago BioSciences, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfOS0xLTEtMS0xMzE2MTg_bc25a7bf-4cea-43c8-8289-40019cf71366">1,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfOS0zLTEtMS0xMzE2MTg_263abef6-bec6-41af-9959-6ace0ce88fcc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTAtMS0xLTEtMTMxNjE4_0de064bb-1471-4c23-b18e-ea756677c8aa">277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTAtMy0xLTEtMTMxNjE4_d5beb90c-dfa4-4c17-a15e-1cf6443250b7">338</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTEtMS0xLTEtMTMxNjE4_1696e982-58c0-41ab-a25d-8c5349da8e33">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTEtMy0xLTEtMTMxNjE4_f6ba5549-ebbc-4423-bd0b-c0b78a6431eb">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTItMS0xLTEtMTMxNjE4_6f34df55-0d21-410f-9940-256f6a21d765">197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTItMy0xLTEtMTMxNjE4_124ca8e5-2693-42b6-bcdd-2688d99aedd2">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net changes in assets and liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:IncreaseDecreaseInOperatingCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTMtMS0xLTEtMTMxNjE4_bd556e0f-f8b2-4c05-95af-01089814842a">2,890</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInOperatingCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTMtMy0xLTEtMTMxNjE4_d4095305-7596-4cc2-9835-39d54c0ed506">1,299</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Cash Provided by Operating Activities </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTQtMS0xLTEtMTMxNjE4_d4fa6fde-1e10-4b5e-8a1f-81058bd4bc86">1,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTQtMy0xLTEtMTMxNjE4_bf1fd024-50c7-49e6-a734-16e6ac7ca85d">4,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTYtMS0xLTEtMTMxNjE4_d1497e77-af35-4705-a186-9a00da0399b9">1,007</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTYtMy0xLTEtMTMxNjE4_60dd1360-f35f-417f-aeb4-8f3cdf07fdbf">984</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of securities and other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTctMS0xLTEtMTMxNjE4_485191f7-5ee4-4524-b344-fedabc168793">562</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTctMy0xLTEtMTMxNjE4_12420839-30b0-4a6f-885c-cfe8d9051c4f">372</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales of securities and other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTgtMS0xLTEtMTMxNjE4_621f6940-d559-4c6f-9c20-b5d0d60f38f5">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTgtMy0xLTEtMTMxNjE4_92e6b1fe-156e-49da-8aac-385142f90edc">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of Imago BioSciences, Inc., net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTktMS0xLTEtMTMxNjE4_a16e09fe-9bab-4028-b7f4-62014a0f001f">1,327</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTktMy0xLTEtMTMxNjE4_457175af-1125-4f41-ae7f-ffd55d717a9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjEtMS0xLTEtMTMxNjE4_9fcf7baf-941d-4861-86d5-fadb2ce37601">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjEtMy0xLTEtMTMxNjE4_042b8b62-02b2-4cab-8dac-173b990d06e5">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Cash Used in Investing Activities </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjItMS0xLTEtMTMxNjE4_dde27029-013a-4f21-9d1d-da96e9b5c8e2">2,359</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjItMy0xLTEtMTMxNjE4_3d3e0417-06f2-4516-a14e-3d98aede7085">1,173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjUtMS0xLTEtMTMxNjE4_5aad0010-ef4c-45b6-8002-7e8c4d53da42">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjUtMy0xLTEtMTMxNjE4_78e76ae4-7af1-4a54-9154-39553da4bd71">1,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjctMS0xLTEtMTMxNjE4_34a99e25-8882-4dbb-99f4-0a118d022c7b">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjctMy0xLTEtMTMxNjE4_547ab818-36b8-46c6-8216-1f164b119103">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends paid to stockholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjgtMS0xLTEtMTMxNjE4_a9e81bee-bfbb-4c85-a95f-51adb653ac90">1,853</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjgtMy0xLTEtMTMxNjE4_887f60e0-ce30-4a24-9aa1-c194599fab6f">1,745</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjktMS0xLTEtMTMxNjE4_9fda3d61-3899-45cb-afdb-726d11db379a">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjktMy0xLTEtMTMxNjE4_ae6beb2f-1113-4127-974b-19e7718f0947">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzAtMS0xLTEtMTMxNjE4_84a0d387-1f44-49fd-a73b-1f3774e740f0">81</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzAtMy0xLTEtMTMxNjE4_6f818a21-e15d-4163-93dc-c948bf8acf5d">103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Cash Used in Financing Activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzEtMS0xLTEtMTMxNjE4_a29a9e77-4dba-4e43-808d-2537b985aa5f">2,054</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzEtMy0xLTEtMTMxNjE4_a5a219d0-be6a-4d13-8306-9c72bfe5372d">3,086</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzctMS0xLTEtMTMxNjE4_cc1d4d3f-1239-48a6-9633-85cd7548fcc8">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzctMy0xLTEtMTMxNjE4_e5fd50f1-af3c-44b9-9ac2-f6863a65efdc">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzgtMS0xLTEtMTMxNjE4_6f769ff9-7bc0-4809-a8a1-cb9bd2cd4327">2,987</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzgtMy0xLTEtMTMxNjE4_b2fb9306-ccd7-4c95-8e12-84beb46b61dd">447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzktMC0xLTEtMTMxNjE4L3RleHRyZWdpb246ZTQwNmNiNmMwNWZjNDI3Y2I0ODk3ZjkyMGI2ZDgxYTBfOTg_9415480a-1c90-4b11-a9f7-715a776bda3e">79</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if2cb2241175c4c8c8fd5daf0a86385e3_I20211231" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzktMC0xLTEtMTMxNjE4L3RleHRyZWdpb246ZTQwNmNiNmMwNWZjNDI3Y2I0ODk3ZjkyMGI2ZDgxYTBfMTA1_864b1408-ebf8-4800-a362-7266f39b0329">71</ix:nonFraction> at January 1, 2023 and 2022, respectively, included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzktMS0xLTEtMTMxNjE4_c330c56f-4e92-499f-ab27-745afc28c960">12,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cb2241175c4c8c8fd5daf0a86385e3_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzktMy0xLTEtMTMxNjE4_e1bb938c-2e47-4577-9f92-528f4ad0ee01">8,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $<ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfNDAtMC0xLTEtMTMxNjE4L3RleHRyZWdpb246ZDRjYjdjYjExZDRmNGEwYjllZWY0ZGNkNGFhZTQ3YTdfOTM_4136cb22-f5b0-48ae-9788-19eeb5a2ec2c">79</ix:nonFraction> </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">and $<ix:nonFraction unitRef="usd" contextRef="i1ff3b595ae954906bf225b8a7cc58b69_I20220331" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfNDAtMC0xLTEtMTMxNjE4L3RleHRyZWdpb246ZDRjYjdjYjExZDRmNGEwYjllZWY0ZGNkNGFhZTQ3YTdfMTAx_b39ba864-55bf-43af-b36b-ee05f41e4d25">58</ix:nonFraction> at March&#160;31, 2023 and 2022, respectively, included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfNDAtMS0xLTEtMTMxNjE4_5e444c09-8ef4-47ec-a166-77e567aa8423">9,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ff3b595ae954906bf225b8a7cc58b69_I20220331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfNDAtMy0xLTEtMTMxNjE4_2f82e097-732a-4893-bc44-d945a285b65d">8,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of this condensed consolidated financial statement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 5 -</span></div></div></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span></div></div><div style="text-align:justify"><span><br/></span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_31"></div><div style="margin-top:15pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1.    <ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zMS9mcmFnOmExOGMwMGVjNDM2MDQyMDU4YWFkMDBmOWM2ZDEyNjE2L3RleHRyZWdpb246YTE4YzAwZWM0MzYwNDIwNThhYWQwMGY5YzZkMTI2MTZfNTIzNA_c8ad131b-6693-448d-bbd5-b63555253a56" continuedAt="i24e8f43604e34b07bbba9e8ea2dde53a" escape="true"><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zMS9mcmFnOmExOGMwMGVjNDM2MDQyMDU4YWFkMDBmOWM2ZDEyNjE2L3RleHRyZWdpb246YTE4YzAwZWM0MzYwNDIwNThhYWQwMGY5YzZkMTI2MTZfNTIzNQ_be0e9094-f28a-4ad5-bc4b-deefad9b251e" continuedAt="i1e30c1b455044ee5a97e3d654002065f" escape="true">Basis of Presentation</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i1e30c1b455044ee5a97e3d654002065f" continuedAt="i5a1ab3d0b4f64632935d15cd40f64de6"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i24e8f43604e34b07bbba9e8ea2dde53a" continuedAt="iccc0a77790fa49f2998c53f9bcb8968a">The accompanying unaudited condensed consolidated financial statements of Merck&#160;&amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck&#8217;s Form 10-K filed on February&#160;24, 2023. </ix:continuation></span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="iccc0a77790fa49f2998c53f9bcb8968a">The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company&#8217;s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature.</ix:continuation> <ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zMS9mcmFnOmExOGMwMGVjNDM2MDQyMDU4YWFkMDBmOWM2ZDEyNjE2L3RleHRyZWdpb246YTE4YzAwZWM0MzYwNDIwNThhYWQwMGY5YzZkMTI2MTZfMjc0ODc3OTA4NDAyOA_2b498c63-3def-40b4-ba4d-64960898e05f" escape="true">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zMS9mcmFnOmExOGMwMGVjNDM2MDQyMDU4YWFkMDBmOWM2ZDEyNjE2L3RleHRyZWdpb246YTE4YzAwZWM0MzYwNDIwNThhYWQwMGY5YzZkMTI2MTZfNTIzNw_c72c5834-99e5-4a52-a79f-874615827d46" continuedAt="ifd0592ca47024d039cf9a6878e440cab" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standard</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The Company adopted the guidance effective January 1, 2023. The adoption of this guidance did not have an impact on the Company&#8217;s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standard Not Yet Adopted</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i5a1ab3d0b4f64632935d15cd40f64de6"><ix:continuation id="ifd0592ca47024d039cf9a6878e440cab">In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company does not expect there to be an impact to its consolidated financial statements upon adoption</ix:continuation></ix:continuation>. </span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_40"></div><div style="margin-top:15pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTA0ODY_07d1381a-5073-4c20-9340-d3077ff62e74" continuedAt="i3fa3ce8621c7476e99a0489dad5c8030" escape="true">Acquisitions, Research Collaborations and Licensing Agreements</ix:nonNumeric></span></div><ix:continuation id="i3fa3ce8621c7476e99a0489dad5c8030" continuedAt="i48fc4b45a466458f9160f80c0e908e8e"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company&#8217;s financial results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2023, Merck announced an agreement to acquire Prometheus Biosciences, Inc. (Prometheus), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. Prometheus&#8217; lead candidate, PRA023, is a humanized monoclonal antibody directed to tumor necrosis factor-like ligand 1A, a target associated with both intestinal inflammation and fibrosis. Prometheus is developing PRA023 for the treatment of immune-mediated diseases including ulcerative colitis, Crohn&#8217;s disease, and other autoimmune conditions. Under the terms of the acquisition agreement, Merck, through a subsidiary, will acquire all of the outstanding shares of Prometheus for $<ix:nonFraction unitRef="usdPerShare" contextRef="i1302ee97335a4b8a864d880d15a75ffd_I20230430" decimals="2" name="mrk:AssetAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfNTQ5NzU1ODM4Mzg3_d4c63538-f831-47fe-97bf-4ae60d30ba4d">200</ix:nonFraction> per share in cash for a total equity value of approximately $<ix:nonFraction unitRef="usd" contextRef="i2c03ed79efac404d85fb217647f60f9e_D20230401-20230430" decimals="-8" name="us-gaap:AssetAcquisitionPriceOfAcquisitionExpected" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfNTQ5NzU1ODM4Mzc5_a5ddbb2e-e454-48d8-b02f-37b14b029855">10.8</ix:nonFraction> billion. The acquisition is subject to Prometheus shareholder approval. The closing of the proposed transaction will be subject to certain conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. The transaction is expected to close in the third quarter of 2023. If the proposed transaction closes, the Company anticipates it will be accounted for as an asset acquisition, which would result in a charge of approximately $<ix:nonFraction unitRef="usd" contextRef="id017497421574c008e33bacea591637e_D20230701-20230930" decimals="-8" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfNTQ5NzU1ODM5MDQz_614062ba-076a-491b-a741-beef8d298826">10.3</ix:nonFraction>&#160;billion in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2023, Merck and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.) closed a license and collaboration agreement expanding their relationship in which Merck gained exclusive rights for the research, development, manufacture and commercialization of up to seven investigational preclinical antibody drug conjugates (ADCs) for the treatment of cancer. Kelun-Biotech retained the right to research, develop, manufacture and commercialize certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau. Merck made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i1e8e4ea1abaf40778222b2bb6dcfb639_D20230201-20230228" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTY0OTI2NzQ1NDU2OA_ce532234-2516-49a3-a45c-3e4563d6c39f">175</ix:nonFraction> million, which was recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in the first quarter of 2023. In addition, Kelun-Biotech is eligible to receive future contingent development-related payments aggregating up to $<ix:nonFraction unitRef="usd" contextRef="ib9dedd741503427183ecc62df92f5085_I20230228" decimals="-8" name="mrk:CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTY0OTI2NzQ1NDU4NA_7c1b2c89-c79e-43d3-8e94-a6e5875046db">1.0</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="ib9dedd741503427183ecc62df92f5085_I20230228" decimals="-8" name="mrk:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTY0OTI2NzQ1NDYwMg_0f19d466-0cbe-4518-b989-72855a941e0a">2.8</ix:nonFraction> billion in regulatory milestones, and $<ix:nonFraction unitRef="usd" contextRef="ib9dedd741503427183ecc62df92f5085_I20230228" decimals="-8" name="mrk:CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTY0OTI2NzQ1NDYxOA_6f4bc67c-fc4e-48bd-92f1-367c2868853f">5.5</ix:nonFraction> billion in sales-based milestones if Kelun-Biotech does not retain Chinese mainland, Hong Kong and Macau rights for the option ADCs and all candidates achieve regulatory approval. In addition, Kelun-Biotech is eligible to receive tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested $<ix:nonFraction unitRef="usd" contextRef="i3c175c60a55e4c3eb9ac840966e13ebf_I20230131" decimals="-6" name="mrk:CollaborativeArrangementPreferredStockInvestmentInCounterparty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTY0OTI2NzQ1NDYzNA_a4e29fb2-141c-487d-a9dc-93ba5790ad83">100</ix:nonFraction> million in Kelun-Biotech&#8217;s Series B preferred shares in January 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2023, Merck acquired Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, for $<ix:nonFraction unitRef="usd" contextRef="i609e1582535d4dfb834b95904e849c27_D20230101-20230131" decimals="-7" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTY0OTI2NzQ1NDY1MQ_5cbcd9f1-00c7-4a03-9f41-13945323aab5">1.35</ix:nonFraction> billion </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 6 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div style="margin-top:6pt;text-align:justify"><ix:continuation id="i48fc4b45a466458f9160f80c0e908e8e"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(including payments to settle share-based equity awards) and also incurred approximately $<ix:nonFraction unitRef="usd" contextRef="i609e1582535d4dfb834b95904e849c27_D20230101-20230131" decimals="-6" name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTY0OTI2NzQ1NDY4Nw_77edc5e1-884d-4bb6-ab2b-f1846940a192">60</ix:nonFraction>&#160;million of transaction costs. Imago&#8217;s lead candidate bomedemstat, MK-3543 (formerly IMG-7289), is an investigational orally available lysine-specific demethylase 1 inhibitor currently being evaluated in multiple Phase 2 clinical trials for the treatment of essential thrombocythemia, myelofibrosis, and polycythemia vera, in addition to other indications. The transaction was accounted for as an acquisition of an asset since bomedemstat represented substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded net assets of $<ix:nonFraction unitRef="usd" contextRef="i8f3adb7e1a4d42dd925db11dbf71eac5_I20230131" decimals="-6" name="mrk:AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTY0OTI2NzQ1NDY4Mw_654d2a2e-1736-4ca5-9721-99373993720e">219</ix:nonFraction> million, as well as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses of $<ix:nonFraction unitRef="usd" contextRef="i609e1582535d4dfb834b95904e849c27_D20230101-20230131" decimals="-8" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTY0OTI2NzQ1NDY2Nw_9303e97a-c62b-475e-b1ff-9e4f0e3b2f10">1.2</ix:nonFraction> billion in the first quarter of 2023 related to the transaction. There are no future contingent payments associated with the acquisition.</span></ix:continuation></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_43"></div><div style="margin-top:15pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTE2NDQ_1c37924b-3e7c-4c80-8b87-e898179b99e7" continuedAt="i5fe098dab8694a46a5ee8f44afec41e9" escape="true">Collaborative Arrangements</ix:nonNumeric></span></div><ix:continuation id="i5fe098dab8694a46a5ee8f44afec41e9" continuedAt="ica67ba0d241a433f932b911fe84143f5"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck&#8217;s more significant collaborative arrangements are discussed below. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AstraZeneca</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca&#8217;s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (pembrolizumab) and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca&#8217;s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo&#160;monotherapy and non-PD-L1/PD-1 combination therapy opportunities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Profits from Lynparza and Koselugo&#160;product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the first quarter of 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $<ix:nonFraction unitRef="usd" contextRef="i58a876d3681e4986805915e1bac18ff1_D20220101-20220331" decimals="-6" name="mrk:ProbableContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMjE3Mw_b56b74e0-0535-4054-9690-16a469ab5856">600</ix:nonFraction>&#160;million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $<ix:nonFraction unitRef="usd" contextRef="i3c3d2c4bb8cc45efb4e93d046dd6a753_I20220331" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMjI2Mw_c9c8ddb2-95d1-46ef-9bf9-d3eda777afcb">600</ix:nonFraction>&#160;million liability (which remained accrued at March 31, 2023) and a corresponding increase to the intangible asset related to Lynparza. Merck also recognized $<ix:nonFraction unitRef="usd" contextRef="i6a91adde5a68413fbc1cfab655dbcbe6_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMjM3Mg_dce96547-b25d-4615-b1f8-f1ac4fd3a91e">250</ix:nonFraction>&#160;million of cumulative amortization catch-up expense related to the recognition of this milestone in the first quarter of 2022. Also in the first quarter of 2022, Merck made a sales-based milestone payment to AstraZeneca (which had been previously accrued for) of $<ix:nonFraction unitRef="usd" contextRef="i350e44c40f67467ba477b370f98d41fc_D20220101-20220331" decimals="-6" name="mrk:MilestonePaymentsSalesBased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMjYyNw_f41fe619-0e01-4c3b-a78c-60b89ae7a08c">400</ix:nonFraction>&#160;million. Potential future sales-based milestone payments of $<ix:nonFraction unitRef="usd" contextRef="id6b1412b32dd45bf9b2dc2c9740d6c6f_I20230331" decimals="-8" name="mrk:PotentialFutureMilestonePaymentsSalesBased" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMjc2MA_e59d6705-d747-42e9-86fa-6bbabcc85ac5">2.1</ix:nonFraction> billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In the first quarter of 2023, Merck made a regulatory milestone payment to AstraZeneca (which had been previously accrued for) of $<ix:nonFraction unitRef="usd" contextRef="i71ce1d5e1bd141539620a96cb8b2ec10_I20221231" decimals="-6" name="mrk:CollaborativeArrangementRegulatoryMilestonePaymentsAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMzg0ODI5MDcxNjA5Ng_f445abb1-99a6-4c1c-8e73-b288eeef069a">105</ix:nonFraction>&#160;million. In 2022, Lynparza received regulatory approvals triggering capitalized milestone payments of $<ix:nonFraction unitRef="usd" contextRef="idf9cd10c9efe4059a13ad6f64f232a85_D20220101-20221231" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMjk3Mg_3f2815ff-b48a-427c-86a5-7933c1e6eb84">250</ix:nonFraction>&#160;million from Merck to AstraZeneca. Potential future regulatory milestone payments of $<ix:nonFraction unitRef="usd" contextRef="id6b1412b32dd45bf9b2dc2c9740d6c6f_I20230331" decimals="-8" name="mrk:PotentialFutureMilestonePaymentsRegulatory" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMzA1Mg_864b5908-03da-4517-8564-21624333da2e">1.1</ix:nonFraction> billion remain under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $<ix:nonFraction unitRef="usd" contextRef="i654e8b5924d8442fa9eb55859bbc8647_I20230331" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMzIxMQ_e0014abc-695c-4555-b300-4c43a2adb0e5">1.5</ix:nonFraction> billion at March&#160;31, 2023 and is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 7 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="ica67ba0d241a433f932b911fe84143f5" continuedAt="id0cd72df7b02460784d57bb56560359d"><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTE2NTc_3c242269-2707-49af-af00-29a650ff88ce" continuedAt="i7fd958410862453fb5c377626a03a601" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.089%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib681c644ca864f3286e965d6d7324aa4_D20230101-20230331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMi0xLTEtMS0xMzE2MTg_74799bc7-1ca0-4041-a9d1-784e79d4724a">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide79c33fd45c49b19bce108416c71788_D20220101-20220331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMi0zLTEtMS0xMzE2MTg_2445dbff-4eb4-46d6-b22b-4a8bf9abe3c1">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i525916f3d1464ab9b6f291401c761233_D20230101-20230331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMy0xLTEtMS0xMzE2MTg_d0a05f97-6fd7-4ee2-8d43-c2faa2305371">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e95ebf7c1884a0396c7c91a0e223ee6_D20220101-20220331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMy0zLTEtMS0xMzE2MTg_6afd9307-c819-4227-a213-cdfe99dd151c">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6d877e0a5147208fe56690fbb929b0_D20230101-20230331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfNC0xLTEtMS0xMzE2MTg_b2155d73-8814-4f50-bf37-8ed20429ee2e">298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cdf23392f5642ba818b20d852b014a9_D20220101-20220331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfNC0zLTEtMS0xMzE2MTg_be895c9b-c589-47d8-914e-8187cb5166aa">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46e9161a43a44a2fa59e52960034468a_D20230101-20230331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfNi0xLTEtMS0xMzE2MTg_a68e8f3c-31d9-45e0-9bdd-7df16a360b50">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71ffa17774c44d2287fe9111206866c3_D20220101-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfNi0zLTEtMS0xMzE2MTg_2f37606e-2c17-448f-820a-d0d9575d6d07">299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba6c247720a049d28349afa51cec42a7_D20230101-20230331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfNy0xLTEtMS0xMzE2MTg_510db6bc-d4e3-4767-9ad1-0f39921b337d">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22834ff470f4f1aa7da131a94ad1d29_D20220101-20220331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfNy0zLTEtMS0xMzE2MTg_941eda5a-d0e6-4139-80a2-5e8d720047eb">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6500964c8d3f4d06b28f3f23cada56e5_D20230101-20230331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfOC0xLTEtMS0xMzE2MTg_ac61b060-8225-4634-a588-fa0168539d11">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2de578164e434980f14d63a2153220_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfOC0zLTEtMS0xMzE2MTg_e788dba8-1bd1-4ec6-9893-12a63f3d4f63">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5973fb4a5d684bcca7a62270623ac406_I20230331" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMTEtMS0xLTEtMTM1MDU5_854b54f9-ca63-4780-8dfd-acdedb4a61e9">303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb9ff33d56484784be92a715ee774c2d_I20221231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMTEtMy0xLTEtMTM1MDU5_fbaf5877-e3f0-4f5a-ac6f-fc1171938592">303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife24131bdfa1419d8d2708d8b616e5b9_I20230331" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMTItMS0xLTEtMTM1MDU5_c5b00a61-6e39-4056-add7-365bf9702589">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaae108da197453bb8b3b58a2cd21d7c_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMTItMy0xLTEtMTM1MDU5_6742257a-287b-4aca-92f9-3599893f8593">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i492255c072c74c9f8a70fdd6212cfe65_I20230331" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMTMtMS0xLTEtMTM1MDU5_c8186b42-96de-4c6d-8a64-2e65cbc35478">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie92cc5b201cf42e9a6a395bf77ad597c_I20221231" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMTMtMy0xLTEtMTM1MDU5_e8fdc6fd-77eb-48b2-9a4f-25a04e1cd41a">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amount in the first quarter of 2022 includes $<ix:nonFraction unitRef="usd" contextRef="i46e9161a43a44a2fa59e52960034468a_D20230101-20230331" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMzYwNQ_37b61bd6-0fe6-42cb-b27c-7f980b54667a">250</ix:nonFraction>&#160;million of cumulative amortization catch-up expense as noted above.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Eisai</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and Lenvima.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights. In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the first quarter of 2023, Merck determined it was probable that sales of Lenvima in the future would trigger a $<ix:nonFraction unitRef="usd" contextRef="i00731f51ddd64c099bf1f3a866d6e0ff_D20230101-20230331" decimals="-6" name="mrk:ProbableContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTY0OTI2NzQ2MDA4Nw_b29673ef-c363-4cab-8a66-34060a0c9421">125</ix:nonFraction>&#160;million sales-based milestone payment from Merck to Eisai. Accordingly, Merck recorded a $<ix:nonFraction unitRef="usd" contextRef="ia8a01e007c934b3285178dc642a890ea_I20230331" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTY0OTI2NzQ2MDEwMQ_e986925c-8b1f-43b7-b251-90b33e20d1b3">125</ix:nonFraction>&#160;million liability and a corresponding increase to the intangible asset related to Lenvima. Merck also recognized $<ix:nonFraction unitRef="usd" contextRef="ibcf5abe1e04c438f81048ecae5f02ed4_D20230101-20230331" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTY0OTI2NzQ2MDI2MQ_00156a08-5ef2-4cba-8d1f-d66362e0fc04">72</ix:nonFraction>&#160;million of cumulative amortization catch-up expense related to the recognition of this milestone. In 2022, Merck made sales-based milestone payments to Eisai (which had been previously accrued for) aggregating $<ix:nonFraction unitRef="usd" contextRef="i364cafd01c114c558bf6c571df9b34b1_D20220101-20221231" decimals="-6" name="mrk:MilestonePaymentsSalesBased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfNTI1Ng_013770cb-4688-4be6-868d-9d2308d196ff">600</ix:nonFraction> million (of which $<ix:nonFraction unitRef="usd" contextRef="i2d145059533c4960b5fc110813a1fdbf_D20220101-20220331" decimals="-6" name="mrk:MilestonePaymentsSalesBased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMzg0ODI5MDcxNjExMA_41529f8d-a1b5-4d86-850a-3113422a1d37">300</ix:nonFraction>&#160;million was paid in the first quarter of 2022). Potential future sales-based milestone payments of $<ix:nonFraction unitRef="usd" contextRef="ief58ac433ad9415a802f0001cc903fa8_I20230331" decimals="-8" name="mrk:PotentialFutureMilestonePaymentsSalesBased" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfNTMxMQ_07a0f1e3-df84-4466-b4a2-795fe78eb01e">2.4</ix:nonFraction> billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In 2022, Lenvima received regulatory approvals triggering capitalized milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i364cafd01c114c558bf6c571df9b34b1_D20220101-20221231" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfNTUyMg_24f3de46-2e58-4eca-90c0-8a6a4db624ba">50</ix:nonFraction>&#160;million from Merck to Eisai (of which $<ix:nonFraction unitRef="usd" contextRef="i2d145059533c4960b5fc110813a1fdbf_D20220101-20220331" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMzg0ODI5MDcxNjEyNA_1f0e6b02-7acf-4fff-aafc-0b0fe0d4499f">25</ix:nonFraction>&#160;million was paid in the first quarter of 2022). There are no regulatory milestone payments remaining under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $<ix:nonFraction unitRef="usd" contextRef="ifde6e88a8c324b84b8e1ac90ed088a69_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfNTc0Nw_aadc8296-443e-45d9-abc8-4b055cf6fc05">812</ix:nonFraction> million at March&#160;31, 2023 and is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 8 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="id0cd72df7b02460784d57bb56560359d" continuedAt="i30bf41d5bf9d483fabf7abc80e674a5f"><ix:continuation id="i7fd958410862453fb5c377626a03a601" continuedAt="i6a660a5e740143c88e7b0bad6f66f976"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.674%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e956d6285d1456abb720e32551e7288_D20230101-20230331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfMi0xLTEtMS0xMzE2MTg_5704adaf-06bf-4c77-a032-5b6148ea4449">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3779054dfc7a4a51b4e90d43a5ac3684_D20220101-20220331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfMi0zLTEtMS0xMzE2MTg_b4106292-b8b0-40bc-bbc4-9ca2f8ca4b31">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7eff0028e2f4952bfe2bb459510ff9f_D20230101-20230331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfNC0xLTEtMS0xMzE2MTg_4fba7867-22c0-4102-9fb4-22bb6a55f2f5">126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia56fd7048ad14abf96162c372b142909_D20220101-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfNC0zLTEtMS0xMzE2MTg_c1927729-3453-42d1-b7b2-1c0d658d7e49">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iace54ff30d73465189a461975d7b6b99_D20230101-20230331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfNS0xLTEtMS0xMzE2MTg_cf0131c2-2434-4c9f-b1d1-9bb902dce42f">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1e72c11f4d449889cefb13617918cd0_D20220101-20220331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfNS0zLTEtMS0xMzE2MTg_b3620da4-3001-4e38-add8-957229556c9a">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d825d4c2aa44c79bf5a2366a7a86a9b_D20230101-20230331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfNi0xLTEtMS0xMzE2MTg_1d608a63-360d-4e67-baf3-36d2d5ac8709">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c9458bb97f476b867db620d779e5fb_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfNi0zLTEtMS0xMzE2MTg_8f2be031-2a7b-4b31-9087-eadee4437a0a">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie01022120e7d4f7cb61fb037b2355db5_I20230331" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfOS0xLTEtMS0xMzUwNzI_ebf8203c-9b93-4f0c-b124-e3c4d8cb08f0">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if29e83faad31423b801afdcfcba98e44_I20221231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfOS0zLTEtMS0xMzUwNzI_efd8494d-cbee-4cb1-969e-2786013d9dc2">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a73485be36248258f5601b826d7bfed_I20230331" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfMTAtMS0xLTEtMTM1MDcy_63caf6e9-fbe8-4a2f-8936-3ed71bc08231">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d20b318541f4dd2831d35fd11a17b0f_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfMTAtMy0xLTEtMTM1MDcy_950c665c-6fe0-497f-a721-2429be7cbc57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amount in the first quarter of 2023 includes $<ix:nonFraction unitRef="usd" contextRef="ibcf5abe1e04c438f81048ecae5f02ed4_D20230101-20230331" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTY0OTI2NzQ2MDUyOA_605e6f9f-ddab-4fd3-a609-fb8f81ecce5a">72</ix:nonFraction>&#160;million of cumulative amortization catch-up expense as noted above.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents an accrued milestone payment.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bayer AG</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer&#8217;s Adempas (riociguat). The two companies have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer&#8217;s Verquvo (vericiguat), which was approved in the U.S., the European Union (EU) and Japan in 2021, and has since been approved in several other markets. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck&#8217;s share of profits from sales of Adempas and Verquvo in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer&#8217;s share of profits from sales in Merck&#8217;s marketing territories. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. In the first quarter of 2022, Merck made the final $<ix:nonFraction unitRef="usd" contextRef="i3399af7b61814371b4415a2165606deb_D20220101-20220331" decimals="-6" name="mrk:MilestonePaymentsSalesBased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfNzUwMQ_86568ae3-2a89-4b8f-a220-fe9f79af8dca">400</ix:nonFraction> million sales-based milestone payment under this collaboration to Bayer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $<ix:nonFraction unitRef="usd" contextRef="i80a8ac9e73b64ff18bab741a42d8fdcd_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfNzg3MA_431359ce-6d67-4076-8b06-01b44e89df07">613</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i260c8037bbf543e0aa66e359ab18b50f_I20230331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfNzg3Nw_dbb0fcf2-9914-4459-9f9e-0c340834576d">56</ix:nonFraction> million, respectively, at March&#160;31, 2023 and are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing. </span></div><ix:continuation id="i6a660a5e740143c88e7b0bad6f66f976" continuedAt="i01ac50b0494a41c3969c743d5b80e870"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.943%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ea6ddc3ada9445c95b033d7e07dd561_D20230101-20230331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfMi0xLTEtMS0xMzE2MTg_bee6db62-be92-422b-8426-ff8cac6972d4">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaa0511b79e949c7a6547505b9ae5551_D20220101-20220331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfMi0zLTEtMS0xMzE2MTg_3861b94a-aa37-4fff-b524-d2f4bb8521a0">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e52ba3989df4480ab8a8c4136af64aa_D20230101-20230331" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfMy0xLTEtMS0xMzE2MTg_fc0d7477-fe6b-4792-8abc-07b33daafeba">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68f851c07e23480aa9ff233e42d37d7a_D20220101-20220331" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfMy0zLTEtMS0xMzE2MTg_ff653039-52c5-4302-8654-7717b393fbb9">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Verquvo recorded by Merck</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6191c4207cdc459d90d7c79d3e4e64e5_D20230101-20230331" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfNC0xLTEtMS0xMzE2MTg_04da46d6-2120-41d1-b059-ca09e33c2341">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbe1869e706149f48a2091f4b9534dd9_D20220101-20220331" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfNC0zLTEtMS0xMzE2MTg_084b60d3-b978-487a-bf1b-40c2143d9508">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ea6ddc3ada9445c95b033d7e07dd561_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfNS0xLTEtMS0xMzE2MTg_cf129a58-23ac-4ee9-8614-df5b63a53506">165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaa0511b79e949c7a6547505b9ae5551_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfNS0zLTEtMS0xMzE2MTg_f9d25f4a-8836-467d-bf76-1dcf058258bb">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef0c87d5feb45e381dc0a07c2d16382_D20230101-20230331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfNy0xLTEtMS0xMzE2MTg_6c504c59-edb6-429f-b395-4b500f6e9560">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63cb28ee8d6845b3bc89ee74ee01ff67_D20220101-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfNy0zLTEtMS0xMzE2MTg_ae266853-f516-4de1-9bbc-b7946cdd4760">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58e10bfa620942c4bcb811e0f171d36b_D20230101-20230331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfOC0xLTEtMS0xMzE2MTg_48b431af-91b6-46c3-8b7f-926ced1a0cad">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e3019b3c61c4b70a15610624c8a4983_D20220101-20220331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfOC0zLTEtMS0xMzE2MTg_6f5cd3da-684a-434e-b53f-d0f2c213d7a3">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i650127b972c04c1cbed3bec6d5fdfa9b_D20230101-20230331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfOS0xLTEtMS0xMzE2MTg_3e26c119-276d-40f4-9a44-b046efc7a254">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2ae3db4c9364ff8843c87c364bab42b_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfOS0zLTEtMS0xMzE2MTg_09db9b21-8a8b-4c8d-810e-1d2f92316943">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9056f175eca54119943d05559433e20d_I20230331" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfMTEtMS0xLTEtMTM1MDkw_565df713-1d25-4420-b05c-4af6f3a39e85">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib66da4be09b7447ab23b1c1811b5724d_I20221231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfMTEtMy0xLTEtMTM1MDkw_6de8499f-c9bf-4d75-b520-7100e5db6bba">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Bayer included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36c8f57b20ce4f26a522df11b2be6320_I20230331" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfMTItMS0xLTEtMTM1MDkw_5d84ed63-e6e7-4fba-b06a-66279c3afc44">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i644d973253b54d3e94a4aa3644bbe995_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfMTItMy0xLTEtMTM1MDkw_e27df872-02ba-4cda-98e5-10f393e99d9c">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes amortization of intangible assets. </span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Ridgeback Biotherapeutics LP</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, entered into a collaboration agreement to develop </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (molnupiravir), an investigational orally available antiviral candidate for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 9 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i30bf41d5bf9d483fabf7abc80e674a5f"><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">related molecules. Following initial authorizations in certain markets in the fourth quarter of 2021, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> has since received multiple additional authorizations worldwide.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit-sharing calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit-sharing amounts recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback&#8217;s share of profits) are reflected as decreases to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. </span></div><ix:continuation id="i01ac50b0494a41c3969c743d5b80e870"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.943%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">recorded by Merck</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2a085dfeaeb40a083f13e8a59287e8c_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfMi0xLTEtMS0xMzE2MTg_67a5aab8-5077-4e5f-88fa-025487baace4">392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5173a42466784ad9a8ffe86302cb3b87_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfMi0zLTEtMS0xMzE2MTg_9056897f-e7c4-4892-a7a1-facb86398168">3,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebdfd787169843bcaba790e915fc305b_D20230101-20230331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfNC0xLTEtMS0xMzE2MTg_2473cf88-0755-486e-9e2b-48342ce2077f">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd3bb7ee67904313b2975cfef294c50b_D20220101-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfNC0zLTEtMS0xMzE2MTg_1bec1812-312a-4d69-8255-c92dc59a04aa">1,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice904109d2ef48fd8e8ed1324f5c2c59_D20230101-20230331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfNS0xLTEtMS0xMzE2MTg_22b3e4c4-e28a-478a-9fca-aafba988135a">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic51d50d985d84a3f8f588fda28be3ce3_D20220101-20220331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfNS0zLTEtMS0xMzE2MTg_9862c8c0-3a0e-4e86-905a-e6006d1189a5">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25207351676d4c9e9e6961bf25936afd_D20230101-20230331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfNi0xLTEtMS0xMzE2MTg_425e7ca2-e1d0-4e0f-b08b-a454303317c5">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d5dff37e3ab4823ab8be6c8611cc6d4_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfNi0zLTEtMS0xMzE2MTg_c5a0a898-96ee-4e25-a5e2-4cec541e804d">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Ridgeback included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2404a6eca015453d8c2bb0e08613ae7b_I20230331" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfOS0xLTEtMS0xMzUxMjE_8e2b2622-60c6-4834-8027-b1eece7661b2">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec1c506714374a9baa8471e96e643d5b_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfOS0zLTEtMS0xMzUxMjE_100467b4-2fdd-4b1d-a49b-643cf66bcef9">348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes royalty expense and amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Expenses include an allocation for overhead charges.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued royalties. Amount at December 31, 2022 also includes an accrued milestone payment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bristol Myers Squibb</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol Myers Squibb (BMS). Reblozyl is approved in the U.S., Europe and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and will co-promote all future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives a <ix:nonFraction unitRef="number" contextRef="idc4d047e87e6460984a1241620741fc2_D20230101-20230331" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTEwMDQ_fe59036a-22cd-47d6-bd25-cbf115e3d0d3">20</ix:nonFraction>% sales royalty from BMS which could increase to a maximum of <ix:nonFraction unitRef="number" contextRef="i386e5b3e2b1d4771ae602c8544c7de85_D20230101-20230331" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTEwNjc_1ca41360-8f30-4a1d-b874-e65cdef8801a">24</ix:nonFraction>% based on sales levels. This royalty will be reduced by <ix:nonFraction unitRef="number" contextRef="i402d58f25e9e45a68055eb38b7d1d4ab_D20230101-20230331" decimals="2" name="mrk:RoyaltyRateDeductionPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTExMjU_b2a05f76-a071-45be-b934-0a18a3078515">50</ix:nonFraction>% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="i0175444d0549416fb305c38749b41b24_D20230101-20230331" decimals="-6" name="mrk:ContingentProceedsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTEzMzM_fd6c5905-a32e-468d-a322-c8beec1f7a47">80</ix:nonFraction>&#160;million. Merck recorded alliance revenue related to this collaboration within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> of $<ix:nonFraction unitRef="usd" contextRef="i245cacaf455e42329f9ae587d1a10cad_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTEzNzI_5ac0347c-c6aa-4452-b4ea-1238bcadc98f">43</ix:nonFraction> million in the first quarter of 2023 (consisting of royalties) compared with $<ix:nonFraction unitRef="usd" contextRef="i2dba74425a51433497fa7e5529627e25_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfNTQ5NzU1ODMxOTE4_d2de489b-6e5b-416d-916d-149a5274be6e">52</ix:nonFraction> million in the first quarter of 2022 (consisting of royalties of $<ix:nonFraction unitRef="usd" contextRef="i9cff7fdd9228489e9a08ae8b3a149a6e_D20220101-20220331" decimals="-6" name="us-gaap:RoyaltyIncomeNonoperating" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTE1Njk_4e146289-a74f-4594-9d6c-f3e1f5079f44">32</ix:nonFraction>&#160;million and the receipt of a regulatory approval milestone payment of $<ix:nonFraction unitRef="usd" contextRef="id17be879320f41af82dedebba088c13f_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTE2NDI_052a299e-edac-420a-a3f3-f166108216fd">20</ix:nonFraction>&#160;million).</span></div></ix:continuation><div id="i3ccccf37677d43f88002f8d995e2fd3c_34"></div><div style="margin-top:15pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">4.     <ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfNDg0MQ_b5a23f81-a507-423d-8706-1fcfa30e2f3b" continuedAt="if4b8220d835f42d5bd564e25245eae36" escape="true">Spin-Off of Organon &amp; Co. </ix:nonNumeric></span></div><ix:continuation id="if4b8220d835f42d5bd564e25245eae36" continuedAt="i64f812861e1b4999b82bcb6a39652095"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On June 2, 2021, Merck completed the spin-off of Organon through a distribution of Organon&#8217;s publicly traded stock to Company shareholders. In connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck is providing Organon various services and, similarly, Organon is providing Merck various services. The provision of services under the TSA generally will terminate within <ix:nonNumeric contextRef="ie3d1e57b1dd24ae193bd71c6385b8769_D20210602-20210602" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMTUxMg_aac2e37f-a343-4c72-afc8-bb397287c7f9">25</ix:nonNumeric> months following the spin-off; however, the provision of certain services has been extended to <ix:nonNumeric contextRef="if4eb1aad4f8349af99fa7c51391e5966_D20210602-20210602" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMTYwMw_5b6e89e7-82a9-411c-8518-8e624a6d6d2a">35</ix:nonNumeric> months. Merck and Organon also entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck is continuing to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon. Under such interim operating agreements and in accordance with the separation and distribution agreement, Merck is continuing operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck is (a) manufacturing and supplying certain active pharmaceutical ingredients for Organon, (b) manufacturing and supplying certain formulated pharmaceutical products for Organon, and (c) packaging and labeling certain finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon is (a) manufacturing and supplying certain formulated pharmaceutical products for Merck, and (b) packaging and labeling certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from <ix:nonNumeric contextRef="ie7ee924f05bc48c787f3fd1d8f6303b6_D20210602-20210602" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMjk1NQ_90e85114-8b2b-4494-832f-45932804432f">four years</ix:nonNumeric> to <ix:nonNumeric contextRef="i1fd80dbdbfb341a2a9372748079c59e5_D20210602-20210602" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMjk2MQ_563a61c3-4bc3-44ac-8272-fbe62a6349d7">ten years</ix:nonNumeric>. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The amounts included in the condensed consolidated statement of income for the above MSAs include sales of $<ix:nonFraction unitRef="usd" contextRef="iad59a4cb91a64620bac9b9c19d9f7cc5_D20230101-20230331" decimals="-6" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMzA3Mw_2a79e7ae-c051-4dc9-bca1-d38df893f1c2">94</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i185eb227b4104468b3c29dc49352d43a_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMzA4MA_e17d3db0-edd5-42cd-8f6b-33c990b5c880">99</ix:nonFraction>&#160;million and related cost of sales of $<ix:nonFraction unitRef="usd" contextRef="iad59a4cb91a64620bac9b9c19d9f7cc5_D20230101-20230331" decimals="-6" name="us-gaap:RelatedPartiesAmountInCostOfSales" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMzExMg_eba6c3e0-d041-4cec-a37f-9e2acdd983c6">107</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i185eb227b4104468b3c29dc49352d43a_D20220101-20220331" decimals="-6" name="us-gaap:RelatedPartiesAmountInCostOfSales" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMzExOQ_163f4501-f901-4427-8ea4-8ac3494dea99">105</ix:nonFraction>&#160;million for the first quarter of 2023 and 2022, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 10 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i64f812861e1b4999b82bcb6a39652095"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">respectively. Amounts included in the condensed consolidated statement of income for the TSAs were immaterial for both the first quarter of 2023 and 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The amounts due from Organon under all of the above agreements were $<ix:nonFraction unitRef="usd" contextRef="i60b11c4ee8724493ae377bee597f7db8_I20230331" decimals="-6" name="us-gaap:DueFromRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMzQ5Mg_08229b35-c1d3-42ba-a466-5d781af56091">473</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i834db89c47b44369b713641fdff58447_I20221231" decimals="-6" name="us-gaap:DueFromRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMzQ5OQ_b4666865-911d-4add-a4f4-c28e32c9af6a">511</ix:nonFraction>&#160;million at March&#160;31, 2023 and December&#160;31, 2022, respectively, and are reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amounts due to Organon under these agreements were $<ix:nonFraction unitRef="usd" contextRef="i60b11c4ee8724493ae377bee597f7db8_I20230331" decimals="-6" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMzYyOA_7467b4b9-7bd7-4b1a-8d8e-eead26f7c4a3">229</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i834db89c47b44369b713641fdff58447_I20221231" decimals="-6" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMzYzNQ_5dcf5beb-98d1-48cd-a595-cb00c82453e4">345</ix:nonFraction>&#160;million at March&#160;31, 2023 and December&#160;31, 2022, respectively, and are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div id="i3ccccf37677d43f88002f8d995e2fd3c_46"></div><div style="margin-top:15pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfMzM1MQ_1e02db7c-e14c-4516-9136-6df3038e5a2b" continuedAt="i774d7d39ad90454d9c7b6f7c5a26f484" escape="true">Restructuring</ix:nonNumeric></span></div><ix:continuation id="i774d7d39ad90454d9c7b6f7c5a26f484" continuedAt="i05ce9cd238ab46cd829db61779679284"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2019, Merck&#160;approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on optimizing the Company&#8217;s manufacturing and supply network, as well as reducing its global real estate footprint.&#160;The actions contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $<ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-8" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfNjE5_d1022dea-a367-4f63-a2e1-45a406210bbf">3.7</ix:nonFraction> billion. The Company estimates that approximately <ix:nonFraction unitRef="number" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="2" name="mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfNjY0_a746e296-63ef-4ebb-a029-d7bf219d8394">70</ix:nonFraction>% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately <ix:nonFraction unitRef="number" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="2" name="mrk:EstimateOfCumulativePreTaxCostsThatWillBeNoncash" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfODIw_27019124-db5f-4dec-ac7b-54c7f3a8de7d">30</ix:nonFraction>% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recorded total pretax costs of $<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfMTAwNw_ee23e170-d0db-4e22-822b-21f8988ead88">97</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfMTAxNA_4f021e93-9e6d-4db2-90ee-ad854f55aa0c">127</ix:nonFraction> million in the first quarter of 2023 and 2022, respectively, related to restructuring program activities. Since inception of the Restructuring Program through March&#160;31, 2023, Merck has recorded total pretax accumulated costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-8" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfMTMwMg_293ebde1-b892-4487-bc89-ef8ee5a5f249">3.4</ix:nonFraction> billion. For the full year of 2023, the Company expects to record charges of approximately $<ix:nonFraction unitRef="usd" contextRef="i7966ec436ac148489c841a585ea76477_I20231231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfMTM4Ng_4a45ee3e-51e4-4d53-925c-07198671e920">400</ix:nonFraction> million related to the Restructuring Program. For segment reporting, restructuring charges are unallocated expenses.</span></div><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfMzM0OQ_1c377b1c-7694-47ec-b7eb-7632e83f3320" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize the charges related to restructuring program activities by type of cost:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.654%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870f46cf31cd4dd99b24227fb3adf06f_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfMi0xLTEtMS0xMzE2MTg_4a251308-c167-4b29-8fe8-461fe78e61d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibde26f5431b54da79586ebd96e74a36d_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfMi0zLTEtMS0xMzE2MTg_2395dd4d-2ce0-4681-ab97-a60a91c5dde1">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6616b6afece4195a3a8c81945ca5296_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfMi01LTEtMS0xMzE2MTg_5058d124-6a72-400d-bf95-6bd11f4c00f0">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111e37e345c242418c65ff71f8df4aa4_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfMi03LTEtMS0xMzE2MTg_6a6305bb-f574-432d-9882-271d7725a466">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia85fb7ebe86e48688eaa6cca6140b251_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfMy0xLTEtMS0xMzE2MTg_9fcfdf77-13da-4ca1-9584-5457e8cc0332">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7968694bdd844dcb91cdee1fa81b0c2_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfMy0zLTEtMS0xMzE2MTg_95bafa5e-a430-4fc6-a802-0aec5c5e0220">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c124834ee87435999488308f1f35177_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfMy01LTEtMS0xMzE2MTg_cf7ae6ce-c484-4b9e-827a-0e7cae20ab92">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie333238530bd43c2ac7bdbedf60929b5_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfMy03LTEtMS0xMzE2MTg_b812dee7-97fb-4b7b-a2de-bf71eef6a619">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39ffed41bf6448378d17f953bc0cc54b_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfNS0xLTEtMS0xMzE2MTg_f4d7d166-18e4-495a-91bf-55603ee2b242">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8831ff53ddb4e9384dd1c730f73c0d1_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfNS0zLTEtMS0xMzE2MTg_1f26925d-456a-4f98-aa2f-e6ebf1183f50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92816509cf8240d2ab4f3e2c2a61c6b0_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfNS01LTEtMS0xMzE2MTg_cda6bde9-3780-4b1b-b0fd-e5b59e22bdb2">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfa73697ee0a454c9ad0fdef7eff7f65_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfNS03LTEtMS0xMzE2MTg_c65a8966-412b-4ac1-a612-a0d2ad49edf7">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d8c3e3d493941b186866861d3cad3af_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfNi0xLTEtMS0xMzE2MTg_d7b785a0-0061-4ad0-ab49-4f6146b6d364">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaa6e70cf90547429286cee866cabd66_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfNi0zLTEtMS0xMzE2MTg_09de9cbc-62dc-4b24-ab8e-f701f3170f0e">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifef7767f302e4418af53b34093c57a9d_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfNi01LTEtMS0xMzE2MTg_a76f26cb-16ee-4657-8a77-527132e0f727">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfNi03LTEtMS0xMzE2MTg_a4187f63-7784-418f-b73b-d6c01aceee92">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.531%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i620edf85a16d4e4880ceb84b22f3cfab_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfMi0xLTEtMS0xMzE2MTg_e8b87523-455b-46f9-a71b-5290e11305b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bc8fc361d904fbeb6492f5e521452f8_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfMi0zLTEtMS0xMzE2MTg_86a9681c-7543-4563-9066-7b8d8cb54fda">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf782824e144ac698d3c52441494fa9_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfMi01LTEtMS0xMzE2MTg_80941371-5ecc-48c2-9ee8-8f64bb3bb234">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie23cb3149ce14b15a9a4f74c76232a80_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfMi03LTEtMS0xMzE2MTg_2d205baf-6619-4a8e-af1f-ce78a6c45bd9">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb61832d74f44b15bb6f7e1e80aefe10_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfMy0xLTEtMS0xMzE2MTg_17e107e1-c573-4a67-8ae9-2f6a7c73e660">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd263f21d9824f4d88448a933573382e_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfMy0zLTEtMS0xMzE2MTg_0f04cb32-1412-4388-b8d7-bba5c07a66f1">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7916bd167a5949cf9496c5497260c4da_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfMy01LTEtMS0xMzE2MTg_7f77a7c6-0af0-47ba-ba71-6aa4d5af4c58">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59bdd8e429324f6985da2aa4f9cee50f_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfMy03LTEtMS0xMzE2MTg_c5d89087-b149-4fbe-abd7-5330cf2f779d">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia26db14d5dfb4db6936c0133c122c21a_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNC0xLTEtMS0xMzE2MTg_4ffb78c2-848a-4cf4-bb72-e298d67c4b5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb9eb1916f044d189f47e32c6cf11a65_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNC0zLTEtMS0xMzE2MTg_5eb49cf0-334b-4d55-9a0b-18d41ccb05fc">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd41c6996df44f5ad0c156034845a9e_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNC01LTEtMS0xMzE2MTg_3f35dc14-b85b-4a50-b77a-de2cf96c2640">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f7c7de6a3b4eb69f814c83aa49e79c_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNC03LTEtMS0xMzE2MTg_608d6eac-f46b-40b3-87dc-ab7e1e82771f">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f8fc3f059d944d8ad12e7fed7bcc36b_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNS0xLTEtMS0xMzE2MTg_1ede5b46-b774-4818-9522-c5ced7592c03">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53768e8ff51d41dabfcdf8423e6ee2fa_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNS0zLTEtMS0xMzE2MTg_0ed644ee-6e32-41c4-8e46-a9257c65a89e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46e4f372c2f54684954722f000f9b4fb_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNS01LTEtMS0xMzE2MTg_7247cabc-464b-4aa8-889b-9656841bdd4b">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72738ef779d443e9ae3f451aa08e9bd5_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNS03LTEtMS0xMzE2MTg_f499b2ed-5ee4-4cc3-8a45-7d4cd376e50f">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dbe9c123ccc49ce80d7ee4225c7c4d8_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNi0xLTEtMS0xMzE2MTg_5adb07b1-ca85-41e7-9ec6-5d4dcf4e1046">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09b391351ac84dc89ccba17bcc925ec9_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNi0zLTEtMS0xMzE2MTg_c8c01545-83a4-4345-9eec-e8d2c2d51064">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80771ba562bd4e098155333659c919c8_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNi01LTEtMS0xMzE2MTg_143e66b4-e4e5-4ff0-8031-5d716e770f8c">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNi03LTEtMS0xMzE2MTg_54b00390-2085-48c2-a043-6bffa0b72e98">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Separation costs are associated with actual headcount reductions, as well as involuntary headcount reductions which were probable and could be reasonably estimated. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the program. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other activity in 2023 and 2022 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note&#160;10) and share-based compensation.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 11 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i05ce9cd238ab46cd829db61779679284" continuedAt="i41e45d7961c34b3095acef5e6e3fc3ff"><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfMzM0Nw_e70e3132-acf5-4b6d-b90b-d1e766b2fc0a" continuedAt="ic31c53bb1c6e4a6ab53e18b6ea245c8e" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities for the three months ended March&#160;31, 2023:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves January&#160;1, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i735d6ae1f2044389b4cd1ff056ef3646_I20221231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMS0xLTEtMS0xMzE2MTg_cb6cf49d-2d9e-4458-9517-cd2a0d9f9112">479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cce1bf91c214333b3b50c15e3d7461c_I20221231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMS0zLTEtMS0xMzE2MTg_8a0be797-80a0-43e0-ab29-a5e2e4625193">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40da318aa247452bac9b3018762feece_I20221231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMS01LTEtMS0xMzE2MTg_aed67f0a-c975-4425-8315-95b55f90a0fd">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMS03LTEtMS0xMzE2MTg_6bba8055-6d8b-4be1-a927-501c0718a7de">513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d8c3e3d493941b186866861d3cad3af_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMi0xLTEtMS0xMzE2MTg_75f61ce1-ef48-4355-9c4f-97acad05698a">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaa6e70cf90547429286cee866cabd66_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMi0zLTEtMS0xMzE2MTg_ce85565c-61cb-4cc4-80fc-41a7a91eb2e6">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifef7767f302e4418af53b34093c57a9d_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMi01LTEtMS0xMzE2MTg_456fd158-30b1-429d-bda9-ebc41e412fa3">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMi03LTEtMS0xMzE2MTg_beb15f2e-c1f2-4912-9b61-30d94be7957f">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d8c3e3d493941b186866861d3cad3af_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMy0xLTEtMS0xMzE2MTg_7c7914b2-dbb7-4a5e-a3ee-c66511650972">47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaa6e70cf90547429286cee866cabd66_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMy0zLTEtMS0xMzE2MTg_6cd89a9c-30dc-4ee6-8511-f58b5d662548">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifef7767f302e4418af53b34093c57a9d_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMy01LTEtMS0xMzE2MTg_dfea054e-6596-45ed-aa6b-d0f84b213ce5">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMy03LTEtMS0xMzE2MTg_e8a98298-8bb1-4a74-8299-53cd6e086d99">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d8c3e3d493941b186866861d3cad3af_D20230101-20230331" decimals="-6" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfNC0xLTEtMS0xMzE2MTg_d389b604-ecda-4b40-a790-41625208270c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaaa6e70cf90547429286cee866cabd66_D20230101-20230331" decimals="-6" sign="-" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfNC0zLTEtMS0xMzE2MTg_2106c809-de45-469e-aea6-d9be2af9ee2a">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifef7767f302e4418af53b34093c57a9d_D20230101-20230331" decimals="-6" sign="-" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfNC01LTEtMS0xMzE2MTg_b9e78c78-6d00-4744-a0cf-85258aeee6f5">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfNC03LTEtMS0xMzE2MTg_a9d10e8c-c90f-465f-8163-551d866b31ee">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves March&#160;31, 2023 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i993831891ccf428592c3e2f850548d44_I20230331" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfNS0xLTEtMS0xMzE2MTg_750a11c7-350e-4550-aa6b-db78757b1423">473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5739c18be2b4077ac27f27ef7c6e9f6_I20230331" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfNS0zLTEtMS0xMzE2MTg_2cad3c1e-f71e-4142-91db-0843db847afc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb4e20bd4ba34d448a2f3a3397c0d521_I20230331" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfNS01LTEtMS0xMzE2MTg_7bbf4e47-7616-47aa-a0a7-1f431d67b69f">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfNS03LTEtMS0xMzE2MTg_4f54125c-4ed5-4c8f-bc48-a02df57368fc">506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"><ix:continuation id="i41e45d7961c34b3095acef5e6e3fc3ff" continuedAt="ie3fbd895d937437eb813de3752429394"><ix:continuation id="ic31c53bb1c6e4a6ab53e18b6ea245c8e" continuedAt="i1833ce52b314418b8be9535aeec18e44">(1)</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:3.45pt"><ix:continuation id="ie3fbd895d937437eb813de3752429394"><ix:continuation id="i1833ce52b314418b8be9535aeec18e44">The remaining cash outlays are expected to be largely completed by the end of 2025.</ix:continuation></ix:continuation> </span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_49"></div><div style="margin-top:15pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg5NTg_9664b5fd-2815-482e-ab6e-1acd36eab700" continuedAt="i72dd6368c7264f47a92f483478e95258" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i72dd6368c7264f47a92f483478e95258" continuedAt="i279048b7cdac4d16993ea98b81a84696"><div style="margin-top:5pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A significant portion of the Company&#8217;s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company&#8217;s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than <ix:nonNumeric contextRef="i7e6cc36740bb4d71a793d4cb817b4486_D20230101-20230331" name="us-gaap:DerivativeAverageRemainingMaturity1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTQ2Ng_fb4b5cd1-943b-4df2-8adc-e5a587e8e26a">two years</ix:nonNumeric> into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Other Comprehensive Loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and reclassified into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> each period. The cash&#160;flows from both designated and non-designated contracts are reported as operating activities&#160;in the Condensed Consolidated Statement of&#160;Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company also uses a balance sheet risk management program to mitigate the exposure of such assets and liabilities from the effects of volatility in foreign exchange. Merck principally utilizes forward exchange contracts to offset the effects of exchange in developed country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar, Australian dollar and Swiss franc. For exposures in developing country currencies, including the Chinese renminbi, the Company will enter into forward contracts to offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The forward contracts are not designated as hedges and are marked to market through </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than <ix:nonNumeric contextRef="i44fa00da50de4c2abe7a97b20631529f_D20230101-20230331" name="us-gaap:DerivativeAverageRemainingMaturity1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfNTA2Mg_45af942e-783a-4b0f-a194-91858dd76916">six months</ix:nonNumeric>. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 12 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i279048b7cdac4d16993ea98b81a84696" continuedAt="i3b95c8167d444f11b36ba48c91fbd2b3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and remain in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange risk is also managed through the use of foreign currency debt. The Company&#8217;s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg5NTE_4d780aad-70cf-4542-9884-2e315547e0ae" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effects of the Company&#8217;s net investment hedges on </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.227%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ade1a511bd04605a075fd4b05ec6eca_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjk2NGM0MDg0ODQ1ZjRjZjE4YWFiYzY1YzQ4NzZmN2FiL3RhYmxlcmFuZ2U6OTY0YzQwODQ4NDVmNGNmMThhYWJjNjVjNDg3NmY3YWJfNC0xLTEtMS0xMzE2MTg_cbaa9f8d-c1ed-4b35-a63c-f34c2ffc193e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54ec372484874e4680d7e4b7645c44f7_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjk2NGM0MDg0ODQ1ZjRjZjE4YWFiYzY1YzQ4NzZmN2FiL3RhYmxlcmFuZ2U6OTY0YzQwODQ4NDVmNGNmMThhYWJjNjVjNDg3NmY3YWJfNC0zLTEtMS0xMzE2MTg_40ad9e37-c988-4b43-9d96-abfb9abcdd29">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i313438c53a3745f5a9c308e10580003d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjk2NGM0MDg0ODQ1ZjRjZjE4YWFiYzY1YzQ4NzZmN2FiL3RhYmxlcmFuZ2U6OTY0YzQwODQ4NDVmNGNmMThhYWJjNjVjNDg3NmY3YWJfNC05LTEtMS0xMzE2MTg_9ce8243e-127e-4228-87f7-58158488bd1c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13663e430fa9440c8b9b613386d03310_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjk2NGM0MDg0ODQ1ZjRjZjE4YWFiYzY1YzQ4NzZmN2FiL3RhYmxlcmFuZ2U6OTY0YzQwODQ4NDVmNGNmMThhYWJjNjVjNDg3NmY3YWJfNC0xMS0xLTEtMTMxNjE4_ec6b82a9-e19e-4dbd-9563-a1037ca3ae1a">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3459fac4643e42e29a49394546d2d3b7_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjk2NGM0MDg0ODQ1ZjRjZjE4YWFiYzY1YzQ4NzZmN2FiL3RhYmxlcmFuZ2U6OTY0YzQwODQ4NDVmNGNmMThhYWJjNjVjNDg3NmY3YWJfNS0xLTEtMS0xMzE2MTg_cc87d1a8-cfb9-46d5-97f5-52ec34b8fe3f">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9f85f59e99b4ea189c2a085734df397_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjk2NGM0MDg0ODQ1ZjRjZjE4YWFiYzY1YzQ4NzZmN2FiL3RhYmxlcmFuZ2U6OTY0YzQwODQ4NDVmNGNmMThhYWJjNjVjNDg3NmY3YWJfNS0zLTEtMS0xMzE2MTg_2fc0068c-85ec-47d2-8d5f-df4fe374df15">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c1922ae96df4166a7397fffeb3375e7_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjk2NGM0MDg0ODQ1ZjRjZjE4YWFiYzY1YzQ4NzZmN2FiL3RhYmxlcmFuZ2U6OTY0YzQwODQ4NDVmNGNmMThhYWJjNjVjNDg3NmY3YWJfNS05LTEtMS0xMzE2MTg_3517fea1-6c70-4dce-9a2a-f23ac47e017b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b9f469b4df444f7b96723d7a5c8b223_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjk2NGM0MDg0ODQ1ZjRjZjE4YWFiYzY1YzQ4NzZmN2FiL3RhYmxlcmFuZ2U6OTY0YzQwODQ4NDVmNGNmMThhYWJjNjVjNDg3NmY3YWJfNS0xMS0xLTEtMTMxNjE4_64671865-e101-4ddf-b81a-0e1bf4ab1062">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">No amounts were reclassified from AOCL into income related to the sale of a subsidiary.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk. In March 2023, the Company entered into <ix:nonFraction unitRef="interest_rate_swap" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="0" name="us-gaap:NumberOfInterestRateDerivativesHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfNTQ5NzU1ODM4OTQz_dde3febc-0da7-4b23-b7a6-41b04e76643b">five</ix:nonFraction> forward starting swaps and in April 2023 entered into <ix:nonFraction unitRef="interest_rate_swap" contextRef="i336c99147cdf41e191d86c13d2a751dc_I20230430" decimals="0" name="us-gaap:NumberOfInterestRateDerivativesHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfNTQ5NzU1ODM5NDA2_34f70cf4-a002-438a-99ad-58ec8ffee05b">two</ix:nonFraction> additional forward starting swaps, each with a notional amount of $<ix:nonFraction unitRef="usd" contextRef="i7029fd7c7a6f43aca68f42e012aec70b_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfNTQ5NzU1ODM4OTQ3_23d8d92b-0d78-4b08-b738-32e64b745d3a"><ix:nonFraction unitRef="usd" contextRef="i95f9d19ca7854b0288a0454768961670_I20230430" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfNTQ5NzU1ODM4OTQ3_4d8435be-b8d0-4716-812c-aaaecb689bc7">100</ix:nonFraction></ix:nonFraction>&#160;million.</span></div><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg5ODA_55be7146-6521-4eae-b448-5ea6359c9678" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair&#160;Value&#160;of&#160;Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair&#160;Value&#160;of&#160;Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0xLTEtMS0xMzE2MTg_cdf39073-c7a9-42f3-a873-70852c2d806a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0xLTEtMS0xMzE2MTg_eaa07838-14e0-4387-8b95-9bb43c3d8ff8">Other Assets</span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i548bda88a4fe4bd5bffaa38757444dad_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0yLTEtMS0xMzE2MTg_50a2c904-4c16-4a93-a288-3f287aca7d62">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bdddb9610a348a48e757c57cc1a2387_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC02LTEtMS0xMzE2MTg_21f0afa5-a11e-4f3a-a8ec-4a019f6f7a4a">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbdf486ae9934cc9a2a5283fa0638116_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC04LTEtMS0xMzE2MTg_ed6c9da5-4ba0-433d-a263-18490c9bcb41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic70cbdc57c9f458abe55135c7b061c1d_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0xMi0xLTEtMTMxNjE4_f841f82a-303f-4d87-9bfa-d7225d0b9487">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xNDUxMzg_9df5cddc-66b1-4a33-8e29-a18d74bcc019"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xNDUxMzg_f3c8a52d-a48a-4e54-b19b-78f16a11f45d">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i548bda88a4fe4bd5bffaa38757444dad_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS00LTEtMS0xNDMwOTA_18840083-892c-49b6-97a6-78494d07fcf1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i425bb66138fc4a51933c6b6df28796a6_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS02LTEtMS0xNDMwOTA_a054f779-db89-4e8a-a1fb-b0d922f96892">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbdf486ae9934cc9a2a5283fa0638116_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xMC0xLTEtMTQzMDkw_aecd975b-7bf3-4a61-9406-9fa9119e68a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i294f553218424e8cb257f3d9f97e01a5_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xMi0xLTEtMTQzMDkw_2f1bf1e8-05c4-4a3b-9861-e52acced7935">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xMzE2MTg_408692a5-0d77-4a04-a36c-28872dc58415"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xMzE2MTg_4a4e35a6-2d31-4c12-be2f-2f5f0ad91a6c">Other current assets</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cd028c906f84a42bf0bf29e3a3a9fcb_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0yLTEtMS0xMzE2MTg_d2691c45-411b-4be9-beb2-e0575fe0ca39">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cd028c906f84a42bf0bf29e3a3a9fcb_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS02LTEtMS0xMzE2MTg_030715d4-bf1c-4933-a93c-0b3e414453cf">4,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaac2668425b4eb4bfaea2c9834fd061_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS04LTEtMS0xMzE2MTg_e54cbddf-083f-4d5c-80d1-029f586b1e27">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaac2668425b4eb4bfaea2c9834fd061_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xMi0xLTEtMTMxNjE4_a3ed3c28-263d-47b9-9f44-a16216111c9b">4,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0xLTEtMS0xMzE2MTg_81797372-b85c-4d09-ac25-516d3f440479"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0xLTEtMS0xMzE2MTg_ab1b0a2e-c0bf-439c-9322-21e04e73f4f5">Other Assets</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e8fab7c6eb24761b65cc3256e0b926b_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0yLTEtMS0xMzE2MTg_f313614b-040a-4301-b5ef-d66777afb721">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e8fab7c6eb24761b65cc3256e0b926b_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi02LTEtMS0xMzE2MTg_e1124fa7-28bc-4cef-a7de-1f6c3cd58fd5">1,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03be4f41b99a4232bdc4d5da0449f285_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi04LTEtMS0xMzE2MTg_64e192d2-d430-4c23-8618-3c76ecc8443d">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03be4f41b99a4232bdc4d5da0449f285_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0xMi0xLTEtMTMxNjE4_206c49a7-0bc2-4f0a-9a54-96169319ffd0">1,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xLTEtMS0xMzE2MTg_3132afe6-dbe8-4b79-81d1-621892c284e2"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xLTEtMS0xMzE2MTg_99d4d534-f137-4781-a93f-a2c418043a22">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50b43bd94e56461888fca904c9a7ca24_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy00LTEtMS0xMzE2MTg_a4054cbb-da6a-4acf-bf95-3fd6183ce447">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50b43bd94e56461888fca904c9a7ca24_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy02LTEtMS0xMzE2MTg_b8d632d6-a636-4a97-96e5-e014436314c5">3,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i143c9f2549384565bcdcfdd243771159_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xMC0xLTEtMTMxNjE4_381550ec-ae84-4a6b-8cfd-c04702f63f40">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i143c9f2549384565bcdcfdd243771159_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xMi0xLTEtMTMxNjE4_f7fca098-f954-48c9-825d-db0f82e20dd2">2,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xLTEtMS0xMzE2MTg_11e2508b-56af-4ce8-a9f2-c0ca375d810e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xLTEtMS0xMzE2MTg_c087e16f-89b4-40c0-959b-f2b2cdd6e23c">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdf30ba2b8b34d4e8df46f5379e5e821_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC00LTEtMS0xMzE2MTg_89192b89-afdd-473c-b1cf-983403ceb15c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdf30ba2b8b34d4e8df46f5379e5e821_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC02LTEtMS0xMzE2MTg_2e598751-aa1f-442a-b425-f16522b0c50d">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice27572fdfbf445cabdf5a62a7d76022_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xMC0xLTEtMTMxNjE4_9bf90ced-8fec-4c64-a19e-7a2f605efefb">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice27572fdfbf445cabdf5a62a7d76022_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xMi0xLTEtMTMxNjE4_0be777f1-a5a1-4ec6-b0e6-ff59c6feb14a">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a06f418da43474f9f2f260add8790b3_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOS0yLTEtMS0xMzE2MTg_3fcbf349-b567-4e91-9e0c-46dca51c752e">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a06f418da43474f9f2f260add8790b3_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOS00LTEtMS0xMzE2MTg_13a208cc-4199-49e3-b92a-1a853251cfc4">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a06f418da43474f9f2f260add8790b3_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOS02LTEtMS0xMzE2MTg_52a1ad54-6986-4218-b10f-59d3b60e3b46">10,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf11d32e52ad425f979acb12dcd9aaac_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOS04LTEtMS0xMzE2MTg_b1c7ea18-fbb7-409f-94b5-398c3c053779">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf11d32e52ad425f979acb12dcd9aaac_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOS0xMC0xLTEtMTMxNjE4_75df709b-935a-457b-99ea-a5f3fd899fa0">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf11d32e52ad425f979acb12dcd9aaac_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOS0xMi0xLTEtMTMxNjE4_57f78cee-525f-4109-937d-071952783e21">9,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMS0xLTEtMTMxNjE4_05e962d8-08ac-4061-91f8-80526dc22b48"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMS0xLTEtMTMxNjE4_c1218d47-d091-44ba-967a-61df1ed0b192">Other current assets</span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac10665025d84f23872225d16c92ffed_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMi0xLTEtMTMxNjE4_86edffdf-b6a2-486c-9ae5-f5354250882a">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac10665025d84f23872225d16c92ffed_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtNi0xLTEtMTMxNjE4_bdb4b795-912c-47ef-8be2-7863d07933e0">9,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45afba88d4004605825fe82844d7a4a7_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtOC0xLTEtMTMxNjE4_f84e4d3b-19a1-4620-bb3b-40a7a8d524e7">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45afba88d4004605825fe82844d7a4a7_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMTItMS0xLTEzMTYxOA_53cdffa0-4b7f-44ba-8465-9f64f9646dd0">8,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMS0xLTEtMTQ1MTQy_1096f2ac-e5f3-4efe-9d17-7ead4689602e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMS0xLTEtMTQ1MTQy_c4114de6-2d78-4e8c-8218-b4ecfaa65a61">Other Assets</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf2336f30cc046a28a77fd6f2dc4b465_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMi0xLTEtMTQyNTQx_c6cc6fa1-1969-40df-8e42-6d42b9ed64f6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf2336f30cc046a28a77fd6f2dc4b465_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtNi0xLTEtMTQyNTQx_4924fbff-1928-4a87-b397-2a7c30d530e8">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a23903b67354e33a6fc1a8676a4b984_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtOC0xLTEtMTQyNTQx_b5a47de5-1eb9-4d35-9f8b-0883412bec1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a23903b67354e33a6fc1a8676a4b984_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMTItMS0xLTE0MjU0MQ_7dedba2e-068c-4459-979a-8c3e8b365653">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMS0xLTEtMTMxNjE4_8e46edaf-73d3-4fb2-a39e-a898b16444e0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMS0xLTEtMTMxNjE4_a38bf2e0-7e23-4be7-a57d-412372f2f6e0">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a542fc8b3854857bda9666e66bd056e_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItNC0xLTEtMTMxNjE4_69f37321-46fb-4389-8671-1136127008af">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a542fc8b3854857bda9666e66bd056e_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItNi0xLTEtMTMxNjE4_2d0806cb-1295-4aa7-afe1-c8c37686a706">10,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4fad0e8da324f249b5dc3a9f01637f7_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMTAtMS0xLTEzMTYxOA_db0536fb-8574-4554-9ed9-e5b96979e6ba">307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4fad0e8da324f249b5dc3a9f01637f7_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMTItMS0xLTEzMTYxOA_42ac5322-fc22-404c-a467-b7c7904dd591">10,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMS0xLTEtMTQ1MTQ3_0f134479-ab12-4419-8818-0dec3ce2d2eb"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMS0xLTEtMTQ1MTQ3_8586bfb3-f29a-42c6-a48d-599f102341da">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie091883aa8d84ebf868769397c540276_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtNC0xLTEtMTQzMTAy_3bf77e6b-3339-402e-9e91-11d304209122">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie091883aa8d84ebf868769397c540276_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtNi0xLTEtMTQzMTAy_db72235a-32cd-4983-ae11-0046a19a1efb">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib057b0780b1b420d824cb8350acd5ba2_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMTAtMS0xLTE0MzEwMg_6046560d-992b-4a5c-b1c0-3461145925c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib057b0780b1b420d824cb8350acd5ba2_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMTItMS0xLTE0MzEwMg_3b179ff9-c812-436d-a5f3-0207d0dc51a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaadad87b63f48448ddf5360530646a9_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMi0xLTEtMTMxNjE4_6e23a723-e2cf-4614-8922-054d5c03e151">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaadad87b63f48448ddf5360530646a9_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtNC0xLTEtMTMxNjE4_858d4e90-e122-45e9-96a3-ddc132677cbb">165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaadad87b63f48448ddf5360530646a9_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtNi0xLTEtMTMxNjE4_d97a9276-f9dc-4299-ae70-82b99dfdc920">20,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7161bc9f4ef34d54a1dd7e0b07640a30_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtOC0xLTEtMTMxNjE4_d4fdbe62-6fe6-441d-b156-8502179cdcab">186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7161bc9f4ef34d54a1dd7e0b07640a30_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMTAtMS0xLTEzMTYxOA_2b813906-7f95-44e1-a533-9c1abd8f82db">307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7161bc9f4ef34d54a1dd7e0b07640a30_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMTItMS0xLTEzMTYxOA_ad1d41c9-5f8f-49f6-995f-714e54d2840b">19,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTQtMi0xLTEtMTMxNjE4_abbde945-b8ad-48b0-96a9-7e26a2d3652a">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTQtNC0xLTEtMTMxNjE4_e1414130-a896-4356-b90b-9a7e2e94051c">284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTQtNi0xLTEtMTMxNjE4_399a16b7-5043-49b0-a894-eedbc04640d0">30,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTQtOC0xLTEtMTMxNjE4_439859eb-bd4a-42e8-a23b-1263f01c21ec">433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTQtMTAtMS0xLTEzMTYxOA_e5fdafd1-8bd9-4b88-a121-14249c9e871b">409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTQtMTItMS0xLTEzMTYxOA_8e014bfc-64c6-405b-98ea-4d2f6e4ba46b">28,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 13 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i3b95c8167d444f11b36ba48c91fbd2b3" continuedAt="i11a2e7c9e69f45f3a7c26739fe5c7338"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> below). <ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="mrk:OffsettingAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg5MDg_1489cfad-b0d8-4a6c-9617-0c63dbc04c06" continuedAt="i65a8d26977364441bb4ba47722745959" escape="true">The following table provides information on the Company&#8217;s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i65a8d26977364441bb4ba47722745959"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:64.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts recognized in the condensed consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfMi0xLTEtMS0xMzE2MTg_9df851ad-05b0-4cb7-a118-8dcd34af6bb4">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfMi0zLTEtMS0xMzE2MTg_cf885fb0-f77a-48e2-880a-2a3f2232ce2c">284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfMi01LTEtMS0xMzE2MTg_95bfdd0c-fd01-44cc-8fcb-b7af0acbb9c5">433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfMi03LTEtMS0xMzE2MTg_e20b1bd6-5591-426d-9d2b-c1668b77785f">409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfMy0xLTEtMS0xMzE2MTg_7a18f736-2c52-4549-9689-4c27b80deaf8">148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfMy0zLTEtMS0xMzE2MTg_968cd43a-1197-4975-b402-73bf4b0f752e">148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfMy01LTEtMS0xMzE2MTg_51a1ca3b-19cb-4728-ab5e-1f686d3ff3f8">220</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfMy03LTEtMS0xMzE2MTg_cbe65719-231a-479d-9d29-c7a436bcc183">220</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collateral received/posted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfNC0xLTEtMS0xMzE2MTg_3d2e90e5-0268-4744-a79b-98331c0a1f59">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfNC0zLTEtMS0xMzE2MTg_70aa5d34-636f-47e9-9840-7ab920e6adc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfNC01LTEtMS0xMzE2MTg_34435864-a062-484c-a0b7-eecd4406f5be">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfNC03LTEtMS0xMzE2MTg_057b96d1-06dd-463a-86c5-b86d743050ce">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfNS0xLTEtMS0xMzE2MTg_6ff7b00d-76fd-4681-b6d3-102be2e6e492">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfNS0zLTEtMS0xMzE2MTg_1b470521-5647-4f2f-84c5-e0fe577a1026">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfNS01LTEtMS0xMzE2MTg_6cd0b0ab-075c-440f-93aa-e969c056e979">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfNS03LTEtMS0xMzE2MTg_dcfc3945-172a-44ad-8388-083c6c353023">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg5MDM_4c32dc9a-ed6a-4369-8e71-7d8b8f02e82b" escape="true"><div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Caption in which Effects of Fair Value or Cash Flow </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Hedges are Recorded</span></div></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMy0xLTEtMS0xMzE2MTg_22a948dc-764f-4b1e-bd35-1d8c5714fc99">14,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMy0zLTEtMS0xMzE2MTg_bce1380b-87c8-407a-9c79-f8ebd0e11ede">15,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMy01LTEtMS0xMzE2MTg_179cbe9b-cbaf-4611-ab53-9332ca253bc5">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMy03LTEtMS0xMzE2MTg_1b228471-d719-454e-9351-e1fae4b738aa">708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMy05LTEtMS0xMzE2MTg_a155be89-531e-4713-8f68-5c9b4a90f298">115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMy0xMS0xLTEtMTMxNjE4_541f339b-0eed-442f-b7e5-fcb548e271b6">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hedged items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86b17d802f304918b52da353344f6ac4_D20230101-20230331" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfNi01LTEtMS0xMzE2MTg_e452a98b-c70d-41d7-a482-30f1838cc726">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i028e5b27f0e04f339d7c2f519b8ae259_D20220101-20220331" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfNi03LTEtMS0xMzE2MTg_16071167-afc5-4664-948f-741ee9249a4b">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86b17d802f304918b52da353344f6ac4_D20230101-20230331" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfNy01LTEtMS0xMzE2MTg_c46d858e-ad70-4175-b211-ef3a8f53bfd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028e5b27f0e04f339d7c2f519b8ae259_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfNy03LTEtMS0xMzE2MTg_d6ac96c8-7b59-42cf-a66c-7f0513662586">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of (loss) gain recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ade1a511bd04605a075fd4b05ec6eca_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTAtOS0xLTEtMTMxNjE4_c0b72b8a-70b7-4926-bcdb-721039df42d1">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54ec372484874e4680d7e4b7645c44f7_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTAtMTEtMS0xLTEzMTYxOA_7f52f705-25fc-46fe-898a-a2416c811c71">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increase in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9ff469b241a4cd5972223863bfda226_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTEtMS0xLTEtMTMxNjE4_63ad98ab-1fb8-4feb-9763-9f0a72e303d1">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b677da60364882b5bc1b825a50fabe_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTEtMy0xLTEtMTMxNjE4_6d2194a2-cff0-4fee-a90b-a8f77910b7c3">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ade1a511bd04605a075fd4b05ec6eca_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTEtOS0xLTEtMTMxNjE4_e526cf4a-d599-4614-981f-ed23c3e2c0d4">101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54ec372484874e4680d7e4b7645c44f7_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTEtMTEtMS0xLTEzMTYxOA_2804f17e-7256-4031-9d63-8fd5a771a8a9">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i330867f88a774fb08f247e81d478866e_D20230101-20230331" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTMtNS0xLTEtMTMxNjE4_8bce689f-00d6-4a8e-96fe-978f0144a70e">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8118cf7c392f4ea598bfcb18b7bbd4d2_D20220101-20220331" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTMtNy0xLTEtMTMxNjE4_229d3661-b791-403b-ace3-ae50abdbca42">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i330867f88a774fb08f247e81d478866e_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTQtOS0xLTEtMTMxNjE4_44fcba0c-30ee-49d3-bb0d-76ea24a4d7f8">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8118cf7c392f4ea598bfcb18b7bbd4d2_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTQtMTEtMS0xLTEzMTYxOA_8447855c-5ef4-45cb-a2d1-bc3296421787">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Interest expense is a component of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg5MTc_52cb4752-d5ed-47eb-9821-c6371bb02c13" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.359%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if03eefb0e5be4080ba5289591b557e4d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjEyNmFmYjljZWYwZDQ3OGE5NDk5YTRkNjVmNGUzMDg3L3RhYmxlcmFuZ2U6MTI2YWZiOWNlZjBkNDc4YTk0OTlhNGQ2NWY0ZTMwODdfNC0zLTEtMS0xMzE2MTg_6d07b28c-4812-4146-81ea-f4a2fca3b9d0">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b6b9e2b940749269dcc355aa0ed57d7_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjEyNmFmYjljZWYwZDQ3OGE5NDk5YTRkNjVmNGUzMDg3L3RhYmxlcmFuZ2U6MTI2YWZiOWNlZjBkNDc4YTk0OTlhNGQ2NWY0ZTMwODdfNC01LTEtMS0xMzE2MTg_34791cc4-bf9b-46f3-90f1-665d28024c67">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc7fb1fb9fd543aba08f396008a05eb0_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjEyNmFmYjljZWYwZDQ3OGE5NDk5YTRkNjVmNGUzMDg3L3RhYmxlcmFuZ2U6MTI2YWZiOWNlZjBkNDc4YTk0OTlhNGQ2NWY0ZTMwODdfNS0zLTEtMS0xMzE2MTg_e728eec8-5f0c-4f93-9d57-82d50a4c42d2">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3fb850e1f5f434f8e8a95228021a73d_D20220101-20220331" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjEyNmFmYjljZWYwZDQ3OGE5NDk5YTRkNjVmNGUzMDg3L3RhYmxlcmFuZ2U6MTI2YWZiOWNlZjBkNDc4YTk0OTlhNGQ2NWY0ZTMwODdfNS01LTEtMS0xMzE2MTg_02f54c1c-197b-43ae-91dc-30cd1f2ffb14">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts serve as economic hedges of forecasted transactions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At March&#160;31, 2023, the Company estimates $<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfOTgyOQ_fddfd25d-1e22-47d1-bbfe-f36c4ba9f792">71</ix:nonFraction> million of pretax net unrealized losses on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amount ultimately reclassified to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 14 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i11a2e7c9e69f45f3a7c26739fe5c7338" continuedAt="id4ba55aae8404f9f9711fe5c98183e92"><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Investments in Debt and Equity Securities</span></div><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg5MTg_9432e5ed-20f3-4378-849b-4fa3d5b83c6e" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776fb83d7a1241a0826d11f6ebe76e81_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0xLTEtMS0xMzU4NDQ_ebb3f79e-28e4-4edf-a924-8fdd8e33daaf">663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776fb83d7a1241a0826d11f6ebe76e81_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0zLTEtMS0xMzU4NDQ_c50bcca5-2665-47dd-9a37-7a04ba0ac298">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776fb83d7a1241a0826d11f6ebe76e81_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy01LTEtMS0xMzU4NDQ_62978d6b-f095-4383-b06a-c328926964c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i776fb83d7a1241a0826d11f6ebe76e81_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy03LTEtMS0xMzgyODg_95724fca-3830-4875-a860-9c1c21299590">663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a3f219a7d404a31bf65ab7515e23942_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy05LTEtMS0xMzU4NDQ_609d66b2-1f18-4a58-ad09-df256f3ea0b0">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a3f219a7d404a31bf65ab7515e23942_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0xMS0xLTEtMTM1ODQ0_8e28da52-4455-40e0-8137-9dcfe8db9182">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a3f219a7d404a31bf65ab7515e23942_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0xMy0xLTEtMTM1ODQ0_881c0c90-3f1f-4580-82b3-53e4fc336028">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a3f219a7d404a31bf65ab7515e23942_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0xNS0xLTEtMTM3MDI1_1317ee72-f6a4-4f57-ab7d-7ca5768baa3b">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e566c5f87a6490788ae30ee3d6f3b50_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0xLTEtMS0xMzE2MTg_1c0a6358-3e8d-4355-b789-ff35995fb9f9">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e566c5f87a6490788ae30ee3d6f3b50_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0zLTEtMS0xMzE2MTg_e4f3191f-8505-4052-952e-8cce6662cc70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e566c5f87a6490788ae30ee3d6f3b50_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy01LTEtMS0xMzE2MTg_17046ae1-855b-4652-ad2c-490e7ede0e87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e566c5f87a6490788ae30ee3d6f3b50_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy03LTEtMS0xMzE2MTg_8e8bf003-394c-47c5-a608-560951f1289f">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a140256baa4686a25015671d14aa5b_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy05LTEtMS0xMzE2MTg_440cdd91-ac34-4899-b413-5b57c68da8b7">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a140256baa4686a25015671d14aa5b_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0xMS0xLTEtMTMxNjE4_c19d8c2a-b8db-4e5b-b64f-d78a3014c888">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a140256baa4686a25015671d14aa5b_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0xMy0xLTEtMTMxNjE4_ec604bca-89ef-46c2-a045-52f1e2a2289e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92a140256baa4686a25015671d14aa5b_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0xNS0xLTEtMTMxNjE4_da336add-720b-4c04-ba66-9de88b38852d">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93df6ced8a7748a4abd5d6c32906498c_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNS0xLTEtMS0xMzE2MTg_9e10429e-a1f3-46b3-964e-6dfb201cf33f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93df6ced8a7748a4abd5d6c32906498c_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNS0zLTEtMS0xMzE2MTg_a9c7cd83-64a8-4550-bba7-52f3aa32437d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93df6ced8a7748a4abd5d6c32906498c_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNS01LTEtMS0xMzE2MTg_062e8e8c-9124-49f1-9295-1a7c0414a109">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93df6ced8a7748a4abd5d6c32906498c_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNS03LTEtMS0xMzE2MTg_80243d15-5cbb-44a9-ab4d-3e6ab08f8e08">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aa6408da9024f3ea458c3189fa1916d_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNS05LTEtMS0xMzE2MTg_47c5d10e-de64-4295-8fab-5a7e4d1d6c15">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aa6408da9024f3ea458c3189fa1916d_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNS0xMS0xLTEtMTMxNjE4_6b5633d0-f8e7-4ba7-bac1-87b9e2ae8cfa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aa6408da9024f3ea458c3189fa1916d_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNS0xMy0xLTEtMTMxNjE4_c0cca5ce-fb86-4548-9bde-d904cc94ac08">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aa6408da9024f3ea458c3189fa1916d_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNS0xNS0xLTEtMTMxNjE4_ac586d21-f44b-4a6d-bec1-49054b0701fa">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1f2bc401a074570afe7c168856f7ee2_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNi0xLTEtMS0xMzE2MTg_e37c5043-2f2a-4783-bb90-9fc3807a9cb8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1f2bc401a074570afe7c168856f7ee2_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNi0zLTEtMS0xMzE2MTg_43888fd8-aa07-4f41-9d84-f953c88ffd8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1f2bc401a074570afe7c168856f7ee2_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNi01LTEtMS0xMzE2MTg_2bdd5689-59ff-4aaa-a11a-2693b6b00d88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1f2bc401a074570afe7c168856f7ee2_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNi03LTEtMS0xMzE2MTg_b1341752-58cc-4e67-8a83-5ea253fc5603">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85028f8c5acd441497714b4e936b0ece_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNi05LTEtMS0xMzE2MTg_9760707e-49fb-47c5-b677-6b01c4a58a43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85028f8c5acd441497714b4e936b0ece_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNi0xMS0xLTEtMTMxNjE4_fdf3ea92-14e9-436e-bd39-072624ab4ab0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85028f8c5acd441497714b4e936b0ece_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNi0xMy0xLTEtMTMxNjE4_0341e4c2-18a9-45a8-bf88-456ab3cdeb39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85028f8c5acd441497714b4e936b0ece_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNi0xNS0xLTEtMTMxNjE4_a92132e2-5f8b-4d47-bcc1-1f3c3beb97fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNy0xLTEtMS0xMzE2MTg_eca26d5e-0c5d-4a81-aada-dd3182c057e4">760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNy0zLTEtMS0xMzE2MTg_47dec290-97f4-41f0-87e6-0aa6e194ffa2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNy01LTEtMS0xMzE2MTg_3ff9fd31-4578-4ea8-bc11-34dee56af85c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNy03LTEtMS0xMzE2MTg_5f904d27-87dd-4ead-826e-cfcad94392d9">760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNy05LTEtMS0xMzE2MTg_8f9fcbae-ebe5-4e48-b7dd-cfe150e2e2ba">569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNy0xMS0xLTEtMTMxNjE4_a7e1b47f-4469-4e68-9be9-ea2934fbe819">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNy0xMy0xLTEtMTMxNjE4_efb397d7-4228-4663-b5b2-e9e01c28004a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNy0xNS0xLTEtMTMxNjE4_4a229de1-c21a-45a5-8243-e93e7befdcb8">569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfOC03LTEtMS0xMzE2MTg_cce764db-ff9e-45fa-ad78-e99c726545a1">1,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfOC0xNS0xLTEtMTMxNjE4_db920bff-366b-4fc4-a49e-42206d6c385d">1,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="mrk:DebtSecuritiesandEquitySecuritiesFVNI" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfOS03LTEtMS0xMzE2MTg_a37b903a-f00d-4e98-a016-145a168486d5">2,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="mrk:DebtSecuritiesandEquitySecuritiesFVNI" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfOS0xNS0xLTEtMTMxNjE4_23b11816-8ae4-407e-84c3-5a6ef8ee4d36">1,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net gains of $<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTAzNDg_e8a02200-6507-4d0c-a5d2-b7286057cebb">338</ix:nonFraction>&#160;million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in the first quarter of 2023 on equity securities still held at March&#160;31, 2023. Unrealized net losses of $<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTA1MzQ_a8000f2a-ccb3-4531-80e8-0b58870ce2a6">225</ix:nonFraction> million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in the first quarter of 2022 on equity securities still held at March&#160;31, 2022.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At March&#160;31, 2023 and March&#160;31, 2022, the Company also had $<ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTA3MjI_a659a1b6-1257-4cdf-b474-b5ba6d0f1efc">942</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1ff3b595ae954906bf225b8a7cc58b69_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTA3Mjk_7819aab3-e59e-4f18-8c63-036852492128">643</ix:nonFraction> million, respectively, of equity investments without readily determinable fair values included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. During the first quarter</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">of 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> the Company recorded unrealized gains of $<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTEyMTc_51a9dc70-2c78-4a34-9674-9808fc360cdb">1</ix:nonFraction> million and unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTEyNDk_d679b3be-650f-4c6e-9795-f99c84c84168">21</ix:nonFraction>&#160;million related to certain of these equity investments still held at March&#160;31, 2023. During the first quarter</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">of 2022</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> the Company recorded unrealized gains of $<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTEzOTI_74087441-f2d2-45d0-a05a-2e00f3713822">14</ix:nonFraction>&#160;million related to certain of these investments still held at March&#160;31, 2022. Cumulative unrealized gains and cumulative unrealized losses based on observable price changes for investments in equity investments without readily determinable fair values still held at March&#160;31, 2023 were $<ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTE2Nzc_ccb6be9f-f29d-49e3-b207-2dd0148e3798">287</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTE2ODQ_896b0127-dafc-4b24-bf8e-dafc5c2e3610">40</ix:nonFraction> million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At March&#160;31, 2023 and March&#160;31, 2022, the Company also had $<ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTE3Mzg_707ed689-9e7e-41d7-b4c2-1ecf26a109d1">725</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1ff3b595ae954906bf225b8a7cc58b69_I20220331" decimals="-8" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTE3NDU_5fd15a6e-0e70-4b43-8844-730c36416d88">1.2</ix:nonFraction>&#160;billion, respectively, recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for equity securities held through ownership interests in investment funds. (Gains) losses recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> relating to these investment funds were $(<ix:nonFraction unitRef="usd" contextRef="i17a0e0f674094afda5f097dcbf70b93d_D20230101-20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTE5NTk_d0a5bedc-df10-442d-b6f3-0be90a69b09e">132</ix:nonFraction>)&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0cda95f4db4a4d1e892c7b8b8c2bdd34_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTE5NjY_c4f6aadd-5e59-4935-a503-5822ab65e29e">509</ix:nonFraction>&#160;million for the first quarter of 2023 and 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level&#160;1 having the highest priority and Level 3 having the lowest: </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Quoted prices (unadjusted) in active markets for identical assets or liabilities; </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> -</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 15 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="id4ba55aae8404f9f9711fe5c98183e92" continuedAt="i4aa981479cc240b99204444f93effa2b"><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg5ODM_093e36d5-cacb-4300-a433-140a801df272" escape="true"><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis are summarized below:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i020b0ff9857f4f16af9e432e1869c1f7_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNS0xLTEtMS0xMzE2MTg_0e54fa1c-6aee-4acd-afaa-e1c5986265b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c700750162434c9390aee0f12c47d9_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNS0zLTEtMS0xMzE2MTg_9c68e298-88c0-43d6-a0da-ffe9c74ab8d0">663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if47442341eb14e6e97a2cc3f6b5bba11_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNS01LTEtMS0xMzE2MTg_efccf205-5d4b-45a5-b28a-e6a0f9b21ce3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bffc0a6380440728c91dc8b47e0f31e_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNS03LTEtMS0xMzE2MTg_d58408ae-0aa1-4580-8160-e3a3785039be">663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a8f3e37e4904159af4dd090e1bc5731_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNS05LTEtMS0xMzE2MTg_0e3b5efe-4ae2-4279-a9c0-3d2fcb842c76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a49b37db2544c739f3f57a6c315a232_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNS0xMS0xLTEtMTMxNjE4_2567dea2-5b34-4959-9afa-0aebc308d036">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66cafb3d313644a3b3ba17dc3c1b05da_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNS0xMy0xLTEtMTMxNjE4_6a3b23e8-737e-4e94-a723-b9edab0124d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a99f61d5d9c4df5b63c5274b8898116_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNS0xNS0xLTEtMTMxNjE4_2daf049c-b11c-46b4-bea6-6d6092124d1c">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9e79091e5045c68d0f830e6ac4c990_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0xLTEtMS0xNDI4MDU_aaa59637-fab3-4866-bae2-6f1af816ed4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2795fcc4916b4738ba959e843ff69ec3_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0zLTEtMS0xNDI4MDU_3bdea0bc-5356-4ac3-83c4-02670e8f3cfe">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96de2214f40e4ba59e7b629d43ba4d91_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi01LTEtMS0xNDI4MDU_6e332e58-a88a-4104-91d8-b79cf7ec9891">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i451160fbee604ab990070211ebeba8de_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi03LTEtMS0xNDI4OTc_73ccbfd9-b77c-4f26-82e8-74a1dc481dad">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46d67fffc7944fb8af71441dc67f9462_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi05LTEtMS0xNDI4MTQ_56c2e6aa-9ae5-48e3-8a38-844f5394bde4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb8445329cbd40e38c431a9cab4cb4d6_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0xMS0xLTEtMTQyODE0_d9140173-e53b-454d-8a03-30994ddf7301">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3beec2a915ab4328b794d0b11fbc0788_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0xMy0xLTEtMTQyODE0_84b9095b-f1f2-47a2-8ffd-aa1517f0b3da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814823701512438f9446387df4b6adcf_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0xNS0xLTEtMTQyODk3_ebaa5901-0aaa-4ca8-ad5a-741b7e77e61e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d93e6ac796f4cc0a31cd2625e3240a0_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0xLTEtMS0xMzE2MTg_884af47b-a529-4cc6-9685-b638d5df485d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idef3c5cc57074bf7bab4f63f14c711d4_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0zLTEtMS0xMzE2MTg_1fccf83e-484b-4e05-bba2-62d03e5eb4d1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia38b8466a7354dcfb672c615593eeffb_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi01LTEtMS0xMzE2MTg_2f535a18-44ac-455f-a8db-c795d14bd486">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i743f68c0230549c8bfbd0ad0a8901f37_I20230331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi03LTEtMS0xMzE2MTg_78cf2b88-306a-4f88-b54f-d383655d2f69">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d3fb0c5d5a24db099308a75d6d48348_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi05LTEtMS0xMzE2MTg_ae698376-872f-46fc-b710-53b2468985f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4232e5688d9417880fdb23acd1671dc_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0xMS0xLTEtMTMxNjE4_4475b2b7-02c6-46c5-aae9-97b6fac707cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c5ea1c804e54b9da2cfa1e35191be79_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0xMy0xLTEtMTMxNjE4_fe1f1e39-6c59-4492-a54d-f6057804f23c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c000934f3b49b4a1049b7c5825c3d0_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0xNS0xLTEtMTMxNjE4_e55660ab-f3d2-48b4-a76a-b60223b51e11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i012d7bd208a247b4b543d54583a218ef_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNy0xLTEtMS0xMzE2MTg_b26b196d-d28e-4b44-80d1-ae7a4000970f">1,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07338fb5662b49d5bc2528a3307c626b_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNy0zLTEtMS0xMzE2MTg_767b5fb1-432c-4252-8b7f-b5a1c59bdbce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic115d2d37fd44d80b15e651843a0417f_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNy01LTEtMS0xMzE2MTg_19ae8582-9021-47e0-ae04-3bf16d691cb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8d827d1b17a45afbc3e288430a5dc82_I20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNy03LTEtMS0xMzE2MTg_035fdb1c-cf4d-41d1-b7c4-e3c11a1af9d2">1,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bb17c88faa0435c933b88267089cb0f_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNy05LTEtMS0xMzE2MTg_fcd82b47-bbc0-4c85-a37b-631874a80b4a">1,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib04f9b00c03c4e4ea6423dcfad58d6b3_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNy0xMS0xLTEtMTMxNjE4_7efdc7f9-72d3-4b34-9816-0d9d31a1e50b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie908803a7baf418983f47014731e40ea_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNy0xMy0xLTEtMTMxNjE4_1f84d769-2780-471a-89c0-f9076e0a54b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1db38063fdeb45aaa60b2e97a4474133_I20221231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNy0xNS0xLTEtMTMxNjE4_21988a98-02bb-41b5-a30d-e1dc03b4c60f">1,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idebf467c560c4d1d9245b765b6e590d9_I20230331" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfOC0xLTEtMS0xMzE2MTg_4e4e971f-a4b0-41c0-890c-e274b7e2923d">1,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89142ce181ae48e3a2d77a9f72861963_I20230331" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfOC0zLTEtMS0xMzE2MTg_f6e2f1a6-d2b2-4586-8abe-6e4bde4e8b74">686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae55075eed47cdb14839b87c57acd5_I20230331" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfOC01LTEtMS0xMzE2MTg_a8f16158-84ce-4260-bf3e-1a2b77537f23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f4032436bb84e00a3478c08a4a4bac8_I20230331" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfOC03LTEtMS0xMzE2MTg_4c724860-a9a6-401b-b051-7756ecc7b7c6">1,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd81adc1667472a96ce3692b39fdda2_I20221231" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfOC05LTEtMS0xMzE2MTg_2e52ab60-a4d3-4acc-9d80-ead68654c649">1,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i871a358ebbbd48f496202064b0918f47_I20221231" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfOC0xMS0xLTEtMTMxNjE4_b0794eec-ed80-419b-b140-9eb616a79d80">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e90f41ec72b4d99ab066bfbad83afec_I20221231" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfOC0xMy0xLTEtMTMxNjE4_80c26481-74a1-4d11-83d1-231c47605b71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a48a4589b004511be5ec5ad70c7e2da_I20221231" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfOC0xNS0xLTEtMTMxNjE4_0e575ddb-093d-4dce-a701-a729e92740f4">1,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9e79091e5045c68d0f830e6ac4c990_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTAtMS0xLTEtMTMxNjE4_b7c1774b-3226-4605-88f3-ffd02dbb5576">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2795fcc4916b4738ba959e843ff69ec3_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTAtMy0xLTEtMTMxNjE4_d80dfe03-f2c8-46d3-8d9d-ae292b277c45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96de2214f40e4ba59e7b629d43ba4d91_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTAtNS0xLTEtMTMxNjE4_5696dfda-858a-44f8-aa3f-0f1de3e51b31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i451160fbee604ab990070211ebeba8de_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTAtNy0xLTEtMTMxNjE4_96f45da5-f6a7-428b-9c26-420e3f43d14e">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46d67fffc7944fb8af71441dc67f9462_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTAtOS0xLTEtMTMxNjE4_c4c7ec95-902b-44e1-9a72-0cc089655c01">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb8445329cbd40e38c431a9cab4cb4d6_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTAtMTEtMS0xLTEzMTYxOA_8e6882df-69cc-43b6-92c5-6b02032038bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3beec2a915ab4328b794d0b11fbc0788_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTAtMTMtMS0xLTEzMTYxOA_f478da74-6cfe-494e-9c7c-d312ae56e06b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i814823701512438f9446387df4b6adcf_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTAtMTUtMS0xLTEzMTYxOA_e0dbc358-8f5c-4477-adb7-e1f332799b80">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c30409b333846a0b003f5261f708353_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTEtMS0xLTEtMTMxNjE4_5f566187-2eb1-48c2-97f7-2c159c59ea87">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d1c02180ad34f3e83fbb3df043ae3f5_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTEtMy0xLTEtMTMxNjE4_7c5c3aa8-c0b3-4a1f-8d99-d5b536f050c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6288684e9335426a899ee4586882280c_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTEtNS0xLTEtMTMxNjE4_26355afe-92f3-46f1-ba80-d9110584de78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i305ac9c4908a4bffa1b9ce0a56239183_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTEtNy0xLTEtMTMxNjE4_b4bd97eb-c6c3-4491-b71f-d23814cf4375">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eaafa1e0ba64836a551188797cd7c7c_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTEtOS0xLTEtMTMxNjE4_5a24c76e-6057-4665-8584-a8e8f721fc56">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic36ef238f34c4ab180d3b3a52624eb9d_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTEtMTEtMS0xLTEzMTYxOA_3a8192b4-d20e-4fa4-88ad-fe6c85e7ed87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib784c86ce67446f7940a517458674fd1_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTEtMTMtMS0xLTEzMTYxOA_ca1d9860-b54f-460d-9830-bf60df710d8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i004682e5e94d4b12b9f2913eefd3a7fb_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTEtMTUtMS0xLTEzMTYxOA_c53c81dd-ecab-4af7-accf-670d4d759793">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i012d7bd208a247b4b543d54583a218ef_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTItMS0xLTEtMTMxNjE4_0c5b3078-6b13-4fa4-867c-93f3112b530f">301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07338fb5662b49d5bc2528a3307c626b_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTItMy0xLTEtMTMxNjE4_dd65fcb2-a6bd-4fb6-bc1d-10911ad2ef40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic115d2d37fd44d80b15e651843a0417f_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTItNS0xLTEtMTMxNjE4_84b98074-1b42-42c2-823d-5feee64de00e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8d827d1b17a45afbc3e288430a5dc82_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTItNy0xLTEtMTMxNjE4_01172adc-e976-43c7-b190-2dc1de853e05">301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bb17c88faa0435c933b88267089cb0f_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTItOS0xLTEtMTMxNjE4_d8e922eb-e03c-4a4b-a32b-c7854d522014">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib04f9b00c03c4e4ea6423dcfad58d6b3_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTItMTEtMS0xLTEzMTYxOA_cc97dd16-0871-4d57-ac48-cac4203bccfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie908803a7baf418983f47014731e40ea_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTItMTMtMS0xLTEzMTYxOA_de47a288-b36d-44b8-97d1-b01f8b3b73bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1db38063fdeb45aaa60b2e97a4474133_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTItMTUtMS0xLTEzMTYxOA_7b34bd22-cd04-4cbd-91e1-7a917f7e7eaf">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idebf467c560c4d1d9245b765b6e590d9_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTMtMS0xLTEtMTMxNjE4_292d338b-e4a7-46ab-b976-e6e4607c57f3">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89142ce181ae48e3a2d77a9f72861963_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTMtMy0xLTEtMTMxNjE4_4825e079-11ba-4dea-80d4-9e0817058aec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae55075eed47cdb14839b87c57acd5_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTMtNS0xLTEtMTMxNjE4_0ab20310-6b48-4e18-9499-a4d6eea90eb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f4032436bb84e00a3478c08a4a4bac8_I20230331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTMtNy0xLTEtMTMxNjE4_9783e758-1216-4218-b674-8ab5f9ee62c1">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd81adc1667472a96ce3692b39fdda2_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTMtOS0xLTEtMTMxNjE4_fcd41c03-7b67-4fce-8ca4-3317b93b11e5">340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i871a358ebbbd48f496202064b0918f47_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTMtMTEtMS0xLTEzMTYxOA_5d8904c2-de85-4a36-809a-a1c1f6ae4b82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e90f41ec72b4d99ab066bfbad83afec_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTMtMTMtMS0xLTEzMTYxOA_d3fe0a7c-5618-490a-95b7-9982c5fe7220">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a48a4589b004511be5ec5ad70c7e2da_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTMtMTUtMS0xLTEzMTYxOA_29f75233-134b-465e-b19b-49dfb159de7c">340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34260a2a17d947768f68d2798eb0f8c1_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTYtMS0xLTEtMTMxNjE4_ca36872b-5bfe-42b2-93b4-a0b8b968576a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b068359fb3948a182327c67ab308fb4_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTYtMy0xLTEtMTMxNjE4_b0cd73d8-2b57-4754-be46-a5fd56f17be3">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f7806f9be14762977b7e08e79e4daf_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTYtNS0xLTEtMTMxNjE4_3546d76f-fdfb-41cb-903a-68bb4d765c65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a2e484401b24c479443887a01bf805c_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTYtNy0xLTEtMTMxNjE4_dfa00044-779f-41b4-a83f-12d03be91fe4">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b1b40aabc7a4eedbc4ba7ac12424d0c_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTYtOS0xLTEtMTMxNjE4_df1f3877-2282-48e1-b140-7768875f1dbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5265c6f93c7f46d1ab829156c30fdf74_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTYtMTEtMS0xLTEzMTYxOA_2fe12f6d-57a4-4776-a315-8d550fb49a97">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic497e29b39d04693be035586e02049ba_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTYtMTMtMS0xLTEzMTYxOA_3bc604fd-c461-4663-af44-8be75b1e76c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i970e6180f53c4baeb53fdd14d90061da_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTYtMTUtMS0xLTEzMTYxOA_b28c6326-6031-44db-9fdd-bd862903f773">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i075080b8fa0045b6adf42ad9d680a586_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTctMS0xLTEtMTQyNzM5_0c24c1b0-0975-465c-9422-c5059618e9ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if826811b47d7448eb6e1f3d6c36b5841_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTctMy0xLTEtMTQyNzM5_b9066cb5-337e-4246-9d51-c2408a0ea254">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96e781b662154001934e50bb59beb7cd_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTctNS0xLTEtMTQyNzM5_d24738f0-8879-4bac-84e6-699c957684ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffb1c0f1856491795524f9ede8241fc_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTctNy0xLTEtMTQyNzM5_f9ceb638-bc1a-49ae-8c1a-31e382cdddb8">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ba1c7342bdd4e82a5d14645ae050399_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTctOS0xLTEtMTQyNzM5_bfd9b65a-26e5-49bd-ad0b-8392d0378711">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i294603384e1e48b1b1962054c70f8781_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTctMTEtMS0xLTE0MjczOQ_0d7ae1eb-e839-4658-bdd8-3a60b50c9151">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2707a83a0684b81b3f82c21c1a7d1e9_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTctMTMtMS0xLTE0MjczOQ_95ea9c4a-7172-4401-b15d-5eb65d8b05f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia524db85b9fb4e5faaed403cdac7f778_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTctMTUtMS0xLTE0MjczOQ_749b4f51-5f97-4cf5-9ff1-8d9b6ce4f5f4">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4b65ea8a7a94fb5acbe089d34abecfd_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMS0xLTEtMTQyNjM5_359fe91c-b543-42a8-846f-a49881989970">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe9381ed615477a8d395b385d4bfc96_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMy0xLTEtMTQyNjM5_add84cbf-83a4-4e47-9505-f779aa30b8ba">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec2a2a2cde214dcf9145e7fed863dfaf_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtNS0xLTEtMTQyNjM5_a98df310-7cd0-4565-9a0a-dd4677e59b62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0fdebb01cd44ff4b7dd90a3757e19a8_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtNy0xLTEtMTQyOTAw_1935a71d-f60f-42c0-b621-d68401600e44">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92b2724f66144388bc9d877014d99971_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtOS0xLTEtMTQyNjM5_4a9e2ed3-83ef-49ec-a881-f2d27ce14dba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i402e5d3ff33d4949b0046490210e38a1_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMTEtMS0xLTE0MjYzOQ_17f6df11-b755-4b6f-8c28-622c23fe9c63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4a496ea51974c41968d7d7ece436a35_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMTMtMS0xLTE0MjYzOQ_4e142787-e72f-4516-8e1a-15d8679c2fc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04e31d8852884bf89e5bcb8b4f124896_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMTUtMS0xLTE0MjkwMA_410446bf-d1af-4dcf-906a-f57c822644ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idebf467c560c4d1d9245b765b6e590d9_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMS0xLTEtMTMxNjE4_9b24cb78-a48f-4a20-91f2-b2cc52391c8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89142ce181ae48e3a2d77a9f72861963_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMy0xLTEtMTMxNjE4_53abf6f3-62df-4e76-9697-be441d83fb49">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae55075eed47cdb14839b87c57acd5_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtNS0xLTEtMTMxNjE4_4e7d2486-4293-46dc-8206-1f6d8d93321d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f4032436bb84e00a3478c08a4a4bac8_I20230331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtNy0xLTEtMTMxNjE4_8ed6e4b1-9fbf-44d5-b2ad-4671b6263c58">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd81adc1667472a96ce3692b39fdda2_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtOS0xLTEtMTMxNjE4_5d074d82-04a0-4fe5-b072-81bf95f40d1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i871a358ebbbd48f496202064b0918f47_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMTEtMS0xLTEzMTYxOA_cc2a570a-97b1-44ce-af07-5f0c1a640cb7">433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e90f41ec72b4d99ab066bfbad83afec_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMTMtMS0xLTEzMTYxOA_8ae18f96-6d3b-43ed-ba57-67240c0dfd12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a48a4589b004511be5ec5ad70c7e2da_I20221231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMTUtMS0xLTEzMTYxOA_284f4954-e0c9-43b7-9bf0-10fa07c5e1b1">433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idebf467c560c4d1d9245b765b6e590d9_I20230331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTktMS0xLTEtMTMxNjE4_58916fb2-9d1b-40e8-9f85-0d1c3c679c51">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89142ce181ae48e3a2d77a9f72861963_I20230331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTktMy0xLTEtMTMxNjE4_5f3bf00a-64cc-4917-a293-bfdbcef934c9">945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae55075eed47cdb14839b87c57acd5_I20230331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTktNS0xLTEtMTMxNjE4_b655d779-28b5-4cd1-8d8b-5fc9761830d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f4032436bb84e00a3478c08a4a4bac8_I20230331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTktNy0xLTEtMTMxNjE4_6b4d4136-85e1-4f14-b3b9-9e3fa023da9f">2,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd81adc1667472a96ce3692b39fdda2_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTktOS0xLTEtMTMxNjE4_f2cf04e7-a236-4643-bcb8-2eed165c7855">1,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i871a358ebbbd48f496202064b0918f47_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTktMTEtMS0xLTEzMTYxOA_76cedcc4-4a6b-4536-8477-c41e9d972482">931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e90f41ec72b4d99ab066bfbad83afec_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTktMTMtMS0xLTEzMTYxOA_4960d5cd-0675-4292-b1f8-eafce8616e9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a48a4589b004511be5ec5ad70c7e2da_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTktMTUtMS0xLTEzMTYxOA_a8330c04-4d6c-417b-b9c7-123fa114b6db">2,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idebf467c560c4d1d9245b765b6e590d9_I20230331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjItMS0xLTEtMTMxNjE4_483e8c09-8fd3-4704-b97d-002e40b38d10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89142ce181ae48e3a2d77a9f72861963_I20230331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjItMy0xLTEtMTMxNjE4_8d1fbb4d-d276-4025-80cb-7537cc352a36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae55075eed47cdb14839b87c57acd5_I20230331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjItNS0xLTEtMTMxNjE4_9a72a642-8e82-4e99-b714-adb309aa9824">353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f4032436bb84e00a3478c08a4a4bac8_I20230331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjItNy0xLTEtMTMxNjE4_d25bf528-9231-4ba8-9aec-b1bbc9947029">353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd81adc1667472a96ce3692b39fdda2_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjItOS0xLTEtMTMxNjE4_88da0802-966b-4747-a7d3-89fc8d1761f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i871a358ebbbd48f496202064b0918f47_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjItMTEtMS0xLTEzMTYxOA_67dc2411-5000-4474-b67a-7c69401f7c52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e90f41ec72b4d99ab066bfbad83afec_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjItMTMtMS0xLTEzMTYxOA_19d25332-f73b-4c80-ac60-db5e4d1d038b">456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a48a4589b004511be5ec5ad70c7e2da_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjItMTUtMS0xLTEzMTYxOA_84bfb37e-b89d-48e0-a3f3-08164eb33d77">456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i075080b8fa0045b6adf42ad9d680a586_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjQtMS0xLTEtMTMxNjE4_7fb4b891-f36b-4b58-93ee-1865502b2ff1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if826811b47d7448eb6e1f3d6c36b5841_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjQtMy0xLTEtMTMxNjE4_849178a0-9960-4c32-bbdf-897b019c2a76">276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96e781b662154001934e50bb59beb7cd_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjQtNS0xLTEtMTMxNjE4_30447676-6124-476e-84e4-6e98b6c6496e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffb1c0f1856491795524f9ede8241fc_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjQtNy0xLTEtMTMxNjE4_db589160-61c7-41fd-94b5-e1b0c9c35dfa">276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ba1c7342bdd4e82a5d14645ae050399_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjQtOS0xLTEtMTMxNjE4_2cecf214-d3fe-4d3b-b75d-dbf3dbb49a68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i294603384e1e48b1b1962054c70f8781_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjQtMTEtMS0xLTEzMTYxOA_2c5212ca-19aa-4b55-acd7-24f2d0b1691e">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2707a83a0684b81b3f82c21c1a7d1e9_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjQtMTMtMS0xLTEzMTYxOA_97006aaa-a6f2-4c7c-a096-bfd142a55687">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia524db85b9fb4e5faaed403cdac7f778_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjQtMTUtMS0xLTEzMTYxOA_9b23a4de-9f1f-4733-893a-f2c6bd10d8f6">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34260a2a17d947768f68d2798eb0f8c1_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjUtMS0xLTEtMTMxNjE4_eba8a516-d7d5-413d-8f4c-2538153b6e7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b068359fb3948a182327c67ab308fb4_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjUtMy0xLTEtMTMxNjE4_0cfb45d0-81a5-425b-9a07-f2b8b369f752">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f7806f9be14762977b7e08e79e4daf_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjUtNS0xLTEtMTMxNjE4_b533cf8b-13ee-4517-ace8-a52379956989">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a2e484401b24c479443887a01bf805c_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjUtNy0xLTEtMTMxNjE4_3dd0ac8c-acb4-4e00-ac7a-10d0f9a6c305">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b1b40aabc7a4eedbc4ba7ac12424d0c_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjUtOS0xLTEtMTMxNjE4_05325343-7ff4-4597-b6a5-a8b6dc33f8a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5265c6f93c7f46d1ab829156c30fdf74_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjUtMTEtMS0xLTEzMTYxOA_762439c4-93ca-4fc0-91c3-1854b6061e9a">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic497e29b39d04693be035586e02049ba_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjUtMTMtMS0xLTEzMTYxOA_4f213633-9202-409e-8c29-923e8db35773">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i970e6180f53c4baeb53fdd14d90061da_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjUtMTUtMS0xLTEzMTYxOA_6a1cb643-070f-4b60-a5e0-0f20fbe6eae3">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4b65ea8a7a94fb5acbe089d34abecfd_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMS0xLTEtMTQyNjYy_024ffe50-d376-4c95-bce6-99e121e627fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe9381ed615477a8d395b385d4bfc96_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMy0xLTEtMTQyNjYy_fca214be-cfa6-4cef-84fe-cc43d44ab8d0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec2a2a2cde214dcf9145e7fed863dfaf_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctNS0xLTEtMTQyNjYy_51aa7166-3ebe-4ee0-87ba-fbbb12541b7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0fdebb01cd44ff4b7dd90a3757e19a8_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctNy0xLTEtMTQyOTA1_d40c5be6-44a8-41c9-bd2f-aa6dd24efd34">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92b2724f66144388bc9d877014d99971_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctOS0xLTEtMTQyNjYy_495c74db-3a49-4c66-8949-318bc67356bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i402e5d3ff33d4949b0046490210e38a1_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMTEtMS0xLTE0MjY2Mg_269bf6d4-76e1-47dd-be52-efb7022fefea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4a496ea51974c41968d7d7ece436a35_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMTMtMS0xLTE0MjY2Mg_6df333ce-8880-4bd8-a301-c400065f1764">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04e31d8852884bf89e5bcb8b4f124896_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMTUtMS0xLTE0MjkwNQ_4d7d9ef9-ca6c-4d6f-8128-1a8750b46d18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idebf467c560c4d1d9245b765b6e590d9_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjYtMS0xLTEtMTMxNjE4_b857af57-9d2e-4eb5-9dd5-1f34bf374b7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89142ce181ae48e3a2d77a9f72861963_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjYtMy0xLTEtMTMxNjE4_5535b5e1-3f27-403e-a8ef-1bc6a00ccd1a">284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae55075eed47cdb14839b87c57acd5_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjYtNS0xLTEtMTMxNjE4_bcca3703-a77d-4d28-9c9f-ef89a99462b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f4032436bb84e00a3478c08a4a4bac8_I20230331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjYtNy0xLTEtMTMxNjE4_fd46a7fd-f447-45bf-8841-88f4e7c8d3dd">284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd81adc1667472a96ce3692b39fdda2_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjYtOS0xLTEtMTMxNjE4_dee273a3-9619-4474-96b8-49885d93ac42">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i871a358ebbbd48f496202064b0918f47_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjYtMTEtMS0xLTEzMTYxOA_ecaddc40-f9eb-4e29-9dfa-e2cec2451f9e">409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e90f41ec72b4d99ab066bfbad83afec_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjYtMTMtMS0xLTEzMTYxOA_d0af7ed3-95ce-4a5d-9629-e463ec23d3e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a48a4589b004511be5ec5ad70c7e2da_I20221231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjYtMTUtMS0xLTEzMTYxOA_473cf8ad-74c1-4db0-9ec0-5b2db273d472">409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idebf467c560c4d1d9245b765b6e590d9_I20230331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMS0xLTEtMTMxNjE4_0c86ec9e-e6fd-42b1-82ce-8d4cbc61cb18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89142ce181ae48e3a2d77a9f72861963_I20230331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMy0xLTEtMTMxNjE4_820c292d-a492-40f2-ae40-217bfcf5d286">284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ae55075eed47cdb14839b87c57acd5_I20230331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctNS0xLTEtMTMxNjE4_229c5749-4671-4364-985a-21d5f134e1d7">353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f4032436bb84e00a3478c08a4a4bac8_I20230331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctNy0xLTEtMTMxNjE4_9152b670-9b27-4261-be56-a76cbb6c1ad0">637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd81adc1667472a96ce3692b39fdda2_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctOS0xLTEtMTMxNjE4_3cef6eb2-da16-40ac-a2d3-c8696cf3e143">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i871a358ebbbd48f496202064b0918f47_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMTEtMS0xLTEzMTYxOA_5979c81c-86d2-4e6c-8da4-ad307b8cc0b9">409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e90f41ec72b4d99ab066bfbad83afec_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMTMtMS0xLTEzMTYxOA_4843c7b6-5dde-4aa6-a5c3-005f3e625252">456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a48a4589b004511be5ec5ad70c7e2da_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMTUtMS0xLTEzMTYxOA_6853952c-b498-47a2-b79c-07d82b45501c">865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#8217;s own credit risk, the effects of which were not significant.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> included $<ix:nonFraction unitRef="usd" contextRef="i8dcc8586471c42e6a0ee92dda4a6bd01_I20230331" decimals="-8" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTQyMzE_756d628a-d2cf-4408-96d7-4b7016dc49da">8.8</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i8f39864d8e8e466da61d331c664f14db_I20221231" decimals="-8" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTQyMzg_569481a9-ffb8-4b27-bad8-0e5c06ddb3a7">11.3</ix:nonFraction> billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg5Nzk_77d6f099-347e-4ded-9d4d-8c753d5a96ab" escape="true"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:80.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfMS0xLTEtMS0xMzE2MTg_144665d5-ea1c-43c1-9aef-5f5684399d89">456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cb2241175c4c8c8fd5daf0a86385e3_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfMS0zLTEtMS0xMzE2MTg_f44b2f37-b77f-411d-977f-63b293cb5d5a">777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in estimated fair value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfMi0xLTEtMS0xMzE2MTg_3eebe763-44f1-4be7-85bd-478614d9db0c">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfMi0zLTEtMS0xMzE2MTg_a2cfc153-5828-4ebf-97fb-c3ee10feb3b6">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfMy0xLTEtMS0xMzE2MTg_4d12b177-9678-4d70-b824-edfc1a591885">117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfMy0zLTEtMS0xMzE2MTg_446bc6f6-c8ff-442d-b484-b2d78e5f4d91">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfNC0xLTEtMS0xMzE2MTg_f34d6fff-2ba0-47a0-9b9d-b7014565b79a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfNC0zLTEtMS0xMzE2MTg_9e60961c-a4d4-4846-bf26-70f7a060b5a9">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value March 31 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfNS0xLTEtMS0xMzE2MTg_937a569b-3c02-4cb3-b545-8f46e95255c6">353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ff3b595ae954906bf225b8a7cc58b69_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfNS0zLTEtMS0xMzE2MTg_f5c083dd-45d4-43c3-8187-91a5c8278e76">572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cost of sales, Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">At March&#160;31, 2023, $<ix:nonFraction unitRef="usd" contextRef="i8ae2044462124fec8e736b9c160ff048_I20230331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTQ2ODE_f0029f4c-363a-4329-b0ee-b08014ee1ee9">263</ix:nonFraction> million of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of <ix:nonFraction unitRef="number" contextRef="i8ae2044462124fec8e736b9c160ff048_I20230331" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTQ4NzI_84ce529a-09f8-40ac-bd31-4ab974671ecd">11.5</ix:nonFraction>% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at March&#160;31, 2023 includes $<ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTUxODk_e22e0c6e-3065-42f2-9080-127c8d38a9af">127</ix:nonFraction> million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The payments of contingent consideration in both periods relate to the Sanofi Pasteur MSD liabilities described above.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 16 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i4aa981479cc240b99204444f93effa2b" continuedAt="i42f07933ba0a422aa7ce77acefa705ad"><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Fair Value Measurements</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Some of the Company&#8217;s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimated fair value of loans payable and long-term debt (including current portion) at March&#160;31, 2023, was $<ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-8" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTU3NDc_dd08989f-2216-4edb-b796-c503fe479885">28.2</ix:nonFraction> billion compared with a carrying value of $<ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-8" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTU3ODQ_4bddb375-cd4d-4b80-8747-ec3b4e5fd365">30.7</ix:nonFraction> billion and at December&#160;31, 2022, was $<ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-8" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTU4MDI_fb050a51-0b39-4b7b-aefb-34671fcd6d62">26.7</ix:nonFraction> billion compared with a carrying value of $<ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-8" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTU4Mzk_ca6ef105-6c3d-4d8a-a844-b11cccd7a0b6">30.7</ix:nonFraction> billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company&#8217;s investment policy guidelines. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers and retailers, hospitals and government agencies.&#160;The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-8" name="us-gaap:AccountsReceivableSale" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTcxNzI_3b64962b-ba67-4dfa-8d8c-68996b3eee4a">2.4</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i8fbdfdee6afe4e74be18dd0c62050372_D20220101-20220630" decimals="-8" name="us-gaap:AccountsReceivableSale" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTcxNzk_3508a104-7358-486a-84b3-3fd5843cf9e9">2.5</ix:nonFraction> billion of accounts receivable as of March&#160;31, 2023 and December&#160;31, 2022, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. As of March&#160;31, 2023 and December&#160;31, 2022, the Company had collected $<ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTc3MTE_29b14408-9971-40df-802b-4c63e56ae094">31</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTc3MTg_ab0d93d2-301c-48bb-abea-677752a41a12">67</ix:nonFraction>&#160;million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and the related obligation to remit the cash within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company remitted the cash to the financial institutions in April 2023 and January 2023, respectively. The net cash flows related to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><ix:continuation id="i42f07933ba0a422aa7ce77acefa705ad" continuedAt="id92d384b2ecf4ee6b3b13fd8ebaad63d"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company&#8217;s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company&#8217;s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $<ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg3Njg_d0033a4b-116f-4d9e-afb2-d46a836a0099">13</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg3NzU_3583c354-e49f-4b24-8233-399cd07c5518">66</ix:nonFraction>&#160;million at March&#160;31, 2023 and December&#160;31, 2022, respectively. The obligation to return such collateral is recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="id92d384b2ecf4ee6b3b13fd8ebaad63d">. Cash collateral advanced by the Company to various counterparties was $<ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfNTQ5NzU1ODQyNDM0_3a44d50f-65f2-4ace-ae90-ba4fdee12ef2">19</ix:nonFraction>&#160;million at December&#160;31, 2022.</ix:continuation> </span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_52"></div><div style="margin-top:15pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RleHRyZWdpb246ZjlkNGE0ODA3MmViNDkyZTlkMGQ0ODIxNzlkNjBlMjZfNDE1_4c332579-e324-41dd-9b03-06a4608d6fe6" continuedAt="iac5659fedc284494badfce0aad989599" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="iac5659fedc284494badfce0aad989599"><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RleHRyZWdpb246ZjlkNGE0ODA3MmViNDkyZTlkMGQ0ODIxNzlkNjBlMjZfNDA5_5283fbab-b21a-4cc0-a45c-e64bf59e84a6" escape="true"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories consisted of:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfMS0xLTEtMS0xMzE2MTg_e1f6b193-23f4-45f6-a0ff-65afe27b34ec">1,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfMS0zLTEtMS0xMzE2MTg_dfd8aeb2-f296-41b7-b8be-0329788b9701">1,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:InventoryWorkInProcessAndRawMaterials" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfMi0xLTEtMS0xMzE2MTg_a1fc6eec-983f-49e3-a65d-e8dd0b1f9b93">7,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:InventoryWorkInProcessAndRawMaterials" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfMi0zLTEtMS0xMzE2MTg_63aa8994-a633-4972-934d-ce15a670318a">7,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:OtherInventorySupplies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfMy0xLTEtMS0xMzE2MTg_8af8aeca-6237-43ab-877f-433e3133ea01">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:OtherInventorySupplies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfMy0zLTEtMS0xMzE2MTg_5c3f5a84-2d10-46d4-915e-43ab902e6726">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfNC0xLTEtMS0xMzE2MTg_a885691e-a5f3-49e1-a1ec-dbb2526192e0">9,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfNC0zLTEtMS0xMzE2MTg_8dc1d0d1-7d74-490c-9e5a-1bcab747bc63">9,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:InventoryLIFOReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfNS0xLTEtMS0xMzE2MTg_11a9a970-489b-405e-8b07-ac844e2ad6e9">350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:InventoryLIFOReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfNS0zLTEtMS0xMzE2MTg_b959ab9b-2ed9-4237-8288-871c069d11d6">293</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="mrk:InventoryNetAndInventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfNi0xLTEtMS0xMzE2MTg_0f4ba765-458d-4eff-8f69-7ca34c91bf12">9,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="mrk:InventoryNetAndInventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfNi0zLTEtMS0xMzE2MTg_1b4eba78-0003-4fee-9a6a-cb4475c2773d">8,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfOC0xLTEtMS0xMzE2MTg_59a83081-cdc6-481b-a41d-a5fa08b70c85">5,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfOC0zLTEtMS0xMzE2MTg_8381d8f5-0cb0-4788-bdf7-520cc25f1f91">5,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfOS0xLTEtMS0xMzE2MTg_2f636f35-37e8-4a37-9a84-f3e6e0032938">3,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfOS0zLTEtMS0xMzE2MTg_9a179ab2-4d38-4998-99b4-6e89a5f22c91">2,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amounts recognized as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> are comprised almost entirely of raw materials and work in process inventories. At March&#160;31, 2023 and December&#160;31, 2022, these amounts included $<ix:nonFraction unitRef="usd" contextRef="idf5ff6cbdf22489b9efa70ffb318b8aa_I20230331" decimals="-8" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RleHRyZWdpb246ZjlkNGE0ODA3MmViNDkyZTlkMGQ0ODIxNzlkNjBlMjZfMTky_99619c2c-e46e-4e78-84fe-2645edfe4d6d">2.7</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ie2fc780817394ba39db27d26c677ae95_I20221231" decimals="-8" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RleHRyZWdpb246ZjlkNGE0ODA3MmViNDkyZTlkMGQ0ODIxNzlkNjBlMjZfMTk5_bc507a30-3a03-4bd0-ad9d-68d00864527a">2.4</ix:nonFraction> billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $<ix:nonFraction unitRef="usd" contextRef="i49dd486feefe4b749fbe2cca62e80318_I20230331" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RleHRyZWdpb246ZjlkNGE0ODA3MmViNDkyZTlkMGQ0ODIxNzlkNjBlMjZfMzA5_aca92398-3c98-4b83-a9ed-0ee0fac2032e">590</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3e717c1f26e14e87978e3de102e7c698_I20221231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RleHRyZWdpb246ZjlkNGE0ODA3MmViNDkyZTlkMGQ0ODIxNzlkNjBlMjZfMzE2_b00c67e1-0554-464d-8b73-541b7e4fada9">516</ix:nonFraction> million at March&#160;31, 2023 and December&#160;31, 2022, respectively, of inventories produced in preparation for product launches.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 17 -</span></div></div></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div style="margin-top:15pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfMjM4Njk_a2d92dec-e1f1-4934-9a15-0b554c1df578" continuedAt="iad3de5c413d84d71a4dabb1b11cbf4d6" escape="true">Contingencies</ix:nonNumeric></span></div><ix:continuation id="iad3de5c413d84d71a4dabb1b11cbf4d6" continuedAt="i6254f56b1fa9408da148277f1ce1f8d6"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company&#8217;s financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i)&#160;what claims, if any, will survive dispositive motion practice, (ii)&#160;the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii)&#160;how the discovery process will affect the litigation, (iv)&#160;the settlement posture of the other parties to the litigation and (v)&#160;any other factors that may have a material effect on the litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. <ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:LegalCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfMjM4ODI_742de232-8515-4d34-814a-a249c63924e4" escape="true">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil 9</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck is a defendant in product liability lawsuits in the U.S. involving </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). As of March&#160;31, 2023, approximately <ix:nonFraction unitRef="case" contextRef="ie81327a316a94b36974954a7e8642bc5_I20230331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfNjM4Mg_077e1822-fc37-45b9-a87e-2b9a60f0b7fb">95</ix:nonFraction> cases were filed and pending against Merck in either federal or state court. In these actions, plaintiffs allege, among other things, that they suffered various personal injuries after vaccination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9, with postural orthostatic tachycardia syndrome as a predominate alleged injury. In August 2022, the Judicial Panel on Multidistrict Litigation ordered that </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9 product liability cases pending in federal courts nationwide be transferred to Judge Robert J. Conrad in the Western District of North Carolina for coordinated pre-trial proceedings. There are fewer than <ix:nonFraction unitRef="case" contextRef="ide0712a78628418ab61bbe9bb313aae7_I20230331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfNjk5MQ_66d877f2-2855-4d20-a17d-2356ffed2073">15</ix:nonFraction> product liability cases pending outside the U.S., including <ix:nonFraction unitRef="case" contextRef="i7358a61460544d15a70b0957807efa73_I20230331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfNzA1NA_7d77d8a9-f37b-4c13-845a-debef74650e7">one</ix:nonFraction> purported class action in Colombia.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Governmental Proceedings</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company&#8217;s subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company&#8217;s policy is to cooperate with these authorities and to provide responses as appropriate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.</span></div><div style="margin-top:12pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commercial and Other Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, Merck, Merck Sharp &amp; Dohme, LLC. (MSD), Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in a number of lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases were consolidated in a federal multidistrict litigation (the Zetia MDL) before Judge Rebecca Beach Smith in the Eastern District of Virginia.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. In August 2020, the district court granted in part the direct purchasers&#8217; motion for class certification and certified a class of <ix:nonFraction unitRef="direct_purchaser" contextRef="i674ee2f2e244467391945b56813ef740_I20200831" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfOTE3MQ_27bedc13-deb8-4aff-a0a0-29ea498e6a54">35</ix:nonFraction> direct purchasers. In August 2021, the Fourth Circuit vacated the district court&#8217;s class certification order and remanded for further proceedings consistent with the court&#8217;s ruling. In September 2021, the direct purchaser plaintiffs filed a renewed motion for class certification. In April 2022, the district court denied the direct purchaser plaintiffs&#8217; renewed motion for class certification. In August 2021, the district court granted certification of a class of indirect purchasers.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 18 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i6254f56b1fa9408da148277f1ce1f8d6" continuedAt="ib3b3a881bb004b039ab4088546d4e89b"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2020 and 2021, United Healthcare Services, Inc., Humana Inc., Centene Corporation and others, and Kaiser Foundation Health Plan, Inc. (collectively, the Insurer Plaintiffs), each filed a lawsuit in a jurisdiction outside of the Eastern District of Virginia against the Merck Defendants and others, making similar allegations as those made in the Zetia MDL, as well as additional allegations about Vytorin. These cases have been transferred to the Eastern District of Virginia to proceed with the Zetia MDL and remain pending.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2022, the Insurer Plaintiffs filed amended complaints. In March 2022, the Merck Defendants, jointly with other defendants, moved to dismiss certain aspects of the Insurer Plaintiffs&#8217; complaints, including any claims for Vytorin damages. That motion to dismiss the Vytorin-related claims is still pending.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2022, the direct purchaser plaintiffs moved for an order setting a deadline for direct purchasers of Zetia not currently parties to the case to file cases against defendants in order for those cases to be coordinated for trial with the existing direct purchaser plaintiffs and other MDL plaintiff groups. The court granted that motion, setting a deadline of June 30, 2022 for unnamed direct purchasers to file claims. On June 30, 2022, <ix:nonFraction unitRef="claim" contextRef="i486acde0965b4e4fa567b783874fdd1b_D20220630-20220630" decimals="0" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfMTExNTU_67e7e2c1-fcb5-42eb-8851-48b975b16c89">23</ix:nonFraction> new entities, many related, brought new complaints against defendants or otherwise sought to intervene. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On February 10, 2023, the district court denied the Merck Defendants&#8217; and Glenmark Defendants&#8217; motions for summary judgment. In April 2023, the Merck Defendants reached settlements with the direct purchaser and retailer plaintiffs and a proposed settlement, subject to court approval, with the indirect purchaser class. Under these agreements, Merck will pay $<ix:nonFraction unitRef="usd" contextRef="i07e39fac74fc4d08a501e1e14a991816_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfNTQ5NzU1OTAwNzMx_80c4d5be-3421-4a0a-b221-69ca44c1f0e1">572.5</ix:nonFraction> million to resolve the direct purchaser, retailer, and indirect purchaser plaintiffs&#8217; claims, which was recorded as an expense in the Company&#8217;s first quarter 2023 financial results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq Antitrust Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On March 3, 2023, the Mayor and City Council of Baltimore filed a putative class action against MSD in the Eastern District of Pennsylvania on behalf of all third-party payors in <ix:nonFraction unitRef="state" contextRef="i88f1868d275a4b89ac8e4f956b24ddc5_I20230303" decimals="0" name="mrk:LossContingencyNumberOfStatesInWhichPlaintiffsReside" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfMjc0ODc3OTE1NjQwNA_7d9cd40d-964c-4f9f-9203-61ffda2d796a">35</ix:nonFraction> states that indirectly purchased, paid, and/or provided reimbursement for some or all of the purchase price of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Rotavirus Vaccine, Live Oral, Pentavalent), other than for resale, from March 3, 2019 to the present. Plaintiff alleges that MSD violated federal and state antitrust laws and state consumer protection laws. Plaintiff alleges that MSD has implemented an anticompetitive vaccine bundling scheme whereby MSD leverages its alleged monopoly power in certain pediatric vaccine markets to maintain its alleged monopoly power in the U.S. market for rotavirus vaccines in order to charge supracompetitive prices for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Plaintiff seeks permanent injunctive relief and unspecified monetary damages on purchases of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, trebled, and fees and costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in January 2020, the Company was served with a complaint in the U.S. District Court for the District of New Jersey. Following motion practice, the plaintiffs filed a second amended complaint on July 1, 2021, seeking to certify a nationwide class action of purchasers or users of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (fluralaner) products in the U.S. or its territories between May 1, 2014 and July 1, 2021. Plaintiffs contend </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> causes neurological events in dogs and cats and alleges violations of the New Jersey Consumer Fraud Act, Breach of Warranty, Product Liability, and related theories. The Company moved to dismiss or, alternatively, to strike the class allegations from the second amended complaint, and that motion is pending. A similar case was filed in Quebec, Canada in May 2019. The Superior Court certified a class of dog owners in Quebec who gave </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Chew to their dogs between February 16, 2017 and November 2, 2018 whose dogs experienced one of the conditions in the post-marketing adverse reactions section of the labeling approved on November 2, 2018. The Company and plaintiffs each appealed the class certification decision. The Court of Appeal of Quebec heard the appeal in February 2022 and issued a decision in April 2022 allowing both parties&#8217; appeals in part. The Court of Appeal amended the class period to start on July 2, 2014, allowed a second plaintiff to serve as a class representative, and modified the list of conditions in the class definition by adding &#8220;death&#8221; and removing &#8220;lack of efficacy.&#8221; The Court of Appeal also added to the list of questions to be considered by the trial court the questions of whether the Consumer Protection Act of Quebec applies to the sale of a veterinary product and, if so, whether it was breached. The Company sought leave to appeal to the Supreme Court of Canada, which was denied. The case is proceeding in the Superior Court.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company&#8217;s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company&#8217;s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (sugammadex) Injection.&#160;In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies.&#160;All actions in the District of New Jersey have been consolidated. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 19 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="ib3b3a881bb004b039ab4088546d4e89b" continuedAt="id1ac567cfbb14c319494434cb0fe4474"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">may occur earlier. The West Virginia case was jointly dismissed with prejudice on August 8, 2022 in favor of proceeding in New Jersey. The remaining defendants in the New Jersey action have stipulated to infringement of the asserted claims and have stated they are withdrawing all remaining claims and defenses other than a defense seeking to shorten the patent term extension of the sugammadex patent to December 2022. The U.S. District Court for the District of New Jersey held a <ix:nonNumeric contextRef="i4305661e65274f559b5b59766d3c5cc3_D20221219-20221219" name="mrk:LossContingencyTrialPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfMjc0ODc3OTE1NjQwNw_9663f7fe-ce41-4262-9103-cfb75f192549">one-day</ix:nonNumeric> trial on December 19, 2022 on this remaining patent term extension calculation defense. The court ordered post-trial briefing on this defense and held closing arguments on February 3, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has settled with <ix:nonFraction unitRef="company" contextRef="i4bd3fe27e3bf4036897cd39ae0448f14_D20230101-20230331" decimals="INF" name="us-gaap:LossContingencyClaimsSettledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfMTU2NDc_e41291d9-fbdc-4ace-adb5-d485d6a1750a">five</ix:nonFraction> generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company has agreed to stay the lawsuit filed against <ix:nonFraction unitRef="company" contextRef="i79aeb0bcc641443b80308ef30bbad1d3_I20230331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfMTU5NDE_97198d3d-5fdf-4063-9c7a-e7ddd8204303">two</ix:nonFraction> generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to the market before January 2026 or later, depending on any applicable pediatric exclusivity, unless the Company receives an adverse court decision.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia, Janumet, Janumet XR</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> As previously disclosed, the FDA granted pediatric exclusivity with respect to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(sitagliptin), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(sitagliptin/metformin HCI), and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (sitagliptin and metformin HCl extended-release), which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA&#8217;s Orange Book. Adding this exclusivity to the term of the key patent protection extended exclusivity on these products to January 2023. However, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin that expires in May 2027, including pediatric exclusivity (2027 salt/polymorph patent). In 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> following expiration of key patent protection, but prior to the expiration of the 2027 salt/polymorph patent, and a later granted patent owned by the Company covering the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> formulation where its term plus the pediatric exclusivity ends in 2029. The Company also filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel on Multidistrict Litigation entered an order transferring the Company&#8217;s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior to the beginning of the scheduled October 2021 trial in the U.S. District Court for the District of Delaware on invalidity issues, the Company settled with all defendants scheduled to participate in that trial. In the Company&#8217;s case against Mylan, a bench trial was held in December 2021 in the U.S. District Court for the Northern District of West Virginia, and the closing arguments were held in April 2022. In September 2022, the District Court for the Northern District of West Virginia issued a decision in the Company&#8217;s favor, upholding all asserted patent claims. Mylan (now Viatris) appealed to the U.S. Court of Appeals for the Federal Circuit. The parties have now settled the matter, and Mylan has agreed to voluntarily dismiss the appeal following entry of an amended final judgment by the district court.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, in 2019, Mylan filed a petition for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> review (IPR) at the U.S. Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2027 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial was held in February 2021 and a final decision was rendered in May 2021, holding that all of the challenged claims were not invalid. Mylan appealed the USPTO&#8217;s decision to the U.S. Court of Appeals for the Federal Circuit, and a hearing was held in August 2022. In September 2022, the U.S. Court of Appeals for the Federal Circuit ruled in the Company&#8217;s favor, upholding the USPTO&#8217;s decision. Mylan submitted a combined petition for panel rehearing and rehearing en banc, for which the Company was invited by the court to provide a response. On February 3, 2023, the court issued a per curiam decision denying both rehearing requests.</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In total, the Company has settled with <ix:nonFraction unitRef="company" contextRef="id8407355ea334e558a58d39cf813e848_D20230101-20230331" decimals="INF" name="us-gaap:LossContingencyClaimsSettledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfNTQ5NzU1ODUzOTg3_58fcfea1-9958-4bb9-8d6b-bc828abcfaed">25</ix:nonFraction> generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to the market in May 2026 or earlier under certain circumstances, and their generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to the market in July 2026 or earlier under certain circumstances.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus&#8217;s NDA seeking approval of its sitagliptin tablets. In December 2022, the parties reached settlement that included dismissal of the case without prejudice enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2023, the Company received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Zydus has filed a NDA seeking approval of sitagliptin/metformin HCl tablets and certifying that no valid or enforceable claim of any of the patents listed in FDA&#8217;s Orange Book for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will be infringed by the proposed Zydus product. In March 2023, the parties reached settlement enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a result of these favorable court rulings and settlement agreements related to the later expiring patent directed to the specific sitagliptin salt form of the products, the Company expects that </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will not lose market exclusivity in </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 20 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="id1ac567cfbb14c319494434cb0fe4474"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">the U.S. until May 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will not lose market exclusivity in the U.S. until July 2026</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, although another non-automatically substitutable form of sitagliptin is likely to be available prior to 2026</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Supplementary Protection Certificates (SPCs) for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expired between April 7 and 10, 2023, for the majority of European countries. Prior to expiration, generic companies sought revocation of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> SPCs in a number of European countries. In February 2022, a Finnish court referred certain questions to the Court of Justice of the European Union (CJEU) that could determine the validity of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SPCs in Europe, for which an oral hearing was held on March 8, 2023, and an Advocate General Opinion is expected on July 13, 2023. If the CJEU renders a decision that negatively impacts the validity of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> SPCs throughout Europe, generic companies that were prevented from launching products during the SPC period in certain European countries may have an action for damages. Those countries include Belgium, Czech Republic, Ireland, Finland, France, Slovakia and Switzerland. If the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SPCs are ultimately upheld, the Company has reserved its rights related to the pursuit of damages for those countries where a generic launched prior to expiry of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SPC.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company filed a complaint against The Johns Hopkins University (JHU) on November 29, 2022, in the District Court of Maryland. This action concerns patents emerging from a joint research collaboration between Merck and JHU regarding the use of pembrolizumab, which Merck sells under the trade name </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Merck and JHU partnered to design and conduct a clinical study administering </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to cancer patients having tumors that had the genetic biomarker known as microsatellite instability-high (MSI-H). After the conclusion of the study, JHU secured U.S. patents citing the joint research study. Merck alleges that JHU has breached the collaboration agreement by filing and obtaining these patents without informing or involving Merck and then licensing the patents to others. Merck therefore brought this action for breach of contract; declaratory judgment of noninfringement; and promissory estoppel. JHU answered the complaint on April 13, 2023, denying Merck&#8217;s claims, and counterclaiming for willful infringement of <ix:nonFraction unitRef="patent" contextRef="i270837c6ca8b41c49574b8b379172454_D20230413-20230413" decimals="0" name="us-gaap:LossContingencyPatentsAllegedlyInfringedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfNTQ5NzU1ODU0MDIz_db06a4e7-66fd-4e4a-afcb-a46d2bbdd18b">five</ix:nonFraction> issued U.S. patents, including a demand for damages.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In December 2022, AstraZeneca Pharmaceuticals LP received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Natco Pharma Limited (Natco) has filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2023, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Natco. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2025 or until an adverse court decision, if any, whichever may occur earlier.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company&#8217;s financial condition, results of operations or cash flows either individually or in the aggregate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Legal Defense Reserves</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company&#8217;s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of March&#160;31, 2023 and December&#160;31, 2022 of approximately $<ix:nonFraction unitRef="usd" contextRef="i5913ce6cd24f4f45a393b8a13ce74d4d_I20230331" decimals="-6" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfMjMyNjg_3cea9046-e2cc-4593-8c4b-44b32a39b73f">225</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ica1e472338aa4a5298e4b867322ded49_I20221231" decimals="-6" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfNTQ5NzU1ODU0MjMy_7de2f884-2dc4-4988-9930-4051c329a43b">230</ix:nonFraction> million, respectively, represents the Company&#8217;s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.</span></div></ix:continuation><div id="i3ccccf37677d43f88002f8d995e2fd3c_61"></div><div style="margin-top:15pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 21 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div style="margin-top:15pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RleHRyZWdpb246YjZhODViNTUxOGFlNDk3OWEzZTZlYWM5YmY3ZmNkMTlfMjA_a3624188-3689-4101-958b-3de4cf30928e" continuedAt="i80bb926a9500493e81dbc0907f32396e" escape="true">Equity</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:justify"><ix:continuation id="i80bb926a9500493e81dbc0907f32396e"><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RleHRyZWdpb246YjZhODViNTUxOGFlNDk3OWEzZTZlYWM5YmY3ZmNkMTlfMzA_69ef70d4-a187-4028-b94e-703e168d085e" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:29.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Par&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia75c3b66a14446a7b7855544f19742bf_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMy0xLTEtMS0xMzE2MTg_00e39d87-4530-4b70-af6d-4051e5b842b3">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia75c3b66a14446a7b7855544f19742bf_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMy0yLTEtMS0xMzE2MTg_4ddc6db0-4b61-43ec-b275-702ca36a6335">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice6bdceaee0c415785e978b1546e824f_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMy0zLTEtMS0xMzE2MTg_2bff4825-46c6-4871-8a42-dfdda7ef581f">44,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f9c7cab12f84742bc529ca888140834_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMy00LTEtMS0xMzE2MTg_7af0b20a-1f5d-4b8c-8931-e73c20ffc589">53,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c01235f9a47471bbfd246c179b8ec70_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMy01LTEtMS0xMzE2MTg_f5edb140-e0b3-4b62-b7f4-dbd1f5ffd6ef">4,429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa0666b9b0854af18214a4de1da949d6_I20211231" decimals="-6" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMy02LTEtMS0xMzE2MTg_193ab8bd-5208-430b-b226-2f784e403788">1,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa0666b9b0854af18214a4de1da949d6_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMy03LTEtMS0xMzE2MTg_49b4d697-57b2-4a04-b3b7-d90db55b09fc">57,109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i957a5e7283804544961eeffd229d90ef_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMy04LTEtMS0xMzE2MTg_efc21552-1da4-413f-9ca5-fa493bef71c8">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cb2241175c4c8c8fd5daf0a86385e3_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMy05LTEtMS0xMzE2MTg_479c921e-7b99-4e2a-b26e-3dd32b9624ae">38,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieba2932606cf4136b76cf64715d17f5c_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfNC00LTEtMS0xMzE2MTg_7ee6c7b2-ac48-495f-b230-f84f45694b37">4,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfNC05LTEtMS0xMzE2MTg_6829220b-b062-4f31-a045-b1a7c53f88e7">4,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifce529878ee94fbc97ff3cdc8e49ccb4_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfNS01LTEtMS0xMzE2MTg_0039b2f6-f0ee-43ca-9820-36979d9df1e7">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfNS05LTEtMS0xMzE2MTg_903c0510-1faa-445d-baf6-e24595d17b18">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfNi0wLTEtMS0xMzE2MTgvdGV4dHJlZ2lvbjo4NjIzMzlmYTg1Mjg0YjA5YjU1ZWQwMjNmNDMxYzljNl80NQ_c8eaff0d-d63b-42c3-8300-eea32f0c3040">0.69</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieba2932606cf4136b76cf64715d17f5c_D20220101-20220331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfNi00LTEtMS0xMzE2MTg_eef64ab9-ceac-4d12-a773-31a0349ced8a">1,754</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfNi05LTEtMS0xMzE2MTg_83146dbb-86de-4d39-a50e-febd3580a5ef">1,754</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i918170e5b2fc416bb5213a74ad72646f_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfOC0zLTEtMS0xMzE2MTg_6ec3c77d-efae-4b88-a41b-118c6d8adb57">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6faee1c09a204c63baa2f8635ef78da4_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfOC03LTEtMS0xMzE2MTg_bf3018f8-1928-4e6d-8489-c663bc3cd424">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfOC05LTEtMS0xMzE2MTg_434ef5ac-1204-4ce4-a6ac-e84e9e547ee6">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4725be788d3c4f1f966fba475c841405_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfOS04LTEtMS0xMzE2MTg_db25c73b-064f-4387-997b-18b202361271">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfOS05LTEtMS0xMzE2MTg_1c3da830-c2b5-42ab-b273-eb255e45a8df">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e2497db5f4b4eda93858dd1c188cfb5_I20220331" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTEtMS0xLTEtMTMxNjE4_64786792-553d-4c53-925d-d075e2799de7">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e2497db5f4b4eda93858dd1c188cfb5_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTEtMi0xLTEtMTMxNjE4_1cbf0e51-20e5-4105-9a31-09794fe159b7">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08889407a4ca4fa69735b8332945794b_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTEtMy0xLTEtMTMxNjE4_a79cd451-8411-4f1a-a131-bb354873202b">44,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc9c8d75d064da9855b8d3b37c02b10_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTEtNC0xLTEtMTMxNjE4_6f2b82bd-1d18-4c4f-af22-1e5116bb94ff">56,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42da78b36e31450dab3194041180b0ee_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTEtNS0xLTEtMTMxNjE4_557a9836-7ad8-46a3-935a-00932fd70e16">4,369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id895bb14f7154486a761071e11a287ca_I20220331" decimals="-6" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTEtNi0xLTEtMTMxNjE4_e8ef6fb9-4bfc-4800-b351-5e04b6d58a25">1,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id895bb14f7154486a761071e11a287ca_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTEtNy0xLTEtMTMxNjE4_9006f905-2967-4620-869f-6b10a7badd5f">57,063</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4350e7d8d13e45848709eed82cdba738_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTEtOC0xLTEtMTMxNjE4_1809f653-65d3-4a1e-b698-943e127d3e2c">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ff3b595ae954906bf225b8a7cc58b69_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTEtOS0xLTEtMTMxNjE4_271ac0f6-c83c-4eb0-8ff9-5f89970b1acd">40,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15d6c8aebc384e4b973cac8799704239_I20221231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTItMS0xLTEtMTMxNjE4_009c386e-688d-4ce3-830e-210049a2807c">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d6c8aebc384e4b973cac8799704239_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTItMi0xLTEtMTMxNjE4_f2bbb453-e234-4bac-8248-772151c439f5">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb5a854388ff4957836b5593bd4f37e4_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTItMy0xLTEtMTMxNjE4_8b67cc09-b6eb-4d1e-9398-0fc5705d094d">44,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7b73a7dc82c4055afd7242f0e94f662_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTItNC0xLTEtMTMxNjE4_4f2ccda2-ed8b-4189-856c-5e26cfd31fa0">61,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b21fb880d134a06abed66e7d998914f_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTItNS0xLTEtMTMxNjE4_35542f8a-cf77-4c65-a246-c6addc3425d4">4,768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i796d55aed90341e6a68727c28ffcab70_I20221231" decimals="-6" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTItNi0xLTEtMTMxNjE4_93597b8b-97b0-4928-a347-b7260c51e041">1,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i796d55aed90341e6a68727c28ffcab70_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTItNy0xLTEtMTMxNjE4_81a6fee2-ed67-4c4f-bee6-cb46c6262f1e">56,489</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bc10dff04eb494ba85791126e4db053_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTItOC0xLTEtMTMxNjE4_ca799a99-a538-4b54-af0e-7338ccfc3e3b">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTItOS0xLTEtMTMxNjE4_7cb7a964-11ac-4a10-872b-984fba4248b5">46,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87e04afadbc24d00bf0c906ad452972e_D20230101-20230331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTMtNC0xLTEtMTMxNjE4_77490c9b-2824-4712-b2dc-a5598ef4cec5">2,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTMtOS0xLTEtMTMxNjE4_6b1597ce-de1d-45ae-a2fb-dce203385551">2,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe63a010ec0a40ed91fe4b6b16e51a63_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTQtNS0xLTEtMTMxNjE4_211c4cd3-8f60-4393-bee7-5f1b5240aa14">115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTQtOS0xLTEtMTMxNjE4_158da7f7-bc51-4522-a2d2-ef6c9564860a">115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTUtMC0xLTEtMTMxNjE4L3RleHRyZWdpb246MDIwZjA5OGQxNDVlNDFlMzkyYjViM2VmNDY0MDQzZDZfNDU_93a1a064-af7d-43b4-b1e4-ba0cc5ecd5e2">0.73</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87e04afadbc24d00bf0c906ad452972e_D20230101-20230331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTUtNC0xLTEtMTMxNjE4_d097457b-ecdf-45ea-b8d7-fa6140ea494b">1,863</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTUtOS0xLTEtMTMxNjE4_aac68bce-43bc-4ea2-bc21-4d8637534e8a">1,863</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic41cc6c0be824cbeb1598b4ddbddb1ed_D20230101-20230331" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTYtNi0xLTEtMTM3ODE5_1b9678c8-10a3-47d3-be0b-b983b0909850">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic41cc6c0be824cbeb1598b4ddbddb1ed_D20230101-20230331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTYtNy0xLTEtMTM3ODE5_1654c72c-4652-4fd7-bce0-6eb4976632d9">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTYtOS0xLTEtMTM3ODE5_60570ec4-daf6-43d7-948f-b4696c83b26e">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied44c0afd9384c30953e94941daa0cb0_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTYtMy0xLTEtMTMxNjE4_bfb140c9-53be-488c-ae2b-be5a2f37f9c0">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic41cc6c0be824cbeb1598b4ddbddb1ed_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTYtNy0xLTEtMTMxNjE4_a6149862-b2f5-4ff8-a2cf-4b83052e1aff">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTYtOS0xLTEtMTMxNjE4_b1f25aab-cbf7-4b89-9e81-c5d02327e2c1">149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65afee1f42ae486f84514163f3843f68_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTctOC0xLTEtMTMxNjE4_548eff4e-54fc-4857-ac1c-28935f703c7b">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTctOS0xLTEtMTMxNjE4_9ca324f8-7231-43ee-ab3e-53121d69602f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1742aab8c35467db6f531e481322561_I20230331" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTktMS0xLTEtMTMxNjE4_5e8636c3-f860-4177-8d79-69d9e020965c">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1742aab8c35467db6f531e481322561_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTktMi0xLTEtMTMxNjE4_3a6cfe71-aa08-4117-b5b6-70c8c954676d">1,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b3b6bd9f9044238b1478ab578648204_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTktMy0xLTEtMTMxNjE4_835da5bc-b1ed-412c-99b8-6e363da3232f">44,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18372378d12a4968ac3f82433fa9ffdd_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTktNC0xLTEtMTMxNjE4_0cee5ce6-7fa5-4bf0-a945-bd94cbdda1b4">62,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60e7a6142fec4b32aa305b679a0d9a87_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTktNS0xLTEtMTMxNjE4_0f900243-0722-4d81-8828-c9462d27c4ba">4,883</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4437cb5ce2e4c6cb15d052910fc825b_I20230331" decimals="-6" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTktNi0xLTEtMTMxNjE4_96f2ad4c-fd9c-45b4-b596-106d27e47a1c">1,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4437cb5ce2e4c6cb15d052910fc825b_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTktNy0xLTEtMTMxNjE4_b397eb37-0a27-4cd2-84f8-9d320d35eebc">56,577</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aa514bfad3f4f6883b1d3d93683f530_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTktOC0xLTEtMTMxNjE4_d7db5414-8597-4614-b692-73f44d934a00">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTktOS0xLTEtMTMxNjE4_60259264-e5ec-44d1-aa27-82518ff19967">46,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:0.730%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_64"></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RleHRyZWdpb246YzRiMjQ5MmIzMjMxNGRhNmJhMzhkMTgyMTFmOTUwZDlfOQ_0f12f849-f5a4-4846-863e-6737f43a2e6f" continuedAt="i2252ca3ead0b4fa2a4febf86edf1aee5" escape="true">Pension and Other Postretirement Benefit Plans</ix:nonNumeric></span></div><ix:continuation id="i2252ca3ead0b4fa2a4febf86edf1aee5" continuedAt="ifd50c5804b224d7c822c41c5e8babaab"><ix:nonNumeric contextRef="id12f95a53e9f4822b4ac3324b1225c13_D20230101-20230331" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RleHRyZWdpb246YzRiMjQ5MmIzMjMxNGRhNmJhMzhkMTgyMTFmOTUwZDlfMjM3NA_27e92262-4dcb-446c-83d7-b3bf5dd3bc32" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost (credit) of such plans consisted of the following components:&#160;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.677%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ae890426d14159b7b476af5430efdb_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMy0xLTEtMS0xMzE2MTg_bc50d610-0f0e-4ec7-972a-239d01f1578b">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fc54055a2e1411986ddfe6f5fa717bb_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMy0zLTEtMS0xMzE2MTg_e925becf-d54a-4a3e-9f71-d06d95ef6b0b">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfb8b583363441eba27b2030dcb092df_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMy01LTEtMS0xMzE2MTg_bce15ca3-af33-4069-b8ae-cf90a91668a9">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9f187d5e3f441eacceb4c421ba47e0_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMy03LTEtMS0xMzE2MTg_360fe79a-ce15-4b0d-9ddf-a36b730563da">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ae890426d14159b7b476af5430efdb_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNC0xLTEtMS0xMzE2MTg_ce68275b-2586-4ad3-98a5-e060e1147a83">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fc54055a2e1411986ddfe6f5fa717bb_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNC0zLTEtMS0xMzE2MTg_eaefb7de-0edd-454b-a7c9-42dab90ee439">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfb8b583363441eba27b2030dcb092df_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNC01LTEtMS0xMzE2MTg_46f55eaa-ff9e-4c24-a5cf-ce02b3dd74f6">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9f187d5e3f441eacceb4c421ba47e0_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNC03LTEtMS0xMzE2MTg_85c474bc-135d-4e46-bc7f-220fdbc2acf1">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6ae890426d14159b7b476af5430efdb_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNS0xLTEtMS0xMzE2MTg_7f0a9699-e219-4ab9-8d41-929217a8c069">187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fc54055a2e1411986ddfe6f5fa717bb_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNS0zLTEtMS0xMzE2MTg_1bec951e-9ef8-4389-a54f-ac365441058e">128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfb8b583363441eba27b2030dcb092df_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNS01LTEtMS0xMzE2MTg_f178e151-3c0e-4b7f-8d49-44457f298800">196</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9f187d5e3f441eacceb4c421ba47e0_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNS03LTEtMS0xMzE2MTg_2d032457-09d4-402a-875f-8a2dd780f0d3">101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ae890426d14159b7b476af5430efdb_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNi0xLTEtMS0xMzE2MTg_0d92a81f-84cd-411d-a033-71d5121cb9b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fc54055a2e1411986ddfe6f5fa717bb_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNi0zLTEtMS0xMzE2MTg_0bdda1e1-1499-4eb3-b56d-8e4f9bf0fcd5">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfb8b583363441eba27b2030dcb092df_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNi01LTEtMS0xMzE2MTg_83365e9f-dfc1-407a-ac75-37d8c7011f50">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c9f187d5e3f441eacceb4c421ba47e0_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNi03LTEtMS0xMzE2MTg_50eec8d2-c0b7-479b-96ab-77ccc96224aa">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (gain) loss amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ae890426d14159b7b476af5430efdb_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNy0xLTEtMS0xMzE2MTg_9c541295-0226-4cb9-86e7-5c2193ac6913">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fc54055a2e1411986ddfe6f5fa717bb_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNy0zLTEtMS0xMzE2MTg_041f3f1f-9aae-4e00-99eb-5d47589d6706">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfb8b583363441eba27b2030dcb092df_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNy01LTEtMS0xMzE2MTg_40f055d0-feaa-482a-b292-414119447d2a">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9f187d5e3f441eacceb4c421ba47e0_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNy03LTEtMS0xMzE2MTg_291f4111-2046-45e1-afdf-a65cf991e4c6">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ae890426d14159b7b476af5430efdb_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfOS0xLTEtMS0xMzE2MTg_5a9d163e-2113-4feb-9c1a-6a70693bdade">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fc54055a2e1411986ddfe6f5fa717bb_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfOS0zLTEtMS0xMzE2MTg_88d0d1de-80d6-401d-a96c-8b24230aef7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfb8b583363441eba27b2030dcb092df_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfOS01LTEtMS0xMzE2MTg_3a61c696-8c48-4940-bc29-306a9f1e7d4f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9f187d5e3f441eacceb4c421ba47e0_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfOS03LTEtMS0xMzE2MTg_c4d51d50-96f0-4fdf-8267-35a0eb0f8227">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ae890426d14159b7b476af5430efdb_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMTAtMS0xLTEtMTMxNjE4_bb68c941-c06c-44a0-97b7-d1311bfb71be">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fc54055a2e1411986ddfe6f5fa717bb_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMTAtMy0xLTEtMTMxNjE4_5af1743a-1dbe-4e1c-b8a3-9895e6eb73e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfb8b583363441eba27b2030dcb092df_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMTAtNS0xLTEtMTMxNjE4_83756ca4-5ec6-4c1d-96fb-cf1d82aa3d9e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9f187d5e3f441eacceb4c421ba47e0_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMTAtNy0xLTEtMTMxNjE4_b6f9fee0-967e-4741-a199-e7b1f4da27ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ae890426d14159b7b476af5430efdb_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMTEtMS0xLTEtMTMxNjE4_d02a4bee-a295-4c96-9430-48656b02422e">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fc54055a2e1411986ddfe6f5fa717bb_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMTEtMy0xLTEtMTMxNjE4_9a6d5834-5eab-45f7-ae3a-343937984d65">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfb8b583363441eba27b2030dcb092df_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMTEtNS0xLTEtMTMxNjE4_89e75757-00de-4678-8b9a-6d5a91652ef4">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9f187d5e3f441eacceb4c421ba47e0_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMTEtNy0xLTEtMTMxNjE4_3579012d-8762-40f2-9a32-d6765d80f3d3">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i48e93ba87cab4afc961e66db38e74311_D20230101-20230331" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RleHRyZWdpb246YzRiMjQ5MmIzMjMxNGRhNmJhMzhkMTgyMTFmOTUwZDlfMjM3Ng_d22f16e8-c377-4bb7-9a6d-ffb833ba1a39" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components:&#160;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.943%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e93ba87cab4afc961e66db38e74311_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfMi0xLTEtMS0xMzE2MTg_29f68b7d-a0e6-4222-b8db-c03b4dbc62e4">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae10b4b780a435b8e0e8fa9ac83e826_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfMi0zLTEtMS0xMzE2MTg_73d10c4f-c0d9-43d0-85c2-b3bc9d15aa44">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48e93ba87cab4afc961e66db38e74311_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfMy0xLTEtMS0xMzE2MTg_674b1119-47ff-4351-8d19-21a0f55b9b85">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae10b4b780a435b8e0e8fa9ac83e826_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfMy0zLTEtMS0xMzE2MTg_1c0ff7b5-0ab1-4bd8-ad72-fd338c79a089">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48e93ba87cab4afc961e66db38e74311_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfNC0xLTEtMS0xMzE2MTg_d12fa7c3-e5c6-4a47-baa2-cb65d0132be4">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ae10b4b780a435b8e0e8fa9ac83e826_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfNC0zLTEtMS0xMzE2MTg_a2d31808-20ba-4d3c-a083-2566a4668cd7">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48e93ba87cab4afc961e66db38e74311_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfNS0xLTEtMS0xMzE2MTg_4b486b63-924c-4404-9650-39c984ee3c28">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ae10b4b780a435b8e0e8fa9ac83e826_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfNS0zLTEtMS0xMzE2MTg_1e432350-0b2c-47a3-afee-290511ee84c1">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net gain amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48e93ba87cab4afc961e66db38e74311_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfNi0xLTEtMS0xMzE2MTg_9b783ab4-019e-4537-8a64-ee3f17e999ea">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ae10b4b780a435b8e0e8fa9ac83e826_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfNi0zLTEtMS0xMzE2MTg_abb38f13-6628-4b0f-b3f6-c614699880fd">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48e93ba87cab4afc961e66db38e74311_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfOS0xLTEtMS0xMzE2MTg_afb053dd-c992-46c5-931f-3bd631f868db">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1ae10b4b780a435b8e0e8fa9ac83e826_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfOS0zLTEtMS0xMzE2MTg_e6da31f9-161f-4433-9748-f9b5db3a3923">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 22 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="ifd50c5804b224d7c822c41c5e8babaab"><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with restructuring actions (see Note&#160;5), termination charges were recorded on pension plans related to expanded eligibility for certain employees e</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">iting Merck. Also, in connection with these restructuring activities, curtailments were recorded on certain pension plans. In addition, lump sum payments to U.S. pension plan participants triggered a partial settlement resulting in a charge of $<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RleHRyZWdpb246YzRiMjQ5MmIzMjMxNGRhNmJhMzhkMTgyMTFmOTUwZDlfNTQ5NzU1ODIwNDQz_fec62dca-f4d5-4970-a61a-e106e8a55058">21</ix:nonFraction>&#160;million in the first quarter of 2023. This partial settlement triggered a remeasurement of some of the Company&#8217;s U.S. pension plans. The remeasurement, which was calculated using discount rates and asset values as of March&#160;31, 2023, resulted in a net increase of $<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RleHRyZWdpb246YzRiMjQ5MmIzMjMxNGRhNmJhMzhkMTgyMTFmOTUwZDlfMTU0OQ_8511f4af-951b-4e83-9a3c-07c449cb9124">44</ix:nonFraction>&#160;million to net pension liabilities and also resulted in a related adjustment to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of net periodic benefit cost (credit) other than the service cost component are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (see Note&#160;11), with the exception of certain amounts for termination benefits and curtailments which are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> if the event giving rise to the termination benefits or curtailment is related to restructuring actions.</span></div></ix:continuation><div id="i3ccccf37677d43f88002f8d995e2fd3c_67"></div><div style="margin-top:15pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RleHRyZWdpb246NjE1MGViYjZiZjJkNDdjYjhhOWEzMDkzYWYxOGI2MmFfNTQz_77d6322f-495b-49a8-abe5-645edbc9682b" continuedAt="i0555b90d0ab446f1af73828fd6d69ac1" escape="true">Other (Income) Expense, Net</ix:nonNumeric></span></div><ix:continuation id="i0555b90d0ab446f1af73828fd6d69ac1"><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RleHRyZWdpb246NjE1MGViYjZiZjJkNDdjYjhhOWEzMDkzYWYxOGI2MmFfNTMy_b340d380-d644-4b04-86a2-e75946091343" continuedAt="i2f4bb311276246489f1576f0021f51e1" escape="true"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:&#160;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfMi0xLTEtMS0xMzE2MTg_417fcad4-7b2b-41f6-8340-2c6e3a29e34e">112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfMi0zLTEtMS0xMzE2MTg_dd8f0efd-258b-47ee-a5e6-d7c668c3fbf5">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfMy0xLTEtMS0xMzE2MTg_0f7948f9-55b1-4158-93d3-4eb7ae5a810a">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfMy0zLTEtMS0xMzE2MTg_a440762d-f421-41a8-9e57-736957bf4a0f">243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfNC0xLTEtMS0xMzE2MTg_fe389e9d-6841-45c0-aaff-5db521a10efa">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfNC0zLTEtMS0xMzE2MTg_7d48caf1-fdc9-4581-80b8-ef7cf2932001">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Income) loss from investments in equity securities, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfNS0xLTEtMS0xMzE2MTg_a6e95474-b090-4279-82a8-4ca384d387cb">450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfNS0zLTEtMS0xMzE2MTg_f65933b2-02ac-461e-ae1c-d94d55becdf0">708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfNi0xLTEtMS0xMzE2MTg_19d0878c-2c26-4d71-bfdf-e13e344c1061">115</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfNi0zLTEtMS0xMzE2MTg_a83031d2-9eaa-4ded-bb72-ebfd78c4321b">121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="mrk:OtherNonoperatingIncomeExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfNy0xLTEtMS0xMzE2MTg_a270fae4-fab0-4298-a8c7-791e19be4d4b">463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="mrk:OtherNonoperatingIncomeExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfNy0zLTEtMS0xMzE2MTg_318ff1a0-1f99-4c29-84e6-f8d6582406c9">154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfOC0xLTEtMS0xMzE2MTg_a42a836e-c95a-4390-a982-934bb9261b30">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfOC0zLTEtMS0xMzE2MTg_40411eb7-290c-4a99-a4ed-b3c1efe6db04">708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"><ix:continuation id="i2f4bb311276246489f1576f0021f51e1" continuedAt="i8c7d1597efe84e9c971ff53e030a5a04">(1)&#160;&#160;&#160;&#160;</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i8c7d1597efe84e9c971ff53e030a5a04">Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag.</ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other, net (as reflected in the table above) in the first quarter of 2023 includes a $<ix:nonFraction unitRef="usd" contextRef="i07e39fac74fc4d08a501e1e14a991816_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RleHRyZWdpb246NjE1MGViYjZiZjJkNDdjYjhhOWEzMDkzYWYxOGI2MmFfNTQ5NzU1ODE1MzA2_80c4d5be-3421-4a0a-b221-69ca44c1f0e1">572.5</ix:nonFraction>&#160;million charge related to settlements with certain plaintiffs in the Zetia antitrust litigation (see Note&#160;8).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest paid for the three months ended March&#160;31, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RleHRyZWdpb246NjE1MGViYjZiZjJkNDdjYjhhOWEzMDkzYWYxOGI2MmFfNTA5_3f9fe702-c913-446d-aac7-906079c5f2a9">208</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RleHRyZWdpb246NjE1MGViYjZiZjJkNDdjYjhhOWEzMDkzYWYxOGI2MmFfNTE2_073f6b7d-7d2b-4bad-9e07-a8cd40c69667">211</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="i3ccccf37677d43f88002f8d995e2fd3c_70"></div><div style="margin-top:15pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183MC9mcmFnOmZjYjk5MjQxZTI4YjQ4MzViYTY0Y2FmNmVjZjUyNmQ1L3RleHRyZWdpb246ZmNiOTkyNDFlMjhiNDgzNWJhNjRjYWY2ZWNmNTI2ZDVfMTcyNA_b561dd59-fd06-4f46-abf2-b8bae80c0c1e" continuedAt="i5f9a6462f59e4d29a559e26f10fff701" escape="true">Taxes on Income</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i5f9a6462f59e4d29a559e26f10fff701">The effective income tax rates were <ix:nonFraction unitRef="number" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183MC9mcmFnOmZjYjk5MjQxZTI4YjQ4MzViYTY0Y2FmNmVjZjUyNmQ1L3RleHRyZWdpb246ZmNiOTkyNDFlMjhiNDgzNWJhNjRjYWY2ZWNmNTI2ZDVfNzY_4f83916f-7825-4290-9b6e-3241daa35023">22.6</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183MC9mcmFnOmZjYjk5MjQxZTI4YjQ4MzViYTY0Y2FmNmVjZjUyNmQ1L3RleHRyZWdpb246ZmNiOTkyNDFlMjhiNDgzNWJhNjRjYWY2ZWNmNTI2ZDVfODM_8e518908-0a2f-4b5d-9662-4c93fb2d26fc">11.4</ix:nonFraction>% for the first quarter of 2023 and 2022, respectively. The effective income tax rate for the first quarter of 2023 reflects the unfavorable discrete impact of a charge for the acquisition of Imago for which <ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="0" name="mrk:TaxBenefitResultingFromAcquisitionCharge" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183MC9mcmFnOmZjYjk5MjQxZTI4YjQ4MzViYTY0Y2FmNmVjZjUyNmQ1L3RleHRyZWdpb246ZmNiOTkyNDFlMjhiNDgzNWJhNjRjYWY2ZWNmNTI2ZDVfMjc0ODc3OTA3NTc0OA_d609f97d-72fd-428b-a143-99ff04b22871">no</ix:nonFraction> tax benefit was recognized, as well as higher foreign taxes, the impact of the R&amp;D capitalization provision of the Tax Cuts and Jobs Act of 2017 on the Company&#8217;s U.S. global intangible low-taxed income inclusion, and net unrealized gains from investments in equity securities, which were taxed at the U.S. tax rate, partially offset by higher foreign tax credits. The effective income tax rate in the first quarter of 2022 includes the favorable impact of net unrealized losses from investments in equity securities, which were taxed at the U.S. tax rate.</ix:continuation> </span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_73"></div><div style="margin-top:15pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RleHRyZWdpb246NjUxNWU3ZDMyOTZjNGQ1YmI2Zjc5MDM4ZDA1MjMxMTJfNDQ5_15ab1976-79a2-4368-a526-5e8b16739d87" continuedAt="id7bdd4ddb51e4cbc8e99c42132b2607b" escape="true">Earnings Per Share</ix:nonNumeric></span></div><ix:continuation id="id7bdd4ddb51e4cbc8e99c42132b2607b" continuedAt="ied25165a21e34e2d9fbc0d9f93759d7d"><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RleHRyZWdpb246NjUxNWU3ZDMyOTZjNGQ1YmI2Zjc5MDM4ZDA1MjMxMTJfNDYx_78002e68-a337-4efc-967c-d79086e29177" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The calculations of earnings per share are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.236%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income Attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNC0xLTEtMS0xMzE2MTg_83d23b6a-af3a-441b-a01d-dc74e3c73fd3"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNC0xLTEtMS0xMzE2MTg_bf7181b2-d549-480f-8afb-653e35103a42">2,821</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNC0zLTEtMS0xMzE2MTg_648701dc-ed48-46bf-8e67-e2c62d4ed953"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNC0zLTEtMS0xMzE2MTg_7e7c14f8-226a-4f08-bd98-2e83b3a39731">4,310</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNS0xLTEtMS0xMzE2MTg_615ef519-aa4a-49c3-a94f-efebfc5aafce">2,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNS0zLTEtMS0xMzE2MTg_d076aaf5-53ab-4897-b20b-e76cf27118de">2,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNi0xLTEtMS0xMzE2MTg_40b45c6c-53d6-485e-a9c9-ac5d349900d8">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNi0zLTEtMS0xMzE2MTg_a5404a0a-54c8-4549-bf26-9631509c4344">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNy0xLTEtMS0xMzE2MTg_af551db3-0e9a-4d33-8b9f-c988c9ae2b7b">2,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNy0zLTEtMS0xMzE2MTg_7db26e1d-bd26-4f41-b587-f8ab48a0c996">2,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfMTEtMS0xLTEtMTMxNjE4_f16f05ec-d3f7-4a8d-895b-fba44d7e42bb">1.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfMTEtMy0xLTEtMTMxNjE4_2dfe0dfd-0e6a-455d-92ee-ca8926c301c4">1.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfMTUtMS0xLTEtMTMxNjE4_16f50926-d120-46fc-bc50-68cd6f7b308a">1.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfMTUtMy0xLTEtMTMxNjE4_cfab628f-6e32-4deb-8ae3-a2f9342604bc">1.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Issuable primarily under share-based compensation plans.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="ied25165a21e34e2d9fbc0d9f93759d7d">For the first quarter of 2023 and 2022, <ix:nonFraction unitRef="shares" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RleHRyZWdpb246NjUxNWU3ZDMyOTZjNGQ1YmI2Zjc5MDM4ZDA1MjMxMTJfMTYw_c557fab6-60e1-44aa-9ae4-80a542395262">1</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RleHRyZWdpb246NjUxNWU3ZDMyOTZjNGQ1YmI2Zjc5MDM4ZDA1MjMxMTJfMTY3_4ff01dad-53bb-492d-9c5e-5f0bf55ce9c4">7</ix:nonFraction> million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 23 -</span></div></div></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div style="margin-top:15pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RleHRyZWdpb246Njc5OWNmZTk5MmM4NDc1MWFmMDZhMTU3OGNjZjM4MDRfMzMz_b15db8b0-2371-4e6f-a81d-7feb1e9577cc" continuedAt="iaebf7ec259554eecabb3f99e0c60dfb4" escape="true">Other Comprehensive Income (Loss)</ix:nonNumeric></span></div><ix:continuation id="iaebf7ec259554eecabb3f99e0c60dfb4"><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RleHRyZWdpb246Njc5OWNmZTk5MmM4NDc1MWFmMDZhMTU3OGNjZjM4MDRfMzQ2_d99aa86d-93d7-40a8-b05d-693303caf62b" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in each component of other comprehensive income (loss) are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i041db7ac9be74d218c0c23a960fc9a27_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMi0xLTEtMS0xMzE2MTg_44810d6b-12bb-4ebb-8780-dffbe96bc17e">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33af4ad78921440a981af5aa4715c88a_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMi0zLTEtMS0xMzE2MTg_fde501ed-d121-4679-b37c-d87cf6ff2b15">2,743</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad527aecfb724bf3b4777b628fefa6b2_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMi01LTEtMS0xMzE2MTg_5602d1b7-f946-476a-8997-6eb898f303a7">1,830</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c01235f9a47471bbfd246c179b8ec70_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMi03LTEtMS0xMzE2MTg_86f111b7-a84a-4ec2-8fa0-8d4c7aecc3d7">4,429</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d1fa90756944324a7e1f45d9b688361_D20220101-20220331" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMy0xLTEtMS0xMzE2MTg_f2fc2a50-705d-4181-8e01-d40afc780aab">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c46eee324f4931a0808813b06bc0f2_D20220101-20220331" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMy0zLTEtMS0xMzE2MTg_3807828e-c921-43fb-a2e4-420df6bc9e02">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39397ad3a95445e39f9ab9b845a9867d_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMy01LTEtMS0xMzE2MTg_49165ab9-5dc3-491c-93b5-6c6dca697ead">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMy03LTEtMS0xMzE2MTg_c753905e-3607-400f-ab2b-98429325ca82">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d1fa90756944324a7e1f45d9b688361_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNC0xLTEtMS0xMzE2MTg_04ff338a-2b90-4ed6-bd79-ff2bdb702b7b">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74c46eee324f4931a0808813b06bc0f2_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNC0zLTEtMS0xMzE2MTg_25df2b21-d481-4186-9aba-138314bfc60e">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39397ad3a95445e39f9ab9b845a9867d_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNC01LTEtMS0xMzE2MTg_44893c5d-f0cd-4c9f-b3ae-7391902ee51e">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNC03LTEtMS0xMzE2MTg_57c55961-6700-4334-a0a0-ccc8a40d8554">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d1fa90756944324a7e1f45d9b688361_D20220101-20220331" decimals="-6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNS0xLTEtMS0xMzE2MTg_67a46a52-066d-4c51-a37c-449d8572b4a9">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74c46eee324f4931a0808813b06bc0f2_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNS0zLTEtMS0xMzE2MTg_20bb398a-30a0-4cc7-957b-ca1b82e0250f">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39397ad3a95445e39f9ab9b845a9867d_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNS01LTEtMS0xMzE2MTg_0385cb5f-45ba-48d6-a250-801c15473624">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNS03LTEtMS0xMzE2MTg_d0370e0b-025a-4978-a6cd-57946ac7a4ae">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d1fa90756944324a7e1f45d9b688361_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNi0xLTEtMS0xMzE2MTg_f1d504c7-965c-498c-ad7a-6b46731d82f7">68</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c46eee324f4931a0808813b06bc0f2_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNi0zLTEtMS0xMzE2MTg_66e937a9-6b49-46e9-b62a-f533e2db84a3">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39397ad3a95445e39f9ab9b845a9867d_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNi01LTEtMS0xMzE2MTg_ef33b7e4-9433-46b9-838b-e5ea08fa1518">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNi03LTEtMS0xMzE2MTg_cbba4b1b-94c1-4c62-8d93-af7c5579c4bd">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d1fa90756944324a7e1f45d9b688361_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNy0xLTEtMS0xMzE2MTg_c25c89a8-5c00-459e-b1ff-6f88ec6b5e90">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i74c46eee324f4931a0808813b06bc0f2_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNy0zLTEtMS0xMzE2MTg_a4f92724-44d0-4daf-8b05-4729e90d9fc7">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39397ad3a95445e39f9ab9b845a9867d_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNy01LTEtMS0xMzE2MTg_9c4c0598-222b-437f-8ea6-25de9ddb3994">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNy03LTEtMS0xMzE2MTg_33ec11d8-bc14-4b4c-bc6d-85e941a4568c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d1fa90756944324a7e1f45d9b688361_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfOC0xLTEtMS0xMzE2MTg_c3dfe168-cd5a-4f39-9c20-eb02a0955b31">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c46eee324f4931a0808813b06bc0f2_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfOC0zLTEtMS0xMzE2MTg_c44ae61e-5e89-4caf-bee2-ffbd9054338f">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39397ad3a95445e39f9ab9b845a9867d_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfOC01LTEtMS0xMzE2MTg_6c6779ea-a1ab-485a-aed7-a460e5b997a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfOC03LTEtMS0xMzE2MTg_51d07f75-ab80-4ccc-9d39-4c6e3b953679">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d1fa90756944324a7e1f45d9b688361_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfOS0xLTEtMS0xMzE2MTg_cc363569-8c98-4432-a380-783b8897dd6e">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74c46eee324f4931a0808813b06bc0f2_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfOS0zLTEtMS0xMzE2MTg_76bc7884-3d22-4bfd-86e4-8eea8b88704b">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39397ad3a95445e39f9ab9b845a9867d_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfOS01LTEtMS0xMzE2MTg_5c4d85cf-db10-4870-bb0a-baeac0608b62">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfOS03LTEtMS0xMzE2MTg_1333dd8e-1dd4-4fd0-aa63-aaee814d686f">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance March 31, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2319d946cd342759a8f984524b58ad8_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTAtMS0xLTEtMTMxNjE4_c2753a79-c7f8-4191-b5bf-b15be4baa965">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95a7d6e4f3b642ac849cb5b1af84aca1_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTAtMy0xLTEtMTMxNjE4_c706ce6c-c0f4-4619-8b4e-68a78f04c417">2,711</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8a93158890945a9aa15c60a05506723_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTAtNS0xLTEtMTMxNjE4_b9c63d63-f143-4dd5-bff7-18bb4a37200e">1,865</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42da78b36e31450dab3194041180b0ee_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTAtNy0xLTEtMTMxNjE4_54b20997-795c-4b88-8a83-b4e674de0736">4,369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2023, net of taxes</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31f76fe0b880480684d05d01c6f398ff_I20221231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTEtMS0xLTEtMTMxNjE4_0c887a02-21c7-4164-8bf5-2436f00cf930">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b83eed87b2d41c1a8c610f98765bba3_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTEtMy0xLTEtMTMxNjE4_8cc9cd45-d572-480f-9303-8093278de5d6">2,408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d63d8c8b08843008160820a9757c059_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTEtNS0xLTEtMTMxNjE4_abac9ac0-2b80-4356-955e-c4ff9861b4b1">2,433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b21fb880d134a06abed66e7d998914f_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTEtNy0xLTEtMTMxNjE4_65f6608a-8bb6-4134-ba6d-0fd93184f36a">4,768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d68872fd99d4719972b30864e232d1d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTItMS0xLTEtMTMxNjE4_dd84de2f-d242-43bb-bfc8-d3bfc2b1f317">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad583d8b44fc49feb98cc9caf016d5a4_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTItMy0xLTEtMTMxNjE4_ba64b2ae-e33b-4ac2-9008-af2eab88bf17">47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife1d684ce4c949b38894572598414983_D20230101-20230331" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTItNS0xLTEtMTMxNjE4_49703699-5a0b-4652-b159-d9582b6e1bd4">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTItNy0xLTEtMTMxNjE4_04560a5c-3dfc-4d30-a247-8f4b359633b2">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d68872fd99d4719972b30864e232d1d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTMtMS0xLTEtMTMxNjE4_50ed424b-af09-43d9-8c57-614acbe8fc3c">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad583d8b44fc49feb98cc9caf016d5a4_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTMtMy0xLTEtMTMxNjE4_e7ed1079-0111-47da-b167-d28477d37c03">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ife1d684ce4c949b38894572598414983_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTMtNS0xLTEtMTMxNjE4_d80d2519-6c46-40d3-aa2c-6a8694a40e6f">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTMtNy0xLTEtMTMxNjE4_46b07516-ed3d-4dab-8bb0-d8c42dff25d3">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d68872fd99d4719972b30864e232d1d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTQtMS0xLTEtMTMxNjE4_022d8ce9-b8e4-4661-8a14-9303534f5856">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad583d8b44fc49feb98cc9caf016d5a4_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTQtMy0xLTEtMTMxNjE4_bfbb089e-3f91-402d-b77f-5adb5e3ea779">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife1d684ce4c949b38894572598414983_D20230101-20230331" decimals="-6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTQtNS0xLTEtMTMxNjE4_1a5f7e54-b3e8-41ee-967d-d1c54eaf2691">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTQtNy0xLTEtMTMxNjE4_62892b5a-89a4-4b87-96f6-9a5f03c5d2ad">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d68872fd99d4719972b30864e232d1d_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTUtMS0xLTEtMTMxNjE4_293f7994-d602-466b-935c-f543c7e00401">102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad583d8b44fc49feb98cc9caf016d5a4_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTUtMy0xLTEtMTMxNjE4_95bc1f2f-6e9d-47ed-a883-b9253a1e702e">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife1d684ce4c949b38894572598414983_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTUtNS0xLTEtMTMxNjE4_74113e62-de86-43ee-9b17-91a562957a47">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTUtNy0xLTEtMTMxNjE4_cc32a334-3561-4a30-8ebb-aff6c9524b91">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d68872fd99d4719972b30864e232d1d_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTYtMS0xLTEtMTMxNjE4_86bbacad-7c71-4512-b74c-b4ba1c7ada8a">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad583d8b44fc49feb98cc9caf016d5a4_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTYtMy0xLTEtMTMxNjE4_592cef05-3b2d-4d8f-adb8-efd416df6083">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife1d684ce4c949b38894572598414983_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTYtNS0xLTEtMTMxNjE4_6575f2c5-b139-4798-a59e-f0e68418f78e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTYtNy0xLTEtMTMxNjE4_0f37f855-e7ed-48b0-a551-4e9c3a0dd067">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d68872fd99d4719972b30864e232d1d_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTctMS0xLTEtMTMxNjE4_c5281d00-1799-4705-8807-e57fe3d60973">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad583d8b44fc49feb98cc9caf016d5a4_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTctMy0xLTEtMTMxNjE4_c003d93a-807f-4383-a9fc-338e9c7f152a">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife1d684ce4c949b38894572598414983_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTctNS0xLTEtMTMxNjE4_44e31216-07b2-4f62-8efc-09d529966ff3">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTctNy0xLTEtMTMxNjE4_df0d3458-7957-4239-a78a-85082040b024">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d68872fd99d4719972b30864e232d1d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTgtMS0xLTEtMTMxNjE4_36bdebc4-d9a8-4f3a-bdfc-df10e562783b">133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad583d8b44fc49feb98cc9caf016d5a4_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTgtMy0xLTEtMTMxNjE4_a83f2f5e-7ff0-4639-86b7-f9a9bc1f22aa">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife1d684ce4c949b38894572598414983_D20230101-20230331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTgtNS0xLTEtMTMxNjE4_66b67526-37cc-452f-92c5-8ba4ee1fc1cc">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTgtNy0xLTEtMTMxNjE4_3c343a9e-abab-4fc7-8b65-6d2ffa3d911f">115</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance March 31, 2023, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7af996fcfb0942ebab3aa1e8cea2e1a4_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTktMS0xLTEtMTMxNjE4_775755c5-b1e3-42c5-987c-45e712d0bc7c">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e5c54f51e5440dd9db7d51479f49629_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTktMy0xLTEtMTMxNjE4_e7a84c46-8fc0-498f-84eb-0dd64cdde26a">2,458</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44331becfc824debbd8e96c96c590f56_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTktNS0xLTEtMTMxNjE4_5a930cdf-1510-45e2-bae6-314e19b2f150">2,365</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60e7a6142fec4b32aa305b679a0d9a87_I20230331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTktNy0xLTEtMTMxNjE4_58b4c4dd-a9fc-4a7b-b764-001bc601d98b">4,883</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Primarily relates to foreign currency cash flow hedges that were reclassified from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note&#160;10).</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.339%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_79"></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfNTQ3Mw_8877f9a1-419b-4a94-a407-cc796264c2c3" continuedAt="i79eca66fbd23468eb11ae08138ccd36f" escape="true">Segment Reporting</ix:nonNumeric></span></div><ix:continuation id="i79eca66fbd23468eb11ae08138ccd36f" continuedAt="i74bb392a12e842148b0779ee79ecd6be"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s operations are principally managed on a product basis and include <ix:nonFraction unitRef="segment" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfOTM_92d0a8f5-7ea6-4292-a1d9-a4cf9e489335">two</ix:nonFraction> operating segments, Pharmaceutical and Animal Health, both of which are reportable segments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S.&#160;Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 24 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i74bb392a12e842148b0779ee79ecd6be" continuedAt="if966040dffa94db3a20e72cb255d69b1"><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfNTUwNQ_05fdad2b-f964-4b65-a6aa-55463b2bfa68" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales of the Company&#8217;s products were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.631%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8df183ec48194fc4a2c6f8e8d986193f_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNS0xLTEtMS0xMzE2MTg_ef2b120d-82cf-425c-bf17-0d8b4328bf97">3,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf2b65d0efcd4588b8eaf74e00590ea7_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNS0zLTEtMS0xMzE2MTg_15002e29-bc96-473e-b310-574b29a87c4d">2,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie772b761081d4a3f88dd5b139a18cde5_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNS01LTEtMS0xMzE2MTg_91234f17-3414-4369-8991-7bb8006a9ad8">5,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23605aa21764c15b522d6ea781638b6_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNS03LTEtMS0xMzE2MTg_044f057b-9ed0-4726-8254-cc91383def5f">2,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b1fe39c7ec246f0a53097e0b00b0803_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNS05LTEtMS0xMzE2MTg_e64bb3b1-06cb-4484-aeb3-b34f27343f26">2,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7caeaf606112447a8aa0d87b20c8f163_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNS0xMS0xLTEtMTMxNjE4_2e409739-686b-48f2-8fab-a534ed940485">4,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if193ecf6603e436e9bc55f3e4f86a576_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNi0xLTEtMS0xMzE2MTg_94ed05c5-b448-447e-a261-e3ae0e338382">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b3b69956cc9411da3f54f428aeeeb42_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNi0zLTEtMS0xMzE2MTg_3890109d-7d86-4663-ab06-325348a981e7">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ef00ecad3374cfaa1259915898dc915_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNi01LTEtMS0xMzE2MTg_81acfbca-54ce-459b-a4a9-7a228af04df4">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0d6b8513dcd4021a200090641fe0bff_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNi03LTEtMS0xMzE2MTg_2d4fdf33-6355-4938-81b0-59a862f9decd">141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0666b87a008d48918f71fa4e40a3259d_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNi05LTEtMS0xMzE2MTg_6a4dfb95-4059-4e70-bac1-52736254fad7">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied5a517f75814ffdacb6613032349a19_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNi0xMS0xLTEtMTMxNjE4_ce2b4fb0-4458-4df5-b9f9-262c161c6911">266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Lenvima</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bdd7b02457a4826aeec0e25dbfa4df0_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNy0xLTEtMS0xMzE2MTg_790133c1-4058-4f19-b508-bc9bc557581f">153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i373f00d87cd7457d9b079c9415e0c4ad_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNy0zLTEtMS0xMzE2MTg_9f347d7a-9176-4027-9b86-4f7b621ad47a">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic416d710ef924adc9df8131effd1c200_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNy01LTEtMS0xMzE2MTg_5eecc9b5-6917-4325-bbef-8d586cf33296">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i421974800c0844798343dd8cfc3f3a20_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNy03LTEtMS0xMzE2MTg_0e5c0569-f11f-47c5-b2c1-bd7635281d6c">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f185cbe1da4f4e89a1e2093171e27b_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNy05LTEtMS0xMzE2MTg_2c60a0aa-f6b9-488c-8055-0108620030f1">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7706e3163ae4d58a5f8660cb640d5ba_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNy0xMS0xLTEtMTMxNjE4_aa3611ea-2e5f-44d0-94e4-2e9cb44b77f4">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Reblozyl</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf21fc9f03d342bbbd66be0123de6225_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOC0xLTEtMS0xMzE2MTg_ba66b2ec-a0bf-45fe-afb1-9dc52dcb8eb7">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i943ebcf31d20440ea90b753cb238fe02_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOC0zLTEtMS0xMzE2MTg_34b8ac87-3d93-491d-bc80-5e62ced6a1f9">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i245cacaf455e42329f9ae587d1a10cad_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOC01LTEtMS0xMzE2MTg_5ac0347c-c6aa-4452-b4ea-1238bcadc98f">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia13e94e1a90043bcaea2ffba6d27061a_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOC03LTEtMS0xMzE2MTg_d6fa372a-29db-4d93-95ec-373ad653729e">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f73d3370a5348dda651da8166f72bfc_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOC05LTEtMS0xMzE2MTg_254485a1-b420-4ddb-9070-730a8d7af23d">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dba74425a51433497fa7e5529627e25_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOC0xMS0xLTEtMTMxNjE4_d2de489b-6e5b-416d-916d-149a5274be6e">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Welireg</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie40a08ab45e2491eaad9788d31bc031d_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOS0xLTEtMS0xMzc0NDA_1adb609a-9bce-4383-888e-7e300a6c7e79">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98d5687c5bca4aa0ae8be180444502a5_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOS0zLTEtMS0xMzc0NDA_ec4c6f90-c108-4860-81c2-091efdc43173">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148665041c5d4969a1b7468fc0b3306f_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOS01LTEtMS0xMzc0NDA_93b9bbaa-586a-49b0-8a26-b18af9af0238">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i245f27c3d3884d16886e2a02a3bea2be_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOS03LTEtMS0xMzc0NDA_9eca8a7a-0ddb-4fe0-8ff9-0956abb9f30c">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i683c95eda6cc4e83a3f200cd8c1ae979_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOS05LTEtMS0xMzc0NDA_a4b6e895-f779-4b5d-bf36-1df737ecc25c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabc5de1d9ad9496abbed9093f2560c7e_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOS0xMS0xLTEtMTM3NDQw_6254b731-d2a1-4cdd-aeaa-054c8deeb219">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d15bac232384d3d9b567829ed8b4e4c_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTAtMS0xLTEtMTMxNjE4_f9bed54c-4a2f-4ae3-afa7-37e2080b714e">416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eb110c2888a401a99ce08584a59ae29_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTAtMy0xLTEtMTMxNjE4_6d44ab5a-ef76-43cf-96e2-f5cb3e63075b">1,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0622fda057824fe2acccd535fdedb1c4_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTAtNS0xLTEtMTMxNjE4_752bbfd3-712e-4866-a1ec-3c2c19d4af3a">1,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1317f96f8242416cb217168b296ac180_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTAtNy0xLTEtMTMxNjE4_d5569185-a478-4ce6-9edd-eebb5f7b0ed5">418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15590b4a502a4441b2031cb5e67c164c_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTAtOS0xLTEtMTMxNjE4_0176a57a-43a0-417f-82c1-6ef19d14c304">1,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0272e13e3911432484c3574c4d88dea4_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTAtMTEtMS0xLTEzMTYxOA_27e46f8e-652a-4297-b949-a2c714973d97">1,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">II</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">/Varivax</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1dd61290d2e4c28bdc142b28449b630_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTEtMS0xLTEtMTMxNjE4_df881402-b4dd-42bc-bdb9-ca896f30bb73">421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0676bda79d3444beb30669ea1761cefa_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTEtMy0xLTEtMTMxNjE4_771f5bf0-476b-4f0b-a74d-eb96033d23c6">107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92cf8249b51045fc9f74f556cbb77945_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTEtNS0xLTEtMTMxNjE4_7525428d-e657-4a74-9c6b-ce730da27cd1">528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd868d1665e843e8ba8e68820863660a_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTEtNy0xLTEtMTMxNjE4_340fe18e-f036-43be-a7cd-607a0c021571">371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85dada8cd49f441ca2211b4790538075_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTEtOS0xLTEtMTMxNjE4_9fb82f91-48f4-40c2-8966-74fb8360589b">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e7b43ab9aca461cbd07c3408576229d_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTEtMTEtMS0xLTEzMTYxOA_1e49a012-3af6-49c5-84d2-c2517239dff5">470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i502537b5bd3244cba8148fdcded195c1_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTItMS0xLTEtMTMxNjE4_9e2ced00-99ed-4dfc-8db1-e55a286f0405">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd1279562a9049789bcf67e36e1345e6_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTItMy0xLTEtMTMxNjE4_46cacb43-eb46-476d-ac6e-22f3a4566e80">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if12d006ccf6947e59b7e26e27405537e_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTItNS0xLTEtMTMxNjE4_392ae0ce-1b6c-487a-b804-9d84727fe8b5">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2caa7eb6734e47f694c35387f0b24c5e_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTItNy0xLTEtMTMxNjE4_9a44aaaa-f945-43cc-b00d-e80c2f15b178">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe80ade170b452d810ea857bfb36486_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTItOS0xLTEtMTMxNjE4_042a94b0-50cd-43f1-a354-450f88805877">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i168a16270ba04bf5bd0a98c57f6e7453_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTItMTEtMS0xLTEzMTYxOA_b7b7d7d7-8539-4fe0-ac52-89f511647ca5">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaxneuvance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f3c51ed3c142088d512d3cf86a4e85_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtMS0xLTEtMTQwNzkz_fc2a3e1a-08d8-49b5-afe3-55dc744da2ae">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5facb3a2afd54e37a08fcb30616f2d40_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtMy0xLTEtMTQwNzkz_8781e8e5-aa49-4852-a335-1835e13b37ed">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71c307b84c814567af562b778b4c1b53_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtNS0xLTEtMTQwNzkz_b62c2169-ae8e-45f4-829f-f7fbdccaeb49">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8a9542dc59a4777a668cd31211b6c7a_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtNy0xLTEtMTQwNzkz_fa20673d-0873-435f-a672-e41474cdc1c3">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa6e384e748d4e74833d7c8bd58e5051_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtOS0xLTEtMTQwNzkz_8d2ad58d-1417-45e4-9671-0cfc84a0d7ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a9cd1b2796b45cd823635c3a4ca1ec1_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtMTEtMS0xLTE0MDc5Mw_636c85f0-b166-4bf3-ab44-efdc270ecfa3">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc1f221331e847f78e9890ad89af8d80_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTMtMS0xLTEtMTMxNjE4_624b7c58-4c09-42ba-9447-131afd4d1d2c">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iced6646c844d4419a1591abce5241bc1_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTMtMy0xLTEtMTMxNjE4_4fbabf03-716b-4068-8111-4078d3877b7a">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d46a1bed5b64222a563d18e9091ab03_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTMtNS0xLTEtMTMxNjE4_32f352ba-63ba-44a6-96f7-a420dc4101d7">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee7d83d494044d17ac974c40323b8bfa_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTMtNy0xLTEtMTMxNjE4_b6a38190-85ca-435a-aa28-090efeb5cf60">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf3bf82a5181435e9e26d6dfe9ccb7a1_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTMtOS0xLTEtMTMxNjE4_5452738d-004d-4b75-bd3b-7b66f362051e">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83f5ca79492e42dba088722bf7ae9575_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTMtMTEtMS0xLTEzMTYxOA_c77eb623-e028-4786-bf10-3dde2d6851fc">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i556f1c52ae734ae6910cf6d6b9d26d16_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtMS0xLTEtMTMxNjE4_a39766a8-ac1e-4069-8f30-14db5ac60474">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70b1f6ac9824c5c9604f2e6cda7b721_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtMy0xLTEtMTMxNjE4_a07d1e82-aa60-406d-96a2-a927daf3aede">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13c7df0a730141689941ffc740882c67_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtNS0xLTEtMTMxNjE4_b2136ab7-b707-40b2-8c01-c9840620503f">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie19b5dd8e1da4e7ca8d5114cd25d465e_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtNy0xLTEtMTMxNjE4_725ba813-1e18-4fa5-bc5a-b79c6aa50921">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8845bbae207945c29f58ed0faa7c916d_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtOS0xLTEtMTMxNjE4_c7648a55-100c-43ae-85e7-44e046e71261">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ce84ce5bc4d4fd09f2f2edef567c63f_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtMTEtMS0xLTEzMTYxOA_2879c2b0-801a-41d2-98b6-ae9386bd854b">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3307d951777433f9183e38cea7b0eee_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTYtMS0xLTEtMTMxNjE4_69b43d5d-2874-4f77-b3df-8d67ccb08c83">276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie514f725ab204576a9d82e520a0747cc_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTYtMy0xLTEtMTMxNjE4_3dc80213-b2be-4a0f-8a14-060d68004459">210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3c351d397e549f08a5550b64c7bd217_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTYtNS0xLTEtMTMxNjE4_165198a2-3775-4392-a7fd-6eb73797b0cf">487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia85cef5855f74b3aa28b80d7e773c5e5_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTYtNy0xLTEtMTMxNjE4_4008ef98-0426-480a-9ffa-f5529d725532">195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d745b43d42740a2a636f93305a10162_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTYtOS0xLTEtMTMxNjE4_e370ffbd-5012-4819-8941-96cb8a65a5c7">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idffa9ebb25b04dc3ab346d0e2525d0f5_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTYtMTEtMS0xLTEzMTYxOA_ca912eb9-d99e-45fc-93fb-1b421f68dc9c">395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81842dbc49284aeb8c307b130fc51daf_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTctMS0xLTEtMTMxNjE4_cde0af28-b4bb-4b65-8ac5-e34587a7e814">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ae5e82b75cb428f864e7695e7ca9c03_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTctMy0xLTEtMTMxNjE4_34051f84-3cdc-403f-85ce-cb9aaa6d3f3f">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c5c36e08c35436d890e3cc5e49a26b5_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTctNS0xLTEtMTMxNjE4_2052c7b7-1767-4ac3-9bd0-83b9c61560e8">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63dd5e6b38074752a8397afebca2f449_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTctNy0xLTEtMTMxNjE4_c3c1de80-0c8b-4c8f-beb3-94c3a07d008b">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a6d9596af343fe9fbfaadc1d8d3d34_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTctOS0xLTEtMTMxNjE4_e67d7ccd-e0af-4148-a301-b0c15a434335">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cb822f6f0d24e56b21b1ba8cf3c5144_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTctMTEtMS0xLTEzMTYxOA_17c8f864-f3e0-430e-a0e3-fa97a9934af7">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1a2a61f6cc34473ab9936b7066ad51b_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtMS0xLTEtMTQwNzgw_e2db4b26-2581-47a5-8c63-4455c67ca5b6">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6b9400d903e47749af467e683ebf4b8_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtMy0xLTEtMTQwNzgw_82bedd10-76e6-4d7d-bf2a-cdc4ced4bb8d">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e28d66cb4d143f5b15da4ce16a7ff80_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtNS0xLTEtMTQwNzgw_460a5fb3-cfd5-4122-a8f0-3eaa52f20421">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83dc7aa4430a4932893b4dc1505dc632_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtNy0xLTEtMTQwNzgw_131401d6-6a0e-4418-ae95-b1f812dcfaa5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd11a9dea94b46ed9112ffcc77e533a5_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtOS0xLTEtMTQwNzgw_307d7b22-1799-402a-8b68-cf1e17fd113d">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa49ff54d4904fb783f4f755bf9c4739_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtMTEtMS0xLTE0MDc4MA_a68309f8-de33-4763-8109-cc42f11af76b">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Dificid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16385f11510546058467040c76602eda_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTgtMS0xLTEtMTMxNjE4_f6048126-f496-4593-8a4f-23f8a614720d">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97cacd287b274b7283ca51aef88bed26_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTgtMy0xLTEtMTMxNjE4_00af82de-c4cf-4e2a-9289-bafcf93b0132">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied566206459a4f21bda9d764fbd67597_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTgtNS0xLTEtMTMxNjE4_940cb2d9-3fe8-4cc7-9fb4-b581c42f6421">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c13b48a7232487dade4344d3bd6fef4_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTgtNy0xLTEtMTMxNjE4_43d7bb5c-962f-4e34-baf6-7d986541fbf4">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36f1883cf7ee41de9a38e097ff1eebdc_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTgtOS0xLTEtMTMxNjE4_2f141819-9699-4a22-99b6-892e9f2623aa">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1f696b0a7e848ffa8cd28bc5f62be74_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTgtMTEtMS0xLTEzMTYxOA_eb9b2e43-4811-4a67-a118-35d137ecfe7a">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33013fc5c1544b508c1f023d7e114799_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtMS0xLTEtMTMxNjE4_a655c2cd-de64-49f3-8391-fc00e85d4f43">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8189ab3ff1aa4b3fac07ab4d084ef309_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtMy0xLTEtMTMxNjE4_b91ed4a7-918b-4d10-9ea5-8c6c09eeec57">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0934dfe57f25400aabf7629e013bf2d9_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtNS0xLTEtMTMxNjE4_82d8444d-4060-4c3a-80ab-6a3dd1b0e618">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia482068e1c6841608dd3a6fc8530cff5_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtNy0xLTEtMTMxNjE4_4764bde1-b2f7-4ff4-816f-d5b4ddfcc733">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36f337569e6e4b90b6c49162eccc9245_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtOS0xLTEtMTMxNjE4_0b46e29e-a5cf-4454-b391-96b7caa9011a">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i370790356a1f4d0f910d0150c46829ba_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtMTEtMS0xLTEzMTYxOA_292325fc-1429-4db9-936f-1d5917f6ff71">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3ad548049e7437392c37716ac4a83fb_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjMtMS0xLTEtMTMxNjE4_e0c48a8f-2572-4686-ba40-7085bc440f90">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3025f3862fa34281bb1ddc0c23288056_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjMtMy0xLTEtMTMxNjE4_fc6e5ef3-d88c-4071-8f8e-81e20bd96439">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadcf254d19a94241a8a193b57dc553f7_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjMtNS0xLTEtMTMxNjE4_b5873064-3610-414f-a44e-06e93d18ac4f">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1be1a7ec6a2548d4861b2e925582acb3_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjMtNy0xLTEtMTMxNjE4_8adaf06a-1d02-44d4-a2f7-68457466bff4">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ece7f9fc39047fbaf47a27cce6b32ab_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjMtOS0xLTEtMTMxNjE4_7eb9b714-2767-4c28-9362-8fa73debc790">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c4d7a0899854fe795ccaec1a0161a84_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjMtMTEtMS0xLTEzMTYxOA_3709754b-3cbf-463d-ba03-8137f05831a3">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Adempas/Verquvo </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01970431619244f9a83fb73990c5cf14_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjUtMS0xLTEtMTMxNjE4_8362f82e-1c98-49c0-a1e4-13b640813631">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i958da05d9055499a88d25a539d74f6b9_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjUtMy0xLTEtMTMxNjE4_0e5c4fa6-ed5c-4b86-9379-14336022f583">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82a61880f039405d9d8e1832fd26a2d0_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjUtNS0xLTEtMTMxNjE4_7702f13b-b60f-41ec-8bbb-9b36eba7021e">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06d3dc01e4cd4880b999376bd99d6191_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjUtNy0xLTEtMTMxNjE4_7d306b7f-4787-4bf0-9467-a33f85c6ee55">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7414168e369644d7a58d58414fbde705_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjUtOS0xLTEtMTMxNjE4_ff53446a-30e3-4375-b4ec-cf72de9b587a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d7e8ff816e241f199e0011935427e7a_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjUtMTEtMS0xLTEzMTYxOA_b1b33d9e-cd4d-4c8a-9e05-96f96049c279">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad4d2d0ea13747a1b99b669cf7ce5f36_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjYtMS0xLTEtMTMxNjE4_009088eb-775e-4a93-83e0-7a0dba8d40a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01c8b28beea44e9998a1034bce51e508_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjYtMy0xLTEtMTMxNjE4_f93d0d7a-77a7-4d32-ac0d-1bd53ffb54b4">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc25085e4f3246fcbff1828176d06cb2_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjYtNS0xLTEtMTMxNjE4_b42464fc-f701-469a-a8e1-cf7dbccff949">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42b4b84e15304e879f573aebe7198888_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjYtNy0xLTEtMTMxNjE4_d44cc367-4687-4822-83ad-dfef01970e0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1abbf56d966442aea56ac371531ef7d4_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjYtOS0xLTEtMTMxNjE4_26ad746c-5c90-4465-81df-ba7138dab08f">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46444b1898a945a692f90d2a907898a2_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjYtMTEtMS0xLTEzMTYxOA_8a605ae1-6bdc-4d94-880c-ac5663de8009">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i745ba7617eb74e15ad18bf9b1bb5709e_D20230101-20230331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjgtMS0xLTEtMTMxNjE4_d2e02649-10c3-4966-94b2-8a5438a5b354">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d35a8760f2f49e89952d761b1399baf_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjgtMy0xLTEtMTMxNjE4_c3078931-c03e-4b6b-be9e-1fdb050615d1">394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i185e17abc9a24ea38c9ca4921fa60212_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjgtNS0xLTEtMTMxNjE4_c45526d4-afc9-4353-9af9-e2372ab0ab98">392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69279d4f3a814a78996b4c54c84aba07_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjgtNy0xLTEtMTMxNjE4_272525b6-f820-45e5-ab38-eae0f0127194">1,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if658e80c557842d4a20c5570140db4b6_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjgtOS0xLTEtMTMxNjE4_b9724a28-b5ad-461f-a863-3d5234b58db9">1,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0feca83d79141c7aa9f2bbb6f89ece9_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjgtMTEtMS0xLTEzMTYxOA_59e90e64-dd82-4bb7-9f1d-e938906902bf">3,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">HD</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9ab213a9fd74c98afcb44eb19dbc18a_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjktMS0xLTEtMTMxNjE4_ebbc4ea9-5fd8-485b-b3ff-8a2383782f29">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b3ad2cd408f4af38f724dabed4a97ef_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjktMy0xLTEtMTMxNjE4_cd5ae235-c1eb-46c3-a30b-34c6eb8de73a">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d330794d9a24933add16f9c3e14c0e6_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjktNS0xLTEtMTMxNjE4_0434947b-2e95-4df9-a1a0-2d22279ae247">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90f3bbf8132048e7a806ef1c700bcb02_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjktNy0xLTEtMTMxNjE4_5c844838-6108-4091-ad9a-852e9fd0d85d">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c033c7782a84654914962664067c0b5_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjktOS0xLTEtMTMxNjE4_4d36f132-0cf7-4f4c-9c52-6ab9c1a3841c">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic44db3f3e64b400fbb66bf36b4d59948_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjktMTEtMS0xLTEzMTYxOA_df855e64-6908-494b-b24d-89bb704193df">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f47191ae984e44a0ea39f24de59ca8_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzEtMS0xLTEtMTMxNjE4_ed3dc208-fdef-436e-ab28-b29584635cab">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica88e8e09cf5471f8ec81237bf2424e8_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzEtMy0xLTEtMTMxNjE4_901d919a-c006-419f-981f-a9a04c94fc8a">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf3db16464a242348f5f5ec6b303e8e8_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzEtNS0xLTEtMTMxNjE4_f1b96916-cd2f-476b-b304-3f0431533b6c">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5dcef3812b24f21b01ed1f074b5e48e_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzEtNy0xLTEtMTMxNjE4_c58ebf9a-c33e-453d-bf47-b0d1a528cabc">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie078fe8aa4b049019f87a49fe7163a94_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzEtOS0xLTEtMTMxNjE4_6f5f230c-e941-434c-849c-f530228ecacb">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic81d4335a8564f6893a52c09eee896bb_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzEtMTEtMS0xLTEzMTYxOA_fcc29d89-cf9e-4f7d-a2a2-c686323c34bb">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f8338e607f4961b4e06e5ad59f06d1_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzMtMS0xLTEtMTMxNjE4_06586f62-37aa-4215-a57c-bc3b32fbf8db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i481c25e1dc4042e583fd9ae56af1ea83_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzMtMy0xLTEtMTMxNjE4_a43a37bf-cae2-4b71-a63a-064ec2f0ba6e">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ab42425f0e84d0fa9cc1faa24e50ad9_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzMtNS0xLTEtMTMxNjE4_d39446ea-dae2-4f8a-9c46-7c0895ffcb9f">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f1f69903f024330aa3cd5f89dfe4aef_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzMtNy0xLTEtMTMxNjE4_a44eb7cb-344e-47fd-bf4d-41a9d3faa265">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f18afff1f924a87aca15181db888f45_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzMtOS0xLTEtMTMxNjE4_71baa138-34ee-4828-9898-5e30552159cb">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f2b65669412421487fc5a293c2d0226_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzMtMTEtMS0xLTEzMTYxOA_21e54091-77a9-4e76-ac29-67c14dd4e092">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i252bf97a988d4ca089b4880ef38b9f6f_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzQtMS0xLTEtMTMxNjE4_2dce8da4-7855-4324-9b0b-ef2a881bf53a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ac3b496e9b7497bbd0a8568c2c05058_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzQtMy0xLTEtMTMxNjE4_b35356f6-7be8-4495-82ef-69c3b0e3f9db">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ba905ef97ef4ea2a2b74f044e828215_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzQtNS0xLTEtMTMxNjE4_323184cb-6ee3-4bb3-999b-22fb850bd3ba">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i341c1828f974489ca631fd2f6fd5de33_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzQtNy0xLTEtMTMxNjE4_2d64884c-59bc-4cde-a8fb-e6294649db9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91767bfb04eb4bad8b4c74cc699c4f11_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzQtOS0xLTEtMTMxNjE4_6df05aec-8419-4a1b-a946-7149a51584dc">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i078db72152b7433b892f65578b578811_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzQtMTEtMS0xLTEzMTYxOA_dec801b9-74bc-47a9-89c8-fb0995af45b0">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d3ed97dcb1048b9b00df266e47fef85_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzYtMS0xLTEtMTMxNjE4_42abdd8d-d8a7-46eb-878b-f611b122ae16">271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7f29b275f343aeb93a10d0bc96a43a_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzYtMy0xLTEtMTMxNjE4_efa28396-43f0-4f4e-a554-dd19047b69cb">280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c5a4e651d8048d0bb7be915788d3451_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzYtNS0xLTEtMTMxNjE4_7bfa03f7-8536-4454-9aa0-75d5b9978061">551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfe3cd40147f4e2bbdcc6daea5c4f648_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzYtNy0xLTEtMTMxNjE4_93f7770b-9c4f-4460-abda-cee60e110b9a">325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc375c5fb83442ce960061c4c1e7d3d2_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzYtOS0xLTEtMTMxNjE4_eda8d58e-a5b4-4bed-9fe5-a754b0e43797">454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1068453fd58a43ed853c52e49d369635_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzYtMTEtMS0xLTEzMTYxOA_85db9919-9c69-4015-9a49-43423005b538">779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a170523e4784bd68826594b94740470_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzctMS0xLTEtMTMxNjE4_9a8f0c4f-f5e9-4d59-8500-869cc42f442a">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd460b0376004e6c9a2f91d187784dc9_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzctMy0xLTEtMTMxNjE4_796f7198-0fe6-4f0c-9a95-6bf417495824">272</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5c0d77138754544a2110eafaf9ef1de_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzctNS0xLTEtMTMxNjE4_1c6001ef-90d8-404e-8e2f-529c0f165852">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie30c6b82c81544b2a213a66f88a666e6_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzctNy0xLTEtMTMxNjE4_fa47f488-9d24-47b5-91a1-916fdd657552">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i944297bc97294b85b64026a5234105db_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzctOS0xLTEtMTMxNjE4_39b78dcc-d7f3-4ffa-9641-18af1df42b3a">391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6714caf41ce2406282b4c22d36869265_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzctMTEtMS0xLTEzMTYxOA_06efb935-6747-493c-aed9-a854a591d8c0">454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib880b79c41404a7f9ccb683284f4a657_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzgtMS0xLTEtMTMxNjE4_c90feffd-32e6-4616-b76a-a71541b516ed">172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7242924d01844781882444c559d8edd7_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzgtMy0xLTEtMTMxNjE4_b54c44ca-13db-41b8-b587-e4d6cd1205e3">414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b5149a7a9724ba099430ae94f3eb7f9_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzgtNS0xLTEtMTMxNjE4_243f0539-7b6a-4534-b610-52a29988e70d">584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f44546bfba04d3182b566c995d1d6a5_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzgtNy0xLTEtMTMxNjE4_4b5acf86-2bdf-4361-ab00-713955542104">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea28f75c29f9495d97b2490ad495e473_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzgtOS0xLTEtMTMxNjE4_98e25f04-1ba2-4e87-bb96-468b98dda3f2">443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c30e990884c453a8e86bf31356441ab_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzgtMTEtMS0xLTEzMTYxOA_5eecc931-c9fe-4033-a930-f31aabe63709">602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1de53f2d14549978ff86137b26acfdf_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzktMS0xLTEtMTMxNjE4_464bca47-180b-4995-ae73-5430c55e334a">6,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea0edbdebc194dbda6f583be24a5f5be_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzktMy0xLTEtMTMxNjE4_a1642759-028f-4ab1-b5e0-b83e9a525c7a">6,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff180f6730404c2fb6244e53cad88916_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzktNS0xLTEtMTMxNjE4_49ed9b4e-a36f-44ed-8ada-c3f29974cc8f">12,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc67e8a229ad434b9d2759887e18dcff_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzktNy0xLTEtMTMxNjE4_50228069-c141-4870-8dea-ec78d994cde3">6,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ecc10254bda49bf803e6b76575554b2_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzktOS0xLTEtMTMxNjE4_e9848f28-e5a8-4f0a-9bce-565597bed367">7,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia58fab4c69fb453394fb53a0a9cb3d93_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzktMTEtMS0xLTEzMTYxOA_819143ad-b68a-4e33-833a-826bc508a5ca">14,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08f54d2fb7c74345a43dd8eb5652ccb9_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDEtMS0xLTEtMTMxNjE4_43d124bd-db25-4181-8e18-8bf953c34b32">174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia99f107296c340309c3405bc2810419c_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDEtMy0xLTEtMTMxNjE4_2dd1f72f-3611-4256-ae55-0cbb477ce99f">676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied991033c3cc4ae8b1774bcbdfbc6a61_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDEtNS0xLTEtMTMxNjE4_c3ca8c54-26b5-4b9e-9105-4bd209bcb0a3">849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48ac0207dbb24fba961de45411f8f863_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDEtNy0xLTEtMTMxNjE4_43d77804-b7e3-4a3e-8501-a4a3248a094b">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d344caa1af4fadaeddfdde40462eb2_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDEtOS0xLTEtMTMxNjE4_45770cb1-fe8f-4ddd-926e-ac9acf8b58b9">661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c73bc1480c5460787fa096cbca3e186_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDEtMTEtMS0xLTEzMTYxOA_18e494e8-8760-40ef-a709-0ec4834fb2b0">832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4136a4c6588c473b8dbc29bd43446a8c_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDItMS0xLTEtMTMxNjE4_8f160c29-8390-4d1f-8c10-48edc7fe4fc0">308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if77a7432ec784877b792884b4331e9ee_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDItMy0xLTEtMTMxNjE4_9551723d-4994-42b3-b696-31c42fe8280e">334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id486cc4b73964a048598ee4145a36f51_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDItNS0xLTEtMTMxNjE4_2f231c72-adca-4969-9d92-dc2512e75e9d">642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i260d3e7cbd5a4346b6de45c5013de1eb_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDItNy0xLTEtMTMxNjE4_9d295a3c-76b9-4c1c-b1d0-f4f41aca9362">302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2913a3930e88428aacc1ff729877e753_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDItOS0xLTEtMTMxNjE4_103c718c-a7ed-48ff-bb15-8a1c71265ddf">348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if553fafbad26405cad25ce4550638d3f_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDItMTEtMS0xLTEzMTYxOA_22fcbfa2-f551-423a-a4f1-505f6939cc41">650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i660405fd34d447fbac3495f01c37c868_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDMtMS0xLTEtMTMxNjE4_c9a2c592-3dd8-4252-a381-4877e061c9b3">482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic90971f816384ed793878fbed1daf9b9_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDMtMy0xLTEtMTMxNjE4_63bee262-7be2-4492-8ebb-928b3fc2a1e4">1,010</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i904e8e179a1a49698833ce1b0110d5b4_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDMtNS0xLTEtMTMxNjE4_787cdef4-0937-4cd8-9959-d62cbc8ece21">1,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a26625eb0434b3aa7c78f6443da31d6_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDMtNy0xLTEtMTMxNjE4_92ccec34-9d1f-4be5-9427-06903dd8c13a">473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7dcf8dd27b941e6a6224761d29aa39d_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDMtOS0xLTEtMTMxNjE4_b889ca21-8e1f-4102-9a6f-42eb9b83d401">1,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83fa1e7afed046c4a90965eb45e55ef4_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDMtMTEtMS0xLTEzMTYxOA_2ef2246b-6c21-471d-a5d9-5058c75f6b4a">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i296f4d5ae9ac48818a1c814d83edd6c5_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDQtMS0xLTEtMTMxNjE4_5feb8fa3-515c-44b8-a057-7beb9b1aa868">6,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i541f7bde3cb144d6a1a06f324c128077_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDQtMy0xLTEtMTMxNjE4_84ac04c5-039c-4583-aa02-a6b0077cd1c5">7,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8c4caa074434a8c891a4dbc9477a1df_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDQtNS0xLTEtMTMxNjE4_ae37c227-14ed-4741-a155-a31b659ec67c">14,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2171622cc8164fae9f90806cca105ee4_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDQtNy0xLTEtMTMxNjE4_d672ec05-7276-450b-9914-34d058f42b75">7,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0201d118d8574b6db54cf6f7f5bb5c3e_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDQtOS0xLTEtMTMxNjE4_a63e5363-8419-459c-a2fb-39864fd958ca">8,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc177dc034fa4f9ca0cad6e36eb33f5d_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDQtMTEtMS0xLTEzMTYxOA_ec4af8fa-e539-4a8e-abe3-fb15cb243fb9">15,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfa83b7726804a0da22e28fcde9c5ed2_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDUtMS0xLTEtMTMxNjE4_64b6e335-bef7-4f7a-bd55-506876f02edd">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70a11b67918c44d3bfc01126c08b9fc2_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDUtMy0xLTEtMTMxNjE4_9deb4a1a-ad98-43e0-96c3-604cafb07109">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf8c3545f0134eebae2941403b2e022b_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDUtNS0xLTEtMTMxNjE4_f1712555-79c6-4dc2-b6f3-1aa090f88bc1">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f24746bebef41f9a462c02b830d6110_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDUtNy0xLTEtMTMxNjE4_a3b98f10-18b0-43e1-878f-f51f7cc352c3">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i307318101eaf48d785d4b776c386341a_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDUtOS0xLTEtMTMxNjE4_d2c21f26-4598-4b74-a022-6a0acaae81cc">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69fe081e83e44b89e1642cb41b84015_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDUtMTEtMS0xLTEzMTYxOA_ecfa1695-f3e6-4910-bb2a-a7b31d8b1404">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb136461a4e8aa85239cb391d845b_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDYtMS0xLTEtMTMxNjE4_32d6a6fa-9829-49dc-ae00-7544dae524f8">6,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a97503f4be84d46bdeff57349e01c23_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDYtMy0xLTEtMTMxNjE4_0ebaf935-cd67-4312-afd6-c22068f8f875">7,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDYtNS0xLTEtMTMxNjE4_caa70205-c25a-4785-b056-9ed26b521571">14,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i809f9ceab45b4cc88ceaa644a4ed41d8_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDYtNy0xLTEtMTMxNjE4_a3d3fc3f-e336-4c7e-8ce8-58f6034c877c">7,339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic58118074eba4189a105e403b1233b58_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDYtOS0xLTEtMTMxNjE4_b31c0435-9612-4186-a2cf-2f2b4cd99a36">8,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDYtMTEtMS0xLTEzMTYxOA_f82df2d4-7ac0-4665-899e-343f53d34937">15,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Lynparza and Lenvima represents Merck&#8217;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note&#160;3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Reblozyl represents royalties and, for 2022, also includes the receipt of a regulatory approval milestone payment (see Note&#160;3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Adempas/Verquvo represents Merck&#8217;s share of profits from sales in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note&#160;3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(5)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased sales by $<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="mrk:IncreaseDecreaseInHedgeRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfNTQ5NzU1ODIwNzc5_627192b8-5092-4f99-b82d-e675cc6c2a03">99</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="mrk:IncreaseDecreaseInHedgeRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfNTQ5NzU1ODIwNzg3_6e7eca59-4393-451f-9bff-d822ae6b6c49">69</ix:nonFraction>&#160;million for the three months ended March&#160;31, 2023 and 2022, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the three months ended March&#160;31, 2023 and 2022 also includes $<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfMjgxMA_c41639be-76e7-4717-b6ce-90797ecc2923">51</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfMjgxNw_06d0af1b-4675-4859-ba6e-576293ec3c38">114</ix:nonFraction>&#160;million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 25 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="if966040dffa94db3a20e72cb255d69b1"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by $<ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-8" name="mrk:SalesDiscounts" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfMzQ2MQ_1b0585f9-763e-42aa-80ad-e4740e0504b5">3.1</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-8" name="mrk:SalesDiscounts" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfMzQ2OA_a8953536-8d80-4270-8c7f-08a18bbbcaef">2.9</ix:nonFraction> billion for the three months ended March&#160;31, 2023 and 2022, respectively. </span></div><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfNTQ4NA_024fa4e0-421d-4f84-b58b-b8dd4c7c6dc7" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.674%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9cb136461a4e8aa85239cb391d845b_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfMi0xLTEtMS0xMzE2MTg_8acfbe8a-4750-4cde-a751-509b9b1eb504">6,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i809f9ceab45b4cc88ceaa644a4ed41d8_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfMi0zLTEtMS0xMzE2MTg_db062b2a-335b-4968-b37a-b2150da16643">7,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i679d69340bf54bb4a090a15b7ce9076e_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfMy0xLTEtMS0xMzE2MTg_420ef679-9547-4710-9c21-f01436be7491">3,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4067fe86262c405cb2919284c7e1f31c_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfMy0zLTEtMS0xMzE2MTg_75c92b69-79d2-499a-a8ac-856ae32e665b">4,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib86ae90471ee4ab18226e2683b749444_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfNC0xLTEtMS0xMzE2MTg_f7f0799b-6755-4818-b812-430b4d78156c">1,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6b67a7073245c79ad8b17846729383_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfNC0zLTEtMS0xMzE2MTg_0678dfe1-7865-4389-bbb4-a3509289d339">1,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1279d9656246229165b6071a908fe4_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfNS0xLTEtMS0xNDQ0OTM_bd13176d-2d50-423b-a924-c122f38f11db">846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1eaefd10a6d4f75bc5b01e6fd6e7612_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfNS0zLTEtMS0xNDQ0OTM_419bff35-b60d-426b-967f-6d40bf428195">930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice769ebe11cd4873b0e7fae638d4de55_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfNS0xLTEtMS0xMzE2MTg_af0989cb-f3b3-4a2b-b90e-596cae6763e3">758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77d9b85158ec4e37be193731477b820f_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfNS0zLTEtMS0xMzE2MTg_212e8a97-0d62-4365-a0c5-008ea6205e0f">989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83848e68f3b04891aad523922cca52c7_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfNy0xLTEtMS0xMzE2MTg_16895df7-1630-48a7-bbb7-6051b41df14b">661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9bae06748084a678545ae2a472fc025_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfNy0zLTEtMS0xMzE2MTg_69feecdc-cfde-4be8-8467-f14c6d88b417">607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49396c3fa3284569b4be0611825c2214_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfOC0xLTEtMS0xMzE2MTg_0c43bbc3-ad75-4e76-a4b1-d88a82af73e2">545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i492a23d281624d04895b84c347c42464_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfOC0zLTEtMS0xMzE2MTg_14d13378-92e4-4e44-b0e2-abf3ba81de9b">534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfOS0xLTEtMS0xMzE2MTg_9a32c585-90c8-4774-8e80-2891c0f92fe4">14,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfOS0zLTEtMS0xMzE2MTg_58dcbd93-aa7c-442f-8864-d21733a8306c">15,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfNTQ3Nw_271793ba-f9b9-491b-bb6c-038502f74f6f" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income Before Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.528%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff180f6730404c2fb6244e53cad88916_D20230101-20230331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMy0xLTEtMS0xMzE2MTg_db560a57-eb51-4c7c-8620-c1e229fc8122">9,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia58fab4c69fb453394fb53a0a9cb3d93_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMy0zLTEtMS0xMzE2MTg_4563d745-d4b6-4773-914b-99b8875bb0a7">9,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i904e8e179a1a49698833ce1b0110d5b4_D20230101-20230331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfNC0xLTEtMS0xMzE2MTg_25406fb4-7cb7-42f5-87dd-0de77af4d93c">566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83fa1e7afed046c4a90965eb45e55ef4_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfNC0zLTEtMS0xMzE2MTg_7aa88ea1-e238-4033-b889-1b0ab25b8897">585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8c4caa074434a8c891a4dbc9477a1df_D20230101-20230331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfNS0xLTEtMS0xMzE2MTg_2128dfa3-e31a-46e6-bd91-7748d93123f5">9,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc177dc034fa4f9ca0cad6e36eb33f5d_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfNS0zLTEtMS0xMzE2MTg_93d39df7-ee23-45bc-a1b7-dc2f71ca2e32">10,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf8c3545f0134eebae2941403b2e022b_D20230101-20230331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfNi0xLTEtMS0xMzE2MTg_fd5b5857-916f-4978-b7c1-626225946bfa">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69fe081e83e44b89e1642cb41b84015_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfNi0zLTEtMS0xMzE2MTg_7a6bf9c1-77d4-4df5-b32e-3bbd30d79cf7">194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i158cbb622490428d9efea6420c58fc6b_D20230101-20230331" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfOC0xLTEtMS0xMzE2MTg_55627434-dec2-4436-a779-6573f08f0ec0">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bc970a022044625a53b9bc92456c9d4_D20220101-20220331" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfOC0zLTEtMS0xMzE2MTg_eb0d237c-8981-4b04-8370-95c4ed45f849">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i158cbb622490428d9efea6420c58fc6b_D20230101-20230331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfOS0xLTEtMS0xMzE2MTg_f99e5cd7-ab3b-4ddb-a1f4-f42f80028599">242</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bc970a022044625a53b9bc92456c9d4_D20220101-20220331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfOS0zLTEtMS0xMzE2MTg_cfe94af6-c88b-4446-956c-258a0eb24f5d">243</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i158cbb622490428d9efea6420c58fc6b_D20230101-20230331" decimals="-6" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTAtMS0xLTEtMTMxNjE4_c1e92fd2-fbe5-43cd-864a-430d251cdee1">543</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bc970a022044625a53b9bc92456c9d4_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTAtMy0xLTEtMTMxNjE4_6a62b77f-d8fb-4884-b6d6-b562bcf8961e">699</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i158cbb622490428d9efea6420c58fc6b_D20230101-20230331" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTEtMS0xLTEtMTMxNjE4_33f222f5-9e60-4f0b-a385-a98bf01fc58e">398</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bc970a022044625a53b9bc92456c9d4_D20220101-20220331" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTEtMy0xLTEtMTMxNjE4_86811367-cac3-44d1-9e87-2b9614469684">378</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i158cbb622490428d9efea6420c58fc6b_D20230101-20230331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTItMS0xLTEtMTMxNjE4_da141c0a-bf31-44ee-be5f-8677d0402bea">4,147</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bc970a022044625a53b9bc92456c9d4_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTItMy0xLTEtMTMxNjE4_46891065-8529-4e23-b938-853fee2538b7">2,446</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i158cbb622490428d9efea6420c58fc6b_D20230101-20230331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTMtMS0xLTEtMTMxNjE4_d580a05c-b9a3-46b3-9f33-e43ee7694fce">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bc970a022044625a53b9bc92456c9d4_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTMtMy0xLTEtMTMxNjE4_67754d23-a072-4bb8-bbd7-f729d89f6637">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charge for Zetia antitrust litigation settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i158cbb622490428d9efea6420c58fc6b_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTQtMS0xLTEtMTQ0MTUw_4626e948-711d-48d0-8395-d4398490d415">573</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bc970a022044625a53b9bc92456c9d4_D20220101-20220331" decimals="-3" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTQtMy0xLTEtMTQ0MTUw_a90df1b5-4a33-4f81-87ee-b6711bbefeec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i158cbb622490428d9efea6420c58fc6b_D20230101-20230331" decimals="-6" name="mrk:SegmentReportingUnallocatedOtherExpensesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTQtMS0xLTEtMTMxNjE4_9e832d62-b9eb-46a8-9804-da7ad83ecf3b">362</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9bc970a022044625a53b9bc92456c9d4_D20220101-20220331" decimals="-6" name="mrk:SegmentReportingUnallocatedOtherExpensesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTQtMy0xLTEtMTMxNjE4_6bafc467-d4f6-4298-a10a-cc89692c24d4">1,607</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTUtMS0xLTEtMTMxNjE4_b3c84d4c-c521-4439-9afb-f564a0d7abd1">3,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTUtMy0xLTEtMTMxNjE4_7eedbb30-3c6e-4dc9-8db5-844f77725fd7">4,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company&#8217;s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and purchase accounting adjustments are not allocated to segments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing arrangements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 26 -</span></div></div></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-top:15pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_85"></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Business Developments</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Below is a summary of significant business development activity thus far in 2023. See Note&#160;2 to the condensed consolidated financial statements for additional information.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2023, Merck announced an agreement to acquire Prometheus Biosciences, Inc. (Prometheus), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. Prometheus&#8217; lead candidate, PRA023, is a humanized monoclonal antibody directed to tumor necrosis factor-like ligand 1A, a target associated with both intestinal inflammation and fibrosis. Prometheus is developing PRA023 for the treatment of immune-mediated diseases including ulcerative colitis, Crohn&#8217;s disease, and other autoimmune conditions. Under the terms of the acquisition agreement, Merck, through a subsidiary, will acquire all of the outstanding shares of Prometheus for $200 per share in cash for a total equity value of approximately $10.8 billion. The acquisition is subject to Prometheus shareholder approval. The closing of the proposed transaction will be subject to certain conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. The transaction is expected to close in the third quarter of 2023. If the proposed transaction closes, the Company anticipates it will be accounted for as an asset acquisition, which would result in a charge of approximately $10.3&#160;billion in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">expenses or approximately $4.00 per share. Additionally, Merck anticipates earnings per share (EPS) will be negatively affected by approximately $0.25 in the first 12 months following the closing of the transaction resulting from investments to advance the related pipeline assets, as well as the cost of financing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2023, Merck and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.) closed a license and collaboration agreement expanding their relationship in which Merck gained exclusive rights for the research, development, manufacture and commercialization of up to seven investigational preclinical antibody drug conjugates (ADCs) for the treatment of cancer. Kelun-Biotech retained the right to research, develop, manufacture and commercialize certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau. Merck made an upfront payment of $175 million, which was recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in the first quarter of 2023. In addition, Kelun-Biotech is eligible to receive future contingent milestone payments and tiered royalties on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested $100 million in Kelun-Biotech&#8217;s Series B preferred shares in January 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2023, Merck acquired Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, for $1.35 billion (including payments to settle share-based equity awards) and also incurred approximately $60&#160;million of transaction costs. Imago&#8217;s lead candidate bomedemstat, MK-3543 (formerly IMG-7289), is an investigational orally available lysine-specific demethylase 1 inhibitor currently being evaluated in multiple Phase 2 clinical trials for the treatment of essential thrombocythemia, myelofibrosis, and polycythemia vera, in addition to other indications. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $219 million, as well as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses of $1.2 billion in the first quarter of 2023 related to the transaction. There are no future contingent payments associated with the acquisition.</span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_88"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Pricing</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide. Changes to the U.S. health care system enacted in prior years as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company&#8217;s sales performance in the first three months of 2023 was negatively affected by other cost-reduction measures taken by governments and other third parties to lower health care costs. In 2022, the U.S. Congress passed the Inflation Reduction Act, which makes significant changes to how drugs are covered and paid for under the Medicare program, including the creation of financial penalties for drugs whose prices rise faster than the rate of inflation, redesign of the Medicare Part D program to require manufacturers to bear more of the liability for certain drug benefits, and government price-setting for certain Medicare Part D drugs (starting in 2026) and Medicare Part B drugs (starting in 2028). In the U.S., the Biden Administration and Congress continue to discuss legislation designed to control health care costs, including the cost of drugs. The Company anticipates all of these actions and additional actions in the future will negatively affect sales and profits.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Supply Chain</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a result of global macroeconomic conditions, the Company is experiencing some minor disruption and volatility in its global supply chain network. These disruptions could increase in the future and cause delays in shipments of raw materials and packaging, as well as related cost inflation.</span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_91"></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 27 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Sales</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,487&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,901&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide sales declined 9% to $14.5 billion in the first quarter of 2023 primarily due to lower sales in the virology franchise, largely attributable to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (molnupiravir), which had sales of $392 million in the first quarter of 2023 compared with $3.2 billion in the first quarter of 2022. Also contributing to the revenue decline in the first quarter of 2023 were lower sales in the diabetes franchise due to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (sitagliptin) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (sitagliptin and metformin HCl), as well as lower sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 23 (pneumococcal vaccine polyvalent). The sales decline in the first quarter of 2023 was partially offset by higher sales in the oncology franchise, largely driven by strong growth of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (pembrolizumab), higher sales in the vaccines franchise, primarily attributable to growth of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9 (Human Papillomavirus 9-valent Vaccine, Recombinant) and the ongoing launch of</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> Vaxneuvance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Pneumococcal 15-valent Conjugate Vaccine) for pediatric use, as well as higher sales of hospital acute care products, including </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (sugammadex) Injection. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See Note&#160;15 to the condensed consolidated financial statements for details on sales of the Company&#8217;s products. A discussion of performance for select products in the franchises follows.</span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_94"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pharmaceutical Segment</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Oncology</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,809&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance Revenue - Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance Revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lenvima</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance Revenue </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">- </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reblozyl </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Welireg</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">* &gt; 100%</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue represents Merck&#8217;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note&#160;3 to the condensed consolidated financial statements).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue represents royalties and, for 2022, also includes a payment received related to the achievement of a regulatory approval milestone (see Note&#160;3 to the consolidated financial statements).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is an anti-PD-1 (programmed death receptor-1) therapy that has been approved as monotherapy for the treatment of certain patients with cervical cancer, classical Hodgkin lymphoma, cutaneous squamous cell carcinoma, esophageal or gastroesophageal junction (GEJ) carcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), non-small-cell lung cancer (NSCLC), melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer (solid tumors) including MSI-H/dMMR colorectal cancer, MSI-H/dMMR advanced endometrial carcinoma, primary mediastinal large B-cell lymphoma (PMBCL), tumor mutational burden-high (TMB-H) cancer (solid tumors), and urothelial carcinoma including non-muscle invasive bladder cancer. Additionally, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is approved as monotherapy for the adjuvant treatment of certain patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence and for certain patients with completely resected stage IIB, IIC or III melanoma, and for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage 1B (T2a &#8805;4 cm), II, or IIIA NSCLC. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is also approved for certain patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. In addition, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is approved for the treatment of certain patients in combination with chemotherapy for metastatic squamous and nonsquamous NSCLC, in combination with chemotherapy with or without bevacizumab for advanced cervical cancer, in combination with chemotherapy for esophageal cancer, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for human epidermal growth factor 2 (HER2)-positive gastric or GEJ adenocarcinoma, in combination with chemotherapy for HNSCC, in combination with chemotherapy for locally recurrent unresectable or metastatic TNBC, in combination with axitinib for advanced RCC, in combination with Lenvima for certain patients with advanced endometrial carcinoma or advanced RCC, and in combination with enfortumab vedotin for certain patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy. The </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> clinical development program includes studies across a broad range of cancer types. See &#8220;Research and Development Update&#8221; below. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> grew 20% in the first quarter of 2023. Sales growth was primarily driven by higher demand as the Company continues to launch </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> with multiple new indications globally. Sales growth in the U.S. reflects increased </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 28 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">uptake across earlier-stage indications including in high-risk early stage TNBC, as well as certain types of RCC and melanoma, and higher demand across the multiple approved metastatic indications, in particular for the treatment of certain types of RCC, NSCLC, TNBC, and HNSCC cancers. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> sales growth in international markets reflects higher demand for the HNSCC and RCC metastatic indications, as well as uptake in earlier-stage indications, particularly in Europe and Latin America. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> received the following regulatory approvals thus far in 2023.</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Approval</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2023</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FDA approval as a single agent for adjuvant treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB (T2a &#8805;4 cm), II, or IIIA NSCLC, based on the KEYNOTE-091 trial.</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2023</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">FDA full approval for the treatment of adult and pediatric patients with unresectable or metastatic MSI-H or dMMR solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. The conversion from an accelerated to a full (regular) approval is based on results from the Phase 2 KEYNOTE-158, KEYNOTE-164 and KEYNOTE-051 trials.</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2023</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">FDA accelerated approval in combination with enfortumab vedotin-ejfv for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy, based on data from the KEYNOTE-869 trial dose escalation cohort, Cohort A and Cohort K, which was conducted in collaboration with Seagen and Astellas. </span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lynparza (olaparib) is an oral poly (ADP-ribose) polymerase (PARP) inhibitor being developed as part of a collaboration with AstraZeneca PLC (AstraZeneca) (see Note&#160;3 to the condensed consolidated financial statements). Lynparza is approved for the treatment of certain types of advanced or recurrent ovarian, early or metastatic breast, metastatic pancreatic and metastatic castration-resistant prostate cancers. Alliance revenue related to Lynparza increased 3% in the first quarter of 2023 largely driven by higher demand, particularly in Europe in certain patients with ovarian cancer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lenvima is an oral receptor tyrosine kinase inhibitor being developed as part of a collaboration with Eisai Co., Ltd. (Eisai) (see Note&#160;3 to the condensed consolidated financial statements). Lenvima is approved for the treatment of certain types of thyroid cancer, RCC, HCC, in combination with everolimus for certain patients with advanced RCC, and in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for certain patients with advanced endometrial carcinoma or advanced RCC. Alliance revenue related to Lenvima grew 2% in the first quarter of 2023 reflecting uptake in the advanced RCC indication in Europe, partially offset by lower volumes in China. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol Myers Squibb (see Note&#160;3 to the condensed consolidated financial statements). Reblozyl is approved for the treatment of anemia in certain rare blood disorders. Merck recorded alliance revenue related to this collaboration of $43 million in the first quarter of 2023 (consisting of royalties) compared with $52 million in the first quarter of 2022 (consisting of royalties of $32&#160;million and the receipt of a regulatory approval milestone payment of $20&#160;million).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Welireg </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(belzutifan), for the treatment of adult patients with certain von Hippel-Lindau disease-associated tumors, were $42 million in the first quarter of 2023 compared with $18 million in the first quarter of 2022 due to continued uptake in the U.S. following launch in 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Vaccines</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,972&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">ProQuad</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">M-M-R </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">II</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Varivax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Vaxneuvance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax 23</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">* &gt; 100%</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Combined worldwide sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9, vaccines to help prevent certain cancers and other diseases caused by certain types of human papillomavirus (HPV), grew 35% in the first quarter of 2023 driven primarily by strong demand outside of the U.S., particularly in China, which also benefited from the timing of shipments and increased supply. Sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9 in the U.S. were essentially flat in the first quarter of 2023 as lower sales due to public sector buying patterns were offset by higher pricing. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">ProQuad</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Measles, Mumps, Rubella and Varicella Virus Vaccine Live), a pediatric combination vaccine to help protect against measles, mumps, rubella and varicella, increased 17% in the first quarter of 2023 primarily reflecting higher demand and pricing in the U.S. and higher demand in Europe.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 29 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">M-M-R</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> II (Measles, Mumps and Rubella Virus Vaccine Live), a vaccine to help protect against measles, mumps and rubella, declined 1% in the first quarter of 2023 primarily due to lower tenders in Latin America, largely offset by higher pricing and demand in the U.S.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Varivax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Varicella Virus Vaccine Live), a vaccine to help prevent chickenpox (varicella), grew 15% in the first quarter of 2023 primarily attributable to higher demand and pricing in the U.S. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Rotavirus Vaccine, Live Oral, Pentavalent), a vaccine to help protect against rotavirus gastroenteritis in infants and children, grew 38% in the first quarter of 2023 primarily due to inventory stocking in China.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, a vaccine to help prevent invasive pneumococcal disease, increased to $106 million in the first quarter of 2023 primarily due to continued uptake in the pediatric indication in the U.S. following launch in 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 23, a vaccine to help prevent pneumococcal disease, declined 44% in the first quarter of 2023 primarily reflecting lower demand in the U.S. as the market continues to shift toward newer adult pneumococcal conjugate vaccines following changes in the recommendations of the U.S. Centers for Disease Control and Prevention&#8217;s Advisory Committee on Immunization Practices in 2021. The Company expects the decline in U.S. sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 23 to continue. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Hospital Acute Care</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, for the reversal of two types of neuromuscular blocking agents used during surgery, grew 23% in the first quarter of 2023 primarily due to higher demand, particularly in the U.S., reflecting </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8217;s growing share among neuromuscular blockade reversal agents. The patent that provides market exclusivity for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in the European Union (EU) will expire in July 2023; the Company anticipates sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in these markets will decline thereafter.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Prevymis </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(letermovir), a medicine for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogenic hematopoietic stem cell transplant, grew 38% in the first quarter of 2023 due to higher demand in the U.S. and Europe, as well as uptake from the 2022 launch in China. In February 2023, the FDA granted priority review for a supplemental New Drug Application (NDA) for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Prevymis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for prophylaxis of CMV disease in adult kidney transplant recipients at high risk (D+/R-); the Prescription Drug User Fee Act (PDUFA), or target action, date is June 5, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cardiovascular</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance Revenue - Adempas/Verquvo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> Alliance revenue represents Merck&#8217;s share of profits from sales in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note&#160;3 to the condensed consolidated financial statements).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adempas (riociguat) and Verquvo (vericiguat) are part of a worldwide collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators (see Note&#160;3 to the condensed consolidated financial statements). Adempas is approved for the treatment of certain types of pulmonary arterial hypertension and chronic pulmonary hypertension. Verquvo is approved to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in adults with symptomatic chronic heart failure and reduced ejection fraction. Verquvo was approved in the U.S., the EU and Japan in 2021 and has since been approved in several other markets. Alliance revenue from the collaboration grew 38% in the first quarter of 2023 primarily due to higher profit sharing reflecting increased demand in Bayer&#8217;s marketing territories. Revenue also includes sales of Adempas and Verquvo in Merck&#8217;s marketing territories. Sales of Adempas in Merck&#8217;s marketing territories were nearly flat in the first quarter of 2023 compared with the prior year.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Virology</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress HD</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 30 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is an investigational oral antiviral COVID-19 medicine being developed in a collaboration with Ridgeback (see Note&#160;3 to the condensed consolidated financial statements). Following initial authorizations in certain markets in the fourth quarter of 2021, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> has since received multiple additional authorizations worldwide. Sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> declined 88% in the first quarter of 2023 largely attributable to sales in the U.S. and UK markets in the first quarter of 2022 that did not recur in the first quarter of 2023. The </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> sales decline was also attributable to lower sales in Japan and Australia. The Company expects full-year 2023 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> sales to be approximately $1.0 billion. In April 2023, Japan&#8217;s Ministry of Health, Labor and Welfare granted full approval for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> was previously granted Special Approval for Emergency in Japan in December 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Global combined sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (raltegravir), an HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection, declined 23% in the first quarter of 2023 primarily due to lower global demand, reflecting in part competitive pressure particularly in Europe and the U.S. The Company expects competitive pressure for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to continue.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The patent that provides market exclusivity for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in the EU will expire in July 2023; the Company anticipates sales declines of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in these markets will accelerate thereafter.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Diabetes</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Januvia/Janumet</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,233&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Worldwide combined sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, medicines that help lower blood sugar levels in adults with type 2 diabetes, declined 29% in the first quarter of 2023 primarily reflecting the loss of exclusivity in several markets in Europe and the Asia Pacific region, as well as in Canada, coupled with lower demand and pricing in the U.S. due to competitive pressures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">While the key U.S. patent for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> claiming the sitagliptin compound expired in January 2023, as a result of favorable court rulings and settlement agreements related to a later expiring patent directed to the specific sitagliptin salt form of the products (see Note&#160;8 to the condensed consolidated financial statements), the Company expects that </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will not lose market exclusivity in the U.S. until May 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will not lose market exclusivity in the U.S. until July 2026, although </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">another non-automatically substitutable form of sitagliptin is likely to be available prior to 2026</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. As a result of competitive pressures, the Company anticipates pricing and volume declines for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in the U.S. for the remainder of 2023 and thereafter. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company lost market exclusivity for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in all of the EU and for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in some European countries in September 2022. Exclusivity for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> was lost in other European countries in April 2023. While the Company lost market exclusivity for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in China in 2022 with the launch of a generic equivalent product, the impact on sales in 2023 is expected to be modest. Although several generic equivalents of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> have been approved in China, none have launched, and the Company expects it is unlikely that any will launch prior to December 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Combined sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in Europe, China and the U.S. represented 11%, 13% and 37%, respectively, of total combined </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> sales for the first quarter of 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In response to a request from a regulatory authority, Merck evaluated its sitagliptin-containing products for the presence of nitrosamines. Nitrosamines are organic compounds found at trace levels in water and food. Nitrosamines can also result from chemical reactions and can form in drugs either due to the drug&#8217;s manufacturing process, chemical structure, or the conditions in which the drugs are stored or packaged. The Company detected a nitrosamine identified as Nitroso-STG-19 (NTTP) in some batches of its sitagliptin-containing medicines. The Company has engaged with major health authorities around the world and has implemented additional quality controls to ensure its portfolio of sitagliptin-containing products meet health authorities&#8217; interim acceptable NTTP limits for continuing distribution of product to the market. The Company is making progress in its efforts to reduce the level of nitrosamines in its sitagliptin-containing medicines. However, difficulties in reducing those levels, or achieving timely regulatory approvals for required changes, could result in product shortages. </span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_97"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Animal Health Segment</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.947%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change <br/>Excluding <br/>Foreign<br/>Exchange</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Livestock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Companion Animal</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales of livestock products grew 2% in the first quarter of 2023 primarily reflecting strong demand in the ruminant and poultry product portfolio, which includes technology solution products, as well as higher pricing. Sales of companion animal products declined 1% in the first quarter of 2023. Excluding the unfavorable effect of foreign exchange, companion animal sales performance primarily reflects higher pricing. Sales of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (fluralaner) parasiticide line of products were $314 million in both the first quarter of 2023 and the first quarter of 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 31 -</span></div></div></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Costs, Expenses and Other</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.945%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,926&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,837&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,040&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of sales decreased 27% in the first quarter of 2023. Cost of sales includes $221 million and $1.7 billion in the first quarter of 2023 and 2022, respectively, related to sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which is being developed in a collaboration with Ridgeback</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(see Note&#160;3 to the condensed consolidated financial statements). Cost of sales also includes the amortization of intangible assets recorded in connection with acquisitions, collaborations, and licensing arrangements, which totaled $532 million and $683 million in the first quarter of 2023 and 2022, respectively. Amortization expense in the first quarter of 2023 and 2022 includes $72&#160;million and $250&#160;million, respectively, of cumulative catch-up amortization related to Merck&#8217;s collaborations with Eisai and AstraZeneca, respectively, (see Note&#160;3 to the condensed consolidated financial statements). Also included in cost of sales are expenses associated with restructuring activities, which amounted to $29 million and $46 million in the first quarter of 2023 and 2022, respectively, including accelerated depreciation and asset write-offs related to the planned sale or closure of manufacturing facilities. Separation costs associated with manufacturing-related headcount reductions have been incurred and are reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross margin was 72.9% in the first quarter of 2023 compared with 66.2% in the first quarter of 2022. The gross margin improvement primarily reflects the favorable impacts of lower </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> sales (which have a low gross margin), product mix and lower amortization of intangible assets (noted above).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, general and administrative (SG&amp;A) expenses increased 7% in the first quarter of 2023 primarily due to higher administrative costs and increased promotional spending, partially offset by the favorable effect of foreign exchange. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development (R&amp;D) expenses increased 66% to $4.3 billion in the first quarter of 2023 primarily due to a $1.2 billion charge for the acquisition of Imago, as well as higher upfront charges related to collaborations and licensing arrangements. Also contributing to the increase in R&amp;D expenses were higher compensation and benefit costs, reflecting in part increased headcount to support clinical development activity, higher investments in discovery research and early drug development, as well as increased clinical development spending. The increase in R&amp;D expenses was partially offset by the favorable effect of foreign exchange.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">R&amp;D expenses are comprised of the costs directly incurred by Merck Research Laboratories (MRL), the Company&#8217;s research and development division that focuses on human health-related activities, which were $2.1 billion and $1.8 billion for the first quarter of 2023 and 2022, respectively. Also included in R&amp;D expenses are Animal Health research costs, licensing costs and costs incurred by other divisions in support of R&amp;D activities, including depreciation, production and general and administrative, which in the aggregate were approximately $2.2 billion and $750 million for the first quarter of 2023 and 2022, respectively. The increase in these expenses in the first quarter of 2023 was largely attributable to a $1.2 billion charge for the acquisition of Imago (as noted above) and a $175 million charge for a license and collaboration agreement with Kelun-Biotech. See Note&#160;2 for additional information related to business development activity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2019, Merck&#160;approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on optimizing the Company&#8217;s manufacturing and supply network, as well as reducing its global real estate footprint.&#160;The actions contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.7 billion. Merck expects to record charges of approximately $400 million for the full year of 2023 related to the Restructuring Program. The Company anticipates the actions under the Restructuring Program will result in cumulative annual net cost savings of approximately $900 million by the end of 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restructuring costs, primarily representing separation and other related costs associated with these restructuring activities, were $67 million and $53 million for the first quarter of 2023 and 2022, respectively. Separation costs incurred were associated with actual headcount reductions, as well as estimated expenses under existing severance programs for involuntary headcount reductions that were probable and could be reasonably estimated. Also included in restructuring costs are asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 32 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">termination charges associated with pension and other postretirement benefit plans and share-based compensation plan costs. For segment reporting, restructuring costs are unallocated expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additional costs associated with the Company&#8217;s restructuring activities are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> costs. The Company recorded aggregate pretax costs of $97 million and $127 million in the first quarter of 2023 and 2022, respectively, related to restructuring program activities (see Note&#160;5 to the condensed consolidated financial statements). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (Income) Expense, Net</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income) expense, net, was $89 million of expense in the first quarter of 2023 compared with $708 million of expense in the first quarter of 2022. The change was primarily due to net unrealized gains from investments in equity securities recorded in the first quarter of 2023 compared with net unrealized losses recorded in the first quarter of 2022, as well as higher interest income in the first quarter of 2023. The favorability was partially offset by a $572.5 million charge in the first quarter of 2023 related to settlements with certain plaintiffs in the Zetia antitrust litigation (see Note&#160;8 to the consolidated financial statements). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For details on the components of Other (income) expense, net, see Note&#160;11 to the condensed consolidated financial statements. </span></div><div style="margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Segment Profits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical segment profits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health segment profits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,056)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,225)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income Before Taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,650&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,861&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as SG&amp;A expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as SG&amp;A and R&amp;D expenses directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, R&amp;D expenses incurred by MRL, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. Also excluded from the determination of segment profits are costs related to restructuring activities and acquisition- and divestiture-related costs, including the amortization of intangible assets and amortization of purchase accounting adjustments, intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Additionally, segment profits do not reflect other expenses from corporate and manufacturing cost centers and other miscellaneous income or expense. These unallocated items are reflected in &#8220;Other&#8221; in the above table. Also included in &#8220;Other&#8221; are miscellaneous corporate profits (losses), as well as operating profits (losses) related to third-party manufacturing arrangements. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pharmaceutical segment profits declined 4% in the first quarter of 2023 reflecting lower sales, largely attributable to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, as well as higher administrative and promotional costs, and the unfavorable effect of foreign exchange. Animal Health segment profits declined 3% in the first quarter of 2023 reflecting higher administrative and promotional costs, as well as increased research and development expenses. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Taxes on Income</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effective income tax rates were 22.6% and 11.4% for the first quarter of 2023 and 2022, respectively. The effective income tax rate for the first quarter of 2023 reflects the unfavorable discrete impact of a charge for the acquisition of Imago for which no tax benefit was recognized, as well as higher foreign taxes, the impact of the R&amp;D capitalization provision of the Tax Cuts and Jobs Act of 2017 on the Company&#8217;s U.S. global intangible low-taxed income inclusion, and net unrealized gains from investments in equity securities, which were taxed at the U.S. tax rate, partially offset by higher foreign tax credits. The effective income tax rate in the first quarter of 2022 includes the favorable impact of net unrealized losses from investments in equity securities, which were taxed at the U.S. tax rate. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-GAAP Income and Non-GAAP EPS</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&#160;EPS are alternative views of the Company&#8217;s performance that Merck is providing because management believes this information enhances investors&#8217; understanding of the Company&#8217;s results since management uses non-GAAP measures to assess performance. Non-GAAP income and non-GAAP EPS exclude certain items because of the nature of these items and the impact that they have on the analysis of underlying business performance and trends. The excluded items (which should not be considered non-recurring) consist of acquisition- and divestiture-related costs, restructuring costs, income and losses from investments in equity securities, and certain other items. These excluded items are significant components in understanding and assessing financial performance. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 33 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&#160;EPS are important internal measures for the Company. Senior management receives a monthly analysis of operating results that includes a non-GAAP&#160;EPS metric. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, senior management&#8217;s annual compensation is derived in part using a non-GAAP pretax income metric. Since non-GAAP income and non-GAAP&#160;EPS are not measures determined in accordance with GAAP, they have no standardized meaning prescribed by GAAP and, therefore, may not be comparable to the calculation of similar measures of other companies. The information on non-GAAP income and non-GAAP&#160;EPS should be considered in addition to, but not as a substitute for or superior to, net income and EPS prepared in accordance with generally accepted accounting principles in the U.S. (GAAP). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation between GAAP financial measures and non-GAAP financial measures is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.063%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.212%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before taxes as reported under GAAP</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase (decrease) for excluded items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition- and divestiture-related costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Income) loss from investments in equity securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(429)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charge for Zetia antitrust litigation settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP income before taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,481&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,309&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes on income as reported under GAAP</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Estimated tax benefit on excluded items</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP taxes on income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">883&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP net income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,568&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,426&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Net income (loss) attributable to noncontrolling interests as reported under GAAP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,564&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,429&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EPS assuming dilution as reported under GAAP</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.11&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.70&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EPS difference</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP EPS assuming dilution</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.40&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.14&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated tax impact on the excluded items is determined by applying the statutory rate of the originating territory of the non-GAAP adjustments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Acquisition- and Divestiture-Related Costs</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&#160;EPS exclude the impact of certain amounts recorded in connection with acquisitions and divestitures of businesses. These amounts include the amortization of intangible assets and amortization of purchase accounting adjustments to inventories, as well as intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Also excluded are integration, transaction, and certain other costs associated with acquisitions and divestitures of businesses. Non-GAAP income and non-GAAP EPS also exclude amortization of intangible assets related to collaborations and licensing arrangements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&#160;EPS exclude costs related to restructuring actions (see Note&#160;5 to the condensed consolidated financial statements). These amounts include employee separation costs and accelerated depreciation associated with facilities to be closed or divested. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. Restructuring costs also include asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation costs. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income and Losses from Investments in Equity Securities</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&#160;EPS exclude realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Certain Other Items</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP EPS exclude certain other items. These items are adjusted for after evaluating them on an individual basis, considering their quantitative and qualitative aspects. Typically, these consist of items that are unusual in nature, significant to the results of a particular period or not indicative of future operating results. Excluded from non-GAAP income and non-GAAP EPS in 2023 is a charge related to settlements with certain plaintiffs in the Zetia antitrust litigation (see Note&#160;8 to the condensed consolidated financial statements). </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 34 -</span></div></div></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Research and Development Update</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company currently has several candidates under regulatory review in the U.S. and internationally.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MK-4482, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, is an investigational oral antiviral medicine for the treatment of mild to moderate COVID-19 in adults who are at risk for progressing to severe disease. Merck is developing </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in collaboration with Ridgeback. The FDA granted Emergency Use Authorization for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in December 2021; last issued in February 2023, to authorize </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for the treatment of adults with a current diagnosis of mild to moderate COVID-19, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate. The authorization is based on the Phase 3 MOVe-OUT trial. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is not approved for any use in the U.S. and is authorized only for the duration of the declaration that circumstances exist justifying the authorization of its emergency use under the Food, Drug and Cosmetic Act, unless the authorization is terminated or revoked sooner. In November 2021, the European Medicines Agency (EMA) issued a positive scientific opinion for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which is intended to support national decision-making on the possible use of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> prior to marketing authorization. In October 2021, the EMA initiated a rolling review for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for the treatment of COVID-19 in adults. In February 2023, Merck and Ridgeback announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has recommended the refusal of the marketing authorization application (MAA) for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Merck and Ridgeback have appealed the decision and requested a re-examination of the MAA. Applications to other regulatory bodies are underway. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MK-7264, gefapixant, is an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory chronic cough or unexplained chronic cough in adults under review by the FDA and the EMA. The marketing applications for gefapixant are based on results from the COUGH-1 and COUGH-2 clinical trials. In January 2022, the FDA issued a Complete Response Letter (CRL) regarding Merck&#8217;s NDA for gefapixant. In the CRL, the FDA requested additional information related to the cough counting system that was used to assess efficacy. The CRL was not related to the safety of gefapixant. The Company is performing additional analyses and anticipates submitting this information to the FDA in the second quarter of 2023 in response to the CRL. The review period in the EU was extended pending the receipt of additional information, which Merck submitted to the EMA in the first quarter of 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MK-3475, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, is an anti-PD-1 therapy approved for the treatment of many cancers that is in clinical development for expanded indications. These approvals were the result of a broad clinical development program that currently encompasses more than 30 cancer types including: biliary, estrogen receptor positive breast cancer, cervical, colorectal, cutaneous squamous cell, endometrial, esophageal, gastric, glioblastoma, head and neck, hepatocellular, Hodgkin lymphoma, non-Hodgkin lymphoma, non-small-cell lung, small-cell lung, melanoma, mesothelioma, ovarian, prostate, renal, triple-negative breast, and urothelial, many of which are currently in Phase 3 clinical development. Further trials are being planned for other cancers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is under review by the FDA for the treatment of patients with previously treated advanced HCC. This submission is based on data from the Phase 3 KEYNOTE-394 trial along with supportive data from the KEYNOTE-240 and KEYNOTE-224 trials. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is approved for this indication in the U.S. under the FDA&#8217;s accelerated approval process. This submission is to convert the accelerated approval to full (regular) approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is under review by the FDA for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. This submission is based on data from the Phase 3 KEYNOTE-913 trial. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is approved for this indication in the U.S. under the FDA&#8217;s accelerated approval process. This submission is to convert the accelerated approval to full (regular) approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is also under review by the FDA in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma. The submission is based on data from the KEYNOTE-859 trial, in which </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> plus chemotherapy demonstrated a statistically significant improvement in overall survival versus chemotherapy alone, regardless of PD-L1 expression, in patients who were HER2 negative. The FDA set a PDUFA date of December 16, 2023. KEYNOTE-859 is also under review in the EU.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is under review by the FDA as a perioperative treatment regimen for patients with resectable stage II, IIIA or IIIB NSCLC based on the KEYNOTE-671 study. A perioperative treatment regimen includes treatment before surgery (neoadjuvant) and continued after surgery (adjuvant). The FDA set a PDUFA date of October 16, 2023. KEYNOTE-671 is also under review in the EU.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is under review in the EU for the adjuvant treatment of patients with stage IB (&#8805;4 cm), II or IIIA NSCLC following complete surgical resection. The submission is based on data from the pivotal Phase 3 KEYNOTE-091 trial, also known as EORTC-1416-LCG/ETOP-8-15 &#8211; PEARLS. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is under review in Japan for the treatment of patients with relapsed or refractory PMBCL. This submission is based on data from the Phase 2 KEYNOTE-170 study and the Phase 1 KEYNOTE-A33 study.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2023, Merck announced it was discontinuing the Phase 3 KEYNOTE-641 trial evaluating </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in combination with enzalutamide and androgen deprivation therapy (ADT) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) based on the recommendation of an independent Data Monitoring Committee. At an interim analysis, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in combination with enzalutamide and ADT did not demonstrate an improvement in radiographic progression-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 35 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">free survival or overall survival, the trial&#8217;s dual primary endpoints, compared to placebo plus enzalutamide and ADT, and crossed a pre-specified futility boundary for overall survival.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2023, Merck provided an update on the open-label arm of the non-registrational Phase 2 KeyVibe-002 trial. KeyVibe-002 is evaluating MK-7684A, a coformulation of vibostolimab, an anti-TIGIT therapy, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, with or without docetaxel for the treatment of patients with metastatic NSCLC with progressive disease after treatment with immunotherapy and platinum-doublet chemotherapy. KeyVibe-002, a partially blinded study, was designed with two primary objectives: 1) to evaluate the efficacy of MK-7684A alone compared with docetaxel, a standard of care; and 2) in a blinded assessment, evaluate the efficacy of adding MK-7684A to docetaxel compared with docetaxel alone. Results from the open-label arm of the study evaluating MK-7684A alone showed that the coformulation did not reach statistical significance for the primary endpoint of progression-free survival and was numerically less effective compared with docetaxel. The blinded arms of the study will continue to further evaluate MK-7684A with docetaxel versus docetaxel alone. Results will be presented at an upcoming medical meeting once further data from the blinded study arms are available.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MK-7339, Lynparza, is an oral PARP inhibitor currently approved for the treatment of several cancers being co-developed for additional cancer types as part of a collaboration with AstraZeneca (see Note&#160;3 to the condensed consolidated financial statements). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2023, the FDA convened its </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Oncologic Drugs Advisory Committee (ODAC) to discuss the supplemental NDA for use of Lynparza in combination with abiraterone and prednisone or prednisolone (abi/pred) for the treatment of adult patients with mCRPC, based on the results of the Phase 3 PROpel trial. By a vote of 11 to 1 with one abstention, the OADC supported FDA approval of Lynparza plus abi/pred for the first-line treatment of adult patients with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">BRCA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">-mutated (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">BRCA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">m) mCRPC. The committee voted that the FDA should restrict use of Lynparza plus abi/pred to these </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">BRCA</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">m mCRPC patients, recommending against approval beyond this patient population. The ODAC provides the FDA with independent, expert advice and recommendations on marketed and investigational medicines for use in the treatment of cancer. The FDA is not bound by the committee&#8217;s guidance but takes its advice into consideration. AstraZeneca and Merck will continue to work with the FDA as the agency completes its review of the application. Lynparza is also under review in Japan for the treatment of certain patients with mCRPC based on the PROpel trial. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">MK-7902, Lenvima, is an oral receptor tyrosine kinase inhibitor currently approved for the treatment of several cancers being developed as part of a collaboration with Eisai. Merck and Eisai are studying the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> plus Lenvima combination through the LEAP (LEnvatinib And Pembrolizumab) clinical program.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2023, Merck and Eisai announced the discontinuation of the Phase 3 LEAP-003 trial evaluating </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> plus Lenvima for the first-line treatment of adults with unresectable or metastatic melanoma based on the recommendation of an independent Data Monitoring Committee, which reviewed data from a planned interim analysis and determined </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> plus Lenvima did not demonstrate an improvement in overall survival, one of the study&#8217;s dual primary endpoints, versus </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> alone. Merck and Eisai also provided an update on the Phase 3 LEAP-017 trial evaluating </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> plus Lenvima for the treatment of patients with unresectable and metastatic colorectal cancer that is mismatch repair proficient or not MSI-H who experienced disease progression on, or became intolerant to, prior therapy. The trial did not meet statistical significance for its primary endpoint of overall survival in the final pre-specified analysis.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The charts below reflect the Company&#8217;s research pipeline as of May 3, 2023. Candidates shown in Phase 3 include the date such candidate entered into Phase 3 development. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase 1, additional indications in the same therapeutic area (other than with respect to cancer) and additional claims, line extensions or formulations for in-line products are not shown.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 36 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:28.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.490%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Phase 2</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-0482</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%"> </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Non-Small-Cell Lung</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-1308 (quavonlimab)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="padding-left:13.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-1308A (quavonlimab+pembrolizumab)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Colorectal</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Hepatocellular </span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Melanoma</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Small-Cell Lung</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-2140 (zilovertamab vedotin)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Bladder</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Breast</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Gastric</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Hematological Malignancies</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Ovarian</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Pancreatic</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-2870</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(3)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Neoplasm Malignant</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-3475 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:110%">Keytruda</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Prostate</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-3543 (bomedemstat)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Myeloproliferative Disorders</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-4280 (favezelimab)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%"> </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;Non-Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-4280A (favezelimab+pembrolizumab)</span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Baldder     </span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Esophageal</span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Melanoma</span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Renal Cell</span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Small-Cell Lung        </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-4830</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Colorectal</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Esophageal</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Melanoma</span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Ovarian</span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Renal Cell</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-5684</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Prostate</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-5890 (boserolimab)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Non-Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Small-Cell Lung</span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span><br/></span></div><div style="text-indent:9pt"><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">MK-6440 (ladiratuzumab vedotin)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(3)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Breast</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Esophageal</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Gastric</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Head and Neck</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Melanoma</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Prostate</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:115%">MK-6482 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:115%">Welireg</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Biliary</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Colorectal</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Endometrial</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Esophageal</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Hepatocellular</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Pancreatic</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Rare cancers</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Von Hippel-Lindau Disease-Associated Tumors (EU)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7119 Tukysa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Biliary</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Bladder</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Cervical</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Endometrial</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Gastric</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7339 Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(3)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7684A (vibostolimab+pembrolizumab)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Biliary</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Bladder</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Breast</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Cervical</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Colorectal</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Endometrial</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Esophageal</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Gastric</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Head and Neck</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Hematological Malignancies</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Hepatocellular</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Ovarian</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Prostate</span></div><div style="text-indent:9pt"><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7902 Lenvima</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(2)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Biliary</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Melanoma</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Pancreatic</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Prostate</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">V940</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(2)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Melanoma</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Dengue Fever Virus Vaccine</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">V181</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">HIV-1 Infection</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-8591B (islatravir+MK-8507)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-8591D (islatravir+lenacapavir)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(5)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Hypercholesterolemia</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-0616</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Nonalcoholic Steatohepatitis (NASH)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-6024 (efinopegdutide)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Pulmonary Arterial Hypertension</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-5475</span></div><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Pulmonary Hypertension Due To Left Heart Disease</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7962 (sotatercept)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Schizophrenia</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-8189</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(6)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Thrombosis</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-2060</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Treatment Resistant Depression</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-1942</span></div><div style="text-indent:9pt"><span><br/></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 37 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Phase 3 (Phase 3 entry date)</span></td><td colspan="6" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Under Review</span></td></tr><tr style="height:236pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Antiviral COVID-19</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-4482 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:110%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%"> (U.S.) (May 2021)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(7)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-1026 (nemtabrutinib)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#160;&#160;&#160;&#160;&#160;Hematological Malignancies (March 2023)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-1308A (quavonlimab+pembrolizumab)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Renal Cell (April 2021)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-3475 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:110%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Biliary (September 2019)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Cutaneous Squamous Cell (August 2019) (EU)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Hepatocellular (May 2016) (EU)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Mesothelioma (May 2018)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Ovarian (December 2018)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Small-Cell Lung (May 2017)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-3475 (pembrolizumab subcutaneous) </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (August 2021)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-3475A (pembrolizumab+hyaluronidase subcutaneous) </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (February 2023)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-4280A (favezelimab+pembrolizumab)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Colorectal (November 2021)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Hematological Malignancies (October 2022)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-6482 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:110%">Welireg</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Renal Cell (February 2020)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7119 Tukysa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Breast (October 2019)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Colorectal (August 2022)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7339 Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(2)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (June 2019)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Small-Cell Lung (December 2020)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7684A (vibostolimab+pembrolizumab)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Melanoma (January 2023)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (April 2021)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Small-Cell Lung (March 2022)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7902 Lenvima</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(2)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Esophageal (July 2021)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Gastric (December 2020)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Head and Neck (February 2020)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (March 2019)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">HIV-1 Infection</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-8591A (doravirine+islatravir) (February 2020)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Pneumococcal Vaccine Adult</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">V116 (July 2022)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Pulmonary Arterial Hypertension</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7962 (sotatercept) (January 2021)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Respiratory Syncytial Virus</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-1654 (clesrovimab) (November 2021)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">New Molecular Entities</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Antiviral COVID-19</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-4482 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:110%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%"> (EU)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)(8)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Cough</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7264 (gefapixant) (U.S.)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%"> (EU)</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br/></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Certain Supplemental Filings</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-3475 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:110%">Keytruda</span></div><div style="padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#8226;    Second-Line Hepatocellular Carcinoma</span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">(KEYNOTE-394) (U.S.) </span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#8226;    Locally Advanced or Metastatic Merkel Cell Carcinoma </span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">(KEYNOTE-913) (U.S.)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#8226;    First-Line HER2 Negative Locally Advanced Unresectable or Metastatic Gastric Cancer</span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">(KEYNOTE-859) (U.S.) (EU)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#8226;    Resectable Stage II, IIIA or IIIB NSCLC</span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">(KEYNOTE-671) (U.S.) (EU)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#8226;    Adjuvant Non-Small-Cell Lung Cancer</span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">(KEYNOTE-091) (EU)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#8226;    Relapsed or Refractory Primary Mediastinal B-Cell Lymphoma </span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">(KEYNOTE-170/KEYNOTE-A33) (JPN)</span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span><br/></span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">MK-7339 Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">&#8226;    First-Line Metastatic Prostate Cancer </span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">(PROpel) (U.S.) (JPN)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div></td></tr><tr style="height:180pt"><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Footnotes:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Being developed in a collaboration.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">  Being developed in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">  Being developed as monotherapy and/or in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Keytruda.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">  On FDA clinical hold.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">  On FDA partial clinical hold for higher doses than those used in current clinical trials.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">  Phase 2b development costs are being co-funded.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">  Available in the U.S. under Emergency Use Authorization.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">  Requested re-examination of EU MAA following CHMP recommendation for the refusal of the marketing authorization.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(9)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">In response to the CRL received from the FDA for this application in January 2022, Merck is performing additional analyses and anticipates submitting this information to the FDA in the second quarter of 2023.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span><br/></span></div></td></tr></table></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_106"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Analysis of Liquidity and Capital Resources</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Working capital</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,271&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,483&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt to total liabilities and equity</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash provided by operating activities was $1.3 billion in the first three months of 2023 compared with $4.8 billion in the first three months of 2022 primarily reflecting the impact of lower </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> sales. Cash provided by operating activities was reduced by milestone payments related to certain collaborations of $115 million and $1.2 billion in the first three months of 2023 and 2022, respectively. Cash provided by operating activities continues to be the Company&#8217;s primary source of funds to finance operating needs, with excess cash serving as the primary source of funds to finance business development transactions, capital expenditures, dividends paid to shareholders and treasury stock purchases.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash used in investing activities was $2.4 billion in the first three months of 2023 compared with $1.2 billion in the first three months of 2022. The higher use of cash in investing activities was primarily due to the acquisition of Imago and higher purchases of securities and other investments, partially offset by higher proceeds from sales of securities and other investments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash used in financing activities was $2.1 billion in the first three months of 2023 compared with $3.1 billion in the first three months of 2022. The decrease in cash used in financing activities was primarily due to lower payments on long-term debt, partially offset by treasury stock purchases and higher dividends paid to shareholders. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures totaled $1.0 billion in the first three months of 2023 compared with $984 million in the first three months of 2022. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 38 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.4 billion and $2.5 billion of accounts receivable at March&#160;31, 2023 and December&#160;31, 2022, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. The net cash flows relating to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividends paid to stockholders were $1.9 billion and $1.7 billion for the first three months of 2023 and 2022, respectively.&#160;In January 2023, the Board of Directors declared a quarterly dividend of $0.73 per share on the Company&#8217;s outstanding common stock for the first quarter that was paid in April 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As discussed above, in April 2023, Merck announced an agreement to acquire Prometheus for $200 per share in cash for a total equity value of approximately $10.8 billion. The acquisition is subject to Prometheus shareholder approval. The closing of the proposed transaction will be subject to certain conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. The transaction is expected to close in the third quarter of 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2022, the Company&#8217;s $1.25 billion, 2.35% notes matured in accordance with their terms and were repaid. In September 2022, the Company&#8217;s $1.0&#160;billion, 2.40% notes matured in accordance with their terms and were repaid. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2018, Merck&#8217;s Board of Directors authorized purchases of up to $10 billion of Merck&#8217;s common stock for its treasury. The treasury stock purchase authorization has no time limit and will be made over time in open-market transactions, block transactions on or off an exchange, or in privately negotiated transactions. The Company anticipates making modest share repurchases under this program in 2023. During the first three months of 2023, the Company purchased $149 million (1 million shares) of its common stock for its treasury under this program. As of March&#160;31, 2023, the Company&#8217;s remaining share repurchase authorization was $4.9&#160;billion. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has a $6.0 billion credit facility that matures in June 2026. The facility provides backup liquidity for the Company&#8217;s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.</span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_109"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s significant accounting policies, which include management&#8217;s best estimates and judgments, are included in Note&#160;2 to the consolidated financial statements for the year ended December&#160;31, 2022 included in Merck&#8217;s Form 10&#8209;K filed on February&#160;24, 2023. See Note&#160;1 to the condensed consolidated financial statements for information on the adoption of new accounting standards during 2023. A discussion of accounting estimates considered critical because of the potential for a significant impact on the financial statements due to the inherent uncertainty in such estimates are disclosed in the Critical Accounting Estimates section of Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in Merck&#8217;s Form 10-K. There have been no significant changes in the Company&#8217;s critical accounting estimates since December&#160;31, 2022. </span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_112"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For a discussion of recently issued accounting standards, see Note&#160;1 to the condensed consolidated financial statements.</span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_115"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There have been no material changes in market risk exposures that affect the disclosures presented in &#8220;Item 7A. Quantitative and Qualitative Disclosures about Market Risk&#8221; in the Company&#8217;s 2022 Form 10-K filed on February&#160;24, 2023. </span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_118"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;4. Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures over financial reporting. Based on their evaluation, the Company&#8217;s Chief Executive Officer and Chief Financial Officer have concluded that as of March&#160;31, 2023, the Company&#8217;s disclosure controls and procedures are effective. During the quarter, the Company upgraded its financial consolidation system to the latest software version and moved it to an externally hosted cloud-based environment. The Company completed testing of this system prior to its launch, continues to monitor impacted financial and business processes and believes that an effective control environment has been maintained post-implementation.</span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_121"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This report and other written reports and oral statements made from time to time by the Company may contain so-called &#8220;forward-looking statements,&#8221; all of which are based on management&#8217;s current expectations and are subject to risks and uncertainties which may cause results to differ materially from those set forth in the statements. One can identify these forward-looking statements by their use of words such as &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;will,&#8221; &#8220;estimates,&#8221; &#8220;forecasts,&#8221; &#8220;projects&#8221; and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 39 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">other words of similar meaning, or negative variations of any of the foregoing. One can&#160;also identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address the Company&#8217;s growth strategy, financial results, product approvals, product potential, development programs, environmental or other sustainability initiatives, and may include statements related to the expected impact of the COVID-19 pandemic. One must carefully consider any such statement and should understand that many factors could cause actual results to differ materially from the Company&#8217;s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company does not assume the obligation to update any forward-looking statement. One should carefully evaluate such statements in light of factors, including risk factors, described in the Company&#8217;s filings with the Securities and Exchange Commission, especially on Forms 10-K, 10-Q and 8-K. In Item&#160;1A. &#8220;Risk Factors&#8221; of the Company&#8217;s Annual Report on Form 10&#8209;K for the year ended December&#160;31, 2022, filed on February&#160;24, 2023, the Company discusses in&#160;more detail various important risk factors that could cause actual results to differ from expected or historic results. The Company notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. One should understand that it is not possible to predict or identify all such factors. Consequently, the reader should not consider any such list&#160;to be a&#160;complete statement of all potential risks or uncertainties.</span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_124"></div><div style="margin-top:14pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">PART II - Other Information</span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_127"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;1. Legal Proceedings</span></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The information called for by this Item is incorporated herein by reference to Note&#160;8 included in Part I, Item&#160;1, Financial Statements (unaudited) &#8212; Notes to Condensed Consolidated Financial Statements.</span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_133"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Issuer purchases of equity securities for the three months ended March&#160;31, 2023 were as follows:</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($&#160;in&#160;millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total&#160;Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">of Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Purchased </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average&#160;Price<br/>Paid Per<br/>Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Approximate&#160;Dollar&#160;Value&#160;of&#160;Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">That May Yet Be Purchased</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Under the Plans or Programs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 1 - January 31</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$5,047</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 1 - February 28</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">328,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$108.43</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">328,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$5,012</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1 - March 31</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,066,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$106.55</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,066,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$4,898</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,395,737&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$107.00</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,395,737&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Shares purchased during the period were made as part of a plan approved by the Board of Directors in October 2018 to purchase up to $10 billion of Merck&#8217;s common stock for its treasury.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 40 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_136"></div><div style="-sec-extract:summary;margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;6. Exhibits</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312509223917/dex31.htm">Restated Certificate of Incorporation of Merck &amp; Co., Inc. (November 3, 2009) &#8211; Incorporated by reference to Merck &amp; Co., Inc.'s Current Report on Form 8-K filed on November&#160;4, 2009 (No. 1-6571)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015822000006/exhibit31-byxlawsasamended.htm">By-Laws of Merck &amp; Co., Inc. (effective March 22, 2022) &#8211; Incorporated by reference to Merck &amp; Co., Inc.'s Current Report on Form 8-K filed on March 25, 2022 (No. 1-6571)</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311-rule13ax14a15dx.htm">Rule 13a &#8211; 14(a)/15d &#8211; 14(a) Certification of Chief Executive Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312-rule13ax14a15dx.htm">Rule 13a &#8211; 14(a)/15d &#8211; 14(a) Certification of Chief Financial Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321-section1350cert.htm">Section 1350 Certification of Chief Executive Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322-section1350cert.htm">Section 1350 Certification of Chief Financial Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 41 -</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div id="i3ccccf37677d43f88002f8d995e2fd3c_139"></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">Signatures</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MERCK &amp; CO., INC.</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Date:  May 5, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Jennifer Zachary</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JENNIFER ZACHARY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Executive Vice President and General Counsel</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Date:  May 5, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ Rita A. Karachun</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RITA A. KARACHUN</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Vice President Finance - Global Controller</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">- 42 -</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit311-rule13ax14a15dx.htm
<DESCRIPTION>RULE 13A-14(A)/15D-14(A) CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i45005a7a0af34ebd9c3d87e7cb6506dd_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Robert M. Davis, certify that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Merck&#160;&#38; Co., Inc.&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;5, 2023 </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:12pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.614%"><tr><td style="width:1.0%"></td><td style="width:9.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.324%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert M. Davis</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROBERT M. DAVIS<br>Chairman, Chief Executive Officer and President</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit312-rule13ax14a15dx.htm
<DESCRIPTION>RULE 13A-14(A)/15D-14(A) CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie2e0174c8a86488487a3c63d94fffd6c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 31.2</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Caroline Litchfield, certify that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Merck&#160;&#38; Co., Inc.&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;&#160;May&#160;5, 2023 </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.345%"><tr><td style="width:1.0%"></td><td style="width:9.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.490%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Caroline Litchfield</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAROLINE LITCHFIELD<br>Executive Vice President, Chief Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit321-section1350cert.htm
<DESCRIPTION>SECTION 1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic34963291eca4e55ab96b2180bec3954_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 32.1 </font></div><div style="margin-top:15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;1350 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Executive Officer </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section&#160;1350, the undersigned officer of Merck&#160;&#38; Co., Inc. (the &#8220;Company&#8221;), hereby certifies that the Company's Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2023 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.115%"><tr><td style="width:1.0%"></td><td style="width:50.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.407%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;5, 2023</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Robert M. Davis</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;<br>Title&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROBERT M. DAVIS<br>Chairman, Chief&#160;Executive&#160;Officer and President</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit322-section1350cert.htm
<DESCRIPTION>SECTION 1350 CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i97a3f4687b0346e4ad1ea67d5a97a5e2_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 32.2 </font></div><div style="margin-top:15pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;1350 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Financial Officer </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section&#160;1350, the undersigned officer of Merck&#160;&#38; Co., Inc. (the &#8220;Company&#8221;), hereby certifies that the Company's Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2023 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:50.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.983%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;  May&#160;5, 2023</font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Caroline Litchfield</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;<br>Title&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAROLINE LITCHFIELD<br>Executive Vice President, Chief Financial Officer</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>mrk-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:f17f1926-1a01-4baa-a406-054ce45079f2,g:c6b1c5ce-74aa-44b6-956b-90e243d128be-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mrk="http://www.merck.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.merck.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrk-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrk-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrk-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mrk-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.merck.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME">
        <link:definition>0000002 - Statement - CONDENSED CONSOLIDATED STATEMENT OF INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME">
        <link:definition>0000003 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEET" roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET">
        <link:definition>0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical">
        <link:definition>0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS">
        <link:definition>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical" roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical">
        <link:definition>0000007 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentation" roleURI="http://www.merck.com/role/BasisofPresentation">
        <link:definition>0000008 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinOffofOrganonCo" roleURI="http://www.merck.com/role/SpinOffofOrganonCo">
        <link:definition>0000009 - Disclosure - Spin-Off of Organon &amp; Co.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsResearchCollaborationsandLicenseAgreements" roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements">
        <link:definition>0000010 - Disclosure - Acquisitions, Research Collaborations and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeArrangements" roleURI="http://www.merck.com/role/CollaborativeArrangements">
        <link:definition>0000011 - Disclosure - Collaborative Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://www.merck.com/role/Restructuring">
        <link:definition>0000012 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.merck.com/role/FinancialInstruments">
        <link:definition>0000013 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.merck.com/role/Inventories">
        <link:definition>0000014 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.merck.com/role/Contingencies">
        <link:definition>0000015 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.merck.com/role/Equity">
        <link:definition>0000016 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlans" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans">
        <link:definition>0000017 - Disclosure - Pension and Other Postretirement Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNet" roleURI="http://www.merck.com/role/OtherIncomeExpenseNet">
        <link:definition>0000018 - Disclosure - Other (Income) Expense, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncome" roleURI="http://www.merck.com/role/TaxesonIncome">
        <link:definition>0000019 - Disclosure - Taxes on Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.merck.com/role/EarningsPerShare">
        <link:definition>0000020 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLoss" roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLoss">
        <link:definition>0000021 - Disclosure - Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.merck.com/role/SegmentReporting">
        <link:definition>0000022 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationPolicies" roleURI="http://www.merck.com/role/BasisofPresentationPolicies">
        <link:definition>0000023 - Disclosure - Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeArrangementsTables" roleURI="http://www.merck.com/role/CollaborativeArrangementsTables">
        <link:definition>0000024 - Disclosure - Collaborative Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringTables" roleURI="http://www.merck.com/role/RestructuringTables">
        <link:definition>0000025 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.merck.com/role/FinancialInstrumentsTables">
        <link:definition>0000026 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.merck.com/role/InventoriesTables">
        <link:definition>0000027 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.merck.com/role/EquityTables">
        <link:definition>0000028 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansTables" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables">
        <link:definition>0000029 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNetTables" roleURI="http://www.merck.com/role/OtherIncomeExpenseNetTables">
        <link:definition>0000030 - Disclosure - Other (Income) Expense, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.merck.com/role/EarningsPerShareTables">
        <link:definition>0000031 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossTables" roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossTables">
        <link:definition>0000032 - Disclosure - Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.merck.com/role/SegmentReportingTables">
        <link:definition>0000033 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinOffofOrganonCoDetails" roleURI="http://www.merck.com/role/SpinOffofOrganonCoDetails">
        <link:definition>0000034 - Disclosure - Spin-Off of Organon &amp; Co. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails">
        <link:definition>0000035 - Disclosure - Acquisitions, Research Collaborations and License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeArrangementsNarrativeDetails" roleURI="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails">
        <link:definition>0000036 - Disclosure - Collaborative Arrangements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeArrangementsFinancialInformationDetails" roleURI="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails">
        <link:definition>0000037 - Disclosure - Collaborative Arrangements - Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringNarrativeDetails" roleURI="http://www.merck.com/role/RestructuringNarrativeDetails">
        <link:definition>0000038 - Disclosure - Restructuring - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesActivitiesbyTypeofCostDetails" roleURI="http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails">
        <link:definition>0000039 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringActivitiesbyProgramDetails" roleURI="http://www.merck.com/role/RestructuringActivitiesbyProgramDetails">
        <link:definition>0000040 - Disclosure - Restructuring - Activities by Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>0000041 - Disclosure - Financial Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsEffectofNetInvestmentHedgesDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails">
        <link:definition>0000042 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails">
        <link:definition>0000043 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails">
        <link:definition>0000044 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails">
        <link:definition>0000045 - Disclosure - Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails">
        <link:definition>0000046 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails">
        <link:definition>0000047 - Disclosure - Financial Instruments - Information on Available-for-sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>0000048 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" roleURI="http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails">
        <link:definition>0000049 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesScheduleofInventoriesDetails" roleURI="http://www.merck.com/role/InventoriesScheduleofInventoriesDetails">
        <link:definition>0000050 - Disclosure - Inventories - Schedule of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesScheduleofInventoriesDetails_1" roleURI="http://www.merck.com/role/InventoriesScheduleofInventoriesDetails_1">
        <link:definition>0000050 - Disclosure - Inventories - Schedule of Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNarrativeDetails" roleURI="http://www.merck.com/role/InventoriesNarrativeDetails">
        <link:definition>0000051 - Disclosure - Inventories - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesDetails" roleURI="http://www.merck.com/role/ContingenciesDetails">
        <link:definition>0000052 - Disclosure - Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityDetails" roleURI="http://www.merck.com/role/EquityDetails">
        <link:definition>0000053 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails">
        <link:definition>0000054 - Disclosure - Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionandOtherPostretirementBenefitPlansNarrativeDetails" roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails">
        <link:definition>0000055 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" roleURI="http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails">
        <link:definition>0000056 - Disclosure - Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeExpenseNetNarrativeDetails" roleURI="http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails">
        <link:definition>0000057 - Disclosure - Other (Income) Expense, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxesonIncomeDetails" roleURI="http://www.merck.com/role/TaxesonIncomeDetails">
        <link:definition>0000058 - Disclosure - Taxes on Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareCalculationsofEarningsPerShareDetails" roleURI="http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails">
        <link:definition>0000059 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareNarrativeDetails" roleURI="http://www.merck.com/role/EarningsPerShareNarrativeDetails">
        <link:definition>0000060 - Disclosure - Earnings Per Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherComprehensiveIncomeLossDetails" roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails">
        <link:definition>0000061 - Disclosure - Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingNarrativeDetails" roleURI="http://www.merck.com/role/SegmentReportingNarrativeDetails">
        <link:definition>0000062 - Disclosure - Segment Reporting - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingSalesfromProductsDetails" roleURI="http://www.merck.com/role/SegmentReportingSalesfromProductsDetails">
        <link:definition>0000063 - Disclosure - Segment Reporting - Sales from Products (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingConsolidatedSalesbyGeographicAreaDetails" roleURI="http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails">
        <link:definition>0000064 - Disclosure - Segment Reporting - Consolidated Sales by Geographic Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" roleURI="http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails">
        <link:definition>0000065 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mrk_SalesBasedMilestonesMember" abstract="true" name="SalesBasedMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AllianceRevenueAdempasVerquvoMember" abstract="true" name="AllianceRevenueAdempasVerquvoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" abstract="false" name="AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mrk_PharmaceuticalsegmentMember" abstract="true" name="PharmaceuticalsegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" abstract="false" name="EstimateOfCumulativePreTaxCostsThatWillBeNoncash" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_AllianceRevenueKoselugoMember" abstract="true" name="AllianceRevenueKoselugoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember" abstract="true" name="DeferredIncomeTaxesAndOtherAssetsCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A1.875Notesdue2026Member" abstract="true" name="A1.875Notesdue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_LynparzaMember" abstract="true" name="LynparzaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_RidgebackBiotherapeuticsLPMember" abstract="true" name="RidgebackBiotherapeuticsLPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty" abstract="false" name="CollaborativeArrangementPreferredStockInvestmentInCounterparty" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_AllianceRevenueReblozylMember" abstract="true" name="AllianceRevenueReblozylMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_EurodominatedNotesMember" abstract="true" name="EurodominatedNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_StockholdersEquityTable" abstract="true" name="StockholdersEquityTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued" abstract="false" name="CollaborativeArrangementRegulatoryMilestonePaymentsAccrued" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_ComplaintAgainstTheJohnsHopkinsUniversityMember" abstract="true" name="ComplaintAgainstTheJohnsHopkinsUniversityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_WeliregMember" abstract="true" name="WeliregMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CollaborativeArrangementSalesNet" abstract="false" name="CollaborativeArrangementSalesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_SimponiMember" abstract="true" name="SimponiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_BayerAGMember" abstract="true" name="BayerAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_InternationalMember" abstract="true" name="InternationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AssetAcquisitionSharePrice" abstract="false" name="AssetAcquisitionSharePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="mrk_InventoryNetAndInventoryNoncurrent" abstract="false" name="InventoryNetAndInventoryNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_StockholdersEquityLineItems" abstract="true" name="StockholdersEquityLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_JanuviaMember" abstract="true" name="JanuviaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A2.500Notesdue2034Member" abstract="true" name="A2.500Notesdue2034Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_IsentressIsentressHDMember" abstract="true" name="IsentressIsentressHDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DificidMember" abstract="true" name="DificidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_OtherPharmaceuticalMember" abstract="true" name="OtherPharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_IncreaseDecreaseInHedgeRevenue" abstract="false" name="IncreaseDecreaseInHedgeRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_LossContingencyNumberOfStatesInWhichPlaintiffsReside" abstract="false" name="LossContingencyNumberOfStatesInWhichPlaintiffsReside" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mrk_SanofiPasteurMember" abstract="true" name="SanofiPasteurMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_BridionMember" abstract="true" name="BridionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_VaqtaMember" abstract="true" name="VaqtaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ProQuadMMRIIVarivaxMember" abstract="true" name="ProQuadMMRIIVarivaxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ProbableContingentPaymentsCollaborativeArrangement" abstract="false" name="ProbableContingentPaymentsCollaborativeArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_PrevymisMember" abstract="true" name="PrevymisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_Pneumovax23Member" abstract="true" name="Pneumovax23Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_TransitionServicesAgreementMember" abstract="true" name="TransitionServicesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember" abstract="true" name="DeferredIncomeTaxesAndOtherAssetsNoncurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" abstract="false" name="RestructuringReserveIncreaseDecreaseNoncashActivity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_OrganonCoMember" abstract="true" name="OrganonCoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_MilestonePaymentsMadetoCollaborativePartner" abstract="false" name="MilestonePaymentsMadetoCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_LagevrioMember" abstract="true" name="LagevrioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_JanuviaAndJanumetMember" abstract="true" name="JanuviaAndJanumetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_TaxBenefitResultingFromAcquisitionCharge" abstract="false" name="TaxBenefitResultingFromAcquisitionCharge" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember" abstract="true" name="SichuanKelunBiotechBiopharmaceuticalCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_InventoriesProducedinPreparationforProductLaunchesMember" abstract="true" name="InventoriesProducedinPreparationforProductLaunchesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_LossContingencyTrialPeriod" abstract="false" name="LossContingencyTrialPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mrk_RoyaltyRatePercentage" abstract="false" name="RoyaltyRatePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_PrometheusBiosciencesIncMember" abstract="true" name="PrometheusBiosciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CollaborativeArrangementProfitSharing" abstract="false" name="CollaborativeArrangementProfitSharing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_RemicadeMember" abstract="true" name="RemicadeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_LegalDefenseCostsMember" abstract="true" name="LegalDefenseCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_VaxneuvanceMember" abstract="true" name="VaxneuvanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AnimalHealthsegmentMember" abstract="true" name="AnimalHealthsegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A1.375Notesdue2036Member" abstract="true" name="A1.375Notesdue2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_OtherNonoperatingIncomeExpenseOther" abstract="false" name="OtherNonoperatingIncomeExpenseOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_SalesDiscounts" abstract="false" name="SalesDiscounts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_CompanionAnimalsMember" abstract="true" name="CompanionAnimalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_RecognizedAsAbstract" abstract="true" name="RecognizedAsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_ZerbaxaMember" abstract="true" name="ZerbaxaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_OtherCountriesMember" abstract="true" name="OtherCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_LivestockMember" abstract="true" name="LivestockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_A0.500Notesdue2024Member" abstract="true" name="A0.500Notesdue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_PrimaxinMember" abstract="true" name="PrimaxinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_LenvimaMember" abstract="true" name="LenvimaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" abstract="true" name="InventoryNotExpectedtobeSoldWithinOneYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_EisaiMember" abstract="true" name="EisaiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AstraZenecaMember" abstract="true" name="AstraZenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_BristolMyersSquibbMember" abstract="true" name="BristolMyersSquibbMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CollaborativeArrangementsAbstract" abstract="true" name="CollaborativeArrangementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mrk_GardasilGardasil9Member" abstract="true" name="GardasilGardasil9Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" abstract="false" name="EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="mrk_PotentialFutureMilestonePaymentsSalesBased" abstract="false" name="PotentialFutureMilestonePaymentsSalesBased" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_ImagoBioSciencesIncMember" abstract="true" name="ImagoBioSciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_MilestonePaymentsSalesBased" abstract="false" name="MilestonePaymentsSalesBased" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_ContingentProceedsCollaborativeArrangement" abstract="false" name="ContingentProceedsCollaborativeArrangement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_RoyaltyRateDeductionPercentage" abstract="false" name="RoyaltyRateDeductionPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="mrk_InventoryTable" abstract="true" name="InventoryTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="mrk_RotaTeqAntitrustLitigationMember" abstract="true" name="RotaTeqAntitrustLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_RegulatoryMilestonesMember" abstract="true" name="RegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CostsExpensesAndOther" abstract="false" name="CostsExpensesAndOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_AlliancerevenueLynparzaMember" abstract="true" name="AlliancerevenueLynparzaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_SegmentReportingUnallocatedOtherExpensesNet" abstract="false" name="SegmentReportingUnallocatedOtherExpensesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" abstract="false" name="OffsettingAssetsAndLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="mrk_KeytrudaMember" abstract="true" name="KeytrudaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_RotateqMember" abstract="true" name="RotateqMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_NoxafilMember" abstract="true" name="NoxafilMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_AcceleratedDepreciationMember" abstract="true" name="AcceleratedDepreciationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_JanumetMember" abstract="true" name="JanumetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ManufacturingAndSupplyAgreementsMember" abstract="true" name="ManufacturingAndSupplyAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_BelsomraMember" abstract="true" name="BelsomraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_VerquvoMember" abstract="true" name="VerquvoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_ZetiaantitrustlitigationMember" abstract="true" name="ZetiaantitrustlitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_PotentialFutureMilestonePaymentsRegulatory" abstract="false" name="PotentialFutureMilestonePaymentsRegulatory" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" abstract="false" name="AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mrk_AdempasMember" abstract="true" name="AdempasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mrk_DebtSecuritiesandEquitySecuritiesFVNI" abstract="false" name="DebtSecuritiesandEquitySecuritiesFVNI" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>mrk-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:f17f1926-1a01-4baa-a406-054ce45079f2,g:c6b1c5ce-74aa-44b6-956b-90e243d128be-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" xlink:type="simple" xlink:href="mrk-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15fbbaa4-886b-4417-afd1-b8eb3f093042" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_330c2d07-363b-4a8f-b241-b84c729cc994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15fbbaa4-886b-4417-afd1-b8eb3f093042" xlink:to="loc_us-gaap_Revenues_330c2d07-363b-4a8f-b241-b84c729cc994" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CostsExpensesAndOther_6a6a494f-21ce-4e60-9ad1-bd719a29fcf9" xlink:href="mrk-20230331.xsd#mrk_CostsExpensesAndOther"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15fbbaa4-886b-4417-afd1-b8eb3f093042" xlink:to="loc_mrk_CostsExpensesAndOther_6a6a494f-21ce-4e60-9ad1-bd719a29fcf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CostsExpensesAndOther_57c60c9e-1543-4316-a80d-63a9c63dadcc" xlink:href="mrk-20230331.xsd#mrk_CostsExpensesAndOther"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2fa1c3a6-42da-422e-87e0-d6d104e488b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_57c60c9e-1543-4316-a80d-63a9c63dadcc" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2fa1c3a6-42da-422e-87e0-d6d104e488b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b69e33cd-8ab2-464f-b85c-49c0d109ef17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_57c60c9e-1543-4316-a80d-63a9c63dadcc" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b69e33cd-8ab2-464f-b85c-49c0d109ef17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_063b4e8c-0820-4850-b651-7e9f0a55475e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_57c60c9e-1543-4316-a80d-63a9c63dadcc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_063b4e8c-0820-4850-b651-7e9f0a55475e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_8418ff6a-93db-41c2-9d1e-7aa3040aaa63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_57c60c9e-1543-4316-a80d-63a9c63dadcc" xlink:to="loc_us-gaap_RestructuringCharges_8418ff6a-93db-41c2-9d1e-7aa3040aaa63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_06f08939-e3ea-4539-abe3-b25e4a4d077c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_CostsExpensesAndOther_57c60c9e-1543-4316-a80d-63a9c63dadcc" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_06f08939-e3ea-4539-abe3-b25e4a4d077c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_62d84666-be61-457a-9f59-d05873f806b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_af04a7a6-4e33-409f-b22d-4a56a35e443e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_62d84666-be61-457a-9f59-d05873f806b2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_af04a7a6-4e33-409f-b22d-4a56a35e443e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_77930cab-c1f4-4553-9fae-b2ee4ab7920f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_62d84666-be61-457a-9f59-d05873f806b2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_77930cab-c1f4-4553-9fae-b2ee4ab7920f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d0ea410c-3b9f-4980-b26f-6b0da548b96b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_d09488a3-b9bc-4aaf-9dc8-14a7733dca51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d0ea410c-3b9f-4980-b26f-6b0da548b96b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_d09488a3-b9bc-4aaf-9dc8-14a7733dca51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c76a5090-73b2-410e-8fdd-5f56e78296eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d0ea410c-3b9f-4980-b26f-6b0da548b96b" xlink:to="loc_us-gaap_ProfitLoss_c76a5090-73b2-410e-8fdd-5f56e78296eb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="mrk-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7d554185-e1ca-4521-8d3d-cf00fedcf9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_189ffb58-87c5-4439-8c6e-6ed267edffb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7d554185-e1ca-4521-8d3d-cf00fedcf9a5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_189ffb58-87c5-4439-8c6e-6ed267edffb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_ce21d2e0-f0d5-4a96-9f13-4bd2a799863a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7d554185-e1ca-4521-8d3d-cf00fedcf9a5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_ce21d2e0-f0d5-4a96-9f13-4bd2a799863a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_58279ab9-88cd-4f1b-ac21-de7e8918c42e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7d554185-e1ca-4521-8d3d-cf00fedcf9a5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_58279ab9-88cd-4f1b-ac21-de7e8918c42e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_16e7ac90-afc8-4442-9432-911b5cba9d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2019cc52-feba-41b3-9219-0a93e451ec53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_16e7ac90-afc8-4442-9432-911b5cba9d50" xlink:to="loc_us-gaap_NetIncomeLoss_2019cc52-feba-41b3-9219-0a93e451ec53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_80f82122-875b-4b8d-9cc1-8f6e4ac8dc35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_16e7ac90-afc8-4442-9432-911b5cba9d50" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_80f82122-875b-4b8d-9cc1-8f6e4ac8dc35" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" xlink:type="simple" xlink:href="mrk-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEET"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3084dd26-cb08-4073-8a29-aebe340b25fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bc5818ae-1528-4974-a50c-4c247e4b74f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3084dd26-cb08-4073-8a29-aebe340b25fc" xlink:to="loc_us-gaap_StockholdersEquity_bc5818ae-1528-4974-a50c-4c247e4b74f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_379bf2b6-2f52-4ca9-8193-972d2dffc535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3084dd26-cb08-4073-8a29-aebe340b25fc" xlink:to="loc_us-gaap_MinorityInterest_379bf2b6-2f52-4ca9-8193-972d2dffc535" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c52b9855-7c43-44bf-8761-ac033cfc598b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_28eff159-48ba-4989-b2e7-fb6755f47798" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c52b9855-7c43-44bf-8761-ac033cfc598b" xlink:to="loc_us-gaap_AccountsPayableCurrent_28eff159-48ba-4989-b2e7-fb6755f47798" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_37de7c3b-f376-4b15-8c45-9a68bcad44b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c52b9855-7c43-44bf-8761-ac033cfc598b" xlink:to="loc_us-gaap_DebtCurrent_37de7c3b-f376-4b15-8c45-9a68bcad44b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4a15d3c4-15d1-49da-b0b6-65b23e132682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c52b9855-7c43-44bf-8761-ac033cfc598b" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_4a15d3c4-15d1-49da-b0b6-65b23e132682" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_1ff3311e-4474-4c63-b4f1-316efa23e41e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c52b9855-7c43-44bf-8761-ac033cfc598b" xlink:to="loc_us-gaap_DividendsPayableCurrent_1ff3311e-4474-4c63-b4f1-316efa23e41e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_f6ae5910-1953-4fe3-9478-b69bcb7d25a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_c52b9855-7c43-44bf-8761-ac033cfc598b" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_f6ae5910-1953-4fe3-9478-b69bcb7d25a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_93b6bfa6-78f2-4072-937a-4bd0405f1f70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_8befdd5c-fc92-43b9-9d66-7c4749aa64c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_93b6bfa6-78f2-4072-937a-4bd0405f1f70" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_8befdd5c-fc92-43b9-9d66-7c4749aa64c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e729719d-82d0-4a06-9d74-63db52b4991d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_93b6bfa6-78f2-4072-937a-4bd0405f1f70" xlink:to="loc_us-gaap_Goodwill_e729719d-82d0-4a06-9d74-63db52b4991d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6c2da891-54bd-4eb4-947a-efdc483cfe93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_93b6bfa6-78f2-4072-937a-4bd0405f1f70" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6c2da891-54bd-4eb4-947a-efdc483cfe93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_61f1d48f-226a-4a09-a79f-eff38c8a0c67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_93b6bfa6-78f2-4072-937a-4bd0405f1f70" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_61f1d48f-226a-4a09-a79f-eff38c8a0c67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5bd08306-20c4-4769-99e0-dab6d8135bce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_93b6bfa6-78f2-4072-937a-4bd0405f1f70" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5bd08306-20c4-4769-99e0-dab6d8135bce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b003832c-659f-4253-9e39-ad1f3b1aa542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_93b6bfa6-78f2-4072-937a-4bd0405f1f70" xlink:to="loc_us-gaap_AssetsCurrent_b003832c-659f-4253-9e39-ad1f3b1aa542" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_c7edec46-8005-43a2-9358-e984b733016d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d1bad252-9f27-43d2-82b3-d9f93c8dd4db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_c7edec46-8005-43a2-9358-e984b733016d" xlink:to="loc_us-gaap_CommonStockValue_d1bad252-9f27-43d2-82b3-d9f93c8dd4db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ed518072-ca4b-485f-90c1-cedf3e25a264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_c7edec46-8005-43a2-9358-e984b733016d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ed518072-ca4b-485f-90c1-cedf3e25a264" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_09cf8829-77fe-48b7-a6f9-64b1175f0359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_c7edec46-8005-43a2-9358-e984b733016d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_09cf8829-77fe-48b7-a6f9-64b1175f0359" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_85efaaf6-1fd0-4926-9a4d-b24f035e7297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_c7edec46-8005-43a2-9358-e984b733016d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_85efaaf6-1fd0-4926-9a4d-b24f035e7297" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_692f6bdd-8eb0-46a0-9b42-5403710174c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_892aca7e-ad45-4dc9-b9f2-aead148506b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_692f6bdd-8eb0-46a0-9b42-5403710174c2" xlink:to="loc_us-gaap_LiabilitiesCurrent_892aca7e-ad45-4dc9-b9f2-aead148506b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_14b225af-53d1-4e3f-aa74-34eee7700fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_692f6bdd-8eb0-46a0-9b42-5403710174c2" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_14b225af-53d1-4e3f-aa74-34eee7700fcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_4223f087-ce8c-4c76-8e02-9d42dcac5df5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_692f6bdd-8eb0-46a0-9b42-5403710174c2" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_4223f087-ce8c-4c76-8e02-9d42dcac5df5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6c4cdbc9-b238-43a3-b767-18e948810b95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_692f6bdd-8eb0-46a0-9b42-5403710174c2" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6c4cdbc9-b238-43a3-b767-18e948810b95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f702be07-17ae-45a7-ac11-6aa4e3718ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_692f6bdd-8eb0-46a0-9b42-5403710174c2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f702be07-17ae-45a7-ac11-6aa4e3718ae2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_35a9e68d-5f48-4fe7-a30c-52aed7ddc8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_1e68814a-52ff-496b-bc59-ee87fc7e4c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_35a9e68d-5f48-4fe7-a30c-52aed7ddc8c6" xlink:to="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_1e68814a-52ff-496b-bc59-ee87fc7e4c65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_ce037c5b-4dad-4255-939a-44f7f74f9865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_35a9e68d-5f48-4fe7-a30c-52aed7ddc8c6" xlink:to="loc_us-gaap_TreasuryStockCommonValue_ce037c5b-4dad-4255-939a-44f7f74f9865" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f02da8b5-b32b-4c8f-a461-45cffcedca2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_49d45aba-fee8-4509-ac06-a5556aff4880" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f02da8b5-b32b-4c8f-a461-45cffcedca2c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_49d45aba-fee8-4509-ac06-a5556aff4880" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent_9b645d2d-d071-4cf4-a189-e4ef43054b02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f02da8b5-b32b-4c8f-a461-45cffcedca2c" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent_9b645d2d-d071-4cf4-a189-e4ef43054b02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_12d681dc-b556-47a3-9f74-1c360d73d301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f02da8b5-b32b-4c8f-a461-45cffcedca2c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_12d681dc-b556-47a3-9f74-1c360d73d301" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_30a9f829-23e6-43a5-b196-4526b433d2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f02da8b5-b32b-4c8f-a461-45cffcedca2c" xlink:to="loc_us-gaap_InventoryNet_30a9f829-23e6-43a5-b196-4526b433d2e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_f7eecbb9-8572-435e-b8ec-456bd9aadc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f02da8b5-b32b-4c8f-a461-45cffcedca2c" xlink:to="loc_us-gaap_ShortTermInvestments_f7eecbb9-8572-435e-b8ec-456bd9aadc8a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="simple" xlink:href="mrk-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a42fa1b5-2158-4ad0-ada5-81763f611eff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_1a997f64-1181-4717-b63d-293d7872c724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a42fa1b5-2158-4ad0-ada5-81763f611eff" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_1a997f64-1181-4717-b63d-293d7872c724" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_bbd81411-901c-492b-819a-29afff93b3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a42fa1b5-2158-4ad0-ada5-81763f611eff" xlink:to="loc_us-gaap_AdjustmentForAmortization_bbd81411-901c-492b-819a-29afff93b3d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e3775795-6636-4e8e-a589-33a461558da8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a42fa1b5-2158-4ad0-ada5-81763f611eff" xlink:to="loc_us-gaap_ShareBasedCompensation_e3775795-6636-4e8e-a589-33a461558da8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_eed82f33-9816-4e25-a448-1c7bbb3618c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a42fa1b5-2158-4ad0-ada5-81763f611eff" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_eed82f33-9816-4e25-a448-1c7bbb3618c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_b293f4bb-8461-4ea4-b1a7-43c4ed594af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a42fa1b5-2158-4ad0-ada5-81763f611eff" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_b293f4bb-8461-4ea4-b1a7-43c4ed594af4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_402ec409-6ce0-4a6b-810e-7b71f5c334c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a42fa1b5-2158-4ad0-ada5-81763f611eff" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_402ec409-6ce0-4a6b-810e-7b71f5c334c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_e43ffd5c-3953-4a98-a8ab-cda664379fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a42fa1b5-2158-4ad0-ada5-81763f611eff" xlink:to="loc_us-gaap_Depreciation_e43ffd5c-3953-4a98-a8ab-cda664379fd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_6d9a9392-6b7f-4080-9cf4-a76bfb362202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a42fa1b5-2158-4ad0-ada5-81763f611eff" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_6d9a9392-6b7f-4080-9cf4-a76bfb362202" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_57152ead-ce80-43ff-9a69-e47ad9195429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a42fa1b5-2158-4ad0-ada5-81763f611eff" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_57152ead-ce80-43ff-9a69-e47ad9195429" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2fc18e39-100e-429a-90be-011d7cba5869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_56b8abbf-e602-462b-9629-c4b07b67de0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2fc18e39-100e-429a-90be-011d7cba5869" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_56b8abbf-e602-462b-9629-c4b07b67de0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f480eeda-3e9a-41db-b4d3-c9389ad929b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2fc18e39-100e-429a-90be-011d7cba5869" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f480eeda-3e9a-41db-b4d3-c9389ad929b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_7d8d5391-5a3f-4810-be6d-6f9bbc09b867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2fc18e39-100e-429a-90be-011d7cba5869" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_7d8d5391-5a3f-4810-be6d-6f9bbc09b867" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_dbf3260e-62fb-4f16-8ebf-d8fe7ba857f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2fc18e39-100e-429a-90be-011d7cba5869" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_dbf3260e-62fb-4f16-8ebf-d8fe7ba857f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3e8f9292-2f52-47bb-a86d-6a65442fe45f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2fc18e39-100e-429a-90be-011d7cba5869" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3e8f9292-2f52-47bb-a86d-6a65442fe45f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bce3ac6c-be9c-446d-b0c8-4517dc635c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1292abd4-2c66-4367-9203-732f9b056e15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bce3ac6c-be9c-446d-b0c8-4517dc635c9b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1292abd4-2c66-4367-9203-732f9b056e15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3b73fa01-f422-428d-b49c-6f60c1fa85a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bce3ac6c-be9c-446d-b0c8-4517dc635c9b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3b73fa01-f422-428d-b49c-6f60c1fa85a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f6f28361-a227-425e-8c1e-3676f49bdc80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bce3ac6c-be9c-446d-b0c8-4517dc635c9b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f6f28361-a227-425e-8c1e-3676f49bdc80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b02ca4f2-215d-44d0-b48d-d6e8f4c8a09f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bce3ac6c-be9c-446d-b0c8-4517dc635c9b" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b02ca4f2-215d-44d0-b48d-d6e8f4c8a09f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2bddb345-47e1-49db-93c7-4968db82b29f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7d0ff5d3-03ec-4e84-87c5-ed78527c3348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2bddb345-47e1-49db-93c7-4968db82b29f" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_7d0ff5d3-03ec-4e84-87c5-ed78527c3348" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_b3d29f20-badd-40ff-b614-8c34011b257c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2bddb345-47e1-49db-93c7-4968db82b29f" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_b3d29f20-badd-40ff-b614-8c34011b257c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_4e53a349-dd23-42e5-a455-11aad49d0eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2bddb345-47e1-49db-93c7-4968db82b29f" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_4e53a349-dd23-42e5-a455-11aad49d0eef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_74568879-3581-4bad-bcf5-21b0067e4759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2bddb345-47e1-49db-93c7-4968db82b29f" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_74568879-3581-4bad-bcf5-21b0067e4759" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_e26acac9-b2a3-4edc-a200-94de671144cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2bddb345-47e1-49db-93c7-4968db82b29f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_e26acac9-b2a3-4edc-a200-94de671144cf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#CollaborativeArrangementsFinancialInformationDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_501f4f6e-ea45-4b62-9eff-6610c1922156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementProfitSharing_f4064f06-7ff6-4263-a6f9-6682ccde59d3" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementProfitSharing"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_501f4f6e-ea45-4b62-9eff-6610c1922156" xlink:to="loc_mrk_CollaborativeArrangementProfitSharing_f4064f06-7ff6-4263-a6f9-6682ccde59d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementSalesNet_96f7a33e-982d-477d-b944-9fa9ba0886e4" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementSalesNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_501f4f6e-ea45-4b62-9eff-6610c1922156" xlink:to="loc_mrk_CollaborativeArrangementSalesNet_96f7a33e-982d-477d-b944-9fa9ba0886e4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_1bb59dc8-b9b4-43cb-b597-b106927f43cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_70d0e606-fea0-4ae3-85a1-5f3bbb8de167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_1bb59dc8-b9b4-43cb-b597-b106927f43cd" xlink:to="loc_us-gaap_DerivativeLiabilities_70d0e606-fea0-4ae3-85a1-5f3bbb8de167" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_662b8ea2-fc4e-48b1-9b21-78bd3788cd73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_1bb59dc8-b9b4-43cb-b597-b106927f43cd" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_662b8ea2-fc4e-48b1-9b21-78bd3788cd73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_3195722d-c0ff-4aa3-b5db-fcf328861162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_1bb59dc8-b9b4-43cb-b597-b106927f43cd" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_3195722d-c0ff-4aa3-b5db-fcf328861162" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_65ee8228-646e-4e34-8ed1-c2d0d7d79fff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_f330aff8-225c-4a7c-954c-68d1310e6189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_65ee8228-646e-4e34-8ed1-c2d0d7d79fff" xlink:to="loc_us-gaap_DerivativeAssets_f330aff8-225c-4a7c-954c-68d1310e6189" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_3cc6f38c-707e-40bd-afe7-74143dac255e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_65ee8228-646e-4e34-8ed1-c2d0d7d79fff" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_3cc6f38c-707e-40bd-afe7-74143dac255e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_9035a1aa-ffff-43fd-9d4e-7854aabe5977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_65ee8228-646e-4e34-8ed1-c2d0d7d79fff" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_9035a1aa-ffff-43fd-9d4e-7854aabe5977" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_d82b6907-05f1-4040-abf4-044f2fc9cb6a" xlink:href="mrk-20230331.xsd#mrk_DebtSecuritiesandEquitySecuritiesFVNI"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ecf9912-a1bf-45f3-9b30-983a4f813fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_d82b6907-05f1-4040-abf4-044f2fc9cb6a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ecf9912-a1bf-45f3-9b30-983a4f813fa4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_6eeb9f57-3b0d-44a2-904b-0de2b798d15f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_d82b6907-05f1-4040-abf4-044f2fc9cb6a" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_6eeb9f57-3b0d-44a2-904b-0de2b798d15f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d7698bd8-4083-4a2b-91c2-d3e4aef50f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1b52d586-adcc-43f8-86cd-35160f6bf2a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d7698bd8-4083-4a2b-91c2-d3e4aef50f05" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1b52d586-adcc-43f8-86cd-35160f6bf2a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0a136b00-515d-47ed-a408-af28849b72ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d7698bd8-4083-4a2b-91c2-d3e4aef50f05" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0a136b00-515d-47ed-a408-af28849b72ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5a597db0-d96b-4a07-8eaa-ffa873cb5c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d7698bd8-4083-4a2b-91c2-d3e4aef50f05" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5a597db0-d96b-4a07-8eaa-ffa873cb5c1f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_5501c69e-4070-4c66-b9bc-fe35096b747a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_aba867d0-e143-4574-9003-4f162d1b9c81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TradingSecurities_5501c69e-4070-4c66-b9bc-fe35096b747a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_aba867d0-e143-4574-9003-4f162d1b9c81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_d8d50f21-450c-4e13-84f8-26490d98a0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TradingSecurities_5501c69e-4070-4c66-b9bc-fe35096b747a" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_d8d50f21-450c-4e13-84f8-26490d98a0dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_0a17f7c3-0849-44ce-9985-002cefad87da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_8ff79ad0-3530-4934-a63f-815f34ce7e56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_0a17f7c3-0849-44ce-9985-002cefad87da" xlink:to="loc_us-gaap_TradingSecurities_8ff79ad0-3530-4934-a63f-815f34ce7e56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_111c965f-2180-4929-9798-9fcdb1a0ed76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_0a17f7c3-0849-44ce-9985-002cefad87da" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_111c965f-2180-4929-9798-9fcdb1a0ed76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_b46f2460-0ac4-4871-b6b7-44a1ff2fbcaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_0a17f7c3-0849-44ce-9985-002cefad87da" xlink:to="loc_us-gaap_DerivativeAssets_b46f2460-0ac4-4871-b6b7-44a1ff2fbcaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_bd05e305-08b3-49ea-b394-a4b8a6b0135d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_99e77657-eddf-47b4-acb0-9b3c11eee563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_bd05e305-08b3-49ea-b394-a4b8a6b0135d" xlink:to="loc_us-gaap_DerivativeLiabilities_99e77657-eddf-47b4-acb0-9b3c11eee563" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_28da0cad-0255-463e-8386-4eb525b56f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_bd05e305-08b3-49ea-b394-a4b8a6b0135d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_28da0cad-0255-463e-8386-4eb525b56f98" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNetAndInventoryNoncurrent_004a0b03-bb68-4031-b1d9-f6e6ef8d0ebe" xlink:href="mrk-20230331.xsd#mrk_InventoryNetAndInventoryNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_67713b23-f522-412a-90fc-b4ae74d0a1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent_004a0b03-bb68-4031-b1d9-f6e6ef8d0ebe" xlink:to="loc_us-gaap_InventoryNet_67713b23-f522-412a-90fc-b4ae74d0a1f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_e031fffe-0e2d-48af-99d7-e8ece683fafb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent_004a0b03-bb68-4031-b1d9-f6e6ef8d0ebe" xlink:to="loc_us-gaap_InventoryNoncurrent_e031fffe-0e2d-48af-99d7-e8ece683fafb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_326fcfa3-2f7f-43a7-9a97-09520af6a3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_0e0d64c1-30d0-4a26-8de3-9064d340ec7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_326fcfa3-2f7f-43a7-9a97-09520af6a3f6" xlink:to="loc_us-gaap_InventoryFinishedGoods_0e0d64c1-30d0-4a26-8de3-9064d340ec7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_d2cbc8d2-d435-4995-ba3b-dab57313ce0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_326fcfa3-2f7f-43a7-9a97-09520af6a3f6" xlink:to="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_d2cbc8d2-d435-4995-ba3b-dab57313ce0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventorySupplies_51a209e3-e67f-4b68-b4fa-8a3c2be122f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventorySupplies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_326fcfa3-2f7f-43a7-9a97-09520af6a3f6" xlink:to="loc_us-gaap_OtherInventorySupplies_51a209e3-e67f-4b68-b4fa-8a3c2be122f2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesScheduleofInventoriesDetails_1" xlink:type="simple" xlink:href="mrk-20230331.xsd#InventoriesScheduleofInventoriesDetails_1"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/InventoriesScheduleofInventoriesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNetAndInventoryNoncurrent_6accbe9c-e8e7-45e8-8fbf-4e32444d7b35" xlink:href="mrk-20230331.xsd#mrk_InventoryNetAndInventoryNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_c2fe0608-c3d6-4963-bee2-93144286d1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent_6accbe9c-e8e7-45e8-8fbf-4e32444d7b35" xlink:to="loc_us-gaap_InventoryGross_c2fe0608-c3d6-4963-bee2-93144286d1c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReserve_d65ab97e-90dc-492b-a78d-59a3baae763e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReserve"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent_6accbe9c-e8e7-45e8-8fbf-4e32444d7b35" xlink:to="loc_us-gaap_InventoryLIFOReserve_d65ab97e-90dc-492b-a78d-59a3baae763e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d4774103-0cb4-41df-865e-e622c7314b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_723a67ee-76f3-49d4-a638-c22b5db10dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d4774103-0cb4-41df-865e-e622c7314b47" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_723a67ee-76f3-49d4-a638-c22b5db10dc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_5c21b2fc-7837-495d-9f4e-818c25923bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d4774103-0cb4-41df-865e-e622c7314b47" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_5c21b2fc-7837-495d-9f4e-818c25923bf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_666926f9-0d73-46f3-bcfd-902188fa35c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d4774103-0cb4-41df-865e-e622c7314b47" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_666926f9-0d73-46f3-bcfd-902188fa35c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_2078635f-2d46-4cd4-ae28-02fe76483681" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d4774103-0cb4-41df-865e-e622c7314b47" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_2078635f-2d46-4cd4-ae28-02fe76483681" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_fdfac405-ebf1-4a40-8f8d-1f9f531f2398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d4774103-0cb4-41df-865e-e622c7314b47" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_fdfac405-ebf1-4a40-8f8d-1f9f531f2398" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_cab05ffa-833e-4685-8789-05bf436fedc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d4774103-0cb4-41df-865e-e622c7314b47" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_cab05ffa-833e-4685-8789-05bf436fedc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_6e57b7a9-0833-4f9a-8e0b-cb2ec4cd786e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d4774103-0cb4-41df-865e-e622c7314b47" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_6e57b7a9-0833-4f9a-8e0b-cb2ec4cd786e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c742d123-db59-481d-8c01-df7f071c87ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_5abd7306-a035-4846-9548-b65df4fc33ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_c742d123-db59-481d-8c01-df7f071c87ee" xlink:to="loc_us-gaap_InvestmentIncomeInterest_5abd7306-a035-4846-9548-b65df4fc33ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f6abaa62-433e-4e03-878c-a0659ebd6795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_c742d123-db59-481d-8c01-df7f071c87ee" xlink:to="loc_us-gaap_InterestExpense_f6abaa62-433e-4e03-878c-a0659ebd6795" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8568dfa1-bf95-4cb0-98fd-ab45364936d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_c742d123-db59-481d-8c01-df7f071c87ee" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_8568dfa1-bf95-4cb0-98fd-ab45364936d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_da1002a2-322c-4ce1-9c56-7380be3f6958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_c742d123-db59-481d-8c01-df7f071c87ee" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_da1002a2-322c-4ce1-9c56-7380be3f6958" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_6389b6b4-12e5-4c0a-a291-bfe1ffabf79e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_c742d123-db59-481d-8c01-df7f071c87ee" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_6389b6b4-12e5-4c0a-a291-bfe1ffabf79e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherNonoperatingIncomeExpenseOther_4f7d6f48-f8c6-438e-b461-364ee392bd90" xlink:href="mrk-20230331.xsd#mrk_OtherNonoperatingIncomeExpenseOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_c742d123-db59-481d-8c01-df7f071c87ee" xlink:to="loc_mrk_OtherNonoperatingIncomeExpenseOther_4f7d6f48-f8c6-438e-b461-364ee392bd90" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#EarningsPerShareCalculationsofEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d941b601-daab-4cae-87b3-88e9c79f0353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ae853e14-a111-4104-8515-da58207406f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d941b601-daab-4cae-87b3-88e9c79f0353" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ae853e14-a111-4104-8515-da58207406f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_a0e54d96-8e11-4f16-880c-e82d096b1990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d941b601-daab-4cae-87b3-88e9c79f0353" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_a0e54d96-8e11-4f16-880c-e82d096b1990" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#OtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_7d39c2ac-c04e-45a5-8ed1-402ee6b521fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_d4d4023b-669d-4c1e-96e6-2ec0e4617314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_7d39c2ac-c04e-45a5-8ed1-402ee6b521fa" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_d4d4023b-669d-4c1e-96e6-2ec0e4617314" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_b0076b0a-f725-49cd-80fb-337fcae74ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_7d39c2ac-c04e-45a5-8ed1-402ee6b521fa" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_b0076b0a-f725-49cd-80fb-337fcae74ac3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_663a5523-c5fa-4f38-8feb-a04e0e4d657f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_06214fff-ff8c-478c-8e73-1dee0348a878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_663a5523-c5fa-4f38-8feb-a04e0e4d657f" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_06214fff-ff8c-478c-8e73-1dee0348a878" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_02ac4e4f-a444-4434-9641-7703f0d7f3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_663a5523-c5fa-4f38-8feb-a04e0e4d657f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_02ac4e4f-a444-4434-9641-7703f0d7f3c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3cf0e2d2-5d0c-4ac7-9615-7ac88cbee287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_5008a85a-f0f7-4097-b770-195a4e834414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3cf0e2d2-5d0c-4ac7-9615-7ac88cbee287" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_5008a85a-f0f7-4097-b770-195a4e834414" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_02346648-d133-49e5-862e-d2b4f5c0999b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3cf0e2d2-5d0c-4ac7-9615-7ac88cbee287" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_02346648-d133-49e5-862e-d2b4f5c0999b" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>mrk-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:f17f1926-1a01-4baa-a406-054ce45079f2,g:c6b1c5ce-74aa-44b6-956b-90e243d128be-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.merck.com/role/CoverPage" xlink:type="simple" xlink:href="mrk-20230331.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CoverPage" xlink:type="extended" id="i882ffebeecc34f198ed0835913e43641_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_7aa65ef5-25ff-4af6-80fa-e1b7a712d4a4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_DocumentType_7aa65ef5-25ff-4af6-80fa-e1b7a712d4a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_92e08b77-a7bb-48cd-bf65-4cc0cad0c1fd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_DocumentQuarterlyReport_92e08b77-a7bb-48cd-bf65-4cc0cad0c1fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3a75ec54-ed45-4004-9afb-4b2dc5b020be" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_DocumentPeriodEndDate_3a75ec54-ed45-4004-9afb-4b2dc5b020be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4ba45462-de14-425c-a16e-43e3025db647" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_DocumentTransitionReport_4ba45462-de14-425c-a16e-43e3025db647" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d7d74ade-1666-479a-8185-6385a17b9205" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityFileNumber_d7d74ade-1666-479a-8185-6385a17b9205" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2533cf0b-84d4-4a21-baae-81b03897f89e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityRegistrantName_2533cf0b-84d4-4a21-baae-81b03897f89e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_9bf29a06-b981-4d71-b654-53d86c51edde" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_9bf29a06-b981-4d71-b654-53d86c51edde" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6cabebb1-d64d-45da-861c-cdb198cbbe28" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityTaxIdentificationNumber_6cabebb1-d64d-45da-861c-cdb198cbbe28" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_958e2ce8-b5b1-49a3-90bd-c5417e5ed367" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityAddressAddressLine1_958e2ce8-b5b1-49a3-90bd-c5417e5ed367" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_eaa36e45-8755-48f0-a726-7a160c382470" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityAddressCityOrTown_eaa36e45-8755-48f0-a726-7a160c382470" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0d7a4a13-ec9f-4b8a-8948-3bda83e1ae4b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityAddressStateOrProvince_0d7a4a13-ec9f-4b8a-8948-3bda83e1ae4b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_2853ad2b-5b8f-4955-a82a-4db090a9877d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityAddressPostalZipCode_2853ad2b-5b8f-4955-a82a-4db090a9877d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ec6977ce-8684-4e31-b956-ae7efb5a6bfe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_CityAreaCode_ec6977ce-8684-4e31-b956-ae7efb5a6bfe" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e4b10b07-1d98-4294-ace1-948e3ca45b82" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_LocalPhoneNumber_e4b10b07-1d98-4294-ace1-948e3ca45b82" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_9d53c856-24c1-4162-966d-8d80f9266fdd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_Security12bTitle_9d53c856-24c1-4162-966d-8d80f9266fdd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3bbf8bc2-b199-42df-85d3-609bed055f9d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_TradingSymbol_3bbf8bc2-b199-42df-85d3-609bed055f9d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c01b21de-0055-4085-8b7f-e82a22b9088d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_SecurityExchangeName_c01b21de-0055-4085-8b7f-e82a22b9088d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_82bf359f-ed54-4ae1-b38b-eb5ce4e62c26" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityCurrentReportingStatus_82bf359f-ed54-4ae1-b38b-eb5ce4e62c26" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_42d31649-a8e8-48db-8f6e-cf11e7c1f8f1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityInteractiveDataCurrent_42d31649-a8e8-48db-8f6e-cf11e7c1f8f1" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_5d465f7c-e4bb-45dc-b4e7-a09bf2f5ef87" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityFilerCategory_5d465f7c-e4bb-45dc-b4e7-a09bf2f5ef87" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ddb125b8-ce21-40b0-99e2-73a54e738fe4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntitySmallBusiness_ddb125b8-ce21-40b0-99e2-73a54e738fe4" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_8029d1bc-bd13-4f6c-a75b-16dc1785f611" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityEmergingGrowthCompany_8029d1bc-bd13-4f6c-a75b-16dc1785f611" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_591ae62f-20ed-4fd5-b347-d0b947789131" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityShellCompany_591ae62f-20ed-4fd5-b347-d0b947789131" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f4d9508b-44a2-4a3a-973a-ef7da510e70a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f4d9508b-44a2-4a3a-973a-ef7da510e70a" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_bf3d40c5-32e5-4815-b0f1-b826a28b82d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_AmendmentFlag_bf3d40c5-32e5-4815-b0f1-b826a28b82d9" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b97eef82-de50-4efc-a5e3-31551f70ef96" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_DocumentFiscalYearFocus_b97eef82-de50-4efc-a5e3-31551f70ef96" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_7d4f9294-ef53-4c55-9040-1d8d7f01fd1f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_DocumentFiscalPeriodFocus_7d4f9294-ef53-4c55-9040-1d8d7f01fd1f" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_64655201-47e3-481b-b7bb-fc33c899a8c9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityCentralIndexKey_64655201-47e3-481b-b7bb-fc33c899a8c9" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_4fea230a-8d76-4fba-8b81-b6c8cda8a2b8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_CurrentFiscalYearEndDate_4fea230a-8d76-4fba-8b81-b6c8cda8a2b8" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_56b36af4-91da-49bc-be07-454c9f83473b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntitiesTable_56b36af4-91da-49bc-be07-454c9f83473b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_15b39e48-66d0-44e7-b1fc-ddddc98b1fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_56b36af4-91da-49bc-be07-454c9f83473b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_15b39e48-66d0-44e7-b1fc-ddddc98b1fe8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_15b39e48-66d0-44e7-b1fc-ddddc98b1fe8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_15b39e48-66d0-44e7-b1fc-ddddc98b1fe8" xlink:to="loc_us-gaap_ClassOfStockDomain_15b39e48-66d0-44e7-b1fc-ddddc98b1fe8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_31180b7a-9485-40f3-815a-5ae3d8db526d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_15b39e48-66d0-44e7-b1fc-ddddc98b1fe8" xlink:to="loc_us-gaap_ClassOfStockDomain_31180b7a-9485-40f3-815a-5ae3d8db526d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5950f7e1-3d06-48ac-9c23-2679b5e76e55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_31180b7a-9485-40f3-815a-5ae3d8db526d" xlink:to="loc_us-gaap_CommonStockMember_5950f7e1-3d06-48ac-9c23-2679b5e76e55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.500Notesdue2024Member_9c84fd4f-8e9c-4562-a468-9611996e1d43" xlink:href="mrk-20230331.xsd#mrk_A0.500Notesdue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_31180b7a-9485-40f3-815a-5ae3d8db526d" xlink:to="loc_mrk_A0.500Notesdue2024Member_9c84fd4f-8e9c-4562-a468-9611996e1d43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.875Notesdue2026Member_f55198b1-0098-4848-9ab6-c6cd43ed02a9" xlink:href="mrk-20230331.xsd#mrk_A1.875Notesdue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_31180b7a-9485-40f3-815a-5ae3d8db526d" xlink:to="loc_mrk_A1.875Notesdue2026Member_f55198b1-0098-4848-9ab6-c6cd43ed02a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.500Notesdue2034Member_98e9dfd2-5da8-45cb-8267-3bda5d194e2d" xlink:href="mrk-20230331.xsd#mrk_A2.500Notesdue2034Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_31180b7a-9485-40f3-815a-5ae3d8db526d" xlink:to="loc_mrk_A2.500Notesdue2034Member_98e9dfd2-5da8-45cb-8267-3bda5d194e2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.375Notesdue2036Member_5111eba8-b12e-4191-96ee-1f4ad3ae5dce" xlink:href="mrk-20230331.xsd#mrk_A1.375Notesdue2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_31180b7a-9485-40f3-815a-5ae3d8db526d" xlink:to="loc_mrk_A1.375Notesdue2036Member_5111eba8-b12e-4191-96ee-1f4ad3ae5dce" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" xlink:type="simple" xlink:href="mrk-20230331.xsd#PensionandOtherPostretirementBenefitPlansTables"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" xlink:type="extended" id="i051a7de37cba4635803779a6c171989b_PensionandOtherPostretirementBenefitPlansTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94472863-f615-4cf9-a894-13095b4ddb66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_80239726-1f49-4a52-8a3c-a9600e9dc6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94472863-f615-4cf9-a894-13095b4ddb66" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_80239726-1f49-4a52-8a3c-a9600e9dc6e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_80f0f3a3-725c-4951-a9ab-a3e574f941aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94472863-f615-4cf9-a894-13095b4ddb66" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_80f0f3a3-725c-4951-a9ab-a3e574f941aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_9df11bef-3c04-43f3-9549-7cca74ef932f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_80f0f3a3-725c-4951-a9ab-a3e574f941aa" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_9df11bef-3c04-43f3-9549-7cca74ef932f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_9df11bef-3c04-43f3-9549-7cca74ef932f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_9df11bef-3c04-43f3-9549-7cca74ef932f" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_9df11bef-3c04-43f3-9549-7cca74ef932f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_2db486b6-c020-4ff4-90a0-dcd73356b6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_9df11bef-3c04-43f3-9549-7cca74ef932f" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_2db486b6-c020-4ff4-90a0-dcd73356b6fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_084d0779-0bc0-4fc6-909c-15c4118ab83c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_2db486b6-c020-4ff4-90a0-dcd73356b6fa" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_084d0779-0bc0-4fc6-909c-15c4118ab83c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_5235371a-3725-4104-a065-9fe537235a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_2db486b6-c020-4ff4-90a0-dcd73356b6fa" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_5235371a-3725-4104-a065-9fe537235a39" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SpinOffofOrganonCoDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#SpinOffofOrganonCoDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SpinOffofOrganonCoDetails" xlink:type="extended" id="ia84681a62f9140e1b6012c9b1011c555_SpinOffofOrganonCoDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_24a69840-2f05-4280-9561-62167705be84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_03ae9688-4cc7-4718-9e73-4a769ebf489e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_24a69840-2f05-4280-9561-62167705be84" xlink:to="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_03ae9688-4cc7-4718-9e73-4a769ebf489e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_fb0a2d8e-ff9e-4771-b9de-17e3d9ae5400" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_24a69840-2f05-4280-9561-62167705be84" xlink:to="loc_us-gaap_RevenueFromRelatedParties_fb0a2d8e-ff9e-4771-b9de-17e3d9ae5400" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartiesAmountInCostOfSales_912d4a17-cad6-4575-9968-c046b1debacd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartiesAmountInCostOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_24a69840-2f05-4280-9561-62167705be84" xlink:to="loc_us-gaap_RelatedPartiesAmountInCostOfSales_912d4a17-cad6-4575-9968-c046b1debacd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_49801570-df2a-47c4-b2c6-f8fe997c20f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_24a69840-2f05-4280-9561-62167705be84" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_49801570-df2a-47c4-b2c6-f8fe997c20f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_1a262039-7d43-4b79-ae09-a142a48888cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_24a69840-2f05-4280-9561-62167705be84" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_1a262039-7d43-4b79-ae09-a142a48888cf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18f193dc-df84-46c5-b9b5-f18ba5ad153c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_24a69840-2f05-4280-9561-62167705be84" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18f193dc-df84-46c5-b9b5-f18ba5ad153c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5ef04929-6304-47d4-baab-24f3cc3bd782" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18f193dc-df84-46c5-b9b5-f18ba5ad153c" xlink:to="loc_srt_RangeAxis_5ef04929-6304-47d4-baab-24f3cc3bd782" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5ef04929-6304-47d4-baab-24f3cc3bd782_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5ef04929-6304-47d4-baab-24f3cc3bd782" xlink:to="loc_srt_RangeMember_5ef04929-6304-47d4-baab-24f3cc3bd782_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8cbe5494-4e6a-4944-8d4c-5329b1bbbc8b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5ef04929-6304-47d4-baab-24f3cc3bd782" xlink:to="loc_srt_RangeMember_8cbe5494-4e6a-4944-8d4c-5329b1bbbc8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_41ae77f7-487f-433e-8019-a7246311b7c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8cbe5494-4e6a-4944-8d4c-5329b1bbbc8b" xlink:to="loc_srt_MinimumMember_41ae77f7-487f-433e-8019-a7246311b7c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_604d1f42-343d-45b9-b6d6-6f73f363ac53" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8cbe5494-4e6a-4944-8d4c-5329b1bbbc8b" xlink:to="loc_srt_MaximumMember_604d1f42-343d-45b9-b6d6-6f73f363ac53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_30545cdb-7bfa-487d-ae10-d99293687c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18f193dc-df84-46c5-b9b5-f18ba5ad153c" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_30545cdb-7bfa-487d-ae10-d99293687c83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_30545cdb-7bfa-487d-ae10-d99293687c83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_30545cdb-7bfa-487d-ae10-d99293687c83" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_30545cdb-7bfa-487d-ae10-d99293687c83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_3922b065-25e2-4af2-b86f-f7616d4c0907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_30545cdb-7bfa-487d-ae10-d99293687c83" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_3922b065-25e2-4af2-b86f-f7616d4c0907" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TransitionServicesAgreementMember_2f78c4aa-1852-4744-9024-8ddab8ccdb4a" xlink:href="mrk-20230331.xsd#mrk_TransitionServicesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3922b065-25e2-4af2-b86f-f7616d4c0907" xlink:to="loc_mrk_TransitionServicesAgreementMember_2f78c4aa-1852-4744-9024-8ddab8ccdb4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ManufacturingAndSupplyAgreementsMember_236da62c-56e2-439a-8960-20d94b01a4e5" xlink:href="mrk-20230331.xsd#mrk_ManufacturingAndSupplyAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3922b065-25e2-4af2-b86f-f7616d4c0907" xlink:to="loc_mrk_ManufacturingAndSupplyAgreementsMember_236da62c-56e2-439a-8960-20d94b01a4e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_19248b45-627c-4ee8-818b-93b3954efb29" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18f193dc-df84-46c5-b9b5-f18ba5ad153c" xlink:to="loc_srt_CounterpartyNameAxis_19248b45-627c-4ee8-818b-93b3954efb29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19248b45-627c-4ee8-818b-93b3954efb29_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_19248b45-627c-4ee8-818b-93b3954efb29" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19248b45-627c-4ee8-818b-93b3954efb29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32edf50a-429e-474c-ae1f-1bbf4845e661" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_19248b45-627c-4ee8-818b-93b3954efb29" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32edf50a-429e-474c-ae1f-1bbf4845e661" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrganonCoMember_33fcb8f3-a286-4c72-90e0-a0f535ca4bda" xlink:href="mrk-20230331.xsd#mrk_OrganonCoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32edf50a-429e-474c-ae1f-1bbf4845e661" xlink:to="loc_mrk_OrganonCoMember_33fcb8f3-a286-4c72-90e0-a0f535ca4bda" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" xlink:type="extended" id="i63f2d897977b43fd8df91f0c25adc6f1_AcquisitionsResearchCollaborationsandLicenseAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f4cb6234-51c1-4280-9540-031212cb121c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetAcquisitionSharePrice_c77d1fc0-0af9-4293-8c7b-c314c3144540" xlink:href="mrk-20230331.xsd#mrk_AssetAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4cb6234-51c1-4280-9540-031212cb121c" xlink:to="loc_mrk_AssetAcquisitionSharePrice_c77d1fc0-0af9-4293-8c7b-c314c3144540" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected_a97d74cc-302a-4ce1-8434-e0133827f780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionPriceOfAcquisitionExpected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4cb6234-51c1-4280-9540-031212cb121c" xlink:to="loc_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected_a97d74cc-302a-4ce1-8434-e0133827f780" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_504c663b-4d25-4a0e-867e-8c0cfc1c5578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4cb6234-51c1-4280-9540-031212cb121c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_504c663b-4d25-4a0e-867e-8c0cfc1c5578" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments_e7bda1b8-e735-4b6f-ba8d-1d854ff18254" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4cb6234-51c1-4280-9540-031212cb121c" xlink:to="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments_e7bda1b8-e735-4b6f-ba8d-1d854ff18254" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_2a77c56c-1126-44c9-a306-e35b163df918" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4cb6234-51c1-4280-9540-031212cb121c" xlink:to="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_2a77c56c-1126-44c9-a306-e35b163df918" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments_d093e1d7-63b8-48b3-8435-c8a6c046e56a" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4cb6234-51c1-4280-9540-031212cb121c" xlink:to="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments_d093e1d7-63b8-48b3-8435-c8a6c046e56a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty_1a09db89-cefb-450a-8f46-3a000885f295" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4cb6234-51c1-4280-9540-031212cb121c" xlink:to="loc_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty_1a09db89-cefb-450a-8f46-3a000885f295" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_9a6c6a3c-f5ca-477a-b4a2-2528ad2c42c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4cb6234-51c1-4280-9540-031212cb121c" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_9a6c6a3c-f5ca-477a-b4a2-2528ad2c42c3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_0ff84ae7-1d21-42e2-8f4c-2c6ea80b934f" xlink:href="mrk-20230331.xsd#mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4cb6234-51c1-4280-9540-031212cb121c" xlink:to="loc_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_0ff84ae7-1d21-42e2-8f4c-2c6ea80b934f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_9f59c9c9-8ba7-4288-8020-e0d40d075671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4cb6234-51c1-4280-9540-031212cb121c" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_9f59c9c9-8ba7-4288-8020-e0d40d075671" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_388387b7-0cd1-466f-a161-bb633a7e2681" xlink:href="mrk-20230331.xsd#mrk_MilestonePaymentsMadetoCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4cb6234-51c1-4280-9540-031212cb121c" xlink:to="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_388387b7-0cd1-466f-a161-bb633a7e2681" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b94167b-0604-4f80-abc9-11b110c081f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4cb6234-51c1-4280-9540-031212cb121c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b94167b-0604-4f80-abc9-11b110c081f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3e9d692c-0e0e-4f54-b0a0-9d86bb46898c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b94167b-0604-4f80-abc9-11b110c081f4" xlink:to="loc_srt_CounterpartyNameAxis_3e9d692c-0e0e-4f54-b0a0-9d86bb46898c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e9d692c-0e0e-4f54-b0a0-9d86bb46898c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3e9d692c-0e0e-4f54-b0a0-9d86bb46898c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3e9d692c-0e0e-4f54-b0a0-9d86bb46898c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9fe0e91e-0a5c-4eb8-b174-b3b0f33a6742" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3e9d692c-0e0e-4f54-b0a0-9d86bb46898c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9fe0e91e-0a5c-4eb8-b174-b3b0f33a6742" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember_24fa11d6-bce8-4b35-8817-fe5f6d57ffd6" xlink:href="mrk-20230331.xsd#mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9fe0e91e-0a5c-4eb8-b174-b3b0f33a6742" xlink:to="loc_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember_24fa11d6-bce8-4b35-8817-fe5f6d57ffd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember_931db962-248b-44d3-b0f3-e63fb8f1d560" xlink:href="mrk-20230331.xsd#mrk_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9fe0e91e-0a5c-4eb8-b174-b3b0f33a6742" xlink:to="loc_mrk_EisaiMember_931db962-248b-44d3-b0f3-e63fb8f1d560" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_419f4259-731a-41a8-b179-54df77686fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b94167b-0604-4f80-abc9-11b110c081f4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_419f4259-731a-41a8-b179-54df77686fa0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_419f4259-731a-41a8-b179-54df77686fa0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_419f4259-731a-41a8-b179-54df77686fa0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_419f4259-731a-41a8-b179-54df77686fa0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b635f307-4577-4eae-ab06-01ec87a54ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_419f4259-731a-41a8-b179-54df77686fa0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b635f307-4577-4eae-ab06-01ec87a54ad7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d63c003c-ac6b-4412-a454-3926d16819ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b635f307-4577-4eae-ab06-01ec87a54ad7" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d63c003c-ac6b-4412-a454-3926d16819ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_7629fd22-1c27-49b7-9267-34b85971447e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b94167b-0604-4f80-abc9-11b110c081f4" xlink:to="loc_us-gaap_AssetAcquisitionAxis_7629fd22-1c27-49b7-9267-34b85971447e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_7629fd22-1c27-49b7-9267-34b85971447e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_7629fd22-1c27-49b7-9267-34b85971447e" xlink:to="loc_us-gaap_AssetAcquisitionDomain_7629fd22-1c27-49b7-9267-34b85971447e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_3067b195-4f71-4fcc-8fcd-226448199f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_7629fd22-1c27-49b7-9267-34b85971447e" xlink:to="loc_us-gaap_AssetAcquisitionDomain_3067b195-4f71-4fcc-8fcd-226448199f6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrometheusBiosciencesIncMember_193a6ee9-0461-4cca-b675-41dbd0866ad1" xlink:href="mrk-20230331.xsd#mrk_PrometheusBiosciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_3067b195-4f71-4fcc-8fcd-226448199f6c" xlink:to="loc_mrk_PrometheusBiosciencesIncMember_193a6ee9-0461-4cca-b675-41dbd0866ad1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ImagoBioSciencesIncMember_f8abb7c0-e757-49e2-a4ea-d2deca72c23d" xlink:href="mrk-20230331.xsd#mrk_ImagoBioSciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_3067b195-4f71-4fcc-8fcd-226448199f6c" xlink:to="loc_mrk_ImagoBioSciencesIncMember_f8abb7c0-e757-49e2-a4ea-d2deca72c23d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e4b388d7-5bf5-4df0-ace6-868881bac236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b94167b-0604-4f80-abc9-11b110c081f4" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e4b388d7-5bf5-4df0-ace6-868881bac236" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e4b388d7-5bf5-4df0-ace6-868881bac236_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e4b388d7-5bf5-4df0-ace6-868881bac236" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e4b388d7-5bf5-4df0-ace6-868881bac236_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2c0da96d-eb4d-498c-94f9-1c656a8d9184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e4b388d7-5bf5-4df0-ace6-868881bac236" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2c0da96d-eb4d-498c-94f9-1c656a8d9184" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3aeb711a-e783-4cfb-972c-306f4ea450fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2c0da96d-eb4d-498c-94f9-1c656a8d9184" xlink:to="loc_us-gaap_SubsequentEventMember_3aeb711a-e783-4cfb-972c-306f4ea450fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_898f3318-4d87-477d-8e00-1a4c06875fdd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b94167b-0604-4f80-abc9-11b110c081f4" xlink:to="loc_srt_StatementScenarioAxis_898f3318-4d87-477d-8e00-1a4c06875fdd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_898f3318-4d87-477d-8e00-1a4c06875fdd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_898f3318-4d87-477d-8e00-1a4c06875fdd" xlink:to="loc_srt_ScenarioUnspecifiedDomain_898f3318-4d87-477d-8e00-1a4c06875fdd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_5ed7fc1e-96ea-4d66-873f-8b76f10025b3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_898f3318-4d87-477d-8e00-1a4c06875fdd" xlink:to="loc_srt_ScenarioUnspecifiedDomain_5ed7fc1e-96ea-4d66-873f-8b76f10025b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_14e29b08-956e-4597-bfd7-16207cba1ffd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_5ed7fc1e-96ea-4d66-873f-8b76f10025b3" xlink:to="loc_srt_ScenarioForecastMember_14e29b08-956e-4597-bfd7-16207cba1ffd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_26ca938e-8418-4668-8d60-0e8f885f510d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b94167b-0604-4f80-abc9-11b110c081f4" xlink:to="loc_srt_ProductOrServiceAxis_26ca938e-8418-4668-8d60-0e8f885f510d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_26ca938e-8418-4668-8d60-0e8f885f510d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_26ca938e-8418-4668-8d60-0e8f885f510d" xlink:to="loc_srt_ProductsAndServicesDomain_26ca938e-8418-4668-8d60-0e8f885f510d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3ebf4e95-418a-4842-8bf6-e825d64ba963" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_26ca938e-8418-4668-8d60-0e8f885f510d" xlink:to="loc_srt_ProductsAndServicesDomain_3ebf4e95-418a-4842-8bf6-e825d64ba963" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_89c11883-e7fa-4bef-afd0-ff913b5891f5" xlink:href="mrk-20230331.xsd#mrk_LenvimaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3ebf4e95-418a-4842-8bf6-e825d64ba963" xlink:to="loc_mrk_LenvimaMember_89c11883-e7fa-4bef-afd0-ff913b5891f5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#CollaborativeArrangementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="extended" id="i2194556ad5504145b341caa95cde5c13_CollaborativeArrangementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement_507fc0e3-70fe-47b8-a45a-0a276ba8bd3d" xlink:href="mrk-20230331.xsd#mrk_ProbableContingentPaymentsCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement_507fc0e3-70fe-47b8-a45a-0a276ba8bd3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8c396042-b265-4642-9936-6563f479720d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_us-gaap_Liabilities_8c396042-b265-4642-9936-6563f479720d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_7ff83cd3-0dc4-4ea1-b83d-847d763a8eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_us-gaap_AdjustmentForAmortization_7ff83cd3-0dc4-4ea1-b83d-847d763a8eca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsSalesBased_426c95ed-b669-4c02-b5d2-a2f544d86469" xlink:href="mrk-20230331.xsd#mrk_MilestonePaymentsSalesBased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_mrk_MilestonePaymentsSalesBased_426c95ed-b669-4c02-b5d2-a2f544d86469" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PotentialFutureMilestonePaymentsSalesBased_bf2fc0d3-0c69-469d-b580-f434cf2dcdbe" xlink:href="mrk-20230331.xsd#mrk_PotentialFutureMilestonePaymentsSalesBased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_mrk_PotentialFutureMilestonePaymentsSalesBased_bf2fc0d3-0c69-469d-b580-f434cf2dcdbe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued_6a4bd815-d146-4b9b-a3ef-6af7c3973b85" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued_6a4bd815-d146-4b9b-a3ef-6af7c3973b85" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_39d447b6-a288-4f5f-849a-cdded4dcfc47" xlink:href="mrk-20230331.xsd#mrk_MilestonePaymentsMadetoCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_39d447b6-a288-4f5f-849a-cdded4dcfc47" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PotentialFutureMilestonePaymentsRegulatory_49e5a8e1-6cd6-4e83-8c66-b9461a78ee68" xlink:href="mrk-20230331.xsd#mrk_PotentialFutureMilestonePaymentsRegulatory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_mrk_PotentialFutureMilestonePaymentsRegulatory_49e5a8e1-6cd6-4e83-8c66-b9461a78ee68" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_206c4a06-6061-459e-a10f-23bd25a6ac1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_206c4a06-6061-459e-a10f-23bd25a6ac1d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRatePercentage_452801f2-b0b7-4423-abfc-450ef8c087b5" xlink:href="mrk-20230331.xsd#mrk_RoyaltyRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_mrk_RoyaltyRatePercentage_452801f2-b0b7-4423-abfc-450ef8c087b5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRateDeductionPercentage_4597a5ca-fe89-4a77-b4f0-3ad775f905c0" xlink:href="mrk-20230331.xsd#mrk_RoyaltyRateDeductionPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_mrk_RoyaltyRateDeductionPercentage_4597a5ca-fe89-4a77-b4f0-3ad775f905c0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_74d23a9c-7579-4888-a3fa-10727d4f9dee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_us-gaap_Revenues_74d23a9c-7579-4888-a3fa-10727d4f9dee" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_bf952042-9131-4dc9-a0c5-00c41d57744e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_bf952042-9131-4dc9-a0c5-00c41d57744e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_e3a49c62-2166-451e-8741-634fd68b8b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_us-gaap_ProceedsFromCollaborators_e3a49c62-2166-451e-8741-634fd68b8b6c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentProceedsCollaborativeArrangement_9d92d363-33fe-4fd6-b4a0-ca09e3231f4b" xlink:href="mrk-20230331.xsd#mrk_ContingentProceedsCollaborativeArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_mrk_ContingentProceedsCollaborativeArrangement_9d92d363-33fe-4fd6-b4a0-ca09e3231f4b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85d4dceb-48f1-4870-b701-87c2853368eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85d4dceb-48f1-4870-b701-87c2853368eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_72b3654f-9f23-4576-b0b6-d1c4446e681a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85d4dceb-48f1-4870-b701-87c2853368eb" xlink:to="loc_srt_CounterpartyNameAxis_72b3654f-9f23-4576-b0b6-d1c4446e681a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_72b3654f-9f23-4576-b0b6-d1c4446e681a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_72b3654f-9f23-4576-b0b6-d1c4446e681a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_72b3654f-9f23-4576-b0b6-d1c4446e681a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03a5402d-e08f-48ab-ba39-6ffe8b480525" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_72b3654f-9f23-4576-b0b6-d1c4446e681a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03a5402d-e08f-48ab-ba39-6ffe8b480525" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_a3898083-eff3-42a6-b3f8-2def5e6f56a6" xlink:href="mrk-20230331.xsd#mrk_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03a5402d-e08f-48ab-ba39-6ffe8b480525" xlink:to="loc_mrk_AstraZenecaMember_a3898083-eff3-42a6-b3f8-2def5e6f56a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember_f77e284d-bb0d-4af9-8c78-2c0912519e74" xlink:href="mrk-20230331.xsd#mrk_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03a5402d-e08f-48ab-ba39-6ffe8b480525" xlink:to="loc_mrk_EisaiMember_f77e284d-bb0d-4af9-8c78-2c0912519e74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember_721b493b-05a4-49d9-9ecd-5270c9c2a7e8" xlink:href="mrk-20230331.xsd#mrk_BayerAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03a5402d-e08f-48ab-ba39-6ffe8b480525" xlink:to="loc_mrk_BayerAGMember_721b493b-05a4-49d9-9ecd-5270c9c2a7e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BristolMyersSquibbMember_4465cf4e-e076-4b9f-8254-fe528d61aea9" xlink:href="mrk-20230331.xsd#mrk_BristolMyersSquibbMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03a5402d-e08f-48ab-ba39-6ffe8b480525" xlink:to="loc_mrk_BristolMyersSquibbMember_4465cf4e-e076-4b9f-8254-fe528d61aea9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_d6e27cab-4d80-4d0b-bdfe-90e9600ccabf" xlink:href="mrk-20230331.xsd#mrk_LenvimaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03a5402d-e08f-48ab-ba39-6ffe8b480525" xlink:to="loc_mrk_LenvimaMember_d6e27cab-4d80-4d0b-bdfe-90e9600ccabf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5787f12f-e26d-4f12-9460-d117ab57c4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85d4dceb-48f1-4870-b701-87c2853368eb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5787f12f-e26d-4f12-9460-d117ab57c4ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5787f12f-e26d-4f12-9460-d117ab57c4ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5787f12f-e26d-4f12-9460-d117ab57c4ac" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5787f12f-e26d-4f12-9460-d117ab57c4ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_69ffc595-7647-435d-a57f-906ca17a014d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5787f12f-e26d-4f12-9460-d117ab57c4ac" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_69ffc595-7647-435d-a57f-906ca17a014d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_fd672cc9-2f30-445d-942a-c7b9e2d0329f" xlink:href="mrk-20230331.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_69ffc595-7647-435d-a57f-906ca17a014d" xlink:to="loc_mrk_SalesBasedMilestonesMember_fd672cc9-2f30-445d-942a-c7b9e2d0329f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_380bf4b0-4c40-42b3-9613-84a6e0754cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_69ffc595-7647-435d-a57f-906ca17a014d" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_380bf4b0-4c40-42b3-9613-84a6e0754cd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_b70a787f-a8c8-425c-822f-f4097d5939ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_69ffc595-7647-435d-a57f-906ca17a014d" xlink:to="loc_us-gaap_LicensingAgreementsMember_b70a787f-a8c8-425c-822f-f4097d5939ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_acdda68a-1761-4fc4-81e3-00cb7a130d0e" xlink:href="mrk-20230331.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_69ffc595-7647-435d-a57f-906ca17a014d" xlink:to="loc_mrk_RegulatoryMilestonesMember_acdda68a-1761-4fc4-81e3-00cb7a130d0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5db1f15d-c1ac-446d-ac8c-97ae6114b249" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85d4dceb-48f1-4870-b701-87c2853368eb" xlink:to="loc_srt_ProductOrServiceAxis_5db1f15d-c1ac-446d-ac8c-97ae6114b249" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5db1f15d-c1ac-446d-ac8c-97ae6114b249_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5db1f15d-c1ac-446d-ac8c-97ae6114b249" xlink:to="loc_srt_ProductsAndServicesDomain_5db1f15d-c1ac-446d-ac8c-97ae6114b249_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8076c10a-ff99-461b-829a-d7b853a8d705" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5db1f15d-c1ac-446d-ac8c-97ae6114b249" xlink:to="loc_srt_ProductsAndServicesDomain_8076c10a-ff99-461b-829a-d7b853a8d705" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember_2f319cd1-10af-4d21-a7ce-04d78141eb46" xlink:href="mrk-20230331.xsd#mrk_LynparzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8076c10a-ff99-461b-829a-d7b853a8d705" xlink:to="loc_mrk_LynparzaMember_2f319cd1-10af-4d21-a7ce-04d78141eb46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_dd3faa64-adf0-4e58-8ee4-38a2d0e4af84" xlink:href="mrk-20230331.xsd#mrk_LenvimaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8076c10a-ff99-461b-829a-d7b853a8d705" xlink:to="loc_mrk_LenvimaMember_dd3faa64-adf0-4e58-8ee4-38a2d0e4af84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VerquvoMember_b6f12ab5-50bf-41a3-963e-8d889c9a87d7" xlink:href="mrk-20230331.xsd#mrk_VerquvoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8076c10a-ff99-461b-829a-d7b853a8d705" xlink:to="loc_mrk_VerquvoMember_b6f12ab5-50bf-41a3-963e-8d889c9a87d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_abd2837f-610a-4adc-8120-e7bd1f79279f" xlink:href="mrk-20230331.xsd#mrk_AdempasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8076c10a-ff99-461b-829a-d7b853a8d705" xlink:to="loc_mrk_AdempasMember_abd2837f-610a-4adc-8120-e7bd1f79279f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueReblozylMember_f51cbfb4-df5d-440b-86f3-8a84a8bd3868" xlink:href="mrk-20230331.xsd#mrk_AllianceRevenueReblozylMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8076c10a-ff99-461b-829a-d7b853a8d705" xlink:to="loc_mrk_AllianceRevenueReblozylMember_f51cbfb4-df5d-440b-86f3-8a84a8bd3868" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ae8cd831-ca82-4273-97cf-a6c6e8fbedd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85d4dceb-48f1-4870-b701-87c2853368eb" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ae8cd831-ca82-4273-97cf-a6c6e8fbedd8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ae8cd831-ca82-4273-97cf-a6c6e8fbedd8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ae8cd831-ca82-4273-97cf-a6c6e8fbedd8" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ae8cd831-ca82-4273-97cf-a6c6e8fbedd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_fc215f16-9333-4761-965a-157fc72ab91d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ae8cd831-ca82-4273-97cf-a6c6e8fbedd8" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_fc215f16-9333-4761-965a-157fc72ab91d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_e6740c82-2902-41df-a06a-72d4d9fb995a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fc215f16-9333-4761-965a-157fc72ab91d" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_e6740c82-2902-41df-a06a-72d4d9fb995a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_7966a642-f367-448a-bb51-eded2b497440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fc215f16-9333-4761-965a-157fc72ab91d" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_7966a642-f367-448a-bb51-eded2b497440" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c32f8954-6cfb-4e21-be9a-a99996a5ddb6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85d4dceb-48f1-4870-b701-87c2853368eb" xlink:to="loc_srt_RangeAxis_c32f8954-6cfb-4e21-be9a-a99996a5ddb6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c32f8954-6cfb-4e21-be9a-a99996a5ddb6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c32f8954-6cfb-4e21-be9a-a99996a5ddb6" xlink:to="loc_srt_RangeMember_c32f8954-6cfb-4e21-be9a-a99996a5ddb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_98cc4131-e745-49bf-bfc8-784481ed559e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c32f8954-6cfb-4e21-be9a-a99996a5ddb6" xlink:to="loc_srt_RangeMember_98cc4131-e745-49bf-bfc8-784481ed559e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_52d5883c-6b55-4605-9ab2-a91528afddf0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_98cc4131-e745-49bf-bfc8-784481ed559e" xlink:to="loc_srt_MinimumMember_52d5883c-6b55-4605-9ab2-a91528afddf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cbe35d50-25fd-4f49-987c-e0819bcdfc84" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_98cc4131-e745-49bf-bfc8-784481ed559e" xlink:to="loc_srt_MaximumMember_cbe35d50-25fd-4f49-987c-e0819bcdfc84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_c4de6bfb-5381-4b2c-92fd-5f40649b6a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85d4dceb-48f1-4870-b701-87c2853368eb" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_c4de6bfb-5381-4b2c-92fd-5f40649b6a1c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_c4de6bfb-5381-4b2c-92fd-5f40649b6a1c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_c4de6bfb-5381-4b2c-92fd-5f40649b6a1c" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_c4de6bfb-5381-4b2c-92fd-5f40649b6a1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_8b79a195-ae47-490e-88e4-e96c278c500c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_c4de6bfb-5381-4b2c-92fd-5f40649b6a1c" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_8b79a195-ae47-490e-88e4-e96c278c500c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_aaaf326b-fc37-4163-9add-6383d1f8bab0" xlink:href="mrk-20230331.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_8b79a195-ae47-490e-88e4-e96c278c500c" xlink:to="loc_mrk_SalesBasedMilestonesMember_aaaf326b-fc37-4163-9add-6383d1f8bab0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_9cc862e8-6ebb-4a1a-9f49-03bff54396f9" xlink:href="mrk-20230331.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_8b79a195-ae47-490e-88e4-e96c278c500c" xlink:to="loc_mrk_RegulatoryMilestonesMember_9cc862e8-6ebb-4a1a-9f49-03bff54396f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_2e7fbdd4-c2f6-4a5d-a973-bcee3be06319" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85d4dceb-48f1-4870-b701-87c2853368eb" xlink:to="loc_srt_ConsolidationItemsAxis_2e7fbdd4-c2f6-4a5d-a973-bcee3be06319" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_2e7fbdd4-c2f6-4a5d-a973-bcee3be06319_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_2e7fbdd4-c2f6-4a5d-a973-bcee3be06319" xlink:to="loc_srt_ConsolidationItemsDomain_2e7fbdd4-c2f6-4a5d-a973-bcee3be06319_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_cdd786f4-a85f-464d-bea2-f60d94b60eb3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_2e7fbdd4-c2f6-4a5d-a973-bcee3be06319" xlink:to="loc_srt_ConsolidationItemsDomain_cdd786f4-a85f-464d-bea2-f60d94b60eb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_d9645879-598e-4824-81b4-2288f0bc0abd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_cdd786f4-a85f-464d-bea2-f60d94b60eb3" xlink:to="loc_us-gaap_OperatingSegmentsMember_d9645879-598e-4824-81b4-2288f0bc0abd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b8904a68-2f95-45c7-af5a-1773e8e393d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85d4dceb-48f1-4870-b701-87c2853368eb" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b8904a68-2f95-45c7-af5a-1773e8e393d2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b8904a68-2f95-45c7-af5a-1773e8e393d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b8904a68-2f95-45c7-af5a-1773e8e393d2" xlink:to="loc_us-gaap_SegmentDomain_b8904a68-2f95-45c7-af5a-1773e8e393d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f9f1d1f6-ba82-40ee-99c7-cb1635241b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b8904a68-2f95-45c7-af5a-1773e8e393d2" xlink:to="loc_us-gaap_SegmentDomain_f9f1d1f6-ba82-40ee-99c7-cb1635241b9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_0e21dd53-66f2-4785-b3d4-cd36186d7b78" xlink:href="mrk-20230331.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f9f1d1f6-ba82-40ee-99c7-cb1635241b9b" xlink:to="loc_mrk_PharmaceuticalsegmentMember_0e21dd53-66f2-4785-b3d4-cd36186d7b78" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#CollaborativeArrangementsFinancialInformationDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" xlink:type="extended" id="ie693e0e7906e4ea1ac39e8be7b7540aa_CollaborativeArrangementsFinancialInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bb5589e-ddc3-4068-856c-a5cc161017b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementProfitSharing_e1f9d76d-a52b-4bca-8ebd-4e2b7a2621a7" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementProfitSharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bb5589e-ddc3-4068-856c-a5cc161017b0" xlink:to="loc_mrk_CollaborativeArrangementProfitSharing_e1f9d76d-a52b-4bca-8ebd-4e2b7a2621a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementSalesNet_6fd2f290-4c3e-41b2-9f8e-b19a8dea0aea" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementSalesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bb5589e-ddc3-4068-856c-a5cc161017b0" xlink:to="loc_mrk_CollaborativeArrangementSalesNet_6fd2f290-4c3e-41b2-9f8e-b19a8dea0aea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4f07ef63-7ade-4eee-9840-800a56ad8311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bb5589e-ddc3-4068-856c-a5cc161017b0" xlink:to="loc_us-gaap_Revenues_4f07ef63-7ade-4eee-9840-800a56ad8311" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5ffea7aa-9ffd-4d06-a527-5f376d6e9350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bb5589e-ddc3-4068-856c-a5cc161017b0" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5ffea7aa-9ffd-4d06-a527-5f376d6e9350" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_440e2667-755f-48f4-98cb-537e17ccacea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bb5589e-ddc3-4068-856c-a5cc161017b0" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_440e2667-755f-48f4-98cb-537e17ccacea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d133c76b-cb14-4103-8780-c0f03d592ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bb5589e-ddc3-4068-856c-a5cc161017b0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d133c76b-cb14-4103-8780-c0f03d592ca0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_230d95c7-cbd1-48db-80e4-f89d1879c0a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bb5589e-ddc3-4068-856c-a5cc161017b0" xlink:to="loc_us-gaap_ReceivablesNetCurrent_230d95c7-cbd1-48db-80e4-f89d1879c0a2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4e62d63c-6d9a-4395-b57b-ad6fd5a74c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bb5589e-ddc3-4068-856c-a5cc161017b0" xlink:to="loc_us-gaap_LiabilitiesCurrent_4e62d63c-6d9a-4395-b57b-ad6fd5a74c40" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_f938b0c3-d22a-4c73-9248-e1d21cc742ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bb5589e-ddc3-4068-856c-a5cc161017b0" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_f938b0c3-d22a-4c73-9248-e1d21cc742ca" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3e044b3d-ddf1-4674-b584-d471eee983a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bb5589e-ddc3-4068-856c-a5cc161017b0" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3e044b3d-ddf1-4674-b584-d471eee983a3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_3ba897ac-f7a8-4746-95a4-24c26d41ad3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bb5589e-ddc3-4068-856c-a5cc161017b0" xlink:to="loc_us-gaap_AdjustmentForAmortization_3ba897ac-f7a8-4746-95a4-24c26d41ad3a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83b41c7a-5f25-4f9d-a13a-031a5dfa45f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bb5589e-ddc3-4068-856c-a5cc161017b0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83b41c7a-5f25-4f9d-a13a-031a5dfa45f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_56031da0-816d-49a7-9b08-68ae2204ac8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83b41c7a-5f25-4f9d-a13a-031a5dfa45f7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_56031da0-816d-49a7-9b08-68ae2204ac8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_56031da0-816d-49a7-9b08-68ae2204ac8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_56031da0-816d-49a7-9b08-68ae2204ac8d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_56031da0-816d-49a7-9b08-68ae2204ac8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4b5d1829-7906-4e50-8a9b-86001f10c155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_56031da0-816d-49a7-9b08-68ae2204ac8d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4b5d1829-7906-4e50-8a9b-86001f10c155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_e96aa27c-03ea-42b7-b86d-2dbd5d7caaa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4b5d1829-7906-4e50-8a9b-86001f10c155" xlink:to="loc_us-gaap_SalesMember_e96aa27c-03ea-42b7-b86d-2dbd5d7caaa7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_a1c7c8f6-0cf6-4fe9-8f44-0e64ae91e276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4b5d1829-7906-4e50-8a9b-86001f10c155" xlink:to="loc_us-gaap_CostOfSalesMember_a1c7c8f6-0cf6-4fe9-8f44-0e64ae91e276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5b93c431-4a19-4517-bbc3-93e333426571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4b5d1829-7906-4e50-8a9b-86001f10c155" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5b93c431-4a19-4517-bbc3-93e333426571" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4e4cbb1c-41a1-4c29-8539-8cb5b29c2a83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4b5d1829-7906-4e50-8a9b-86001f10c155" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4e4cbb1c-41a1-4c29-8539-8cb5b29c2a83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e8f61fc3-6639-4f97-84dd-e5e84cf0982f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83b41c7a-5f25-4f9d-a13a-031a5dfa45f7" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e8f61fc3-6639-4f97-84dd-e5e84cf0982f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e8f61fc3-6639-4f97-84dd-e5e84cf0982f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e8f61fc3-6639-4f97-84dd-e5e84cf0982f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e8f61fc3-6639-4f97-84dd-e5e84cf0982f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_00c94d59-f024-4687-a7c8-e2b87d32d505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e8f61fc3-6639-4f97-84dd-e5e84cf0982f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_00c94d59-f024-4687-a7c8-e2b87d32d505" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_b1796ff9-ffb6-41b8-85c1-a2523b30021f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_00c94d59-f024-4687-a7c8-e2b87d32d505" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_b1796ff9-ffb6-41b8-85c1-a2523b30021f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_3a1ec093-3696-462b-a48e-3919fb6307d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_00c94d59-f024-4687-a7c8-e2b87d32d505" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_3a1ec093-3696-462b-a48e-3919fb6307d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a3d48c33-48d3-4822-a985-42d33d89f571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_00c94d59-f024-4687-a7c8-e2b87d32d505" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a3d48c33-48d3-4822-a985-42d33d89f571" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_509980f1-0301-4239-8507-1540edb597ce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83b41c7a-5f25-4f9d-a13a-031a5dfa45f7" xlink:to="loc_srt_CounterpartyNameAxis_509980f1-0301-4239-8507-1540edb597ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_509980f1-0301-4239-8507-1540edb597ce_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_509980f1-0301-4239-8507-1540edb597ce" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_509980f1-0301-4239-8507-1540edb597ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcb74f7a-448c-4421-8e44-86d7a4f5e9a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_509980f1-0301-4239-8507-1540edb597ce" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcb74f7a-448c-4421-8e44-86d7a4f5e9a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_6e1e851c-61b9-4e26-8f69-35d7619cb98d" xlink:href="mrk-20230331.xsd#mrk_AstraZenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcb74f7a-448c-4421-8e44-86d7a4f5e9a4" xlink:to="loc_mrk_AstraZenecaMember_6e1e851c-61b9-4e26-8f69-35d7619cb98d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember_60d90368-098f-420b-bd54-fa06a72f4af0" xlink:href="mrk-20230331.xsd#mrk_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcb74f7a-448c-4421-8e44-86d7a4f5e9a4" xlink:to="loc_mrk_EisaiMember_60d90368-098f-420b-bd54-fa06a72f4af0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember_fd16219a-1798-4a7d-bb8c-9d2727293935" xlink:href="mrk-20230331.xsd#mrk_BayerAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcb74f7a-448c-4421-8e44-86d7a4f5e9a4" xlink:to="loc_mrk_BayerAGMember_fd16219a-1798-4a7d-bb8c-9d2727293935" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RidgebackBiotherapeuticsLPMember_1191226c-5179-4604-acd0-829f023cafb7" xlink:href="mrk-20230331.xsd#mrk_RidgebackBiotherapeuticsLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcb74f7a-448c-4421-8e44-86d7a4f5e9a4" xlink:to="loc_mrk_RidgebackBiotherapeuticsLPMember_1191226c-5179-4604-acd0-829f023cafb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_806bc5ec-80a7-4d45-bdf4-874c460b7f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83b41c7a-5f25-4f9d-a13a-031a5dfa45f7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_806bc5ec-80a7-4d45-bdf4-874c460b7f37" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_806bc5ec-80a7-4d45-bdf4-874c460b7f37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_806bc5ec-80a7-4d45-bdf4-874c460b7f37" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_806bc5ec-80a7-4d45-bdf4-874c460b7f37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_74a15f7c-6bfd-4c74-931f-b6cfca4270e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_806bc5ec-80a7-4d45-bdf4-874c460b7f37" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_74a15f7c-6bfd-4c74-931f-b6cfca4270e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_d29f6ee7-6063-4709-9d6f-00269e810702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_74a15f7c-6bfd-4c74-931f-b6cfca4270e3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_d29f6ee7-6063-4709-9d6f-00269e810702" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_92de8b30-a01d-4fba-83b7-769de509a715" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83b41c7a-5f25-4f9d-a13a-031a5dfa45f7" xlink:to="loc_srt_ProductOrServiceAxis_92de8b30-a01d-4fba-83b7-769de509a715" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_92de8b30-a01d-4fba-83b7-769de509a715_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_92de8b30-a01d-4fba-83b7-769de509a715" xlink:to="loc_srt_ProductsAndServicesDomain_92de8b30-a01d-4fba-83b7-769de509a715_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e91c1974-d21f-409d-945a-202c70ad581a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_92de8b30-a01d-4fba-83b7-769de509a715" xlink:to="loc_srt_ProductsAndServicesDomain_e91c1974-d21f-409d-945a-202c70ad581a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember_917ce7fe-28d9-46f3-bdab-6f25c8eec9d3" xlink:href="mrk-20230331.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e91c1974-d21f-409d-945a-202c70ad581a" xlink:to="loc_mrk_AlliancerevenueLynparzaMember_917ce7fe-28d9-46f3-bdab-6f25c8eec9d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueKoselugoMember_f7041dbd-aa85-4de6-964e-e5915814ad75" xlink:href="mrk-20230331.xsd#mrk_AllianceRevenueKoselugoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e91c1974-d21f-409d-945a-202c70ad581a" xlink:to="loc_mrk_AllianceRevenueKoselugoMember_f7041dbd-aa85-4de6-964e-e5915814ad75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_e1a3525b-1010-4892-b019-dc7469cacf40" xlink:href="mrk-20230331.xsd#mrk_AdempasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e91c1974-d21f-409d-945a-202c70ad581a" xlink:to="loc_mrk_AdempasMember_e1a3525b-1010-4892-b019-dc7469cacf40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VerquvoMember_8e3b4bb1-9488-46fc-b7a6-53df66e7fc3b" xlink:href="mrk-20230331.xsd#mrk_VerquvoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e91c1974-d21f-409d-945a-202c70ad581a" xlink:to="loc_mrk_VerquvoMember_8e3b4bb1-9488-46fc-b7a6-53df66e7fc3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LagevrioMember_33eed587-a0ed-4f87-b2f4-51af0ba56943" xlink:href="mrk-20230331.xsd#mrk_LagevrioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e91c1974-d21f-409d-945a-202c70ad581a" xlink:to="loc_mrk_LagevrioMember_33eed587-a0ed-4f87-b2f4-51af0ba56943" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_10e2846d-75fd-4b70-bca5-57a6a0b70c75" xlink:href="mrk-20230331.xsd#mrk_LenvimaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e91c1974-d21f-409d-945a-202c70ad581a" xlink:to="loc_mrk_LenvimaMember_10e2846d-75fd-4b70-bca5-57a6a0b70c75" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#RestructuringNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="extended" id="i4d13679321c74fcba009c6e66970dca1_RestructuringNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_df48fc18-abd4-4efd-8268-d53adda6c202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_00deda33-655c-413c-9e07-f5b474d8bd50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_df48fc18-abd4-4efd-8268-d53adda6c202" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_00deda33-655c-413c-9e07-f5b474d8bd50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_a109ef07-1c21-4669-b736-4d10e769933c" xlink:href="mrk-20230331.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_df48fc18-abd4-4efd-8268-d53adda6c202" xlink:to="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_a109ef07-1c21-4669-b736-4d10e769933c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_0ef26d44-fe23-43b3-bebf-5e04f044d681" xlink:href="mrk-20230331.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_df48fc18-abd4-4efd-8268-d53adda6c202" xlink:to="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_0ef26d44-fe23-43b3-bebf-5e04f044d681" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_affe1bd2-67e5-46a8-8395-2e92499b9894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_df48fc18-abd4-4efd-8268-d53adda6c202" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_affe1bd2-67e5-46a8-8395-2e92499b9894" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_d40ba93b-6db9-4c1d-b3e4-30f0f55b0962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_df48fc18-abd4-4efd-8268-d53adda6c202" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_d40ba93b-6db9-4c1d-b3e4-30f0f55b0962" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cd1b4cff-05fe-40e1-b42d-4ae9d0362333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_df48fc18-abd4-4efd-8268-d53adda6c202" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cd1b4cff-05fe-40e1-b42d-4ae9d0362333" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_e9fe7ed3-23ab-45da-976c-f0146071e2ec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cd1b4cff-05fe-40e1-b42d-4ae9d0362333" xlink:to="loc_srt_StatementScenarioAxis_e9fe7ed3-23ab-45da-976c-f0146071e2ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e9fe7ed3-23ab-45da-976c-f0146071e2ec_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_e9fe7ed3-23ab-45da-976c-f0146071e2ec" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e9fe7ed3-23ab-45da-976c-f0146071e2ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b957c484-c933-4107-a9cd-d0087812dff0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_e9fe7ed3-23ab-45da-976c-f0146071e2ec" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b957c484-c933-4107-a9cd-d0087812dff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_c0d21dfb-b1c2-420b-acd3-0a9026111421" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_b957c484-c933-4107-a9cd-d0087812dff0" xlink:to="loc_srt_ScenarioForecastMember_c0d21dfb-b1c2-420b-acd3-0a9026111421" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#RestructuringChargesActivitiesbyTypeofCostDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" xlink:type="extended" id="i133aaa3561534b619536ef32acccca46_RestructuringChargesActivitiesbyTypeofCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_330bd6c3-5a24-4614-90f5-2667829285f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_7368c482-4d8e-410b-b217-930d685e32a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_330bd6c3-5a24-4614-90f5-2667829285f9" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_7368c482-4d8e-410b-b217-930d685e32a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_46e8aaf3-2e9a-404c-b470-c951dfe84d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_330bd6c3-5a24-4614-90f5-2667829285f9" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_46e8aaf3-2e9a-404c-b470-c951dfe84d78" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_11ccd8de-4be3-4e3b-ab89-c904ae650a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_46e8aaf3-2e9a-404c-b470-c951dfe84d78" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_11ccd8de-4be3-4e3b-ab89-c904ae650a4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_11ccd8de-4be3-4e3b-ab89-c904ae650a4d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_11ccd8de-4be3-4e3b-ab89-c904ae650a4d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_11ccd8de-4be3-4e3b-ab89-c904ae650a4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5f2d17f6-531d-44b8-82c4-1c93a1a61844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_11ccd8de-4be3-4e3b-ab89-c904ae650a4d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5f2d17f6-531d-44b8-82c4-1c93a1a61844" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_85f2b28c-239e-4e17-9681-157630e9d4de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5f2d17f6-531d-44b8-82c4-1c93a1a61844" xlink:to="loc_us-gaap_CostOfSalesMember_85f2b28c-239e-4e17-9681-157630e9d4de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b85108d3-e1fb-48cf-a256-37c25346cd37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5f2d17f6-531d-44b8-82c4-1c93a1a61844" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b85108d3-e1fb-48cf-a256-37c25346cd37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_69a02802-4490-4712-9396-a31bdde29e54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5f2d17f6-531d-44b8-82c4-1c93a1a61844" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_69a02802-4490-4712-9396-a31bdde29e54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_db21a38b-14d0-4341-873f-89c39d98a13f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5f2d17f6-531d-44b8-82c4-1c93a1a61844" xlink:to="loc_us-gaap_RestructuringChargesMember_db21a38b-14d0-4341-873f-89c39d98a13f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_b65357de-b83f-4991-b8f4-8c38045d8bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_46e8aaf3-2e9a-404c-b470-c951dfe84d78" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_b65357de-b83f-4991-b8f4-8c38045d8bf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_b65357de-b83f-4991-b8f4-8c38045d8bf2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_b65357de-b83f-4991-b8f4-8c38045d8bf2" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_b65357de-b83f-4991-b8f4-8c38045d8bf2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_d76ab1c8-a991-4917-9737-58a7080e6302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_b65357de-b83f-4991-b8f4-8c38045d8bf2" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_d76ab1c8-a991-4917-9737-58a7080e6302" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_4b046952-0c67-4ec3-b6af-706528f7ed60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d76ab1c8-a991-4917-9737-58a7080e6302" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_4b046952-0c67-4ec3-b6af-706528f7ed60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember_def5458e-08a6-453c-a5dc-787e668432aa" xlink:href="mrk-20230331.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d76ab1c8-a991-4917-9737-58a7080e6302" xlink:to="loc_mrk_AcceleratedDepreciationMember_def5458e-08a6-453c-a5dc-787e668432aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_6b08ce18-119b-4af0-b52b-daf2c0e45706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d76ab1c8-a991-4917-9737-58a7080e6302" xlink:to="loc_us-gaap_OtherRestructuringMember_6b08ce18-119b-4af0-b52b-daf2c0e45706" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#RestructuringActivitiesbyProgramDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" xlink:type="extended" id="i81b48f512f8f450191a218585becc9cf_RestructuringActivitiesbyProgramDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_6a1bc533-88ca-4c4a-b4ef-fe21d94cf4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_cf782d11-b2c4-4b76-a7fc-7e4608859a31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6a1bc533-88ca-4c4a-b4ef-fe21d94cf4cc" xlink:to="loc_us-gaap_RestructuringReserveRollForward_cf782d11-b2c4-4b76-a7fc-7e4608859a31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_870bea63-f7bb-4fce-8c5b-c1dcc11601ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_cf782d11-b2c4-4b76-a7fc-7e4608859a31" xlink:to="loc_us-gaap_RestructuringReserve_870bea63-f7bb-4fce-8c5b-c1dcc11601ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_41ad91bf-eb11-49a3-925d-2454b42b3020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_cf782d11-b2c4-4b76-a7fc-7e4608859a31" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_41ad91bf-eb11-49a3-925d-2454b42b3020" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_6dcd65a5-134b-46c8-b9cf-442db1975f01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_cf782d11-b2c4-4b76-a7fc-7e4608859a31" xlink:to="loc_us-gaap_PaymentsForRestructuring_6dcd65a5-134b-46c8-b9cf-442db1975f01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_019d2d9b-f8fa-458e-91f3-e0ef2638014d" xlink:href="mrk-20230331.xsd#mrk_RestructuringReserveIncreaseDecreaseNoncashActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_cf782d11-b2c4-4b76-a7fc-7e4608859a31" xlink:to="loc_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_019d2d9b-f8fa-458e-91f3-e0ef2638014d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_39fe9df4-88c8-4186-b8b4-62b6bfca6004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_89b8378f-d294-4b8c-8e1a-373cca76411b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6a1bc533-88ca-4c4a-b4ef-fe21d94cf4cc" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_89b8378f-d294-4b8c-8e1a-373cca76411b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_b03a8be2-6fa1-4988-9f7e-5d988e017afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_89b8378f-d294-4b8c-8e1a-373cca76411b" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_b03a8be2-6fa1-4988-9f7e-5d988e017afd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_b03a8be2-6fa1-4988-9f7e-5d988e017afd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_b03a8be2-6fa1-4988-9f7e-5d988e017afd" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_b03a8be2-6fa1-4988-9f7e-5d988e017afd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_e887c16f-f774-4d9d-9d1c-4d047b3738c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_b03a8be2-6fa1-4988-9f7e-5d988e017afd" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_e887c16f-f774-4d9d-9d1c-4d047b3738c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_524d48be-08f3-48fb-8daa-fe63dc0550fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e887c16f-f774-4d9d-9d1c-4d047b3738c9" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_524d48be-08f3-48fb-8daa-fe63dc0550fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember_1f476ca9-59e1-4047-8e72-c1fc100d450d" xlink:href="mrk-20230331.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e887c16f-f774-4d9d-9d1c-4d047b3738c9" xlink:to="loc_mrk_AcceleratedDepreciationMember_1f476ca9-59e1-4047-8e72-c1fc100d450d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_593911f3-b541-4294-9dde-9fcd414fd215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e887c16f-f774-4d9d-9d1c-4d047b3738c9" xlink:to="loc_us-gaap_OtherRestructuringMember_593911f3-b541-4294-9dde-9fcd414fd215" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="i40ce793e1d194be4923a1fc4a2ee9bed_FinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAverageRemainingMaturity1_9662c1c9-153b-430e-8d6e-9adec0e948c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAverageRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_DerivativeAverageRemainingMaturity1_9662c1c9-153b-430e-8d6e-9adec0e948c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_6957225b-3878-4050-9dc3-0ef2fe2cf6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_6957225b-3878-4050-9dc3-0ef2fe2cf6bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_12319904-8127-429f-b088-eed4da43425d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_DerivativeNotionalAmount_12319904-8127-429f-b088-eed4da43425d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_34a9862e-f246-4713-b81c-c7e8e744c523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_34a9862e-f246-4713-b81c-c7e8e744c523" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_dec463ec-3552-46a6-8778-e872e0578e86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_dec463ec-3552-46a6-8778-e872e0578e86" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_986a2089-798f-42e6-ae41-7ebfb9b70e27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_986a2089-798f-42e6-ae41-7ebfb9b70e27" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_b85f42b8-0cdf-4fa5-ade9-b3d57baaf03c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_b85f42b8-0cdf-4fa5-ade9-b3d57baaf03c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_fbe6f53a-9842-4921-b77b-57305a0e0537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_fbe6f53a-9842-4921-b77b-57305a0e0537" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_aaca2110-f16e-401e-aaec-90c41f95a655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_aaca2110-f16e-401e-aaec-90c41f95a655" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_a3f95e56-b627-4e66-8c96-59b23ded9fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_a3f95e56-b627-4e66-8c96-59b23ded9fcb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_092a0a7a-4d88-4f90-ba5e-d9ef3c374add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_092a0a7a-4d88-4f90-ba5e-d9ef3c374add" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_9961cf57-5b60-4f3f-b900-7bbe445c355f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_9961cf57-5b60-4f3f-b900-7bbe445c355f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_3ff67028-8778-42ef-9a24-d263a3788888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_DebtInstrumentFairValue_3ff67028-8778-42ef-9a24-d263a3788888" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_c2135d2b-ea81-4816-8e12-d9c65e70baa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_c2135d2b-ea81-4816-8e12-d9c65e70baa6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableSale_d4567437-0cab-45e5-b7f5-71113137ddbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_AccountsReceivableSale_d4567437-0cab-45e5-b7f5-71113137ddbb" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_8cdbc1c3-d258-4099-a782-651a43a1eb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_RestrictedCashCurrent_8cdbc1c3-d258-4099-a782-651a43a1eb5a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_8e16ca33-41fe-40f7-97f0-28cc3f289b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_8e16ca33-41fe-40f7-97f0-28cc3f289b87" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimSecurities_269e676e-7e7e-4dab-9345-e6854e4734c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralRightToReclaimSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimSecurities_269e676e-7e7e-4dab-9345-e6854e4734c4" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_57eb3ec6-d74c-4509-8682-781543d21ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_DerivativeTable_57eb3ec6-d74c-4509-8682-781543d21ad4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2e110df5-65fa-4dc0-81a1-40b6af85f26b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_57eb3ec6-d74c-4509-8682-781543d21ad4" xlink:to="loc_srt_RangeAxis_2e110df5-65fa-4dc0-81a1-40b6af85f26b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2e110df5-65fa-4dc0-81a1-40b6af85f26b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2e110df5-65fa-4dc0-81a1-40b6af85f26b" xlink:to="loc_srt_RangeMember_2e110df5-65fa-4dc0-81a1-40b6af85f26b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_10ad1d7c-67d3-45eb-8d0b-0b186f9abada" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2e110df5-65fa-4dc0-81a1-40b6af85f26b" xlink:to="loc_srt_RangeMember_10ad1d7c-67d3-45eb-8d0b-0b186f9abada" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_afd89191-4f27-4ca5-851f-2e515115834a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_10ad1d7c-67d3-45eb-8d0b-0b186f9abada" xlink:to="loc_srt_MaximumMember_afd89191-4f27-4ca5-851f-2e515115834a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_413f0886-ee0d-417d-87df-3375c7f93c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_57eb3ec6-d74c-4509-8682-781543d21ad4" xlink:to="loc_us-gaap_HedgingDesignationAxis_413f0886-ee0d-417d-87df-3375c7f93c01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_413f0886-ee0d-417d-87df-3375c7f93c01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_413f0886-ee0d-417d-87df-3375c7f93c01" xlink:to="loc_us-gaap_HedgingDesignationDomain_413f0886-ee0d-417d-87df-3375c7f93c01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_95e24a3a-2858-4ab3-afc1-e5cbe501b3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_413f0886-ee0d-417d-87df-3375c7f93c01" xlink:to="loc_us-gaap_HedgingDesignationDomain_95e24a3a-2858-4ab3-afc1-e5cbe501b3fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d40f7374-ba2c-46b6-b88e-2c50db1fdf2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_95e24a3a-2858-4ab3-afc1-e5cbe501b3fc" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d40f7374-ba2c-46b6-b88e-2c50db1fdf2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_971443b7-8a6b-4df7-896a-bd6f0c1eb1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_95e24a3a-2858-4ab3-afc1-e5cbe501b3fc" xlink:to="loc_us-gaap_NondesignatedMember_971443b7-8a6b-4df7-896a-bd6f0c1eb1ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e570b19a-1c61-47ee-8cbd-38a31d265161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_57eb3ec6-d74c-4509-8682-781543d21ad4" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e570b19a-1c61-47ee-8cbd-38a31d265161" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e570b19a-1c61-47ee-8cbd-38a31d265161_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e570b19a-1c61-47ee-8cbd-38a31d265161" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e570b19a-1c61-47ee-8cbd-38a31d265161_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2c566614-4517-4e53-9c86-b7988cbd876b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e570b19a-1c61-47ee-8cbd-38a31d265161" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2c566614-4517-4e53-9c86-b7988cbd876b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_75268db3-d311-479a-b136-684e4ebdd70e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2c566614-4517-4e53-9c86-b7988cbd876b" xlink:to="loc_us-gaap_InterestRateSwapMember_75268db3-d311-479a-b136-684e4ebdd70e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d2ff864-8621-4255-8629-990bac0b450e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_57eb3ec6-d74c-4509-8682-781543d21ad4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d2ff864-8621-4255-8629-990bac0b450e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0d2ff864-8621-4255-8629-990bac0b450e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d2ff864-8621-4255-8629-990bac0b450e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0d2ff864-8621-4255-8629-990bac0b450e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31754ad0-53e8-44e2-a5e1-4b2fd2f33c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d2ff864-8621-4255-8629-990bac0b450e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31754ad0-53e8-44e2-a5e1-4b2fd2f33c57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d9166e8f-da3a-4256-b81c-3d707d26950d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31754ad0-53e8-44e2-a5e1-4b2fd2f33c57" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d9166e8f-da3a-4256-b81c-3d707d26950d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_4088f8cb-44fb-4796-8b25-70d345885f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_57eb3ec6-d74c-4509-8682-781543d21ad4" xlink:to="loc_us-gaap_InvestmentTypeAxis_4088f8cb-44fb-4796-8b25-70d345885f5e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4088f8cb-44fb-4796-8b25-70d345885f5e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_4088f8cb-44fb-4796-8b25-70d345885f5e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4088f8cb-44fb-4796-8b25-70d345885f5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_ac56674d-6d57-473c-9fe8-46f003d54a06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_4088f8cb-44fb-4796-8b25-70d345885f5e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_ac56674d-6d57-473c-9fe8-46f003d54a06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFundsMember_9f08f950-1731-4372-9845-5f0545b9792d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_ac56674d-6d57-473c-9fe8-46f003d54a06" xlink:to="loc_us-gaap_EquityFundsMember_9f08f950-1731-4372-9845-5f0545b9792d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_06852af4-d22f-46b6-9252-486ee1401e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_57eb3ec6-d74c-4509-8682-781543d21ad4" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_06852af4-d22f-46b6-9252-486ee1401e6f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_06852af4-d22f-46b6-9252-486ee1401e6f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_06852af4-d22f-46b6-9252-486ee1401e6f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_06852af4-d22f-46b6-9252-486ee1401e6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_049f7e78-1aee-47e4-b218-6f49274f611c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_06852af4-d22f-46b6-9252-486ee1401e6f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_049f7e78-1aee-47e4-b218-6f49274f611c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5884390b-9b99-4ea4-b451-5286a3ff4314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_049f7e78-1aee-47e4-b218-6f49274f611c" xlink:to="loc_us-gaap_SubsequentEventMember_5884390b-9b99-4ea4-b451-5286a3ff4314" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#FinancialInstrumentsEffectofNetInvestmentHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="extended" id="i1cd8d4f6b3c849eb8d3b7dca547b48aa_FinancialInstrumentsEffectofNetInvestmentHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_54c81a36-cb17-426c-8c1a-b5c39eb162c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_333be458-14f5-44ca-ad64-e9ec973df8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_54c81a36-cb17-426c-8c1a-b5c39eb162c4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_333be458-14f5-44ca-ad64-e9ec973df8f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_14015323-ffe5-4313-bc82-a1f4f5205737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_54c81a36-cb17-426c-8c1a-b5c39eb162c4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_14015323-ffe5-4313-bc82-a1f4f5205737" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_80544a5c-47f8-4ae0-8271-4ccbb6926a20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_54c81a36-cb17-426c-8c1a-b5c39eb162c4" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_80544a5c-47f8-4ae0-8271-4ccbb6926a20" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_9700c71c-b35f-4eab-b916-17e4968d040b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_80544a5c-47f8-4ae0-8271-4ccbb6926a20" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_9700c71c-b35f-4eab-b916-17e4968d040b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9700c71c-b35f-4eab-b916-17e4968d040b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9700c71c-b35f-4eab-b916-17e4968d040b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9700c71c-b35f-4eab-b916-17e4968d040b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0fe2be11-8ffb-4458-9274-3d14d4ef9f85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9700c71c-b35f-4eab-b916-17e4968d040b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0fe2be11-8ffb-4458-9274-3d14d4ef9f85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_b2499734-f2b8-4dcd-aeec-a38ef72bfcac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0fe2be11-8ffb-4458-9274-3d14d4ef9f85" xlink:to="loc_us-gaap_ForeignExchangeContractMember_b2499734-f2b8-4dcd-aeec-a38ef72bfcac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EurodominatedNotesMember_c5f95c5a-c885-4416-b387-b19b21ee5184" xlink:href="mrk-20230331.xsd#mrk_EurodominatedNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0fe2be11-8ffb-4458-9274-3d14d4ef9f85" xlink:to="loc_mrk_EurodominatedNotesMember_c5f95c5a-c885-4416-b387-b19b21ee5184" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e62d5a4d-ba82-41e7-9d52-f84b4b454411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_80544a5c-47f8-4ae0-8271-4ccbb6926a20" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e62d5a4d-ba82-41e7-9d52-f84b4b454411" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e62d5a4d-ba82-41e7-9d52-f84b4b454411_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e62d5a4d-ba82-41e7-9d52-f84b4b454411" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e62d5a4d-ba82-41e7-9d52-f84b4b454411_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4d020dce-f1d7-4166-b1d8-90decfa89890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e62d5a4d-ba82-41e7-9d52-f84b4b454411" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4d020dce-f1d7-4166-b1d8-90decfa89890" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_fb544bee-663f-4000-8c62-29443c32926a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4d020dce-f1d7-4166-b1d8-90decfa89890" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_fb544bee-663f-4000-8c62-29443c32926a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended" id="i4e9a6a7e9de7495587c953c446a9dded_FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_e4b897f5-ff82-40b9-9e0a-73372c7b5ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_82f55d83-8bba-436a-83ca-d9bece06b473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e4b897f5-ff82-40b9-9e0a-73372c7b5ecf" xlink:to="loc_us-gaap_DerivativeAssets_82f55d83-8bba-436a-83ca-d9bece06b473" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_2fdf82b8-c064-4b84-810d-f3d2081d548a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e4b897f5-ff82-40b9-9e0a-73372c7b5ecf" xlink:to="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_2fdf82b8-c064-4b84-810d-f3d2081d548a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_cd6b06c4-fcfc-451e-8d53-2a1d5c9ae47b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e4b897f5-ff82-40b9-9e0a-73372c7b5ecf" xlink:to="loc_us-gaap_DerivativeLiabilities_cd6b06c4-fcfc-451e-8d53-2a1d5c9ae47b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_aad03e89-f6ff-408b-8509-4132ec8b2693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e4b897f5-ff82-40b9-9e0a-73372c7b5ecf" xlink:to="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_aad03e89-f6ff-408b-8509-4132ec8b2693" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_8270ba77-5fb0-4dac-a63b-0724452b513e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e4b897f5-ff82-40b9-9e0a-73372c7b5ecf" xlink:to="loc_us-gaap_DerivativeNotionalAmount_8270ba77-5fb0-4dac-a63b-0724452b513e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0c237fd0-771b-4c9c-a4bc-1ee8acca9df2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e4b897f5-ff82-40b9-9e0a-73372c7b5ecf" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0c237fd0-771b-4c9c-a4bc-1ee8acca9df2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1c616a11-029c-49ab-9077-d5b8ebe4ba66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0c237fd0-771b-4c9c-a4bc-1ee8acca9df2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1c616a11-029c-49ab-9077-d5b8ebe4ba66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1c616a11-029c-49ab-9077-d5b8ebe4ba66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1c616a11-029c-49ab-9077-d5b8ebe4ba66" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1c616a11-029c-49ab-9077-d5b8ebe4ba66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d1b1e165-c050-4214-b0fd-0dc51ccc8484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1c616a11-029c-49ab-9077-d5b8ebe4ba66" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d1b1e165-c050-4214-b0fd-0dc51ccc8484" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_2d93cb68-0fa2-4023-835f-b12bde42d467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d1b1e165-c050-4214-b0fd-0dc51ccc8484" xlink:to="loc_us-gaap_InterestRateContractMember_2d93cb68-0fa2-4023-835f-b12bde42d467" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_0c57ed2a-6a2c-4f7b-8259-b11d9a2b046d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d1b1e165-c050-4214-b0fd-0dc51ccc8484" xlink:to="loc_us-gaap_ForeignExchangeContractMember_0c57ed2a-6a2c-4f7b-8259-b11d9a2b046d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_d2fcbeb2-db64-42d5-a0c0-fb3549884b19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0c237fd0-771b-4c9c-a4bc-1ee8acca9df2" xlink:to="loc_us-gaap_HedgingDesignationAxis_d2fcbeb2-db64-42d5-a0c0-fb3549884b19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_d2fcbeb2-db64-42d5-a0c0-fb3549884b19_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_d2fcbeb2-db64-42d5-a0c0-fb3549884b19" xlink:to="loc_us-gaap_HedgingDesignationDomain_d2fcbeb2-db64-42d5-a0c0-fb3549884b19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_4b30c852-c39c-4663-a17f-988d937db2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_d2fcbeb2-db64-42d5-a0c0-fb3549884b19" xlink:to="loc_us-gaap_HedgingDesignationDomain_4b30c852-c39c-4663-a17f-988d937db2c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_58b5c60a-c116-4cfe-8c59-8b7d37138057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_4b30c852-c39c-4663-a17f-988d937db2c1" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_58b5c60a-c116-4cfe-8c59-8b7d37138057" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_79c2ba7b-faa0-444f-a159-05a510cb9fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_4b30c852-c39c-4663-a17f-988d937db2c1" xlink:to="loc_us-gaap_NondesignatedMember_79c2ba7b-faa0-444f-a159-05a510cb9fc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1c58f9a8-5ef8-43f4-924d-39b14caa95a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0c237fd0-771b-4c9c-a4bc-1ee8acca9df2" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1c58f9a8-5ef8-43f4-924d-39b14caa95a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1c58f9a8-5ef8-43f4-924d-39b14caa95a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1c58f9a8-5ef8-43f4-924d-39b14caa95a6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1c58f9a8-5ef8-43f4-924d-39b14caa95a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1650257d-0928-44da-b63b-dbe6846cdb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1c58f9a8-5ef8-43f4-924d-39b14caa95a6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1650257d-0928-44da-b63b-dbe6846cdb5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember_fec54764-3233-41c8-ac5e-cf134eb3cc06" xlink:href="mrk-20230331.xsd#mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1650257d-0928-44da-b63b-dbe6846cdb5a" xlink:to="loc_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember_fec54764-3233-41c8-ac5e-cf134eb3cc06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_c6ab3054-0b09-4cfd-adff-1be73a3c7d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1650257d-0928-44da-b63b-dbe6846cdb5a" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_c6ab3054-0b09-4cfd-adff-1be73a3c7d28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember_bd3ab7c0-6b9d-46a2-a1da-ebeb73edcc30" xlink:href="mrk-20230331.xsd#mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1650257d-0928-44da-b63b-dbe6846cdb5a" xlink:to="loc_mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember_bd3ab7c0-6b9d-46a2-a1da-ebeb73edcc30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_18108347-86a6-4407-b4e0-021c4c4a8ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1650257d-0928-44da-b63b-dbe6846cdb5a" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_18108347-86a6-4407-b4e0-021c4c4a8ae6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" xlink:type="extended" id="i1643b04767e84398bf188613b3c4b508_FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04bd5596-9e59-4e21-bb63-5504a6d701c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7c17dcae-378b-43ef-999a-4932aff09a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04bd5596-9e59-4e21-bb63-5504a6d701c1" xlink:to="loc_us-gaap_Revenues_7c17dcae-378b-43ef-999a-4932aff09a38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7791fcc8-7eee-4a63-a4ac-5115d59911ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04bd5596-9e59-4e21-bb63-5504a6d701c1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7791fcc8-7eee-4a63-a4ac-5115d59911ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_702870ea-bb09-4179-a2aa-c84bda047387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04bd5596-9e59-4e21-bb63-5504a6d701c1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_702870ea-bb09-4179-a2aa-c84bda047387" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_770abd8e-04d3-4dbf-ab09-095d7bd3e070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04bd5596-9e59-4e21-bb63-5504a6d701c1" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_770abd8e-04d3-4dbf-ab09-095d7bd3e070" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_351a2e12-f281-4135-b6a8-4bcc06a10411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04bd5596-9e59-4e21-bb63-5504a6d701c1" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_351a2e12-f281-4135-b6a8-4bcc06a10411" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_d7486c82-586a-4874-b027-13705f494189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04bd5596-9e59-4e21-bb63-5504a6d701c1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_d7486c82-586a-4874-b027-13705f494189" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_d6c0d4bb-40b5-4c28-88e8-9731f2d936a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04bd5596-9e59-4e21-bb63-5504a6d701c1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_d6c0d4bb-40b5-4c28-88e8-9731f2d936a2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_86b027ba-d0f3-43ad-9a29-017210bac50b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04bd5596-9e59-4e21-bb63-5504a6d701c1" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_86b027ba-d0f3-43ad-9a29-017210bac50b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_073ddd72-6073-4854-952e-7eff50ac51c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04bd5596-9e59-4e21-bb63-5504a6d701c1" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_073ddd72-6073-4854-952e-7eff50ac51c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d1581905-5631-4f52-9a90-4fd5b383b8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_073ddd72-6073-4854-952e-7eff50ac51c5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d1581905-5631-4f52-9a90-4fd5b383b8fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d1581905-5631-4f52-9a90-4fd5b383b8fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d1581905-5631-4f52-9a90-4fd5b383b8fd" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d1581905-5631-4f52-9a90-4fd5b383b8fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e5d80fc0-5122-4b43-bffe-9da5d8d644d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d1581905-5631-4f52-9a90-4fd5b383b8fd" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e5d80fc0-5122-4b43-bffe-9da5d8d644d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_0ea3088e-64a4-4a6d-84bd-d9fe06b55549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e5d80fc0-5122-4b43-bffe-9da5d8d644d5" xlink:to="loc_us-gaap_InterestRateSwapMember_0ea3088e-64a4-4a6d-84bd-d9fe06b55549" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_5f6637aa-43d7-456d-9047-90b797f8ee23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e5d80fc0-5122-4b43-bffe-9da5d8d644d5" xlink:to="loc_us-gaap_ForeignExchangeContractMember_5f6637aa-43d7-456d-9047-90b797f8ee23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_c01c9f87-19cb-482d-836a-12ada1cb2c35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_073ddd72-6073-4854-952e-7eff50ac51c5" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_c01c9f87-19cb-482d-836a-12ada1cb2c35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_c01c9f87-19cb-482d-836a-12ada1cb2c35_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_c01c9f87-19cb-482d-836a-12ada1cb2c35" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_c01c9f87-19cb-482d-836a-12ada1cb2c35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_dc0be77c-1a71-416c-83bb-8f6f2035852e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_c01c9f87-19cb-482d-836a-12ada1cb2c35" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_dc0be77c-1a71-416c-83bb-8f6f2035852e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_2eb16209-4dcc-433e-b622-c19ac62d7a65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_dc0be77c-1a71-416c-83bb-8f6f2035852e" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_2eb16209-4dcc-433e-b622-c19ac62d7a65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7a7c2216-d79b-4ddc-b01d-ccbe5b090a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_073ddd72-6073-4854-952e-7eff50ac51c5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7a7c2216-d79b-4ddc-b01d-ccbe5b090a2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7a7c2216-d79b-4ddc-b01d-ccbe5b090a2c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7a7c2216-d79b-4ddc-b01d-ccbe5b090a2c" xlink:to="loc_us-gaap_EquityComponentDomain_7a7c2216-d79b-4ddc-b01d-ccbe5b090a2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9da5e7cc-5fa8-4598-a85a-6f24927aa746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7a7c2216-d79b-4ddc-b01d-ccbe5b090a2c" xlink:to="loc_us-gaap_EquityComponentDomain_9da5e7cc-5fa8-4598-a85a-6f24927aa746" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_89f849cb-d2ad-4215-83a9-d65aa057006e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9da5e7cc-5fa8-4598-a85a-6f24927aa746" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_89f849cb-d2ad-4215-83a9-d65aa057006e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f404f11d-c280-48a9-bf38-0c020615328d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_073ddd72-6073-4854-952e-7eff50ac51c5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f404f11d-c280-48a9-bf38-0c020615328d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f404f11d-c280-48a9-bf38-0c020615328d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f404f11d-c280-48a9-bf38-0c020615328d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f404f11d-c280-48a9-bf38-0c020615328d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4a775af0-d088-42b0-8b21-d07096b9ffef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f404f11d-c280-48a9-bf38-0c020615328d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4a775af0-d088-42b0-8b21-d07096b9ffef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_ed03c8f4-59fe-4441-8d9b-66f78de82b35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4a775af0-d088-42b0-8b21-d07096b9ffef" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_ed03c8f4-59fe-4441-8d9b-66f78de82b35" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended" id="i02da061be67a4a0c88c52471430ff665_FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_e0e2d988-570b-4c66-9acb-aa295c5a22c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_e900d9da-688a-473e-9f1b-18178f85d9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_e0e2d988-570b-4c66-9acb-aa295c5a22c9" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_e900d9da-688a-473e-9f1b-18178f85d9ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_66328265-3441-4f36-a1b4-97d291ab7f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_e0e2d988-570b-4c66-9acb-aa295c5a22c9" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_66328265-3441-4f36-a1b4-97d291ab7f94" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e02e1fe2-1b56-4bc1-8792-cbcdaa6fd7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_66328265-3441-4f36-a1b4-97d291ab7f94" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e02e1fe2-1b56-4bc1-8792-cbcdaa6fd7e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e02e1fe2-1b56-4bc1-8792-cbcdaa6fd7e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e02e1fe2-1b56-4bc1-8792-cbcdaa6fd7e8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e02e1fe2-1b56-4bc1-8792-cbcdaa6fd7e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d4a5d61c-5081-469a-b87c-62e0133dd2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e02e1fe2-1b56-4bc1-8792-cbcdaa6fd7e8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d4a5d61c-5081-469a-b87c-62e0133dd2c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_710aabf2-3a2a-4346-8367-55cf92f5f54f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d4a5d61c-5081-469a-b87c-62e0133dd2c7" xlink:to="loc_us-gaap_CurrencySwapMember_710aabf2-3a2a-4346-8367-55cf92f5f54f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeFutureMember_771998c7-e832-4896-be5b-6fa328185891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeFutureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d4a5d61c-5081-469a-b87c-62e0133dd2c7" xlink:to="loc_us-gaap_ForeignExchangeFutureMember_771998c7-e832-4896-be5b-6fa328185891" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_094de9dc-37e2-4bb4-92eb-cd6398360c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_66328265-3441-4f36-a1b4-97d291ab7f94" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_094de9dc-37e2-4bb4-92eb-cd6398360c66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_094de9dc-37e2-4bb4-92eb-cd6398360c66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_094de9dc-37e2-4bb4-92eb-cd6398360c66" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_094de9dc-37e2-4bb4-92eb-cd6398360c66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_022d3790-ac67-40ae-8a4c-6fe6034b3a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_094de9dc-37e2-4bb4-92eb-cd6398360c66" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_022d3790-ac67-40ae-8a4c-6fe6034b3a18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_d908ae43-ff31-47b8-8755-0a2866e20699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_022d3790-ac67-40ae-8a4c-6fe6034b3a18" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_d908ae43-ff31-47b8-8755-0a2866e20699" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_3e4b0640-67b5-46ec-9b36-d70f335a1e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_022d3790-ac67-40ae-8a4c-6fe6034b3a18" xlink:to="loc_us-gaap_SalesMember_3e4b0640-67b5-46ec-9b36-d70f335a1e98" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" xlink:type="extended" id="id177be12dd814fd999e9ba1359f17a84_FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84a68e47-a22b-4c24-82f0-80ec2828330d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_866bf826-1948-413b-a5b9-2a1337fe4a50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84a68e47-a22b-4c24-82f0-80ec2828330d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_866bf826-1948-413b-a5b9-2a1337fe4a50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_06459323-90ee-45d1-961d-ba81d2a2bfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84a68e47-a22b-4c24-82f0-80ec2828330d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_06459323-90ee-45d1-961d-ba81d2a2bfbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_21dc954c-cb17-4b46-8817-db4b04a6a3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84a68e47-a22b-4c24-82f0-80ec2828330d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_21dc954c-cb17-4b46-8817-db4b04a6a3a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8b4080a0-fee7-4a41-b283-f2494c262f96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84a68e47-a22b-4c24-82f0-80ec2828330d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8b4080a0-fee7-4a41-b283-f2494c262f96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_ecd92dc9-6c13-4c28-b91b-47dcf2304a80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84a68e47-a22b-4c24-82f0-80ec2828330d" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_ecd92dc9-6c13-4c28-b91b-47dcf2304a80" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_d30c1b0c-c4da-4c7d-9148-783edd766680" xlink:href="mrk-20230331.xsd#mrk_DebtSecuritiesandEquitySecuritiesFVNI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84a68e47-a22b-4c24-82f0-80ec2828330d" xlink:to="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_d30c1b0c-c4da-4c7d-9148-783edd766680" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_ea423bfd-6b82-4741-9a46-c5d2ac0f7a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84a68e47-a22b-4c24-82f0-80ec2828330d" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_ea423bfd-6b82-4741-9a46-c5d2ac0f7a7c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2759fbb4-7f2f-4f4d-a460-a55a68518085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84a68e47-a22b-4c24-82f0-80ec2828330d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2759fbb4-7f2f-4f4d-a460-a55a68518085" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0d6e7364-97f1-48a4-87d6-3f19242c88fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2759fbb4-7f2f-4f4d-a460-a55a68518085" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0d6e7364-97f1-48a4-87d6-3f19242c88fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0d6e7364-97f1-48a4-87d6-3f19242c88fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0d6e7364-97f1-48a4-87d6-3f19242c88fa" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0d6e7364-97f1-48a4-87d6-3f19242c88fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e90c64da-8b64-4edd-895e-eae7850c94c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0d6e7364-97f1-48a4-87d6-3f19242c88fa" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e90c64da-8b64-4edd-895e-eae7850c94c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_7a877fcb-bf4e-4d76-8141-ed8ed29e4b42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e90c64da-8b64-4edd-895e-eae7850c94c9" xlink:to="loc_us-gaap_CommercialPaperMember_7a877fcb-bf4e-4d76-8141-ed8ed29e4b42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_38566d1f-d6b7-4e84-9618-b212d0ce5fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e90c64da-8b64-4edd-895e-eae7850c94c9" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_38566d1f-d6b7-4e84-9618-b212d0ce5fae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9457bcd5-de84-47e4-b10e-a1ffe1b615db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e90c64da-8b64-4edd-895e-eae7850c94c9" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9457bcd5-de84-47e4-b10e-a1ffe1b615db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_675c685a-c3ba-46b0-b92f-419b5a56ddc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e90c64da-8b64-4edd-895e-eae7850c94c9" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_675c685a-c3ba-46b0-b92f-419b5a56ddc8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="i0da514ee505d45e19c267d48b6f022c7_FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bfe74377-4cf3-4fd7-938f-2daaa2a74635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_83f9a8f3-fda6-46c5-89ea-6b9f9e830a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bfe74377-4cf3-4fd7-938f-2daaa2a74635" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_83f9a8f3-fda6-46c5-89ea-6b9f9e830a03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0caa0f41-2c7e-4572-8b19-8fa173eb92b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_83f9a8f3-fda6-46c5-89ea-6b9f9e830a03" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0caa0f41-2c7e-4572-8b19-8fa173eb92b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_7949f343-5ba5-4eb3-8a83-61fbc6c7b351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_83f9a8f3-fda6-46c5-89ea-6b9f9e830a03" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_7949f343-5ba5-4eb3-8a83-61fbc6c7b351" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_514b3587-2413-4c49-9d74-6c5e6d8f5cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_83f9a8f3-fda6-46c5-89ea-6b9f9e830a03" xlink:to="loc_us-gaap_TradingSecurities_514b3587-2413-4c49-9d74-6c5e6d8f5cc9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7ba781be-9bdc-420a-8d74-8e3d8fab3fff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_83f9a8f3-fda6-46c5-89ea-6b9f9e830a03" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7ba781be-9bdc-420a-8d74-8e3d8fab3fff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_c94eef3d-c134-4031-beb8-a3b71a8a8f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_83f9a8f3-fda6-46c5-89ea-6b9f9e830a03" xlink:to="loc_us-gaap_DerivativeAssets_c94eef3d-c134-4031-beb8-a3b71a8a8f6d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c12d2636-73ec-450c-acbe-72a63b1a3113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_83f9a8f3-fda6-46c5-89ea-6b9f9e830a03" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_c12d2636-73ec-450c-acbe-72a63b1a3113" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_49fe3725-ae6b-4cd9-b6a7-9dd9d3ce5c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bfe74377-4cf3-4fd7-938f-2daaa2a74635" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_49fe3725-ae6b-4cd9-b6a7-9dd9d3ce5c30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_10eecac3-2707-45cc-b3d9-c6c70343fc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_49fe3725-ae6b-4cd9-b6a7-9dd9d3ce5c30" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_10eecac3-2707-45cc-b3d9-c6c70343fc8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_c3e74e49-b75a-473c-9bb4-95462e4b7544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_49fe3725-ae6b-4cd9-b6a7-9dd9d3ce5c30" xlink:to="loc_us-gaap_DerivativeLiabilities_c3e74e49-b75a-473c-9bb4-95462e4b7544" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_cbabe258-fc50-4912-90a3-bb95709aa8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_49fe3725-ae6b-4cd9-b6a7-9dd9d3ce5c30" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_cbabe258-fc50-4912-90a3-bb95709aa8e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fe228f70-95e3-4668-ae2a-533d7d6fbe68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bfe74377-4cf3-4fd7-938f-2daaa2a74635" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fe228f70-95e3-4668-ae2a-533d7d6fbe68" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eb3d70d1-1070-4af5-b1e4-d056ef8c2f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fe228f70-95e3-4668-ae2a-533d7d6fbe68" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eb3d70d1-1070-4af5-b1e4-d056ef8c2f6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_eb3d70d1-1070-4af5-b1e4-d056ef8c2f6e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eb3d70d1-1070-4af5-b1e4-d056ef8c2f6e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_eb3d70d1-1070-4af5-b1e4-d056ef8c2f6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6e945abc-2b0e-40c6-84bc-ddc6472d21d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eb3d70d1-1070-4af5-b1e4-d056ef8c2f6e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6e945abc-2b0e-40c6-84bc-ddc6472d21d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_cc286788-bbe0-42c7-bc81-058ce85f3628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_6e945abc-2b0e-40c6-84bc-ddc6472d21d5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_cc286788-bbe0-42c7-bc81-058ce85f3628" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6fc1786c-704e-4ff4-8a8f-b022e0fe166f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fe228f70-95e3-4668-ae2a-533d7d6fbe68" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6fc1786c-704e-4ff4-8a8f-b022e0fe166f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fc1786c-704e-4ff4-8a8f-b022e0fe166f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6fc1786c-704e-4ff4-8a8f-b022e0fe166f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6fc1786c-704e-4ff4-8a8f-b022e0fe166f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e1beedd9-3dba-4d92-8c6a-c36e0656433f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6fc1786c-704e-4ff4-8a8f-b022e0fe166f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e1beedd9-3dba-4d92-8c6a-c36e0656433f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_d1d18173-6d2d-49c8-9639-125d77182dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e1beedd9-3dba-4d92-8c6a-c36e0656433f" xlink:to="loc_us-gaap_CommercialPaperMember_d1d18173-6d2d-49c8-9639-125d77182dc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d7311b53-b25f-4e34-ae8a-2740bf58e83f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e1beedd9-3dba-4d92-8c6a-c36e0656433f" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d7311b53-b25f-4e34-ae8a-2740bf58e83f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_4324c6e4-4d0c-4e66-8d8e-c0eed32d6665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e1beedd9-3dba-4d92-8c6a-c36e0656433f" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_4324c6e4-4d0c-4e66-8d8e-c0eed32d6665" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_c0bf5cab-a242-4df2-8c18-74e3309b423f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e1beedd9-3dba-4d92-8c6a-c36e0656433f" xlink:to="loc_us-gaap_EquitySecuritiesMember_c0bf5cab-a242-4df2-8c18-74e3309b423f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_43c8985e-da70-4def-869e-c1176d723f30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e1beedd9-3dba-4d92-8c6a-c36e0656433f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_43c8985e-da70-4def-869e-c1176d723f30" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a337e41e-359d-43f6-a8c5-db0cd822fbad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fe228f70-95e3-4668-ae2a-533d7d6fbe68" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a337e41e-359d-43f6-a8c5-db0cd822fbad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a337e41e-359d-43f6-a8c5-db0cd822fbad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a337e41e-359d-43f6-a8c5-db0cd822fbad" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a337e41e-359d-43f6-a8c5-db0cd822fbad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95f66b87-c37b-46ae-9a67-a4be50633192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a337e41e-359d-43f6-a8c5-db0cd822fbad" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95f66b87-c37b-46ae-9a67-a4be50633192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_bf7145d8-00cd-4732-8f04-1a195cabbe6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95f66b87-c37b-46ae-9a67-a4be50633192" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_bf7145d8-00cd-4732-8f04-1a195cabbe6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_29a10f9a-9e5f-4daa-b56c-6aa558c022dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95f66b87-c37b-46ae-9a67-a4be50633192" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_29a10f9a-9e5f-4daa-b56c-6aa558c022dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_007fb067-11a6-40f2-b000-e1fb1c3b1b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95f66b87-c37b-46ae-9a67-a4be50633192" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_007fb067-11a6-40f2-b000-e1fb1c3b1b63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0fe6e323-f035-4321-a91c-d0f5c17485ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fe228f70-95e3-4668-ae2a-533d7d6fbe68" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0fe6e323-f035-4321-a91c-d0f5c17485ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0fe6e323-f035-4321-a91c-d0f5c17485ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0fe6e323-f035-4321-a91c-d0f5c17485ca" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0fe6e323-f035-4321-a91c-d0f5c17485ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7c010215-9a49-4cad-899d-d1791d0c9cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0fe6e323-f035-4321-a91c-d0f5c17485ca" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7c010215-9a49-4cad-899d-d1791d0c9cb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeOptionMember_ec59e2ea-42d1-4bb4-83b7-01b8b42b7099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7c010215-9a49-4cad-899d-d1791d0c9cb5" xlink:to="loc_us-gaap_ForeignExchangeOptionMember_ec59e2ea-42d1-4bb4-83b7-01b8b42b7099" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_89ebfe32-6222-4fac-bc19-20d22cbaf850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7c010215-9a49-4cad-899d-d1791d0c9cb5" xlink:to="loc_us-gaap_ForeignExchangeContractMember_89ebfe32-6222-4fac-bc19-20d22cbaf850" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_2a0138f7-b186-4f97-a900-8ddf4782b14e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7c010215-9a49-4cad-899d-d1791d0c9cb5" xlink:to="loc_us-gaap_InterestRateSwapMember_2a0138f7-b186-4f97-a900-8ddf4782b14e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="extended" id="i8e61306f4c1244d39995ec72d3806901_FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_d57e5b2c-c112-41a7-9b04-81a57cd73af0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2155c958-104e-4aa8-85b6-11322e42dfe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_d57e5b2c-c112-41a7-9b04-81a57cd73af0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2155c958-104e-4aa8-85b6-11322e42dfe0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d6e0c358-36b8-4b96-aaf8-beda3f846a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2155c958-104e-4aa8-85b6-11322e42dfe0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d6e0c358-36b8-4b96-aaf8-beda3f846a66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_cfbe0afe-9ce4-4a98-bff0-cf5f4401f62d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2155c958-104e-4aa8-85b6-11322e42dfe0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_cfbe0afe-9ce4-4a98-bff0-cf5f4401f62d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_a42a0064-1d45-4d31-a928-9013543c2bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2155c958-104e-4aa8-85b6-11322e42dfe0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_a42a0064-1d45-4d31-a928-9013543c2bbc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_2b463dd1-1788-4ecd-803d-d1990f40a65b" xlink:href="mrk-20230331.xsd#mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2155c958-104e-4aa8-85b6-11322e42dfe0" xlink:to="loc_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_2b463dd1-1788-4ecd-803d-d1990f40a65b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_500f3cda-2ab0-4ce4-b164-2c8ea55a3d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3ebace16-c1f9-455d-8846-d510b2ac7d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_7f9992ff-e31d-47a1-80a7-166c3c758450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2155c958-104e-4aa8-85b6-11322e42dfe0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_7f9992ff-e31d-47a1-80a7-166c3c758450" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_6093f1b8-7b3f-4ada-ac2c-3f9446d1b2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2155c958-104e-4aa8-85b6-11322e42dfe0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_6093f1b8-7b3f-4ada-ac2c-3f9446d1b2e2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e32439d5-2cf7-4272-9810-3ce2de924b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_d57e5b2c-c112-41a7-9b04-81a57cd73af0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e32439d5-2cf7-4272-9810-3ce2de924b6a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_4aba7c7d-040a-44ca-be4a-3284c5521675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e32439d5-2cf7-4272-9810-3ce2de924b6a" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_4aba7c7d-040a-44ca-be4a-3284c5521675" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_4aba7c7d-040a-44ca-be4a-3284c5521675_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_4aba7c7d-040a-44ca-be4a-3284c5521675" xlink:to="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_4aba7c7d-040a-44ca-be4a-3284c5521675_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_1a17827f-c845-4aef-9bb4-e71c8cc10ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_4aba7c7d-040a-44ca-be4a-3284c5521675" xlink:to="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_1a17827f-c845-4aef-9bb4-e71c8cc10ee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SanofiPasteurMember_1f8e8bdb-a61e-4401-ad78-9dccf2fb3879" xlink:href="mrk-20230331.xsd#mrk_SanofiPasteurMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_1a17827f-c845-4aef-9bb4-e71c8cc10ee0" xlink:to="loc_mrk_SanofiPasteurMember_1f8e8bdb-a61e-4401-ad78-9dccf2fb3879" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#InventoriesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="extended" id="i55499c804d6d42e0bf8e45ebf97b7c93_InventoriesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_f451ae0d-4cba-4a50-82c9-9e8e3ab8b0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_ddb5d356-1802-4615-bc29-f24dbef15ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_f451ae0d-4cba-4a50-82c9-9e8e3ab8b0d2" xlink:to="loc_us-gaap_InventoryNoncurrent_ddb5d356-1802-4615-bc29-f24dbef15ea3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryTable_6edc9fc8-e0f8-4fcd-8715-522943f894eb" xlink:href="mrk-20230331.xsd#mrk_InventoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_f451ae0d-4cba-4a50-82c9-9e8e3ab8b0d2" xlink:to="loc_mrk_InventoryTable_6edc9fc8-e0f8-4fcd-8715-522943f894eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_e9ab736c-5ee8-439c-96d4-a2129a74dbc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_InventoryTable_6edc9fc8-e0f8-4fcd-8715-522943f894eb" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_e9ab736c-5ee8-439c-96d4-a2129a74dbc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_e9ab736c-5ee8-439c-96d4-a2129a74dbc0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_e9ab736c-5ee8-439c-96d4-a2129a74dbc0" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_e9ab736c-5ee8-439c-96d4-a2129a74dbc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_ae6cfa8b-f89b-4a47-a872-38ca554609eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_e9ab736c-5ee8-439c-96d4-a2129a74dbc0" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_ae6cfa8b-f89b-4a47-a872-38ca554609eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_196aa7c0-1960-47b0-9dbb-96035e3f9278" xlink:href="mrk-20230331.xsd#mrk_InventoryNotExpectedtobeSoldWithinOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_ae6cfa8b-f89b-4a47-a872-38ca554609eb" xlink:to="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_196aa7c0-1960-47b0-9dbb-96035e3f9278" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember_5494545d-6b5e-4b4f-8e2f-c58e34b3fbf9" xlink:href="mrk-20230331.xsd#mrk_InventoriesProducedinPreparationforProductLaunchesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_ae6cfa8b-f89b-4a47-a872-38ca554609eb" xlink:to="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember_5494545d-6b5e-4b4f-8e2f-c58e34b3fbf9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#ContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/ContingenciesDetails" xlink:type="extended" id="i31a1f5b69b2244bea17806f0db52c122_ContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_d2d5d696-a16b-4227-9cbc-830532db7a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_2a7c2e94-a667-44ce-92a3-e8f004cd1c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d2d5d696-a16b-4227-9cbc-830532db7a29" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_2a7c2e94-a667-44ce-92a3-e8f004cd1c1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_199ab61d-69f6-43b5-9122-77ee7ca64a62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d2d5d696-a16b-4227-9cbc-830532db7a29" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_199ab61d-69f6-43b5-9122-77ee7ca64a62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LossContingencyNumberOfStatesInWhichPlaintiffsReside_0ec42872-ed16-48c9-bec1-991ffe746c4f" xlink:href="mrk-20230331.xsd#mrk_LossContingencyNumberOfStatesInWhichPlaintiffsReside"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d2d5d696-a16b-4227-9cbc-830532db7a29" xlink:to="loc_mrk_LossContingencyNumberOfStatesInWhichPlaintiffsReside_0ec42872-ed16-48c9-bec1-991ffe746c4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LossContingencyTrialPeriod_13d4b388-7c96-4925-9dc7-23a1aa3f18bc" xlink:href="mrk-20230331.xsd#mrk_LossContingencyTrialPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d2d5d696-a16b-4227-9cbc-830532db7a29" xlink:to="loc_mrk_LossContingencyTrialPeriod_13d4b388-7c96-4925-9dc7-23a1aa3f18bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_6c77e30c-45ff-45f5-b1cb-f09fb0d9c24a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d2d5d696-a16b-4227-9cbc-830532db7a29" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_6c77e30c-45ff-45f5-b1cb-f09fb0d9c24a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_a5e26158-f7a5-4693-913c-812e3b76dd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d2d5d696-a16b-4227-9cbc-830532db7a29" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_a5e26158-f7a5-4693-913c-812e3b76dd9d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_52bb0d1a-f116-4434-949e-699d78aeccb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d2d5d696-a16b-4227-9cbc-830532db7a29" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_52bb0d1a-f116-4434-949e-699d78aeccb3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_12294e7d-733c-43e3-b794-200ae3906bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_d2d5d696-a16b-4227-9cbc-830532db7a29" xlink:to="loc_us-gaap_LitigationReserve_12294e7d-733c-43e3-b794-200ae3906bbf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_650ab951-e395-496e-8f2e-02dec2484b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_d2d5d696-a16b-4227-9cbc-830532db7a29" xlink:to="loc_us-gaap_LossContingenciesTable_650ab951-e395-496e-8f2e-02dec2484b97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6ebf0c16-679c-47bf-8de3-40d6490c7a9a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_650ab951-e395-496e-8f2e-02dec2484b97" xlink:to="loc_srt_ProductOrServiceAxis_6ebf0c16-679c-47bf-8de3-40d6490c7a9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6ebf0c16-679c-47bf-8de3-40d6490c7a9a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6ebf0c16-679c-47bf-8de3-40d6490c7a9a" xlink:to="loc_srt_ProductsAndServicesDomain_6ebf0c16-679c-47bf-8de3-40d6490c7a9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dbe9d4ea-d4e6-4ce9-9760-1250d67d32ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6ebf0c16-679c-47bf-8de3-40d6490c7a9a" xlink:to="loc_srt_ProductsAndServicesDomain_dbe9d4ea-d4e6-4ce9-9760-1250d67d32ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member_a02c27e9-63ae-4fe1-80d5-d73fddb49bba" xlink:href="mrk-20230331.xsd#mrk_GardasilGardasil9Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dbe9d4ea-d4e6-4ce9-9760-1250d67d32ad" xlink:to="loc_mrk_GardasilGardasil9Member_a02c27e9-63ae-4fe1-80d5-d73fddb49bba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember_0b2639be-06dd-4fca-a59d-edbb11032ff6" xlink:href="mrk-20230331.xsd#mrk_BridionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dbe9d4ea-d4e6-4ce9-9760-1250d67d32ad" xlink:to="loc_mrk_BridionMember_0b2639be-06dd-4fca-a59d-edbb11032ff6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaAndJanumetMember_2ffa0077-2ccc-4c0d-a6b5-0931a808134f" xlink:href="mrk-20230331.xsd#mrk_JanuviaAndJanumetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dbe9d4ea-d4e6-4ce9-9760-1250d67d32ad" xlink:to="loc_mrk_JanuviaAndJanumetMember_2ffa0077-2ccc-4c0d-a6b5-0931a808134f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_621f699e-e353-447a-92b9-c92d609c5a7d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_650ab951-e395-496e-8f2e-02dec2484b97" xlink:to="loc_srt_LitigationCaseAxis_621f699e-e353-447a-92b9-c92d609c5a7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_621f699e-e353-447a-92b9-c92d609c5a7d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_621f699e-e353-447a-92b9-c92d609c5a7d" xlink:to="loc_srt_LitigationCaseTypeDomain_621f699e-e353-447a-92b9-c92d609c5a7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e9cf97a1-be08-4301-99d6-0938b854b1ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_621f699e-e353-447a-92b9-c92d609c5a7d" xlink:to="loc_srt_LitigationCaseTypeDomain_e9cf97a1-be08-4301-99d6-0938b854b1ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZetiaantitrustlitigationMember_0a01dfc0-ac4a-4085-a4aa-7fa3a3b6b7ba" xlink:href="mrk-20230331.xsd#mrk_ZetiaantitrustlitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e9cf97a1-be08-4301-99d6-0938b854b1ee" xlink:to="loc_mrk_ZetiaantitrustlitigationMember_0a01dfc0-ac4a-4085-a4aa-7fa3a3b6b7ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RotaTeqAntitrustLitigationMember_173dca4d-e166-4bb4-8b1f-c74576766b60" xlink:href="mrk-20230331.xsd#mrk_RotaTeqAntitrustLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e9cf97a1-be08-4301-99d6-0938b854b1ee" xlink:to="loc_mrk_RotaTeqAntitrustLitigationMember_173dca4d-e166-4bb4-8b1f-c74576766b60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_bb31128b-4fcb-45ee-83b1-0ae45bf6c467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e9cf97a1-be08-4301-99d6-0938b854b1ee" xlink:to="loc_us-gaap_PatentsMember_bb31128b-4fcb-45ee-83b1-0ae45bf6c467" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComplaintAgainstTheJohnsHopkinsUniversityMember_bb1577ed-c02a-4d1f-9111-22dd9df5982e" xlink:href="mrk-20230331.xsd#mrk_ComplaintAgainstTheJohnsHopkinsUniversityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e9cf97a1-be08-4301-99d6-0938b854b1ee" xlink:to="loc_mrk_ComplaintAgainstTheJohnsHopkinsUniversityMember_bb1577ed-c02a-4d1f-9111-22dd9df5982e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c078bd5e-441a-4f59-ab43-f923da5335ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_650ab951-e395-496e-8f2e-02dec2484b97" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c078bd5e-441a-4f59-ab43-f923da5335ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_c078bd5e-441a-4f59-ab43-f923da5335ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c078bd5e-441a-4f59-ab43-f923da5335ef" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_c078bd5e-441a-4f59-ab43-f923da5335ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_d156537d-44ef-46de-abd7-58cac23d309b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c078bd5e-441a-4f59-ab43-f923da5335ef" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_d156537d-44ef-46de-abd7-58cac23d309b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LegalDefenseCostsMember_c76bc788-f9a8-48ab-8eb2-d647cba56fc0" xlink:href="mrk-20230331.xsd#mrk_LegalDefenseCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_d156537d-44ef-46de-abd7-58cac23d309b" xlink:to="loc_mrk_LegalDefenseCostsMember_c76bc788-f9a8-48ab-8eb2-d647cba56fc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_f6e89857-edd7-46e5-b583-43c89ef853a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_650ab951-e395-496e-8f2e-02dec2484b97" xlink:to="loc_us-gaap_LitigationStatusAxis_f6e89857-edd7-46e5-b583-43c89ef853a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_f6e89857-edd7-46e5-b583-43c89ef853a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_f6e89857-edd7-46e5-b583-43c89ef853a6" xlink:to="loc_us-gaap_LitigationStatusDomain_f6e89857-edd7-46e5-b583-43c89ef853a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_37fb3968-70ca-451d-a03d-d8e190ce9d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_f6e89857-edd7-46e5-b583-43c89ef853a6" xlink:to="loc_us-gaap_LitigationStatusDomain_37fb3968-70ca-451d-a03d-d8e190ce9d5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_093422f7-fba6-4b5f-bd4a-90111735ec9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_37fb3968-70ca-451d-a03d-d8e190ce9d5f" xlink:to="loc_us-gaap_PendingLitigationMember_093422f7-fba6-4b5f-bd4a-90111735ec9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a9c3540c-ffa0-4718-83a5-4c86000c01c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_650ab951-e395-496e-8f2e-02dec2484b97" xlink:to="loc_srt_StatementGeographicalAxis_a9c3540c-ffa0-4718-83a5-4c86000c01c6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a9c3540c-ffa0-4718-83a5-4c86000c01c6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_a9c3540c-ffa0-4718-83a5-4c86000c01c6" xlink:to="loc_srt_SegmentGeographicalDomain_a9c3540c-ffa0-4718-83a5-4c86000c01c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8fc56877-db6e-4b70-a3d3-1e0db023808a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_a9c3540c-ffa0-4718-83a5-4c86000c01c6" xlink:to="loc_srt_SegmentGeographicalDomain_8fc56877-db6e-4b70-a3d3-1e0db023808a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_24add0a9-017a-4725-9ecd-42735ed44f2b" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8fc56877-db6e-4b70-a3d3-1e0db023808a" xlink:to="loc_country_US_24add0a9-017a-4725-9ecd-42735ed44f2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_cf13a209-ea54-45f3-8f8c-c8644edeb0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8fc56877-db6e-4b70-a3d3-1e0db023808a" xlink:to="loc_us-gaap_NonUsMember_cf13a209-ea54-45f3-8f8c-c8644edeb0f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CO_ff62c915-55d0-48bb-be04-c9cc36870f8d" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CO"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8fc56877-db6e-4b70-a3d3-1e0db023808a" xlink:to="loc_country_CO_ff62c915-55d0-48bb-be04-c9cc36870f8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_cabc04ed-a774-4dd7-a955-530c7dffaed4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_650ab951-e395-496e-8f2e-02dec2484b97" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_cabc04ed-a774-4dd7-a955-530c7dffaed4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cabc04ed-a774-4dd7-a955-530c7dffaed4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cabc04ed-a774-4dd7-a955-530c7dffaed4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cabc04ed-a774-4dd7-a955-530c7dffaed4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_41d9f88c-c86b-4331-8f29-895a6a77e6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cabc04ed-a774-4dd7-a955-530c7dffaed4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_41d9f88c-c86b-4331-8f29-895a6a77e6e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_72aa7c45-34f6-4b97-a347-216946d14ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_41d9f88c-c86b-4331-8f29-895a6a77e6e3" xlink:to="loc_us-gaap_SubsequentEventMember_72aa7c45-34f6-4b97-a347-216946d14ddf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/EquityDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#EquityDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/EquityDetails" xlink:type="extended" id="i5228686ced764854ab94565c1b53805c_EquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_StockholdersEquityLineItems_fdd766b9-3e6f-49b9-99d2-d14eb434a854" xlink:href="mrk-20230331.xsd#mrk_StockholdersEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62a97bd6-18ac-40cf-84ea-3b4d59fdb159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_StockholdersEquityLineItems_fdd766b9-3e6f-49b9-99d2-d14eb434a854" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62a97bd6-18ac-40cf-84ea-3b4d59fdb159" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ea611286-4bb6-47f5-b8f0-18ad87ec5f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62a97bd6-18ac-40cf-84ea-3b4d59fdb159" xlink:to="loc_us-gaap_CommonStockSharesIssued_ea611286-4bb6-47f5-b8f0-18ad87ec5f4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_7a8a5576-9c86-4a58-b132-8cd4e5699c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62a97bd6-18ac-40cf-84ea-3b4d59fdb159" xlink:to="loc_us-gaap_TreasuryStockCommonShares_7a8a5576-9c86-4a58-b132-8cd4e5699c92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_72e3966c-187b-4877-803e-7fe70c6501ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62a97bd6-18ac-40cf-84ea-3b4d59fdb159" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_72e3966c-187b-4877-803e-7fe70c6501ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4e5ab4ec-f247-412e-b177-a7cb855e2d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62a97bd6-18ac-40cf-84ea-3b4d59fdb159" xlink:to="loc_us-gaap_NetIncomeLoss_4e5ab4ec-f247-412e-b177-a7cb855e2d2b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9780f832-4f26-4711-be14-1a8155323f54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62a97bd6-18ac-40cf-84ea-3b4d59fdb159" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9780f832-4f26-4711-be14-1a8155323f54" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_65b6ce94-6653-42fd-ac16-842ee0daa298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62a97bd6-18ac-40cf-84ea-3b4d59fdb159" xlink:to="loc_us-gaap_DividendsCommonStockCash_65b6ce94-6653-42fd-ac16-842ee0daa298" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_30f89a96-07de-4461-9e76-d5ee399bbe28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62a97bd6-18ac-40cf-84ea-3b4d59fdb159" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_30f89a96-07de-4461-9e76-d5ee399bbe28" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_1944b47e-8abb-41ff-9ffb-d0206949b3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62a97bd6-18ac-40cf-84ea-3b4d59fdb159" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_1944b47e-8abb-41ff-9ffb-d0206949b3d4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_8d455bd7-888f-488b-b734-291330d47db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62a97bd6-18ac-40cf-84ea-3b4d59fdb159" xlink:to="loc_us-gaap_StockholdersEquityOther_8d455bd7-888f-488b-b734-291330d47db7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d9fbdb58-f7ee-4156-b4be-5f366e06f990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62a97bd6-18ac-40cf-84ea-3b4d59fdb159" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d9fbdb58-f7ee-4156-b4be-5f366e06f990" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_414be515-5797-4484-8edd-29436e25dd74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_9dddf2f2-e75f-4886-bd52-9ac930d2131d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4cdfe5bc-c3de-4284-9e3f-5434fe89de7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_b28afb15-d226-4a8c-9ff9-c4f996856244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mrk_StockholdersEquityLineItems_fdd766b9-3e6f-49b9-99d2-d14eb434a854" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_b28afb15-d226-4a8c-9ff9-c4f996856244" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_StockholdersEquityTable_0fb36e09-9e92-4788-886d-bd9a2661a568" xlink:href="mrk-20230331.xsd#mrk_StockholdersEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mrk_StockholdersEquityLineItems_fdd766b9-3e6f-49b9-99d2-d14eb434a854" xlink:to="loc_mrk_StockholdersEquityTable_0fb36e09-9e92-4788-886d-bd9a2661a568" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6cfe47b6-6369-4df4-9c18-2d12fd2936bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mrk_StockholdersEquityTable_0fb36e09-9e92-4788-886d-bd9a2661a568" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6cfe47b6-6369-4df4-9c18-2d12fd2936bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6cfe47b6-6369-4df4-9c18-2d12fd2936bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6cfe47b6-6369-4df4-9c18-2d12fd2936bc" xlink:to="loc_us-gaap_EquityComponentDomain_6cfe47b6-6369-4df4-9c18-2d12fd2936bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4ac8eb4b-65c2-4d39-95e1-da7f8da78ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6cfe47b6-6369-4df4-9c18-2d12fd2936bc" xlink:to="loc_us-gaap_EquityComponentDomain_4ac8eb4b-65c2-4d39-95e1-da7f8da78ea7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d41a12ff-2980-4577-bfb4-f8147a96a2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4ac8eb4b-65c2-4d39-95e1-da7f8da78ea7" xlink:to="loc_us-gaap_CommonStockMember_d41a12ff-2980-4577-bfb4-f8147a96a2d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_342e0291-b54a-43e4-84bd-2059a4e35fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4ac8eb4b-65c2-4d39-95e1-da7f8da78ea7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_342e0291-b54a-43e4-84bd-2059a4e35fe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_68d30792-029c-47e4-b581-08b45851565e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4ac8eb4b-65c2-4d39-95e1-da7f8da78ea7" xlink:to="loc_us-gaap_RetainedEarningsMember_68d30792-029c-47e4-b581-08b45851565e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_712653de-e30d-4ed4-af54-e36fd29a3498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4ac8eb4b-65c2-4d39-95e1-da7f8da78ea7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_712653de-e30d-4ed4-af54-e36fd29a3498" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_05f29079-d94a-45b2-be85-1f0ac77703c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4ac8eb4b-65c2-4d39-95e1-da7f8da78ea7" xlink:to="loc_us-gaap_TreasuryStockCommonMember_05f29079-d94a-45b2-be85-1f0ac77703c0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_57d41bb3-febb-46d4-b2c0-692b40348113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4ac8eb4b-65c2-4d39-95e1-da7f8da78ea7" xlink:to="loc_us-gaap_NoncontrollingInterestMember_57d41bb3-febb-46d4-b2c0-692b40348113" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" xlink:type="extended" id="iebd9cafe7f8f4f848fb2e46ec204a1d6_PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f96a4ced-baf8-4eb2-ab1b-f8f6b2e59db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_f7db2f50-f495-44b9-b0cd-0ae39503de2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f96a4ced-baf8-4eb2-ab1b-f8f6b2e59db7" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_f7db2f50-f495-44b9-b0cd-0ae39503de2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_e4d89e1d-38e8-46f7-bad3-8a44502d7ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f96a4ced-baf8-4eb2-ab1b-f8f6b2e59db7" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_e4d89e1d-38e8-46f7-bad3-8a44502d7ba9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_a842083b-44fc-40c5-8838-1ec2c8ea0ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f96a4ced-baf8-4eb2-ab1b-f8f6b2e59db7" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_a842083b-44fc-40c5-8838-1ec2c8ea0ca0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_5ca13a16-4241-4b2c-8fe1-925fd9ade80d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f96a4ced-baf8-4eb2-ab1b-f8f6b2e59db7" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_5ca13a16-4241-4b2c-8fe1-925fd9ade80d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_1e861b81-d69a-493a-8cd1-9d3cfcc07125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f96a4ced-baf8-4eb2-ab1b-f8f6b2e59db7" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_1e861b81-d69a-493a-8cd1-9d3cfcc07125" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_f8851e04-f9ed-4af3-93a3-98879ac1903e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f96a4ced-baf8-4eb2-ab1b-f8f6b2e59db7" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_f8851e04-f9ed-4af3-93a3-98879ac1903e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_6af4c5c2-5605-463d-aaef-ef65ad129985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f96a4ced-baf8-4eb2-ab1b-f8f6b2e59db7" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_6af4c5c2-5605-463d-aaef-ef65ad129985" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_4a09d364-69c9-44f8-9f0d-14d9ef9e2b05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f96a4ced-baf8-4eb2-ab1b-f8f6b2e59db7" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_4a09d364-69c9-44f8-9f0d-14d9ef9e2b05" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_dd29fa37-91d3-4f45-9bb9-be859dabdf4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f96a4ced-baf8-4eb2-ab1b-f8f6b2e59db7" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_dd29fa37-91d3-4f45-9bb9-be859dabdf4f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_349874cc-fe9a-4177-8f9a-6fa7650ea3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_dd29fa37-91d3-4f45-9bb9-be859dabdf4f" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_349874cc-fe9a-4177-8f9a-6fa7650ea3d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_349874cc-fe9a-4177-8f9a-6fa7650ea3d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_349874cc-fe9a-4177-8f9a-6fa7650ea3d7" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_349874cc-fe9a-4177-8f9a-6fa7650ea3d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_1d913667-1d08-42f2-8123-10cfe04a91e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_349874cc-fe9a-4177-8f9a-6fa7650ea3d7" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_1d913667-1d08-42f2-8123-10cfe04a91e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_87346acd-a812-4ecd-a9f2-e663e38fe6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_1d913667-1d08-42f2-8123-10cfe04a91e1" xlink:to="loc_us-gaap_DomesticPlanMember_87346acd-a812-4ecd-a9f2-e663e38fe6cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_e1209795-abb3-4bc2-9d27-6fb0e98e76d4" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_87346acd-a812-4ecd-a9f2-e663e38fe6cf" xlink:to="loc_country_US_e1209795-abb3-4bc2-9d27-6fb0e98e76d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_e4ec84b4-1a9c-4935-a6a9-6a7498c78f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_1d913667-1d08-42f2-8123-10cfe04a91e1" xlink:to="loc_us-gaap_ForeignPlanMember_e4ec84b4-1a9c-4935-a6a9-6a7498c78f8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_eb3adfa5-3165-4a3a-9adf-cd2705c18585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_dd29fa37-91d3-4f45-9bb9-be859dabdf4f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_eb3adfa5-3165-4a3a-9adf-cd2705c18585" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_eb3adfa5-3165-4a3a-9adf-cd2705c18585_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_eb3adfa5-3165-4a3a-9adf-cd2705c18585" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_eb3adfa5-3165-4a3a-9adf-cd2705c18585_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_532aae6f-0069-40d4-9c35-0459fde1ed84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_eb3adfa5-3165-4a3a-9adf-cd2705c18585" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_532aae6f-0069-40d4-9c35-0459fde1ed84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_a761599d-093a-46e5-88aa-61f3aaf00c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_532aae6f-0069-40d4-9c35-0459fde1ed84" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_a761599d-093a-46e5-88aa-61f3aaf00c5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_84a0bd8a-0463-42ad-85ef-d19de1afbb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_532aae6f-0069-40d4-9c35-0459fde1ed84" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_84a0bd8a-0463-42ad-85ef-d19de1afbb6a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#OtherIncomeExpenseNetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" xlink:type="extended" id="i01025d3f66fd434b9b697ce361abb8e5_OtherIncomeExpenseNetNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_bd46ddbf-34eb-4bbc-a1ea-d32b6663123d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_f387aa6d-aeb9-456e-9abf-65b116ca503a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_bd46ddbf-34eb-4bbc-a1ea-d32b6663123d" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_f387aa6d-aeb9-456e-9abf-65b116ca503a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_4a6dc763-2fe3-4fd3-95f2-bfb34d651fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_bd46ddbf-34eb-4bbc-a1ea-d32b6663123d" xlink:to="loc_us-gaap_InterestPaid_4a6dc763-2fe3-4fd3-95f2-bfb34d651fd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_4a30b67a-1022-4f2d-9c88-41c501e2e13f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_bd46ddbf-34eb-4bbc-a1ea-d32b6663123d" xlink:to="loc_us-gaap_LossContingenciesTable_4a30b67a-1022-4f2d-9c88-41c501e2e13f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_5d14f88e-aa37-499c-a731-caafe6568a82" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_4a30b67a-1022-4f2d-9c88-41c501e2e13f" xlink:to="loc_srt_LitigationCaseAxis_5d14f88e-aa37-499c-a731-caafe6568a82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_5d14f88e-aa37-499c-a731-caafe6568a82_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_5d14f88e-aa37-499c-a731-caafe6568a82" xlink:to="loc_srt_LitigationCaseTypeDomain_5d14f88e-aa37-499c-a731-caafe6568a82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_294a9a9e-048e-43eb-ba46-b4b9141e6979" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_5d14f88e-aa37-499c-a731-caafe6568a82" xlink:to="loc_srt_LitigationCaseTypeDomain_294a9a9e-048e-43eb-ba46-b4b9141e6979" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZetiaantitrustlitigationMember_161d2314-09b5-4b78-aea4-09c9b13651c4" xlink:href="mrk-20230331.xsd#mrk_ZetiaantitrustlitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_294a9a9e-048e-43eb-ba46-b4b9141e6979" xlink:to="loc_mrk_ZetiaantitrustlitigationMember_161d2314-09b5-4b78-aea4-09c9b13651c4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#OtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="extended" id="ie1eef37d189144b99d51aa15432419e9_OtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_adc53b7d-b6ce-44a3-9c74-31bffcc55fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_3e1dbd47-10c8-4af0-88f9-d814e5ecd7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_adc53b7d-b6ce-44a3-9c74-31bffcc55fa0" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_3e1dbd47-10c8-4af0-88f9-d814e5ecd7c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_844ea414-1654-42f1-9a65-64c2d5a027cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_3e1dbd47-10c8-4af0-88f9-d814e5ecd7c3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_844ea414-1654-42f1-9a65-64c2d5a027cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_27b7c216-35e5-458d-914d-7e89c6c29ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_3e1dbd47-10c8-4af0-88f9-d814e5ecd7c3" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_27b7c216-35e5-458d-914d-7e89c6c29ce9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_b61ac4d5-e0a9-4542-8a75-982ec25d0b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_3e1dbd47-10c8-4af0-88f9-d814e5ecd7c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_b61ac4d5-e0a9-4542-8a75-982ec25d0b24" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_0ba0de75-c068-4fd5-a4be-af1bfc062420" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_3e1dbd47-10c8-4af0-88f9-d814e5ecd7c3" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_0ba0de75-c068-4fd5-a4be-af1bfc062420" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_65fe0fbd-4b36-4c20-b06b-1b264ce788d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_3e1dbd47-10c8-4af0-88f9-d814e5ecd7c3" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_65fe0fbd-4b36-4c20-b06b-1b264ce788d5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_003db404-2b57-4040-96e4-b832d648b76e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_3e1dbd47-10c8-4af0-88f9-d814e5ecd7c3" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_003db404-2b57-4040-96e4-b832d648b76e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_e85abdc2-8381-4cb0-af7c-98a68e8c7a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_3e1dbd47-10c8-4af0-88f9-d814e5ecd7c3" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_e85abdc2-8381-4cb0-af7c-98a68e8c7a0c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b43252be-319c-4e60-ad5c-9782822c5271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_3e1dbd47-10c8-4af0-88f9-d814e5ecd7c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b43252be-319c-4e60-ad5c-9782822c5271" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7f3881a5-92f3-47eb-8f3f-0b258c7975c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_905648d6-8fa7-411e-acc0-51439956c72e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_adc53b7d-b6ce-44a3-9c74-31bffcc55fa0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_905648d6-8fa7-411e-acc0-51439956c72e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8f65f551-ce9d-471b-927c-ede5dcc4e92c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_905648d6-8fa7-411e-acc0-51439956c72e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8f65f551-ce9d-471b-927c-ede5dcc4e92c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8f65f551-ce9d-471b-927c-ede5dcc4e92c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8f65f551-ce9d-471b-927c-ede5dcc4e92c" xlink:to="loc_us-gaap_EquityComponentDomain_8f65f551-ce9d-471b-927c-ede5dcc4e92c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_36f94033-6daf-4dee-9126-12ebba987c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8f65f551-ce9d-471b-927c-ede5dcc4e92c" xlink:to="loc_us-gaap_EquityComponentDomain_36f94033-6daf-4dee-9126-12ebba987c7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_5ceb7e31-e2bc-474f-8655-b7dde10b7cec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_36f94033-6daf-4dee-9126-12ebba987c7e" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_5ceb7e31-e2bc-474f-8655-b7dde10b7cec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_3f977e2c-99c2-4730-9ddd-b48123d2a217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_36f94033-6daf-4dee-9126-12ebba987c7e" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_3f977e2c-99c2-4730-9ddd-b48123d2a217" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_36d91505-0ed3-4510-8378-043c92f0e353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_36f94033-6daf-4dee-9126-12ebba987c7e" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_36d91505-0ed3-4510-8378-043c92f0e353" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7d6628ba-f26f-4349-b046-13f5d50f64fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_36f94033-6daf-4dee-9126-12ebba987c7e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7d6628ba-f26f-4349-b046-13f5d50f64fd" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#SegmentReportingSalesfromProductsDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" xlink:type="extended" id="i1ce307c861da4fb6b5f671a890f3668e_SegmentReportingSalesfromProductsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_457ebd84-b5de-4694-ac37-202346e83902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ed286271-f6b9-411c-89e8-ee287cfb58a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_457ebd84-b5de-4694-ac37-202346e83902" xlink:to="loc_us-gaap_Revenues_ed286271-f6b9-411c-89e8-ee287cfb58a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_ad405855-dd3e-4d14-89db-109f320a74d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_457ebd84-b5de-4694-ac37-202346e83902" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_ad405855-dd3e-4d14-89db-109f320a74d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncreaseDecreaseInHedgeRevenue_0d14d1f4-8df1-47a7-8c1e-0be737b45487" xlink:href="mrk-20230331.xsd#mrk_IncreaseDecreaseInHedgeRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_457ebd84-b5de-4694-ac37-202346e83902" xlink:to="loc_mrk_IncreaseDecreaseInHedgeRevenue_0d14d1f4-8df1-47a7-8c1e-0be737b45487" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3b8609de-4df5-40dc-8285-7d0aaeb86ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_457ebd84-b5de-4694-ac37-202346e83902" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3b8609de-4df5-40dc-8285-7d0aaeb86ef7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_66642774-eceb-4263-8d03-7cf05d6e8531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3b8609de-4df5-40dc-8285-7d0aaeb86ef7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_66642774-eceb-4263-8d03-7cf05d6e8531" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_66642774-eceb-4263-8d03-7cf05d6e8531_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_66642774-eceb-4263-8d03-7cf05d6e8531" xlink:to="loc_us-gaap_SegmentDomain_66642774-eceb-4263-8d03-7cf05d6e8531_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2d75e731-6fe8-409c-b28c-76f2c3216af6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_66642774-eceb-4263-8d03-7cf05d6e8531" xlink:to="loc_us-gaap_SegmentDomain_2d75e731-6fe8-409c-b28c-76f2c3216af6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_b2369f5b-b709-4aaa-8c7e-590d70b333a7" xlink:href="mrk-20230331.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2d75e731-6fe8-409c-b28c-76f2c3216af6" xlink:to="loc_mrk_PharmaceuticalsegmentMember_b2369f5b-b709-4aaa-8c7e-590d70b333a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_85ec9d84-3431-4355-96e6-e7a471c63a09" xlink:href="mrk-20230331.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2d75e731-6fe8-409c-b28c-76f2c3216af6" xlink:to="loc_mrk_AnimalHealthsegmentMember_85ec9d84-3431-4355-96e6-e7a471c63a09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_cde2d4bd-e739-445f-93a7-fbb10a832a7d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3b8609de-4df5-40dc-8285-7d0aaeb86ef7" xlink:to="loc_srt_ConsolidationItemsAxis_cde2d4bd-e739-445f-93a7-fbb10a832a7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_cde2d4bd-e739-445f-93a7-fbb10a832a7d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_cde2d4bd-e739-445f-93a7-fbb10a832a7d" xlink:to="loc_srt_ConsolidationItemsDomain_cde2d4bd-e739-445f-93a7-fbb10a832a7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_6b52e8e7-78b3-477f-a6d3-49d5a943da26" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_cde2d4bd-e739-445f-93a7-fbb10a832a7d" xlink:to="loc_srt_ConsolidationItemsDomain_6b52e8e7-78b3-477f-a6d3-49d5a943da26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_5edda63d-db0d-4a87-982d-0339dad58b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_6b52e8e7-78b3-477f-a6d3-49d5a943da26" xlink:to="loc_us-gaap_OperatingSegmentsMember_5edda63d-db0d-4a87-982d-0339dad58b32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_ea51c7b8-019f-4dd4-be46-20944864fd13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_6b52e8e7-78b3-477f-a6d3-49d5a943da26" xlink:to="loc_us-gaap_CorporateNonSegmentMember_ea51c7b8-019f-4dd4-be46-20944864fd13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1c0b9af9-bbaf-4bdd-a176-8f9be533db9e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3b8609de-4df5-40dc-8285-7d0aaeb86ef7" xlink:to="loc_srt_ProductOrServiceAxis_1c0b9af9-bbaf-4bdd-a176-8f9be533db9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1c0b9af9-bbaf-4bdd-a176-8f9be533db9e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1c0b9af9-bbaf-4bdd-a176-8f9be533db9e" xlink:to="loc_srt_ProductsAndServicesDomain_1c0b9af9-bbaf-4bdd-a176-8f9be533db9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1c0b9af9-bbaf-4bdd-a176-8f9be533db9e" xlink:to="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_KeytrudaMember_e2528591-c22e-48e1-9910-b2a59771dfee" xlink:href="mrk-20230331.xsd#mrk_KeytrudaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_KeytrudaMember_e2528591-c22e-48e1-9910-b2a59771dfee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember_fc3becc6-1914-4a9d-9be1-56edfcea44cd" xlink:href="mrk-20230331.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_AlliancerevenueLynparzaMember_fc3becc6-1914-4a9d-9be1-56edfcea44cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_cd5f58a9-4abc-438c-962b-042997be8005" xlink:href="mrk-20230331.xsd#mrk_LenvimaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_LenvimaMember_cd5f58a9-4abc-438c-962b-042997be8005" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueReblozylMember_b88b7850-d6d2-479b-9ebd-5af5d9eac7a0" xlink:href="mrk-20230331.xsd#mrk_AllianceRevenueReblozylMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_AllianceRevenueReblozylMember_b88b7850-d6d2-479b-9ebd-5af5d9eac7a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_WeliregMember_e60e4c6c-ee2e-4288-924c-7799fd358f2e" xlink:href="mrk-20230331.xsd#mrk_WeliregMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_WeliregMember_e60e4c6c-ee2e-4288-924c-7799fd358f2e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member_840e7dcc-dabc-4b9c-a700-e400499ae793" xlink:href="mrk-20230331.xsd#mrk_GardasilGardasil9Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_GardasilGardasil9Member_840e7dcc-dabc-4b9c-a700-e400499ae793" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProQuadMMRIIVarivaxMember_98fc194a-b45e-4d7f-9aae-dc98a5df9c1a" xlink:href="mrk-20230331.xsd#mrk_ProQuadMMRIIVarivaxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_ProQuadMMRIIVarivaxMember_98fc194a-b45e-4d7f-9aae-dc98a5df9c1a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RotateqMember_b7893e58-5ce8-4132-a982-f9c8357c91bd" xlink:href="mrk-20230331.xsd#mrk_RotateqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_RotateqMember_b7893e58-5ce8-4132-a982-f9c8357c91bd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VaxneuvanceMember_0c266234-2d38-425a-b149-7dcb1b56c7ec" xlink:href="mrk-20230331.xsd#mrk_VaxneuvanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_VaxneuvanceMember_0c266234-2d38-425a-b149-7dcb1b56c7ec" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_Pneumovax23Member_cc3b5a6a-be11-4842-94e4-4827c26691e3" xlink:href="mrk-20230331.xsd#mrk_Pneumovax23Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_Pneumovax23Member_cc3b5a6a-be11-4842-94e4-4827c26691e3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VaqtaMember_92a4c24f-a958-4cad-969e-daedd9732c74" xlink:href="mrk-20230331.xsd#mrk_VaqtaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_VaqtaMember_92a4c24f-a958-4cad-969e-daedd9732c74" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember_0bdf52de-9189-45b6-a99a-00689b3d708c" xlink:href="mrk-20230331.xsd#mrk_BridionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_BridionMember_0bdf52de-9189-45b6-a99a-00689b3d708c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrevymisMember_c20e9441-f154-4291-b4ed-9ad898bc9291" xlink:href="mrk-20230331.xsd#mrk_PrevymisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_PrevymisMember_c20e9441-f154-4291-b4ed-9ad898bc9291" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrimaxinMember_72d6a7de-fe9e-49ca-bfdb-6322315b3d2d" xlink:href="mrk-20230331.xsd#mrk_PrimaxinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_PrimaxinMember_72d6a7de-fe9e-49ca-bfdb-6322315b3d2d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DificidMember_54150494-6f23-4f50-8e0d-1623bc8f1c82" xlink:href="mrk-20230331.xsd#mrk_DificidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_DificidMember_54150494-6f23-4f50-8e0d-1623bc8f1c82" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NoxafilMember_a034c131-7240-4a9b-8bee-e26af650fba5" xlink:href="mrk-20230331.xsd#mrk_NoxafilMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_NoxafilMember_a034c131-7240-4a9b-8bee-e26af650fba5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZerbaxaMember_36e048da-34bd-4b73-8ab3-1ca98c37970d" xlink:href="mrk-20230331.xsd#mrk_ZerbaxaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_ZerbaxaMember_36e048da-34bd-4b73-8ab3-1ca98c37970d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueAdempasVerquvoMember_24b9a81e-61ae-489b-b560-3db1df0015dc" xlink:href="mrk-20230331.xsd#mrk_AllianceRevenueAdempasVerquvoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_AllianceRevenueAdempasVerquvoMember_24b9a81e-61ae-489b-b560-3db1df0015dc" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_c52e97d2-7a6b-4432-9e88-e5b91a2315e0" xlink:href="mrk-20230331.xsd#mrk_AdempasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_AdempasMember_c52e97d2-7a6b-4432-9e88-e5b91a2315e0" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LagevrioMember_652cc713-c35d-4162-917f-613e2b5096c5" xlink:href="mrk-20230331.xsd#mrk_LagevrioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_LagevrioMember_652cc713-c35d-4162-917f-613e2b5096c5" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IsentressIsentressHDMember_f174abee-901b-4ce0-8ced-5b4630d5d268" xlink:href="mrk-20230331.xsd#mrk_IsentressIsentressHDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_IsentressIsentressHDMember_f174abee-901b-4ce0-8ced-5b4630d5d268" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BelsomraMember_60d322e3-36b7-4df9-8d46-fa1fbf302e45" xlink:href="mrk-20230331.xsd#mrk_BelsomraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_BelsomraMember_60d322e3-36b7-4df9-8d46-fa1fbf302e45" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SimponiMember_38003fc9-6739-4e74-b7a1-3bd18e3d9f0a" xlink:href="mrk-20230331.xsd#mrk_SimponiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_SimponiMember_38003fc9-6739-4e74-b7a1-3bd18e3d9f0a" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RemicadeMember_b56c47f3-54e1-40f8-adc2-a2a9197b1a63" xlink:href="mrk-20230331.xsd#mrk_RemicadeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_RemicadeMember_b56c47f3-54e1-40f8-adc2-a2a9197b1a63" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaMember_43868c0f-a884-4c2f-b5c2-8e77bb0c1494" xlink:href="mrk-20230331.xsd#mrk_JanuviaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_JanuviaMember_43868c0f-a884-4c2f-b5c2-8e77bb0c1494" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanumetMember_577d2282-ea85-4935-8f3e-179e3a101f27" xlink:href="mrk-20230331.xsd#mrk_JanumetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_JanumetMember_577d2282-ea85-4935-8f3e-179e3a101f27" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPharmaceuticalMember_3f5507ff-fd34-497f-a057-631aa4291ce3" xlink:href="mrk-20230331.xsd#mrk_OtherPharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_OtherPharmaceuticalMember_3f5507ff-fd34-497f-a057-631aa4291ce3" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LivestockMember_9d2f97ae-e510-43c4-95a4-fe48b7072cd2" xlink:href="mrk-20230331.xsd#mrk_LivestockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_LivestockMember_9d2f97ae-e510-43c4-95a4-fe48b7072cd2" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CompanionAnimalsMember_151c9b0b-212b-48bc-8c69-d3febf1641c0" xlink:href="mrk-20230331.xsd#mrk_CompanionAnimalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_CompanionAnimalsMember_151c9b0b-212b-48bc-8c69-d3febf1641c0" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2a5f01cf-9f36-448c-8dd7-68b358f9641e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3b8609de-4df5-40dc-8285-7d0aaeb86ef7" xlink:to="loc_srt_StatementGeographicalAxis_2a5f01cf-9f36-448c-8dd7-68b358f9641e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2a5f01cf-9f36-448c-8dd7-68b358f9641e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_2a5f01cf-9f36-448c-8dd7-68b358f9641e" xlink:to="loc_srt_SegmentGeographicalDomain_2a5f01cf-9f36-448c-8dd7-68b358f9641e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_37953abc-e1e1-439b-a168-261e6dfd0436" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_2a5f01cf-9f36-448c-8dd7-68b358f9641e" xlink:to="loc_srt_SegmentGeographicalDomain_37953abc-e1e1-439b-a168-261e6dfd0436" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_023611b0-8d84-48f7-8bcf-0d8f86856735" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_37953abc-e1e1-439b-a168-261e6dfd0436" xlink:to="loc_country_US_023611b0-8d84-48f7-8bcf-0d8f86856735" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InternationalMember_4f9f8c7c-f71f-4de7-9174-f8f18ef1030a" xlink:href="mrk-20230331.xsd#mrk_InternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_37953abc-e1e1-439b-a168-261e6dfd0436" xlink:to="loc_mrk_InternationalMember_4f9f8c7c-f71f-4de7-9174-f8f18ef1030a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#SegmentReportingConsolidatedSalesbyGeographicAreaDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" xlink:type="extended" id="ia56f7d9ecb2d435286c4cc7e479230f2_SegmentReportingConsolidatedSalesbyGeographicAreaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_18d3656b-3d7e-4f48-a1e4-fe46f1234495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9f40aa96-7637-45d2-8630-c59a1c852fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_18d3656b-3d7e-4f48-a1e4-fe46f1234495" xlink:to="loc_us-gaap_Revenues_9f40aa96-7637-45d2-8630-c59a1c852fbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_251631f9-2bc0-4645-a592-bc4affbe5d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_18d3656b-3d7e-4f48-a1e4-fe46f1234495" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_251631f9-2bc0-4645-a592-bc4affbe5d90" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_40227c5c-edcb-4065-b4c4-01a5ae6a2bdf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_251631f9-2bc0-4645-a592-bc4affbe5d90" xlink:to="loc_srt_StatementGeographicalAxis_40227c5c-edcb-4065-b4c4-01a5ae6a2bdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_40227c5c-edcb-4065-b4c4-01a5ae6a2bdf_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_40227c5c-edcb-4065-b4c4-01a5ae6a2bdf" xlink:to="loc_srt_SegmentGeographicalDomain_40227c5c-edcb-4065-b4c4-01a5ae6a2bdf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f9cac776-5ac3-44dc-b1a2-38017f04cafd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_40227c5c-edcb-4065-b4c4-01a5ae6a2bdf" xlink:to="loc_srt_SegmentGeographicalDomain_f9cac776-5ac3-44dc-b1a2-38017f04cafd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_578de624-8b74-4504-9561-fe1add15c664" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f9cac776-5ac3-44dc-b1a2-38017f04cafd" xlink:to="loc_country_US_578de624-8b74-4504-9561-fe1add15c664" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_a3305ffc-8af4-42bf-a505-a92e175303da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f9cac776-5ac3-44dc-b1a2-38017f04cafd" xlink:to="loc_us-gaap_EMEAMember_a3305ffc-8af4-42bf-a505-a92e175303da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_d11e23b0-deef-4579-b4b6-f554680a0b1c" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f9cac776-5ac3-44dc-b1a2-38017f04cafd" xlink:to="loc_country_CN_d11e23b0-deef-4579-b4b6-f554680a0b1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_14f71368-baa3-43c4-88b0-8b30977715a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f9cac776-5ac3-44dc-b1a2-38017f04cafd" xlink:to="loc_srt_AsiaPacificMember_14f71368-baa3-43c4-88b0-8b30977715a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_1b1ca5be-a114-46f8-8bc2-80cb5099caca" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f9cac776-5ac3-44dc-b1a2-38017f04cafd" xlink:to="loc_country_JP_1b1ca5be-a114-46f8-8bc2-80cb5099caca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember_99d7dd78-5f35-4797-9437-8b39ec32e1dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LatinAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f9cac776-5ac3-44dc-b1a2-38017f04cafd" xlink:to="loc_srt_LatinAmericaMember_99d7dd78-5f35-4797-9437-8b39ec32e1dd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherCountriesMember_7a22dbca-7d90-4da9-a4b8-5e06ba1e6574" xlink:href="mrk-20230331.xsd#mrk_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f9cac776-5ac3-44dc-b1a2-38017f04cafd" xlink:to="loc_mrk_OtherCountriesMember_7a22dbca-7d90-4da9-a4b8-5e06ba1e6574" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" xlink:type="extended" id="i4dd446fd92d840a5b344d0932fc299f7_SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_30074cc5-bb89-4c8f-89f3-07110754954b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_688788f3-3af0-40de-beff-664b17ac520e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30074cc5-bb89-4c8f-89f3-07110754954b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_688788f3-3af0-40de-beff-664b17ac520e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_067127ec-af70-40a5-90b1-4d14b20f73b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30074cc5-bb89-4c8f-89f3-07110754954b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_067127ec-af70-40a5-90b1-4d14b20f73b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8f35fcb8-554c-42a8-8b76-af7c1e228f54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30074cc5-bb89-4c8f-89f3-07110754954b" xlink:to="loc_us-gaap_InterestExpense_8f35fcb8-554c-42a8-8b76-af7c1e228f54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_3a3ed2fa-e610-461d-8cbb-94191ead61dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30074cc5-bb89-4c8f-89f3-07110754954b" xlink:to="loc_us-gaap_AdjustmentForAmortization_3a3ed2fa-e610-461d-8cbb-94191ead61dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_946b75ff-f19a-4dc3-983c-6c07eb5ae9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30074cc5-bb89-4c8f-89f3-07110754954b" xlink:to="loc_us-gaap_Depreciation_946b75ff-f19a-4dc3-983c-6c07eb5ae9a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_40ef73f5-4b53-4025-bdca-7850cc83804b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30074cc5-bb89-4c8f-89f3-07110754954b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_40ef73f5-4b53-4025-bdca-7850cc83804b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_7ff1629b-7bd4-4680-b7a1-613cf16165da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30074cc5-bb89-4c8f-89f3-07110754954b" xlink:to="loc_us-gaap_RestructuringCharges_7ff1629b-7bd4-4680-b7a1-613cf16165da" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_33aea500-09c5-4077-acb7-db09e7d6ceea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30074cc5-bb89-4c8f-89f3-07110754954b" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_33aea500-09c5-4077-acb7-db09e7d6ceea" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet_5f69e695-27da-4a34-bb33-573e366dcb99" xlink:href="mrk-20230331.xsd#mrk_SegmentReportingUnallocatedOtherExpensesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30074cc5-bb89-4c8f-89f3-07110754954b" xlink:to="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet_5f69e695-27da-4a34-bb33-573e366dcb99" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_448a2c00-b70c-4a86-90c0-2a4e65243783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30074cc5-bb89-4c8f-89f3-07110754954b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_448a2c00-b70c-4a86-90c0-2a4e65243783" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_9e394cc8-17f3-42ff-8f1b-eba1440dada7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_448a2c00-b70c-4a86-90c0-2a4e65243783" xlink:to="loc_srt_ConsolidationItemsAxis_9e394cc8-17f3-42ff-8f1b-eba1440dada7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_9e394cc8-17f3-42ff-8f1b-eba1440dada7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_9e394cc8-17f3-42ff-8f1b-eba1440dada7" xlink:to="loc_srt_ConsolidationItemsDomain_9e394cc8-17f3-42ff-8f1b-eba1440dada7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_70f69985-38ce-4c35-a35a-37fa2abab223" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_9e394cc8-17f3-42ff-8f1b-eba1440dada7" xlink:to="loc_srt_ConsolidationItemsDomain_70f69985-38ce-4c35-a35a-37fa2abab223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_52977de5-65be-4d34-951a-044d9675cebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_70f69985-38ce-4c35-a35a-37fa2abab223" xlink:to="loc_us-gaap_OperatingSegmentsMember_52977de5-65be-4d34-951a-044d9675cebe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_a51fadd4-c922-464a-8661-2587b04c365f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_70f69985-38ce-4c35-a35a-37fa2abab223" xlink:to="loc_us-gaap_CorporateNonSegmentMember_a51fadd4-c922-464a-8661-2587b04c365f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_73ae7bfb-54d4-4907-a706-69d57a089918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_70f69985-38ce-4c35-a35a-37fa2abab223" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_73ae7bfb-54d4-4907-a706-69d57a089918" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_06eec99f-850a-4cf3-8fb9-a14d6cf3c72b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_448a2c00-b70c-4a86-90c0-2a4e65243783" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_06eec99f-850a-4cf3-8fb9-a14d6cf3c72b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_06eec99f-850a-4cf3-8fb9-a14d6cf3c72b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_06eec99f-850a-4cf3-8fb9-a14d6cf3c72b" xlink:to="loc_us-gaap_SegmentDomain_06eec99f-850a-4cf3-8fb9-a14d6cf3c72b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7005fa02-c550-49f6-999d-850d9717d957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_06eec99f-850a-4cf3-8fb9-a14d6cf3c72b" xlink:to="loc_us-gaap_SegmentDomain_7005fa02-c550-49f6-999d-850d9717d957" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_cef7f68a-ea37-4924-9652-f8a520ff7f57" xlink:href="mrk-20230331.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_7005fa02-c550-49f6-999d-850d9717d957" xlink:to="loc_mrk_PharmaceuticalsegmentMember_cef7f68a-ea37-4924-9652-f8a520ff7f57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_b013d180-2ba3-44c4-9591-d5a0b4b2c332" xlink:href="mrk-20230331.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_7005fa02-c550-49f6-999d-850d9717d957" xlink:to="loc_mrk_AnimalHealthsegmentMember_b013d180-2ba3-44c4-9591-d5a0b4b2c332" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>mrk-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:f17f1926-1a01-4baa-a406-054ce45079f2,g:c6b1c5ce-74aa-44b6-956b-90e243d128be-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_c6ed80ba-a238-4aac-8795-73e367355d3d_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c7fbd22-5c42-468e-b68d-1d134b8c6f8e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_71cf3625-2c96-4679-897c-6dbb2be38aed_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_296ca0ef-cac4-4571-ad4a-f55e2e661d26_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, pending claims</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_4d242987-7cc1-4de4-8e44-6ad8207d0ac7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementsAbstract_bb8a223c-33c6-4d12-bcd2-77ca5483a121_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements [Abstract]</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementsAbstract_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements [Abstract]</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementsAbstract_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementsAbstract" xlink:to="lab_mrk_CollaborativeArrangementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingSecurities_a3fa02d6-c6a3-47b5-8554-ecf834b92cac_totalLabel_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_TradingSecurities_label_en-US" xlink:label="lab_us-gaap_TradingSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingSecurities" xlink:to="lab_us-gaap_TradingSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_f108f305-9c31-430c-a1bf-a607c74f641a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders Equity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_87172f4e-fa62-45d5-bd5b-fd2c4a887ac8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_90e8e4e3-8584-4db0-a425-d4e7f212cf24_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid to stockholders</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_cbf3c89d-e8d0-4be6-b83d-0154721a30a0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_2ddcbf79-59e5-4fd3-8015-ddc748b592c5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of loans payable and long-term debt, including current portion</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_cc726f45-f1c8-49ed-8268-b9c09ce00b70_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve, beginning balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_aab9e895-d154-44b5-8ec9-675d2ee8f7e2_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve, ending balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_7ed9d807-9586-4448-a7af-973242b54a51_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_2b997dfb-71cb-4f59-a408-5286262cf264_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue related to the sale of the marketing rights</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_8c95ad5b-892a-4407-8b48-0419c85d7712_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LagevrioMember_58ad0478-a8d7-4e56-8c4c-e60554c13e7e_terseLabel_en-US" xlink:label="lab_mrk_LagevrioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lagevrio</link:label>
    <link:label id="lab_mrk_LagevrioMember_label_en-US" xlink:label="lab_mrk_LagevrioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lagevrio [Member]</link:label>
    <link:label id="lab_mrk_LagevrioMember_documentation_en-US" xlink:label="lab_mrk_LagevrioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lagevrio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LagevrioMember" xlink:href="mrk-20230331.xsd#mrk_LagevrioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LagevrioMember" xlink:to="lab_mrk_LagevrioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_ede63a71-070f-45db-a193-75b51aeb91ad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Income) Expense, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ada3882e-7f70-4a06-822f-9b206d0279fd_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_ecbd00bb-cf97-45da-a1d8-33a9584a36f2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_150e7062-ecc4-4c8e-9b0e-985af0158329_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_07097a8a-6f94-4bb5-b8cb-fab1e40681ed_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_dfa8d66d-8539-4c36-aa1b-6effe833a3e5_negatedLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_72bac3c3-0590-42f3-bd01-a3a382086be0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Location and Amount of Pretax Gains and Losses of Derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_6033921c-d160-41ed-962a-cc3fd40c09c4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_218dd105-2540-4cbb-b278-b7f8da75907c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_2f8eee0f-b362-4718-a862-99204782350f_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_ed4cfdaa-51d7-44c9-a571-128ff3e9d0a5_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_e13924c6-c737-45e7-9993-7e2f73a4104d_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_b40e83ea-ce37-4e4c-b713-13eb227e51f7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_BayerAGMember_c19a77f3-9ffe-4f92-b97e-e750230b4367_terseLabel_en-US" xlink:label="lab_mrk_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer AG</link:label>
    <link:label id="lab_mrk_BayerAGMember_label_en-US" xlink:label="lab_mrk_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer AG [Member]</link:label>
    <link:label id="lab_mrk_BayerAGMember_documentation_en-US" xlink:label="lab_mrk_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer AG [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember" xlink:href="mrk-20230331.xsd#mrk_BayerAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_BayerAGMember" xlink:to="lab_mrk_BayerAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_9b2f2a0b-3a6b-4716-9ea7-decc83af2ba8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock shares purchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_e9f793d4-ff97-4b64-9f65-e3d16a62c712_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable to Merck &amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_1591c5aa-dc96-404a-aa3b-e92cda574431_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable to Merck&#160;&amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_bb512824-64e4-4465-a786-73427839383f_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Merck&#160;&amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2616f1ef-9da3-4a47-9129-94e7c087c910_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_02f1455c-a65f-4a26-87d0-b9ea9273d873_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partial settlement charge</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Payment for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_cb53b697-747e-4cb3-89de-3b487378c1df_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_eb04019f-50fa-4e79-8062-e6d467b3bef2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_7a53c059-e31b-45f9-a07a-0e5666ea8ab5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of unrecognized prior service credit</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_c96f773c-288f-4c11-a643-0b5e325e6deb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain_fbacde22-4ce7-4608-8e4b-7e54d19c88a8_terseLabel_en-US" xlink:label="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</link:label>
    <link:label id="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain_label_en-US" xlink:label="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="lab_us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember_261caaa7-6200-4518-87aa-6a242fa2fd13_terseLabel_en-US" xlink:label="lab_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.</link:label>
    <link:label id="lab_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember_label_en-US" xlink:label="lab_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. [Member]</link:label>
    <link:label id="lab_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember_documentation_en-US" xlink:label="lab_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember" xlink:href="mrk-20230331.xsd#mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember" xlink:to="lab_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_81ec7f7c-8722-42cf-8988-030370451163_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_880d8b54-2823-4a9d-859d-d4bc4abb58ae_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_4c7fb378-04c7-43b2-818a-ce094a43b812_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_1af14591-9723-4a10-bfc8-afb381b37e2c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_428210f1-e4fd-427a-bebf-cbaf0fd8f0e4_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of interest rate swaps held (in interest rate swaps)</link:label>
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_label_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Interest Rate Derivatives Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:to="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LegalDefenseCostsMember_90f9fdb3-943d-4e61-84b5-3319dc17e456_terseLabel_en-US" xlink:label="lab_mrk_LegalDefenseCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Defense Costs</link:label>
    <link:label id="lab_mrk_LegalDefenseCostsMember_label_en-US" xlink:label="lab_mrk_LegalDefenseCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Defense Costs [Member]</link:label>
    <link:label id="lab_mrk_LegalDefenseCostsMember_documentation_en-US" xlink:label="lab_mrk_LegalDefenseCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Defense Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LegalDefenseCostsMember" xlink:href="mrk-20230331.xsd#mrk_LegalDefenseCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LegalDefenseCostsMember" xlink:to="lab_mrk_LegalDefenseCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_55e60d58-aaee-414a-a0f7-b0ceb0373461_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less treasury stock, at cost: 1,039,651,210 shares in 2023 and 1,039,269,638 shares in 2022</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5ef1e436-a81d-4d97-8e7f-f6b68e333fed_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1934860d-1e92-4d97-b50b-81813d92b743_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_d00eea98-60c7-4202-bfba-35ded113ff40_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_cc3d17be-7da8-4668-8657-43ae5ef1ef0b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_534e768d-ab00-4ebf-be58-0614a4eeea56_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SalesDiscounts_1842c434-72cb-450c-a81e-d339920d64f5_terseLabel_en-US" xlink:label="lab_mrk_SalesDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales discounts</link:label>
    <link:label id="lab_mrk_SalesDiscounts_label_en-US" xlink:label="lab_mrk_SalesDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Discounts</link:label>
    <link:label id="lab_mrk_SalesDiscounts_documentation_en-US" xlink:label="lab_mrk_SalesDiscounts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesDiscounts" xlink:href="mrk-20230331.xsd#mrk_SalesDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SalesDiscounts" xlink:to="lab_mrk_SalesDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_c135f4a9-1316-4847-9c7e-aaee7ec058fa_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables included in Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AstraZenecaMember_6d480975-a68c-4a79-b75a-427b9afc0ea8_terseLabel_en-US" xlink:label="lab_mrk_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_mrk_AstraZenecaMember_label_en-US" xlink:label="lab_mrk_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_mrk_AstraZenecaMember_documentation_en-US" xlink:label="lab_mrk_AstraZenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember" xlink:href="mrk-20230331.xsd#mrk_AstraZenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AstraZenecaMember" xlink:to="lab_mrk_AstraZenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_effe1e8e-37e5-4f38-b9e2-cbcd5e392f6b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a88fb2fc-9b65-4cff-a235-80025e570122_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_a7716f0c-81c4-47d6-9b8f-a8c8c1383765_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_10f54c94-4c0e-46c2-89e8-ebec1e57d4c2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Loss) Income Net of Taxes:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_6f40b051-4af8-4223-8c6d-e8360910ef7f_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_47fac000-b816-41fb-8cd9-5b9d7ab7f387_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_f2be78bf-09dd-453c-8d79-bc7aeab22d9a_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Derivative, Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_a9a2c870-0272-47bd-af24-c2bd9afdbeaf_netLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross amounts recognized in the consolidated balance sheet, asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_9ec8623e-1d23-47d0-bb8f-1b096df4069c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_3b440518-40fc-4f98-91f9-da7436aaa923_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_468b65de-2c04-47cc-9d8d-a1330ecb3cc6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_2b7be348-ebc1-4058-8455-a516be27c97f_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs, Expenses and Other</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_c73b4048-cdcb-4597-8ac7-bf9336cb4b15_terseLabel_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic defined benefit plan (credit) cost other than service cost</link:label>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_label_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:to="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_cc098661-8137-4ed8-a029-dea0cc2ab238_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected restructuring and related cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AnimalHealthsegmentMember_558a9160-4dcd-48a6-84c2-4325714b63b9_terseLabel_en-US" xlink:label="lab_mrk_AnimalHealthsegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health</link:label>
    <link:label id="lab_mrk_AnimalHealthsegmentMember_0fa712cb-1030-4b67-8751-e0a67bf683f9_verboseLabel_en-US" xlink:label="lab_mrk_AnimalHealthsegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health segment</link:label>
    <link:label id="lab_mrk_AnimalHealthsegmentMember_label_en-US" xlink:label="lab_mrk_AnimalHealthsegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health segment [Member]</link:label>
    <link:label id="lab_mrk_AnimalHealthsegmentMember_documentation_en-US" xlink:label="lab_mrk_AnimalHealthsegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Animal Health segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember" xlink:href="mrk-20230331.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AnimalHealthsegmentMember" xlink:to="lab_mrk_AnimalHealthsegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessAndRawMaterials_22b68f16-8554-4467-ba03-331a35260758_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessAndRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process and Raw Materials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:to="lab_us-gaap_InventoryWorkInProcessAndRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_dae59ff8-19dd-413d-9e87-aba87306dc64_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_3489a768-1a39-4bcf-a722-f8bf7439e508_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AllianceRevenueKoselugoMember_30c2a25c-e0ef-4fe9-ab25-98ff104fda09_terseLabel_en-US" xlink:label="lab_mrk_AllianceRevenueKoselugoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Koselugo</link:label>
    <link:label id="lab_mrk_AllianceRevenueKoselugoMember_label_en-US" xlink:label="lab_mrk_AllianceRevenueKoselugoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Koselugo [Member]</link:label>
    <link:label id="lab_mrk_AllianceRevenueKoselugoMember_documentation_en-US" xlink:label="lab_mrk_AllianceRevenueKoselugoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Koselugo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueKoselugoMember" xlink:href="mrk-20230331.xsd#mrk_AllianceRevenueKoselugoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AllianceRevenueKoselugoMember" xlink:to="lab_mrk_AllianceRevenueKoselugoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_3181753c-e9c9-42bd-8162-cdc349d934cd_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_85622046-82f1-44d9-b383-4100a9b8d1ce_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_8950b794-5135-4fa6-9897-f781da4d4633_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fab3a4eb-0b35-4231-af6a-6f3b202b650b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_7ac35294-5ca6-4660-88f4-b087b11d621d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimSecurities_31e291c6-d9bd-43b8-8d34-143fde178067_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral advanced to counterparties</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimSecurities_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Security Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralRightToReclaimSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralRightToReclaimSecurities" xlink:to="lab_us-gaap_DerivativeCollateralRightToReclaimSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_3cb8bcf9-657a-40b9-88d3-c0804fddbc30_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableSale_d99122cc-6de4-428d-83fb-cb43727944ef_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Factored accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableSale_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableSale" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableSale" xlink:to="lab_us-gaap_AccountsReceivableSale" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_cf9225ce-847f-41dd-a4d1-f895b25a04a8_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_97c71211-7010-4d9f-b388-f91223f1f3ed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Imago BioSciences, Inc., net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Business Two, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_221c10cb-fe8d-461b-8dfe-bb91af9eb5e6_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_14daa5d1-b4ec-4026-98da-e720b40f92b5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_963bc662-0252-4cbd-a63b-8729beb566bc_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_f477f9a5-5541-4acb-b29f-e46437c6539e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_0a8e81d1-b558-4eb9-b3a8-b706a0f74e97_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_0adb9ee3-2a51-4f6b-aded-c8ac75b1e739_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_4ad9072b-8cd5-4a9a-a87a-c8789c8c13d8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_6a0e03a5-d556-4e4f-b457-d2b6cdc8125f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_e8f70f4f-52f4-42e2-9bf5-00e525134b08_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_0307b6f6-045a-459a-8d5d-e95f95c33c8a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_45ccbc25-1aa3-4d9a-b441-1e3181c04033_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_MilestonePaymentsMadetoCollaborativePartner_6b596ecd-98d0-4b57-9471-340ea4f5eeb8_terseLabel_en-US" xlink:label="lab_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized milestone payment</link:label>
    <link:label id="lab_mrk_MilestonePaymentsMadetoCollaborativePartner_label_en-US" xlink:label="lab_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Made to Collaborative Partner</link:label>
    <link:label id="lab_mrk_MilestonePaymentsMadetoCollaborativePartner_documentation_en-US" xlink:label="lab_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Made to Collaborative Partner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:href="mrk-20230331.xsd#mrk_MilestonePaymentsMadetoCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:to="lab_mrk_MilestonePaymentsMadetoCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_d8ff2729-73bd-401d-9b4c-d44c5a3b22a5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain (loss) recognized in OCI on derivatives</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ComplaintAgainstTheJohnsHopkinsUniversityMember_272f07fb-92d8-4735-9c4d-e563c8867f69_terseLabel_en-US" xlink:label="lab_mrk_ComplaintAgainstTheJohnsHopkinsUniversityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Complaint Against The Johns Hopkins University</link:label>
    <link:label id="lab_mrk_ComplaintAgainstTheJohnsHopkinsUniversityMember_label_en-US" xlink:label="lab_mrk_ComplaintAgainstTheJohnsHopkinsUniversityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Complaint Against The Johns Hopkins University [Member]</link:label>
    <link:label id="lab_mrk_ComplaintAgainstTheJohnsHopkinsUniversityMember_documentation_en-US" xlink:label="lab_mrk_ComplaintAgainstTheJohnsHopkinsUniversityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Complaint Against The Johns Hopkins University</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComplaintAgainstTheJohnsHopkinsUniversityMember" xlink:href="mrk-20230331.xsd#mrk_ComplaintAgainstTheJohnsHopkinsUniversityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ComplaintAgainstTheJohnsHopkinsUniversityMember" xlink:to="lab_mrk_ComplaintAgainstTheJohnsHopkinsUniversityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_79ed9a6f-9d18-4a4a-a9cb-336a9701f997_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_831ce19d-3673-4c1b-9ded-8ed58cb2c9bc_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SanofiPasteurMember_33263316-8a83-4ef5-9e2c-693f78e32543_terseLabel_en-US" xlink:label="lab_mrk_SanofiPasteurMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur</link:label>
    <link:label id="lab_mrk_SanofiPasteurMember_label_en-US" xlink:label="lab_mrk_SanofiPasteurMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur [Member]</link:label>
    <link:label id="lab_mrk_SanofiPasteurMember_documentation_en-US" xlink:label="lab_mrk_SanofiPasteurMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Pasteur [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SanofiPasteurMember" xlink:href="mrk-20230331.xsd#mrk_SanofiPasteurMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SanofiPasteurMember" xlink:to="lab_mrk_SanofiPasteurMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_a215c5d5-45d3-4793-a78c-d5b6231ad664_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_3331f9fe-9be5-4436-a475-53de7ba77b75_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e9b83f69-7958-4aa5-a78a-6eaf35450919_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_JanuviaMember_46bf4e7a-f2a4-47e7-8749-c95ebc201cd3_terseLabel_en-US" xlink:label="lab_mrk_JanuviaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Januvia</link:label>
    <link:label id="lab_mrk_JanuviaMember_label_en-US" xlink:label="lab_mrk_JanuviaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Januvia [Member]</link:label>
    <link:label id="lab_mrk_JanuviaMember_documentation_en-US" xlink:label="lab_mrk_JanuviaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Januvia [Member] .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaMember" xlink:href="mrk-20230331.xsd#mrk_JanuviaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_JanuviaMember" xlink:to="lab_mrk_JanuviaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued_c3a3bee3-474f-4968-ab60-4438858b870c_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory milestone payments accrued</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Regulatory Milestone Payments Accrued</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Regulatory Milestone Payments Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued" xlink:to="lab_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_daab80dd-f67d-4276-82f0-d5da19b45ca0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_2eb1ed99-6762-4ef8-bb8f-68ad9d89cd08_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementProfitSharing_48f1af9d-b7db-4525-bac5-7258eee2f96b_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementProfitSharing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - profit sharing</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementProfitSharing_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementProfitSharing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Profit Sharing</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementProfitSharing_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementProfitSharing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Profit Sharing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementProfitSharing" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementProfitSharing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementProfitSharing" xlink:to="lab_mrk_CollaborativeArrangementProfitSharing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_4d23f8d1-666f-4fb4-a776-9f1a27f7bb28_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_46e7e190-b469-4af3-b0cb-a4620732ce28_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in AOCI by Component</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_f7462d58-59b3-4b94-b3df-1b677eca4555_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5546f431-a830-4209-b655-4096d5502116_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_04889f75-c030-472e-a477-818cda0339ca_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_178fdb3b-d22e-4061-904b-991cecb1a40a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeOptionMember_0f9f9396-a49a-4f05-b046-a5d8231c8a9d_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency options</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeOptionMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeOptionMember" xlink:to="lab_us-gaap_ForeignExchangeOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_6aa3d6df-4801-4d83-aa12-e23e42e93d78_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Publicly traded equity securities, fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_a42d6fd5-4e1c-4623-9354-e0af37a7bc7c_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Publicly traded equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember_cbad1229-bd1c-4423-95dc-2a090c52c711_terseLabel_en-US" xlink:label="lab_mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember_label_en-US" xlink:label="lab_mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Other Assets, Current [Member]</link:label>
    <link:label id="lab_mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember_documentation_en-US" xlink:label="lab_mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember" xlink:href="mrk-20230331.xsd#mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember" xlink:to="lab_mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_19f50770-f9de-4649-aea1-1932bffa0c22_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap contracts</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments_6bbfb134-59ee-4f37-9394-2a9ae16ae4f4_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible future contingent development-related payments (up to)</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments" xlink:to="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_201d5290-38f4-4ac7-b687-5ad8ca6e754c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1b618f3d-0afb-41ff-9410-0e7d5ca2ed09_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Used in Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_622b29c6-91b4-4f58-a8b7-bb83c7413208_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments, net of taxes</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_0cf1dd4a-3b20-4cac-a882-b75d681fe7f8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merck&#160;&amp; Co., Inc. Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6f4ed6ee-7592-4a3c-886b-fcc5e1119362_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Before Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bb0c2f0c-5517-4d8d-86be-90da63bc197d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profits</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RotateqMember_4ccf307a-807e-4f2d-a2c0-33802586b16b_terseLabel_en-US" xlink:label="lab_mrk_RotateqMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RotaTeq</link:label>
    <link:label id="lab_mrk_RotateqMember_label_en-US" xlink:label="lab_mrk_RotateqMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rotateq [Member]</link:label>
    <link:label id="lab_mrk_RotateqMember_documentation_en-US" xlink:label="lab_mrk_RotateqMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RotaTeq [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RotateqMember" xlink:href="mrk-20230331.xsd#mrk_RotateqMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RotateqMember" xlink:to="lab_mrk_RotateqMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAverageRemainingMaturity1_388e529b-47a2-467f-92f3-462966d3009e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAverageRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum average period of maturities of contracts in years (less than)</link:label>
    <link:label id="lab_us-gaap_DerivativeAverageRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeAverageRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Average Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAverageRemainingMaturity1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAverageRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAverageRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeAverageRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_a02d783c-0912-4895-9e70-5a804686bca5_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_TransitionServicesAgreementMember_0acf631d-e397-4e10-b225-185b4f3ef847_terseLabel_en-US" xlink:label="lab_mrk_TransitionServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition services agreement</link:label>
    <link:label id="lab_mrk_TransitionServicesAgreementMember_label_en-US" xlink:label="lab_mrk_TransitionServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition services agreement [Member]</link:label>
    <link:label id="lab_mrk_TransitionServicesAgreementMember_documentation_en-US" xlink:label="lab_mrk_TransitionServicesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition services agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TransitionServicesAgreementMember" xlink:href="mrk-20230331.xsd#mrk_TransitionServicesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_TransitionServicesAgreementMember" xlink:to="lab_mrk_TransitionServicesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_6315f0d3-5766-47cd-97a4-e93126c0cf41_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaid_d78118fb-c787-4782-b272-00571485b8c1_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaid_label_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_1e459048-0d6f-4716-9010-4e9a1a7ff390_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_6dd9976c-cbff-4187-8513-10bf6c689e2f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_83451cb8-275c-42e6-9284-2f01334decf9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, claims settled</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsSettledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsSettledNumber" xlink:to="lab_us-gaap_LossContingencyClaimsSettledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_e5ff2a8f-1e6a-4fce-8afc-675e4d5f3e66_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_5683514f-da3b-400e-a0e7-4a51cc4fb8da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Derivatives on a Gross Basis Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherPharmaceuticalMember_81f948a5-9100-47a6-bac9-0961e59ccd85_terseLabel_en-US" xlink:label="lab_mrk_OtherPharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other pharmaceutical</link:label>
    <link:label id="lab_mrk_OtherPharmaceuticalMember_label_en-US" xlink:label="lab_mrk_OtherPharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Pharmaceutical [Member]</link:label>
    <link:label id="lab_mrk_OtherPharmaceuticalMember_documentation_en-US" xlink:label="lab_mrk_OtherPharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other pharmaceutical.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPharmaceuticalMember" xlink:href="mrk-20230331.xsd#mrk_OtherPharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherPharmaceuticalMember" xlink:to="lab_mrk_OtherPharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_90d3edd5-aa64-4bd1-908a-2e73a1d7fc2d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_482a0ede-2078-4476-b86d-e0ada13c39fe_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_1edaf0c1-c46a-4ae0-a4d6-5e856b3defe5_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_TaxBenefitResultingFromAcquisitionCharge_2c883464-fce8-41dc-ba36-d1a44083db4f_terseLabel_en-US" xlink:label="lab_mrk_TaxBenefitResultingFromAcquisitionCharge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit resulting from acquisition charge</link:label>
    <link:label id="lab_mrk_TaxBenefitResultingFromAcquisitionCharge_label_en-US" xlink:label="lab_mrk_TaxBenefitResultingFromAcquisitionCharge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Benefit Resulting From Acquisition Charge</link:label>
    <link:label id="lab_mrk_TaxBenefitResultingFromAcquisitionCharge_documentation_en-US" xlink:label="lab_mrk_TaxBenefitResultingFromAcquisitionCharge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Benefit Resulting From Acquisition Charge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TaxBenefitResultingFromAcquisitionCharge" xlink:href="mrk-20230331.xsd#mrk_TaxBenefitResultingFromAcquisitionCharge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_TaxBenefitResultingFromAcquisitionCharge" xlink:to="lab_mrk_TaxBenefitResultingFromAcquisitionCharge" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CO_2fc40d94-d208-4ada-82ff-00ef5f3fe57e_terseLabel_en-US" xlink:label="lab_country_CO" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLOMBIA</link:label>
    <link:label id="lab_country_CO_label_en-US" xlink:label="lab_country_CO" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLOMBIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CO" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CO"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CO" xlink:to="lab_country_CO" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_23d14411-e441-499f-8d0c-8359239d1a6a_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_05272869-6508-43e5-b4fd-3c7d84228e3b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_cdbd0274-2f7c-494d-b647-077df354d9fe_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_49840046-bbec-4a0f-9ec7-9f4cdcf6fc4e_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_17392c85-d2fd-4ec6-a562-88b3a30c1945_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_BelsomraMember_16b4f2a5-03b4-417e-bf5e-274c94b32369_terseLabel_en-US" xlink:label="lab_mrk_BelsomraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Belsomra</link:label>
    <link:label id="lab_mrk_BelsomraMember_label_en-US" xlink:label="lab_mrk_BelsomraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Belsomra [Member]</link:label>
    <link:label id="lab_mrk_BelsomraMember_documentation_en-US" xlink:label="lab_mrk_BelsomraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Belsomra [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BelsomraMember" xlink:href="mrk-20230331.xsd#mrk_BelsomraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_BelsomraMember" xlink:to="lab_mrk_BelsomraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_743673f2-36db-416c-b3d5-6eaf51f8e00b_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_Pneumovax23Member_da536449-82a2-424c-9181-57edbc522901_terseLabel_en-US" xlink:label="lab_mrk_Pneumovax23Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pneumovax 23</link:label>
    <link:label id="lab_mrk_Pneumovax23Member_label_en-US" xlink:label="lab_mrk_Pneumovax23Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pneumovax 23 [Member]</link:label>
    <link:label id="lab_mrk_Pneumovax23Member_documentation_en-US" xlink:label="lab_mrk_Pneumovax23Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pneumovax 23[Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_Pneumovax23Member" xlink:href="mrk-20230331.xsd#mrk_Pneumovax23Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_Pneumovax23Member" xlink:to="lab_mrk_Pneumovax23Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EMEAMember_ce3bfff0-95aa-484c-9ed1-328f3e0558ef_terseLabel_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe, Middle East and Africa</link:label>
    <link:label id="lab_us-gaap_EMEAMember_label_en-US" xlink:label="lab_us-gaap_EMEAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMEA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EMEAMember" xlink:to="lab_us-gaap_EMEAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_96338d67-163e-44a5-8231-7a992bbf4160_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_04ac7f2f-725c-441c-a15f-65f8cd5dd2c7_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3ad85885-f450-424e-a323-0fc8d69b6ec0_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0de7fc60-6c3d-4fa1-bdc7-879beccc45d0_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A0.500Notesdue2024Member_e93dba28-47c2-41d1-b2a3-160e80a6efc0_terseLabel_en-US" xlink:label="lab_mrk_A0.500Notesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2024</link:label>
    <link:label id="lab_mrk_A0.500Notesdue2024Member_label_en-US" xlink:label="lab_mrk_A0.500Notesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2024 [Member]</link:label>
    <link:label id="lab_mrk_A0.500Notesdue2024Member_documentation_en-US" xlink:label="lab_mrk_A0.500Notesdue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.500% Notes due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.500Notesdue2024Member" xlink:href="mrk-20230331.xsd#mrk_A0.500Notesdue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A0.500Notesdue2024Member" xlink:to="lab_mrk_A0.500Notesdue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LenvimaMember_a8180a42-e773-4106-9aec-16c933186e87_terseLabel_en-US" xlink:label="lab_mrk_LenvimaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Lenvima</link:label>
    <link:label id="lab_mrk_LenvimaMember_1745a089-5150-4430-9704-3e67f2bdd893_verboseLabel_en-US" xlink:label="lab_mrk_LenvimaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lenvima</link:label>
    <link:label id="lab_mrk_LenvimaMember_label_en-US" xlink:label="lab_mrk_LenvimaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lenvima [Member]</link:label>
    <link:label id="lab_mrk_LenvimaMember_documentation_en-US" xlink:label="lab_mrk_LenvimaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lenvima [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember" xlink:href="mrk-20230331.xsd#mrk_LenvimaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LenvimaMember" xlink:to="lab_mrk_LenvimaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_7e1368d6-3b65-4615-b5b2-fcdbb508b427_terseLabel_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Costs</link:label>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:to="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_121a1770-9e27-4263-9e72-c964ceea60d1_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_5351fa9a-4a55-4a6a-ab2a-dbcf9649c544_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_7ca63b0c-3b74-4b12-9e51-8ced9d7dc590_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_88413c37-1437-4f8d-ad51-d1cc0fa57bde_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_2441c79c-96f7-49d2-998c-9757b67971de_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_e731554a-0769-4909-9632-b62358560d0c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss) before Reclassifications, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_03d8bc2b-cb45-4d07-99dd-97ba7ad48376_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1e09319b-a4f6-4a04-a941-c937ec49a4a9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_c0f7fe41-3a25-4e14-bb7b-062d56a57d61_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">&#160; Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_b9edfdd3-cd20-4d49-a49f-dc566d722657_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AssetAcquisitionSharePrice_9dde2460-3cd3-49f9-87c9-873a5c179d5c_terseLabel_en-US" xlink:label="lab_mrk_AssetAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, share price (in dollars per share)</link:label>
    <link:label id="lab_mrk_AssetAcquisitionSharePrice_label_en-US" xlink:label="lab_mrk_AssetAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition Share Price</link:label>
    <link:label id="lab_mrk_AssetAcquisitionSharePrice_documentation_en-US" xlink:label="lab_mrk_AssetAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price of a single share of a number of saleable stocks paid or offered to be paid in an asset acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetAcquisitionSharePrice" xlink:href="mrk-20230331.xsd#mrk_AssetAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AssetAcquisitionSharePrice" xlink:to="lab_mrk_AssetAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_10a92634-5001-4a5b-81bc-c3ac62397c18_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_e2706749-a374-4025-9f96-dd989232146c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A1.875Notesdue2026Member_6a26f399-7049-4591-b557-dddb42a162ab_terseLabel_en-US" xlink:label="lab_mrk_A1.875Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% Notes due 2026</link:label>
    <link:label id="lab_mrk_A1.875Notesdue2026Member_label_en-US" xlink:label="lab_mrk_A1.875Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% Notes due 2026 [Member]</link:label>
    <link:label id="lab_mrk_A1.875Notesdue2026Member_documentation_en-US" xlink:label="lab_mrk_A1.875Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.875% Notes due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.875Notesdue2026Member" xlink:href="mrk-20230331.xsd#mrk_A1.875Notesdue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A1.875Notesdue2026Member" xlink:to="lab_mrk_A1.875Notesdue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_StockholdersEquityLineItems_aa408c56-756c-4819-a9ff-5f76ffb470f1_terseLabel_en-US" xlink:label="lab_mrk_StockholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity [Line Items]</link:label>
    <link:label id="lab_mrk_StockholdersEquityLineItems_label_en-US" xlink:label="lab_mrk_StockholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity [Line Items]</link:label>
    <link:label id="lab_mrk_StockholdersEquityLineItems_documentation_en-US" xlink:label="lab_mrk_StockholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Stockholders Equity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_StockholdersEquityLineItems" xlink:href="mrk-20230331.xsd#mrk_StockholdersEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_StockholdersEquityLineItems" xlink:to="lab_mrk_StockholdersEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_65ae0d9d-306a-4f64-bd50-7c1924c470bf_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_a3046e76-5b6b-473f-9881-4339661b3664_periodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_037dd83a-98e9-4c96-9ba1-8843424e2157_periodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_6439e626-32e4-46ac-b6d4-ddc261db240e_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_901b8bdb-32fd-42b2-821c-feaf84438c3f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_fd350355-e250-40e2-b545-817871546922_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_a1544961-4a0a-481d-beb5-d7bf2aa5ed5b_negatedLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventorySupplies_c815eda8-22c1-4fdf-833d-b78637c9df9c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventorySupplies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies</link:label>
    <link:label id="lab_us-gaap_OtherInventorySupplies_label_en-US" xlink:label="lab_us-gaap_OtherInventorySupplies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Supplies, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventorySupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventorySupplies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventorySupplies" xlink:to="lab_us-gaap_OtherInventorySupplies" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement_9f4e09fd-aefc-40df-8db3-04f5bb294571_terseLabel_en-US" xlink:label="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable contingent payments</link:label>
    <link:label id="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement_label_en-US" xlink:label="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable Contingent Payments Collaborative Arrangement</link:label>
    <link:label id="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement_documentation_en-US" xlink:label="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable Contingent Payments Collaborative Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:href="mrk-20230331.xsd#mrk_ProbableContingentPaymentsCollaborativeArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:to="lab_mrk_ProbableContingentPaymentsCollaborativeArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_8e48dbe2-0460-49bc-8536-fade29e60453_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_99e0a5ad-2ddf-4883-b79a-95782b0db5d1_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8cb8ddad-9d7f-495c-9b05-d9241fc7bfd4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_b351d618-99b6-492d-bd9c-2bca03650eba_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from related parties, current</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueFromRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IsentressIsentressHDMember_3c33c864-75fa-43cf-b88d-4eb7a327c6cc_terseLabel_en-US" xlink:label="lab_mrk_IsentressIsentressHDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Isentress/Isentress HD</link:label>
    <link:label id="lab_mrk_IsentressIsentressHDMember_label_en-US" xlink:label="lab_mrk_IsentressIsentressHDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Isentress/Isentress HD [Member]</link:label>
    <link:label id="lab_mrk_IsentressIsentressHDMember_documentation_en-US" xlink:label="lab_mrk_IsentressIsentressHDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Isentress/Isentress HD [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IsentressIsentressHDMember" xlink:href="mrk-20230331.xsd#mrk_IsentressIsentressHDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IsentressIsentressHDMember" xlink:to="lab_mrk_IsentressIsentressHDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_a8aad6c2-80de-4299-9150-8e3545bc874b_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_Revenues_c054fb83-38bf-402d-b0aa-142f27649a30_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InventoryTable_af4cbdcf-6578-4d85-9b31-44e3aee962e0_terseLabel_en-US" xlink:label="lab_mrk_InventoryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Table]</link:label>
    <link:label id="lab_mrk_InventoryTable_label_en-US" xlink:label="lab_mrk_InventoryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Table]</link:label>
    <link:label id="lab_mrk_InventoryTable_documentation_en-US" xlink:label="lab_mrk_InventoryTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryTable" xlink:href="mrk-20230331.xsd#mrk_InventoryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InventoryTable" xlink:to="lab_mrk_InventoryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_e95aa991-417b-49a3-8a02-e65e6a491528_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative costs since program inception</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_e60e901a-af9c-4088-b08a-66ddaf68bbd8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on Income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_ee5a9de1-046a-48c7-ab59-dc2089a1f0dc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from related party</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_4d3ec1b9-7670-416c-82e3-d641bbafe102_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_757fffd8-0d72-471e-8dc5-eaa846f7a292_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic Earnings Per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_8fc72310-b242-4947-92ca-90b8b18d59e7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, carrying amount</link:label>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_label_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Long-Term and Short-Term, Combined Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_54fa2351-c352-4704-bfda-4500a2459921_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RecognizedAsAbstract_17ee9536-9fb9-4055-8646-14fea5a0bec9_terseLabel_en-US" xlink:label="lab_mrk_RecognizedAsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized as:</link:label>
    <link:label id="lab_mrk_RecognizedAsAbstract_label_en-US" xlink:label="lab_mrk_RecognizedAsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized As [Abstract]</link:label>
    <link:label id="lab_mrk_RecognizedAsAbstract_documentation_en-US" xlink:label="lab_mrk_RecognizedAsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized as.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RecognizedAsAbstract" xlink:href="mrk-20230331.xsd#mrk_RecognizedAsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RecognizedAsAbstract" xlink:to="lab_mrk_RecognizedAsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ImagoBioSciencesIncMember_1091ea37-5b90-4aa1-a88f-e79832bb74a3_terseLabel_en-US" xlink:label="lab_mrk_ImagoBioSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imago Bio Sciences, Inc.</link:label>
    <link:label id="lab_mrk_ImagoBioSciencesIncMember_label_en-US" xlink:label="lab_mrk_ImagoBioSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imago Bio Sciences, Inc. [Member]</link:label>
    <link:label id="lab_mrk_ImagoBioSciencesIncMember_documentation_en-US" xlink:label="lab_mrk_ImagoBioSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imago Bio Sciences, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ImagoBioSciencesIncMember" xlink:href="mrk-20230331.xsd#mrk_ImagoBioSciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ImagoBioSciencesIncMember" xlink:to="lab_mrk_ImagoBioSciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_7d364669-4873-4634-a3bb-e2d10c304bb1_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_e5c9e040-9436-4fd3-b1cb-cc27c60c2a3d_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_36c157e8-f947-4c19-9fe5-f14dfe0994a9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PrimaxinMember_a59c68cc-9c9c-46a0-b57c-6fa6759ff20f_terseLabel_en-US" xlink:label="lab_mrk_PrimaxinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primaxin</link:label>
    <link:label id="lab_mrk_PrimaxinMember_label_en-US" xlink:label="lab_mrk_PrimaxinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primaxin [Member]</link:label>
    <link:label id="lab_mrk_PrimaxinMember_documentation_en-US" xlink:label="lab_mrk_PrimaxinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primaxin [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrimaxinMember" xlink:href="mrk-20230331.xsd#mrk_PrimaxinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PrimaxinMember" xlink:to="lab_mrk_PrimaxinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_98ba3782-2619-4bea-9ec7-9f104585dc4c_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_43bb2595-4f06-4b96-bc23-cdbb25aa2215_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Merck&#160;&amp; Co., Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_1a5f8c9b-9c64-4c74-8115-e7f3fca244ff_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition costs</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Transaction Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_5b4103f8-fb0d-4adb-8278-db71c6c8a5e3_terseLabel_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of cumulative pre tax costs that will result in cash outlays</link:label>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_label_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate Of Cumulative Pre Tax Costs That Will Result In Cash Outlays</link:label>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_documentation_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:href="mrk-20230331.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:to="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_7c259ade-5e4a-4e98-8d53-32f16511d57e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_63eb218b-6223-4731-bd67-ac626bd798b9_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_VaqtaMember_623b739b-265b-447d-9182-29b8233041bc_terseLabel_en-US" xlink:label="lab_mrk_VaqtaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaqta</link:label>
    <link:label id="lab_mrk_VaqtaMember_label_en-US" xlink:label="lab_mrk_VaqtaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaqta [Member]</link:label>
    <link:label id="lab_mrk_VaqtaMember_documentation_en-US" xlink:label="lab_mrk_VaqtaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaqta [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VaqtaMember" xlink:href="mrk-20230331.xsd#mrk_VaqtaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_VaqtaMember" xlink:to="lab_mrk_VaqtaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_e8d2ee11-d4b8-4945-b0ec-95508254293b_negatedTerseLabel_en-US" xlink:label="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_label_en-US" xlink:label="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other</link:label>
    <link:label id="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_documentation_en-US" xlink:label="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" xlink:href="mrk-20230331.xsd#mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" xlink:to="lab_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_c22cd5d9-b0b9-4b1c-a161-3ad557f12590_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information About the Changes in Liabilities for Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_da3db01c-160e-4a8f-9c9b-5a7e5f2c012e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_9f3473be-1958-47e2-ab7f-2a396938b95d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_5e2f0d9a-c4e6-4f06-b868-172919dfbd2a_negatedLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared on common stock</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_48e38169-6aff-4edc-8434-86633f75bccc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss related to litigation settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_3025fb04-a6a0-4b3b-a082-51bd50575b52_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge for Zetia antitrust litigation settlements</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_d872ac4a-7eb8-4d52-a4e6-23f62b218bc3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PotentialFutureMilestonePaymentsSalesBased_d6e204e9-8382-4848-9796-d646d0af16cb_terseLabel_en-US" xlink:label="lab_mrk_PotentialFutureMilestonePaymentsSalesBased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future sales-based milestone payments</link:label>
    <link:label id="lab_mrk_PotentialFutureMilestonePaymentsSalesBased_label_en-US" xlink:label="lab_mrk_PotentialFutureMilestonePaymentsSalesBased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Sales-Based</link:label>
    <link:label id="lab_mrk_PotentialFutureMilestonePaymentsSalesBased_documentation_en-US" xlink:label="lab_mrk_PotentialFutureMilestonePaymentsSalesBased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Sales-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PotentialFutureMilestonePaymentsSalesBased" xlink:href="mrk-20230331.xsd#mrk_PotentialFutureMilestonePaymentsSalesBased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PotentialFutureMilestonePaymentsSalesBased" xlink:to="lab_mrk_PotentialFutureMilestonePaymentsSalesBased" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_NoxafilMember_8ec87033-b9f5-4269-86ce-87d8a00ed510_terseLabel_en-US" xlink:label="lab_mrk_NoxafilMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noxafil</link:label>
    <link:label id="lab_mrk_NoxafilMember_label_en-US" xlink:label="lab_mrk_NoxafilMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noxafil [Member]</link:label>
    <link:label id="lab_mrk_NoxafilMember_documentation_en-US" xlink:label="lab_mrk_NoxafilMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noxafil [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NoxafilMember" xlink:href="mrk-20230331.xsd#mrk_NoxafilMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_NoxafilMember" xlink:to="lab_mrk_NoxafilMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_745da92b-60e3-4166-ab3e-81f57543e17b_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_8193a542-5d7c-419d-b281-de14b1560ce2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock ($0.50&#160;par value)</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_4621ca9a-269e-420d-af80-6d948e3a6687_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">&#160;&#160; Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_240afbc0-0ef1-4f61-9fac-8b8afa53ee25_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ce937f5e-45f0-41fc-ac4b-f0093c65f8d2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_59c1e4e5-ff0b-4bd5-8b99-a7dad9cb92ad_totalLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassification adjustments, net of taxes</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, before Reclassifications, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_36492295-45d3-44be-9dbf-07a66ebe6cfb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapital_0a6f9060-182f-42a8-8d4f-4513a858c00a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapital_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_07f6d1b3-81ad-41ed-9270-c0ab3bd4eee8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_b6863bd0-57b8-4842-b4a6-a477fb60d2c0_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_27bcb0b5-0cf6-49f4-b72c-c4159351e5b5_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_b0969039-8a91-48d2-9c4a-d9a3d781cb8f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_457556e5-fb21-457c-8393-e360f7617bea_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_312b42eb-a815-4868-b1a6-2d14b30a984b_verboseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables included in Other current assets</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_0ddb5f56-cf19-4c48-97b3-cb86b7b796d5_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_4b5bd47d-9469-46eb-bb33-5343cbad514e_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6d1eedfa-15a1-4cc8-8fa2-422b92ba72c4_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_47e6c3e7-07ae-46dd-b87c-96c42dbe8d09_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_b8a4f81b-d960-4da6-82ed-2f28cda864b2_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit plan net (loss) gain and prior service (cost) credit, net of amortization</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_ec0b895b-9690-4d77-abd9-60cbd272d3e6_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_d298c928-80f1-484d-ba51-a9938147c4b4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge for the acquisition of Imago BioSciences, Inc.</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_710a6cb2-367d-4b0c-ac33-415a231d5dc4_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock shares purchased (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_12cf3972-956f-4bc9-95dc-cbb3a9b40ed1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_JanuviaAndJanumetMember_f903761e-b177-4176-ac03-6a34c3a06c8c_terseLabel_en-US" xlink:label="lab_mrk_JanuviaAndJanumetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Januvia and Janumet</link:label>
    <link:label id="lab_mrk_JanuviaAndJanumetMember_label_en-US" xlink:label="lab_mrk_JanuviaAndJanumetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Januvia and Janumet [Member]</link:label>
    <link:label id="lab_mrk_JanuviaAndJanumetMember_documentation_en-US" xlink:label="lab_mrk_JanuviaAndJanumetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Januvia and Janumet</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaAndJanumetMember" xlink:href="mrk-20230331.xsd#mrk_JanuviaAndJanumetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_JanuviaAndJanumetMember" xlink:to="lab_mrk_JanuviaAndJanumetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_e9ee5314-2817-41f6-8a24-8a3fda4a81bc_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_6dad8cf7-8710-4fdb-8f74-75b33bb93808_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4382c81a-7ff8-4c0c-8990-2cab020e560b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ProQuadMMRIIVarivaxMember_d9b31376-a627-4ef9-80b1-fdb9ef43bca8_terseLabel_en-US" xlink:label="lab_mrk_ProQuadMMRIIVarivaxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProQuad/M-M-R II/Varivax</link:label>
    <link:label id="lab_mrk_ProQuadMMRIIVarivaxMember_label_en-US" xlink:label="lab_mrk_ProQuadMMRIIVarivaxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProQuad MMR II Varivax [Member]</link:label>
    <link:label id="lab_mrk_ProQuadMMRIIVarivaxMember_documentation_en-US" xlink:label="lab_mrk_ProQuadMMRIIVarivaxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProQuad/M-M-R II/Varivax [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProQuadMMRIIVarivaxMember" xlink:href="mrk-20230331.xsd#mrk_ProQuadMMRIIVarivaxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ProQuadMMRIIVarivaxMember" xlink:to="lab_mrk_ProQuadMMRIIVarivaxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_dfdcaf4a-bd0a-4ddd-a940-269ab458896e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_89a2f598-0705-4f87-82e2-d048e123fa33_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_afa15764-c2d0-43a5-ae8d-86acab2e38d3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable (net of allowance for doubtful accounts of $76 in 2023 and $72 in 2022)</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_14410bb5-0051-4ae2-adbd-14a103f73b96_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of securities and other investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_e792506c-b0f2-44a6-a417-14815edbb144_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_44e34711-8f1f-4bd4-8481-efc52b57afdd_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_83a84e1e-4e87-45cd-8ae9-bbd9b3e9ab2c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_bf60ecc0-8dd6-4ffb-ab22-11de9b292d55_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_e55f3526-833e-4310-99a0-0726759e91ef_terseLabel_en-US" xlink:label="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis</link:label>
    <link:label id="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offsetting Assets And Liabilities [Table Text Block]</link:label>
    <link:label id="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:href="mrk-20230331.xsd#mrk_OffsettingAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_fa9438b8-5446-466b-9b0c-6ae9324e48eb_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_012f9174-9e57-489c-b024-8fdec9781278_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_9add6b8c-ff96-4784-8ac0-dbafdc6659d6_terseLabel_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of cumulative pre tax costs that will be noncash</link:label>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_label_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate Of Cumulative Pre Tax Costs That Will Be Noncash</link:label>
    <link:label id="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_documentation_en-US" xlink:label="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of cumulative pre tax costs that will be noncash.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:href="mrk-20230331.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:to="lab_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_990387fa-0989-4171-8886-ae87750a6d91_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SimponiMember_7a9c80bc-66e3-41b0-b2ae-368f6ccdf447_terseLabel_en-US" xlink:label="lab_mrk_SimponiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi</link:label>
    <link:label id="lab_mrk_SimponiMember_label_en-US" xlink:label="lab_mrk_SimponiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi [Member]</link:label>
    <link:label id="lab_mrk_SimponiMember_documentation_en-US" xlink:label="lab_mrk_SimponiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SimponiMember" xlink:href="mrk-20230331.xsd#mrk_SimponiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SimponiMember" xlink:to="lab_mrk_SimponiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI_b23a9fde-f0da-49a6-823c-d8bad2a80a65_totalLabel_en-US" xlink:label="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt and publicly traded equity securities, fair value</link:label>
    <link:label id="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI_label_en-US" xlink:label="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities and Equity Securities, FV-NI</link:label>
    <link:label id="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI_documentation_en-US" xlink:label="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities and Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:href="mrk-20230331.xsd#mrk_DebtSecuritiesandEquitySecuritiesFVNI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:to="lab_mrk_DebtSecuritiesandEquitySecuritiesFVNI" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_9447c4d7-aa82-4772-ac4e-71576782e9ee_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_b3d7aece-cb5b-4a6c-93df-2791d5285e7e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_425f8a92-29dd-4cc5-b887-9270f48cc992_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_8e2ad8ab-6379-4b3c-a013-e06f7db9a723_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_347b6bbc-21aa-4921-a20b-b6878f5d33b6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in estimated fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ae7c9a7c-f4ce-42a1-afc2-f7925d551243_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5454320f-2cd8-4023-9476-5cf6d6221c2a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_36760a11-3241-4f90-bd25-bc0d74e97adb_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_40d30de1-8078-4d84-9d63-729a06da4c0a_negatedLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustments, pretax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_ac564a00-8fda-4c02-960e-54d7f2b4c38a_terseLabel_en-US" xlink:label="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash activity</link:label>
    <link:label id="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_label_en-US" xlink:label="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Increase (Decrease) Noncash Activity</link:label>
    <link:label id="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_documentation_en-US" xlink:label="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash activity affecting the restructuring reserve, including accelerated depreciation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" xlink:href="mrk-20230331.xsd#mrk_RestructuringReserveIncreaseDecreaseNoncashActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" xlink:to="lab_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_a9ccf3ae-c96a-46c8-8b69-d89161d6ab9d_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_65d74aee-d007-484e-903d-df7bc0918d54_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative unrealized losses on investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_c418f562-e01f-42f0-a03f-1af3d2cf90fb_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherNonoperatingIncomeExpenseOther_ca7e4e47-2c6b-414b-905b-37a07c462969_negatedLabel_en-US" xlink:label="lab_mrk_OtherNonoperatingIncomeExpenseOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_mrk_OtherNonoperatingIncomeExpenseOther_label_en-US" xlink:label="lab_mrk_OtherNonoperatingIncomeExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income Expense, Other</link:label>
    <link:label id="lab_mrk_OtherNonoperatingIncomeExpenseOther_documentation_en-US" xlink:label="lab_mrk_OtherNonoperatingIncomeExpenseOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other nonoperating income and expense items not separately disclosed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherNonoperatingIncomeExpenseOther" xlink:href="mrk-20230331.xsd#mrk_OtherNonoperatingIncomeExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherNonoperatingIncomeExpenseOther" xlink:to="lab_mrk_OtherNonoperatingIncomeExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_d7efca6a-e0e5-45e3-96f1-3fa4facaae53_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_5516b87f-58ed-42ab-95d9-0025a8bfd704_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_769df755-359d-461d-a323-175cfddb9107_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_a684fe9a-3746-411a-8788-e118b383a6cd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_755f6636-e9c2-4511-bf34-161bceb8150a_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Standards and Recently Issued Accounting Standards Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_1e12b330-f655-47d2-8f6b-9a1dd75d1bc6_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_KeytrudaMember_e0ee05c5-5df1-4190-adb9-afb97c981d5c_terseLabel_en-US" xlink:label="lab_mrk_KeytrudaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Keytruda</link:label>
    <link:label id="lab_mrk_KeytrudaMember_label_en-US" xlink:label="lab_mrk_KeytrudaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Keytruda [Member]</link:label>
    <link:label id="lab_mrk_KeytrudaMember_documentation_en-US" xlink:label="lab_mrk_KeytrudaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Keytruda [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_KeytrudaMember" xlink:href="mrk-20230331.xsd#mrk_KeytrudaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_KeytrudaMember" xlink:to="lab_mrk_KeytrudaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_29709199-4127-4b21-b95c-30fa611188a2_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments without readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LossContingencyNumberOfStatesInWhichPlaintiffsReside_8b510340-8029-4021-a17a-9f7719d78e86_terseLabel_en-US" xlink:label="lab_mrk_LossContingencyNumberOfStatesInWhichPlaintiffsReside" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, number of states in which plaintiffs reside</link:label>
    <link:label id="lab_mrk_LossContingencyNumberOfStatesInWhichPlaintiffsReside_label_en-US" xlink:label="lab_mrk_LossContingencyNumberOfStatesInWhichPlaintiffsReside" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of States In Which Plaintiffs Reside</link:label>
    <link:label id="lab_mrk_LossContingencyNumberOfStatesInWhichPlaintiffsReside_documentation_en-US" xlink:label="lab_mrk_LossContingencyNumberOfStatesInWhichPlaintiffsReside" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of States In Which Plaintiffs Reside</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LossContingencyNumberOfStatesInWhichPlaintiffsReside" xlink:href="mrk-20230331.xsd#mrk_LossContingencyNumberOfStatesInWhichPlaintiffsReside"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LossContingencyNumberOfStatesInWhichPlaintiffsReside" xlink:to="lab_mrk_LossContingencyNumberOfStatesInWhichPlaintiffsReside" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LossContingencyTrialPeriod_c78b3db4-d81a-47a7-8340-3cdfb6bb82b1_terseLabel_en-US" xlink:label="lab_mrk_LossContingencyTrialPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, trial period</link:label>
    <link:label id="lab_mrk_LossContingencyTrialPeriod_label_en-US" xlink:label="lab_mrk_LossContingencyTrialPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Trial Period</link:label>
    <link:label id="lab_mrk_LossContingencyTrialPeriod_documentation_en-US" xlink:label="lab_mrk_LossContingencyTrialPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Trial Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LossContingencyTrialPeriod" xlink:href="mrk-20230331.xsd#mrk_LossContingencyTrialPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LossContingencyTrialPeriod" xlink:to="lab_mrk_LossContingencyTrialPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_950550ea-caa3-4930-903b-8bc5698dc617_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (approximates current cost)</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_b8a3f2fe-a9d4-46b4-982b-664c75dee242_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_d8df7c4e-e3f6-432b-895a-20b1479590d8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_7eb378d0-9430-49a8-9da9-59b8139ab73f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityFundsMember_4313110e-820d-4755-ae97-0d8e8d572944_terseLabel_en-US" xlink:label="lab_us-gaap_EquityFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Funds</link:label>
    <link:label id="lab_us-gaap_EquityFundsMember_label_en-US" xlink:label="lab_us-gaap_EquityFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityFundsMember" xlink:to="lab_us-gaap_EquityFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AllianceRevenueAdempasVerquvoMember_d3f62929-44db-454a-8628-7db8c51cf5d0_terseLabel_en-US" xlink:label="lab_mrk_AllianceRevenueAdempasVerquvoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Adempas/Verquvo</link:label>
    <link:label id="lab_mrk_AllianceRevenueAdempasVerquvoMember_label_en-US" xlink:label="lab_mrk_AllianceRevenueAdempasVerquvoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Adempas/Verquvo [Member]</link:label>
    <link:label id="lab_mrk_AllianceRevenueAdempasVerquvoMember_documentation_en-US" xlink:label="lab_mrk_AllianceRevenueAdempasVerquvoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Adempas/Verquvo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueAdempasVerquvoMember" xlink:href="mrk-20230331.xsd#mrk_AllianceRevenueAdempasVerquvoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AllianceRevenueAdempasVerquvoMember" xlink:to="lab_mrk_AllianceRevenueAdempasVerquvoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_032613e7-40f6-4344-99da-b3791ba2710b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_222ec138-992c-406d-8331-ae0524103067_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on Income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_25a11009-1a7f-4cfb-8f6f-b60dc47df26a_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b8a84108-a866-49c5-a6a3-0c0f0e1456cd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_479643db-e4e6-40f9-b710-b825cb212f45_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_9049d4e8-64ec-4651-b5ed-436d26196dc9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_272612ca-a8aa-45bf-8882-98d982d98775_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_2c4990f8-217d-458d-a73c-16af4684d8cd_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_93d60ffd-3608-45b0-bb1a-82c1d3b102ea_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_20a23152-d72a-4ee2-851a-69261dfbb57f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_dcb8af0a-3834-4749-9387-93d2b4bb2dc6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SalesBasedMilestonesMember_aa768878-76bf-464d-88a8-5471c6e9eda2_terseLabel_en-US" xlink:label="lab_mrk_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestones</link:label>
    <link:label id="lab_mrk_SalesBasedMilestonesMember_label_en-US" xlink:label="lab_mrk_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestones [Member]</link:label>
    <link:label id="lab_mrk_SalesBasedMilestonesMember_documentation_en-US" xlink:label="lab_mrk_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember" xlink:href="mrk-20230331.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SalesBasedMilestonesMember" xlink:to="lab_mrk_SalesBasedMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_0603b323-5ceb-421d-ab92-dc53b4048d38_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_61ae200f-16a1-4e8b-9a50-5ee45989ca55_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average common shares outstanding assuming dilution (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_031c2d47-5940-4e34-b663-21f4432fde13_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_86783e39-084b-4465-ba76-99c9d1e5987d_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral received, liability</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralRightToReclaimCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:to="lab_us-gaap_DerivativeCollateralRightToReclaimCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_324d50e4-bf19-4ad8-84af-53e8f7d22bb6_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Derivative, Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_386965ab-d5db-45d0-8314-2120a17d488d_netLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross amounts recognized in the consolidated balance sheet, liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_2a74bfba-c6a0-41e3-b710-abfc0a6cb33f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_69c8d409-a27c-48cf-9129-e7d85e07b2c4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty_8c15af68-a763-4261-b5fa-37060d900105_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock investment in counterparty</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Preferred Stock Investment In Counterparty</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Preferred Stock Investment In Counterparty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty" xlink:to="lab_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_f989d453-d1dc-4a73-a0a7-dd13196d9e6b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_761ab990-e5d9-48dc-9445-053c3e445c51_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_69db64f8-19e8-4fa2-bdbe-42e72e2ff462_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities, noncurrent</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFVNINoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFVNINoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f954aa90-6d6e-4331-b71d-ea97a1c7f889_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_0f97b27e-dcb3-4fef-9c3a-cdca4836c21c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses recognized on investments in equity securities without readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_99c41357-cf78-4745-a766-f6e8bda9f938_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7fb3f4a2-e3b3-4b70-84a5-fce733415ad5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ManufacturingAndSupplyAgreementsMember_2f9fa145-db8e-4aaa-bbbb-ccb9c2423e45_terseLabel_en-US" xlink:label="lab_mrk_ManufacturingAndSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and supply agreements</link:label>
    <link:label id="lab_mrk_ManufacturingAndSupplyAgreementsMember_label_en-US" xlink:label="lab_mrk_ManufacturingAndSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and supply agreements [Member]</link:label>
    <link:label id="lab_mrk_ManufacturingAndSupplyAgreementsMember_documentation_en-US" xlink:label="lab_mrk_ManufacturingAndSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing and supply agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ManufacturingAndSupplyAgreementsMember" xlink:href="mrk-20230331.xsd#mrk_ManufacturingAndSupplyAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ManufacturingAndSupplyAgreementsMember" xlink:to="lab_mrk_ManufacturingAndSupplyAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_dd1faa57-e7d2-455f-b3b1-5b7121b61595_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information on Investments in Debt and Equity Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_dfe875bb-f2a9-4c98-a18f-c45af67832d3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2023 and 2022</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesMember_0a74ac52-4fb8-49ca-9831-e8ef276b7953_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesMember_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesMember" xlink:to="lab_us-gaap_RestructuringChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartiesAmountInCostOfSales_9ec9eac2-0a3e-4702-aeb2-dbb4e7c0b45c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartiesAmountInCostOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party amount in cost of sales</link:label>
    <link:label id="lab_us-gaap_RelatedPartiesAmountInCostOfSales_label_en-US" xlink:label="lab_us-gaap_RelatedPartiesAmountInCostOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Parties Amount in Cost of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartiesAmountInCostOfSales" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartiesAmountInCostOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartiesAmountInCostOfSales" xlink:to="lab_us-gaap_RelatedPartiesAmountInCostOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_628231b7-8d18-4dbc-bb65-fd154ef21701_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of patents allegedly infringed</link:label>
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:to="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LynparzaMember_f0b04210-43d9-4f8c-9849-dae83a53447f_terseLabel_en-US" xlink:label="lab_mrk_LynparzaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lynparza</link:label>
    <link:label id="lab_mrk_LynparzaMember_label_en-US" xlink:label="lab_mrk_LynparzaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lynparza [Member]</link:label>
    <link:label id="lab_mrk_LynparzaMember_documentation_en-US" xlink:label="lab_mrk_LynparzaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lynparza [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember" xlink:href="mrk-20230331.xsd#mrk_LynparzaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LynparzaMember" xlink:to="lab_mrk_LynparzaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AsiaPacificMember_b27d9081-e16c-42ac-9f3d-f519c0d3e94d_terseLabel_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific (other than China and Japan)</link:label>
    <link:label id="lab_srt_AsiaPacificMember_label_en-US" xlink:label="lab_srt_AsiaPacificMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia Pacific [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AsiaPacificMember" xlink:to="lab_srt_AsiaPacificMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8c93cee4-a2d4-493b-a4a5-91bc06ab1769_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_0498a843-61ca-4f92-91f0-82b5dfb710ab_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_b9e6b904-d4e1-489e-8905-ab1d2bae76b1_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InventoryNetAndInventoryNoncurrent_f588996c-a01d-4373-bd67-68c7568ec2fa_totalLabel_en-US" xlink:label="lab_mrk_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current and noncurrent inventories</link:label>
    <link:label id="lab_mrk_InventoryNetAndInventoryNoncurrent_label_en-US" xlink:label="lab_mrk_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Net And Inventory Noncurrent</link:label>
    <link:label id="lab_mrk_InventoryNetAndInventoryNoncurrent_documentation_en-US" xlink:label="lab_mrk_InventoryNetAndInventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of current and noncurrent inventories.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNetAndInventoryNoncurrent" xlink:href="mrk-20230331.xsd#mrk_InventoryNetAndInventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InventoryNetAndInventoryNoncurrent" xlink:to="lab_mrk_InventoryNetAndInventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_f672ab6c-43c1-49b6-b77e-5fb89722a265_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Net Investment Hedges on OCI and the Consolidated Statement of Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e727acdc-dbbb-4267-bca2-2f15791cef1a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $79 and $71 at January 1, 2023 and 2022, respectively, included in Other current assets)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e54c1dc2-9a93-4f18-bcf3-719c8ee6bcdf_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $79 and $58 at March&#160;31, 2023 and 2022, respectively, included in Other current assets)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ZetiaantitrustlitigationMember_48ecf95b-ca38-49b4-b139-4c5ac53a5e35_terseLabel_en-US" xlink:label="lab_mrk_ZetiaantitrustlitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zetia antitrust litigation</link:label>
    <link:label id="lab_mrk_ZetiaantitrustlitigationMember_label_en-US" xlink:label="lab_mrk_ZetiaantitrustlitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zetia antitrust litigation [Member]</link:label>
    <link:label id="lab_mrk_ZetiaantitrustlitigationMember_documentation_en-US" xlink:label="lab_mrk_ZetiaantitrustlitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zetia antitrust litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZetiaantitrustlitigationMember" xlink:href="mrk-20230331.xsd#mrk_ZetiaantitrustlitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ZetiaantitrustlitigationMember" xlink:to="lab_mrk_ZetiaantitrustlitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_93ee6b19-0437-4dbf-844d-f9a402b6d9cb_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock_efe1f842-dfbf-40be-b9b7-01e6f3107bb5_terseLabel_en-US" xlink:label="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, Research Collaborations and License Agreements</link:label>
    <link:label id="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock_label_en-US" xlink:label="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions Research Collaborations And License Agreements [Text Block]</link:label>
    <link:label id="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock_documentation_en-US" xlink:label="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to acquisitions, divestitures, research collaborations and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:href="mrk-20230331.xsd#mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:to="lab_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5a1b5914-336a-4ca5-a89d-14aa81bb4d1d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_697262d5-18e5-4a93-8893-aa60d42c4a5c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_cebf79fd-f2e7-48d1-b046-47fa17bb2bcd_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Merck &amp; Co., Inc., basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_11b07ff7-e072-4b6e-bbe4-b443c380c850_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_0fe07d26-c27c-4937-8842-70ee6e412342_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_27013987-3c52-45b3-a19e-380573a88620_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_89c6f8a2-d519-4f48-bd3c-2b5405cd0741_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_b7eeace5-05dd-4918-99fb-78f391c44c2f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A1.375Notesdue2036Member_68102db8-7969-43e7-b4f0-6bae6c1a8712_terseLabel_en-US" xlink:label="lab_mrk_A1.375Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2036</link:label>
    <link:label id="lab_mrk_A1.375Notesdue2036Member_label_en-US" xlink:label="lab_mrk_A1.375Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2036 [Member]</link:label>
    <link:label id="lab_mrk_A1.375Notesdue2036Member_documentation_en-US" xlink:label="lab_mrk_A1.375Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.375% Notes due 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.375Notesdue2036Member" xlink:href="mrk-20230331.xsd#mrk_A1.375Notesdue2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A1.375Notesdue2036Member" xlink:to="lab_mrk_A1.375Notesdue2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0c68251f-22eb-4392-a42e-a2f74306f981_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange losses</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_be280341-e2a5-4cbc-ba08-fd0dbf1c7637_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_3be18827-c4b9-481c-a814-593e546c7dc0_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_2db20ba2-a06b-46e6-be56-30cf2d7c490b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3d4596d1-4c06-48a0-ace7-b75699554ac7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets and Liabilities Measured at Fair Value on Recurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AllianceRevenueReblozylMember_15aef195-c1e6-4544-84c3-577bfebfaaca_terseLabel_en-US" xlink:label="lab_mrk_AllianceRevenueReblozylMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance Revenue - Reblozyl</link:label>
    <link:label id="lab_mrk_AllianceRevenueReblozylMember_label_en-US" xlink:label="lab_mrk_AllianceRevenueReblozylMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance Revenue - Reblozyl [Member]</link:label>
    <link:label id="lab_mrk_AllianceRevenueReblozylMember_documentation_en-US" xlink:label="lab_mrk_AllianceRevenueReblozylMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance Revenue - Reblozyl</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueReblozylMember" xlink:href="mrk-20230331.xsd#mrk_AllianceRevenueReblozylMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AllianceRevenueReblozylMember" xlink:to="lab_mrk_AllianceRevenueReblozylMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_66837dbf-e5fb-44d2-8629-b6fbdbbd2e1f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0ea9edc2-c94f-454d-afcc-e1fde236398a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Used in Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_eb8f5a8d-0328-43e0-bcd1-3f712c2bc2df_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amounts, asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:to="lab_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_f6359df1-8077-4e66-8fb6-b6e7cace67b6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_0181951f-7030-4421-801d-9269f8f7f17c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bb108c2b-647a-4a3e-90d0-2b4d1becbb37_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_ce467094-a5a9-4af4-856b-faf8d44b9afd_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, new claims filed</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_1ffe9855-154a-4bf4-89a0-2365741f47cd_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income Attributable to Merck&#160;&amp; Co., Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_6d94290e-11ed-4735-b2b5-f43a4b6f266a_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PotentialFutureMilestonePaymentsRegulatory_cb3300f2-50a8-47d9-9654-73e72422a221_terseLabel_en-US" xlink:label="lab_mrk_PotentialFutureMilestonePaymentsRegulatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future regulatory milestone payments</link:label>
    <link:label id="lab_mrk_PotentialFutureMilestonePaymentsRegulatory_label_en-US" xlink:label="lab_mrk_PotentialFutureMilestonePaymentsRegulatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Regulatory</link:label>
    <link:label id="lab_mrk_PotentialFutureMilestonePaymentsRegulatory_documentation_en-US" xlink:label="lab_mrk_PotentialFutureMilestonePaymentsRegulatory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Regulatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PotentialFutureMilestonePaymentsRegulatory" xlink:href="mrk-20230331.xsd#mrk_PotentialFutureMilestonePaymentsRegulatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PotentialFutureMilestonePaymentsRegulatory" xlink:to="lab_mrk_PotentialFutureMilestonePaymentsRegulatory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ab409ea5-f0d8-4b62-b3bf-8ad181db91d9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_365e8916-4739-440c-977a-0f18e672c8f2_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_8a564a7f-472a-4ed5-a7be-d0b35c065164_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_42aead98-c611-4208-95d9-9f6a2a440ef4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RidgebackBiotherapeuticsLPMember_883c3658-885d-4267-8de2-8bfd5941e79c_terseLabel_en-US" xlink:label="lab_mrk_RidgebackBiotherapeuticsLPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ridgeback Biotherapeutics LP</link:label>
    <link:label id="lab_mrk_RidgebackBiotherapeuticsLPMember_label_en-US" xlink:label="lab_mrk_RidgebackBiotherapeuticsLPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ridgeback Biotherapeutics LP [Member]</link:label>
    <link:label id="lab_mrk_RidgebackBiotherapeuticsLPMember_documentation_en-US" xlink:label="lab_mrk_RidgebackBiotherapeuticsLPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ridgeback Biotherapeutics LP</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RidgebackBiotherapeuticsLPMember" xlink:href="mrk-20230331.xsd#mrk_RidgebackBiotherapeuticsLPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RidgebackBiotherapeuticsLPMember" xlink:to="lab_mrk_RidgebackBiotherapeuticsLPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_205294a9-4ef2-4b71-94a4-35b5acb78b7e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Payments) receipts, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CostsExpensesAndOther_2cd56ca6-fc1a-4fec-b1bd-183c5fd54bc9_totalLabel_en-US" xlink:label="lab_mrk_CostsExpensesAndOther" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Costs, Expenses and Other</link:label>
    <link:label id="lab_mrk_CostsExpensesAndOther_label_en-US" xlink:label="lab_mrk_CostsExpensesAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Expenses And Other</link:label>
    <link:label id="lab_mrk_CostsExpensesAndOther_documentation_en-US" xlink:label="lab_mrk_CostsExpensesAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of cost of sales, operating expenses and nonoperating income or expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CostsExpensesAndOther" xlink:href="mrk-20230331.xsd#mrk_CostsExpensesAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CostsExpensesAndOther" xlink:to="lab_mrk_CostsExpensesAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_BristolMyersSquibbMember_52a454db-c86c-4c2d-93ac-5d45abc92b74_terseLabel_en-US" xlink:label="lab_mrk_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb</link:label>
    <link:label id="lab_mrk_BristolMyersSquibbMember_label_en-US" xlink:label="lab_mrk_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb [Member]</link:label>
    <link:label id="lab_mrk_BristolMyersSquibbMember_documentation_en-US" xlink:label="lab_mrk_BristolMyersSquibbMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bristol Myers Squibb</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BristolMyersSquibbMember" xlink:href="mrk-20230331.xsd#mrk_BristolMyersSquibbMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_BristolMyersSquibbMember" xlink:to="lab_mrk_BristolMyersSquibbMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_6977a376-5f97-4e66-85ee-a94d2c3a1434_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_e2bb3a23-848b-4a79-9bcd-5a3acf957462_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:to="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RegulatoryMilestonesMember_1a907128-e170-40c3-9262-c4c4f61ecc89_terseLabel_en-US" xlink:label="lab_mrk_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones</link:label>
    <link:label id="lab_mrk_RegulatoryMilestonesMember_label_en-US" xlink:label="lab_mrk_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_mrk_RegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_mrk_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember" xlink:href="mrk-20230331.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RegulatoryMilestonesMember" xlink:to="lab_mrk_RegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RoyaltyRatePercentage_d67a9a51-f644-40ef-be4b-ddb724e9483b_terseLabel_en-US" xlink:label="lab_mrk_RoyaltyRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty rate</link:label>
    <link:label id="lab_mrk_RoyaltyRatePercentage_label_en-US" xlink:label="lab_mrk_RoyaltyRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate, Percentage</link:label>
    <link:label id="lab_mrk_RoyaltyRatePercentage_documentation_en-US" xlink:label="lab_mrk_RoyaltyRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRatePercentage" xlink:href="mrk-20230331.xsd#mrk_RoyaltyRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RoyaltyRatePercentage" xlink:to="lab_mrk_RoyaltyRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_ebe6a1e9-0d2c-4051-b85c-e1bd87029687_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_d5848d83-e59f-43f6-935b-00f5cbb05b5a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement_fcbd636f-557b-48a6-bd04-1444a147ce33_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase to pension liabilities due to remeasurement</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Remeasurement due to Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_5c141217-ba01-41ac-9ace-598ced22770a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ContingentProceedsCollaborativeArrangement_ac4c399a-dabf-4037-bc76-09106cd26d42_terseLabel_en-US" xlink:label="lab_mrk_ContingentProceedsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent proceeds collaborative arrangement</link:label>
    <link:label id="lab_mrk_ContingentProceedsCollaborativeArrangement_label_en-US" xlink:label="lab_mrk_ContingentProceedsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Proceeds Collaborative Arrangement</link:label>
    <link:label id="lab_mrk_ContingentProceedsCollaborativeArrangement_documentation_en-US" xlink:label="lab_mrk_ContingentProceedsCollaborativeArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents proceeds that may be received in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentProceedsCollaborativeArrangement" xlink:href="mrk-20230331.xsd#mrk_ContingentProceedsCollaborativeArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ContingentProceedsCollaborativeArrangement" xlink:to="lab_mrk_ContingentProceedsCollaborativeArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_aea9c83a-7e4f-4133-99c3-d0c1c660c081_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_00a38e6a-c44d-4da8-8480-31ca2feee394_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation plans and other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1b15d777-6f16-4e4f-8586-cf671ca8abdb_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ab3517e6-d65b-4c47-930e-fb63a7879b35_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a7ca61e7-bf6d-442b-9532-797e1a76f6eb_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c0dccc76-7c05-413c-8aaf-9dd83e6709ee_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,256 in 2023 and $17,985 in 2022</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_e75a855d-0223-484f-a30b-8f1a8db23d10_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_4ef35f87-661a-4e62-b4bd-c4fb08df1433_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_2fd2e5f9-1d03-47b3-95d3-30a8c13ba243_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OtherCountriesMember_91c068f5-1639-4704-8196-49bb5bf572b0_terseLabel_en-US" xlink:label="lab_mrk_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_mrk_OtherCountriesMember_label_en-US" xlink:label="lab_mrk_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:label id="lab_mrk_OtherCountriesMember_documentation_en-US" xlink:label="lab_mrk_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherCountriesMember" xlink:href="mrk-20230331.xsd#mrk_OtherCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OtherCountriesMember" xlink:to="lab_mrk_OtherCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_c7a009f5-35c1-4adf-ac45-a9f550dd6285_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Income) Expense, Net</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_fc88693a-27fd-468d-9879-2f9ba9ec8f73_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_536ede50-9cc8-40c0-8961-b59d4e23d4c7_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_bf5e18db-0e08-4e8b-8e4d-2902076a560d_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_1175d792-0564-4c20-af39-fa78d775f85b_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_a6520efd-126d-4356-9610-8b7934865eae_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_3c3df6e4-fd8d-476d-a2e5-a9ca3205664d_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_b7c667c0-fd65-43e4-8761-c0b4721b785a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_70dbed40-9e31-4a2d-87af-cb411920fd76_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Derivative Pretax (Gain) Loss Recognized in Income</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_3b8a2fda-c5e6-4386-8543-0af8f498060e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b34c307e-5ed8-47a4-a336-657d72bf7cb8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_086d4d46-3cec-4a1f-a4d3-912b98e2faa6_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_a8a56cf3-59dd-47ea-8de3-7422e04354f9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales from Products</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_348e1b42-7dd5-43e3-b9b5-09c8d12fb07d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_75755d9a-31c6-412a-a0ab-59309121ae61_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Sales by Geographic Area</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_bd533695-cc05-49d0-a8d7-eab424b4c833_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_723b0107-5d3c-4406-8c86-99d739d46166_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_da34570b-9127-4880-86d4-773dee6be538_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Effects of Derivatives Not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_a63ed755-b065-40e3-8b00-b41433465cd2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_bda87821-e2b3-408c-9303-a88b6e687790_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Income) loss from investments in equity securities, net</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_ae755e30-0216-4479-9d5a-bea60ef873d0_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (income) from investments in equity securities, net</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_31c62a1a-1a52-4dc7-afc8-b9ad901c766d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_b0d82144-aa3f-4fa2-b387-cda355a99eeb_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_286fcd47-83e2-4244-b2ba-4c4bd5a0c213_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_d0c2638b-c114-44fb-a870-aab13f2a7c26_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_908fb108-62b4-445a-a7c1-211ac5a60210_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized (loss) gain on derivatives, net of reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_9c158cd6-0edd-4b63-807f-edc180a55672_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_37314f34-fc23-4465-b8b7-485811046f02_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_4087af17-e649-4343-88bf-f14c96b826e2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared on common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_4b99e9e8-61d0-43c9-973c-8368f1b6bf00_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Benefit Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_97cd09e7-5e57-4dc9-9f80-2ac30b5d23ad_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_c7f57052-20fe-4e05-98b4-ce04ee0eed32_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PrevymisMember_011fb3cf-0320-4030-9183-17658525d017_terseLabel_en-US" xlink:label="lab_mrk_PrevymisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevymis</link:label>
    <link:label id="lab_mrk_PrevymisMember_label_en-US" xlink:label="lab_mrk_PrevymisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevymis [Member]</link:label>
    <link:label id="lab_mrk_PrevymisMember_documentation_en-US" xlink:label="lab_mrk_PrevymisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prevymis [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrevymisMember" xlink:href="mrk-20230331.xsd#mrk_PrevymisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PrevymisMember" xlink:to="lab_mrk_PrevymisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_VerquvoMember_72737f6c-4c0e-4764-970a-738cf9cff4e9_terseLabel_en-US" xlink:label="lab_mrk_VerquvoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verquvo</link:label>
    <link:label id="lab_mrk_VerquvoMember_label_en-US" xlink:label="lab_mrk_VerquvoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verquvo [Member]</link:label>
    <link:label id="lab_mrk_VerquvoMember_documentation_en-US" xlink:label="lab_mrk_VerquvoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verquvo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VerquvoMember" xlink:href="mrk-20230331.xsd#mrk_VerquvoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_VerquvoMember" xlink:to="lab_mrk_VerquvoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments_4eed53de-0fc7-49bc-86c2-06eac85c3acb_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales milestone payments</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments" xlink:to="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_9aaf5bcc-64d2-4704-99fb-7910bb85f8cf_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_A2.500Notesdue2034Member_24bec149-9762-4fc5-a06c-ec9e1fbcb5ca_terseLabel_en-US" xlink:label="lab_mrk_A2.500Notesdue2034Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.500% Notes due 2034</link:label>
    <link:label id="lab_mrk_A2.500Notesdue2034Member_label_en-US" xlink:label="lab_mrk_A2.500Notesdue2034Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.500% Notes due 2034 [Member]</link:label>
    <link:label id="lab_mrk_A2.500Notesdue2034Member_documentation_en-US" xlink:label="lab_mrk_A2.500Notesdue2034Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.500% Notes due 2034 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.500Notesdue2034Member" xlink:href="mrk-20230331.xsd#mrk_A2.500Notesdue2034Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_A2.500Notesdue2034Member" xlink:to="lab_mrk_A2.500Notesdue2034Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c109b2a6-2a56-4276-a577-428522df7411_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_306032d7-33d6-4cb8-bb10-466a2ddef163_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of securities and other investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_49b45b5f-3030-46df-8021-80d79ed4f60e_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_5a1685cc-6f9c-4775-82d5-484747361d19_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_MilestonePaymentsSalesBased_32c8ec01-9a12-43f4-bd7c-9e3ea9eb81e7_terseLabel_en-US" xlink:label="lab_mrk_MilestonePaymentsSalesBased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based milestone payments</link:label>
    <link:label id="lab_mrk_MilestonePaymentsSalesBased_label_en-US" xlink:label="lab_mrk_MilestonePaymentsSalesBased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Sales-Based</link:label>
    <link:label id="lab_mrk_MilestonePaymentsSalesBased_documentation_en-US" xlink:label="lab_mrk_MilestonePaymentsSalesBased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Sales-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsSalesBased" xlink:href="mrk-20230331.xsd#mrk_MilestonePaymentsSalesBased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_MilestonePaymentsSalesBased" xlink:to="lab_mrk_MilestonePaymentsSalesBased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected_9b2c769e-fafa-48d3-bf27-4bb0da0da063_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, price of acquisition, expected</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Price of Acquisition, Expected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionPriceOfAcquisitionExpected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xlink:to="lab_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_ab1b974a-e574-4473-9ace-c39e9de84d58_terseLabel_en-US" xlink:label="lab_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Assets Acquired And Liabilities Assumed, Net</link:label>
    <link:label id="lab_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_documentation_en-US" xlink:label="lab_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Assets Acquired And Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="mrk-20230331.xsd#mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_881312a6-c056-44a2-97f7-f6ee9462a4fc_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_4ed3456f-5c36-41d1-bc1c-b20955b5a60f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_cd14ac3a-1fcd-4c57-b826-193172ab67f6_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_87a807bd-29ad-444b-9b52-1a9ea92180a9_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_9d4ae9af-e0b0-4d3b-a0ff-b949b5a497f2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain recognized in Other (income) expense, net on derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e684d79a-0ab6-49b7-bc29-49122639cec5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_f14ab881-e2a0-4132-8717-daed8cf12c5e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a4de0e14-dc4f-4e71-a884-482008fe4943_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6813f542-8e25-4b1f-be6a-f2bb15fa7e36_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_46901b2e-0ad5-4fc3-b58e-bfc6f24b6f72_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory milestones payments</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:to="lab_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_d0a24836-117f-4eb4-b5b1-f8461fbd4a63_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative unrealized gains on investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_c1f1804f-6a85-47bd-b8da-c0fd283b5008_terseLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassification adjustments, pretax</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, before Reclassifications, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EurodominatedNotesMember_e7a1dbe0-b76d-46b4-a0ba-e3e5a2ea0f52_terseLabel_en-US" xlink:label="lab_mrk_EurodominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro-denominated notes</link:label>
    <link:label id="lab_mrk_EurodominatedNotesMember_label_en-US" xlink:label="lab_mrk_EurodominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro-dominated Notes [Member]</link:label>
    <link:label id="lab_mrk_EurodominatedNotesMember_documentation_en-US" xlink:label="lab_mrk_EurodominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro-dominated Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EurodominatedNotesMember" xlink:href="mrk-20230331.xsd#mrk_EurodominatedNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EurodominatedNotesMember" xlink:to="lab_mrk_EurodominatedNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_8593236e-c17a-4152-b776-2e9698758d80_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories (excludes inventories of $3,284 in 2023 and $2,938 in 2022 classified in Other assets - see Note&#160;7)</link:label>
    <link:label id="lab_us-gaap_InventoryNet_b60b74ea-8da4-4212-a065-66420d687d5f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_75a25f05-a2bc-4a25-a6da-07c4112d8b5b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_24193464-dbb4-4797-b90f-cd778d5bab1a_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_cc82c762-b14a-41f0-8662-0d9540e9dbe8_negatedLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_e71e7a01-9a86-441e-a2f6-fba735d8c796_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of continuing involvement after disposal</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Period of Continuing Involvement after Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" xlink:to="lab_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RoyaltyRateDeductionPercentage_8985d338-0d44-47b4-be33-3fb34aa87d4a_terseLabel_en-US" xlink:label="lab_mrk_RoyaltyRateDeductionPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty rate, deduction</link:label>
    <link:label id="lab_mrk_RoyaltyRateDeductionPercentage_label_en-US" xlink:label="lab_mrk_RoyaltyRateDeductionPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate, Deduction, Percentage</link:label>
    <link:label id="lab_mrk_RoyaltyRateDeductionPercentage_documentation_en-US" xlink:label="lab_mrk_RoyaltyRateDeductionPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Rate, Deduction, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRateDeductionPercentage" xlink:href="mrk-20230331.xsd#mrk_RoyaltyRateDeductionPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RoyaltyRateDeductionPercentage" xlink:to="lab_mrk_RoyaltyRateDeductionPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_f334cf62-4a1e-46bf-9f59-2dc8585ff655_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_26f06d17-2fca-4156-b8d5-68d39e42a748_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_155f0b02-8265-49d6-a314-e4315693dead_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_BridionMember_67b2c1dd-1024-44e0-9595-d16373e7859e_terseLabel_en-US" xlink:label="lab_mrk_BridionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridion</link:label>
    <link:label id="lab_mrk_BridionMember_label_en-US" xlink:label="lab_mrk_BridionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridion [Member]</link:label>
    <link:label id="lab_mrk_BridionMember_documentation_en-US" xlink:label="lab_mrk_BridionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridion [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember" xlink:href="mrk-20230331.xsd#mrk_BridionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_BridionMember" xlink:to="lab_mrk_BridionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_8d22ac43-f770-4190-a4f0-3bb00241b5cd_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_b76102f9-f476-411b-8317-5077ab788b99_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f02358c8-4a72-4e29-95dc-04ecd62191a6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_8f642983-5feb-45ba-b513-731c6ee92cc6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_2f85b219-b66c-420b-bb98-123d3fff773a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred, asset acquisition</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_EisaiMember_659054b4-133e-4337-a169-a3a1ab4472e0_terseLabel_en-US" xlink:label="lab_mrk_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_mrk_EisaiMember_label_en-US" xlink:label="lab_mrk_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_mrk_EisaiMember_documentation_en-US" xlink:label="lab_mrk_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember" xlink:href="mrk-20230331.xsd#mrk_EisaiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_EisaiMember" xlink:to="lab_mrk_EisaiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_WeliregMember_6613f3d6-904e-40e2-8511-748c4da5edd6_terseLabel_en-US" xlink:label="lab_mrk_WeliregMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Welireg</link:label>
    <link:label id="lab_mrk_WeliregMember_label_en-US" xlink:label="lab_mrk_WeliregMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Welireg [Member]</link:label>
    <link:label id="lab_mrk_WeliregMember_documentation_en-US" xlink:label="lab_mrk_WeliregMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Welireg</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_WeliregMember" xlink:href="mrk-20230331.xsd#mrk_WeliregMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_WeliregMember" xlink:to="lab_mrk_WeliregMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_e909d8b7-a6bc-481b-a7c5-125f2ebb40d0_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_72955d5f-bb1a-497f-bf0c-2962afc06c02_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amounts, liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InternationalMember_beb47ae9-bb91-4313-a539-17b7fb8127bb_terseLabel_en-US" xlink:label="lab_mrk_InternationalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Int&#8217;l</link:label>
    <link:label id="lab_mrk_InternationalMember_label_en-US" xlink:label="lab_mrk_InternationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International [Member]</link:label>
    <link:label id="lab_mrk_InternationalMember_documentation_en-US" xlink:label="lab_mrk_InternationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InternationalMember" xlink:href="mrk-20230331.xsd#mrk_InternationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InternationalMember" xlink:to="lab_mrk_InternationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_0b969b1a-1a58-4e25-9efa-9dc8c34941fc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total swap notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_56db629c-1840-43b7-8782-31baeb64c96f_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S Dollar Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_70599cf2-e732-4bfd-b9e4-c0b71804bbc8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in Sales as a result of AOCL reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_991b4066-f0ae-468e-b148-6573a448bdfb_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_56d05d6d-a1c8-419b-8343-ac8cd730ca71_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_ec316f6c-7cab-409b-bf06-20e7d309fe7f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityBeforeTreasuryStock_a618c330-e717-42e8-ba4f-5131cbb8126a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity before deduction for treasury stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityBeforeTreasuryStock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity before Treasury Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:to="lab_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent_c03f8577-bfed-4da4-889c-4d77e1bb49b7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_fa887e98-7775-4e48-892b-e8e0cc6b3f8d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_c28df925-9e35-44e1-8289-82c0f5396cc9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans payable and current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_a0087c71-75dc-49d3-be91-22fb103f6329_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_e69988c9-4e4c-4a75-a5e2-778e4d294c30_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_b1e9d0db-7745-411d-a0e5-79ecb9fcb4c8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PharmaceuticalsegmentMember_2835cc7f-0425-4db3-9d40-e81ac173e0d2_terseLabel_en-US" xlink:label="lab_mrk_PharmaceuticalsegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical</link:label>
    <link:label id="lab_mrk_PharmaceuticalsegmentMember_6803612c-2398-452b-bb0b-a61b8af205b3_verboseLabel_en-US" xlink:label="lab_mrk_PharmaceuticalsegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical segment</link:label>
    <link:label id="lab_mrk_PharmaceuticalsegmentMember_label_en-US" xlink:label="lab_mrk_PharmaceuticalsegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical segment [Member]</link:label>
    <link:label id="lab_mrk_PharmaceuticalsegmentMember_documentation_en-US" xlink:label="lab_mrk_PharmaceuticalsegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember" xlink:href="mrk-20230331.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PharmaceuticalsegmentMember" xlink:to="lab_mrk_PharmaceuticalsegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_8bf8a1a0-0477-404a-9608-92bcfbe04b6c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_c6a43188-cad3-4d8e-bbe7-e926cca2ddcd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember_0032c470-d7c1-47e3-b51b-c42a8cea0400_terseLabel_en-US" xlink:label="lab_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember_label_en-US" xlink:label="lab_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes And Other Assets, Noncurrent [Member]</link:label>
    <link:label id="lab_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember_documentation_en-US" xlink:label="lab_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes And Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember" xlink:href="mrk-20230331.xsd#mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember" xlink:to="lab_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_3d832140-3979-4a13-9643-7b7a5625cfc6_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_537dc263-cbc8-4506-adb0-ebb96711af30_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- controlling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_c4578f0e-c88b-408c-9de0-9d0e9b0e7047_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_5dee292c-e333-4698-b79f-bc950d8448f7_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total pretax restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_0f95b15f-f394-46a2-bfd6-ca620e62adb5_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_afcf979c-fc3a-45e6-b7cc-152b7d57b392_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RotaTeqAntitrustLitigationMember_73a79ac2-76e3-44a7-9ed2-f4f29d74f2f5_terseLabel_en-US" xlink:label="lab_mrk_RotaTeqAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RotaTeq Antitrust Litigation</link:label>
    <link:label id="lab_mrk_RotaTeqAntitrustLitigationMember_label_en-US" xlink:label="lab_mrk_RotaTeqAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RotaTeq Antitrust Litigation [Member]</link:label>
    <link:label id="lab_mrk_RotaTeqAntitrustLitigationMember_documentation_en-US" xlink:label="lab_mrk_RotaTeqAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RotaTeq Antitrust Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RotaTeqAntitrustLitigationMember" xlink:href="mrk-20230331.xsd#mrk_RotaTeqAntitrustLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RotaTeqAntitrustLitigationMember" xlink:to="lab_mrk_RotaTeqAntitrustLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_1c9f6258-0f14-484b-8fe5-d7545d39cc93_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (gain) loss amortization</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_c1407aa8-25dd-44ac-a15d-a442d273faf5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_VaxneuvanceMember_ae11b0ec-d647-4e01-801b-0c02d2918c67_terseLabel_en-US" xlink:label="lab_mrk_VaxneuvanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaxneuvance</link:label>
    <link:label id="lab_mrk_VaxneuvanceMember_label_en-US" xlink:label="lab_mrk_VaxneuvanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaxneuvance [Member]</link:label>
    <link:label id="lab_mrk_VaxneuvanceMember_documentation_en-US" xlink:label="lab_mrk_VaxneuvanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vaxneuvance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VaxneuvanceMember" xlink:href="mrk-20230331.xsd#mrk_VaxneuvanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_VaxneuvanceMember" xlink:to="lab_mrk_VaxneuvanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_0b48b4cf-9765-433c-a0a7-b3e03f48c68f_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_44ad21dc-785e-4168-a198-71fedc984f5d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged items</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_015947d7-4567-42b1-bb84-68fdd2036050_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_a685d088-905e-45c0-89d5-2b0fa29661cc_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_ce3b1398-3a71-41bd-80a5-423db98d4dc9_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_4c1e24a8-862b-4bef-bdf4-b7fc46b1f0d7_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_28c66aac-7b5d-475d-93f1-50b6cf602530_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember_0157a2c9-b44c-437d-a5c1-8ee063014e15_terseLabel_en-US" xlink:label="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories Produced in Preparation for Product Launches</link:label>
    <link:label id="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember_label_en-US" xlink:label="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories Produced in Preparation for Product Launches [Member]</link:label>
    <link:label id="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember_documentation_en-US" xlink:label="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories Produced in Preparation for Product Launches [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:href="mrk-20230331.xsd#mrk_InventoriesProducedinPreparationforProductLaunchesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:to="lab_mrk_InventoriesProducedinPreparationforProductLaunchesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_10772c1b-7cd6-470f-8e2b-0c4eb4925b81_verboseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_92167ef4-08f0-4e00-89b6-4789381f1070_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_7af5ad1e-0c8e-46be-b6fa-93c3e06e3952_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_56d855df-fd2e-46c6-9138-54f193b698e1_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Segment Profits to Income before Taxes</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_35ce76b6-5a5e-4201-a564-f7b7c25cc383_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_259f3cfa-7719-4703-9e17-ccf18035754f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Merck &amp; Co., Inc., diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_1549545c-88dd-4b18-8b63-ae785d66c5ea_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangibles, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_38c8b273-d785-4a83-8acd-b4f66b26d221_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_c0ef0256-a46b-4e22-bcfb-41d911666de8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_GardasilGardasil9Member_b03ac168-7103-48bd-acfd-8e918006fec8_terseLabel_en-US" xlink:label="lab_mrk_GardasilGardasil9Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gardasil/Gardasil 9</link:label>
    <link:label id="lab_mrk_GardasilGardasil9Member_label_en-US" xlink:label="lab_mrk_GardasilGardasil9Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gardasil/Gardasil 9 [Member]</link:label>
    <link:label id="lab_mrk_GardasilGardasil9Member_documentation_en-US" xlink:label="lab_mrk_GardasilGardasil9Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gardasil/Gardasil 9 [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member" xlink:href="mrk-20230331.xsd#mrk_GardasilGardasil9Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_GardasilGardasil9Member" xlink:to="lab_mrk_GardasilGardasil9Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_2fd0dcfd-b156-43a4-b2e4-58a64076870f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:to="lab_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_2ad03a8b-5a96-4146-a857-474076f0c5f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_218eca97-6eed-4bae-8450-cddca9404cf1_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_8da768ab-6ff5-4c55-bd57-e506ec6d558c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains recognized on investments in equity securities without readily determinable fair value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_cb8ba4b2-6ad2-4a6f-8171-dba6c9e450ff_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_a667869a-f976-48e0-9115-436f71991c59_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables included in Accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_1ed29c4f-cf51-431e-899b-63087a58f154_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_PrometheusBiosciencesIncMember_00819e77-0487-4f39-90e4-97f094b60979_terseLabel_en-US" xlink:label="lab_mrk_PrometheusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prometheus Biosciences, Inc.</link:label>
    <link:label id="lab_mrk_PrometheusBiosciencesIncMember_label_en-US" xlink:label="lab_mrk_PrometheusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prometheus Biosciences, Inc. [Member]</link:label>
    <link:label id="lab_mrk_PrometheusBiosciencesIncMember_documentation_en-US" xlink:label="lab_mrk_PrometheusBiosciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prometheus Biosciences, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrometheusBiosciencesIncMember" xlink:href="mrk-20230331.xsd#mrk_PrometheusBiosciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_PrometheusBiosciencesIncMember" xlink:to="lab_mrk_PrometheusBiosciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_RemicadeMember_43065503-7e16-450f-92f3-5eff1246eeef_terseLabel_en-US" xlink:label="lab_mrk_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade</link:label>
    <link:label id="lab_mrk_RemicadeMember_label_en-US" xlink:label="lab_mrk_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member]</link:label>
    <link:label id="lab_mrk_RemicadeMember_documentation_en-US" xlink:label="lab_mrk_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RemicadeMember" xlink:href="mrk-20230331.xsd#mrk_RemicadeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_RemicadeMember" xlink:to="lab_mrk_RemicadeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_StockholdersEquityTable_77339372-2f5b-425a-9f61-c0cdadbc238d_terseLabel_en-US" xlink:label="lab_mrk_StockholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity [Table]</link:label>
    <link:label id="lab_mrk_StockholdersEquityTable_label_en-US" xlink:label="lab_mrk_StockholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity [Table]</link:label>
    <link:label id="lab_mrk_StockholdersEquityTable_documentation_en-US" xlink:label="lab_mrk_StockholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders Equity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_StockholdersEquityTable" xlink:href="mrk-20230331.xsd#mrk_StockholdersEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_StockholdersEquityTable" xlink:to="lab_mrk_StockholdersEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_d5aa3efe-400c-43fd-91a7-621318c4b4d5_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Publicly traded equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_15d6dfb2-e3c2-4b47-8689-53d6e4bda067_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_62b6a0bd-7a32-4d9c-a3b9-3e0937753030_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spin-Off of Organon &amp; Co.</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_JanumetMember_00834560-2835-4c34-8684-1bbb39fee760_terseLabel_en-US" xlink:label="lab_mrk_JanumetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janumet</link:label>
    <link:label id="lab_mrk_JanumetMember_label_en-US" xlink:label="lab_mrk_JanumetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janumet [Member]</link:label>
    <link:label id="lab_mrk_JanumetMember_documentation_en-US" xlink:label="lab_mrk_JanumetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janumet [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanumetMember" xlink:href="mrk-20230331.xsd#mrk_JanumetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_JanumetMember" xlink:to="lab_mrk_JanumetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_1cb63f30-19c6-43a6-991c-b02213f37dad_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate notes and bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ece45451-003f-43b1-8f09-3f9a89f22a66_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_e8cc02a0-a327-4850-87d0-b06843cd064c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized net (gains) losses</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_457b7d45-77a8-4bd6-81aa-4794dfd7c44e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_8064eaf4-9e88-47c6-803e-4b31e0598737_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_d95c9225-7b80-481f-bbee-f7193ed2173c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign government bonds</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b080a8da-00e9-4848-981d-751c1fb7a956_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_c3422e69-6902-46eb-841c-8deb9083042a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_ZerbaxaMember_dad9f034-f300-4d07-b538-c268e8918ac8_terseLabel_en-US" xlink:label="lab_mrk_ZerbaxaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zerbaxa</link:label>
    <link:label id="lab_mrk_ZerbaxaMember_label_en-US" xlink:label="lab_mrk_ZerbaxaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zerbaxa [Member]</link:label>
    <link:label id="lab_mrk_ZerbaxaMember_documentation_en-US" xlink:label="lab_mrk_ZerbaxaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zerbaxa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZerbaxaMember" xlink:href="mrk-20230331.xsd#mrk_ZerbaxaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_ZerbaxaMember" xlink:to="lab_mrk_ZerbaxaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_d93c2cd4-9ec8-4c56-b8be-87a45e214e45_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_DificidMember_7208906c-8ba3-464f-a90e-3a37b6966533_terseLabel_en-US" xlink:label="lab_mrk_DificidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dificid</link:label>
    <link:label id="lab_mrk_DificidMember_label_en-US" xlink:label="lab_mrk_DificidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dificid [Member]</link:label>
    <link:label id="lab_mrk_DificidMember_documentation_en-US" xlink:label="lab_mrk_DificidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dificid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DificidMember" xlink:href="mrk-20230331.xsd#mrk_DificidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_DificidMember" xlink:to="lab_mrk_DificidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_f6aadcfa-56cd-4136-ac6a-5897d24c0165_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_4a6edb52-5527-4d60-a857-f1883dca5550_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_e667985d-b1ac-412d-a10f-47858bd66132_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_598394da-9aba-45b0-b77c-7093c3250af1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral received from counterparties</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_43cf7213-46f4-46af-a90c-4fe8c85fe9f5_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash collateral received, asset</link:label>
    <link:label id="lab_us-gaap_DerivativeCollateralObligationToReturnCash_label_en-US" xlink:label="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:to="lab_us-gaap_DerivativeCollateralObligationToReturnCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_2b97a18e-09c8-4282-be78-ef372d1ddce3_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_db80a3d9-fa14-46c6-8696-122bbaba01b5_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4169e18b-727c-4442-89df-3a2a4d2e01c0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_61e76cef-3f96-494b-aa3e-136c1c520b29_negatedLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pretax net unrealized losses on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_8a408f2c-60cc-4745-88f5-eb8f91f895ce_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_718e242e-d6ca-4b8e-9f6f-c02466314c2f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories classified in Other assets</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_bc0c2051-3b23-4956-9c14-4fe3aeac337d_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_IncreaseDecreaseInHedgeRevenue_8b7c72fa-3297-46ce-884e-d3bc07831338_terseLabel_en-US" xlink:label="lab_mrk_IncreaseDecreaseInHedgeRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Hedge Revenue</link:label>
    <link:label id="lab_mrk_IncreaseDecreaseInHedgeRevenue_label_en-US" xlink:label="lab_mrk_IncreaseDecreaseInHedgeRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Hedge Revenue</link:label>
    <link:label id="lab_mrk_IncreaseDecreaseInHedgeRevenue_documentation_en-US" xlink:label="lab_mrk_IncreaseDecreaseInHedgeRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Hedge Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncreaseDecreaseInHedgeRevenue" xlink:href="mrk-20230331.xsd#mrk_IncreaseDecreaseInHedgeRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_IncreaseDecreaseInHedgeRevenue" xlink:to="lab_mrk_IncreaseDecreaseInHedgeRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_21b6d2ca-fbff-4af9-8ce1-127a5bb3328e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_0a213d4c-812d-4f35-9aac-2a18b399efc6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AcceleratedDepreciationMember_54da9afe-fe0d-4206-8df8-5fb9ed7e803c_terseLabel_en-US" xlink:label="lab_mrk_AcceleratedDepreciationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Depreciation</link:label>
    <link:label id="lab_mrk_AcceleratedDepreciationMember_label_en-US" xlink:label="lab_mrk_AcceleratedDepreciationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Depreciation [Member]</link:label>
    <link:label id="lab_mrk_AcceleratedDepreciationMember_documentation_en-US" xlink:label="lab_mrk_AcceleratedDepreciationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Depreciation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember" xlink:href="mrk-20230331.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AcceleratedDepreciationMember" xlink:to="lab_mrk_AcceleratedDepreciationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AdempasMember_48c8bd55-4276-4fac-8903-5fddc72e9216_terseLabel_en-US" xlink:label="lab_mrk_AdempasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adempas</link:label>
    <link:label id="lab_mrk_AdempasMember_label_en-US" xlink:label="lab_mrk_AdempasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adempas [Member]</link:label>
    <link:label id="lab_mrk_AdempasMember_documentation_en-US" xlink:label="lab_mrk_AdempasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adempas</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember" xlink:href="mrk-20230331.xsd#mrk_AdempasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AdempasMember" xlink:to="lab_mrk_AdempasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_f3f95811-60c2-4ede-bf15-e3587969ebe6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_23ce2141-1ad6-4943-afa2-4f86fbda5f72_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLIFOReserve_caabcdb8-1125-46bd-b8d5-8a3a035bbaca_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryLIFOReserve" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease to LIFO cost</link:label>
    <link:label id="lab_us-gaap_InventoryLIFOReserve_label_en-US" xlink:label="lab_us-gaap_InventoryLIFOReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, LIFO Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLIFOReserve" xlink:to="lab_us-gaap_InventoryLIFOReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_3843bed6-862e-49c3-afc4-4847f767dbd1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_b67ce1db-02b7-4426-b1c6-5aa9ab402a62_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_AlliancerevenueLynparzaMember_64c63941-162c-4c5f-99bd-b9c5ce8b025f_terseLabel_en-US" xlink:label="lab_mrk_AlliancerevenueLynparzaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Lynparza</link:label>
    <link:label id="lab_mrk_AlliancerevenueLynparzaMember_label_en-US" xlink:label="lab_mrk_AlliancerevenueLynparzaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Lynparza [Member]</link:label>
    <link:label id="lab_mrk_AlliancerevenueLynparzaMember_documentation_en-US" xlink:label="lab_mrk_AlliancerevenueLynparzaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alliance revenue - Lynparza [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember" xlink:href="mrk-20230331.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_AlliancerevenueLynparzaMember" xlink:to="lab_mrk_AlliancerevenueLynparzaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_LivestockMember_8699f699-7647-4b1f-9a06-4847929dd180_terseLabel_en-US" xlink:label="lab_mrk_LivestockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Livestock</link:label>
    <link:label id="lab_mrk_LivestockMember_label_en-US" xlink:label="lab_mrk_LivestockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Livestock [Member]</link:label>
    <link:label id="lab_mrk_LivestockMember_documentation_en-US" xlink:label="lab_mrk_LivestockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Livestock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LivestockMember" xlink:href="mrk-20230331.xsd#mrk_LivestockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_LivestockMember" xlink:to="lab_mrk_LivestockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_0012b3f3-9a3e-4bbc-baf8-e44330a82ce6_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet_5052207a-6993-4d2d-95ef-b5cc95102290_negatedLabel_en-US" xlink:label="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other unallocated, net</link:label>
    <link:label id="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet_label_en-US" xlink:label="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Unallocated Other Expenses Net</link:label>
    <link:label id="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet_documentation_en-US" xlink:label="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other net expenses not allocated to segments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:href="mrk-20230331.xsd#mrk_SegmentReportingUnallocatedOtherExpensesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:to="lab_mrk_SegmentReportingUnallocatedOtherExpensesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_3e32d04c-3801-48ec-89d8-18bc6e6df8e7_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_3efc0b2a-47b9-4af7-89ae-7160c28d9a27_terseLabel_en-US" xlink:label="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories Not Expected to be Sold Within One Year</link:label>
    <link:label id="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_label_en-US" xlink:label="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Not Expected to be Sold Within One Year [Member]</link:label>
    <link:label id="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_documentation_en-US" xlink:label="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Not Expected to be Sold Within One Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:href="mrk-20230331.xsd#mrk_InventoryNotExpectedtobeSoldWithinOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:to="lab_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeFutureMember_038fa2f8-fe9f-49a0-8ef9-d827db00cd45_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeFutureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Future</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeFutureMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeFutureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Future [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeFutureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeFutureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeFutureMember" xlink:to="lab_us-gaap_ForeignExchangeFutureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e7508742-e6d6-43fc-bc11-63d81acc8051_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrencySwapMember_b054ef54-7e69-4d8a-99f6-2d9651be1d79_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_label_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencySwapMember" xlink:to="lab_us-gaap_CurrencySwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_484401bb-5966-4eaf-a262-6929ebd151e9_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_0ff6fb7d-5538-4da6-bab5-505dfa81f996_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges and Spending Relating to Restructuring Activities by Program</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_24979489-c906-4c37-b6fc-073dc47b8e5b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issuable (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_3fe7ee15-e928-4100-9af0-8046278df066_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges Related to Restructuring Program Activities by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_28522bf7-06ee-4136-9f44-4ae5b0e6208b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, measurement input, discount rate</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_364fc605-d279-4a16-bde6-dde792fe40ba_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_de353e39-8dbc-47ba-960a-0606f5da993d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_8e43ba64-a5c3-4775-8c35-b862ff710007_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_2fdbdddb-cef8-47f0-bb39-eceb9c26e822_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_99c0fc19-8f58-4a58-a61f-3d14091d121c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LatinAmericaMember_09dfb764-7fe0-4d33-a0f7-c1f131971711_terseLabel_en-US" xlink:label="lab_srt_LatinAmericaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latin America</link:label>
    <link:label id="lab_srt_LatinAmericaMember_label_en-US" xlink:label="lab_srt_LatinAmericaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Latin America [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LatinAmericaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LatinAmericaMember" xlink:to="lab_srt_LatinAmericaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_8b8d535e-288d-48d6-bdee-57489d49a69b_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OneTimeTerminationBenefitsMember_fa18abaa-f8c8-4b06-a25c-c63f3e2d6a9a_terseLabel_en-US" xlink:label="lab_us-gaap_OneTimeTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation Costs</link:label>
    <link:label id="lab_us-gaap_OneTimeTerminationBenefitsMember_label_en-US" xlink:label="lab_us-gaap_OneTimeTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time Termination Benefits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OneTimeTerminationBenefitsMember" xlink:to="lab_us-gaap_OneTimeTerminationBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserve_3e7e5edc-b560-48f8-b8da-8145591ca364_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal defense costs reserve</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_label_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve" xlink:to="lab_us-gaap_LitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_abb99f12-517a-4b10-af03-6f45036a1f14_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_d6f23af0-4161-4145-9cdf-c79adb513f30_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_404ed176-383e-4790-a33f-954709d434a6_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CompanionAnimalsMember_e670a3ad-a8d9-4947-aad2-f626d0bdfb2c_terseLabel_en-US" xlink:label="lab_mrk_CompanionAnimalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Companion Animals</link:label>
    <link:label id="lab_mrk_CompanionAnimalsMember_label_en-US" xlink:label="lab_mrk_CompanionAnimalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Companion Animals [Member]</link:label>
    <link:label id="lab_mrk_CompanionAnimalsMember_documentation_en-US" xlink:label="lab_mrk_CompanionAnimalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Companion Animals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CompanionAnimalsMember" xlink:href="mrk-20230331.xsd#mrk_CompanionAnimalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CompanionAnimalsMember" xlink:to="lab_mrk_CompanionAnimalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_68dcaa62-9ad4-445b-8d43-d1c716364d97_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties, current</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0944150c-daea-41f7-ae5d-c5a47edbcfd8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_1253bd16-f775-4788-bd26-acd8cbbaa184_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_e15cbf79-35fe-44cc-b90b-72df4ce71ab5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateContractMember_5e5ed970-29bf-4391-8e9f-2d8f7e7500fc_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember" xlink:to="lab_us-gaap_InterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_fbe20c58-03a2-4fc6-bdcb-118c5a280116_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_09cf539c-7465-441a-b2a1-d0955ca97789_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators" xlink:to="lab_us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_dfd95658-fee9-4215-9300-7da3c57c6dfd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Calculations of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_OrganonCoMember_2e5093ab-4bdc-4f11-9736-57f32ec8dd9a_terseLabel_en-US" xlink:label="lab_mrk_OrganonCoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organon &amp; Co.</link:label>
    <link:label id="lab_mrk_OrganonCoMember_label_en-US" xlink:label="lab_mrk_OrganonCoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organon &amp; Co. [Member]</link:label>
    <link:label id="lab_mrk_OrganonCoMember_documentation_en-US" xlink:label="lab_mrk_OrganonCoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organon &amp; Co.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrganonCoMember" xlink:href="mrk-20230331.xsd#mrk_OrganonCoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_OrganonCoMember" xlink:to="lab_mrk_OrganonCoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_91b06573-5c5b-436a-9ddb-dc2a59e33db0_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_b94e7fc7-9e94-424b-b4bb-840f2410af97_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mrk_CollaborativeArrangementSalesNet_86c3d695-5649-41d0-8344-81ef4593cfd3_terseLabel_en-US" xlink:label="lab_mrk_CollaborativeArrangementSalesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net sales by Merck</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementSalesNet_label_en-US" xlink:label="lab_mrk_CollaborativeArrangementSalesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Sales, Net</link:label>
    <link:label id="lab_mrk_CollaborativeArrangementSalesNet_documentation_en-US" xlink:label="lab_mrk_CollaborativeArrangementSalesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Sales, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementSalesNet" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementSalesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mrk_CollaborativeArrangementSalesNet" xlink:to="lab_mrk_CollaborativeArrangementSalesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_f222ad82-de04-45ee-8b5b-aecd4ae8a06c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefit Plans</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_589f72a6-cb08-454c-b328-da0ab6faf6f2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net Income (Loss) Attributable to Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>mrk-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:f17f1926-1a01-4baa-a406-054ce45079f2,g:c6b1c5ce-74aa-44b6-956b-90e243d128be-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.merck.com/role/CoverPage" xlink:type="simple" xlink:href="mrk-20230331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_9952c392-d74f-4949-98dc-52e12e3a8290" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_56b36af4-91da-49bc-be07-454c9f83473b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9952c392-d74f-4949-98dc-52e12e3a8290" xlink:to="loc_dei_EntitiesTable_56b36af4-91da-49bc-be07-454c9f83473b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_15b39e48-66d0-44e7-b1fc-ddddc98b1fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_56b36af4-91da-49bc-be07-454c9f83473b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_15b39e48-66d0-44e7-b1fc-ddddc98b1fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_31180b7a-9485-40f3-815a-5ae3d8db526d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_15b39e48-66d0-44e7-b1fc-ddddc98b1fe8" xlink:to="loc_us-gaap_ClassOfStockDomain_31180b7a-9485-40f3-815a-5ae3d8db526d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5950f7e1-3d06-48ac-9c23-2679b5e76e55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_31180b7a-9485-40f3-815a-5ae3d8db526d" xlink:to="loc_us-gaap_CommonStockMember_5950f7e1-3d06-48ac-9c23-2679b5e76e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A0.500Notesdue2024Member_9c84fd4f-8e9c-4562-a468-9611996e1d43" xlink:href="mrk-20230331.xsd#mrk_A0.500Notesdue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_31180b7a-9485-40f3-815a-5ae3d8db526d" xlink:to="loc_mrk_A0.500Notesdue2024Member_9c84fd4f-8e9c-4562-a468-9611996e1d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.875Notesdue2026Member_f55198b1-0098-4848-9ab6-c6cd43ed02a9" xlink:href="mrk-20230331.xsd#mrk_A1.875Notesdue2026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_31180b7a-9485-40f3-815a-5ae3d8db526d" xlink:to="loc_mrk_A1.875Notesdue2026Member_f55198b1-0098-4848-9ab6-c6cd43ed02a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A2.500Notesdue2034Member_98e9dfd2-5da8-45cb-8267-3bda5d194e2d" xlink:href="mrk-20230331.xsd#mrk_A2.500Notesdue2034Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_31180b7a-9485-40f3-815a-5ae3d8db526d" xlink:to="loc_mrk_A2.500Notesdue2034Member_98e9dfd2-5da8-45cb-8267-3bda5d194e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_A1.375Notesdue2036Member_5111eba8-b12e-4191-96ee-1f4ad3ae5dce" xlink:href="mrk-20230331.xsd#mrk_A1.375Notesdue2036Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_31180b7a-9485-40f3-815a-5ae3d8db526d" xlink:to="loc_mrk_A1.375Notesdue2036Member_5111eba8-b12e-4191-96ee-1f4ad3ae5dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_56b36af4-91da-49bc-be07-454c9f83473b" xlink:to="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_7aa65ef5-25ff-4af6-80fa-e1b7a712d4a4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_DocumentType_7aa65ef5-25ff-4af6-80fa-e1b7a712d4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_92e08b77-a7bb-48cd-bf65-4cc0cad0c1fd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_DocumentQuarterlyReport_92e08b77-a7bb-48cd-bf65-4cc0cad0c1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3a75ec54-ed45-4004-9afb-4b2dc5b020be" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_DocumentPeriodEndDate_3a75ec54-ed45-4004-9afb-4b2dc5b020be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4ba45462-de14-425c-a16e-43e3025db647" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_DocumentTransitionReport_4ba45462-de14-425c-a16e-43e3025db647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d7d74ade-1666-479a-8185-6385a17b9205" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityFileNumber_d7d74ade-1666-479a-8185-6385a17b9205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2533cf0b-84d4-4a21-baae-81b03897f89e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityRegistrantName_2533cf0b-84d4-4a21-baae-81b03897f89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_9bf29a06-b981-4d71-b654-53d86c51edde" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_9bf29a06-b981-4d71-b654-53d86c51edde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6cabebb1-d64d-45da-861c-cdb198cbbe28" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityTaxIdentificationNumber_6cabebb1-d64d-45da-861c-cdb198cbbe28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_958e2ce8-b5b1-49a3-90bd-c5417e5ed367" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityAddressAddressLine1_958e2ce8-b5b1-49a3-90bd-c5417e5ed367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_eaa36e45-8755-48f0-a726-7a160c382470" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityAddressCityOrTown_eaa36e45-8755-48f0-a726-7a160c382470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0d7a4a13-ec9f-4b8a-8948-3bda83e1ae4b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityAddressStateOrProvince_0d7a4a13-ec9f-4b8a-8948-3bda83e1ae4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_2853ad2b-5b8f-4955-a82a-4db090a9877d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityAddressPostalZipCode_2853ad2b-5b8f-4955-a82a-4db090a9877d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ec6977ce-8684-4e31-b956-ae7efb5a6bfe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_CityAreaCode_ec6977ce-8684-4e31-b956-ae7efb5a6bfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_e4b10b07-1d98-4294-ace1-948e3ca45b82" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_LocalPhoneNumber_e4b10b07-1d98-4294-ace1-948e3ca45b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_9d53c856-24c1-4162-966d-8d80f9266fdd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_Security12bTitle_9d53c856-24c1-4162-966d-8d80f9266fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3bbf8bc2-b199-42df-85d3-609bed055f9d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_TradingSymbol_3bbf8bc2-b199-42df-85d3-609bed055f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c01b21de-0055-4085-8b7f-e82a22b9088d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_SecurityExchangeName_c01b21de-0055-4085-8b7f-e82a22b9088d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_82bf359f-ed54-4ae1-b38b-eb5ce4e62c26" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityCurrentReportingStatus_82bf359f-ed54-4ae1-b38b-eb5ce4e62c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_42d31649-a8e8-48db-8f6e-cf11e7c1f8f1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityInteractiveDataCurrent_42d31649-a8e8-48db-8f6e-cf11e7c1f8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_5d465f7c-e4bb-45dc-b4e7-a09bf2f5ef87" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityFilerCategory_5d465f7c-e4bb-45dc-b4e7-a09bf2f5ef87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ddb125b8-ce21-40b0-99e2-73a54e738fe4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntitySmallBusiness_ddb125b8-ce21-40b0-99e2-73a54e738fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_8029d1bc-bd13-4f6c-a75b-16dc1785f611" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityEmergingGrowthCompany_8029d1bc-bd13-4f6c-a75b-16dc1785f611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_591ae62f-20ed-4fd5-b347-d0b947789131" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityShellCompany_591ae62f-20ed-4fd5-b347-d0b947789131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f4d9508b-44a2-4a3a-973a-ef7da510e70a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f4d9508b-44a2-4a3a-973a-ef7da510e70a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_bf3d40c5-32e5-4815-b0f1-b826a28b82d9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_AmendmentFlag_bf3d40c5-32e5-4815-b0f1-b826a28b82d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b97eef82-de50-4efc-a5e3-31551f70ef96" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_DocumentFiscalYearFocus_b97eef82-de50-4efc-a5e3-31551f70ef96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_7d4f9294-ef53-4c55-9040-1d8d7f01fd1f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_DocumentFiscalPeriodFocus_7d4f9294-ef53-4c55-9040-1d8d7f01fd1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_64655201-47e3-481b-b7bb-fc33c899a8c9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_EntityCentralIndexKey_64655201-47e3-481b-b7bb-fc33c899a8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_4fea230a-8d76-4fba-8b81-b6c8cda8a2b8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_49c8c90f-2aa3-4f2b-8cb8-30f029ebfdb1" xlink:to="loc_dei_CurrentFiscalYearEndDate_4fea230a-8d76-4fba-8b81-b6c8cda8a2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" xlink:type="simple" xlink:href="mrk-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_f8d9c46c-6de1-4e64-bb04-aca91506cec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4859be0b-8ffc-4fd7-99ef-b223d283cbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f8d9c46c-6de1-4e64-bb04-aca91506cec7" xlink:to="loc_us-gaap_Revenues_4859be0b-8ffc-4fd7-99ef-b223d283cbd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_aa4e0275-a266-4e94-a170-89a6ed5c69b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f8d9c46c-6de1-4e64-bb04-aca91506cec7" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_aa4e0275-a266-4e94-a170-89a6ed5c69b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d3541f84-cfaf-4e02-bd62-dee09ab038ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_aa4e0275-a266-4e94-a170-89a6ed5c69b7" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d3541f84-cfaf-4e02-bd62-dee09ab038ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_936c1f9e-49e9-47bf-b25d-357a7b7e39d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_aa4e0275-a266-4e94-a170-89a6ed5c69b7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_936c1f9e-49e9-47bf-b25d-357a7b7e39d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2dad1f01-b12f-4b29-aafa-67fa91be89e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_aa4e0275-a266-4e94-a170-89a6ed5c69b7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2dad1f01-b12f-4b29-aafa-67fa91be89e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_250ce3c8-80d0-47b0-8636-3cd20111f347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_aa4e0275-a266-4e94-a170-89a6ed5c69b7" xlink:to="loc_us-gaap_RestructuringCharges_250ce3c8-80d0-47b0-8636-3cd20111f347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f763705f-aab9-4f36-96a5-f771d3560b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_aa4e0275-a266-4e94-a170-89a6ed5c69b7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f763705f-aab9-4f36-96a5-f771d3560b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CostsExpensesAndOther_58ad0224-4942-40b3-923e-136f92600e2e" xlink:href="mrk-20230331.xsd#mrk_CostsExpensesAndOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_aa4e0275-a266-4e94-a170-89a6ed5c69b7" xlink:to="loc_mrk_CostsExpensesAndOther_58ad0224-4942-40b3-923e-136f92600e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_76fc328e-b2b9-47b0-ba81-931a42910b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f8d9c46c-6de1-4e64-bb04-aca91506cec7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_76fc328e-b2b9-47b0-ba81-931a42910b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_fab493cc-715f-4944-8b15-ec18c22e2e05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f8d9c46c-6de1-4e64-bb04-aca91506cec7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_fab493cc-715f-4944-8b15-ec18c22e2e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_461e3c6a-f2af-4a44-a93b-d546ee09dcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f8d9c46c-6de1-4e64-bb04-aca91506cec7" xlink:to="loc_us-gaap_ProfitLoss_461e3c6a-f2af-4a44-a93b-d546ee09dcd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_73e64f27-ed9b-4efc-9c67-c92f94cf95bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f8d9c46c-6de1-4e64-bb04-aca91506cec7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_73e64f27-ed9b-4efc-9c67-c92f94cf95bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b023d1b0-2969-47d5-9c3f-94a00e34fb83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f8d9c46c-6de1-4e64-bb04-aca91506cec7" xlink:to="loc_us-gaap_NetIncomeLoss_b023d1b0-2969-47d5-9c3f-94a00e34fb83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_366abd5e-7132-4809-b104-328e3378bbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f8d9c46c-6de1-4e64-bb04-aca91506cec7" xlink:to="loc_us-gaap_EarningsPerShareBasic_366abd5e-7132-4809-b104-328e3378bbb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_df88a39d-f8b8-444a-9246-3117e4798126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f8d9c46c-6de1-4e64-bb04-aca91506cec7" xlink:to="loc_us-gaap_EarningsPerShareDiluted_df88a39d-f8b8-444a-9246-3117e4798126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="mrk-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_029539d1-1f85-4651-9d57-10a6653ccab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4411a59d-c693-4ea2-b06d-2123fee70445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_029539d1-1f85-4651-9d57-10a6653ccab7" xlink:to="loc_us-gaap_NetIncomeLoss_4411a59d-c693-4ea2-b06d-2123fee70445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_556714b8-3a63-48b4-939f-cbc182e6e826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_029539d1-1f85-4651-9d57-10a6653ccab7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_556714b8-3a63-48b4-939f-cbc182e6e826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_c8d2d2bf-4389-405e-ac9e-56c1bd3ca265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_556714b8-3a63-48b4-939f-cbc182e6e826" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent_c8d2d2bf-4389-405e-ac9e-56c1bd3ca265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_fd0a2f9e-d0c0-4f6f-9890-8ffe31a77873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_556714b8-3a63-48b4-939f-cbc182e6e826" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_fd0a2f9e-d0c0-4f6f-9890-8ffe31a77873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2b575e7d-14f1-48ed-bee8-dc00d9873352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_556714b8-3a63-48b4-939f-cbc182e6e826" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2b575e7d-14f1-48ed-bee8-dc00d9873352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fcb9391d-d21a-4d28-848b-1fd32f9a0783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_556714b8-3a63-48b4-939f-cbc182e6e826" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_fcb9391d-d21a-4d28-848b-1fd32f9a0783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf7d528b-f265-46f4-bcc3-76bad188d69d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_029539d1-1f85-4651-9d57-10a6653ccab7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_cf7d528b-f265-46f4-bcc3-76bad188d69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" xlink:type="simple" xlink:href="mrk-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEET"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_91898861-b4e4-4ec8-81cb-9c6550764149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_9a406a6c-fd32-47ab-898e-95b384123781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_91898861-b4e4-4ec8-81cb-9c6550764149" xlink:to="loc_us-gaap_AssetsAbstract_9a406a6c-fd32-47ab-898e-95b384123781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_8d28818e-4d28-4514-978a-6c8ee08b1e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9a406a6c-fd32-47ab-898e-95b384123781" xlink:to="loc_us-gaap_AssetsCurrentAbstract_8d28818e-4d28-4514-978a-6c8ee08b1e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9f8d4071-9bc2-47c7-83ff-83ab85307c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8d28818e-4d28-4514-978a-6c8ee08b1e0a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9f8d4071-9bc2-47c7-83ff-83ab85307c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_da4c4eab-4a5a-4650-9efd-9bd3a95ccf18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8d28818e-4d28-4514-978a-6c8ee08b1e0a" xlink:to="loc_us-gaap_ShortTermInvestments_da4c4eab-4a5a-4650-9efd-9bd3a95ccf18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e0ed494a-6280-45ee-b274-e05736e003bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8d28818e-4d28-4514-978a-6c8ee08b1e0a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e0ed494a-6280-45ee-b274-e05736e003bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_431e7a0c-822a-4346-8c4f-95bf3d341633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8d28818e-4d28-4514-978a-6c8ee08b1e0a" xlink:to="loc_us-gaap_InventoryNet_431e7a0c-822a-4346-8c4f-95bf3d341633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent_8ed6fd2e-b2ee-4971-b242-3777d6da139c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8d28818e-4d28-4514-978a-6c8ee08b1e0a" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent_8ed6fd2e-b2ee-4971-b242-3777d6da139c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_057fdef4-d2e5-4f70-90d3-677b0a435f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8d28818e-4d28-4514-978a-6c8ee08b1e0a" xlink:to="loc_us-gaap_AssetsCurrent_057fdef4-d2e5-4f70-90d3-677b0a435f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_5c1b11f9-8017-4ff2-bf70-9efda1b92f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9a406a6c-fd32-47ab-898e-95b384123781" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_5c1b11f9-8017-4ff2-bf70-9efda1b92f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_175ec1f8-4a03-4af7-8e20-3916233d01b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9a406a6c-fd32-47ab-898e-95b384123781" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_175ec1f8-4a03-4af7-8e20-3916233d01b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_dfecdeaa-e177-49bc-9f18-45f086961df4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9a406a6c-fd32-47ab-898e-95b384123781" xlink:to="loc_us-gaap_Goodwill_dfecdeaa-e177-49bc-9f18-45f086961df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_dd273b0b-2857-42aa-b445-60c48effa451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9a406a6c-fd32-47ab-898e-95b384123781" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_dd273b0b-2857-42aa-b445-60c48effa451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_495558d8-161e-48f3-9788-44a1743c5add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9a406a6c-fd32-47ab-898e-95b384123781" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_495558d8-161e-48f3-9788-44a1743c5add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_67dbda23-5a39-482b-bf28-e5a0e8faa15d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9a406a6c-fd32-47ab-898e-95b384123781" xlink:to="loc_us-gaap_Assets_67dbda23-5a39-482b-bf28-e5a0e8faa15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_429b6d18-708d-4f79-9a33-bf7898cb6c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_91898861-b4e4-4ec8-81cb-9c6550764149" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_429b6d18-708d-4f79-9a33-bf7898cb6c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_d676bb0c-5bb0-4971-bc42-f6e8967b6c87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_429b6d18-708d-4f79-9a33-bf7898cb6c2d" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_d676bb0c-5bb0-4971-bc42-f6e8967b6c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_bb8cf9d4-023b-4da0-9679-891232f251a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d676bb0c-5bb0-4971-bc42-f6e8967b6c87" xlink:to="loc_us-gaap_DebtCurrent_bb8cf9d4-023b-4da0-9679-891232f251a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_53801bd8-8234-4e47-ae29-d09970a17509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d676bb0c-5bb0-4971-bc42-f6e8967b6c87" xlink:to="loc_us-gaap_AccountsPayableCurrent_53801bd8-8234-4e47-ae29-d09970a17509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_263cd249-8b0a-45c6-bad4-5433524c2a88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d676bb0c-5bb0-4971-bc42-f6e8967b6c87" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_263cd249-8b0a-45c6-bad4-5433524c2a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_efc5dbe2-fe10-4120-bf8b-2898c129b2da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d676bb0c-5bb0-4971-bc42-f6e8967b6c87" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_efc5dbe2-fe10-4120-bf8b-2898c129b2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_cbf31c0a-8b5e-4f0c-b2d3-7cce6014d203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d676bb0c-5bb0-4971-bc42-f6e8967b6c87" xlink:to="loc_us-gaap_DividendsPayableCurrent_cbf31c0a-8b5e-4f0c-b2d3-7cce6014d203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c36472b7-b230-455b-b7ee-47933cefee89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d676bb0c-5bb0-4971-bc42-f6e8967b6c87" xlink:to="loc_us-gaap_LiabilitiesCurrent_c36472b7-b230-455b-b7ee-47933cefee89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_32f7e1e0-538f-4dcc-9328-048c05dfe73d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_429b6d18-708d-4f79-9a33-bf7898cb6c2d" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_32f7e1e0-538f-4dcc-9328-048c05dfe73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a2520c57-51d8-4034-b0a2-8a401e6250d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_429b6d18-708d-4f79-9a33-bf7898cb6c2d" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_a2520c57-51d8-4034-b0a2-8a401e6250d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_aa662a53-bcc7-4397-9fbe-f9f77e1032a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_429b6d18-708d-4f79-9a33-bf7898cb6c2d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_aa662a53-bcc7-4397-9fbe-f9f77e1032a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_10b5cc39-d217-42fe-9ada-a90457a24cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_429b6d18-708d-4f79-9a33-bf7898cb6c2d" xlink:to="loc_us-gaap_StockholdersEquityAbstract_10b5cc39-d217-42fe-9ada-a90457a24cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_bbcff600-b3b6-469b-a0be-66fc19f98fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_10b5cc39-d217-42fe-9ada-a90457a24cfe" xlink:to="loc_us-gaap_CommonStockValue_bbcff600-b3b6-469b-a0be-66fc19f98fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2ad97d5f-445d-43fe-afb3-5834146c3b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_10b5cc39-d217-42fe-9ada-a90457a24cfe" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2ad97d5f-445d-43fe-afb3-5834146c3b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7f689fb5-f41c-49ee-96a1-2aab9ef1551c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_10b5cc39-d217-42fe-9ada-a90457a24cfe" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7f689fb5-f41c-49ee-96a1-2aab9ef1551c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6abc57f0-a1ab-4139-ac80-ef928b211e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_10b5cc39-d217-42fe-9ada-a90457a24cfe" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6abc57f0-a1ab-4139-ac80-ef928b211e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_fb9f924f-ae68-4900-b519-703d66327891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_10b5cc39-d217-42fe-9ada-a90457a24cfe" xlink:to="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_fb9f924f-ae68-4900-b519-703d66327891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_fc9feac2-683b-4387-b72b-cfbd4e2fc282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_10b5cc39-d217-42fe-9ada-a90457a24cfe" xlink:to="loc_us-gaap_TreasuryStockCommonValue_fc9feac2-683b-4387-b72b-cfbd4e2fc282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_09e05927-112a-4a71-8ac1-c39043c5e25a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_10b5cc39-d217-42fe-9ada-a90457a24cfe" xlink:to="loc_us-gaap_StockholdersEquity_09e05927-112a-4a71-8ac1-c39043c5e25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_edb212c6-5220-40df-afe5-deade5af78c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_10b5cc39-d217-42fe-9ada-a90457a24cfe" xlink:to="loc_us-gaap_MinorityInterest_edb212c6-5220-40df-afe5-deade5af78c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b346fdcf-7e51-4965-ba87-b0071b85352b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_10b5cc39-d217-42fe-9ada-a90457a24cfe" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b346fdcf-7e51-4965-ba87-b0071b85352b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d9e52544-0ee3-4066-8960-da073afd2bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_429b6d18-708d-4f79-9a33-bf7898cb6c2d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d9e52544-0ee3-4066-8960-da073afd2bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" xlink:type="simple" xlink:href="mrk-20230331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_86f333f1-f005-4d8b-ad64-0ce590e9db4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_77583519-8af6-480e-86a0-cb4576d19817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_86f333f1-f005-4d8b-ad64-0ce590e9db4b" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_77583519-8af6-480e-86a0-cb4576d19817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_8dcbad60-4c0c-471b-8bb1-5584608e4610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_86f333f1-f005-4d8b-ad64-0ce590e9db4b" xlink:to="loc_us-gaap_InventoryNoncurrent_8dcbad60-4c0c-471b-8bb1-5584608e4610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a26c910c-ffed-418c-b9cc-cbbe65fa4edc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_86f333f1-f005-4d8b-ad64-0ce590e9db4b" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a26c910c-ffed-418c-b9cc-cbbe65fa4edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_224db734-19ca-4567-bbeb-a48011cbb1e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_86f333f1-f005-4d8b-ad64-0ce590e9db4b" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_224db734-19ca-4567-bbeb-a48011cbb1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c8cfa716-5f29-40a2-88b1-f2f0bf92b017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_86f333f1-f005-4d8b-ad64-0ce590e9db4b" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c8cfa716-5f29-40a2-88b1-f2f0bf92b017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1ca8d084-a6c3-4b09-94bf-91fdd831815f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_86f333f1-f005-4d8b-ad64-0ce590e9db4b" xlink:to="loc_us-gaap_CommonStockSharesIssued_1ca8d084-a6c3-4b09-94bf-91fdd831815f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_ffda99b4-1043-4f97-9cdb-98a932d3b809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_86f333f1-f005-4d8b-ad64-0ce590e9db4b" xlink:to="loc_us-gaap_TreasuryStockCommonShares_ffda99b4-1043-4f97-9cdb-98a932d3b809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="simple" xlink:href="mrk-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_202c51df-e811-46c2-9b2e-7360dd4cccee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_469b8b80-91b8-400f-a88e-f886a023e9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_202c51df-e811-46c2-9b2e-7360dd4cccee" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_469b8b80-91b8-400f-a88e-f886a023e9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_762cb3c2-ab07-42a1-a6fb-adba55a08e05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_469b8b80-91b8-400f-a88e-f886a023e9bb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_762cb3c2-ab07-42a1-a6fb-adba55a08e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_77a03ccc-1bfd-486e-b460-de432a12ac0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_469b8b80-91b8-400f-a88e-f886a023e9bb" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_77a03ccc-1bfd-486e-b460-de432a12ac0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_9b2ad6bc-aefe-46e0-94fd-966298b8bd1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_77a03ccc-1bfd-486e-b460-de432a12ac0b" xlink:to="loc_us-gaap_AdjustmentForAmortization_9b2ad6bc-aefe-46e0-94fd-966298b8bd1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_f99ec0a7-47d5-4f15-8193-99ef5623187f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_77a03ccc-1bfd-486e-b460-de432a12ac0b" xlink:to="loc_us-gaap_Depreciation_f99ec0a7-47d5-4f15-8193-99ef5623187f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_e881f7a5-aca5-4d89-bf81-e0796f67f68b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_77a03ccc-1bfd-486e-b460-de432a12ac0b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_e881f7a5-aca5-4d89-bf81-e0796f67f68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_77c435fc-eca9-4e76-b15d-c3d1933fdeac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_77a03ccc-1bfd-486e-b460-de432a12ac0b" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_77c435fc-eca9-4e76-b15d-c3d1933fdeac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9713ba38-d9cb-44b7-b06b-62bbffeec1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_77a03ccc-1bfd-486e-b460-de432a12ac0b" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9713ba38-d9cb-44b7-b06b-62bbffeec1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3b080713-e8ad-494d-bfa6-1b3973b22b02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_77a03ccc-1bfd-486e-b460-de432a12ac0b" xlink:to="loc_us-gaap_ShareBasedCompensation_3b080713-e8ad-494d-bfa6-1b3973b22b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_6fa55137-b74f-47c5-800f-4e985bce4906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_77a03ccc-1bfd-486e-b460-de432a12ac0b" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_6fa55137-b74f-47c5-800f-4e985bce4906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_eafeb2d0-d8bd-478a-a9c0-e1f4865153e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapital"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_77a03ccc-1bfd-486e-b460-de432a12ac0b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_eafeb2d0-d8bd-478a-a9c0-e1f4865153e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9af62d1d-eaec-423b-a326-1fd1048473b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_469b8b80-91b8-400f-a88e-f886a023e9bb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9af62d1d-eaec-423b-a326-1fd1048473b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_94f998bf-3c58-4699-875a-fd9ce8a9f0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_202c51df-e811-46c2-9b2e-7360dd4cccee" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_94f998bf-3c58-4699-875a-fd9ce8a9f0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_75cf733c-ccbd-4092-a059-352f03b8f8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_94f998bf-3c58-4699-875a-fd9ce8a9f0e9" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_75cf733c-ccbd-4092-a059-352f03b8f8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_92859cd8-495d-457e-b1d9-c635e0aaf8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_94f998bf-3c58-4699-875a-fd9ce8a9f0e9" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_92859cd8-495d-457e-b1d9-c635e0aaf8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_8fa8a5ae-393f-45f3-9a03-bd50bbd0fd65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_94f998bf-3c58-4699-875a-fd9ce8a9f0e9" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_8fa8a5ae-393f-45f3-9a03-bd50bbd0fd65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_5e63cd0f-7efa-41bb-96a1-b4171c4e2a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_94f998bf-3c58-4699-875a-fd9ce8a9f0e9" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_5e63cd0f-7efa-41bb-96a1-b4171c4e2a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_17272640-f045-46ba-84c6-50cfabb69cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_94f998bf-3c58-4699-875a-fd9ce8a9f0e9" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_17272640-f045-46ba-84c6-50cfabb69cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_325dc9c0-6254-473a-abb3-de1d1ced9ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_94f998bf-3c58-4699-875a-fd9ce8a9f0e9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_325dc9c0-6254-473a-abb3-de1d1ced9ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36f1fc4c-c27b-425a-9f79-110aafa522ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_202c51df-e811-46c2-9b2e-7360dd4cccee" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36f1fc4c-c27b-425a-9f79-110aafa522ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_1a382685-e600-4fe0-a64e-7eb505c35305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36f1fc4c-c27b-425a-9f79-110aafa522ae" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_1a382685-e600-4fe0-a64e-7eb505c35305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d60949cf-c39a-4708-b35f-d7cb0e82627b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36f1fc4c-c27b-425a-9f79-110aafa522ae" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d60949cf-c39a-4708-b35f-d7cb0e82627b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_2b074a0f-6c8e-4159-801f-79e201081433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36f1fc4c-c27b-425a-9f79-110aafa522ae" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_2b074a0f-6c8e-4159-801f-79e201081433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_09740c78-ceba-491b-8f7a-de429d4ca6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36f1fc4c-c27b-425a-9f79-110aafa522ae" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_09740c78-ceba-491b-8f7a-de429d4ca6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_af92d80e-7fa6-4b3e-b6ee-0dc15cbacf3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36f1fc4c-c27b-425a-9f79-110aafa522ae" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_af92d80e-7fa6-4b3e-b6ee-0dc15cbacf3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1b75d96d-9242-4a5f-a1d8-72b87a8ad02e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_36f1fc4c-c27b-425a-9f79-110aafa522ae" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1b75d96d-9242-4a5f-a1d8-72b87a8ad02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_47e9c8a4-d13e-4570-92db-009a2333e97e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_202c51df-e811-46c2-9b2e-7360dd4cccee" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_47e9c8a4-d13e-4570-92db-009a2333e97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e3ceea45-4a87-4d55-9d8d-e8f9f2457d36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_202c51df-e811-46c2-9b2e-7360dd4cccee" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e3ceea45-4a87-4d55-9d8d-e8f9f2457d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b04d4c90-f243-47e9-9f33-3759f89e0e35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_202c51df-e811-46c2-9b2e-7360dd4cccee" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b04d4c90-f243-47e9-9f33-3759f89e0e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b3326bf1-e9bb-4b7a-93b9-8371b52d1aef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_202c51df-e811-46c2-9b2e-7360dd4cccee" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b3326bf1-e9bb-4b7a-93b9-8371b52d1aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical" xlink:type="simple" xlink:href="mrk-20230331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_88b52559-8283-4588-8507-11e279447d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_67e72e89-1a6f-42b2-84d8-e9bad429f580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_88b52559-8283-4588-8507-11e279447d13" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_67e72e89-1a6f-42b2-84d8-e9bad429f580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/BasisofPresentation" xlink:type="simple" xlink:href="mrk-20230331.xsd#BasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/BasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dc7db572-512a-42b0-87ce-85a618fc0bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_478f41cd-b775-4d24-bf7c-cd72e9dd4e55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dc7db572-512a-42b0-87ce-85a618fc0bdf" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_478f41cd-b775-4d24-bf7c-cd72e9dd4e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SpinOffofOrganonCo" xlink:type="simple" xlink:href="mrk-20230331.xsd#SpinOffofOrganonCo"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SpinOffofOrganonCo" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_38b7760d-86e1-4a2f-9242-5030bcb7fca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_acb8a7b3-188b-4d04-869c-21e721ed5472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_38b7760d-86e1-4a2f-9242-5030bcb7fca8" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_acb8a7b3-188b-4d04-869c-21e721ed5472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements" xlink:type="simple" xlink:href="mrk-20230331.xsd#AcquisitionsResearchCollaborationsandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_91227832-44cc-4c54-a6a9-91654a090689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock_9289de17-b197-416c-9b00-b1f1d29e3e03" xlink:href="mrk-20230331.xsd#mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_91227832-44cc-4c54-a6a9-91654a090689" xlink:to="loc_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock_9289de17-b197-416c-9b00-b1f1d29e3e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangements" xlink:type="simple" xlink:href="mrk-20230331.xsd#CollaborativeArrangements"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CollaborativeArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract_05f364a7-fee9-4373-8ff1-cfb33e981cea" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_daa7f0bc-0983-4a94-9ec5-042f276db1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_CollaborativeArrangementsAbstract_05f364a7-fee9-4373-8ff1-cfb33e981cea" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_daa7f0bc-0983-4a94-9ec5-042f276db1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/Restructuring" xlink:type="simple" xlink:href="mrk-20230331.xsd#Restructuring"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/Restructuring" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7ec4be5f-cb96-4292-a80d-4bd64eb9b120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_b5922909-419c-4d1c-820c-9889eaf17263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7ec4be5f-cb96-4292-a80d-4bd64eb9b120" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_b5922909-419c-4d1c-820c-9889eaf17263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstruments" xlink:type="simple" xlink:href="mrk-20230331.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_91591123-b4c9-4a2c-b9a0-c38f84e1f1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_9ba8a1c4-15b6-41bd-8248-7745b7703a93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_91591123-b4c9-4a2c-b9a0-c38f84e1f1c6" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_9ba8a1c4-15b6-41bd-8248-7745b7703a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/Inventories" xlink:type="simple" xlink:href="mrk-20230331.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_fef5d88c-6756-484c-989f-923e594631c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_63234c1a-4af2-4720-a432-17845db64ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_fef5d88c-6756-484c-989f-923e594631c1" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_63234c1a-4af2-4720-a432-17845db64ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/Contingencies" xlink:type="simple" xlink:href="mrk-20230331.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bb4c75b7-9b26-48df-a6d0-1fa1d264d8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0475bc3e-aacb-4862-b31f-1b718a6d5393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_bb4c75b7-9b26-48df-a6d0-1fa1d264d8c4" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0475bc3e-aacb-4862-b31f-1b718a6d5393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/Equity" xlink:type="simple" xlink:href="mrk-20230331.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_81ea975f-713e-4eb1-b0ab-0ddb6ab4c6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_25f42a7f-5703-4d58-b42e-f7023351ef4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_81ea975f-713e-4eb1-b0ab-0ddb6ab4c6e1" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_25f42a7f-5703-4d58-b42e-f7023351ef4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans" xlink:type="simple" xlink:href="mrk-20230331.xsd#PensionandOtherPostretirementBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_61ec943c-c78b-4ee9-b1c6-0771474173e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_76e83748-b75c-4eea-b3cb-860b2ae1c164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_61ec943c-c78b-4ee9-b1c6-0771474173e3" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_76e83748-b75c-4eea-b3cb-860b2ae1c164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNet" xlink:type="simple" xlink:href="mrk-20230331.xsd#OtherIncomeExpenseNet"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_9028f08f-39ea-42b4-8121-4171a6478364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_7df2f86a-00c0-4837-abe7-ebda4639341d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9028f08f-39ea-42b4-8121-4171a6478364" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_7df2f86a-00c0-4837-abe7-ebda4639341d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncome" xlink:type="simple" xlink:href="mrk-20230331.xsd#TaxesonIncome"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ee236cd6-6186-4e75-be7a-5d6ca4489731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_c3917b75-fa5f-42bb-be81-53a2a70e642e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ee236cd6-6186-4e75-be7a-5d6ca4489731" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_c3917b75-fa5f-42bb-be81-53a2a70e642e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShare" xlink:type="simple" xlink:href="mrk-20230331.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0e9b503d-9ef6-4f33-a814-e9d4607fddc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_776ca266-7d34-4e1c-8b9c-4fbe63ec562d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0e9b503d-9ef6-4f33-a814-e9d4607fddc0" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_776ca266-7d34-4e1c-8b9c-4fbe63ec562d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="mrk-20230331.xsd#OtherComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f2ebb0b8-eecf-4a4e-8f98-7118bcfcbccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_9b3c8a0d-d72e-4cb9-884c-e01f16f4cd20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f2ebb0b8-eecf-4a4e-8f98-7118bcfcbccd" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_9b3c8a0d-d72e-4cb9-884c-e01f16f4cd20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReporting" xlink:type="simple" xlink:href="mrk-20230331.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_eef2c090-a773-42e3-9559-98b259f246db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_2d269a3f-d248-4bc0-bf31-a88492e4cccc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_eef2c090-a773-42e3-9559-98b259f246db" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_2d269a3f-d248-4bc0-bf31-a88492e4cccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/BasisofPresentationPolicies" xlink:type="simple" xlink:href="mrk-20230331.xsd#BasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/BasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aae34d69-e194-4db0-b977-09ad81b56269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e7089625-ac34-441b-9820-577f7c3f64d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aae34d69-e194-4db0-b977-09ad81b56269" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e7089625-ac34-441b-9820-577f7c3f64d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_14606cf4-ce67-4dd9-9690-bed91452a9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aae34d69-e194-4db0-b977-09ad81b56269" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_14606cf4-ce67-4dd9-9690-bed91452a9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a3944d5a-2a87-4d2c-933d-b78e90a2766e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aae34d69-e194-4db0-b977-09ad81b56269" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a3944d5a-2a87-4d2c-933d-b78e90a2766e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock_02b717e6-3f59-4281-a1a0-904f337d5641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aae34d69-e194-4db0-b977-09ad81b56269" xlink:to="loc_us-gaap_LegalCostsPolicyTextBlock_02b717e6-3f59-4281-a1a0-904f337d5641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsTables" xlink:type="simple" xlink:href="mrk-20230331.xsd#CollaborativeArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract_b0239fc5-3ee4-4209-b46c-8040fc149034" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_09b7e56d-e434-46fa-8a2e-c9277a424cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_CollaborativeArrangementsAbstract_b0239fc5-3ee4-4209-b46c-8040fc149034" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_09b7e56d-e434-46fa-8a2e-c9277a424cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringTables" xlink:type="simple" xlink:href="mrk-20230331.xsd#RestructuringTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/RestructuringTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3415833b-a4a6-4d1d-9b64-7353679ca39f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_238a583f-6441-4c80-afc2-b7ab54ab224c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3415833b-a4a6-4d1d-9b64-7353679ca39f" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_238a583f-6441-4c80-afc2-b7ab54ab224c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_7f7b5468-5c0c-4db8-a6ce-fb23e841e13c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3415833b-a4a6-4d1d-9b64-7353679ca39f" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_7f7b5468-5c0c-4db8-a6ce-fb23e841e13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="mrk-20230331.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bba66b0e-957c-4334-9951-0fa69e816d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8312e125-91a0-4ec4-8d46-8ec15f1bf7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bba66b0e-957c-4334-9951-0fa69e816d5a" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8312e125-91a0-4ec4-8d46-8ec15f1bf7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_5cfd7bf8-16af-43f7-a69d-aaa2880c82e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bba66b0e-957c-4334-9951-0fa69e816d5a" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_5cfd7bf8-16af-43f7-a69d-aaa2880c82e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_c3d987e2-b68b-4491-b2a9-3fb40295394c" xlink:href="mrk-20230331.xsd#mrk_OffsettingAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bba66b0e-957c-4334-9951-0fa69e816d5a" xlink:to="loc_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock_c3d987e2-b68b-4491-b2a9-3fb40295394c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_0a5307ad-d438-4387-bc29-28e531ecb3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bba66b0e-957c-4334-9951-0fa69e816d5a" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_0a5307ad-d438-4387-bc29-28e531ecb3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_8fef5ebb-7da2-411e-ad57-9ef0ed83fea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bba66b0e-957c-4334-9951-0fa69e816d5a" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_8fef5ebb-7da2-411e-ad57-9ef0ed83fea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_f181924e-25c9-4f39-a1b9-7086aec08fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bba66b0e-957c-4334-9951-0fa69e816d5a" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_f181924e-25c9-4f39-a1b9-7086aec08fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0398afa6-5bfa-4fe7-8045-f36a9b481845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bba66b0e-957c-4334-9951-0fa69e816d5a" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0398afa6-5bfa-4fe7-8045-f36a9b481845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_b454f24b-3c1e-4d4d-bb77-22bdc659d943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bba66b0e-957c-4334-9951-0fa69e816d5a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_b454f24b-3c1e-4d4d-bb77-22bdc659d943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesTables" xlink:type="simple" xlink:href="mrk-20230331.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0435e773-0e7a-47cf-925b-034fb4fe97af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5aae83ba-23d2-4260-b53f-0c5bb416e5ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0435e773-0e7a-47cf-925b-034fb4fe97af" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_5aae83ba-23d2-4260-b53f-0c5bb416e5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EquityTables" xlink:type="simple" xlink:href="mrk-20230331.xsd#EquityTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0dc3f249-67e2-4d8a-840a-054e2e3a6b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_2162f2cd-3b98-4e66-853b-3709fc400d08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0dc3f249-67e2-4d8a-840a-054e2e3a6b47" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_2162f2cd-3b98-4e66-853b-3709fc400d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" xlink:type="simple" xlink:href="mrk-20230331.xsd#PensionandOtherPostretirementBenefitPlansTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ccce3c53-59a8-4e43-a51b-4fc7037561f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_80f0f3a3-725c-4951-a9ab-a3e574f941aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_ccce3c53-59a8-4e43-a51b-4fc7037561f7" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_80f0f3a3-725c-4951-a9ab-a3e574f941aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_9df11bef-3c04-43f3-9549-7cca74ef932f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_80f0f3a3-725c-4951-a9ab-a3e574f941aa" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_9df11bef-3c04-43f3-9549-7cca74ef932f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_2db486b6-c020-4ff4-90a0-dcd73356b6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_9df11bef-3c04-43f3-9549-7cca74ef932f" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_2db486b6-c020-4ff4-90a0-dcd73356b6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_084d0779-0bc0-4fc6-909c-15c4118ab83c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_2db486b6-c020-4ff4-90a0-dcd73356b6fa" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_084d0779-0bc0-4fc6-909c-15c4118ab83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_5235371a-3725-4104-a065-9fe537235a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_2db486b6-c020-4ff4-90a0-dcd73356b6fa" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_5235371a-3725-4104-a065-9fe537235a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94472863-f615-4cf9-a894-13095b4ddb66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_80f0f3a3-725c-4951-a9ab-a3e574f941aa" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94472863-f615-4cf9-a894-13095b4ddb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_80239726-1f49-4a52-8a3c-a9600e9dc6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94472863-f615-4cf9-a894-13095b4ddb66" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_80239726-1f49-4a52-8a3c-a9600e9dc6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetTables" xlink:type="simple" xlink:href="mrk-20230331.xsd#OtherIncomeExpenseNetTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_e67e11e1-94f2-4553-8a04-68c7c007e354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_f7c3f831-7742-4ab7-8d05-91ce4c15f20b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_e67e11e1-94f2-4553-8a04-68c7c007e354" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_f7c3f831-7742-4ab7-8d05-91ce4c15f20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="mrk-20230331.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4b7898ed-11fb-4688-83ac-98fe1808a8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3fb9a6ba-48d5-4aaa-9c0e-60032d3b5021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4b7898ed-11fb-4688-83ac-98fe1808a8aa" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3fb9a6ba-48d5-4aaa-9c0e-60032d3b5021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="mrk-20230331.xsd#OtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_88989602-1571-41db-a014-fe8be6c32798" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_5e9fb913-5c58-41ed-808b-f2fda4b7fc7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_88989602-1571-41db-a014-fe8be6c32798" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_5e9fb913-5c58-41ed-808b-f2fda4b7fc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="mrk-20230331.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_81047915-a6e0-4479-9435-a3e62fa1aa8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_9ac2cf35-dfe7-419a-81b5-904d0863a43a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_81047915-a6e0-4479-9435-a3e62fa1aa8f" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_9ac2cf35-dfe7-419a-81b5-904d0863a43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_f1af8691-d409-4f77-a41f-4c91e6f2051c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_81047915-a6e0-4479-9435-a3e62fa1aa8f" xlink:to="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_f1af8691-d409-4f77-a41f-4c91e6f2051c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_a0a81519-b027-464d-a039-ff80f5281061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_81047915-a6e0-4479-9435-a3e62fa1aa8f" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_a0a81519-b027-464d-a039-ff80f5281061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SpinOffofOrganonCoDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#SpinOffofOrganonCoDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SpinOffofOrganonCoDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_67148aaf-255f-4c27-9cfe-7c60133e61a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18f193dc-df84-46c5-b9b5-f18ba5ad153c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_67148aaf-255f-4c27-9cfe-7c60133e61a1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18f193dc-df84-46c5-b9b5-f18ba5ad153c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5ef04929-6304-47d4-baab-24f3cc3bd782" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18f193dc-df84-46c5-b9b5-f18ba5ad153c" xlink:to="loc_srt_RangeAxis_5ef04929-6304-47d4-baab-24f3cc3bd782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8cbe5494-4e6a-4944-8d4c-5329b1bbbc8b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5ef04929-6304-47d4-baab-24f3cc3bd782" xlink:to="loc_srt_RangeMember_8cbe5494-4e6a-4944-8d4c-5329b1bbbc8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_41ae77f7-487f-433e-8019-a7246311b7c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8cbe5494-4e6a-4944-8d4c-5329b1bbbc8b" xlink:to="loc_srt_MinimumMember_41ae77f7-487f-433e-8019-a7246311b7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_604d1f42-343d-45b9-b6d6-6f73f363ac53" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8cbe5494-4e6a-4944-8d4c-5329b1bbbc8b" xlink:to="loc_srt_MaximumMember_604d1f42-343d-45b9-b6d6-6f73f363ac53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_30545cdb-7bfa-487d-ae10-d99293687c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18f193dc-df84-46c5-b9b5-f18ba5ad153c" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_30545cdb-7bfa-487d-ae10-d99293687c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_3922b065-25e2-4af2-b86f-f7616d4c0907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_30545cdb-7bfa-487d-ae10-d99293687c83" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_3922b065-25e2-4af2-b86f-f7616d4c0907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TransitionServicesAgreementMember_2f78c4aa-1852-4744-9024-8ddab8ccdb4a" xlink:href="mrk-20230331.xsd#mrk_TransitionServicesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3922b065-25e2-4af2-b86f-f7616d4c0907" xlink:to="loc_mrk_TransitionServicesAgreementMember_2f78c4aa-1852-4744-9024-8ddab8ccdb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ManufacturingAndSupplyAgreementsMember_236da62c-56e2-439a-8960-20d94b01a4e5" xlink:href="mrk-20230331.xsd#mrk_ManufacturingAndSupplyAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_3922b065-25e2-4af2-b86f-f7616d4c0907" xlink:to="loc_mrk_ManufacturingAndSupplyAgreementsMember_236da62c-56e2-439a-8960-20d94b01a4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_19248b45-627c-4ee8-818b-93b3954efb29" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18f193dc-df84-46c5-b9b5-f18ba5ad153c" xlink:to="loc_srt_CounterpartyNameAxis_19248b45-627c-4ee8-818b-93b3954efb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32edf50a-429e-474c-ae1f-1bbf4845e661" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_19248b45-627c-4ee8-818b-93b3954efb29" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32edf50a-429e-474c-ae1f-1bbf4845e661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OrganonCoMember_33fcb8f3-a286-4c72-90e0-a0f535ca4bda" xlink:href="mrk-20230331.xsd#mrk_OrganonCoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32edf50a-429e-474c-ae1f-1bbf4845e661" xlink:to="loc_mrk_OrganonCoMember_33fcb8f3-a286-4c72-90e0-a0f535ca4bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_24a69840-2f05-4280-9561-62167705be84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_18f193dc-df84-46c5-b9b5-f18ba5ad153c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_24a69840-2f05-4280-9561-62167705be84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_03ae9688-4cc7-4718-9e73-4a769ebf489e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_24a69840-2f05-4280-9561-62167705be84" xlink:to="loc_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal_03ae9688-4cc7-4718-9e73-4a769ebf489e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_fb0a2d8e-ff9e-4771-b9de-17e3d9ae5400" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_24a69840-2f05-4280-9561-62167705be84" xlink:to="loc_us-gaap_RevenueFromRelatedParties_fb0a2d8e-ff9e-4771-b9de-17e3d9ae5400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartiesAmountInCostOfSales_912d4a17-cad6-4575-9968-c046b1debacd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartiesAmountInCostOfSales"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_24a69840-2f05-4280-9561-62167705be84" xlink:to="loc_us-gaap_RelatedPartiesAmountInCostOfSales_912d4a17-cad6-4575-9968-c046b1debacd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_49801570-df2a-47c4-b2c6-f8fe997c20f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_24a69840-2f05-4280-9561-62167705be84" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_49801570-df2a-47c4-b2c6-f8fe997c20f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_1a262039-7d43-4b79-ae09-a142a48888cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_24a69840-2f05-4280-9561-62167705be84" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_1a262039-7d43-4b79-ae09-a142a48888cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6f35b098-006d-44f1-97c8-0ae5b37f4ced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b94167b-0604-4f80-abc9-11b110c081f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6f35b098-006d-44f1-97c8-0ae5b37f4ced" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b94167b-0604-4f80-abc9-11b110c081f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3e9d692c-0e0e-4f54-b0a0-9d86bb46898c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b94167b-0604-4f80-abc9-11b110c081f4" xlink:to="loc_srt_CounterpartyNameAxis_3e9d692c-0e0e-4f54-b0a0-9d86bb46898c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9fe0e91e-0a5c-4eb8-b174-b3b0f33a6742" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3e9d692c-0e0e-4f54-b0a0-9d86bb46898c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9fe0e91e-0a5c-4eb8-b174-b3b0f33a6742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember_24fa11d6-bce8-4b35-8817-fe5f6d57ffd6" xlink:href="mrk-20230331.xsd#mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9fe0e91e-0a5c-4eb8-b174-b3b0f33a6742" xlink:to="loc_mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember_24fa11d6-bce8-4b35-8817-fe5f6d57ffd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember_931db962-248b-44d3-b0f3-e63fb8f1d560" xlink:href="mrk-20230331.xsd#mrk_EisaiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9fe0e91e-0a5c-4eb8-b174-b3b0f33a6742" xlink:to="loc_mrk_EisaiMember_931db962-248b-44d3-b0f3-e63fb8f1d560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_419f4259-731a-41a8-b179-54df77686fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b94167b-0604-4f80-abc9-11b110c081f4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_419f4259-731a-41a8-b179-54df77686fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b635f307-4577-4eae-ab06-01ec87a54ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_419f4259-731a-41a8-b179-54df77686fa0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b635f307-4577-4eae-ab06-01ec87a54ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d63c003c-ac6b-4412-a454-3926d16819ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b635f307-4577-4eae-ab06-01ec87a54ad7" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_d63c003c-ac6b-4412-a454-3926d16819ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_7629fd22-1c27-49b7-9267-34b85971447e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b94167b-0604-4f80-abc9-11b110c081f4" xlink:to="loc_us-gaap_AssetAcquisitionAxis_7629fd22-1c27-49b7-9267-34b85971447e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_3067b195-4f71-4fcc-8fcd-226448199f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_7629fd22-1c27-49b7-9267-34b85971447e" xlink:to="loc_us-gaap_AssetAcquisitionDomain_3067b195-4f71-4fcc-8fcd-226448199f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrometheusBiosciencesIncMember_193a6ee9-0461-4cca-b675-41dbd0866ad1" xlink:href="mrk-20230331.xsd#mrk_PrometheusBiosciencesIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_3067b195-4f71-4fcc-8fcd-226448199f6c" xlink:to="loc_mrk_PrometheusBiosciencesIncMember_193a6ee9-0461-4cca-b675-41dbd0866ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ImagoBioSciencesIncMember_f8abb7c0-e757-49e2-a4ea-d2deca72c23d" xlink:href="mrk-20230331.xsd#mrk_ImagoBioSciencesIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_3067b195-4f71-4fcc-8fcd-226448199f6c" xlink:to="loc_mrk_ImagoBioSciencesIncMember_f8abb7c0-e757-49e2-a4ea-d2deca72c23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e4b388d7-5bf5-4df0-ace6-868881bac236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b94167b-0604-4f80-abc9-11b110c081f4" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e4b388d7-5bf5-4df0-ace6-868881bac236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_2c0da96d-eb4d-498c-94f9-1c656a8d9184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e4b388d7-5bf5-4df0-ace6-868881bac236" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_2c0da96d-eb4d-498c-94f9-1c656a8d9184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_3aeb711a-e783-4cfb-972c-306f4ea450fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_2c0da96d-eb4d-498c-94f9-1c656a8d9184" xlink:to="loc_us-gaap_SubsequentEventMember_3aeb711a-e783-4cfb-972c-306f4ea450fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_898f3318-4d87-477d-8e00-1a4c06875fdd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b94167b-0604-4f80-abc9-11b110c081f4" xlink:to="loc_srt_StatementScenarioAxis_898f3318-4d87-477d-8e00-1a4c06875fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_5ed7fc1e-96ea-4d66-873f-8b76f10025b3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_898f3318-4d87-477d-8e00-1a4c06875fdd" xlink:to="loc_srt_ScenarioUnspecifiedDomain_5ed7fc1e-96ea-4d66-873f-8b76f10025b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_14e29b08-956e-4597-bfd7-16207cba1ffd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_5ed7fc1e-96ea-4d66-873f-8b76f10025b3" xlink:to="loc_srt_ScenarioForecastMember_14e29b08-956e-4597-bfd7-16207cba1ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_26ca938e-8418-4668-8d60-0e8f885f510d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b94167b-0604-4f80-abc9-11b110c081f4" xlink:to="loc_srt_ProductOrServiceAxis_26ca938e-8418-4668-8d60-0e8f885f510d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3ebf4e95-418a-4842-8bf6-e825d64ba963" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_26ca938e-8418-4668-8d60-0e8f885f510d" xlink:to="loc_srt_ProductsAndServicesDomain_3ebf4e95-418a-4842-8bf6-e825d64ba963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_89c11883-e7fa-4bef-afd0-ff913b5891f5" xlink:href="mrk-20230331.xsd#mrk_LenvimaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3ebf4e95-418a-4842-8bf6-e825d64ba963" xlink:to="loc_mrk_LenvimaMember_89c11883-e7fa-4bef-afd0-ff913b5891f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f4cb6234-51c1-4280-9540-031212cb121c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2b94167b-0604-4f80-abc9-11b110c081f4" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_f4cb6234-51c1-4280-9540-031212cb121c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetAcquisitionSharePrice_c77d1fc0-0af9-4293-8c7b-c314c3144540" xlink:href="mrk-20230331.xsd#mrk_AssetAcquisitionSharePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4cb6234-51c1-4280-9540-031212cb121c" xlink:to="loc_mrk_AssetAcquisitionSharePrice_c77d1fc0-0af9-4293-8c7b-c314c3144540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected_a97d74cc-302a-4ce1-8434-e0133827f780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionPriceOfAcquisitionExpected"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4cb6234-51c1-4280-9540-031212cb121c" xlink:to="loc_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected_a97d74cc-302a-4ce1-8434-e0133827f780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_504c663b-4d25-4a0e-867e-8c0cfc1c5578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4cb6234-51c1-4280-9540-031212cb121c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_504c663b-4d25-4a0e-867e-8c0cfc1c5578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments_e7bda1b8-e735-4b6f-ba8d-1d854ff18254" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4cb6234-51c1-4280-9540-031212cb121c" xlink:to="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments_e7bda1b8-e735-4b6f-ba8d-1d854ff18254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_2a77c56c-1126-44c9-a306-e35b163df918" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4cb6234-51c1-4280-9540-031212cb121c" xlink:to="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_2a77c56c-1126-44c9-a306-e35b163df918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments_d093e1d7-63b8-48b3-8435-c8a6c046e56a" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4cb6234-51c1-4280-9540-031212cb121c" xlink:to="loc_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments_d093e1d7-63b8-48b3-8435-c8a6c046e56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty_1a09db89-cefb-450a-8f46-3a000885f295" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4cb6234-51c1-4280-9540-031212cb121c" xlink:to="loc_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty_1a09db89-cefb-450a-8f46-3a000885f295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_9a6c6a3c-f5ca-477a-b4a2-2528ad2c42c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4cb6234-51c1-4280-9540-031212cb121c" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_9a6c6a3c-f5ca-477a-b4a2-2528ad2c42c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_0ff84ae7-1d21-42e2-8f4c-2c6ea80b934f" xlink:href="mrk-20230331.xsd#mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4cb6234-51c1-4280-9540-031212cb121c" xlink:to="loc_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_0ff84ae7-1d21-42e2-8f4c-2c6ea80b934f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_9f59c9c9-8ba7-4288-8020-e0d40d075671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4cb6234-51c1-4280-9540-031212cb121c" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_9f59c9c9-8ba7-4288-8020-e0d40d075671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_388387b7-0cd1-466f-a161-bb633a7e2681" xlink:href="mrk-20230331.xsd#mrk_MilestonePaymentsMadetoCollaborativePartner"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4cb6234-51c1-4280-9540-031212cb121c" xlink:to="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_388387b7-0cd1-466f-a161-bb633a7e2681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#CollaborativeArrangementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract_ca803747-4a10-41f3-b12e-786051be1f9b" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85d4dceb-48f1-4870-b701-87c2853368eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_CollaborativeArrangementsAbstract_ca803747-4a10-41f3-b12e-786051be1f9b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85d4dceb-48f1-4870-b701-87c2853368eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_72b3654f-9f23-4576-b0b6-d1c4446e681a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85d4dceb-48f1-4870-b701-87c2853368eb" xlink:to="loc_srt_CounterpartyNameAxis_72b3654f-9f23-4576-b0b6-d1c4446e681a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03a5402d-e08f-48ab-ba39-6ffe8b480525" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_72b3654f-9f23-4576-b0b6-d1c4446e681a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03a5402d-e08f-48ab-ba39-6ffe8b480525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_a3898083-eff3-42a6-b3f8-2def5e6f56a6" xlink:href="mrk-20230331.xsd#mrk_AstraZenecaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03a5402d-e08f-48ab-ba39-6ffe8b480525" xlink:to="loc_mrk_AstraZenecaMember_a3898083-eff3-42a6-b3f8-2def5e6f56a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember_f77e284d-bb0d-4af9-8c78-2c0912519e74" xlink:href="mrk-20230331.xsd#mrk_EisaiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03a5402d-e08f-48ab-ba39-6ffe8b480525" xlink:to="loc_mrk_EisaiMember_f77e284d-bb0d-4af9-8c78-2c0912519e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember_721b493b-05a4-49d9-9ecd-5270c9c2a7e8" xlink:href="mrk-20230331.xsd#mrk_BayerAGMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03a5402d-e08f-48ab-ba39-6ffe8b480525" xlink:to="loc_mrk_BayerAGMember_721b493b-05a4-49d9-9ecd-5270c9c2a7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BristolMyersSquibbMember_4465cf4e-e076-4b9f-8254-fe528d61aea9" xlink:href="mrk-20230331.xsd#mrk_BristolMyersSquibbMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03a5402d-e08f-48ab-ba39-6ffe8b480525" xlink:to="loc_mrk_BristolMyersSquibbMember_4465cf4e-e076-4b9f-8254-fe528d61aea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_d6e27cab-4d80-4d0b-bdfe-90e9600ccabf" xlink:href="mrk-20230331.xsd#mrk_LenvimaMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_03a5402d-e08f-48ab-ba39-6ffe8b480525" xlink:to="loc_mrk_LenvimaMember_d6e27cab-4d80-4d0b-bdfe-90e9600ccabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5787f12f-e26d-4f12-9460-d117ab57c4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85d4dceb-48f1-4870-b701-87c2853368eb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5787f12f-e26d-4f12-9460-d117ab57c4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_69ffc595-7647-435d-a57f-906ca17a014d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5787f12f-e26d-4f12-9460-d117ab57c4ac" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_69ffc595-7647-435d-a57f-906ca17a014d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_fd672cc9-2f30-445d-942a-c7b9e2d0329f" xlink:href="mrk-20230331.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_69ffc595-7647-435d-a57f-906ca17a014d" xlink:to="loc_mrk_SalesBasedMilestonesMember_fd672cc9-2f30-445d-942a-c7b9e2d0329f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_380bf4b0-4c40-42b3-9613-84a6e0754cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_69ffc595-7647-435d-a57f-906ca17a014d" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_380bf4b0-4c40-42b3-9613-84a6e0754cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_b70a787f-a8c8-425c-822f-f4097d5939ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_69ffc595-7647-435d-a57f-906ca17a014d" xlink:to="loc_us-gaap_LicensingAgreementsMember_b70a787f-a8c8-425c-822f-f4097d5939ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_acdda68a-1761-4fc4-81e3-00cb7a130d0e" xlink:href="mrk-20230331.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_69ffc595-7647-435d-a57f-906ca17a014d" xlink:to="loc_mrk_RegulatoryMilestonesMember_acdda68a-1761-4fc4-81e3-00cb7a130d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5db1f15d-c1ac-446d-ac8c-97ae6114b249" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85d4dceb-48f1-4870-b701-87c2853368eb" xlink:to="loc_srt_ProductOrServiceAxis_5db1f15d-c1ac-446d-ac8c-97ae6114b249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8076c10a-ff99-461b-829a-d7b853a8d705" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5db1f15d-c1ac-446d-ac8c-97ae6114b249" xlink:to="loc_srt_ProductsAndServicesDomain_8076c10a-ff99-461b-829a-d7b853a8d705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LynparzaMember_2f319cd1-10af-4d21-a7ce-04d78141eb46" xlink:href="mrk-20230331.xsd#mrk_LynparzaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8076c10a-ff99-461b-829a-d7b853a8d705" xlink:to="loc_mrk_LynparzaMember_2f319cd1-10af-4d21-a7ce-04d78141eb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_dd3faa64-adf0-4e58-8ee4-38a2d0e4af84" xlink:href="mrk-20230331.xsd#mrk_LenvimaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8076c10a-ff99-461b-829a-d7b853a8d705" xlink:to="loc_mrk_LenvimaMember_dd3faa64-adf0-4e58-8ee4-38a2d0e4af84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VerquvoMember_b6f12ab5-50bf-41a3-963e-8d889c9a87d7" xlink:href="mrk-20230331.xsd#mrk_VerquvoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8076c10a-ff99-461b-829a-d7b853a8d705" xlink:to="loc_mrk_VerquvoMember_b6f12ab5-50bf-41a3-963e-8d889c9a87d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_abd2837f-610a-4adc-8120-e7bd1f79279f" xlink:href="mrk-20230331.xsd#mrk_AdempasMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8076c10a-ff99-461b-829a-d7b853a8d705" xlink:to="loc_mrk_AdempasMember_abd2837f-610a-4adc-8120-e7bd1f79279f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueReblozylMember_f51cbfb4-df5d-440b-86f3-8a84a8bd3868" xlink:href="mrk-20230331.xsd#mrk_AllianceRevenueReblozylMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8076c10a-ff99-461b-829a-d7b853a8d705" xlink:to="loc_mrk_AllianceRevenueReblozylMember_f51cbfb4-df5d-440b-86f3-8a84a8bd3868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ae8cd831-ca82-4273-97cf-a6c6e8fbedd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85d4dceb-48f1-4870-b701-87c2853368eb" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ae8cd831-ca82-4273-97cf-a6c6e8fbedd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_fc215f16-9333-4761-965a-157fc72ab91d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ae8cd831-ca82-4273-97cf-a6c6e8fbedd8" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_fc215f16-9333-4761-965a-157fc72ab91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_e6740c82-2902-41df-a06a-72d4d9fb995a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fc215f16-9333-4761-965a-157fc72ab91d" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_e6740c82-2902-41df-a06a-72d4d9fb995a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_7966a642-f367-448a-bb51-eded2b497440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fc215f16-9333-4761-965a-157fc72ab91d" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_7966a642-f367-448a-bb51-eded2b497440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c32f8954-6cfb-4e21-be9a-a99996a5ddb6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85d4dceb-48f1-4870-b701-87c2853368eb" xlink:to="loc_srt_RangeAxis_c32f8954-6cfb-4e21-be9a-a99996a5ddb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_98cc4131-e745-49bf-bfc8-784481ed559e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c32f8954-6cfb-4e21-be9a-a99996a5ddb6" xlink:to="loc_srt_RangeMember_98cc4131-e745-49bf-bfc8-784481ed559e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_52d5883c-6b55-4605-9ab2-a91528afddf0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_98cc4131-e745-49bf-bfc8-784481ed559e" xlink:to="loc_srt_MinimumMember_52d5883c-6b55-4605-9ab2-a91528afddf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cbe35d50-25fd-4f49-987c-e0819bcdfc84" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_98cc4131-e745-49bf-bfc8-784481ed559e" xlink:to="loc_srt_MaximumMember_cbe35d50-25fd-4f49-987c-e0819bcdfc84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_c4de6bfb-5381-4b2c-92fd-5f40649b6a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85d4dceb-48f1-4870-b701-87c2853368eb" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_c4de6bfb-5381-4b2c-92fd-5f40649b6a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_8b79a195-ae47-490e-88e4-e96c278c500c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_c4de6bfb-5381-4b2c-92fd-5f40649b6a1c" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_8b79a195-ae47-490e-88e4-e96c278c500c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesBasedMilestonesMember_aaaf326b-fc37-4163-9add-6383d1f8bab0" xlink:href="mrk-20230331.xsd#mrk_SalesBasedMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_8b79a195-ae47-490e-88e4-e96c278c500c" xlink:to="loc_mrk_SalesBasedMilestonesMember_aaaf326b-fc37-4163-9add-6383d1f8bab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RegulatoryMilestonesMember_9cc862e8-6ebb-4a1a-9f49-03bff54396f9" xlink:href="mrk-20230331.xsd#mrk_RegulatoryMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_8b79a195-ae47-490e-88e4-e96c278c500c" xlink:to="loc_mrk_RegulatoryMilestonesMember_9cc862e8-6ebb-4a1a-9f49-03bff54396f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_2e7fbdd4-c2f6-4a5d-a973-bcee3be06319" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85d4dceb-48f1-4870-b701-87c2853368eb" xlink:to="loc_srt_ConsolidationItemsAxis_2e7fbdd4-c2f6-4a5d-a973-bcee3be06319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_cdd786f4-a85f-464d-bea2-f60d94b60eb3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_2e7fbdd4-c2f6-4a5d-a973-bcee3be06319" xlink:to="loc_srt_ConsolidationItemsDomain_cdd786f4-a85f-464d-bea2-f60d94b60eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_d9645879-598e-4824-81b4-2288f0bc0abd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_cdd786f4-a85f-464d-bea2-f60d94b60eb3" xlink:to="loc_us-gaap_OperatingSegmentsMember_d9645879-598e-4824-81b4-2288f0bc0abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b8904a68-2f95-45c7-af5a-1773e8e393d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85d4dceb-48f1-4870-b701-87c2853368eb" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b8904a68-2f95-45c7-af5a-1773e8e393d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f9f1d1f6-ba82-40ee-99c7-cb1635241b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b8904a68-2f95-45c7-af5a-1773e8e393d2" xlink:to="loc_us-gaap_SegmentDomain_f9f1d1f6-ba82-40ee-99c7-cb1635241b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_0e21dd53-66f2-4785-b3d4-cd36186d7b78" xlink:href="mrk-20230331.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f9f1d1f6-ba82-40ee-99c7-cb1635241b9b" xlink:to="loc_mrk_PharmaceuticalsegmentMember_0e21dd53-66f2-4785-b3d4-cd36186d7b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_85d4dceb-48f1-4870-b701-87c2853368eb" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement_507fc0e3-70fe-47b8-a45a-0a276ba8bd3d" xlink:href="mrk-20230331.xsd#mrk_ProbableContingentPaymentsCollaborativeArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_mrk_ProbableContingentPaymentsCollaborativeArrangement_507fc0e3-70fe-47b8-a45a-0a276ba8bd3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8c396042-b265-4642-9936-6563f479720d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_us-gaap_Liabilities_8c396042-b265-4642-9936-6563f479720d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_7ff83cd3-0dc4-4ea1-b83d-847d763a8eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_us-gaap_AdjustmentForAmortization_7ff83cd3-0dc4-4ea1-b83d-847d763a8eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsSalesBased_426c95ed-b669-4c02-b5d2-a2f544d86469" xlink:href="mrk-20230331.xsd#mrk_MilestonePaymentsSalesBased"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_mrk_MilestonePaymentsSalesBased_426c95ed-b669-4c02-b5d2-a2f544d86469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PotentialFutureMilestonePaymentsSalesBased_bf2fc0d3-0c69-469d-b580-f434cf2dcdbe" xlink:href="mrk-20230331.xsd#mrk_PotentialFutureMilestonePaymentsSalesBased"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_mrk_PotentialFutureMilestonePaymentsSalesBased_bf2fc0d3-0c69-469d-b580-f434cf2dcdbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued_6a4bd815-d146-4b9b-a3ef-6af7c3973b85" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued_6a4bd815-d146-4b9b-a3ef-6af7c3973b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_39d447b6-a288-4f5f-849a-cdded4dcfc47" xlink:href="mrk-20230331.xsd#mrk_MilestonePaymentsMadetoCollaborativePartner"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_mrk_MilestonePaymentsMadetoCollaborativePartner_39d447b6-a288-4f5f-849a-cdded4dcfc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PotentialFutureMilestonePaymentsRegulatory_49e5a8e1-6cd6-4e83-8c66-b9461a78ee68" xlink:href="mrk-20230331.xsd#mrk_PotentialFutureMilestonePaymentsRegulatory"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_mrk_PotentialFutureMilestonePaymentsRegulatory_49e5a8e1-6cd6-4e83-8c66-b9461a78ee68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_206c4a06-6061-459e-a10f-23bd25a6ac1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_206c4a06-6061-459e-a10f-23bd25a6ac1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRatePercentage_452801f2-b0b7-4423-abfc-450ef8c087b5" xlink:href="mrk-20230331.xsd#mrk_RoyaltyRatePercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_mrk_RoyaltyRatePercentage_452801f2-b0b7-4423-abfc-450ef8c087b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RoyaltyRateDeductionPercentage_4597a5ca-fe89-4a77-b4f0-3ad775f905c0" xlink:href="mrk-20230331.xsd#mrk_RoyaltyRateDeductionPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_mrk_RoyaltyRateDeductionPercentage_4597a5ca-fe89-4a77-b4f0-3ad775f905c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_74d23a9c-7579-4888-a3fa-10727d4f9dee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_us-gaap_Revenues_74d23a9c-7579-4888-a3fa-10727d4f9dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_bf952042-9131-4dc9-a0c5-00c41d57744e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_bf952042-9131-4dc9-a0c5-00c41d57744e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_e3a49c62-2166-451e-8741-634fd68b8b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_us-gaap_ProceedsFromCollaborators_e3a49c62-2166-451e-8741-634fd68b8b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ContingentProceedsCollaborativeArrangement_9d92d363-33fe-4fd6-b4a0-ca09e3231f4b" xlink:href="mrk-20230331.xsd#mrk_ContingentProceedsCollaborativeArrangement"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e167e6f7-ade1-49a1-a666-f23a8fd9a5fc" xlink:to="loc_mrk_ContingentProceedsCollaborativeArrangement_9d92d363-33fe-4fd6-b4a0-ca09e3231f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#CollaborativeArrangementsFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementsAbstract_1c4b7a9e-912f-4e53-bcea-11031244b5d3" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83b41c7a-5f25-4f9d-a13a-031a5dfa45f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_CollaborativeArrangementsAbstract_1c4b7a9e-912f-4e53-bcea-11031244b5d3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83b41c7a-5f25-4f9d-a13a-031a5dfa45f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_56031da0-816d-49a7-9b08-68ae2204ac8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83b41c7a-5f25-4f9d-a13a-031a5dfa45f7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_56031da0-816d-49a7-9b08-68ae2204ac8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4b5d1829-7906-4e50-8a9b-86001f10c155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_56031da0-816d-49a7-9b08-68ae2204ac8d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4b5d1829-7906-4e50-8a9b-86001f10c155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_e96aa27c-03ea-42b7-b86d-2dbd5d7caaa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4b5d1829-7906-4e50-8a9b-86001f10c155" xlink:to="loc_us-gaap_SalesMember_e96aa27c-03ea-42b7-b86d-2dbd5d7caaa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_a1c7c8f6-0cf6-4fe9-8f44-0e64ae91e276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4b5d1829-7906-4e50-8a9b-86001f10c155" xlink:to="loc_us-gaap_CostOfSalesMember_a1c7c8f6-0cf6-4fe9-8f44-0e64ae91e276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5b93c431-4a19-4517-bbc3-93e333426571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4b5d1829-7906-4e50-8a9b-86001f10c155" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5b93c431-4a19-4517-bbc3-93e333426571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4e4cbb1c-41a1-4c29-8539-8cb5b29c2a83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4b5d1829-7906-4e50-8a9b-86001f10c155" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4e4cbb1c-41a1-4c29-8539-8cb5b29c2a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e8f61fc3-6639-4f97-84dd-e5e84cf0982f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83b41c7a-5f25-4f9d-a13a-031a5dfa45f7" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e8f61fc3-6639-4f97-84dd-e5e84cf0982f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_00c94d59-f024-4687-a7c8-e2b87d32d505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e8f61fc3-6639-4f97-84dd-e5e84cf0982f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_00c94d59-f024-4687-a7c8-e2b87d32d505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_b1796ff9-ffb6-41b8-85c1-a2523b30021f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_00c94d59-f024-4687-a7c8-e2b87d32d505" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_b1796ff9-ffb6-41b8-85c1-a2523b30021f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_3a1ec093-3696-462b-a48e-3919fb6307d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_00c94d59-f024-4687-a7c8-e2b87d32d505" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesMember_3a1ec093-3696-462b-a48e-3919fb6307d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a3d48c33-48d3-4822-a985-42d33d89f571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_00c94d59-f024-4687-a7c8-e2b87d32d505" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a3d48c33-48d3-4822-a985-42d33d89f571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_509980f1-0301-4239-8507-1540edb597ce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83b41c7a-5f25-4f9d-a13a-031a5dfa45f7" xlink:to="loc_srt_CounterpartyNameAxis_509980f1-0301-4239-8507-1540edb597ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcb74f7a-448c-4421-8e44-86d7a4f5e9a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_509980f1-0301-4239-8507-1540edb597ce" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcb74f7a-448c-4421-8e44-86d7a4f5e9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AstraZenecaMember_6e1e851c-61b9-4e26-8f69-35d7619cb98d" xlink:href="mrk-20230331.xsd#mrk_AstraZenecaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcb74f7a-448c-4421-8e44-86d7a4f5e9a4" xlink:to="loc_mrk_AstraZenecaMember_6e1e851c-61b9-4e26-8f69-35d7619cb98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EisaiMember_60d90368-098f-420b-bd54-fa06a72f4af0" xlink:href="mrk-20230331.xsd#mrk_EisaiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcb74f7a-448c-4421-8e44-86d7a4f5e9a4" xlink:to="loc_mrk_EisaiMember_60d90368-098f-420b-bd54-fa06a72f4af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BayerAGMember_fd16219a-1798-4a7d-bb8c-9d2727293935" xlink:href="mrk-20230331.xsd#mrk_BayerAGMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcb74f7a-448c-4421-8e44-86d7a4f5e9a4" xlink:to="loc_mrk_BayerAGMember_fd16219a-1798-4a7d-bb8c-9d2727293935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RidgebackBiotherapeuticsLPMember_1191226c-5179-4604-acd0-829f023cafb7" xlink:href="mrk-20230331.xsd#mrk_RidgebackBiotherapeuticsLPMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bcb74f7a-448c-4421-8e44-86d7a4f5e9a4" xlink:to="loc_mrk_RidgebackBiotherapeuticsLPMember_1191226c-5179-4604-acd0-829f023cafb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_806bc5ec-80a7-4d45-bdf4-874c460b7f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83b41c7a-5f25-4f9d-a13a-031a5dfa45f7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_806bc5ec-80a7-4d45-bdf4-874c460b7f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_74a15f7c-6bfd-4c74-931f-b6cfca4270e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_806bc5ec-80a7-4d45-bdf4-874c460b7f37" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_74a15f7c-6bfd-4c74-931f-b6cfca4270e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_d29f6ee7-6063-4709-9d6f-00269e810702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_74a15f7c-6bfd-4c74-931f-b6cfca4270e3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_d29f6ee7-6063-4709-9d6f-00269e810702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_92de8b30-a01d-4fba-83b7-769de509a715" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83b41c7a-5f25-4f9d-a13a-031a5dfa45f7" xlink:to="loc_srt_ProductOrServiceAxis_92de8b30-a01d-4fba-83b7-769de509a715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e91c1974-d21f-409d-945a-202c70ad581a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_92de8b30-a01d-4fba-83b7-769de509a715" xlink:to="loc_srt_ProductsAndServicesDomain_e91c1974-d21f-409d-945a-202c70ad581a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember_917ce7fe-28d9-46f3-bdab-6f25c8eec9d3" xlink:href="mrk-20230331.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e91c1974-d21f-409d-945a-202c70ad581a" xlink:to="loc_mrk_AlliancerevenueLynparzaMember_917ce7fe-28d9-46f3-bdab-6f25c8eec9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueKoselugoMember_f7041dbd-aa85-4de6-964e-e5915814ad75" xlink:href="mrk-20230331.xsd#mrk_AllianceRevenueKoselugoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e91c1974-d21f-409d-945a-202c70ad581a" xlink:to="loc_mrk_AllianceRevenueKoselugoMember_f7041dbd-aa85-4de6-964e-e5915814ad75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_e1a3525b-1010-4892-b019-dc7469cacf40" xlink:href="mrk-20230331.xsd#mrk_AdempasMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e91c1974-d21f-409d-945a-202c70ad581a" xlink:to="loc_mrk_AdempasMember_e1a3525b-1010-4892-b019-dc7469cacf40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VerquvoMember_8e3b4bb1-9488-46fc-b7a6-53df66e7fc3b" xlink:href="mrk-20230331.xsd#mrk_VerquvoMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e91c1974-d21f-409d-945a-202c70ad581a" xlink:to="loc_mrk_VerquvoMember_8e3b4bb1-9488-46fc-b7a6-53df66e7fc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LagevrioMember_33eed587-a0ed-4f87-b2f4-51af0ba56943" xlink:href="mrk-20230331.xsd#mrk_LagevrioMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e91c1974-d21f-409d-945a-202c70ad581a" xlink:to="loc_mrk_LagevrioMember_33eed587-a0ed-4f87-b2f4-51af0ba56943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_10e2846d-75fd-4b70-bca5-57a6a0b70c75" xlink:href="mrk-20230331.xsd#mrk_LenvimaMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e91c1974-d21f-409d-945a-202c70ad581a" xlink:to="loc_mrk_LenvimaMember_10e2846d-75fd-4b70-bca5-57a6a0b70c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bb5589e-ddc3-4068-856c-a5cc161017b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_83b41c7a-5f25-4f9d-a13a-031a5dfa45f7" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bb5589e-ddc3-4068-856c-a5cc161017b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementProfitSharing_e1f9d76d-a52b-4bca-8ebd-4e2b7a2621a7" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementProfitSharing"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bb5589e-ddc3-4068-856c-a5cc161017b0" xlink:to="loc_mrk_CollaborativeArrangementProfitSharing_e1f9d76d-a52b-4bca-8ebd-4e2b7a2621a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CollaborativeArrangementSalesNet_6fd2f290-4c3e-41b2-9f8e-b19a8dea0aea" xlink:href="mrk-20230331.xsd#mrk_CollaborativeArrangementSalesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bb5589e-ddc3-4068-856c-a5cc161017b0" xlink:to="loc_mrk_CollaborativeArrangementSalesNet_6fd2f290-4c3e-41b2-9f8e-b19a8dea0aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4f07ef63-7ade-4eee-9840-800a56ad8311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bb5589e-ddc3-4068-856c-a5cc161017b0" xlink:to="loc_us-gaap_Revenues_4f07ef63-7ade-4eee-9840-800a56ad8311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5ffea7aa-9ffd-4d06-a527-5f376d6e9350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bb5589e-ddc3-4068-856c-a5cc161017b0" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5ffea7aa-9ffd-4d06-a527-5f376d6e9350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_440e2667-755f-48f4-98cb-537e17ccacea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bb5589e-ddc3-4068-856c-a5cc161017b0" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_440e2667-755f-48f4-98cb-537e17ccacea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d133c76b-cb14-4103-8780-c0f03d592ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bb5589e-ddc3-4068-856c-a5cc161017b0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d133c76b-cb14-4103-8780-c0f03d592ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_230d95c7-cbd1-48db-80e4-f89d1879c0a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bb5589e-ddc3-4068-856c-a5cc161017b0" xlink:to="loc_us-gaap_ReceivablesNetCurrent_230d95c7-cbd1-48db-80e4-f89d1879c0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4e62d63c-6d9a-4395-b57b-ad6fd5a74c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bb5589e-ddc3-4068-856c-a5cc161017b0" xlink:to="loc_us-gaap_LiabilitiesCurrent_4e62d63c-6d9a-4395-b57b-ad6fd5a74c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_f938b0c3-d22a-4c73-9248-e1d21cc742ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bb5589e-ddc3-4068-856c-a5cc161017b0" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_f938b0c3-d22a-4c73-9248-e1d21cc742ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3e044b3d-ddf1-4674-b584-d471eee983a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bb5589e-ddc3-4068-856c-a5cc161017b0" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3e044b3d-ddf1-4674-b584-d471eee983a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_3ba897ac-f7a8-4746-95a4-24c26d41ad3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1bb5589e-ddc3-4068-856c-a5cc161017b0" xlink:to="loc_us-gaap_AdjustmentForAmortization_3ba897ac-f7a8-4746-95a4-24c26d41ad3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#RestructuringNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/RestructuringNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6ddbd9f2-e2b7-42e6-90bc-786dc53a2d08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cd1b4cff-05fe-40e1-b42d-4ae9d0362333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6ddbd9f2-e2b7-42e6-90bc-786dc53a2d08" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cd1b4cff-05fe-40e1-b42d-4ae9d0362333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_e9fe7ed3-23ab-45da-976c-f0146071e2ec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cd1b4cff-05fe-40e1-b42d-4ae9d0362333" xlink:to="loc_srt_StatementScenarioAxis_e9fe7ed3-23ab-45da-976c-f0146071e2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b957c484-c933-4107-a9cd-d0087812dff0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_e9fe7ed3-23ab-45da-976c-f0146071e2ec" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b957c484-c933-4107-a9cd-d0087812dff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_c0d21dfb-b1c2-420b-acd3-0a9026111421" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_b957c484-c933-4107-a9cd-d0087812dff0" xlink:to="loc_srt_ScenarioForecastMember_c0d21dfb-b1c2-420b-acd3-0a9026111421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_df48fc18-abd4-4efd-8268-d53adda6c202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_cd1b4cff-05fe-40e1-b42d-4ae9d0362333" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_df48fc18-abd4-4efd-8268-d53adda6c202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_00deda33-655c-413c-9e07-f5b474d8bd50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_df48fc18-abd4-4efd-8268-d53adda6c202" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_00deda33-655c-413c-9e07-f5b474d8bd50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_a109ef07-1c21-4669-b736-4d10e769933c" xlink:href="mrk-20230331.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_df48fc18-abd4-4efd-8268-d53adda6c202" xlink:to="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays_a109ef07-1c21-4669-b736-4d10e769933c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_0ef26d44-fe23-43b3-bebf-5e04f044d681" xlink:href="mrk-20230331.xsd#mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_df48fc18-abd4-4efd-8268-d53adda6c202" xlink:to="loc_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash_0ef26d44-fe23-43b3-bebf-5e04f044d681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_affe1bd2-67e5-46a8-8395-2e92499b9894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_df48fc18-abd4-4efd-8268-d53adda6c202" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_affe1bd2-67e5-46a8-8395-2e92499b9894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_d40ba93b-6db9-4c1d-b3e4-30f0f55b0962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_df48fc18-abd4-4efd-8268-d53adda6c202" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_d40ba93b-6db9-4c1d-b3e4-30f0f55b0962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#RestructuringChargesActivitiesbyTypeofCostDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_df33d4e9-b5cb-4324-a987-79cec46fd85e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_46e8aaf3-2e9a-404c-b470-c951dfe84d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_df33d4e9-b5cb-4324-a987-79cec46fd85e" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_46e8aaf3-2e9a-404c-b470-c951dfe84d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_11ccd8de-4be3-4e3b-ab89-c904ae650a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_46e8aaf3-2e9a-404c-b470-c951dfe84d78" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_11ccd8de-4be3-4e3b-ab89-c904ae650a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5f2d17f6-531d-44b8-82c4-1c93a1a61844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_11ccd8de-4be3-4e3b-ab89-c904ae650a4d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5f2d17f6-531d-44b8-82c4-1c93a1a61844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_85f2b28c-239e-4e17-9681-157630e9d4de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5f2d17f6-531d-44b8-82c4-1c93a1a61844" xlink:to="loc_us-gaap_CostOfSalesMember_85f2b28c-239e-4e17-9681-157630e9d4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b85108d3-e1fb-48cf-a256-37c25346cd37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5f2d17f6-531d-44b8-82c4-1c93a1a61844" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b85108d3-e1fb-48cf-a256-37c25346cd37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_69a02802-4490-4712-9396-a31bdde29e54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5f2d17f6-531d-44b8-82c4-1c93a1a61844" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_69a02802-4490-4712-9396-a31bdde29e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_db21a38b-14d0-4341-873f-89c39d98a13f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5f2d17f6-531d-44b8-82c4-1c93a1a61844" xlink:to="loc_us-gaap_RestructuringChargesMember_db21a38b-14d0-4341-873f-89c39d98a13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_b65357de-b83f-4991-b8f4-8c38045d8bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_46e8aaf3-2e9a-404c-b470-c951dfe84d78" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_b65357de-b83f-4991-b8f4-8c38045d8bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_d76ab1c8-a991-4917-9737-58a7080e6302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_b65357de-b83f-4991-b8f4-8c38045d8bf2" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_d76ab1c8-a991-4917-9737-58a7080e6302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_4b046952-0c67-4ec3-b6af-706528f7ed60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d76ab1c8-a991-4917-9737-58a7080e6302" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_4b046952-0c67-4ec3-b6af-706528f7ed60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember_def5458e-08a6-453c-a5dc-787e668432aa" xlink:href="mrk-20230331.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d76ab1c8-a991-4917-9737-58a7080e6302" xlink:to="loc_mrk_AcceleratedDepreciationMember_def5458e-08a6-453c-a5dc-787e668432aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_6b08ce18-119b-4af0-b52b-daf2c0e45706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d76ab1c8-a991-4917-9737-58a7080e6302" xlink:to="loc_us-gaap_OtherRestructuringMember_6b08ce18-119b-4af0-b52b-daf2c0e45706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_330bd6c3-5a24-4614-90f5-2667829285f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_46e8aaf3-2e9a-404c-b470-c951dfe84d78" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_330bd6c3-5a24-4614-90f5-2667829285f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_7368c482-4d8e-410b-b217-930d685e32a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_330bd6c3-5a24-4614-90f5-2667829285f9" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_7368c482-4d8e-410b-b217-930d685e32a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#RestructuringActivitiesbyProgramDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_61efb428-dc7c-4fe9-afe9-67750d7c2426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_89b8378f-d294-4b8c-8e1a-373cca76411b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_61efb428-dc7c-4fe9-afe9-67750d7c2426" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_89b8378f-d294-4b8c-8e1a-373cca76411b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_b03a8be2-6fa1-4988-9f7e-5d988e017afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_89b8378f-d294-4b8c-8e1a-373cca76411b" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_b03a8be2-6fa1-4988-9f7e-5d988e017afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_e887c16f-f774-4d9d-9d1c-4d047b3738c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_b03a8be2-6fa1-4988-9f7e-5d988e017afd" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_e887c16f-f774-4d9d-9d1c-4d047b3738c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_524d48be-08f3-48fb-8daa-fe63dc0550fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OneTimeTerminationBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e887c16f-f774-4d9d-9d1c-4d047b3738c9" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_524d48be-08f3-48fb-8daa-fe63dc0550fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AcceleratedDepreciationMember_1f476ca9-59e1-4047-8e72-c1fc100d450d" xlink:href="mrk-20230331.xsd#mrk_AcceleratedDepreciationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e887c16f-f774-4d9d-9d1c-4d047b3738c9" xlink:to="loc_mrk_AcceleratedDepreciationMember_1f476ca9-59e1-4047-8e72-c1fc100d450d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_593911f3-b541-4294-9dde-9fcd414fd215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_e887c16f-f774-4d9d-9d1c-4d047b3738c9" xlink:to="loc_us-gaap_OtherRestructuringMember_593911f3-b541-4294-9dde-9fcd414fd215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_6a1bc533-88ca-4c4a-b4ef-fe21d94cf4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_89b8378f-d294-4b8c-8e1a-373cca76411b" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_6a1bc533-88ca-4c4a-b4ef-fe21d94cf4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_cf782d11-b2c4-4b76-a7fc-7e4608859a31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6a1bc533-88ca-4c4a-b4ef-fe21d94cf4cc" xlink:to="loc_us-gaap_RestructuringReserveRollForward_cf782d11-b2c4-4b76-a7fc-7e4608859a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_870bea63-f7bb-4fce-8c5b-c1dcc11601ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_cf782d11-b2c4-4b76-a7fc-7e4608859a31" xlink:to="loc_us-gaap_RestructuringReserve_870bea63-f7bb-4fce-8c5b-c1dcc11601ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_41ad91bf-eb11-49a3-925d-2454b42b3020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_cf782d11-b2c4-4b76-a7fc-7e4608859a31" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_41ad91bf-eb11-49a3-925d-2454b42b3020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_6dcd65a5-134b-46c8-b9cf-442db1975f01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_cf782d11-b2c4-4b76-a7fc-7e4608859a31" xlink:to="loc_us-gaap_PaymentsForRestructuring_6dcd65a5-134b-46c8-b9cf-442db1975f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_019d2d9b-f8fa-458e-91f3-e0ef2638014d" xlink:href="mrk-20230331.xsd#mrk_RestructuringReserveIncreaseDecreaseNoncashActivity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_cf782d11-b2c4-4b76-a7fc-7e4608859a31" xlink:to="loc_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity_019d2d9b-f8fa-458e-91f3-e0ef2638014d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_39fe9df4-88c8-4186-b8b4-62b6bfca6004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_cf782d11-b2c4-4b76-a7fc-7e4608859a31" xlink:to="loc_us-gaap_RestructuringReserve_39fe9df4-88c8-4186-b8b4-62b6bfca6004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_590200d8-ad39-484a-aafe-7b60a147bc03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_57eb3ec6-d74c-4509-8682-781543d21ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_590200d8-ad39-484a-aafe-7b60a147bc03" xlink:to="loc_us-gaap_DerivativeTable_57eb3ec6-d74c-4509-8682-781543d21ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2e110df5-65fa-4dc0-81a1-40b6af85f26b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_57eb3ec6-d74c-4509-8682-781543d21ad4" xlink:to="loc_srt_RangeAxis_2e110df5-65fa-4dc0-81a1-40b6af85f26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_10ad1d7c-67d3-45eb-8d0b-0b186f9abada" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2e110df5-65fa-4dc0-81a1-40b6af85f26b" xlink:to="loc_srt_RangeMember_10ad1d7c-67d3-45eb-8d0b-0b186f9abada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_afd89191-4f27-4ca5-851f-2e515115834a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_10ad1d7c-67d3-45eb-8d0b-0b186f9abada" xlink:to="loc_srt_MaximumMember_afd89191-4f27-4ca5-851f-2e515115834a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_413f0886-ee0d-417d-87df-3375c7f93c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_57eb3ec6-d74c-4509-8682-781543d21ad4" xlink:to="loc_us-gaap_HedgingDesignationAxis_413f0886-ee0d-417d-87df-3375c7f93c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_95e24a3a-2858-4ab3-afc1-e5cbe501b3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_413f0886-ee0d-417d-87df-3375c7f93c01" xlink:to="loc_us-gaap_HedgingDesignationDomain_95e24a3a-2858-4ab3-afc1-e5cbe501b3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d40f7374-ba2c-46b6-b88e-2c50db1fdf2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_95e24a3a-2858-4ab3-afc1-e5cbe501b3fc" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_d40f7374-ba2c-46b6-b88e-2c50db1fdf2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_971443b7-8a6b-4df7-896a-bd6f0c1eb1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_95e24a3a-2858-4ab3-afc1-e5cbe501b3fc" xlink:to="loc_us-gaap_NondesignatedMember_971443b7-8a6b-4df7-896a-bd6f0c1eb1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e570b19a-1c61-47ee-8cbd-38a31d265161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_57eb3ec6-d74c-4509-8682-781543d21ad4" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e570b19a-1c61-47ee-8cbd-38a31d265161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2c566614-4517-4e53-9c86-b7988cbd876b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e570b19a-1c61-47ee-8cbd-38a31d265161" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2c566614-4517-4e53-9c86-b7988cbd876b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_75268db3-d311-479a-b136-684e4ebdd70e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_2c566614-4517-4e53-9c86-b7988cbd876b" xlink:to="loc_us-gaap_InterestRateSwapMember_75268db3-d311-479a-b136-684e4ebdd70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d2ff864-8621-4255-8629-990bac0b450e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_57eb3ec6-d74c-4509-8682-781543d21ad4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d2ff864-8621-4255-8629-990bac0b450e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31754ad0-53e8-44e2-a5e1-4b2fd2f33c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d2ff864-8621-4255-8629-990bac0b450e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31754ad0-53e8-44e2-a5e1-4b2fd2f33c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d9166e8f-da3a-4256-b81c-3d707d26950d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31754ad0-53e8-44e2-a5e1-4b2fd2f33c57" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d9166e8f-da3a-4256-b81c-3d707d26950d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_4088f8cb-44fb-4796-8b25-70d345885f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_57eb3ec6-d74c-4509-8682-781543d21ad4" xlink:to="loc_us-gaap_InvestmentTypeAxis_4088f8cb-44fb-4796-8b25-70d345885f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_ac56674d-6d57-473c-9fe8-46f003d54a06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_4088f8cb-44fb-4796-8b25-70d345885f5e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_ac56674d-6d57-473c-9fe8-46f003d54a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFundsMember_9f08f950-1731-4372-9845-5f0545b9792d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_ac56674d-6d57-473c-9fe8-46f003d54a06" xlink:to="loc_us-gaap_EquityFundsMember_9f08f950-1731-4372-9845-5f0545b9792d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_06852af4-d22f-46b6-9252-486ee1401e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_57eb3ec6-d74c-4509-8682-781543d21ad4" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_06852af4-d22f-46b6-9252-486ee1401e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_049f7e78-1aee-47e4-b218-6f49274f611c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_06852af4-d22f-46b6-9252-486ee1401e6f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_049f7e78-1aee-47e4-b218-6f49274f611c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5884390b-9b99-4ea4-b451-5286a3ff4314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_049f7e78-1aee-47e4-b218-6f49274f611c" xlink:to="loc_us-gaap_SubsequentEventMember_5884390b-9b99-4ea4-b451-5286a3ff4314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_57eb3ec6-d74c-4509-8682-781543d21ad4" xlink:to="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAverageRemainingMaturity1_9662c1c9-153b-430e-8d6e-9adec0e948c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAverageRemainingMaturity1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_DerivativeAverageRemainingMaturity1_9662c1c9-153b-430e-8d6e-9adec0e948c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_6957225b-3878-4050-9dc3-0ef2fe2cf6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_6957225b-3878-4050-9dc3-0ef2fe2cf6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_12319904-8127-429f-b088-eed4da43425d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_DerivativeNotionalAmount_12319904-8127-429f-b088-eed4da43425d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_34a9862e-f246-4713-b81c-c7e8e744c523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_34a9862e-f246-4713-b81c-c7e8e744c523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_dec463ec-3552-46a6-8778-e872e0578e86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_dec463ec-3552-46a6-8778-e872e0578e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_986a2089-798f-42e6-ae41-7ebfb9b70e27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount_986a2089-798f-42e6-ae41-7ebfb9b70e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_b85f42b8-0cdf-4fa5-ade9-b3d57baaf03c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_b85f42b8-0cdf-4fa5-ade9-b3d57baaf03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_fbe6f53a-9842-4921-b77b-57305a0e0537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount_fbe6f53a-9842-4921-b77b-57305a0e0537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_aaca2110-f16e-401e-aaec-90c41f95a655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount_aaca2110-f16e-401e-aaec-90c41f95a655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFVNINoncurrent_a3f95e56-b627-4e66-8c96-59b23ded9fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFVNINoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_EquitySecuritiesFVNINoncurrent_a3f95e56-b627-4e66-8c96-59b23ded9fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_092a0a7a-4d88-4f90-ba5e-d9ef3c374add" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_092a0a7a-4d88-4f90-ba5e-d9ef3c374add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_9961cf57-5b60-4f3f-b900-7bbe445c355f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_9961cf57-5b60-4f3f-b900-7bbe445c355f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_3ff67028-8778-42ef-9a24-d263a3788888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_DebtInstrumentFairValue_3ff67028-8778-42ef-9a24-d263a3788888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_c2135d2b-ea81-4816-8e12-d9c65e70baa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_c2135d2b-ea81-4816-8e12-d9c65e70baa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableSale_d4567437-0cab-45e5-b7f5-71113137ddbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableSale"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_AccountsReceivableSale_d4567437-0cab-45e5-b7f5-71113137ddbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_8cdbc1c3-d258-4099-a782-651a43a1eb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_RestrictedCashCurrent_8cdbc1c3-d258-4099-a782-651a43a1eb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_8e16ca33-41fe-40f7-97f0-28cc3f289b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_8e16ca33-41fe-40f7-97f0-28cc3f289b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimSecurities_269e676e-7e7e-4dab-9345-e6854e4734c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralRightToReclaimSecurities"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_dc68ff6e-c9e6-4aec-8d30-d74af31c8bb9" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimSecurities_269e676e-7e7e-4dab-9345-e6854e4734c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#FinancialInstrumentsEffectofNetInvestmentHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0c8fb405-c971-4c9f-94f1-65d88b4954b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_80544a5c-47f8-4ae0-8271-4ccbb6926a20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0c8fb405-c971-4c9f-94f1-65d88b4954b6" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_80544a5c-47f8-4ae0-8271-4ccbb6926a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_9700c71c-b35f-4eab-b916-17e4968d040b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_80544a5c-47f8-4ae0-8271-4ccbb6926a20" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_9700c71c-b35f-4eab-b916-17e4968d040b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0fe2be11-8ffb-4458-9274-3d14d4ef9f85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9700c71c-b35f-4eab-b916-17e4968d040b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0fe2be11-8ffb-4458-9274-3d14d4ef9f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_b2499734-f2b8-4dcd-aeec-a38ef72bfcac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0fe2be11-8ffb-4458-9274-3d14d4ef9f85" xlink:to="loc_us-gaap_ForeignExchangeContractMember_b2499734-f2b8-4dcd-aeec-a38ef72bfcac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_EurodominatedNotesMember_c5f95c5a-c885-4416-b387-b19b21ee5184" xlink:href="mrk-20230331.xsd#mrk_EurodominatedNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0fe2be11-8ffb-4458-9274-3d14d4ef9f85" xlink:to="loc_mrk_EurodominatedNotesMember_c5f95c5a-c885-4416-b387-b19b21ee5184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e62d5a4d-ba82-41e7-9d52-f84b4b454411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_80544a5c-47f8-4ae0-8271-4ccbb6926a20" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e62d5a4d-ba82-41e7-9d52-f84b4b454411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4d020dce-f1d7-4166-b1d8-90decfa89890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e62d5a4d-ba82-41e7-9d52-f84b4b454411" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4d020dce-f1d7-4166-b1d8-90decfa89890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_fb544bee-663f-4000-8c62-29443c32926a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4d020dce-f1d7-4166-b1d8-90decfa89890" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_fb544bee-663f-4000-8c62-29443c32926a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_54c81a36-cb17-426c-8c1a-b5c39eb162c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_80544a5c-47f8-4ae0-8271-4ccbb6926a20" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_54c81a36-cb17-426c-8c1a-b5c39eb162c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_333be458-14f5-44ca-ad64-e9ec973df8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_54c81a36-cb17-426c-8c1a-b5c39eb162c4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_333be458-14f5-44ca-ad64-e9ec973df8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_14015323-ffe5-4313-bc82-a1f4f5205737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_54c81a36-cb17-426c-8c1a-b5c39eb162c4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_14015323-ffe5-4313-bc82-a1f4f5205737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_298ae2bf-2679-4c0b-a9c2-311830b0c25e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0c237fd0-771b-4c9c-a4bc-1ee8acca9df2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_298ae2bf-2679-4c0b-a9c2-311830b0c25e" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0c237fd0-771b-4c9c-a4bc-1ee8acca9df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1c616a11-029c-49ab-9077-d5b8ebe4ba66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0c237fd0-771b-4c9c-a4bc-1ee8acca9df2" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1c616a11-029c-49ab-9077-d5b8ebe4ba66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d1b1e165-c050-4214-b0fd-0dc51ccc8484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1c616a11-029c-49ab-9077-d5b8ebe4ba66" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d1b1e165-c050-4214-b0fd-0dc51ccc8484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_2d93cb68-0fa2-4023-835f-b12bde42d467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d1b1e165-c050-4214-b0fd-0dc51ccc8484" xlink:to="loc_us-gaap_InterestRateContractMember_2d93cb68-0fa2-4023-835f-b12bde42d467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_0c57ed2a-6a2c-4f7b-8259-b11d9a2b046d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d1b1e165-c050-4214-b0fd-0dc51ccc8484" xlink:to="loc_us-gaap_ForeignExchangeContractMember_0c57ed2a-6a2c-4f7b-8259-b11d9a2b046d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_d2fcbeb2-db64-42d5-a0c0-fb3549884b19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0c237fd0-771b-4c9c-a4bc-1ee8acca9df2" xlink:to="loc_us-gaap_HedgingDesignationAxis_d2fcbeb2-db64-42d5-a0c0-fb3549884b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_4b30c852-c39c-4663-a17f-988d937db2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_d2fcbeb2-db64-42d5-a0c0-fb3549884b19" xlink:to="loc_us-gaap_HedgingDesignationDomain_4b30c852-c39c-4663-a17f-988d937db2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_58b5c60a-c116-4cfe-8c59-8b7d37138057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_4b30c852-c39c-4663-a17f-988d937db2c1" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_58b5c60a-c116-4cfe-8c59-8b7d37138057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_79c2ba7b-faa0-444f-a159-05a510cb9fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_4b30c852-c39c-4663-a17f-988d937db2c1" xlink:to="loc_us-gaap_NondesignatedMember_79c2ba7b-faa0-444f-a159-05a510cb9fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1c58f9a8-5ef8-43f4-924d-39b14caa95a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0c237fd0-771b-4c9c-a4bc-1ee8acca9df2" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1c58f9a8-5ef8-43f4-924d-39b14caa95a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1650257d-0928-44da-b63b-dbe6846cdb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1c58f9a8-5ef8-43f4-924d-39b14caa95a6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1650257d-0928-44da-b63b-dbe6846cdb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember_fec54764-3233-41c8-ac5e-cf134eb3cc06" xlink:href="mrk-20230331.xsd#mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1650257d-0928-44da-b63b-dbe6846cdb5a" xlink:to="loc_mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember_fec54764-3233-41c8-ac5e-cf134eb3cc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_c6ab3054-0b09-4cfd-adff-1be73a3c7d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1650257d-0928-44da-b63b-dbe6846cdb5a" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_c6ab3054-0b09-4cfd-adff-1be73a3c7d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember_bd3ab7c0-6b9d-46a2-a1da-ebeb73edcc30" xlink:href="mrk-20230331.xsd#mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1650257d-0928-44da-b63b-dbe6846cdb5a" xlink:to="loc_mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember_bd3ab7c0-6b9d-46a2-a1da-ebeb73edcc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_18108347-86a6-4407-b4e0-021c4c4a8ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1650257d-0928-44da-b63b-dbe6846cdb5a" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_18108347-86a6-4407-b4e0-021c4c4a8ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_e4b897f5-ff82-40b9-9e0a-73372c7b5ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0c237fd0-771b-4c9c-a4bc-1ee8acca9df2" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_e4b897f5-ff82-40b9-9e0a-73372c7b5ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_82f55d83-8bba-436a-83ca-d9bece06b473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e4b897f5-ff82-40b9-9e0a-73372c7b5ecf" xlink:to="loc_us-gaap_DerivativeAssets_82f55d83-8bba-436a-83ca-d9bece06b473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_2fdf82b8-c064-4b84-810d-f3d2081d548a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e4b897f5-ff82-40b9-9e0a-73372c7b5ecf" xlink:to="loc_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration_2fdf82b8-c064-4b84-810d-f3d2081d548a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_cd6b06c4-fcfc-451e-8d53-2a1d5c9ae47b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e4b897f5-ff82-40b9-9e0a-73372c7b5ecf" xlink:to="loc_us-gaap_DerivativeLiabilities_cd6b06c4-fcfc-451e-8d53-2a1d5c9ae47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_aad03e89-f6ff-408b-8509-4132ec8b2693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e4b897f5-ff82-40b9-9e0a-73372c7b5ecf" xlink:to="loc_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_aad03e89-f6ff-408b-8509-4132ec8b2693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_8270ba77-5fb0-4dac-a63b-0724452b513e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_e4b897f5-ff82-40b9-9e0a-73372c7b5ecf" xlink:to="loc_us-gaap_DerivativeNotionalAmount_8270ba77-5fb0-4dac-a63b-0724452b513e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ddf9a8d8-45ba-4f7f-abdb-3e41de95809a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_5d23ab34-ac5e-4f6b-a5b9-445d90aa30e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ddf9a8d8-45ba-4f7f-abdb-3e41de95809a" xlink:to="loc_us-gaap_DerivativeAssets_5d23ab34-ac5e-4f6b-a5b9-445d90aa30e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_4f0cf6d4-62e3-4dca-b48c-df72e1bb6521" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ddf9a8d8-45ba-4f7f-abdb-3e41de95809a" xlink:to="loc_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction_4f0cf6d4-62e3-4dca-b48c-df72e1bb6521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralObligationToReturnCash_8ac26228-6867-4e04-baee-45e36a47eb71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralObligationToReturnCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ddf9a8d8-45ba-4f7f-abdb-3e41de95809a" xlink:to="loc_us-gaap_DerivativeCollateralObligationToReturnCash_8ac26228-6867-4e04-baee-45e36a47eb71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_ac30abb4-848d-4d2d-90cd-c57cc27bd896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ddf9a8d8-45ba-4f7f-abdb-3e41de95809a" xlink:to="loc_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_ac30abb4-848d-4d2d-90cd-c57cc27bd896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_0248bd08-48c9-4013-b11c-3ffb5e93fc8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ddf9a8d8-45ba-4f7f-abdb-3e41de95809a" xlink:to="loc_us-gaap_DerivativeLiabilities_0248bd08-48c9-4013-b11c-3ffb5e93fc8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_322be67e-a730-478a-86e4-d4156cc1f598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ddf9a8d8-45ba-4f7f-abdb-3e41de95809a" xlink:to="loc_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction_322be67e-a730-478a-86e4-d4156cc1f598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeCollateralRightToReclaimCash_414d61d4-7f1a-4d9b-b279-a3cfdad871d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeCollateralRightToReclaimCash"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ddf9a8d8-45ba-4f7f-abdb-3e41de95809a" xlink:to="loc_us-gaap_DerivativeCollateralRightToReclaimCash_414d61d4-7f1a-4d9b-b279-a3cfdad871d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_3a082dab-7099-420a-9baa-1c2b416c1c08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ddf9a8d8-45ba-4f7f-abdb-3e41de95809a" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection_3a082dab-7099-420a-9baa-1c2b416c1c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_dc431638-02f7-4fd4-964c-376b68699d10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_073ddd72-6073-4854-952e-7eff50ac51c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_dc431638-02f7-4fd4-964c-376b68699d10" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_073ddd72-6073-4854-952e-7eff50ac51c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d1581905-5631-4f52-9a90-4fd5b383b8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_073ddd72-6073-4854-952e-7eff50ac51c5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d1581905-5631-4f52-9a90-4fd5b383b8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e5d80fc0-5122-4b43-bffe-9da5d8d644d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d1581905-5631-4f52-9a90-4fd5b383b8fd" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e5d80fc0-5122-4b43-bffe-9da5d8d644d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_0ea3088e-64a4-4a6d-84bd-d9fe06b55549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e5d80fc0-5122-4b43-bffe-9da5d8d644d5" xlink:to="loc_us-gaap_InterestRateSwapMember_0ea3088e-64a4-4a6d-84bd-d9fe06b55549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_5f6637aa-43d7-456d-9047-90b797f8ee23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e5d80fc0-5122-4b43-bffe-9da5d8d644d5" xlink:to="loc_us-gaap_ForeignExchangeContractMember_5f6637aa-43d7-456d-9047-90b797f8ee23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_c01c9f87-19cb-482d-836a-12ada1cb2c35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_073ddd72-6073-4854-952e-7eff50ac51c5" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_c01c9f87-19cb-482d-836a-12ada1cb2c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_dc0be77c-1a71-416c-83bb-8f6f2035852e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_c01c9f87-19cb-482d-836a-12ada1cb2c35" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_dc0be77c-1a71-416c-83bb-8f6f2035852e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_2eb16209-4dcc-433e-b622-c19ac62d7a65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_dc0be77c-1a71-416c-83bb-8f6f2035852e" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_2eb16209-4dcc-433e-b622-c19ac62d7a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7a7c2216-d79b-4ddc-b01d-ccbe5b090a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_073ddd72-6073-4854-952e-7eff50ac51c5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7a7c2216-d79b-4ddc-b01d-ccbe5b090a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9da5e7cc-5fa8-4598-a85a-6f24927aa746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7a7c2216-d79b-4ddc-b01d-ccbe5b090a2c" xlink:to="loc_us-gaap_EquityComponentDomain_9da5e7cc-5fa8-4598-a85a-6f24927aa746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_89f849cb-d2ad-4215-83a9-d65aa057006e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9da5e7cc-5fa8-4598-a85a-6f24927aa746" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_89f849cb-d2ad-4215-83a9-d65aa057006e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f404f11d-c280-48a9-bf38-0c020615328d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_073ddd72-6073-4854-952e-7eff50ac51c5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f404f11d-c280-48a9-bf38-0c020615328d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4a775af0-d088-42b0-8b21-d07096b9ffef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f404f11d-c280-48a9-bf38-0c020615328d" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4a775af0-d088-42b0-8b21-d07096b9ffef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_ed03c8f4-59fe-4441-8d9b-66f78de82b35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4a775af0-d088-42b0-8b21-d07096b9ffef" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_ed03c8f4-59fe-4441-8d9b-66f78de82b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04bd5596-9e59-4e21-bb63-5504a6d701c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_073ddd72-6073-4854-952e-7eff50ac51c5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04bd5596-9e59-4e21-bb63-5504a6d701c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7c17dcae-378b-43ef-999a-4932aff09a38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04bd5596-9e59-4e21-bb63-5504a6d701c1" xlink:to="loc_us-gaap_Revenues_7c17dcae-378b-43ef-999a-4932aff09a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7791fcc8-7eee-4a63-a4ac-5115d59911ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04bd5596-9e59-4e21-bb63-5504a6d701c1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7791fcc8-7eee-4a63-a4ac-5115d59911ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_702870ea-bb09-4179-a2aa-c84bda047387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04bd5596-9e59-4e21-bb63-5504a6d701c1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_702870ea-bb09-4179-a2aa-c84bda047387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_770abd8e-04d3-4dbf-ab09-095d7bd3e070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04bd5596-9e59-4e21-bb63-5504a6d701c1" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_770abd8e-04d3-4dbf-ab09-095d7bd3e070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_351a2e12-f281-4135-b6a8-4bcc06a10411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04bd5596-9e59-4e21-bb63-5504a6d701c1" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_351a2e12-f281-4135-b6a8-4bcc06a10411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_d7486c82-586a-4874-b027-13705f494189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04bd5596-9e59-4e21-bb63-5504a6d701c1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_d7486c82-586a-4874-b027-13705f494189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_d6c0d4bb-40b5-4c28-88e8-9731f2d936a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04bd5596-9e59-4e21-bb63-5504a6d701c1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_d6c0d4bb-40b5-4c28-88e8-9731f2d936a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_86b027ba-d0f3-43ad-9a29-017210bac50b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_04bd5596-9e59-4e21-bb63-5504a6d701c1" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_86b027ba-d0f3-43ad-9a29-017210bac50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9c79f0a3-90bc-4177-9599-6a4f537bcdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_66328265-3441-4f36-a1b4-97d291ab7f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9c79f0a3-90bc-4177-9599-6a4f537bcdc5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_66328265-3441-4f36-a1b4-97d291ab7f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e02e1fe2-1b56-4bc1-8792-cbcdaa6fd7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_66328265-3441-4f36-a1b4-97d291ab7f94" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e02e1fe2-1b56-4bc1-8792-cbcdaa6fd7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d4a5d61c-5081-469a-b87c-62e0133dd2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e02e1fe2-1b56-4bc1-8792-cbcdaa6fd7e8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d4a5d61c-5081-469a-b87c-62e0133dd2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_710aabf2-3a2a-4346-8367-55cf92f5f54f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d4a5d61c-5081-469a-b87c-62e0133dd2c7" xlink:to="loc_us-gaap_CurrencySwapMember_710aabf2-3a2a-4346-8367-55cf92f5f54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeFutureMember_771998c7-e832-4896-be5b-6fa328185891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeFutureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_d4a5d61c-5081-469a-b87c-62e0133dd2c7" xlink:to="loc_us-gaap_ForeignExchangeFutureMember_771998c7-e832-4896-be5b-6fa328185891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_094de9dc-37e2-4bb4-92eb-cd6398360c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_66328265-3441-4f36-a1b4-97d291ab7f94" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_094de9dc-37e2-4bb4-92eb-cd6398360c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_022d3790-ac67-40ae-8a4c-6fe6034b3a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_094de9dc-37e2-4bb4-92eb-cd6398360c66" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_022d3790-ac67-40ae-8a4c-6fe6034b3a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_d908ae43-ff31-47b8-8755-0a2866e20699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_022d3790-ac67-40ae-8a4c-6fe6034b3a18" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_d908ae43-ff31-47b8-8755-0a2866e20699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_3e4b0640-67b5-46ec-9b36-d70f335a1e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_022d3790-ac67-40ae-8a4c-6fe6034b3a18" xlink:to="loc_us-gaap_SalesMember_3e4b0640-67b5-46ec-9b36-d70f335a1e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_e0e2d988-570b-4c66-9acb-aa295c5a22c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_66328265-3441-4f36-a1b4-97d291ab7f94" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_e0e2d988-570b-4c66-9acb-aa295c5a22c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_e900d9da-688a-473e-9f1b-18178f85d9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_e0e2d988-570b-4c66-9acb-aa295c5a22c9" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_e900d9da-688a-473e-9f1b-18178f85d9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_17ec1286-c9b5-4074-8187-a6e82145bd52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2759fbb4-7f2f-4f4d-a460-a55a68518085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_17ec1286-c9b5-4074-8187-a6e82145bd52" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2759fbb4-7f2f-4f4d-a460-a55a68518085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0d6e7364-97f1-48a4-87d6-3f19242c88fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2759fbb4-7f2f-4f4d-a460-a55a68518085" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0d6e7364-97f1-48a4-87d6-3f19242c88fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e90c64da-8b64-4edd-895e-eae7850c94c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0d6e7364-97f1-48a4-87d6-3f19242c88fa" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e90c64da-8b64-4edd-895e-eae7850c94c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_7a877fcb-bf4e-4d76-8141-ed8ed29e4b42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e90c64da-8b64-4edd-895e-eae7850c94c9" xlink:to="loc_us-gaap_CommercialPaperMember_7a877fcb-bf4e-4d76-8141-ed8ed29e4b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_38566d1f-d6b7-4e84-9618-b212d0ce5fae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e90c64da-8b64-4edd-895e-eae7850c94c9" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_38566d1f-d6b7-4e84-9618-b212d0ce5fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9457bcd5-de84-47e4-b10e-a1ffe1b615db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e90c64da-8b64-4edd-895e-eae7850c94c9" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9457bcd5-de84-47e4-b10e-a1ffe1b615db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_675c685a-c3ba-46b0-b92f-419b5a56ddc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e90c64da-8b64-4edd-895e-eae7850c94c9" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_675c685a-c3ba-46b0-b92f-419b5a56ddc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84a68e47-a22b-4c24-82f0-80ec2828330d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_2759fbb4-7f2f-4f4d-a460-a55a68518085" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84a68e47-a22b-4c24-82f0-80ec2828330d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_866bf826-1948-413b-a5b9-2a1337fe4a50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84a68e47-a22b-4c24-82f0-80ec2828330d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_866bf826-1948-413b-a5b9-2a1337fe4a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_06459323-90ee-45d1-961d-ba81d2a2bfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84a68e47-a22b-4c24-82f0-80ec2828330d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_06459323-90ee-45d1-961d-ba81d2a2bfbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_21dc954c-cb17-4b46-8817-db4b04a6a3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84a68e47-a22b-4c24-82f0-80ec2828330d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_21dc954c-cb17-4b46-8817-db4b04a6a3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8b4080a0-fee7-4a41-b283-f2494c262f96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84a68e47-a22b-4c24-82f0-80ec2828330d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8b4080a0-fee7-4a41-b283-f2494c262f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_ecd92dc9-6c13-4c28-b91b-47dcf2304a80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84a68e47-a22b-4c24-82f0-80ec2828330d" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_ecd92dc9-6c13-4c28-b91b-47dcf2304a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_d30c1b0c-c4da-4c7d-9148-783edd766680" xlink:href="mrk-20230331.xsd#mrk_DebtSecuritiesandEquitySecuritiesFVNI"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84a68e47-a22b-4c24-82f0-80ec2828330d" xlink:to="loc_mrk_DebtSecuritiesandEquitySecuritiesFVNI_d30c1b0c-c4da-4c7d-9148-783edd766680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_ea423bfd-6b82-4741-9a46-c5d2ac0f7a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_84a68e47-a22b-4c24-82f0-80ec2828330d" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_ea423bfd-6b82-4741-9a46-c5d2ac0f7a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f0b3bd22-ebe5-4b6d-8d7a-1042bdcccabd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fe228f70-95e3-4668-ae2a-533d7d6fbe68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f0b3bd22-ebe5-4b6d-8d7a-1042bdcccabd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fe228f70-95e3-4668-ae2a-533d7d6fbe68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eb3d70d1-1070-4af5-b1e4-d056ef8c2f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fe228f70-95e3-4668-ae2a-533d7d6fbe68" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eb3d70d1-1070-4af5-b1e4-d056ef8c2f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6e945abc-2b0e-40c6-84bc-ddc6472d21d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eb3d70d1-1070-4af5-b1e4-d056ef8c2f6e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6e945abc-2b0e-40c6-84bc-ddc6472d21d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_cc286788-bbe0-42c7-bc81-058ce85f3628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_6e945abc-2b0e-40c6-84bc-ddc6472d21d5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_cc286788-bbe0-42c7-bc81-058ce85f3628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6fc1786c-704e-4ff4-8a8f-b022e0fe166f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fe228f70-95e3-4668-ae2a-533d7d6fbe68" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6fc1786c-704e-4ff4-8a8f-b022e0fe166f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e1beedd9-3dba-4d92-8c6a-c36e0656433f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6fc1786c-704e-4ff4-8a8f-b022e0fe166f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e1beedd9-3dba-4d92-8c6a-c36e0656433f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_d1d18173-6d2d-49c8-9639-125d77182dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e1beedd9-3dba-4d92-8c6a-c36e0656433f" xlink:to="loc_us-gaap_CommercialPaperMember_d1d18173-6d2d-49c8-9639-125d77182dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d7311b53-b25f-4e34-ae8a-2740bf58e83f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e1beedd9-3dba-4d92-8c6a-c36e0656433f" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_d7311b53-b25f-4e34-ae8a-2740bf58e83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_4324c6e4-4d0c-4e66-8d8e-c0eed32d6665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e1beedd9-3dba-4d92-8c6a-c36e0656433f" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_4324c6e4-4d0c-4e66-8d8e-c0eed32d6665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_c0bf5cab-a242-4df2-8c18-74e3309b423f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e1beedd9-3dba-4d92-8c6a-c36e0656433f" xlink:to="loc_us-gaap_EquitySecuritiesMember_c0bf5cab-a242-4df2-8c18-74e3309b423f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_43c8985e-da70-4def-869e-c1176d723f30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e1beedd9-3dba-4d92-8c6a-c36e0656433f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_43c8985e-da70-4def-869e-c1176d723f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a337e41e-359d-43f6-a8c5-db0cd822fbad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fe228f70-95e3-4668-ae2a-533d7d6fbe68" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a337e41e-359d-43f6-a8c5-db0cd822fbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95f66b87-c37b-46ae-9a67-a4be50633192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a337e41e-359d-43f6-a8c5-db0cd822fbad" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95f66b87-c37b-46ae-9a67-a4be50633192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_bf7145d8-00cd-4732-8f04-1a195cabbe6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95f66b87-c37b-46ae-9a67-a4be50633192" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_bf7145d8-00cd-4732-8f04-1a195cabbe6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_29a10f9a-9e5f-4daa-b56c-6aa558c022dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95f66b87-c37b-46ae-9a67-a4be50633192" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_29a10f9a-9e5f-4daa-b56c-6aa558c022dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_007fb067-11a6-40f2-b000-e1fb1c3b1b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_95f66b87-c37b-46ae-9a67-a4be50633192" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_007fb067-11a6-40f2-b000-e1fb1c3b1b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_0fe6e323-f035-4321-a91c-d0f5c17485ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fe228f70-95e3-4668-ae2a-533d7d6fbe68" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_0fe6e323-f035-4321-a91c-d0f5c17485ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7c010215-9a49-4cad-899d-d1791d0c9cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_0fe6e323-f035-4321-a91c-d0f5c17485ca" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7c010215-9a49-4cad-899d-d1791d0c9cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeOptionMember_ec59e2ea-42d1-4bb4-83b7-01b8b42b7099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7c010215-9a49-4cad-899d-d1791d0c9cb5" xlink:to="loc_us-gaap_ForeignExchangeOptionMember_ec59e2ea-42d1-4bb4-83b7-01b8b42b7099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_89ebfe32-6222-4fac-bc19-20d22cbaf850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7c010215-9a49-4cad-899d-d1791d0c9cb5" xlink:to="loc_us-gaap_ForeignExchangeContractMember_89ebfe32-6222-4fac-bc19-20d22cbaf850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_2a0138f7-b186-4f97-a900-8ddf4782b14e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7c010215-9a49-4cad-899d-d1791d0c9cb5" xlink:to="loc_us-gaap_InterestRateSwapMember_2a0138f7-b186-4f97-a900-8ddf4782b14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bfe74377-4cf3-4fd7-938f-2daaa2a74635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fe228f70-95e3-4668-ae2a-533d7d6fbe68" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bfe74377-4cf3-4fd7-938f-2daaa2a74635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_83f9a8f3-fda6-46c5-89ea-6b9f9e830a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bfe74377-4cf3-4fd7-938f-2daaa2a74635" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_83f9a8f3-fda6-46c5-89ea-6b9f9e830a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0caa0f41-2c7e-4572-8b19-8fa173eb92b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_83f9a8f3-fda6-46c5-89ea-6b9f9e830a03" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0caa0f41-2c7e-4572-8b19-8fa173eb92b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_7949f343-5ba5-4eb3-8a83-61fbc6c7b351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_83f9a8f3-fda6-46c5-89ea-6b9f9e830a03" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_7949f343-5ba5-4eb3-8a83-61fbc6c7b351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingSecurities_514b3587-2413-4c49-9d74-6c5e6d8f5cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_83f9a8f3-fda6-46c5-89ea-6b9f9e830a03" xlink:to="loc_us-gaap_TradingSecurities_514b3587-2413-4c49-9d74-6c5e6d8f5cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7ba781be-9bdc-420a-8d74-8e3d8fab3fff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_83f9a8f3-fda6-46c5-89ea-6b9f9e830a03" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7ba781be-9bdc-420a-8d74-8e3d8fab3fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_c94eef3d-c134-4031-beb8-a3b71a8a8f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_83f9a8f3-fda6-46c5-89ea-6b9f9e830a03" xlink:to="loc_us-gaap_DerivativeAssets_c94eef3d-c134-4031-beb8-a3b71a8a8f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c12d2636-73ec-450c-acbe-72a63b1a3113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_83f9a8f3-fda6-46c5-89ea-6b9f9e830a03" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_c12d2636-73ec-450c-acbe-72a63b1a3113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_49fe3725-ae6b-4cd9-b6a7-9dd9d3ce5c30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bfe74377-4cf3-4fd7-938f-2daaa2a74635" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_49fe3725-ae6b-4cd9-b6a7-9dd9d3ce5c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_10eecac3-2707-45cc-b3d9-c6c70343fc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_49fe3725-ae6b-4cd9-b6a7-9dd9d3ce5c30" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_10eecac3-2707-45cc-b3d9-c6c70343fc8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_c3e74e49-b75a-473c-9bb4-95462e4b7544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_49fe3725-ae6b-4cd9-b6a7-9dd9d3ce5c30" xlink:to="loc_us-gaap_DerivativeLiabilities_c3e74e49-b75a-473c-9bb4-95462e4b7544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_cbabe258-fc50-4912-90a3-bb95709aa8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_49fe3725-ae6b-4cd9-b6a7-9dd9d3ce5c30" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_cbabe258-fc50-4912-90a3-bb95709aa8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0ace4956-45ae-4413-b08e-1bc10248ff14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e32439d5-2cf7-4272-9810-3ce2de924b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0ace4956-45ae-4413-b08e-1bc10248ff14" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e32439d5-2cf7-4272-9810-3ce2de924b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_4aba7c7d-040a-44ca-be4a-3284c5521675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e32439d5-2cf7-4272-9810-3ce2de924b6a" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_4aba7c7d-040a-44ca-be4a-3284c5521675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_1a17827f-c845-4aef-9bb4-e71c8cc10ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis_4aba7c7d-040a-44ca-be4a-3284c5521675" xlink:to="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_1a17827f-c845-4aef-9bb4-e71c8cc10ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SanofiPasteurMember_1f8e8bdb-a61e-4401-ad78-9dccf2fb3879" xlink:href="mrk-20230331.xsd#mrk_SanofiPasteurMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LegalEntityTypeOfCounterpartyDomain_1a17827f-c845-4aef-9bb4-e71c8cc10ee0" xlink:to="loc_mrk_SanofiPasteurMember_1f8e8bdb-a61e-4401-ad78-9dccf2fb3879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_d57e5b2c-c112-41a7-9b04-81a57cd73af0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_e32439d5-2cf7-4272-9810-3ce2de924b6a" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_d57e5b2c-c112-41a7-9b04-81a57cd73af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2155c958-104e-4aa8-85b6-11322e42dfe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_d57e5b2c-c112-41a7-9b04-81a57cd73af0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2155c958-104e-4aa8-85b6-11322e42dfe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d6e0c358-36b8-4b96-aaf8-beda3f846a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2155c958-104e-4aa8-85b6-11322e42dfe0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d6e0c358-36b8-4b96-aaf8-beda3f846a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_cfbe0afe-9ce4-4a98-bff0-cf5f4401f62d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2155c958-104e-4aa8-85b6-11322e42dfe0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_cfbe0afe-9ce4-4a98-bff0-cf5f4401f62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_a42a0064-1d45-4d31-a928-9013543c2bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2155c958-104e-4aa8-85b6-11322e42dfe0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_a42a0064-1d45-4d31-a928-9013543c2bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_2b463dd1-1788-4ecd-803d-d1990f40a65b" xlink:href="mrk-20230331.xsd#mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2155c958-104e-4aa8-85b6-11322e42dfe0" xlink:to="loc_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther_2b463dd1-1788-4ecd-803d-d1990f40a65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_500f3cda-2ab0-4ce4-b164-2c8ea55a3d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2155c958-104e-4aa8-85b6-11322e42dfe0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_500f3cda-2ab0-4ce4-b164-2c8ea55a3d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3ebace16-c1f9-455d-8846-d510b2ac7d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2155c958-104e-4aa8-85b6-11322e42dfe0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3ebace16-c1f9-455d-8846-d510b2ac7d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_7f9992ff-e31d-47a1-80a7-166c3c758450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2155c958-104e-4aa8-85b6-11322e42dfe0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_7f9992ff-e31d-47a1-80a7-166c3c758450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_6093f1b8-7b3f-4ada-ac2c-3f9446d1b2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_2155c958-104e-4aa8-85b6-11322e42dfe0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_6093f1b8-7b3f-4ada-ac2c-3f9446d1b2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#InventoriesScheduleofInventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_70dbc647-2ef5-4411-b98b-0b9d84c1fd8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_a1f8dada-b782-4d43-8272-66a3a3c3377a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_70dbc647-2ef5-4411-b98b-0b9d84c1fd8b" xlink:to="loc_us-gaap_InventoryFinishedGoods_a1f8dada-b782-4d43-8272-66a3a3c3377a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_2cd48eba-877d-415f-b109-bed7eeaa7258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessAndRawMaterials"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_70dbc647-2ef5-4411-b98b-0b9d84c1fd8b" xlink:to="loc_us-gaap_InventoryWorkInProcessAndRawMaterials_2cd48eba-877d-415f-b109-bed7eeaa7258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventorySupplies_51b65d2e-701b-476a-b8cd-3b319946f8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInventorySupplies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_70dbc647-2ef5-4411-b98b-0b9d84c1fd8b" xlink:to="loc_us-gaap_OtherInventorySupplies_51b65d2e-701b-476a-b8cd-3b319946f8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_43a5f701-7188-43a0-9ab2-edba627b1f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_70dbc647-2ef5-4411-b98b-0b9d84c1fd8b" xlink:to="loc_us-gaap_InventoryGross_43a5f701-7188-43a0-9ab2-edba627b1f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReserve_efcbbf56-c9f2-4679-b9b6-160a60ff1b19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLIFOReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_70dbc647-2ef5-4411-b98b-0b9d84c1fd8b" xlink:to="loc_us-gaap_InventoryLIFOReserve_efcbbf56-c9f2-4679-b9b6-160a60ff1b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNetAndInventoryNoncurrent_0b2a51dd-a9dd-45a1-8c64-87e00d2edfa7" xlink:href="mrk-20230331.xsd#mrk_InventoryNetAndInventoryNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_70dbc647-2ef5-4411-b98b-0b9d84c1fd8b" xlink:to="loc_mrk_InventoryNetAndInventoryNoncurrent_0b2a51dd-a9dd-45a1-8c64-87e00d2edfa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RecognizedAsAbstract_ee4a1ad4-d994-4418-b276-4029f70f9b79" xlink:href="mrk-20230331.xsd#mrk_RecognizedAsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_70dbc647-2ef5-4411-b98b-0b9d84c1fd8b" xlink:to="loc_mrk_RecognizedAsAbstract_ee4a1ad4-d994-4418-b276-4029f70f9b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_12d20a1e-8cbd-4e57-b837-7c0681d48621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_RecognizedAsAbstract_ee4a1ad4-d994-4418-b276-4029f70f9b79" xlink:to="loc_us-gaap_InventoryNet_12d20a1e-8cbd-4e57-b837-7c0681d48621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_b890bf7b-e423-42d5-b7a7-08e5e62e09e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_RecognizedAsAbstract_ee4a1ad4-d994-4418-b276-4029f70f9b79" xlink:to="loc_us-gaap_InventoryNoncurrent_b890bf7b-e423-42d5-b7a7-08e5e62e09e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesScheduleofInventoriesDetails_1" xlink:type="simple" xlink:href="mrk-20230331.xsd#InventoriesScheduleofInventoriesDetails_1"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/InventoriesScheduleofInventoriesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#InventoriesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/InventoriesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_30edd6b3-fc19-4c66-bd57-20c2322f9c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryTable_6edc9fc8-e0f8-4fcd-8715-522943f894eb" xlink:href="mrk-20230331.xsd#mrk_InventoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_30edd6b3-fc19-4c66-bd57-20c2322f9c23" xlink:to="loc_mrk_InventoryTable_6edc9fc8-e0f8-4fcd-8715-522943f894eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_e9ab736c-5ee8-439c-96d4-a2129a74dbc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_InventoryTable_6edc9fc8-e0f8-4fcd-8715-522943f894eb" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_e9ab736c-5ee8-439c-96d4-a2129a74dbc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_ae6cfa8b-f89b-4a47-a872-38ca554609eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_e9ab736c-5ee8-439c-96d4-a2129a74dbc0" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_ae6cfa8b-f89b-4a47-a872-38ca554609eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_196aa7c0-1960-47b0-9dbb-96035e3f9278" xlink:href="mrk-20230331.xsd#mrk_InventoryNotExpectedtobeSoldWithinOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_ae6cfa8b-f89b-4a47-a872-38ca554609eb" xlink:to="loc_mrk_InventoryNotExpectedtobeSoldWithinOneYearMember_196aa7c0-1960-47b0-9dbb-96035e3f9278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember_5494545d-6b5e-4b4f-8e2f-c58e34b3fbf9" xlink:href="mrk-20230331.xsd#mrk_InventoriesProducedinPreparationforProductLaunchesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_ae6cfa8b-f89b-4a47-a872-38ca554609eb" xlink:to="loc_mrk_InventoriesProducedinPreparationforProductLaunchesMember_5494545d-6b5e-4b4f-8e2f-c58e34b3fbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_f451ae0d-4cba-4a50-82c9-9e8e3ab8b0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_InventoryTable_6edc9fc8-e0f8-4fcd-8715-522943f894eb" xlink:to="loc_us-gaap_InventoryLineItems_f451ae0d-4cba-4a50-82c9-9e8e3ab8b0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_ddb5d356-1802-4615-bc29-f24dbef15ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_f451ae0d-4cba-4a50-82c9-9e8e3ab8b0d2" xlink:to="loc_us-gaap_InventoryNoncurrent_ddb5d356-1802-4615-bc29-f24dbef15ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#ContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9c6bf5cf-e799-43cc-aefb-ed75a45516d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_650ab951-e395-496e-8f2e-02dec2484b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9c6bf5cf-e799-43cc-aefb-ed75a45516d4" xlink:to="loc_us-gaap_LossContingenciesTable_650ab951-e395-496e-8f2e-02dec2484b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6ebf0c16-679c-47bf-8de3-40d6490c7a9a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_650ab951-e395-496e-8f2e-02dec2484b97" xlink:to="loc_srt_ProductOrServiceAxis_6ebf0c16-679c-47bf-8de3-40d6490c7a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dbe9d4ea-d4e6-4ce9-9760-1250d67d32ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6ebf0c16-679c-47bf-8de3-40d6490c7a9a" xlink:to="loc_srt_ProductsAndServicesDomain_dbe9d4ea-d4e6-4ce9-9760-1250d67d32ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member_a02c27e9-63ae-4fe1-80d5-d73fddb49bba" xlink:href="mrk-20230331.xsd#mrk_GardasilGardasil9Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dbe9d4ea-d4e6-4ce9-9760-1250d67d32ad" xlink:to="loc_mrk_GardasilGardasil9Member_a02c27e9-63ae-4fe1-80d5-d73fddb49bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember_0b2639be-06dd-4fca-a59d-edbb11032ff6" xlink:href="mrk-20230331.xsd#mrk_BridionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dbe9d4ea-d4e6-4ce9-9760-1250d67d32ad" xlink:to="loc_mrk_BridionMember_0b2639be-06dd-4fca-a59d-edbb11032ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaAndJanumetMember_2ffa0077-2ccc-4c0d-a6b5-0931a808134f" xlink:href="mrk-20230331.xsd#mrk_JanuviaAndJanumetMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dbe9d4ea-d4e6-4ce9-9760-1250d67d32ad" xlink:to="loc_mrk_JanuviaAndJanumetMember_2ffa0077-2ccc-4c0d-a6b5-0931a808134f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_621f699e-e353-447a-92b9-c92d609c5a7d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_650ab951-e395-496e-8f2e-02dec2484b97" xlink:to="loc_srt_LitigationCaseAxis_621f699e-e353-447a-92b9-c92d609c5a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e9cf97a1-be08-4301-99d6-0938b854b1ee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_621f699e-e353-447a-92b9-c92d609c5a7d" xlink:to="loc_srt_LitigationCaseTypeDomain_e9cf97a1-be08-4301-99d6-0938b854b1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZetiaantitrustlitigationMember_0a01dfc0-ac4a-4085-a4aa-7fa3a3b6b7ba" xlink:href="mrk-20230331.xsd#mrk_ZetiaantitrustlitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e9cf97a1-be08-4301-99d6-0938b854b1ee" xlink:to="loc_mrk_ZetiaantitrustlitigationMember_0a01dfc0-ac4a-4085-a4aa-7fa3a3b6b7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RotaTeqAntitrustLitigationMember_173dca4d-e166-4bb4-8b1f-c74576766b60" xlink:href="mrk-20230331.xsd#mrk_RotaTeqAntitrustLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e9cf97a1-be08-4301-99d6-0938b854b1ee" xlink:to="loc_mrk_RotaTeqAntitrustLitigationMember_173dca4d-e166-4bb4-8b1f-c74576766b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_bb31128b-4fcb-45ee-83b1-0ae45bf6c467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e9cf97a1-be08-4301-99d6-0938b854b1ee" xlink:to="loc_us-gaap_PatentsMember_bb31128b-4fcb-45ee-83b1-0ae45bf6c467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ComplaintAgainstTheJohnsHopkinsUniversityMember_bb1577ed-c02a-4d1f-9111-22dd9df5982e" xlink:href="mrk-20230331.xsd#mrk_ComplaintAgainstTheJohnsHopkinsUniversityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e9cf97a1-be08-4301-99d6-0938b854b1ee" xlink:to="loc_mrk_ComplaintAgainstTheJohnsHopkinsUniversityMember_bb1577ed-c02a-4d1f-9111-22dd9df5982e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c078bd5e-441a-4f59-ab43-f923da5335ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_650ab951-e395-496e-8f2e-02dec2484b97" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c078bd5e-441a-4f59-ab43-f923da5335ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_d156537d-44ef-46de-abd7-58cac23d309b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_c078bd5e-441a-4f59-ab43-f923da5335ef" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_d156537d-44ef-46de-abd7-58cac23d309b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LegalDefenseCostsMember_c76bc788-f9a8-48ab-8eb2-d647cba56fc0" xlink:href="mrk-20230331.xsd#mrk_LegalDefenseCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_d156537d-44ef-46de-abd7-58cac23d309b" xlink:to="loc_mrk_LegalDefenseCostsMember_c76bc788-f9a8-48ab-8eb2-d647cba56fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_f6e89857-edd7-46e5-b583-43c89ef853a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_650ab951-e395-496e-8f2e-02dec2484b97" xlink:to="loc_us-gaap_LitigationStatusAxis_f6e89857-edd7-46e5-b583-43c89ef853a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_37fb3968-70ca-451d-a03d-d8e190ce9d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_f6e89857-edd7-46e5-b583-43c89ef853a6" xlink:to="loc_us-gaap_LitigationStatusDomain_37fb3968-70ca-451d-a03d-d8e190ce9d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_093422f7-fba6-4b5f-bd4a-90111735ec9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_37fb3968-70ca-451d-a03d-d8e190ce9d5f" xlink:to="loc_us-gaap_PendingLitigationMember_093422f7-fba6-4b5f-bd4a-90111735ec9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a9c3540c-ffa0-4718-83a5-4c86000c01c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_650ab951-e395-496e-8f2e-02dec2484b97" xlink:to="loc_srt_StatementGeographicalAxis_a9c3540c-ffa0-4718-83a5-4c86000c01c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8fc56877-db6e-4b70-a3d3-1e0db023808a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_a9c3540c-ffa0-4718-83a5-4c86000c01c6" xlink:to="loc_srt_SegmentGeographicalDomain_8fc56877-db6e-4b70-a3d3-1e0db023808a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_24add0a9-017a-4725-9ecd-42735ed44f2b" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8fc56877-db6e-4b70-a3d3-1e0db023808a" xlink:to="loc_country_US_24add0a9-017a-4725-9ecd-42735ed44f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_cf13a209-ea54-45f3-8f8c-c8644edeb0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8fc56877-db6e-4b70-a3d3-1e0db023808a" xlink:to="loc_us-gaap_NonUsMember_cf13a209-ea54-45f3-8f8c-c8644edeb0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CO_ff62c915-55d0-48bb-be04-c9cc36870f8d" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CO"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8fc56877-db6e-4b70-a3d3-1e0db023808a" xlink:to="loc_country_CO_ff62c915-55d0-48bb-be04-c9cc36870f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_cabc04ed-a774-4dd7-a955-530c7dffaed4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_650ab951-e395-496e-8f2e-02dec2484b97" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_cabc04ed-a774-4dd7-a955-530c7dffaed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_41d9f88c-c86b-4331-8f29-895a6a77e6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cabc04ed-a774-4dd7-a955-530c7dffaed4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_41d9f88c-c86b-4331-8f29-895a6a77e6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_72aa7c45-34f6-4b97-a347-216946d14ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_41d9f88c-c86b-4331-8f29-895a6a77e6e3" xlink:to="loc_us-gaap_SubsequentEventMember_72aa7c45-34f6-4b97-a347-216946d14ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_d2d5d696-a16b-4227-9cbc-830532db7a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_650ab951-e395-496e-8f2e-02dec2484b97" xlink:to="loc_us-gaap_LossContingenciesLineItems_d2d5d696-a16b-4227-9cbc-830532db7a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_2a7c2e94-a667-44ce-92a3-e8f004cd1c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d2d5d696-a16b-4227-9cbc-830532db7a29" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_2a7c2e94-a667-44ce-92a3-e8f004cd1c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_199ab61d-69f6-43b5-9122-77ee7ca64a62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d2d5d696-a16b-4227-9cbc-830532db7a29" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_199ab61d-69f6-43b5-9122-77ee7ca64a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LossContingencyNumberOfStatesInWhichPlaintiffsReside_0ec42872-ed16-48c9-bec1-991ffe746c4f" xlink:href="mrk-20230331.xsd#mrk_LossContingencyNumberOfStatesInWhichPlaintiffsReside"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d2d5d696-a16b-4227-9cbc-830532db7a29" xlink:to="loc_mrk_LossContingencyNumberOfStatesInWhichPlaintiffsReside_0ec42872-ed16-48c9-bec1-991ffe746c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LossContingencyTrialPeriod_13d4b388-7c96-4925-9dc7-23a1aa3f18bc" xlink:href="mrk-20230331.xsd#mrk_LossContingencyTrialPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d2d5d696-a16b-4227-9cbc-830532db7a29" xlink:to="loc_mrk_LossContingencyTrialPeriod_13d4b388-7c96-4925-9dc7-23a1aa3f18bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsSettledNumber_6c77e30c-45ff-45f5-b1cb-f09fb0d9c24a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsSettledNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d2d5d696-a16b-4227-9cbc-830532db7a29" xlink:to="loc_us-gaap_LossContingencyClaimsSettledNumber_6c77e30c-45ff-45f5-b1cb-f09fb0d9c24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_a5e26158-f7a5-4693-913c-812e3b76dd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d2d5d696-a16b-4227-9cbc-830532db7a29" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_a5e26158-f7a5-4693-913c-812e3b76dd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_52bb0d1a-f116-4434-949e-699d78aeccb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d2d5d696-a16b-4227-9cbc-830532db7a29" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_52bb0d1a-f116-4434-949e-699d78aeccb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_12294e7d-733c-43e3-b794-200ae3906bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_d2d5d696-a16b-4227-9cbc-830532db7a29" xlink:to="loc_us-gaap_LitigationReserve_12294e7d-733c-43e3-b794-200ae3906bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EquityDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#EquityDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f6772488-e0ef-4028-8540-9204fe07e714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_StockholdersEquityTable_0fb36e09-9e92-4788-886d-bd9a2661a568" xlink:href="mrk-20230331.xsd#mrk_StockholdersEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f6772488-e0ef-4028-8540-9204fe07e714" xlink:to="loc_mrk_StockholdersEquityTable_0fb36e09-9e92-4788-886d-bd9a2661a568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6cfe47b6-6369-4df4-9c18-2d12fd2936bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_StockholdersEquityTable_0fb36e09-9e92-4788-886d-bd9a2661a568" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6cfe47b6-6369-4df4-9c18-2d12fd2936bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4ac8eb4b-65c2-4d39-95e1-da7f8da78ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6cfe47b6-6369-4df4-9c18-2d12fd2936bc" xlink:to="loc_us-gaap_EquityComponentDomain_4ac8eb4b-65c2-4d39-95e1-da7f8da78ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d41a12ff-2980-4577-bfb4-f8147a96a2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4ac8eb4b-65c2-4d39-95e1-da7f8da78ea7" xlink:to="loc_us-gaap_CommonStockMember_d41a12ff-2980-4577-bfb4-f8147a96a2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_342e0291-b54a-43e4-84bd-2059a4e35fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4ac8eb4b-65c2-4d39-95e1-da7f8da78ea7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_342e0291-b54a-43e4-84bd-2059a4e35fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_68d30792-029c-47e4-b581-08b45851565e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4ac8eb4b-65c2-4d39-95e1-da7f8da78ea7" xlink:to="loc_us-gaap_RetainedEarningsMember_68d30792-029c-47e4-b581-08b45851565e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_712653de-e30d-4ed4-af54-e36fd29a3498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4ac8eb4b-65c2-4d39-95e1-da7f8da78ea7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_712653de-e30d-4ed4-af54-e36fd29a3498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_05f29079-d94a-45b2-be85-1f0ac77703c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4ac8eb4b-65c2-4d39-95e1-da7f8da78ea7" xlink:to="loc_us-gaap_TreasuryStockCommonMember_05f29079-d94a-45b2-be85-1f0ac77703c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_57d41bb3-febb-46d4-b2c0-692b40348113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4ac8eb4b-65c2-4d39-95e1-da7f8da78ea7" xlink:to="loc_us-gaap_NoncontrollingInterestMember_57d41bb3-febb-46d4-b2c0-692b40348113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_StockholdersEquityLineItems_fdd766b9-3e6f-49b9-99d2-d14eb434a854" xlink:href="mrk-20230331.xsd#mrk_StockholdersEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_StockholdersEquityTable_0fb36e09-9e92-4788-886d-bd9a2661a568" xlink:to="loc_mrk_StockholdersEquityLineItems_fdd766b9-3e6f-49b9-99d2-d14eb434a854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62a97bd6-18ac-40cf-84ea-3b4d59fdb159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_StockholdersEquityLineItems_fdd766b9-3e6f-49b9-99d2-d14eb434a854" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62a97bd6-18ac-40cf-84ea-3b4d59fdb159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_ea611286-4bb6-47f5-b8f0-18ad87ec5f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62a97bd6-18ac-40cf-84ea-3b4d59fdb159" xlink:to="loc_us-gaap_CommonStockSharesIssued_ea611286-4bb6-47f5-b8f0-18ad87ec5f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_7a8a5576-9c86-4a58-b132-8cd4e5699c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62a97bd6-18ac-40cf-84ea-3b4d59fdb159" xlink:to="loc_us-gaap_TreasuryStockCommonShares_7a8a5576-9c86-4a58-b132-8cd4e5699c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_72e3966c-187b-4877-803e-7fe70c6501ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62a97bd6-18ac-40cf-84ea-3b4d59fdb159" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_72e3966c-187b-4877-803e-7fe70c6501ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4e5ab4ec-f247-412e-b177-a7cb855e2d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62a97bd6-18ac-40cf-84ea-3b4d59fdb159" xlink:to="loc_us-gaap_NetIncomeLoss_4e5ab4ec-f247-412e-b177-a7cb855e2d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9780f832-4f26-4711-be14-1a8155323f54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62a97bd6-18ac-40cf-84ea-3b4d59fdb159" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9780f832-4f26-4711-be14-1a8155323f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_65b6ce94-6653-42fd-ac16-842ee0daa298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62a97bd6-18ac-40cf-84ea-3b4d59fdb159" xlink:to="loc_us-gaap_DividendsCommonStockCash_65b6ce94-6653-42fd-ac16-842ee0daa298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_30f89a96-07de-4461-9e76-d5ee399bbe28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62a97bd6-18ac-40cf-84ea-3b4d59fdb159" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_30f89a96-07de-4461-9e76-d5ee399bbe28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_1944b47e-8abb-41ff-9ffb-d0206949b3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62a97bd6-18ac-40cf-84ea-3b4d59fdb159" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_1944b47e-8abb-41ff-9ffb-d0206949b3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_8d455bd7-888f-488b-b734-291330d47db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62a97bd6-18ac-40cf-84ea-3b4d59fdb159" xlink:to="loc_us-gaap_StockholdersEquityOther_8d455bd7-888f-488b-b734-291330d47db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d9fbdb58-f7ee-4156-b4be-5f366e06f990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62a97bd6-18ac-40cf-84ea-3b4d59fdb159" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d9fbdb58-f7ee-4156-b4be-5f366e06f990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_414be515-5797-4484-8edd-29436e25dd74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62a97bd6-18ac-40cf-84ea-3b4d59fdb159" xlink:to="loc_us-gaap_CommonStockSharesIssued_414be515-5797-4484-8edd-29436e25dd74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_9dddf2f2-e75f-4886-bd52-9ac930d2131d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62a97bd6-18ac-40cf-84ea-3b4d59fdb159" xlink:to="loc_us-gaap_TreasuryStockCommonShares_9dddf2f2-e75f-4886-bd52-9ac930d2131d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4cdfe5bc-c3de-4284-9e3f-5434fe89de7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_62a97bd6-18ac-40cf-84ea-3b4d59fdb159" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4cdfe5bc-c3de-4284-9e3f-5434fe89de7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_b28afb15-d226-4a8c-9ff9-c4f996856244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mrk_StockholdersEquityLineItems_fdd766b9-3e6f-49b9-99d2-d14eb434a854" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_b28afb15-d226-4a8c-9ff9-c4f996856244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5d1e7f67-7328-4b57-9a09-e82c871d0b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_dd29fa37-91d3-4f45-9bb9-be859dabdf4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5d1e7f67-7328-4b57-9a09-e82c871d0b68" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_dd29fa37-91d3-4f45-9bb9-be859dabdf4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_349874cc-fe9a-4177-8f9a-6fa7650ea3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_dd29fa37-91d3-4f45-9bb9-be859dabdf4f" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_349874cc-fe9a-4177-8f9a-6fa7650ea3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_1d913667-1d08-42f2-8123-10cfe04a91e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_349874cc-fe9a-4177-8f9a-6fa7650ea3d7" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_1d913667-1d08-42f2-8123-10cfe04a91e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_87346acd-a812-4ecd-a9f2-e663e38fe6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_1d913667-1d08-42f2-8123-10cfe04a91e1" xlink:to="loc_us-gaap_DomesticPlanMember_87346acd-a812-4ecd-a9f2-e663e38fe6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_e1209795-abb3-4bc2-9d27-6fb0e98e76d4" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_87346acd-a812-4ecd-a9f2-e663e38fe6cf" xlink:to="loc_country_US_e1209795-abb3-4bc2-9d27-6fb0e98e76d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_e4ec84b4-1a9c-4935-a6a9-6a7498c78f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_1d913667-1d08-42f2-8123-10cfe04a91e1" xlink:to="loc_us-gaap_ForeignPlanMember_e4ec84b4-1a9c-4935-a6a9-6a7498c78f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_eb3adfa5-3165-4a3a-9adf-cd2705c18585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_dd29fa37-91d3-4f45-9bb9-be859dabdf4f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_eb3adfa5-3165-4a3a-9adf-cd2705c18585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_532aae6f-0069-40d4-9c35-0459fde1ed84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_eb3adfa5-3165-4a3a-9adf-cd2705c18585" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_532aae6f-0069-40d4-9c35-0459fde1ed84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_a761599d-093a-46e5-88aa-61f3aaf00c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_532aae6f-0069-40d4-9c35-0459fde1ed84" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_a761599d-093a-46e5-88aa-61f3aaf00c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_84a0bd8a-0463-42ad-85ef-d19de1afbb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_532aae6f-0069-40d4-9c35-0459fde1ed84" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_84a0bd8a-0463-42ad-85ef-d19de1afbb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f96a4ced-baf8-4eb2-ab1b-f8f6b2e59db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_dd29fa37-91d3-4f45-9bb9-be859dabdf4f" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f96a4ced-baf8-4eb2-ab1b-f8f6b2e59db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_f7db2f50-f495-44b9-b0cd-0ae39503de2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f96a4ced-baf8-4eb2-ab1b-f8f6b2e59db7" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_f7db2f50-f495-44b9-b0cd-0ae39503de2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_e4d89e1d-38e8-46f7-bad3-8a44502d7ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f96a4ced-baf8-4eb2-ab1b-f8f6b2e59db7" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_e4d89e1d-38e8-46f7-bad3-8a44502d7ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_a842083b-44fc-40c5-8838-1ec2c8ea0ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f96a4ced-baf8-4eb2-ab1b-f8f6b2e59db7" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_a842083b-44fc-40c5-8838-1ec2c8ea0ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_5ca13a16-4241-4b2c-8fe1-925fd9ade80d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f96a4ced-baf8-4eb2-ab1b-f8f6b2e59db7" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_5ca13a16-4241-4b2c-8fe1-925fd9ade80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_1e861b81-d69a-493a-8cd1-9d3cfcc07125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f96a4ced-baf8-4eb2-ab1b-f8f6b2e59db7" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_1e861b81-d69a-493a-8cd1-9d3cfcc07125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_f8851e04-f9ed-4af3-93a3-98879ac1903e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f96a4ced-baf8-4eb2-ab1b-f8f6b2e59db7" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_f8851e04-f9ed-4af3-93a3-98879ac1903e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_6af4c5c2-5605-463d-aaef-ef65ad129985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f96a4ced-baf8-4eb2-ab1b-f8f6b2e59db7" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_6af4c5c2-5605-463d-aaef-ef65ad129985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_4a09d364-69c9-44f8-9f0d-14d9ef9e2b05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_f96a4ced-baf8-4eb2-ab1b-f8f6b2e59db7" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_4a09d364-69c9-44f8-9f0d-14d9ef9e2b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#PensionandOtherPostretirementBenefitPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1be00aa4-f6d7-4265-9801-fbf7ce66b568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_79dad691-806a-493b-a2d6-2c285f432d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1be00aa4-f6d7-4265-9801-fbf7ce66b568" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_79dad691-806a-493b-a2d6-2c285f432d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement_62ecbadd-f4c7-4bac-94fd-e669ae08c99a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1be00aa4-f6d7-4265-9801-fbf7ce66b568" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement_62ecbadd-f4c7-4bac-94fd-e669ae08c99a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_ac6c7474-8e6b-46be-98ae-0a87e0202258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_316fdc95-a302-42a5-a886-aee507a1c18d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ac6c7474-8e6b-46be-98ae-0a87e0202258" xlink:to="loc_us-gaap_InvestmentIncomeInterest_316fdc95-a302-42a5-a886-aee507a1c18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_189fb30c-46bb-49bc-83e2-a6c04a15d197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ac6c7474-8e6b-46be-98ae-0a87e0202258" xlink:to="loc_us-gaap_InterestExpense_189fb30c-46bb-49bc-83e2-a6c04a15d197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0fea35d7-362f-4a1e-afec-c9774b5abe59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ac6c7474-8e6b-46be-98ae-0a87e0202258" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0fea35d7-362f-4a1e-afec-c9774b5abe59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_05ca4689-7f68-49c6-b7ff-cd0b74189176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ac6c7474-8e6b-46be-98ae-0a87e0202258" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_05ca4689-7f68-49c6-b7ff-cd0b74189176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_b0324075-9087-49cc-bbca-6eb4aa26b10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ac6c7474-8e6b-46be-98ae-0a87e0202258" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_b0324075-9087-49cc-bbca-6eb4aa26b10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherNonoperatingIncomeExpenseOther_870c2406-c94b-440c-84ed-2b29a6ecc838" xlink:href="mrk-20230331.xsd#mrk_OtherNonoperatingIncomeExpenseOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ac6c7474-8e6b-46be-98ae-0a87e0202258" xlink:to="loc_mrk_OtherNonoperatingIncomeExpenseOther_870c2406-c94b-440c-84ed-2b29a6ecc838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1f409aa1-b387-42a1-a8e4-19fb3e44a091" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ac6c7474-8e6b-46be-98ae-0a87e0202258" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1f409aa1-b387-42a1-a8e4-19fb3e44a091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#OtherIncomeExpenseNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_02319b9d-18dd-44ef-9770-fdcc369da6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_4a30b67a-1022-4f2d-9c88-41c501e2e13f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_02319b9d-18dd-44ef-9770-fdcc369da6b5" xlink:to="loc_us-gaap_LossContingenciesTable_4a30b67a-1022-4f2d-9c88-41c501e2e13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_5d14f88e-aa37-499c-a731-caafe6568a82" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_4a30b67a-1022-4f2d-9c88-41c501e2e13f" xlink:to="loc_srt_LitigationCaseAxis_5d14f88e-aa37-499c-a731-caafe6568a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_294a9a9e-048e-43eb-ba46-b4b9141e6979" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_5d14f88e-aa37-499c-a731-caafe6568a82" xlink:to="loc_srt_LitigationCaseTypeDomain_294a9a9e-048e-43eb-ba46-b4b9141e6979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZetiaantitrustlitigationMember_161d2314-09b5-4b78-aea4-09c9b13651c4" xlink:href="mrk-20230331.xsd#mrk_ZetiaantitrustlitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_294a9a9e-048e-43eb-ba46-b4b9141e6979" xlink:to="loc_mrk_ZetiaantitrustlitigationMember_161d2314-09b5-4b78-aea4-09c9b13651c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_bd46ddbf-34eb-4bbc-a1ea-d32b6663123d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_4a30b67a-1022-4f2d-9c88-41c501e2e13f" xlink:to="loc_us-gaap_LossContingenciesLineItems_bd46ddbf-34eb-4bbc-a1ea-d32b6663123d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_f387aa6d-aeb9-456e-9abf-65b116ca503a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_bd46ddbf-34eb-4bbc-a1ea-d32b6663123d" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_f387aa6d-aeb9-456e-9abf-65b116ca503a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_4a6dc763-2fe3-4fd3-95f2-bfb34d651fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_bd46ddbf-34eb-4bbc-a1ea-d32b6663123d" xlink:to="loc_us-gaap_InterestPaid_4a6dc763-2fe3-4fd3-95f2-bfb34d651fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/TaxesonIncomeDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#TaxesonIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/TaxesonIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a9e5db4e-5544-4295-8155-baad1b88089e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_56528475-4f9c-495f-8839-1017369d03a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a9e5db4e-5544-4295-8155-baad1b88089e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_56528475-4f9c-495f-8839-1017369d03a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_TaxBenefitResultingFromAcquisitionCharge_3d059072-3d38-4a45-9fd0-43b1c9168dc6" xlink:href="mrk-20230331.xsd#mrk_TaxBenefitResultingFromAcquisitionCharge"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a9e5db4e-5544-4295-8155-baad1b88089e" xlink:to="loc_mrk_TaxBenefitResultingFromAcquisitionCharge_3d059072-3d38-4a45-9fd0-43b1c9168dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#EarningsPerShareCalculationsofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5e047ac9-ccbd-4f6e-9048-58c28dd03d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f5ce9f6c-bd1c-4acf-ab56-b623e64aeaf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5e047ac9-ccbd-4f6e-9048-58c28dd03d7e" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_f5ce9f6c-bd1c-4acf-ab56-b623e64aeaf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_e2b8b71a-4027-4ea7-9b02-cf7ed6145a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5e047ac9-ccbd-4f6e-9048-58c28dd03d7e" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_e2b8b71a-4027-4ea7-9b02-cf7ed6145a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b3c2d145-7c80-4def-9ffc-bdb01da779bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5e047ac9-ccbd-4f6e-9048-58c28dd03d7e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b3c2d145-7c80-4def-9ffc-bdb01da779bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_f35ed70b-386b-410b-a3c6-e5bfe5f5473e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5e047ac9-ccbd-4f6e-9048-58c28dd03d7e" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_f35ed70b-386b-410b-a3c6-e5bfe5f5473e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_573e614d-deb6-4a51-8212-5463d4e6b4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5e047ac9-ccbd-4f6e-9048-58c28dd03d7e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_573e614d-deb6-4a51-8212-5463d4e6b4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_2cf82203-6ed6-480b-bfaf-cb258cbc0c32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5e047ac9-ccbd-4f6e-9048-58c28dd03d7e" xlink:to="loc_us-gaap_EarningsPerShareBasic_2cf82203-6ed6-480b-bfaf-cb258cbc0c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_cd376173-4a7d-4e7a-b7c6-3930b7eccd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5e047ac9-ccbd-4f6e-9048-58c28dd03d7e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_cd376173-4a7d-4e7a-b7c6-3930b7eccd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/EarningsPerShareNarrativeDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#EarningsPerShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/EarningsPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_dd445b6f-1ae5-4bf9-96e3-5dbfe6d86742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d8fde16a-2cef-4bce-8e58-489c12413a75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dd445b6f-1ae5-4bf9-96e3-5dbfe6d86742" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d8fde16a-2cef-4bce-8e58-489c12413a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#OtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_999f42a2-0d4a-44fa-9e01-30f0b00f1764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_905648d6-8fa7-411e-acc0-51439956c72e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_999f42a2-0d4a-44fa-9e01-30f0b00f1764" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_905648d6-8fa7-411e-acc0-51439956c72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8f65f551-ce9d-471b-927c-ede5dcc4e92c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_905648d6-8fa7-411e-acc0-51439956c72e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8f65f551-ce9d-471b-927c-ede5dcc4e92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_36f94033-6daf-4dee-9126-12ebba987c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8f65f551-ce9d-471b-927c-ede5dcc4e92c" xlink:to="loc_us-gaap_EquityComponentDomain_36f94033-6daf-4dee-9126-12ebba987c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_5ceb7e31-e2bc-474f-8655-b7dde10b7cec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_36f94033-6daf-4dee-9126-12ebba987c7e" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_5ceb7e31-e2bc-474f-8655-b7dde10b7cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_3f977e2c-99c2-4730-9ddd-b48123d2a217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_36f94033-6daf-4dee-9126-12ebba987c7e" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_3f977e2c-99c2-4730-9ddd-b48123d2a217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_36d91505-0ed3-4510-8378-043c92f0e353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_36f94033-6daf-4dee-9126-12ebba987c7e" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_36d91505-0ed3-4510-8378-043c92f0e353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7d6628ba-f26f-4349-b046-13f5d50f64fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_36f94033-6daf-4dee-9126-12ebba987c7e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7d6628ba-f26f-4349-b046-13f5d50f64fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_adc53b7d-b6ce-44a3-9c74-31bffcc55fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_905648d6-8fa7-411e-acc0-51439956c72e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_adc53b7d-b6ce-44a3-9c74-31bffcc55fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_3e1dbd47-10c8-4af0-88f9-d814e5ecd7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_adc53b7d-b6ce-44a3-9c74-31bffcc55fa0" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_3e1dbd47-10c8-4af0-88f9-d814e5ecd7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_844ea414-1654-42f1-9a65-64c2d5a027cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_3e1dbd47-10c8-4af0-88f9-d814e5ecd7c3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_844ea414-1654-42f1-9a65-64c2d5a027cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_27b7c216-35e5-458d-914d-7e89c6c29ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_3e1dbd47-10c8-4af0-88f9-d814e5ecd7c3" xlink:to="loc_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent_27b7c216-35e5-458d-914d-7e89c6c29ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_b61ac4d5-e0a9-4542-8a75-982ec25d0b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_3e1dbd47-10c8-4af0-88f9-d814e5ecd7c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_b61ac4d5-e0a9-4542-8a75-982ec25d0b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_0ba0de75-c068-4fd5-a4be-af1bfc062420" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_3e1dbd47-10c8-4af0-88f9-d814e5ecd7c3" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_0ba0de75-c068-4fd5-a4be-af1bfc062420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_65fe0fbd-4b36-4c20-b06b-1b264ce788d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_3e1dbd47-10c8-4af0-88f9-d814e5ecd7c3" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_65fe0fbd-4b36-4c20-b06b-1b264ce788d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_003db404-2b57-4040-96e4-b832d648b76e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_3e1dbd47-10c8-4af0-88f9-d814e5ecd7c3" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_003db404-2b57-4040-96e4-b832d648b76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_e85abdc2-8381-4cb0-af7c-98a68e8c7a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_3e1dbd47-10c8-4af0-88f9-d814e5ecd7c3" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_e85abdc2-8381-4cb0-af7c-98a68e8c7a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b43252be-319c-4e60-ad5c-9782822c5271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_3e1dbd47-10c8-4af0-88f9-d814e5ecd7c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b43252be-319c-4e60-ad5c-9782822c5271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7f3881a5-92f3-47eb-8f3f-0b258c7975c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_3e1dbd47-10c8-4af0-88f9-d814e5ecd7c3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7f3881a5-92f3-47eb-8f3f-0b258c7975c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingNarrativeDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#SegmentReportingNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_090d75b4-ee90-49c2-b017-1e0f4f6f9ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_dd5aa213-cab9-4fd9-8097-1c2f6f77b9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_090d75b4-ee90-49c2-b017-1e0f4f6f9ec3" xlink:to="loc_us-gaap_NumberOfOperatingSegments_dd5aa213-cab9-4fd9-8097-1c2f6f77b9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SalesDiscounts_8e1381e3-4d3b-49ae-9882-ffaeda743538" xlink:href="mrk-20230331.xsd#mrk_SalesDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_090d75b4-ee90-49c2-b017-1e0f4f6f9ec3" xlink:to="loc_mrk_SalesDiscounts_8e1381e3-4d3b-49ae-9882-ffaeda743538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#SegmentReportingSalesfromProductsDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b677adfa-7634-4ea8-a9c2-540a5b705c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3b8609de-4df5-40dc-8285-7d0aaeb86ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b677adfa-7634-4ea8-a9c2-540a5b705c1c" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3b8609de-4df5-40dc-8285-7d0aaeb86ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_66642774-eceb-4263-8d03-7cf05d6e8531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3b8609de-4df5-40dc-8285-7d0aaeb86ef7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_66642774-eceb-4263-8d03-7cf05d6e8531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2d75e731-6fe8-409c-b28c-76f2c3216af6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_66642774-eceb-4263-8d03-7cf05d6e8531" xlink:to="loc_us-gaap_SegmentDomain_2d75e731-6fe8-409c-b28c-76f2c3216af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_b2369f5b-b709-4aaa-8c7e-590d70b333a7" xlink:href="mrk-20230331.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2d75e731-6fe8-409c-b28c-76f2c3216af6" xlink:to="loc_mrk_PharmaceuticalsegmentMember_b2369f5b-b709-4aaa-8c7e-590d70b333a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_85ec9d84-3431-4355-96e6-e7a471c63a09" xlink:href="mrk-20230331.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2d75e731-6fe8-409c-b28c-76f2c3216af6" xlink:to="loc_mrk_AnimalHealthsegmentMember_85ec9d84-3431-4355-96e6-e7a471c63a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_cde2d4bd-e739-445f-93a7-fbb10a832a7d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3b8609de-4df5-40dc-8285-7d0aaeb86ef7" xlink:to="loc_srt_ConsolidationItemsAxis_cde2d4bd-e739-445f-93a7-fbb10a832a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_6b52e8e7-78b3-477f-a6d3-49d5a943da26" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_cde2d4bd-e739-445f-93a7-fbb10a832a7d" xlink:to="loc_srt_ConsolidationItemsDomain_6b52e8e7-78b3-477f-a6d3-49d5a943da26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_5edda63d-db0d-4a87-982d-0339dad58b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_6b52e8e7-78b3-477f-a6d3-49d5a943da26" xlink:to="loc_us-gaap_OperatingSegmentsMember_5edda63d-db0d-4a87-982d-0339dad58b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_ea51c7b8-019f-4dd4-be46-20944864fd13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_6b52e8e7-78b3-477f-a6d3-49d5a943da26" xlink:to="loc_us-gaap_CorporateNonSegmentMember_ea51c7b8-019f-4dd4-be46-20944864fd13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1c0b9af9-bbaf-4bdd-a176-8f9be533db9e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3b8609de-4df5-40dc-8285-7d0aaeb86ef7" xlink:to="loc_srt_ProductOrServiceAxis_1c0b9af9-bbaf-4bdd-a176-8f9be533db9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1c0b9af9-bbaf-4bdd-a176-8f9be533db9e" xlink:to="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_KeytrudaMember_e2528591-c22e-48e1-9910-b2a59771dfee" xlink:href="mrk-20230331.xsd#mrk_KeytrudaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_KeytrudaMember_e2528591-c22e-48e1-9910-b2a59771dfee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AlliancerevenueLynparzaMember_fc3becc6-1914-4a9d-9be1-56edfcea44cd" xlink:href="mrk-20230331.xsd#mrk_AlliancerevenueLynparzaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_AlliancerevenueLynparzaMember_fc3becc6-1914-4a9d-9be1-56edfcea44cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LenvimaMember_cd5f58a9-4abc-438c-962b-042997be8005" xlink:href="mrk-20230331.xsd#mrk_LenvimaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_LenvimaMember_cd5f58a9-4abc-438c-962b-042997be8005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueReblozylMember_b88b7850-d6d2-479b-9ebd-5af5d9eac7a0" xlink:href="mrk-20230331.xsd#mrk_AllianceRevenueReblozylMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_AllianceRevenueReblozylMember_b88b7850-d6d2-479b-9ebd-5af5d9eac7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_WeliregMember_e60e4c6c-ee2e-4288-924c-7799fd358f2e" xlink:href="mrk-20230331.xsd#mrk_WeliregMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_WeliregMember_e60e4c6c-ee2e-4288-924c-7799fd358f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_GardasilGardasil9Member_840e7dcc-dabc-4b9c-a700-e400499ae793" xlink:href="mrk-20230331.xsd#mrk_GardasilGardasil9Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_GardasilGardasil9Member_840e7dcc-dabc-4b9c-a700-e400499ae793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ProQuadMMRIIVarivaxMember_98fc194a-b45e-4d7f-9aae-dc98a5df9c1a" xlink:href="mrk-20230331.xsd#mrk_ProQuadMMRIIVarivaxMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_ProQuadMMRIIVarivaxMember_98fc194a-b45e-4d7f-9aae-dc98a5df9c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RotateqMember_b7893e58-5ce8-4132-a982-f9c8357c91bd" xlink:href="mrk-20230331.xsd#mrk_RotateqMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_RotateqMember_b7893e58-5ce8-4132-a982-f9c8357c91bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VaxneuvanceMember_0c266234-2d38-425a-b149-7dcb1b56c7ec" xlink:href="mrk-20230331.xsd#mrk_VaxneuvanceMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_VaxneuvanceMember_0c266234-2d38-425a-b149-7dcb1b56c7ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_Pneumovax23Member_cc3b5a6a-be11-4842-94e4-4827c26691e3" xlink:href="mrk-20230331.xsd#mrk_Pneumovax23Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_Pneumovax23Member_cc3b5a6a-be11-4842-94e4-4827c26691e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_VaqtaMember_92a4c24f-a958-4cad-969e-daedd9732c74" xlink:href="mrk-20230331.xsd#mrk_VaqtaMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_VaqtaMember_92a4c24f-a958-4cad-969e-daedd9732c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BridionMember_0bdf52de-9189-45b6-a99a-00689b3d708c" xlink:href="mrk-20230331.xsd#mrk_BridionMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_BridionMember_0bdf52de-9189-45b6-a99a-00689b3d708c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrevymisMember_c20e9441-f154-4291-b4ed-9ad898bc9291" xlink:href="mrk-20230331.xsd#mrk_PrevymisMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_PrevymisMember_c20e9441-f154-4291-b4ed-9ad898bc9291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PrimaxinMember_72d6a7de-fe9e-49ca-bfdb-6322315b3d2d" xlink:href="mrk-20230331.xsd#mrk_PrimaxinMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_PrimaxinMember_72d6a7de-fe9e-49ca-bfdb-6322315b3d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_DificidMember_54150494-6f23-4f50-8e0d-1623bc8f1c82" xlink:href="mrk-20230331.xsd#mrk_DificidMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_DificidMember_54150494-6f23-4f50-8e0d-1623bc8f1c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_NoxafilMember_a034c131-7240-4a9b-8bee-e26af650fba5" xlink:href="mrk-20230331.xsd#mrk_NoxafilMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_NoxafilMember_a034c131-7240-4a9b-8bee-e26af650fba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_ZerbaxaMember_36e048da-34bd-4b73-8ab3-1ca98c37970d" xlink:href="mrk-20230331.xsd#mrk_ZerbaxaMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_ZerbaxaMember_36e048da-34bd-4b73-8ab3-1ca98c37970d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AllianceRevenueAdempasVerquvoMember_24b9a81e-61ae-489b-b560-3db1df0015dc" xlink:href="mrk-20230331.xsd#mrk_AllianceRevenueAdempasVerquvoMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_AllianceRevenueAdempasVerquvoMember_24b9a81e-61ae-489b-b560-3db1df0015dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AdempasMember_c52e97d2-7a6b-4432-9e88-e5b91a2315e0" xlink:href="mrk-20230331.xsd#mrk_AdempasMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_AdempasMember_c52e97d2-7a6b-4432-9e88-e5b91a2315e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LagevrioMember_652cc713-c35d-4162-917f-613e2b5096c5" xlink:href="mrk-20230331.xsd#mrk_LagevrioMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_LagevrioMember_652cc713-c35d-4162-917f-613e2b5096c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IsentressIsentressHDMember_f174abee-901b-4ce0-8ced-5b4630d5d268" xlink:href="mrk-20230331.xsd#mrk_IsentressIsentressHDMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_IsentressIsentressHDMember_f174abee-901b-4ce0-8ced-5b4630d5d268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_BelsomraMember_60d322e3-36b7-4df9-8d46-fa1fbf302e45" xlink:href="mrk-20230331.xsd#mrk_BelsomraMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_BelsomraMember_60d322e3-36b7-4df9-8d46-fa1fbf302e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SimponiMember_38003fc9-6739-4e74-b7a1-3bd18e3d9f0a" xlink:href="mrk-20230331.xsd#mrk_SimponiMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_SimponiMember_38003fc9-6739-4e74-b7a1-3bd18e3d9f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_RemicadeMember_b56c47f3-54e1-40f8-adc2-a2a9197b1a63" xlink:href="mrk-20230331.xsd#mrk_RemicadeMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_RemicadeMember_b56c47f3-54e1-40f8-adc2-a2a9197b1a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanuviaMember_43868c0f-a884-4c2f-b5c2-8e77bb0c1494" xlink:href="mrk-20230331.xsd#mrk_JanuviaMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_JanuviaMember_43868c0f-a884-4c2f-b5c2-8e77bb0c1494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_JanumetMember_577d2282-ea85-4935-8f3e-179e3a101f27" xlink:href="mrk-20230331.xsd#mrk_JanumetMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_JanumetMember_577d2282-ea85-4935-8f3e-179e3a101f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherPharmaceuticalMember_3f5507ff-fd34-497f-a057-631aa4291ce3" xlink:href="mrk-20230331.xsd#mrk_OtherPharmaceuticalMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_OtherPharmaceuticalMember_3f5507ff-fd34-497f-a057-631aa4291ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_LivestockMember_9d2f97ae-e510-43c4-95a4-fe48b7072cd2" xlink:href="mrk-20230331.xsd#mrk_LivestockMember"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_LivestockMember_9d2f97ae-e510-43c4-95a4-fe48b7072cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_CompanionAnimalsMember_151c9b0b-212b-48bc-8c69-d3febf1641c0" xlink:href="mrk-20230331.xsd#mrk_CompanionAnimalsMember"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f10a46d9-ab70-4394-8ee1-ac48c3605962" xlink:to="loc_mrk_CompanionAnimalsMember_151c9b0b-212b-48bc-8c69-d3febf1641c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2a5f01cf-9f36-448c-8dd7-68b358f9641e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3b8609de-4df5-40dc-8285-7d0aaeb86ef7" xlink:to="loc_srt_StatementGeographicalAxis_2a5f01cf-9f36-448c-8dd7-68b358f9641e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_37953abc-e1e1-439b-a168-261e6dfd0436" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_2a5f01cf-9f36-448c-8dd7-68b358f9641e" xlink:to="loc_srt_SegmentGeographicalDomain_37953abc-e1e1-439b-a168-261e6dfd0436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_023611b0-8d84-48f7-8bcf-0d8f86856735" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_37953abc-e1e1-439b-a168-261e6dfd0436" xlink:to="loc_country_US_023611b0-8d84-48f7-8bcf-0d8f86856735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_InternationalMember_4f9f8c7c-f71f-4de7-9174-f8f18ef1030a" xlink:href="mrk-20230331.xsd#mrk_InternationalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_37953abc-e1e1-439b-a168-261e6dfd0436" xlink:to="loc_mrk_InternationalMember_4f9f8c7c-f71f-4de7-9174-f8f18ef1030a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_457ebd84-b5de-4694-ac37-202346e83902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3b8609de-4df5-40dc-8285-7d0aaeb86ef7" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_457ebd84-b5de-4694-ac37-202346e83902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ed286271-f6b9-411c-89e8-ee287cfb58a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_457ebd84-b5de-4694-ac37-202346e83902" xlink:to="loc_us-gaap_Revenues_ed286271-f6b9-411c-89e8-ee287cfb58a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_ad405855-dd3e-4d14-89db-109f320a74d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_457ebd84-b5de-4694-ac37-202346e83902" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_ad405855-dd3e-4d14-89db-109f320a74d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_IncreaseDecreaseInHedgeRevenue_0d14d1f4-8df1-47a7-8c1e-0be737b45487" xlink:href="mrk-20230331.xsd#mrk_IncreaseDecreaseInHedgeRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_457ebd84-b5de-4694-ac37-202346e83902" xlink:to="loc_mrk_IncreaseDecreaseInHedgeRevenue_0d14d1f4-8df1-47a7-8c1e-0be737b45487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#SegmentReportingConsolidatedSalesbyGeographicAreaDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_7b5a6c80-8cac-49d4-bd2a-ee83d05ed6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_251631f9-2bc0-4645-a592-bc4affbe5d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7b5a6c80-8cac-49d4-bd2a-ee83d05ed6ca" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_251631f9-2bc0-4645-a592-bc4affbe5d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_40227c5c-edcb-4065-b4c4-01a5ae6a2bdf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_251631f9-2bc0-4645-a592-bc4affbe5d90" xlink:to="loc_srt_StatementGeographicalAxis_40227c5c-edcb-4065-b4c4-01a5ae6a2bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f9cac776-5ac3-44dc-b1a2-38017f04cafd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_40227c5c-edcb-4065-b4c4-01a5ae6a2bdf" xlink:to="loc_srt_SegmentGeographicalDomain_f9cac776-5ac3-44dc-b1a2-38017f04cafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_578de624-8b74-4504-9561-fe1add15c664" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f9cac776-5ac3-44dc-b1a2-38017f04cafd" xlink:to="loc_country_US_578de624-8b74-4504-9561-fe1add15c664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EMEAMember_a3305ffc-8af4-42bf-a505-a92e175303da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EMEAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f9cac776-5ac3-44dc-b1a2-38017f04cafd" xlink:to="loc_us-gaap_EMEAMember_a3305ffc-8af4-42bf-a505-a92e175303da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_d11e23b0-deef-4579-b4b6-f554680a0b1c" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f9cac776-5ac3-44dc-b1a2-38017f04cafd" xlink:to="loc_country_CN_d11e23b0-deef-4579-b4b6-f554680a0b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AsiaPacificMember_14f71368-baa3-43c4-88b0-8b30977715a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AsiaPacificMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f9cac776-5ac3-44dc-b1a2-38017f04cafd" xlink:to="loc_srt_AsiaPacificMember_14f71368-baa3-43c4-88b0-8b30977715a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_1b1ca5be-a114-46f8-8bc2-80cb5099caca" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f9cac776-5ac3-44dc-b1a2-38017f04cafd" xlink:to="loc_country_JP_1b1ca5be-a114-46f8-8bc2-80cb5099caca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LatinAmericaMember_99d7dd78-5f35-4797-9437-8b39ec32e1dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LatinAmericaMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f9cac776-5ac3-44dc-b1a2-38017f04cafd" xlink:to="loc_srt_LatinAmericaMember_99d7dd78-5f35-4797-9437-8b39ec32e1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_OtherCountriesMember_7a22dbca-7d90-4da9-a4b8-5e06ba1e6574" xlink:href="mrk-20230331.xsd#mrk_OtherCountriesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f9cac776-5ac3-44dc-b1a2-38017f04cafd" xlink:to="loc_mrk_OtherCountriesMember_7a22dbca-7d90-4da9-a4b8-5e06ba1e6574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_18d3656b-3d7e-4f48-a1e4-fe46f1234495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_251631f9-2bc0-4645-a592-bc4affbe5d90" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_18d3656b-3d7e-4f48-a1e4-fe46f1234495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9f40aa96-7637-45d2-8630-c59a1c852fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_18d3656b-3d7e-4f48-a1e4-fe46f1234495" xlink:to="loc_us-gaap_Revenues_9f40aa96-7637-45d2-8630-c59a1c852fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" xlink:type="simple" xlink:href="mrk-20230331.xsd#SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a4dc96b4-4de5-45e6-9d97-4f8218e542ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_448a2c00-b70c-4a86-90c0-2a4e65243783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a4dc96b4-4de5-45e6-9d97-4f8218e542ac" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_448a2c00-b70c-4a86-90c0-2a4e65243783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_9e394cc8-17f3-42ff-8f1b-eba1440dada7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_448a2c00-b70c-4a86-90c0-2a4e65243783" xlink:to="loc_srt_ConsolidationItemsAxis_9e394cc8-17f3-42ff-8f1b-eba1440dada7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_70f69985-38ce-4c35-a35a-37fa2abab223" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_9e394cc8-17f3-42ff-8f1b-eba1440dada7" xlink:to="loc_srt_ConsolidationItemsDomain_70f69985-38ce-4c35-a35a-37fa2abab223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_52977de5-65be-4d34-951a-044d9675cebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_70f69985-38ce-4c35-a35a-37fa2abab223" xlink:to="loc_us-gaap_OperatingSegmentsMember_52977de5-65be-4d34-951a-044d9675cebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_a51fadd4-c922-464a-8661-2587b04c365f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_70f69985-38ce-4c35-a35a-37fa2abab223" xlink:to="loc_us-gaap_CorporateNonSegmentMember_a51fadd4-c922-464a-8661-2587b04c365f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_73ae7bfb-54d4-4907-a706-69d57a089918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_70f69985-38ce-4c35-a35a-37fa2abab223" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_73ae7bfb-54d4-4907-a706-69d57a089918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_06eec99f-850a-4cf3-8fb9-a14d6cf3c72b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_448a2c00-b70c-4a86-90c0-2a4e65243783" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_06eec99f-850a-4cf3-8fb9-a14d6cf3c72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7005fa02-c550-49f6-999d-850d9717d957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_06eec99f-850a-4cf3-8fb9-a14d6cf3c72b" xlink:to="loc_us-gaap_SegmentDomain_7005fa02-c550-49f6-999d-850d9717d957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_PharmaceuticalsegmentMember_cef7f68a-ea37-4924-9652-f8a520ff7f57" xlink:href="mrk-20230331.xsd#mrk_PharmaceuticalsegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_7005fa02-c550-49f6-999d-850d9717d957" xlink:to="loc_mrk_PharmaceuticalsegmentMember_cef7f68a-ea37-4924-9652-f8a520ff7f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_AnimalHealthsegmentMember_b013d180-2ba3-44c4-9591-d5a0b4b2c332" xlink:href="mrk-20230331.xsd#mrk_AnimalHealthsegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_7005fa02-c550-49f6-999d-850d9717d957" xlink:to="loc_mrk_AnimalHealthsegmentMember_b013d180-2ba3-44c4-9591-d5a0b4b2c332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_30074cc5-bb89-4c8f-89f3-07110754954b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_448a2c00-b70c-4a86-90c0-2a4e65243783" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_30074cc5-bb89-4c8f-89f3-07110754954b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_688788f3-3af0-40de-beff-664b17ac520e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30074cc5-bb89-4c8f-89f3-07110754954b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_688788f3-3af0-40de-beff-664b17ac520e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_067127ec-af70-40a5-90b1-4d14b20f73b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30074cc5-bb89-4c8f-89f3-07110754954b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_067127ec-af70-40a5-90b1-4d14b20f73b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8f35fcb8-554c-42a8-8b76-af7c1e228f54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30074cc5-bb89-4c8f-89f3-07110754954b" xlink:to="loc_us-gaap_InterestExpense_8f35fcb8-554c-42a8-8b76-af7c1e228f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_3a3ed2fa-e610-461d-8cbb-94191ead61dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30074cc5-bb89-4c8f-89f3-07110754954b" xlink:to="loc_us-gaap_AdjustmentForAmortization_3a3ed2fa-e610-461d-8cbb-94191ead61dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_946b75ff-f19a-4dc3-983c-6c07eb5ae9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30074cc5-bb89-4c8f-89f3-07110754954b" xlink:to="loc_us-gaap_Depreciation_946b75ff-f19a-4dc3-983c-6c07eb5ae9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_40ef73f5-4b53-4025-bdca-7850cc83804b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30074cc5-bb89-4c8f-89f3-07110754954b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_40ef73f5-4b53-4025-bdca-7850cc83804b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_7ff1629b-7bd4-4680-b7a1-613cf16165da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30074cc5-bb89-4c8f-89f3-07110754954b" xlink:to="loc_us-gaap_RestructuringCharges_7ff1629b-7bd4-4680-b7a1-613cf16165da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_33aea500-09c5-4077-acb7-db09e7d6ceea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30074cc5-bb89-4c8f-89f3-07110754954b" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_33aea500-09c5-4077-acb7-db09e7d6ceea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet_5f69e695-27da-4a34-bb33-573e366dcb99" xlink:href="mrk-20230331.xsd#mrk_SegmentReportingUnallocatedOtherExpensesNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_30074cc5-bb89-4c8f-89f3-07110754954b" xlink:to="loc_mrk_SegmentReportingUnallocatedOtherExpensesNet_5f69e695-27da-4a34-bb33-573e366dcb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593223446640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-6571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Merck&#160;& Co., Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-1918501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">126 East Lincoln Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rahway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">740-4000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,537,435,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000310158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock ($0.50&#160;par value)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock ($0.50&#160;par value)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mrk_A0.500Notesdue2024Member', window );">0.500% Notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.500% Notes due 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mrk_A1.875Notesdue2026Member', window );">1.875% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.875% Notes due 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK/26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mrk_A2.500Notesdue2034Member', window );">2.500% Notes due 2034</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.500% Notes due 2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK/34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mrk_A1.375Notesdue2036Member', window );">1.375% Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.375% Notes due 2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MRK 36A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mrk_A0.500Notesdue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mrk_A0.500Notesdue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mrk_A1.875Notesdue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mrk_A1.875Notesdue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mrk_A2.500Notesdue2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mrk_A2.500Notesdue2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mrk_A1.375Notesdue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mrk_A1.375Notesdue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593309679168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF INCOME - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 14,487<span></span>
</td>
<td class="nump">$ 15,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs, Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">3,926<span></span>
</td>
<td class="nump">5,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,479<span></span>
</td>
<td class="nump">2,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">4,276<span></span>
</td>
<td class="nump">2,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">708<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CostsExpensesAndOther', window );">Total Costs, Expenses and Other</a></td>
<td class="nump">10,837<span></span>
</td>
<td class="nump">11,040<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income Before Taxes</a></td>
<td class="nump">3,650<span></span>
</td>
<td class="nump">4,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on Income</a></td>
<td class="nump">825<span></span>
</td>
<td class="nump">554<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income</a></td>
<td class="nump">2,825<span></span>
</td>
<td class="nump">4,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Less: Net Income (Loss) Attributable to Noncontrolling Interests</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income Attributable to Merck &amp; Co., Inc.</a></td>
<td class="nump">$ 2,821<span></span>
</td>
<td class="nump">$ 4,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic Earnings Per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders (in dollars per share)</a></td>
<td class="nump">$ 1.11<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders (in dollars per share)</a></td>
<td class="nump">$ 1.11<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CostsExpensesAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of cost of sales, operating expenses and nonoperating income or expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CostsExpensesAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593223135984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income Attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">$ 2,821<span></span>
</td>
<td class="nump">$ 4,310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other Comprehensive (Loss) Income Net of Taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent', window );">Net unrealized (loss) gain on derivatives, net of reclassifications</a></td>
<td class="num">(133)<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent', window );">Benefit plan net (loss) gain and prior service (cost) credit, net of amortization</a></td>
<td class="num">(50)<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Cumulative translation adjustment</a></td>
<td class="nump">68<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(115)<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive Income Attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">$ 2,706<span></span>
</td>
<td class="nump">$ 4,370<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593219029088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEET - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 9,707<span></span>
</td>
<td class="nump">$ 12,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">680<span></span>
</td>
<td class="nump">498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable (net of allowance for doubtful accounts of $76 in 2023 and $72 in 2022)</a></td>
<td class="nump">10,415<span></span>
</td>
<td class="nump">9,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories (excludes inventories of $3,284 in 2023 and $2,938 in 2022 classified in Other assets - see Note&#160;7)</a></td>
<td class="nump">5,863<span></span>
</td>
<td class="nump">5,911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">6,737<span></span>
</td>
<td class="nump">7,169<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">33,402<span></span>
</td>
<td class="nump">35,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Investments</a></td>
<td class="nump">1,290<span></span>
</td>
<td class="nump">1,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,256 in 2023 and $17,985 in 2022</a></td>
<td class="nump">21,758<span></span>
</td>
<td class="nump">21,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">21,209<span></span>
</td>
<td class="nump">21,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Other Intangibles, Net</a></td>
<td class="nump">19,857<span></span>
</td>
<td class="nump">20,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent', window );">Other Assets</a></td>
<td class="nump">10,280<span></span>
</td>
<td class="nump">9,528<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">107,796<span></span>
</td>
<td class="nump">109,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Loans payable and current portion of long-term debt</a></td>
<td class="nump">2,672<span></span>
</td>
<td class="nump">1,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade accounts payable</a></td>
<td class="nump">3,680<span></span>
</td>
<td class="nump">4,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="nump">14,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">1,872<span></span>
</td>
<td class="nump">1,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="nump">1,907<span></span>
</td>
<td class="nump">1,884<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">23,131<span></span>
</td>
<td class="nump">24,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-Term Debt</a></td>
<td class="nump">28,074<span></span>
</td>
<td class="nump">28,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred Income Taxes</a></td>
<td class="nump">1,442<span></span>
</td>
<td class="nump">1,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other Noncurrent Liabilities</a></td>
<td class="nump">8,244<span></span>
</td>
<td class="nump">8,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Merck&#160;&amp; Co., Inc. Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2023 and 2022</a></td>
<td class="nump">1,788<span></span>
</td>
<td class="nump">1,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Other paid-in capital</a></td>
<td class="nump">44,467<span></span>
</td>
<td class="nump">44,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">62,039<span></span>
</td>
<td class="nump">61,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(4,883)<span></span>
</td>
<td class="num">(4,768)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityBeforeTreasuryStock', window );">Stockholders' equity before deduction for treasury stock</a></td>
<td class="nump">103,411<span></span>
</td>
<td class="nump">102,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Less treasury stock, at cost: 1,039,651,210 shares in 2023 and 1,039,269,638 shares in 2022</a></td>
<td class="nump">56,577<span></span>
</td>
<td class="nump">56,489<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Merck&#160;&amp; Co., Inc. stockholders&#8217; equity</a></td>
<td class="nump">46,834<span></span>
</td>
<td class="nump">45,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling Interests</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">46,905<span></span>
</td>
<td class="nump">46,058<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Liabilities and Equity</a></td>
<td class="nump">$ 107,796<span></span>
</td>
<td class="nump">$ 109,160<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed within one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityBeforeTreasuryStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityBeforeTreasuryStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593222565136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventories classified in Other assets</a></td>
<td class="nump">3,284<span></span>
</td>
<td class="nump">2,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 18,256<span></span>
</td>
<td class="nump">$ 17,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (shares)</a></td>
<td class="nump">6,500,000,000<span></span>
</td>
<td class="nump">6,500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">3,577,103,522<span></span>
</td>
<td class="nump">3,577,103,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">1,039,651,210<span></span>
</td>
<td class="nump">1,039,269,638<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593223185280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income</a></td>
<td class="nump">$ 2,825<span></span>
</td>
<td class="nump">$ 4,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">543<span></span>
</td>
<td class="nump">699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">448<span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">(Income) loss from investments in equity securities, net</a></td>
<td class="num">(450)<span></span>
</td>
<td class="nump">708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Charge for the acquisition of Imago BioSciences, Inc.</a></td>
<td class="nump">1,192<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(277)<span></span>
</td>
<td class="num">(338)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(197)<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapital', window );">Net changes in assets and liabilities</a></td>
<td class="num">(2,890)<span></span>
</td>
<td class="num">(1,299)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Provided by Operating Activities</a></td>
<td class="nump">1,339<span></span>
</td>
<td class="nump">4,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Capital expenditures</a></td>
<td class="num">(1,007)<span></span>
</td>
<td class="num">(984)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of securities and other investments</a></td>
<td class="num">(562)<span></span>
</td>
<td class="num">(372)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from sales of securities and other investments</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired', window );">Acquisition of Imago BioSciences, Inc., net of cash acquired</a></td>
<td class="num">(1,327)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used in Investing Activities</a></td>
<td class="num">(2,359)<span></span>
</td>
<td class="num">(1,173)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payments on debt</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1,250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(149)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends paid to stockholders</a></td>
<td class="num">(1,853)<span></span>
</td>
<td class="num">(1,745)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(81)<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Used in Financing Activities</a></td>
<td class="num">(2,054)<span></span>
</td>
<td class="num">(3,086)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="nump">87<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="num">(2,987)<span></span>
</td>
<td class="nump">447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $79 and $71 at January 1, 2023 and 2022, respectively, included in Other current assets)</a></td>
<td class="nump">12,773<span></span>
</td>
<td class="nump">8,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $79 and $58 at March&#160;31, 2023 and 2022, respectively, included in Other current assets)</a></td>
<td class="nump">$ 9,786<span></span>
</td>
<td class="nump">$ 8,614<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593223310928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593306937328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Merck&#160;&amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck&#8217;s Form 10-K filed on February&#160;24, 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company&#8217;s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standard</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The Company adopted the guidance effective January 1, 2023. The adoption of this guidance did not have an impact on the Company&#8217;s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standard Not Yet Adopted</span></div>In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company does not expect there to be an impact to its consolidated financial statements upon adoption<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593306911568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Spin-Off of Organon &amp; Co.<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Spin-Off of Organon &amp; Co.</a></td>
<td class="text">Spin-Off of Organon &amp; Co. <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On June 2, 2021, Merck completed the spin-off of Organon through a distribution of Organon&#8217;s publicly traded stock to Company shareholders. In connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck is providing Organon various services and, similarly, Organon is providing Merck various services. The provision of services under the TSA generally will terminate within 25 months following the spin-off; however, the provision of certain services has been extended to 35 months. Merck and Organon also entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck is continuing to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon. Under such interim operating agreements and in accordance with the separation and distribution agreement, Merck is continuing operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck is (a) manufacturing and supplying certain active pharmaceutical ingredients for Organon, (b) manufacturing and supplying certain formulated pharmaceutical products for Organon, and (c) packaging and labeling certain finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon is (a) manufacturing and supplying certain formulated pharmaceutical products for Merck, and (b) packaging and labeling certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The amounts included in the condensed consolidated statement of income for the above MSAs include sales of $94&#160;million and $99&#160;million and related cost of sales of $107&#160;million and $105&#160;million for the first quarter of 2023 and 2022, </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">respectively. Amounts included in the condensed consolidated statement of income for the TSAs were immaterial for both the first quarter of 2023 and 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The amounts due from Organon under all of the above agreements were $473&#160;million and $511&#160;million at March&#160;31, 2023 and December&#160;31, 2022, respectively, and are reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amounts due to Organon under these agreements were $229&#160;million and $345&#160;million at March&#160;31, 2023 and December&#160;31, 2022, respectively, and are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593221331408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Research Collaborations and License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock', window );">Acquisitions, Research Collaborations and License Agreements</a></td>
<td class="text">Acquisitions, Research Collaborations and Licensing Agreements<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company&#8217;s financial results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2023, Merck announced an agreement to acquire Prometheus Biosciences, Inc. (Prometheus), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. Prometheus&#8217; lead candidate, PRA023, is a humanized monoclonal antibody directed to tumor necrosis factor-like ligand 1A, a target associated with both intestinal inflammation and fibrosis. Prometheus is developing PRA023 for the treatment of immune-mediated diseases including ulcerative colitis, Crohn&#8217;s disease, and other autoimmune conditions. Under the terms of the acquisition agreement, Merck, through a subsidiary, will acquire all of the outstanding shares of Prometheus for $200 per share in cash for a total equity value of approximately $10.8 billion. The acquisition is subject to Prometheus shareholder approval. The closing of the proposed transaction will be subject to certain conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. The transaction is expected to close in the third quarter of 2023. If the proposed transaction closes, the Company anticipates it will be accounted for as an asset acquisition, which would result in a charge of approximately $10.3&#160;billion in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2023, Merck and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.) closed a license and collaboration agreement expanding their relationship in which Merck gained exclusive rights for the research, development, manufacture and commercialization of up to seven investigational preclinical antibody drug conjugates (ADCs) for the treatment of cancer. Kelun-Biotech retained the right to research, develop, manufacture and commercialize certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau. Merck made an upfront payment of $175 million, which was recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses in the first quarter of 2023. In addition, Kelun-Biotech is eligible to receive future contingent development-related payments aggregating up to $1.0 billion, $2.8 billion in regulatory milestones, and $5.5 billion in sales-based milestones if Kelun-Biotech does not retain Chinese mainland, Hong Kong and Macau rights for the option ADCs and all candidates achieve regulatory approval. In addition, Kelun-Biotech is eligible to receive tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested $100 million in Kelun-Biotech&#8217;s Series B preferred shares in January 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2023, Merck acquired Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, for $1.35 billion </span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(including payments to settle share-based equity awards) and also incurred approximately $60&#160;million of transaction costs. Imago&#8217;s lead candidate bomedemstat, MK-3543 (formerly IMG-7289), is an investigational orally available lysine-specific demethylase 1 inhibitor currently being evaluated in multiple Phase 2 clinical trials for the treatment of essential thrombocythemia, myelofibrosis, and polycythemia vera, in addition to other indications. The transaction was accounted for as an acquisition of an asset since bomedemstat represented substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded net assets of $219 million, as well as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses of $1.2 billion in the first quarter of 2023 related to the transaction. There are no future contingent payments associated with the acquisition.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information related to acquisitions, divestitures, research collaborations and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593221500976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementsAbstract', window );"><strong>Collaborative Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangements</a></td>
<td class="text">Collaborative Arrangements<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck&#8217;s more significant collaborative arrangements are discussed below. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">AstraZeneca</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca&#8217;s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (pembrolizumab) and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca&#8217;s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo&#160;monotherapy and non-PD-L1/PD-1 combination therapy opportunities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Profits from Lynparza and Koselugo&#160;product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the first quarter of 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $600&#160;million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $600&#160;million liability (which remained accrued at March 31, 2023) and a corresponding increase to the intangible asset related to Lynparza. Merck also recognized $250&#160;million of cumulative amortization catch-up expense related to the recognition of this milestone in the first quarter of 2022. Also in the first quarter of 2022, Merck made a sales-based milestone payment to AstraZeneca (which had been previously accrued for) of $400&#160;million. Potential future sales-based milestone payments of $2.1 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In the first quarter of 2023, Merck made a regulatory milestone payment to AstraZeneca (which had been previously accrued for) of $105&#160;million. In 2022, Lynparza received regulatory approvals triggering capitalized milestone payments of $250&#160;million from Merck to AstraZeneca. Potential future regulatory milestone payments of $1.1 billion remain under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.5 billion at March&#160;31, 2023 and is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.089%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amount in the first quarter of 2022 includes $250&#160;million of cumulative amortization catch-up expense as noted above.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Eisai</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and Lenvima.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights. In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In the first quarter of 2023, Merck determined it was probable that sales of Lenvima in the future would trigger a $125&#160;million sales-based milestone payment from Merck to Eisai. Accordingly, Merck recorded a $125&#160;million liability and a corresponding increase to the intangible asset related to Lenvima. Merck also recognized $72&#160;million of cumulative amortization catch-up expense related to the recognition of this milestone. In 2022, Merck made sales-based milestone payments to Eisai (which had been previously accrued for) aggregating $600 million (of which $300&#160;million was paid in the first quarter of 2022). Potential future sales-based milestone payments of $2.4 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In 2022, Lenvima received regulatory approvals triggering capitalized milestone payments of $50&#160;million from Merck to Eisai (of which $25&#160;million was paid in the first quarter of 2022). There are no regulatory milestone payments remaining under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $812 million at March&#160;31, 2023 and is included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.674%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amount in the first quarter of 2023 includes $72&#160;million of cumulative amortization catch-up expense as noted above.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents an accrued milestone payment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bayer AG</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer&#8217;s Adempas (riociguat). The two companies have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer&#8217;s Verquvo (vericiguat), which was approved in the U.S., the European Union (EU) and Japan in 2021, and has since been approved in several other markets. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck&#8217;s share of profits from sales of Adempas and Verquvo in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer&#8217;s share of profits from sales in Merck&#8217;s marketing territories. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. In the first quarter of 2022, Merck made the final $400 million sales-based milestone payment under this collaboration to Bayer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $613 million and $56 million, respectively, at March&#160;31, 2023 and are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.943%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Verquvo recorded by Merck</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Bayer included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes amortization of intangible assets. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Ridgeback Biotherapeutics LP</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, entered into a collaboration agreement to develop </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (molnupiravir), an investigational orally available antiviral candidate for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">related molecules. Following initial authorizations in certain markets in the fourth quarter of 2021, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> has since received multiple additional authorizations worldwide.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit-sharing calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit-sharing amounts recorded within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback&#8217;s share of profits) are reflected as decreases to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.943%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">recorded by Merck</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Ridgeback included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes royalty expense and amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Expenses include an allocation for overhead charges.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued royalties. Amount at December 31, 2022 also includes an accrued milestone payment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Bristol Myers Squibb</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol Myers Squibb (BMS). Reblozyl is approved in the U.S., Europe and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and will co-promote all future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives a 20% sales royalty from BMS which could increase to a maximum of 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $80&#160;million. Merck recorded alliance revenue related to this collaboration within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> of $43 million in the first quarter of 2023 (consisting of royalties) compared with $52 million in the first quarter of 2022 (consisting of royalties of $32&#160;million and the receipt of a regulatory approval milestone payment of $20&#160;million).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593221603632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text">Restructuring<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2019, Merck&#160;approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on optimizing the Company&#8217;s manufacturing and supply network, as well as reducing its global real estate footprint.&#160;The actions contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.7 billion. The Company estimates that approximately 70% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 30% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recorded total pretax costs of $97 million and $127 million in the first quarter of 2023 and 2022, respectively, related to restructuring program activities. Since inception of the Restructuring Program through March&#160;31, 2023, Merck has recorded total pretax accumulated costs of approximately $3.4 billion. For the full year of 2023, the Company expects to record charges of approximately $400 million related to the Restructuring Program. For segment reporting, restructuring charges are unallocated expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize the charges related to restructuring program activities by type of cost:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.654%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.531%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Separation costs are associated with actual headcount reductions, as well as involuntary headcount reductions which were probable and could be reasonably estimated. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the program. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other activity in 2023 and 2022 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note&#160;10) and share-based compensation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities for the three months ended March&#160;31, 2023:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves January&#160;1, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves March&#160;31, 2023 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)The remaining cash outlays are expected to be largely completed by the end of 2025.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593221500976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="margin-top:5pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A significant portion of the Company&#8217;s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company&#8217;s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Other Comprehensive Loss</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and reclassified into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> each period. The cash&#160;flows from both designated and non-designated contracts are reported as operating activities&#160;in the Condensed Consolidated Statement of&#160;Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company also uses a balance sheet risk management program to mitigate the exposure of such assets and liabilities from the effects of volatility in foreign exchange. Merck principally utilizes forward exchange contracts to offset the effects of exchange in developed country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar, Australian dollar and Swiss franc. For exposures in developing country currencies, including the Chinese renminbi, the Company will enter into forward contracts to offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The forward contracts are not designated as hedges and are marked to market through </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than six months. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and remain in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange risk is also managed through the use of foreign currency debt. The Company&#8217;s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effects of the Company&#8217;s net investment hedges on </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.227%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">No amounts were reclassified from AOCL into income related to the sale of a subsidiary.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk. In March 2023, the Company entered into five forward starting swaps and in April 2023 entered into two additional forward starting swaps, each with a notional amount of $100&#160;million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair&#160;Value&#160;of&#160;Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair&#160;Value&#160;of&#160;Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0xLTEtMS0xMzE2MTg_cdf39073-c7a9-42f3-a873-70852c2d806a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0xLTEtMS0xMzE2MTg_eaa07838-14e0-4387-8b95-9bb43c3d8ff8">Other Assets</span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xNDUxMzg_9df5cddc-66b1-4a33-8e29-a18d74bcc019"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xNDUxMzg_f3c8a52d-a48a-4e54-b19b-78f16a11f45d">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xMzE2MTg_408692a5-0d77-4a04-a36c-28872dc58415"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xMzE2MTg_4a4e35a6-2d31-4c12-be2f-2f5f0ad91a6c">Other current assets</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0xLTEtMS0xMzE2MTg_81797372-b85c-4d09-ac25-516d3f440479"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0xLTEtMS0xMzE2MTg_ab1b0a2e-c0bf-439c-9322-21e04e73f4f5">Other Assets</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xLTEtMS0xMzE2MTg_3132afe6-dbe8-4b79-81d1-621892c284e2"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xLTEtMS0xMzE2MTg_99d4d534-f137-4781-a93f-a2c418043a22">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xLTEtMS0xMzE2MTg_11e2508b-56af-4ce8-a9f2-c0ca375d810e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xLTEtMS0xMzE2MTg_c087e16f-89b4-40c0-959b-f2b2cdd6e23c">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,073&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,215&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMS0xLTEtMTMxNjE4_05e962d8-08ac-4061-91f8-80526dc22b48"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMS0xLTEtMTMxNjE4_c1218d47-d091-44ba-967a-61df1ed0b192">Other current assets</span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,507&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,540&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMS0xLTEtMTQ1MTQy_1096f2ac-e5f3-4efe-9d17-7ead4689602e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMS0xLTEtMTQ1MTQy_c4114de6-2d78-4e8c-8218-b4ecfaa65a61">Other Assets</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMS0xLTEtMTMxNjE4_8e46edaf-73d3-4fb2-a39e-a898b16444e0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMS0xLTEtMTMxNjE4_a38bf2e0-7e23-4be7-a57d-412372f2f6e0">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMS0xLTEtMTQ1MTQ3_0f134479-ab12-4419-8818-0dec3ce2d2eb"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMS0xLTEtMTQ1MTQ3_8586bfb3-f29a-42c6-a48d-599f102341da">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,288&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,466&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,361&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,681&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> below). The following table provides information on the Company&#8217;s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:64.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts recognized in the condensed consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collateral received/posted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.900%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Caption in which Effects of Fair Value or Cash Flow </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Hedges are Recorded</span></div></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,487&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,901&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">708&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hedged items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of (loss) gain recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increase in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Interest expense is a component of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.359%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts serve as economic hedges of forecasted transactions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At March&#160;31, 2023, the Company estimates $71 million of pretax net unrealized losses on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The amount ultimately reclassified to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Investments in Debt and Equity Securities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,585&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,345&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,853&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net gains of $338&#160;million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in the first quarter of 2023 on equity securities still held at March&#160;31, 2023. Unrealized net losses of $225 million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in the first quarter of 2022 on equity securities still held at March&#160;31, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At March&#160;31, 2023 and March&#160;31, 2022, the Company also had $942 million and $643 million, respectively, of equity investments without readily determinable fair values included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. During the first quarter</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">of 2023</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> the Company recorded unrealized gains of $1 million and unrealized losses of $21&#160;million related to certain of these equity investments still held at March&#160;31, 2023. During the first quarter</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">of 2022</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> the Company recorded unrealized gains of $14&#160;million related to certain of these investments still held at March&#160;31, 2022. Cumulative unrealized gains and cumulative unrealized losses based on observable price changes for investments in equity investments without readily determinable fair values still held at March&#160;31, 2023 were $287 million and $40 million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At March&#160;31, 2023 and March&#160;31, 2022, the Company also had $725&#160;million and $1.2&#160;billion, respectively, recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> for equity securities held through ownership interests in investment funds. (Gains) losses recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> relating to these investment funds were $(132)&#160;million and $509&#160;million for the first quarter of 2023 and 2022, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level&#160;1 having the highest priority and Level 3 having the lowest: </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Quoted prices (unadjusted) in active markets for identical assets or liabilities; </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> -</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis are summarized below:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.654%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,604&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,355&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,286&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#8217;s own credit risk, the effects of which were not significant.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;31, 2023 and December&#160;31, 2022, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> included $8.8 billion and $11.3 billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:80.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in estimated fair value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value March 31 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cost of sales, Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">At March&#160;31, 2023, $263 million of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at March&#160;31, 2023 includes $127 million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The payments of contingent consideration in both periods relate to the Sanofi Pasteur MSD liabilities described above.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Fair Value Measurements</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Some of the Company&#8217;s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimated fair value of loans payable and long-term debt (including current portion) at March&#160;31, 2023, was $28.2 billion compared with a carrying value of $30.7 billion and at December&#160;31, 2022, was $26.7 billion compared with a carrying value of $30.7 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company&#8217;s investment policy guidelines. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The majority of the Company&#8217;s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers and retailers, hospitals and government agencies.&#160;The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.4 billion and $2.5 billion of accounts receivable as of March&#160;31, 2023 and December&#160;31, 2022, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. As of March&#160;31, 2023 and December&#160;31, 2022, the Company had collected $31&#160;million and $67&#160;million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and the related obligation to remit the cash within </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. The Company remitted the cash to the financial institutions in April 2023 and January 2023, respectively. The net cash flows related to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company&#8217;s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company&#8217;s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $13 million and $66&#160;million at March&#160;31, 2023 and December&#160;31, 2022, respectively. The obligation to return such collateral is recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span>. Cash collateral advanced by the Company to various counterparties was $19&#160;million at December&#160;31, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593221389808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories consisted of:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,883&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,497&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,142&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,147&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,849&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,284&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,938&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amounts recognized as </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> are comprised almost entirely of raw materials and work in process inventories. At March&#160;31, 2023 and December&#160;31, 2022, these amounts included $2.7 billion and $2.4 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $590 million and $516 million at March&#160;31, 2023 and December&#160;31, 2022, respectively, of inventories produced in preparation for product launches.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593221406176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text">Contingencies<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company&#8217;s financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i)&#160;what claims, if any, will survive dispositive motion practice, (ii)&#160;the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii)&#160;how the discovery process will affect the litigation, (iv)&#160;the settlement posture of the other parties to the litigation and (v)&#160;any other factors that may have a material effect on the litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil 9</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Merck is a defendant in product liability lawsuits in the U.S. involving </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). As of March&#160;31, 2023, approximately 95 cases were filed and pending against Merck in either federal or state court. In these actions, plaintiffs allege, among other things, that they suffered various personal injuries after vaccination with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9, with postural orthostatic tachycardia syndrome as a predominate alleged injury. In August 2022, the Judicial Panel on Multidistrict Litigation ordered that </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> 9 product liability cases pending in federal courts nationwide be transferred to Judge Robert J. Conrad in the Western District of North Carolina for coordinated pre-trial proceedings. There are fewer than 15 product liability cases pending outside the U.S., including one purported class action in Colombia.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Governmental Proceedings</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company&#8217;s subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company&#8217;s policy is to cooperate with these authorities and to provide responses as appropriate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.</span></div><div style="margin-top:12pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commercial and Other Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, Merck, Merck Sharp &amp; Dohme, LLC. (MSD), Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in a number of lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases were consolidated in a federal multidistrict litigation (the Zetia MDL) before Judge Rebecca Beach Smith in the Eastern District of Virginia.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. In August 2020, the district court granted in part the direct purchasers&#8217; motion for class certification and certified a class of 35 direct purchasers. In August 2021, the Fourth Circuit vacated the district court&#8217;s class certification order and remanded for further proceedings consistent with the court&#8217;s ruling. In September 2021, the direct purchaser plaintiffs filed a renewed motion for class certification. In April 2022, the district court denied the direct purchaser plaintiffs&#8217; renewed motion for class certification. In August 2021, the district court granted certification of a class of indirect purchasers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In 2020 and 2021, United Healthcare Services, Inc., Humana Inc., Centene Corporation and others, and Kaiser Foundation Health Plan, Inc. (collectively, the Insurer Plaintiffs), each filed a lawsuit in a jurisdiction outside of the Eastern District of Virginia against the Merck Defendants and others, making similar allegations as those made in the Zetia MDL, as well as additional allegations about Vytorin. These cases have been transferred to the Eastern District of Virginia to proceed with the Zetia MDL and remain pending.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In February 2022, the Insurer Plaintiffs filed amended complaints. In March 2022, the Merck Defendants, jointly with other defendants, moved to dismiss certain aspects of the Insurer Plaintiffs&#8217; complaints, including any claims for Vytorin damages. That motion to dismiss the Vytorin-related claims is still pending.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2022, the direct purchaser plaintiffs moved for an order setting a deadline for direct purchasers of Zetia not currently parties to the case to file cases against defendants in order for those cases to be coordinated for trial with the existing direct purchaser plaintiffs and other MDL plaintiff groups. The court granted that motion, setting a deadline of June 30, 2022 for unnamed direct purchasers to file claims. On June 30, 2022, 23 new entities, many related, brought new complaints against defendants or otherwise sought to intervene. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On February 10, 2023, the district court denied the Merck Defendants&#8217; and Glenmark Defendants&#8217; motions for summary judgment. In April 2023, the Merck Defendants reached settlements with the direct purchaser and retailer plaintiffs and a proposed settlement, subject to court approval, with the indirect purchaser class. Under these agreements, Merck will pay $572.5 million to resolve the direct purchaser, retailer, and indirect purchaser plaintiffs&#8217; claims, which was recorded as an expense in the Company&#8217;s first quarter 2023 financial results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq Antitrust Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On March 3, 2023, the Mayor and City Council of Baltimore filed a putative class action against MSD in the Eastern District of Pennsylvania on behalf of all third-party payors in 35 states that indirectly purchased, paid, and/or provided reimbursement for some or all of the purchase price of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Rotavirus Vaccine, Live Oral, Pentavalent), other than for resale, from March 3, 2019 to the present. Plaintiff alleges that MSD violated federal and state antitrust laws and state consumer protection laws. Plaintiff alleges that MSD has implemented an anticompetitive vaccine bundling scheme whereby MSD leverages its alleged monopoly power in certain pediatric vaccine markets to maintain its alleged monopoly power in the U.S. market for rotavirus vaccines in order to charge supracompetitive prices for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Plaintiff seeks permanent injunctive relief and unspecified monetary damages on purchases of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, trebled, and fees and costs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, in January 2020, the Company was served with a complaint in the U.S. District Court for the District of New Jersey. Following motion practice, the plaintiffs filed a second amended complaint on July 1, 2021, seeking to certify a nationwide class action of purchasers or users of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (fluralaner) products in the U.S. or its territories between May 1, 2014 and July 1, 2021. Plaintiffs contend </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> causes neurological events in dogs and cats and alleges violations of the New Jersey Consumer Fraud Act, Breach of Warranty, Product Liability, and related theories. The Company moved to dismiss or, alternatively, to strike the class allegations from the second amended complaint, and that motion is pending. A similar case was filed in Quebec, Canada in May 2019. The Superior Court certified a class of dog owners in Quebec who gave </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Chew to their dogs between February 16, 2017 and November 2, 2018 whose dogs experienced one of the conditions in the post-marketing adverse reactions section of the labeling approved on November 2, 2018. The Company and plaintiffs each appealed the class certification decision. The Court of Appeal of Quebec heard the appeal in February 2022 and issued a decision in April 2022 allowing both parties&#8217; appeals in part. The Court of Appeal amended the class period to start on July 2, 2014, allowed a second plaintiff to serve as a class representative, and modified the list of conditions in the class definition by adding &#8220;death&#8221; and removing &#8220;lack of efficacy.&#8221; The Court of Appeal also added to the list of questions to be considered by the trial court the questions of whether the Consumer Protection Act of Quebec applies to the sale of a veterinary product and, if so, whether it was breached. The Company sought leave to appeal to the Supreme Court of Canada, which was denied. The case is proceeding in the Superior Court.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company&#8217;s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company&#8217;s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (sugammadex) Injection.&#160;In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies.&#160;All actions in the District of New Jersey have been consolidated. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">may occur earlier. The West Virginia case was jointly dismissed with prejudice on August 8, 2022 in favor of proceeding in New Jersey. The remaining defendants in the New Jersey action have stipulated to infringement of the asserted claims and have stated they are withdrawing all remaining claims and defenses other than a defense seeking to shorten the patent term extension of the sugammadex patent to December 2022. The U.S. District Court for the District of New Jersey held a one-day trial on December 19, 2022 on this remaining patent term extension calculation defense. The court ordered post-trial briefing on this defense and held closing arguments on February 3, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has settled with five generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company has agreed to stay the lawsuit filed against two generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to the market before January 2026 or later, depending on any applicable pediatric exclusivity, unless the Company receives an adverse court decision.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia, Janumet, Janumet XR</span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> As previously disclosed, the FDA granted pediatric exclusivity with respect to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(sitagliptin), </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(sitagliptin/metformin HCI), and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (sitagliptin and metformin HCl extended-release), which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA&#8217;s Orange Book. Adding this exclusivity to the term of the key patent protection extended exclusivity on these products to January 2023. However, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin that expires in May 2027, including pediatric exclusivity (2027 salt/polymorph patent). In 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> following expiration of key patent protection, but prior to the expiration of the 2027 salt/polymorph patent, and a later granted patent owned by the Company covering the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> formulation where its term plus the pediatric exclusivity ends in 2029. The Company also filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel on Multidistrict Litigation entered an order transferring the Company&#8217;s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prior to the beginning of the scheduled October 2021 trial in the U.S. District Court for the District of Delaware on invalidity issues, the Company settled with all defendants scheduled to participate in that trial. In the Company&#8217;s case against Mylan, a bench trial was held in December 2021 in the U.S. District Court for the Northern District of West Virginia, and the closing arguments were held in April 2022. In September 2022, the District Court for the Northern District of West Virginia issued a decision in the Company&#8217;s favor, upholding all asserted patent claims. Mylan (now Viatris) appealed to the U.S. Court of Appeals for the Federal Circuit. The parties have now settled the matter, and Mylan has agreed to voluntarily dismiss the appeal following entry of an amended final judgment by the district court.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additionally, in 2019, Mylan filed a petition for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> review (IPR) at the U.S. Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2027 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial was held in February 2021 and a final decision was rendered in May 2021, holding that all of the challenged claims were not invalid. Mylan appealed the USPTO&#8217;s decision to the U.S. Court of Appeals for the Federal Circuit, and a hearing was held in August 2022. In September 2022, the U.S. Court of Appeals for the Federal Circuit ruled in the Company&#8217;s favor, upholding the USPTO&#8217;s decision. Mylan submitted a combined petition for panel rehearing and rehearing en banc, for which the Company was invited by the court to provide a response. On February 3, 2023, the court issued a per curiam decision denying both rehearing requests.</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In total, the Company has settled with 25 generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to the market in May 2026 or earlier under certain circumstances, and their generic versions of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">to the market in July 2026 or earlier under certain circumstances.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus&#8217;s NDA seeking approval of its sitagliptin tablets. In December 2022, the parties reached settlement that included dismissal of the case without prejudice enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In January 2023, the Company received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Zydus has filed a NDA seeking approval of sitagliptin/metformin HCl tablets and certifying that no valid or enforceable claim of any of the patents listed in FDA&#8217;s Orange Book for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will be infringed by the proposed Zydus product. In March 2023, the parties reached settlement enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a result of these favorable court rulings and settlement agreements related to the later expiring patent directed to the specific sitagliptin salt form of the products, the Company expects that </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Januvia </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will not lose market exclusivity in </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">the U.S. until May 2026 and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> will not lose market exclusivity in the U.S. until July 2026</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, although another non-automatically substitutable form of sitagliptin is likely to be available prior to 2026</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Supplementary Protection Certificates (SPCs) for </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> expired between April 7 and 10, 2023, for the majority of European countries. Prior to expiration, generic companies sought revocation of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> SPCs in a number of European countries. In February 2022, a Finnish court referred certain questions to the Court of Justice of the European Union (CJEU) that could determine the validity of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SPCs in Europe, for which an oral hearing was held on March 8, 2023, and an Advocate General Opinion is expected on July 13, 2023. If the CJEU renders a decision that negatively impacts the validity of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> SPCs throughout Europe, generic companies that were prevented from launching products during the SPC period in certain European countries may have an action for damages. Those countries include Belgium, Czech Republic, Ireland, Finland, France, Slovakia and Switzerland. If the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SPCs are ultimately upheld, the Company has reserved its rights related to the pursuit of damages for those countries where a generic launched prior to expiry of the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">SPC.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company filed a complaint against The Johns Hopkins University (JHU) on November 29, 2022, in the District Court of Maryland. This action concerns patents emerging from a joint research collaboration between Merck and JHU regarding the use of pembrolizumab, which Merck sells under the trade name </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. Merck and JHU partnered to design and conduct a clinical study administering </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to cancer patients having tumors that had the genetic biomarker known as microsatellite instability-high (MSI-H). After the conclusion of the study, JHU secured U.S. patents citing the joint research study. Merck alleges that JHU has breached the collaboration agreement by filing and obtaining these patents without informing or involving Merck and then licensing the patents to others. Merck therefore brought this action for breach of contract; declaratory judgment of noninfringement; and promissory estoppel. JHU answered the complaint on April 13, 2023, denying Merck&#8217;s claims, and counterclaiming for willful infringement of five issued U.S. patents, including a demand for damages.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> In December 2022, AstraZeneca Pharmaceuticals LP received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Natco Pharma Limited (Natco) has filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2023, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Natco. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2025 or until an adverse court decision, if any, whichever may occur earlier.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company&#8217;s financial condition, results of operations or cash flows either individually or in the aggregate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Legal Defense Reserves</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company&#8217;s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of March&#160;31, 2023 and December&#160;31, 2022 of approximately $225 million and $230 million, respectively, represents the Company&#8217;s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593221569376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text">Equity<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:29.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Par&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,429)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,109)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.69 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,754)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,754)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,369)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,063)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,953&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,379&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61,081&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,768)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,039&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,489)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,058&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.73 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,863)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,863)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,039&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,883)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,040&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,577)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,905&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593221346496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pension and Other Postretirement Benefit Plans</a></td>
<td class="text">Pension and Other Postretirement Benefit Plans<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost (credit) of such plans consisted of the following components:&#160;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.677%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (gain) loss amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components:&#160;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.943%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net gain amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In connection with restructuring actions (see Note&#160;5), termination charges were recorded on pension plans related to expanded eligibility for certain employees e</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">iting Merck. Also, in connection with these restructuring activities, curtailments were recorded on certain pension plans. In addition, lump sum payments to U.S. pension plan participants triggered a partial settlement resulting in a charge of $21&#160;million in the first quarter of 2023. This partial settlement triggered a remeasurement of some of the Company&#8217;s U.S. pension plans. The remeasurement, which was calculated using discount rates and asset values as of March&#160;31, 2023, resulted in a net increase of $44&#160;million to net pension liabilities and also resulted in a related adjustment to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The components of net periodic benefit cost (credit) other than the service cost component are included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (see Note&#160;11), with the exception of certain amounts for termination benefits and curtailments which are recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> if the event giving rise to the termination benefits or curtailment is related to restructuring actions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593221389808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income) Expense, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Other (Income) Expense, Net</a></td>
<td class="text">Other (Income) Expense, Net<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:&#160;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.478%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.821%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Income) loss from investments in equity securities, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">708&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other, net (as reflected in the table above) in the first quarter of 2023 includes a $572.5&#160;million charge related to settlements with certain plaintiffs in the Zetia antitrust litigation (see Note&#160;8).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest paid for the three months ended March&#160;31, 2023 and 2022 was $208 million and $211 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI https://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI https://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593221386576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Taxes on Income</a></td>
<td class="text">Taxes on IncomeThe effective income tax rates were 22.6% and 11.4% for the first quarter of 2023 and 2022, respectively. The effective income tax rate for the first quarter of 2023 reflects the unfavorable discrete impact of a charge for the acquisition of Imago for which no tax benefit was recognized, as well as higher foreign taxes, the impact of the R&amp;D capitalization provision of the Tax Cuts and Jobs Act of 2017 on the Company&#8217;s U.S. global intangible low-taxed income inclusion, and net unrealized gains from investments in equity securities, which were taxed at the U.S. tax rate, partially offset by higher foreign tax credits. The effective income tax rate in the first quarter of 2022 includes the favorable impact of net unrealized losses from investments in equity securities, which were taxed at the U.S. tax rate.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593221413536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per Share<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The calculations of earnings per share are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.236%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income Attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,538&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,528&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,551&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,537&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.11&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.70&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.11&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.70&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Issuable primarily under share-based compensation plans.</span></div>For the first quarter of 2023 and 2022, 1 million and 7 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593221389808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Other Comprehensive Income (Loss)</a></td>
<td class="text">Other Comprehensive Income (Loss)<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in each component of other comprehensive income (loss) are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,743)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,830)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,429)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance March 31, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,711)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,865)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,369)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2023, net of taxes</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,408)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,433)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,768)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(133)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance March 31, 2023, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,458)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,365)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,883)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Primarily relates to foreign currency cash flow hedges that were reclassified from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note&#160;10).</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.339%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI https://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593221505760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company&#8217;s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S.&#160;Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales of the Company&#8217;s products were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.631%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Lenvima</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Reblozyl</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Welireg</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">II</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">/Varivax</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaxneuvance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Dificid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Adempas/Verquvo </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">HD</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,721&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,599&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,614&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,212&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,246&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,343&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,589&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,659&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,828&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,487&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,339&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,563&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,901&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Lynparza and Lenvima represents Merck&#8217;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note&#160;3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Reblozyl represents royalties and, for 2022, also includes the receipt of a regulatory approval milestone payment (see Note&#160;3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Adempas/Verquvo represents Merck&#8217;s share of profits from sales in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note&#160;3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(5)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased sales by $99&#160;million and $69&#160;million for the three months ended March&#160;31, 2023 and 2022, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the three months ended March&#160;31, 2023 and 2022 also includes $51&#160;million and $114&#160;million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by $3.1 billion and $2.9 billion for the three months ended March&#160;31, 2023 and 2022, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.478%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.674%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,487&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,901&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income Before Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.528%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,706&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,086&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(242)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(243)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(543)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(378)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,446)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charge for Zetia antitrust litigation settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(573)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,607)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,650&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,861&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company&#8217;s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and purchase accounting adjustments are not allocated to segments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing arrangements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593226366512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of PresentationThe accompanying unaudited condensed consolidated financial statements of Merck&#160;&amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck&#8217;s Form 10-K filed on February&#160;24, 2023. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company&#8217;s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Standards and Recently Issued Accounting Standards Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standard</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The Company adopted the guidance effective January 1, 2023. The adoption of this guidance did not have an impact on the Company&#8217;s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standard Not Yet Adopted</span></div>In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company does not expect there to be an impact to its consolidated financial statements upon adoption<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Legal Costs</a></td>
<td class="text">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149975-122751<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593221425552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementsAbstract', window );"><strong>Collaborative Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Collaboration Arrangements</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.089%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amount in the first quarter of 2022 includes $250&#160;million of cumulative amortization catch-up expense as noted above.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.625%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.674%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amount in the first quarter of 2023 includes $72&#160;million of cumulative amortization catch-up expense as noted above.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents an accrued milestone payment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.943%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of Verquvo recorded by Merck</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Bayer included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes amortization of intangible assets. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.943%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net sales of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">recorded by Merck</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payables to Ridgeback included in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes royalty expense and amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Expenses include an allocation for overhead charges.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued royalties. Amount at December 31, 2022 also includes an accrued milestone payment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593221330976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Charges Related to Restructuring Program Activities by Type of Cost</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize the charges related to restructuring program activities by type of cost:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.654%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.531%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Charges and Spending Relating to Restructuring Activities by Program</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities for the three months ended March&#160;31, 2023:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves January&#160;1, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring reserves March&#160;31, 2023 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)The remaining cash outlays are expected to be largely completed by the end of 2025.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593219075808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Effect of Net Investment Hedges on OCI and the Consolidated Statement of Income</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The effects of the Company&#8217;s net investment hedges on </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.227%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">No amounts were reclassified from AOCL into income related to the sale of a subsidiary.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Fair Value of Derivatives on a Gross Basis Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair&#160;Value&#160;of&#160;Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair&#160;Value&#160;of&#160;Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.&#160;Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0xLTEtMS0xMzE2MTg_cdf39073-c7a9-42f3-a873-70852c2d806a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0xLTEtMS0xMzE2MTg_eaa07838-14e0-4387-8b95-9bb43c3d8ff8">Other Assets</span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xNDUxMzg_9df5cddc-66b1-4a33-8e29-a18d74bcc019"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xNDUxMzg_f3c8a52d-a48a-4e54-b19b-78f16a11f45d">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xMzE2MTg_408692a5-0d77-4a04-a36c-28872dc58415"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xMzE2MTg_4a4e35a6-2d31-4c12-be2f-2f5f0ad91a6c">Other current assets</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0xLTEtMS0xMzE2MTg_81797372-b85c-4d09-ac25-516d3f440479"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0xLTEtMS0xMzE2MTg_ab1b0a2e-c0bf-439c-9322-21e04e73f4f5">Other Assets</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xLTEtMS0xMzE2MTg_3132afe6-dbe8-4b79-81d1-621892c284e2"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xLTEtMS0xMzE2MTg_99d4d534-f137-4781-a93f-a2c418043a22">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xLTEtMS0xMzE2MTg_11e2508b-56af-4ce8-a9f2-c0ca375d810e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xLTEtMS0xMzE2MTg_c087e16f-89b4-40c0-959b-f2b2cdd6e23c">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,073&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,215&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMS0xLTEtMTMxNjE4_05e962d8-08ac-4061-91f8-80526dc22b48"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMS0xLTEtMTMxNjE4_c1218d47-d091-44ba-967a-61df1ed0b192">Other current assets</span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,507&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,540&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMS0xLTEtMTQ1MTQy_1096f2ac-e5f3-4efe-9d17-7ead4689602e"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMS0xLTEtMTQ1MTQy_c4114de6-2d78-4e8c-8218-b4ecfaa65a61">Other Assets</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMS0xLTEtMTMxNjE4_8e46edaf-73d3-4fb2-a39e-a898b16444e0"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMS0xLTEtMTMxNjE4_a38bf2e0-7e23-4be7-a57d-412372f2f6e0">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMS0xLTEtMTQ1MTQ3_0f134479-ab12-4419-8818-0dec3ce2d2eb"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMS0xLTEtMTQ1MTQ3_8586bfb3-f29a-42c6-a48d-599f102341da">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,288&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,466&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,361&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,681&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock', window );">Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis</a></td>
<td class="text">The following table provides information on the Company&#8217;s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:64.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts recognized in the condensed consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collateral received/posted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Location and Amount of Pretax Gains and Losses of Derivatives</a></td>
<td class="text"><div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.900%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Caption in which Effects of Fair Value or Cash Flow </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Hedges are Recorded</span></div></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,487&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,901&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">708&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hedged items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of (loss) gain recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Increase in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Interest expense is a component of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Income Statement Effects of Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.847%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.359%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">These derivative contracts serve as economic hedges of forecasted transactions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Information on Investments in Debt and Equity Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gross&#160;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,585&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,345&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,853&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net gains of $338&#160;million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in the first quarter of 2023 on equity securities still held at March&#160;31, 2023. Unrealized net losses of $225 million were recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> in the first quarter of 2022 on equity securities still held at March&#160;31, 2022.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis are summarized below:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.654%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,604&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,355&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,286&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">865&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#8217;s own credit risk, the effects of which were not significant.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Information About the Changes in Liabilities for Contingent Consideration</a></td>
<td class="text"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:80.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">777&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in estimated fair value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value March 31 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Recorded in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cost of sales, Research and development</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">At March&#160;31, 2023, $263 million of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at March&#160;31, 2023 includes $127 million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_OffsettingAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_OffsettingAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593222253536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories consisted of:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,883&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,497&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,142&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,147&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,849&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,284&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,938&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593221508240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">Schedule of Equity</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:29.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Par&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,238&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,429)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,109)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.69 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,754)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,754)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,369)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,063)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,953&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,379&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61,081&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,768)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,039&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,489)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,058&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&#160;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.73 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,863)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,863)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,467&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,039&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,883)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,040&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,577)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,905&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593219982176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Net Benefit Costs</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost (credit) of such plans consisted of the following components:&#160;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.677%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (gain) loss amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Postretirement Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Net Benefit Costs</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components:&#160;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.943%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net gain amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593221508240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income) Expense, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other (Income) Expense, Net</a></td>
<td class="text"><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:&#160;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.478%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.821%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Income) loss from investments in equity securities, net </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">708&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>(1)&#160;&#160;&#160;&#160;Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593221471296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Calculations of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The calculations of earnings per share are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.236%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income Attributable to Merck&#160;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,538&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,528&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,551&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,537&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.11&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.70&#160;</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.11&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.70&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Issuable primarily under share-based compensation plans.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593309643088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Changes in AOCI by Component</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in each component of other comprehensive income (loss) are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,743)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,830)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,429)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance March 31, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,711)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,865)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,369)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2023, net of taxes</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,408)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,433)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,768)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(133)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance March 31, 2023, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,458)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,365)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,883)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Primarily relates to foreign currency cash flow hedges that were reclassified from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note&#160;10).</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.339%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593221344640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Sales from Products</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sales of the Company&#8217;s products were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.631%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int&#8217;l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Lynparza</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Lenvima</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Reblozyl</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Welireg</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">II</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">/Varivax</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaxneuvance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Dificid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Adempas/Verquvo </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">HD</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,721&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,010&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,599&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,614&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,212&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,246&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,343&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,589&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,659&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,828&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,487&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,339&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8,563&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,901&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Lynparza and Lenvima represents Merck&#8217;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note&#160;3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Reblozyl represents royalties and, for 2022, also includes the receipt of a regulatory approval milestone payment (see Note&#160;3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Adempas/Verquvo represents Merck&#8217;s share of profits from sales in Bayer&#8217;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note&#160;3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(5)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased sales by $99&#160;million and $69&#160;million for the three months ended March&#160;31, 2023 and 2022, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the three months ended March&#160;31, 2023 and 2022 also includes $51&#160;million and $114&#160;million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Consolidated Sales by Geographic Area</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.478%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.674%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,487&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,901&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Segment Profits to Income before Taxes</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Income Before Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.528%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,706&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,086&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(242)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(243)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(543)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(398)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(378)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,147)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,446)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Charge for Zetia antitrust litigation settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(573)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,607)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,650&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,861&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593223220320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Spin-Off of Organon &amp; Co. (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 02, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_OrganonCoMember', window );">Organon &amp; Co.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">$ 99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartiesAmountInCostOfSales', window );">Related party amount in cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Due from related parties, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Transition services agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal', window );">Period of continuing involvement after disposal</a></td>
<td class="text">25 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Manufacturing and supply agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal', window );">Period of continuing involvement after disposal</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Transition services agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal', window );">Period of continuing involvement after disposal</a></td>
<td class="text">35 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Manufacturing and supply agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal', window );">Period of continuing involvement after disposal</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of expected continuing involvement with a discontinued operation after the disposal date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartiesAmountInCostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount included in cost of sales related to transactions with related parties incurred and recorded in the statement of operations for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartiesAmountInCostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_OrganonCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_OrganonCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mrk_TransitionServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mrk_TransitionServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=mrk_ManufacturingAndSupplyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=mrk_ManufacturingAndSupplyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593222745056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Research Collaborations and License Agreements (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,276<span></span>
</td>
<td class="nump">$ 2,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=mrk_PrometheusBiosciencesIncMember', window );">Prometheus Biosciences, Inc. | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_AssetAcquisitionSharePrice', window );">Asset acquisition, share price (in dollars per share)</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected', window );">Asset acquisition, price of acquisition, expected</a></td>
<td class="nump">$ 10,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=mrk_ImagoBioSciencesIncMember', window );">Imago Bio Sciences, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Asset acquisition costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Consideration transferred, asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember', window );">Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments', window );">Eligible future contingent development-related payments (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments', window );">Regulatory milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments', window );">Sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty', window );">Preferred stock investment in counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Alliance revenue - Lenvima</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_MilestonePaymentsMadetoCollaborativePartner', window );">Capitalized milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Assets Acquired And Liabilities Assumed, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_AssetAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in an asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_AssetAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Preferred Stock Investment In Counterparty</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_MilestonePaymentsMadetoCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Made to Collaborative Partner</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_MilestonePaymentsMadetoCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 55<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6829253&amp;loc=SL6831962-166255<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionPriceOfAcquisitionExpected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of expected asset acquisition prior to consideration being transferred. Excludes business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionPriceOfAcquisitionExpected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=mrk_PrometheusBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=mrk_PrometheusBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=mrk_ImagoBioSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=mrk_ImagoBioSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LenvimaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LenvimaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593215884944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">$ 543<span></span>
</td>
<td class="nump">$ 699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">14,487<span></span>
</td>
<td class="nump">15,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">14,212<span></span>
</td>
<td class="nump">15,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">12,721<span></span>
</td>
<td class="nump">14,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_LynparzaMember', window );">Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_LynparzaMember', window );">Lynparza | Other Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_LenvimaMember', window );">Lenvima</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_LenvimaMember', window );">Lenvima | Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_LenvimaMember', window );">Lenvima | Other Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets</a></td>
<td class="nump">812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_VerquvoMember', window );">Verquvo | Other Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets</a></td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_AdempasMember', window );">Adempas | Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_AdempasMember', window );">Adempas | Other Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets</a></td>
<td class="nump">613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_AllianceRevenueReblozylMember', window );">Alliance Revenue - Reblozyl | Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember', window );">AstraZeneca | Sales-Based Milestones | Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ProbableContingentPaymentsCollaborativeArrangement', window );">Probable contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember', window );">AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_MilestonePaymentsSalesBased', window );">Sales-based milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_PotentialFutureMilestonePaymentsSalesBased', window );">Potential future sales-based milestone payments</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued', window );">Regulatory milestone payments accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_MilestonePaymentsMadetoCollaborativePartner', window );">Capitalized milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_PotentialFutureMilestonePaymentsRegulatory', window );">Potential future regulatory milestone payments</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai | Sales-Based Milestones | Lenvima</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ProbableContingentPaymentsCollaborativeArrangement', window );">Probable contingent payments</a></td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_EisaiMember', window );">Eisai | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Lenvima</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_MilestonePaymentsSalesBased', window );">Sales-based milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_PotentialFutureMilestonePaymentsSalesBased', window );">Potential future sales-based milestone payments</a></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_MilestonePaymentsMadetoCollaborativePartner', window );">Capitalized milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BayerAGMember', window );">Bayer AG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_MilestonePaymentsSalesBased', window );">Sales-based milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember', window );">Bristol Myers Squibb | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RoyaltyRateDeductionPercentage', window );">Royalty rate, deduction</a></td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyIncomeNonoperating', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember', window );">Bristol Myers Squibb | Licensing Agreements | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_ContingentProceedsCollaborativeArrangement', window );">Contingent proceeds collaborative arrangement</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember', window );">Bristol Myers Squibb | Licensing Agreements | Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from Collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember', window );">Bristol Myers Squibb | Licensing Agreements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty rate</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember', window );">Bristol Myers Squibb | Licensing Agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RoyaltyRatePercentage', window );">Royalty rate</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Regulatory Milestone Payments Accrued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ContingentProceedsCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents proceeds that may be received in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ContingentProceedsCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_MilestonePaymentsMadetoCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Made to Collaborative Partner</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_MilestonePaymentsMadetoCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_MilestonePaymentsSalesBased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments Sales-Based</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_MilestonePaymentsSalesBased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_PotentialFutureMilestonePaymentsRegulatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Future Milestone Payments Regulatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_PotentialFutureMilestonePaymentsRegulatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_PotentialFutureMilestonePaymentsSalesBased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Future Milestone Payments Sales-Based</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_PotentialFutureMilestonePaymentsSalesBased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_ProbableContingentPaymentsCollaborativeArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Probable Contingent Payments Collaborative Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_ProbableContingentPaymentsCollaborativeArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RoyaltyRateDeductionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Rate, Deduction, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RoyaltyRateDeductionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RoyaltyRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Rate, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RoyaltyRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LynparzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LynparzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LenvimaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LenvimaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_VerquvoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_VerquvoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AdempasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AdempasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AllianceRevenueReblozylMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AllianceRevenueReblozylMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mrk_SalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mrk_SalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_BayerAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_BayerAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_BristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_SalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mrk_SalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=mrk_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593215410320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements - Financial Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 14,487<span></span>
</td>
<td class="nump">$ 15,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">3,926<span></span>
</td>
<td class="nump">5,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,479<span></span>
</td>
<td class="nump">2,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">4,276<span></span>
</td>
<td class="nump">2,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Payables included in Accrued and other liabilities</a></td>
<td class="nump">23,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">543<span></span>
</td>
<td class="nump">699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_LenvimaMember', window );">Alliance revenue - Lenvima</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables included in Other current assets</a></td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables included in Other current assets</a></td>
<td class="nump">244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables included in Other current assets</a></td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember', window );">Accounts Payable and Accrued Liabilities | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Payables included in Accrued and other liabilities</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember', window );">Accounts Payable and Accrued Liabilities | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Payables included in Accrued and other liabilities</a></td>
<td class="nump">125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember', window );">Accounts Payable and Accrued Liabilities | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Payables included in Accrued and other liabilities</a></td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember', window );">Accounts Payable and Accrued Liabilities | Ridgeback Biotherapeutics LP | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Payables included in Accrued and other liabilities</a></td>
<td class="nump">191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Payables included in Other Noncurrent Liabilities</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementProfitSharing', window );">Alliance revenue - profit sharing</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | AstraZeneca | Collaborative Arrangement | Alliance revenue - Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementProfitSharing', window );">Alliance revenue - profit sharing</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | AstraZeneca | Collaborative Arrangement | Alliance revenue - Koselugo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementProfitSharing', window );">Alliance revenue - profit sharing</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementProfitSharing', window );">Alliance revenue - profit sharing</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementProfitSharing', window );">Alliance revenue - profit sharing</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Bayer AG | Collaborative Arrangement | Adempas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementSalesNet', window );">Net sales by Merck</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Bayer AG | Collaborative Arrangement | Verquvo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_CollaborativeArrangementSalesNet', window );">Net sales by Merck</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Ridgeback Biotherapeutics LP | Collaborative Arrangement | Lagevrio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">3,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | Ridgeback Biotherapeutics LP | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">1,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Ridgeback Biotherapeutics LP | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Eisai | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Bayer AG | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Ridgeback Biotherapeutics LP | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementProfitSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Profit Sharing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementProfitSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_CollaborativeArrangementSalesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Sales, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_CollaborativeArrangementSalesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LenvimaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LenvimaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_BayerAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_BayerAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mrk_RidgebackBiotherapeuticsLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mrk_RidgebackBiotherapeuticsLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AllianceRevenueKoselugoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AllianceRevenueKoselugoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AdempasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AdempasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_VerquvoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_VerquvoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LagevrioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LagevrioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593223391472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected restructuring and related cost</a></td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays', window );">Estimate of cumulative pre tax costs that will result in cash outlays</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash', window );">Estimate of cumulative pre tax costs that will be noncash</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Cumulative costs since program inception</a></td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected restructuring and related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimate of cumulative pre tax costs that will be noncash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593214993904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Charges Activities by Type of Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">Separation Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember', window );">Accelerated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | Separation Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | Accelerated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Separation Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Accelerated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Separation Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Accelerated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring costs | Separation Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring costs | Accelerated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring costs | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Total pretax restructuring costs</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593215840288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Activities by Program (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning balance</a></td>
<td class="nump">$ 513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Expenses</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">(Payments) receipts, net</a></td>
<td class="num">(74)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity', window );">Non-cash activity</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">Separation Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning balance</a></td>
<td class="nump">479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Expenses</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">(Payments) receipts, net</a></td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity', window );">Non-cash activity</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember', window );">Accelerated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Expenses</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">(Payments) receipts, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity', window );">Non-cash activity</a></td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning balance</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Expenses</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">(Payments) receipts, net</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity', window );">Non-cash activity</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending balance</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RestructuringReserveIncreaseDecreaseNoncashActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash activity affecting the restructuring reserve, including accelerated depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RestructuringReserveIncreaseDecreaseNoncashActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=mrk_AcceleratedDepreciationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593215088560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>interest_rate_swap</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>USD ($) </div>
<div>interest_rate_swap</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of interest rate swaps held (in interest rate swaps) | interest_rate_swap</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total swap notional amount</a></td>
<td class="nump">$ 30,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Pretax net unrealized losses on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales</a></td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity investments without readily determinable fair values</a></td>
<td class="nump">942<span></span>
</td>
<td class="nump">$ 643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount', window );">Unrealized gains recognized on investments in equity securities without readily determinable fair value</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount', window );">Unrealized losses recognized on investments in equity securities without readily determinable fair values</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount', window );">Cumulative unrealized gains on investments</a></td>
<td class="nump">287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount', window );">Cumulative unrealized losses on investments</a></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Equity securities, noncurrent</a></td>
<td class="nump">725<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">(Income) loss from investments in equity securities, net</a></td>
<td class="num">(450)<span></span>
</td>
<td class="nump">708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of loans payable and long-term debt, including current portion</a></td>
<td class="nump">28,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Debt, carrying amount</a></td>
<td class="nump">30,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableSale', window );">Factored accounts receivable</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCollateralObligationToReturnCash', window );">Cash collateral received from counterparties</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCollateralRightToReclaimSecurities', window );">Cash collateral advanced to counterparties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of interest rate swaps held (in interest rate swaps) | interest_rate_swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquityFundsMember', window );">Equity Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">(Income) loss from investments in equity securities, net</a></td>
<td class="num">(132)<span></span>
</td>
<td class="nump">$ 509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">8,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total swap notional amount</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap contracts | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total swap notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total swap notional amount</a></td>
<td class="nump">10,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total swap notional amount</a></td>
<td class="nump">$ 20,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Derivatives Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAverageRemainingMaturity1', window );">Maximum average period of maturities of contracts in years (less than)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAverageRemainingMaturity1', window );">Maximum average period of maturities of contracts in years (less than)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease from sale of accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919244-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAverageRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average remaining period until maturity of the derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAverageRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralObligationToReturnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralObligationToReturnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralRightToReclaimSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of right to receive securities collateral under master netting arrangements that have not been offset against derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralRightToReclaimSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80845-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFVNINoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFVNINoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative loss from downward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfInterestRateDerivativesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of interest rate derivative instruments held by the entity at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfInterestRateDerivativesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquityFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquityFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593220163744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Effect of Net Investment Hedges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">$ (16)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=mrk_EurodominatedNotesMember', window );">Euro-denominated notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</a></td>
<td class="nump">52<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=mrk_EurodominatedNotesMember', window );">Euro-denominated notes | Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=mrk_EurodominatedNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=mrk_EurodominatedNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593215157888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">$ 259<span></span>
</td>
<td class="nump">$ 433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">30,361<span></span>
</td>
<td class="nump">28,681<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">10,073<span></span>
</td>
<td class="nump">9,215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Derivatives Not Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">20,288<span></span>
</td>
<td class="nump">19,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract | Derivatives Designated as Hedging Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other current assets<span></span>
</td>
<td class="text">Other current assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Noncurrent Liabilities<span></span>
</td>
<td class="text">Other Noncurrent Liabilities<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract | Derivatives Designated as Hedging Instruments | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract | Derivatives Designated as Hedging Instruments | Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Assets<span></span>
</td>
<td class="text">Other Assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">$ 1,756<span></span>
</td>
<td class="nump">$ 1,609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Noncurrent Liabilities<span></span>
</td>
<td class="text">Other Noncurrent Liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other current assets<span></span>
</td>
<td class="text">Other current assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">$ 4,253<span></span>
</td>
<td class="nump">$ 4,824<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">$ 116<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">$ 3,444<span></span>
</td>
<td class="nump">$ 2,691<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Assets<span></span>
</td>
<td class="text">Other Assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Noncurrent Liabilities<span></span>
</td>
<td class="text">Other Noncurrent Liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Fair Value of Derivative, Asset</a></td>
<td class="nump">$ 121<span></span>
</td>
<td class="nump">$ 186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other current assets<span></span>
</td>
<td class="text">Other current assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">$ 9,507<span></span>
</td>
<td class="nump">$ 8,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative, Liability</a></td>
<td class="nump">$ 164<span></span>
</td>
<td class="nump">$ 307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">U.S Dollar Notional Amount</a></td>
<td class="nump">$ 10,592<span></span>
</td>
<td class="nump">$ 10,926<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593219917776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Gross amounts recognized in the consolidated balance sheet, asset</a></td>
<td class="nump">$ 259<span></span>
</td>
<td class="nump">$ 433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction', window );">Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset</a></td>
<td class="num">(148)<span></span>
</td>
<td class="num">(220)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCollateralObligationToReturnCash', window );">Cash collateral received, asset</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection', window );">Net amounts, asset</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Gross amounts recognized in the consolidated balance sheet, liability</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction', window );">Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability</a></td>
<td class="num">(148)<span></span>
</td>
<td class="num">(220)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeCollateralRightToReclaimCash', window );">Cash collateral received, liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection', window );">Net amounts, liability</a></td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralObligationToReturnCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralObligationToReturnCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeCollateralRightToReclaimCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeCollateralRightToReclaimCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226016-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593222748896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 14,487<span></span>
</td>
<td class="nump">$ 15,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="nump">89<span></span>
</td>
<td class="nump">708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(115)<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Amount of gain (loss) recognized in OCI on derivatives</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Amount of gain recognized in Other (income) expense, net on derivatives</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap contracts | Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1', window );">Hedged items</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Derivatives designated as hedging instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Amount of gain (loss) recognized in OCI on derivatives</a></td>
<td class="num">(66)<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Increase in Sales as a result of AOCL reclassifications</a></td>
<td class="num">(101)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Reclassification out of Accumulated Other Comprehensive Income | Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 101<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593226272752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Currency Swap | Other (income) expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Amount of Derivative Pretax (Gain) Loss Recognized in Income</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeFutureMember', window );">Foreign Exchange Future | Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Amount of Derivative Pretax (Gain) Loss Recognized in Income</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeFutureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeFutureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593223092128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Information on Available-for-sale Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">$ 760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities, fair value</a></td>
<td class="nump">1,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,284<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_DebtSecuritiesandEquitySecuritiesFVNI', window );">Total debt and publicly traded equity securities, fair value</a></td>
<td class="nump">2,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized net (gains) losses</a></td>
<td class="num">(338)<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Debt securities, unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Debt securities, unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, fair value</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_DebtSecuritiesandEquitySecuritiesFVNI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities and Equity Securities, FV-NI</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_DebtSecuritiesandEquitySecuritiesFVNI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593212285920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">$ 760<span></span>
</td>
<td class="nump">$ 569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">1,585<span></span>
</td>
<td class="nump">1,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">259<span></span>
</td>
<td class="nump">433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">353<span></span>
</td>
<td class="nump">456<span></span>
</td>
<td class="nump">$ 572<span></span>
</td>
<td class="nump">$ 777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">663<span></span>
</td>
<td class="nump">498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Investments</a></td>
<td class="nump">1,970<span></span>
</td>
<td class="nump">1,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">375<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">259<span></span>
</td>
<td class="nump">433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">2,604<span></span>
</td>
<td class="nump">2,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">353<span></span>
</td>
<td class="nump">456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">637<span></span>
</td>
<td class="nump">865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Currency options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Investments</a></td>
<td class="nump">1,284<span></span>
</td>
<td class="nump">1,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">375<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">1,659<span></span>
</td>
<td class="nump">1,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Currency options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1 | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Investments</a></td>
<td class="nump">686<span></span>
</td>
<td class="nump">498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">259<span></span>
</td>
<td class="nump">433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">945<span></span>
</td>
<td class="nump">931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Currency options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2 | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradingSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">353<span></span>
</td>
<td class="nump">456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">353<span></span>
</td>
<td class="nump">456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Currency options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3 | Interest rate swap contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">663<span></span>
</td>
<td class="nump">498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial paper | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial paper | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">663<span></span>
</td>
<td class="nump">498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial paper | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. government and agency securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. government and agency securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. government and agency securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Foreign government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Foreign government bonds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Foreign government bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Foreign government bonds | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Publicly traded equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">1,284<span></span>
</td>
<td class="nump">1,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Publicly traded equity securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">1,284<span></span>
</td>
<td class="nump">1,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Publicly traded equity securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Publicly traded equity securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Publicly traded equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate notes and bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate notes and bonds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate notes and bonds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate notes and bonds | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593223423072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning balance</a></td>
<td class="nump">$ 456<span></span>
</td>
<td class="nump">$ 777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in estimated fair value</a></td>
<td class="nump">14<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(117)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, ending balance</a></td>
<td class="nump">353<span></span>
</td>
<td class="nump">572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">353<span></span>
</td>
<td class="nump">$ 572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current liability</a></td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=mrk_SanofiPasteurMember', window );">Sanofi Pasteur</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, ending balance</a></td>
<td class="nump">263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration, measurement input, discount rate</a></td>
<td class="nump">0.115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=mrk_SanofiPasteurMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=mrk_SanofiPasteurMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593225833488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Schedule of Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">$ 1,883<span></span>
</td>
<td class="nump">$ 1,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessAndRawMaterials', window );">Raw materials and work in process</a></td>
<td class="nump">7,348<span></span>
</td>
<td class="nump">7,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInventorySupplies', window );">Supplies</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total (approximates current cost)</a></td>
<td class="nump">9,497<span></span>
</td>
<td class="nump">9,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLIFOReserve', window );">Decrease to LIFO cost</a></td>
<td class="num">(350)<span></span>
</td>
<td class="num">(293)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_InventoryNetAndInventoryNoncurrent', window );">Total current and noncurrent inventories</a></td>
<td class="nump">9,147<span></span>
</td>
<td class="nump">8,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_RecognizedAsAbstract', window );"><strong>Recognized as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">5,863<span></span>
</td>
<td class="nump">5,911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Other Assets</a></td>
<td class="nump">$ 3,284<span></span>
</td>
<td class="nump">$ 2,938<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_InventoryNetAndInventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of current and noncurrent inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_InventoryNetAndInventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_RecognizedAsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recognized as.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_RecognizedAsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessAndRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessAndRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventorySupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventorySupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593223379296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventories classified in Other assets</a></td>
<td class="nump">$ 3,284<span></span>
</td>
<td class="nump">$ 2,938<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoryNotExpectedtobeSoldWithinOneYearMember', window );">Inventories Not Expected to be Sold Within One Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventories classified in Other assets</a></td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoriesProducedinPreparationforProductLaunchesMember', window );">Inventories Produced in Preparation for Product Launches</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventories classified in Other assets</a></td>
<td class="nump">$ 590<span></span>
</td>
<td class="nump">$ 516<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoryNotExpectedtobeSoldWithinOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoryNotExpectedtobeSoldWithinOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoriesProducedinPreparationforProductLaunchesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=mrk_InventoriesProducedinPreparationforProductLaunchesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593216478784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 13, 2023 </div>
<div>patent</div>
</th>
<th class="th"><div>Dec. 19, 2022</div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>claim</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>case </div>
<div>company</div>
</th>
<th class="th">
<div>Mar. 03, 2023 </div>
<div>state</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>direct_purchaser</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=mrk_LegalDefenseCostsMember', window );">Legal Defense Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Legal defense costs reserve | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 230.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mrk_ZetiaantitrustlitigationMember', window );">Zetia antitrust litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims | direct_purchaser</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Loss related to litigation settlement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 572.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mrk_ZetiaantitrustlitigationMember', window );">Zetia antitrust litigation | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss contingency, new claims filed | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mrk_RotaTeqAntitrustLitigationMember', window );">RotaTeq Antitrust Litigation | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_LossContingencyNumberOfStatesInWhichPlaintiffsReside', window );">Loss Contingency, number of states in which plaintiffs reside | state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mrk_ComplaintAgainstTheJohnsHopkinsUniversityMember', window );">Complaint Against The Johns Hopkins University | Pending Litigation | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber', window );">Loss contingency, number of patents allegedly infringed | patent</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member', window );">Gardasil/Gardasil 9 | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member', window );">Gardasil/Gardasil 9 | Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member', window );">Gardasil/Gardasil 9 | COLOMBIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_BridionMember', window );">Bridion | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsSettledNumber', window );">Loss contingency, claims settled | company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_BridionMember', window );">Bridion | Patents | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Loss contingency, pending claims | company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_LossContingencyTrialPeriod', window );">Loss contingency, trial period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mrk_JanuviaAndJanumetMember', window );">Januvia and Janumet | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsSettledNumber', window );">Loss contingency, claims settled | company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_LossContingencyNumberOfStatesInWhichPlaintiffsReside">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of States In Which Plaintiffs Reside</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_LossContingencyNumberOfStatesInWhichPlaintiffsReside</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_LossContingencyTrialPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Trial Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_LossContingencyTrialPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsSettledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of claims settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsSettledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of another entity's patents that the entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPatentsAllegedlyInfringedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=mrk_LegalDefenseCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=mrk_LegalDefenseCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mrk_ZetiaantitrustlitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mrk_ZetiaantitrustlitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mrk_RotaTeqAntitrustLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mrk_RotaTeqAntitrustLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mrk_ComplaintAgainstTheJohnsHopkinsUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mrk_ComplaintAgainstTheJohnsHopkinsUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CO">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CO</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_BridionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_BridionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_JanuviaAndJanumetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_JanuviaAndJanumetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593220500496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, beginning balance (in shares)</a></td>
<td class="nump">3,577,103,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, beginning balance (in shares)</a></td>
<td class="nump">1,039,269,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="nump">$ 46,058<span></span>
</td>
<td class="nump">$ 38,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">2,821<span></span>
</td>
<td class="nump">4,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(115)<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends declared on common stock</a></td>
<td class="num">(1,863)<span></span>
</td>
<td class="num">(1,754)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury stock shares purchased</a></td>
<td class="num">(149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Share-based compensation plans and other</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, ending balance (in shares)</a></td>
<td class="nump">3,577,103,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, ending balance (in shares)</a></td>
<td class="nump">1,039,651,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="nump">$ 46,905<span></span>
</td>
<td class="nump">$ 40,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared on common stock (in dollars per share)</a></td>
<td class="nump">$ 0.73<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">&#160;&#160; Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, beginning balance (in shares)</a></td>
<td class="nump">3,577,000,000<span></span>
</td>
<td class="nump">3,577,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="nump">$ 1,788<span></span>
</td>
<td class="nump">$ 1,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, ending balance (in shares)</a></td>
<td class="nump">3,577,000,000<span></span>
</td>
<td class="nump">3,577,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="nump">$ 1,788<span></span>
</td>
<td class="nump">$ 1,788<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Other Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="nump">44,379<span></span>
</td>
<td class="nump">44,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Share-based compensation plans and other</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="nump">44,467<span></span>
</td>
<td class="nump">44,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="nump">61,081<span></span>
</td>
<td class="nump">53,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Merck&#160;&amp; Co., Inc.</a></td>
<td class="nump">2,821<span></span>
</td>
<td class="nump">4,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends declared on common stock</a></td>
<td class="num">(1,863)<span></span>
</td>
<td class="num">(1,754)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="nump">62,039<span></span>
</td>
<td class="nump">56,252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="num">(4,768)<span></span>
</td>
<td class="num">(4,429)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(115)<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="num">$ (4,883)<span></span>
</td>
<td class="num">$ (4,369)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">&#160; Treasury Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, beginning balance (in shares)</a></td>
<td class="nump">1,039,000,000<span></span>
</td>
<td class="nump">1,049,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="num">$ (56,489)<span></span>
</td>
<td class="num">$ (57,109)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury stock shares purchased (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury stock shares purchased</a></td>
<td class="num">$ (149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Share-based compensation plans and other</a></td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, ending balance (in shares)</a></td>
<td class="nump">1,040,000,000<span></span>
</td>
<td class="nump">1,049,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="num">$ (56,577)<span></span>
</td>
<td class="num">$ (57,063)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non- controlling Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593214990784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Postretirement Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of unrecognized prior service credit</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Net (gain) loss amortization</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">U.S. | Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(187)<span></span>
</td>
<td class="num">(196)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of unrecognized prior service credit</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Net (gain) loss amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International | Pension Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(128)<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of unrecognized prior service credit</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Net (gain) loss amortization</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost</a></td>
<td class="num">$ (9)<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593306914912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Other Postretirement Benefit Plans - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Partial settlement charge</a></td>
<td class="nump">$ 21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement', window );">Increase to pension liabilities due to remeasurement</a></td>
<td class="nump">$ 44<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease to benefit obligation of defined benefit plan from remeasurement due to settlement. Excludes decrease to benefit obligation for settlement payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(8)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593222521072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">$ (112)<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">242<span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Exchange losses</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Loss (income) from investments in equity securities, net</a></td>
<td class="num">(450)<span></span>
</td>
<td class="nump">708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent', window );">Net periodic defined benefit plan (credit) cost other than service cost</a></td>
<td class="num">(115)<span></span>
</td>
<td class="num">(121)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_OtherNonoperatingIncomeExpenseOther', window );">Other, net</a></td>
<td class="nump">463<span></span>
</td>
<td class="num">(154)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 708<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_OtherNonoperatingIncomeExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other nonoperating income and expense items not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_OtherNonoperatingIncomeExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593220762288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income) Expense, Net - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
<td class="nump">$ 208.0<span></span>
</td>
<td class="nump">$ 211.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mrk_ZetiaantitrustlitigationMember', window );">Zetia antitrust litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Loss related to litigation settlement</a></td>
<td class="nump">$ 572.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mrk_ZetiaantitrustlitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mrk_ZetiaantitrustlitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593220154496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">22.60%<span></span>
</td>
<td class="nump">11.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_TaxBenefitResultingFromAcquisitionCharge', window );">Tax benefit resulting from acquisition charge</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_TaxBenefitResultingFromAcquisitionCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Benefit Resulting From Acquisition Charge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_TaxBenefitResultingFromAcquisitionCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593225832400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Calculations of Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income attributable to Merck &amp; Co., Inc., basic</a></td>
<td class="nump">$ 2,821,000<span></span>
</td>
<td class="nump">$ 4,310,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income attributable to Merck &amp; Co., Inc., diluted</a></td>
<td class="nump">$ 2,821,000<span></span>
</td>
<td class="nump">$ 4,310,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Average common shares outstanding (in shares)</a></td>
<td class="nump">2,538<span></span>
</td>
<td class="nump">2,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Common shares issuable (in shares)</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Average common shares outstanding assuming dilution (in shares)</a></td>
<td class="nump">2,551<span></span>
</td>
<td class="nump">2,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic Earnings Per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders (in dollars per share)</a></td>
<td class="nump">$ 1.11<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders (in dollars per share)</a></td>
<td class="nump">$ 1.11<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593306937328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Narrative (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares (in shares)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593212273664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="nump">$ 46,058<span></span>
</td>
<td class="nump">$ 38,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="num">(34)<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="num">(38)<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification adjustments, pretax</a></td>
<td class="num">(100)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification adjustments, net of taxes</a></td>
<td class="num">(77)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(115)<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="nump">46,905<span></span>
</td>
<td class="nump">40,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="num">(66)<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="nump">14<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="num">(52)<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification adjustments, pretax</a></td>
<td class="num">(102)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification adjustments, net of taxes</a></td>
<td class="num">(81)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(133)<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="num">(60)<span></span>
</td>
<td class="nump">207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Employee Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="num">(2,408)<span></span>
</td>
<td class="num">(2,743)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="num">(47)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="num">(45)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification adjustments, pretax</a></td>
<td class="num">(7)<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification adjustments, net of taxes</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(50)<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="num">(2,458)<span></span>
</td>
<td class="num">(2,711)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="num">(2,433)<span></span>
</td>
<td class="num">(1,830)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassification adjustments, pretax</a></td>
<td class="nump">79<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Tax</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassification adjustments, net of taxes</a></td>
<td class="nump">59<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification adjustments, pretax</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Reclassification adjustments, net of taxes</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="nump">68<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="num">(2,365)<span></span>
</td>
<td class="num">(1,865)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance</a></td>
<td class="num">(4,768)<span></span>
</td>
<td class="num">(4,429)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance</a></td>
<td class="num">$ (4,883)<span></span>
</td>
<td class="num">$ (4,369)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593221526416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Narrative (Details)<br> $ in Billions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_SalesDiscounts', window );">Sales discounts | $</a></td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_SalesDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales Discounts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_SalesDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593210819936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Sales from Products (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 14,487<span></span>
</td>
<td class="nump">$ 15,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Revenue related to the sale of the marketing rights</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_IncreaseDecreaseInHedgeRevenue', window );">Increase (Decrease) In Hedge Revenue</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">6,659<span></span>
</td>
<td class="nump">7,339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_InternationalMember', window );">Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">7,828<span></span>
</td>
<td class="nump">8,563<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">14,212<span></span>
</td>
<td class="nump">15,589<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">6,599<span></span>
</td>
<td class="nump">7,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">7,614<span></span>
</td>
<td class="nump">8,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">12,721<span></span>
</td>
<td class="nump">14,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">6,117<span></span>
</td>
<td class="nump">6,773<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">6,604<span></span>
</td>
<td class="nump">7,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Keytruda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">5,795<span></span>
</td>
<td class="nump">4,809<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Keytruda | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">3,485<span></span>
</td>
<td class="nump">2,779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Keytruda | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">2,310<span></span>
</td>
<td class="nump">2,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Alliance revenue - Lynparza</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Alliance revenue - Lenvima</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Welireg</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Welireg | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Welireg | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Gardasil/Gardasil 9</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,972<span></span>
</td>
<td class="nump">1,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">416<span></span>
</td>
<td class="nump">418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,556<span></span>
</td>
<td class="nump">1,042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">528<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">421<span></span>
</td>
<td class="nump">371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | RotaTeq</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">297<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | RotaTeq | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | RotaTeq | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Vaxneuvance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Vaxneuvance | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Vaxneuvance | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Pneumovax 23</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Pneumovax 23 | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Pneumovax 23 | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Vaqta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Vaqta | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Vaqta | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Bridion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">487<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Bridion | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Bridion | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Prevymis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Prevymis | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Prevymis | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Primaxin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Primaxin | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Primaxin | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Dificid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Dificid | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Dificid | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Noxafil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Noxafil | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Noxafil | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Zerbaxa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Zerbaxa | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Zerbaxa | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Adempas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Adempas | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Adempas | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Lagevrio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">3,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Lagevrio | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">1,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Lagevrio | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">1,723<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Isentress/Isentress HD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Isentress/Isentress HD | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Isentress/Isentress HD | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Belsomra</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Belsomra | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Belsomra | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Simponi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Simponi | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Simponi | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Remicade</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Remicade | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Remicade | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Januvia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">551<span></span>
</td>
<td class="nump">779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Januvia | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Januvia | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">280<span></span>
</td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Janumet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Janumet | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Janumet | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">272<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Other pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">584<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Other pharmaceutical | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember', window );">Pharmaceutical | Operating Segments | Other pharmaceutical | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">414<span></span>
</td>
<td class="nump">443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Animal Health | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,491<span></span>
</td>
<td class="nump">1,482<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Animal Health | Operating Segments | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">482<span></span>
</td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Animal Health | Operating Segments | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,010<span></span>
</td>
<td class="nump">1,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Animal Health | Operating Segments | Livestock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">849<span></span>
</td>
<td class="nump">832<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Animal Health | Operating Segments | Livestock | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Animal Health | Operating Segments | Livestock | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">676<span></span>
</td>
<td class="nump">661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Animal Health | Operating Segments | Companion Animals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">642<span></span>
</td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Animal Health | Operating Segments | Companion Animals | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember', window );">Animal Health | Operating Segments | Companion Animals | Int&#8217;l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">$ 348<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_IncreaseDecreaseInHedgeRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Hedge Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_IncreaseDecreaseInHedgeRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrk_InternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrk_InternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_KeytrudaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_KeytrudaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LenvimaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LenvimaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AllianceRevenueReblozylMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AllianceRevenueReblozylMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_WeliregMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_WeliregMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_RotateqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_RotateqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_VaxneuvanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_VaxneuvanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_Pneumovax23Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_Pneumovax23Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_VaqtaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_VaqtaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_BridionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_BridionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_PrevymisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_PrevymisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_PrimaxinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_PrimaxinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_DificidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_DificidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_NoxafilMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_NoxafilMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_ZerbaxaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_ZerbaxaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasVerquvoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasVerquvoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_AdempasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_AdempasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LagevrioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LagevrioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_BelsomraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_BelsomraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_SimponiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_SimponiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_RemicadeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_RemicadeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_JanuviaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_JanuviaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_JanumetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_JanumetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_LivestockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_LivestockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593225691040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Consolidated Sales by Geographic Area (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 14,487<span></span>
</td>
<td class="nump">$ 15,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">6,659<span></span>
</td>
<td class="nump">7,339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember', window );">Europe, Middle East and Africa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">3,303<span></span>
</td>
<td class="nump">4,359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">1,715<span></span>
</td>
<td class="nump">1,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember', window );">Asia Pacific (other than China and Japan)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">846<span></span>
</td>
<td class="nump">930<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">758<span></span>
</td>
<td class="nump">989<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_LatinAmericaMember', window );">Latin America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">661<span></span>
</td>
<td class="nump">607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=mrk_OtherCountriesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Sales</a></td>
<td class="nump">$ 545<span></span>
</td>
<td class="nump">$ 534<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EMEAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EMEAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaPacificMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaPacificMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_LatinAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_LatinAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=mrk_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=mrk_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140593216676560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Profits</a></td>
<td class="nump">$ 3,650,000<span></span>
</td>
<td class="nump">$ 4,861,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">112,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(242,000)<span></span>
</td>
<td class="num">(243,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="num">(543,000)<span></span>
</td>
<td class="num">(699,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="num">(448,000)<span></span>
</td>
<td class="num">(421,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(4,276,000)<span></span>
</td>
<td class="num">(2,576,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="num">(67,000)<span></span>
</td>
<td class="num">(53,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Profits</a></td>
<td class="nump">9,706,000<span></span>
</td>
<td class="nump">10,086,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Profits</a></td>
<td class="nump">9,140,000<span></span>
</td>
<td class="nump">9,501,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Animal Health segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Profits</a></td>
<td class="nump">566,000<span></span>
</td>
<td class="nump">585,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Profits</a></td>
<td class="nump">164,000<span></span>
</td>
<td class="nump">194,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">112,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(242,000)<span></span>
</td>
<td class="num">(243,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="num">(543,000)<span></span>
</td>
<td class="num">(699,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="num">(398,000)<span></span>
</td>
<td class="num">(378,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="num">(4,147,000)<span></span>
</td>
<td class="num">(2,446,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs</a></td>
<td class="num">(67,000)<span></span>
</td>
<td class="num">(53,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Charge for Zetia antitrust litigation settlements</a></td>
<td class="num">(573,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mrk_SegmentReportingUnallocatedOtherExpensesNet', window );">Other unallocated, net</a></td>
<td class="num">$ (362,000)<span></span>
</td>
<td class="num">$ (1,607,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mrk_SegmentReportingUnallocatedOtherExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other net expenses not allocated to segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mrk_SegmentReportingUnallocatedOtherExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mrk_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>mrk-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mrk="http://www.merck.com/20230331"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mrk-20230331.xsd" xlink:type="simple"/>
    <context id="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i135ab11fbbba4bcfa384c862b2035ddd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i147620f1bebe45a09eb1c534137133ec_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrk:A0.500Notesdue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if2d8e55f082b4b91b405cb32c49e17e5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrk:A1.875Notesdue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i59b625119501404d81b378dc2da40e6e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrk:A2.500Notesdue2034Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia0a22a157b7c4d9491fb9c5367a1371b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mrk:A1.375Notesdue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6f9aa917fb244d03ab52c4fcb13190ea_I20230430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5c3c68968d5a49b98049b259f527466f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if2cb2241175c4c8c8fd5daf0a86385e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ff3b595ae954906bf225b8a7cc58b69_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1302ee97335a4b8a864d880d15a75ffd_I20230430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PrometheusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="i2c03ed79efac404d85fb217647f60f9e_D20230401-20230430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PrometheusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="id017497421574c008e33bacea591637e_D20230701-20230930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:PrometheusBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="i1e8e4ea1abaf40778222b2bb6dcfb639_D20230201-20230228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="ib9dedd741503427183ecc62df92f5085_I20230228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="i3c175c60a55e4c3eb9ac840966e13ebf_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i609e1582535d4dfb834b95904e849c27_D20230101-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:ImagoBioSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="i8f3adb7e1a4d42dd925db11dbf71eac5_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">mrk:ImagoBioSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i58a876d3681e4986805915e1bac18ff1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3c3d2c4bb8cc45efb4e93d046dd6a753_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6a91adde5a68413fbc1cfab655dbcbe6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i350e44c40f67467ba477b370f98d41fc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id6b1412b32dd45bf9b2dc2c9740d6c6f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i71ce1d5e1bd141539620a96cb8b2ec10_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idf9cd10c9efe4059a13ad6f64f232a85_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i654e8b5924d8442fa9eb55859bbc8647_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib681c644ca864f3286e965d6d7324aa4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ide79c33fd45c49b19bce108416c71788_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i525916f3d1464ab9b6f291401c761233_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6e95ebf7c1884a0396c7c91a0e223ee6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2c6d877e0a5147208fe56690fbb929b0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4cdf23392f5642ba818b20d852b014a9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i46e9161a43a44a2fa59e52960034468a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i71ffa17774c44d2287fe9111206866c3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iba6c247720a049d28349afa51cec42a7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id22834ff470f4f1aa7da131a94ad1d29_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6500964c8d3f4d06b28f3f23cada56e5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifc2de578164e434980f14d63a2153220_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5973fb4a5d684bcca7a62270623ac406_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icb9ff33d56484784be92a715ee774c2d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ife24131bdfa1419d8d2708d8b616e5b9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icaae108da197453bb8b3b58a2cd21d7c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i492255c072c74c9f8a70fdd6212cfe65_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie92cc5b201cf42e9a6a395bf77ad597c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i00731f51ddd64c099bf1f3a866d6e0ff_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia8a01e007c934b3285178dc642a890ea_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibcf5abe1e04c438f81048ecae5f02ed4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i364cafd01c114c558bf6c571df9b34b1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2d145059533c4960b5fc110813a1fdbf_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ief58ac433ad9415a802f0001cc903fa8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifde6e88a8c324b84b8e1ac90ed088a69_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4e956d6285d1456abb720e32551e7288_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3779054dfc7a4a51b4e90d43a5ac3684_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib7eff0028e2f4952bfe2bb459510ff9f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia56fd7048ad14abf96162c372b142909_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iace54ff30d73465189a461975d7b6b99_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if1e72c11f4d449889cefb13617918cd0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4d825d4c2aa44c79bf5a2366a7a86a9b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie6c9458bb97f476b867db620d779e5fb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie01022120e7d4f7cb61fb037b2355db5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if29e83faad31423b801afdcfcba98e44_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8a73485be36248258f5601b826d7bfed_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6d20b318541f4dd2831d35fd11a17b0f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3399af7b61814371b4415a2165606deb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i80a8ac9e73b64ff18bab741a42d8fdcd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i260c8037bbf543e0aa66e359ab18b50f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9ea6ddc3ada9445c95b033d7e07dd561_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idaa0511b79e949c7a6547505b9ae5551_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8e52ba3989df4480ab8a8c4136af64aa_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i68f851c07e23480aa9ff233e42d37d7a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6191c4207cdc459d90d7c79d3e4e64e5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icbe1869e706149f48a2091f4b9534dd9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5ef0c87d5feb45e381dc0a07c2d16382_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i63cb28ee8d6845b3bc89ee74ee01ff67_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i58e10bfa620942c4bcb811e0f171d36b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7e3019b3c61c4b70a15610624c8a4983_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i650127b972c04c1cbed3bec6d5fdfa9b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib2ae3db4c9364ff8843c87c364bab42b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9056f175eca54119943d05559433e20d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib66da4be09b7447ab23b1c1811b5724d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i36c8f57b20ce4f26a522df11b2be6320_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i644d973253b54d3e94a4aa3644bbe995_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie2a085dfeaeb40a083f13e8a59287e8c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5173a42466784ad9a8ffe86302cb3b87_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iebdfd787169843bcaba790e915fc305b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifd3bb7ee67904313b2975cfef294c50b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ice904109d2ef48fd8e8ed1324f5c2c59_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic51d50d985d84a3f8f588fda28be3ce3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i25207351676d4c9e9e6961bf25936afd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4d5dff37e3ab4823ab8be6c8611cc6d4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2404a6eca015453d8c2bb0e08613ae7b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iec1c506714374a9baa8471e96e643d5b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idc4d047e87e6460984a1241620741fc2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i386e5b3e2b1d4771ae602c8544c7de85_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i402d58f25e9e45a68055eb38b7d1d4ab_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0175444d0549416fb305c38749b41b24_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i245cacaf455e42329f9ae587d1a10cad_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2dba74425a51433497fa7e5529627e25_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9cff7fdd9228489e9a08ae8b3a149a6e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id17be879320f41af82dedebba088c13f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie3d1e57b1dd24ae193bd71c6385b8769_D20210602-20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:TransitionServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-02</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="if4eb1aad4f8349af99fa7c51391e5966_D20210602-20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:TransitionServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-02</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="ie7ee924f05bc48c787f3fd1d8f6303b6_D20210602-20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-02</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="i1fd80dbdbfb341a2a9372748079c59e5_D20210602-20210602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-02</startDate>
            <endDate>2021-06-02</endDate>
        </period>
    </context>
    <context id="iad59a4cb91a64620bac9b9c19d9f7cc5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i185eb227b4104468b3c29dc49352d43a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i60b11c4ee8724493ae377bee597f7db8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i834db89c47b44369b713641fdff58447_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7966ec436ac148489c841a585ea76477_I20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i870f46cf31cd4dd99b24227fb3adf06f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibde26f5431b54da79586ebd96e74a36d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id6616b6afece4195a3a8c81945ca5296_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i111e37e345c242418c65ff71f8df4aa4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia85fb7ebe86e48688eaa6cca6140b251_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia7968694bdd844dcb91cdee1fa81b0c2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7c124834ee87435999488308f1f35177_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie333238530bd43c2ac7bdbedf60929b5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i39ffed41bf6448378d17f953bc0cc54b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if8831ff53ddb4e9384dd1c730f73c0d1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i92816509cf8240d2ab4f3e2c2a61c6b0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idfa73697ee0a454c9ad0fdef7eff7f65_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4d8c3e3d493941b186866861d3cad3af_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iaaa6e70cf90547429286cee866cabd66_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifef7767f302e4418af53b34093c57a9d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i620edf85a16d4e4880ceb84b22f3cfab_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3bc8fc361d904fbeb6492f5e521452f8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0bf782824e144ac698d3c52441494fa9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie23cb3149ce14b15a9a4f74c76232a80_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idb61832d74f44b15bb6f7e1e80aefe10_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibd263f21d9824f4d88448a933573382e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7916bd167a5949cf9496c5497260c4da_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i59bdd8e429324f6985da2aa4f9cee50f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia26db14d5dfb4db6936c0133c122c21a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifb9eb1916f044d189f47e32c6cf11a65_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6bd41c6996df44f5ad0c156034845a9e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i45f7c7de6a3b4eb69f814c83aa49e79c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2f8fc3f059d944d8ad12e7fed7bcc36b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i53768e8ff51d41dabfcdf8423e6ee2fa_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i46e4f372c2f54684954722f000f9b4fb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i72738ef779d443e9ae3f451aa08e9bd5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1dbe9c123ccc49ce80d7ee4225c7c4d8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i09b391351ac84dc89ccba17bcc925ec9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i80771ba562bd4e098155333659c919c8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i735d6ae1f2044389b4cd1ff056ef3646_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3cce1bf91c214333b3b50c15e3d7461c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i40da318aa247452bac9b3018762feece_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i993831891ccf428592c3e2f850548d44_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic5739c18be2b4077ac27f27ef7c6e9f6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ieb4e20bd4ba34d448a2f3a3397c0d521_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7e6cc36740bb4d71a793d4cb817b4486_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i44fa00da50de4c2abe7a97b20631529f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3ade1a511bd04605a075fd4b05ec6eca_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i54ec372484874e4680d7e4b7645c44f7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i313438c53a3745f5a9c308e10580003d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i13663e430fa9440c8b9b613386d03310_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3459fac4643e42e29a49394546d2d3b7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib9f85f59e99b4ea189c2a085734df397_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7c1922ae96df4166a7397fffeb3375e7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3b9f469b4df444f7b96723d7a5c8b223_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i336c99147cdf41e191d86c13d2a751dc_I20230430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="i7029fd7c7a6f43aca68f42e012aec70b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i95f9d19ca7854b0288a0454768961670_I20230430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="ifbdf486ae9934cc9a2a5283fa0638116_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i548bda88a4fe4bd5bffaa38757444dad_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9bdddb9610a348a48e757c57cc1a2387_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic70cbdc57c9f458abe55135c7b061c1d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i425bb66138fc4a51933c6b6df28796a6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i294f553218424e8cb257f3d9f97e01a5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifaac2668425b4eb4bfaea2c9834fd061_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6cd028c906f84a42bf0bf29e3a3a9fcb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i03be4f41b99a4232bdc4d5da0449f285_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2e8fab7c6eb24761b65cc3256e0b926b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i50b43bd94e56461888fca904c9a7ca24_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i143c9f2549384565bcdcfdd243771159_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icdf30ba2b8b34d4e8df46f5379e5e821_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ice27572fdfbf445cabdf5a62a7d76022_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2a06f418da43474f9f2f260add8790b3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iaf11d32e52ad425f979acb12dcd9aaac_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iac10665025d84f23872225d16c92ffed_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i45afba88d4004605825fe82844d7a4a7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5a23903b67354e33a6fc1a8676a4b984_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaf2336f30cc046a28a77fd6f2dc4b465_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3a542fc8b3854857bda9666e66bd056e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if4fad0e8da324f249b5dc3a9f01637f7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie091883aa8d84ebf868769397c540276_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib057b0780b1b420d824cb8350acd5ba2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibaadad87b63f48448ddf5360530646a9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7161bc9f4ef34d54a1dd7e0b07640a30_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i86b17d802f304918b52da353344f6ac4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i028e5b27f0e04f339d7c2f519b8ae259_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib9ff469b241a4cd5972223863bfda226_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i96b677da60364882b5bc1b825a50fabe_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i330867f88a774fb08f247e81d478866e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8118cf7c392f4ea598bfcb18b7bbd4d2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if03eefb0e5be4080ba5289591b557e4d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6b6b9e2b940749269dcc355aa0ed57d7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibc7fb1fb9fd543aba08f396008a05eb0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeFutureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic3fb850e1f5f434f8e8a95228021a73d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeFutureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i776fb83d7a1241a0826d11f6ebe76e81_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7a3f219a7d404a31bf65ab7515e23942_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2e566c5f87a6490788ae30ee3d6f3b50_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i92a140256baa4686a25015671d14aa5b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i93df6ced8a7748a4abd5d6c32906498c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5aa6408da9024f3ea458c3189fa1916d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if1f2bc401a074570afe7c168856f7ee2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i85028f8c5acd441497714b4e936b0ece_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i17a0e0f674094afda5f097dcbf70b93d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0cda95f4db4a4d1e892c7b8b8c2bdd34_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquityFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i020b0ff9857f4f16af9e432e1869c1f7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i07c700750162434c9390aee0f12c47d9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if47442341eb14e6e97a2cc3f6b5bba11_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8bffc0a6380440728c91dc8b47e0f31e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4a8f3e37e4904159af4dd090e1bc5731_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2a49b37db2544c739f3f57a6c315a232_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i66cafb3d313644a3b3ba17dc3c1b05da_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5a99f61d5d9c4df5b63c5274b8898116_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7f9e79091e5045c68d0f830e6ac4c990_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2795fcc4916b4738ba959e843ff69ec3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i96de2214f40e4ba59e7b629d43ba4d91_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i451160fbee604ab990070211ebeba8de_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i46d67fffc7944fb8af71441dc67f9462_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifb8445329cbd40e38c431a9cab4cb4d6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3beec2a915ab4328b794d0b11fbc0788_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i814823701512438f9446387df4b6adcf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0d93e6ac796f4cc0a31cd2625e3240a0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idef3c5cc57074bf7bab4f63f14c711d4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia38b8466a7354dcfb672c615593eeffb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i743f68c0230549c8bfbd0ad0a8901f37_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4d3fb0c5d5a24db099308a75d6d48348_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic4232e5688d9417880fdb23acd1671dc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4c5ea1c804e54b9da2cfa1e35191be79_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i31c000934f3b49b4a1049b7c5825c3d0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i012d7bd208a247b4b543d54583a218ef_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i07338fb5662b49d5bc2528a3307c626b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic115d2d37fd44d80b15e651843a0417f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id8d827d1b17a45afbc3e288430a5dc82_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6bb17c88faa0435c933b88267089cb0f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib04f9b00c03c4e4ea6423dcfad58d6b3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie908803a7baf418983f47014731e40ea_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1db38063fdeb45aaa60b2e97a4474133_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idebf467c560c4d1d9245b765b6e590d9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i89142ce181ae48e3a2d77a9f72861963_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i57ae55075eed47cdb14839b87c57acd5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6f4032436bb84e00a3478c08a4a4bac8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4bd81adc1667472a96ce3692b39fdda2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i871a358ebbbd48f496202064b0918f47_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6e90f41ec72b4d99ab066bfbad83afec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1a48a4589b004511be5ec5ad70c7e2da_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0c30409b333846a0b003f5261f708353_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4d1c02180ad34f3e83fbb3df043ae3f5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6288684e9335426a899ee4586882280c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i305ac9c4908a4bffa1b9ce0a56239183_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3eaafa1e0ba64836a551188797cd7c7c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic36ef238f34c4ab180d3b3a52624eb9d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib784c86ce67446f7940a517458674fd1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i004682e5e94d4b12b9f2913eefd3a7fb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i34260a2a17d947768f68d2798eb0f8c1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0b068359fb3948a182327c67ab308fb4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia8f7806f9be14762977b7e08e79e4daf_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8a2e484401b24c479443887a01bf805c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2b1b40aabc7a4eedbc4ba7ac12424d0c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5265c6f93c7f46d1ab829156c30fdf74_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic497e29b39d04693be035586e02049ba_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i970e6180f53c4baeb53fdd14d90061da_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i075080b8fa0045b6adf42ad9d680a586_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if826811b47d7448eb6e1f3d6c36b5841_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i96e781b662154001934e50bb59beb7cd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibffb1c0f1856491795524f9ede8241fc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5ba1c7342bdd4e82a5d14645ae050399_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i294603384e1e48b1b1962054c70f8781_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie2707a83a0684b81b3f82c21c1a7d1e9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia524db85b9fb4e5faaed403cdac7f778_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id4b65ea8a7a94fb5acbe089d34abecfd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iefe9381ed615477a8d395b385d4bfc96_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iec2a2a2cde214dcf9145e7fed863dfaf_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie0fdebb01cd44ff4b7dd90a3757e19a8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i92b2724f66144388bc9d877014d99971_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i402e5d3ff33d4949b0046490210e38a1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia4a496ea51974c41968d7d7ece436a35_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i04e31d8852884bf89e5bcb8b4f124896_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8dcc8586471c42e6a0ee92dda4a6bd01_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8f39864d8e8e466da61d331c664f14db_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8ae2044462124fec8e736b9c160ff048_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8fbdfdee6afe4e74be18dd0c62050372_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idf5ff6cbdf22489b9efa70ffb318b8aa_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie2fc780817394ba39db27d26c677ae95_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i49dd486feefe4b749fbe2cca62e80318_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3e717c1f26e14e87978e3de102e7c698_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie81327a316a94b36974954a7e8642bc5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ide0712a78628418ab61bbe9bb313aae7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7358a61460544d15a70b0957807efa73_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CO</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i674ee2f2e244467391945b56813ef740_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:ZetiaantitrustlitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i486acde0965b4e4fa567b783874fdd1b_D20220630-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:ZetiaantitrustlitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i07e39fac74fc4d08a501e1e14a991816_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:ZetiaantitrustlitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i88f1868d275a4b89ac8e4f956b24ddc5_I20230303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:RotaTeqAntitrustLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-03</instant>
        </period>
    </context>
    <context id="i4305661e65274f559b5b59766d3c5cc3_D20221219-20221219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-19</startDate>
            <endDate>2022-12-19</endDate>
        </period>
    </context>
    <context id="i4bd3fe27e3bf4036897cd39ae0448f14_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i79aeb0bcc641443b80308ef30bbad1d3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id8407355ea334e558a58d39cf813e848_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaAndJanumetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i270837c6ca8b41c49574b8b379172454_D20230413-20230413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mrk:ComplaintAgainstTheJohnsHopkinsUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-13</startDate>
            <endDate>2023-04-13</endDate>
        </period>
    </context>
    <context id="i5913ce6cd24f4f45a393b8a13ce74d4d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ica1e472338aa4a5298e4b867322ded49_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia75c3b66a14446a7b7855544f19742bf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ice6bdceaee0c415785e978b1546e824f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4f9c7cab12f84742bc529ca888140834_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0c01235f9a47471bbfd246c179b8ec70_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa0666b9b0854af18214a4de1da949d6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i957a5e7283804544961eeffd229d90ef_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieba2932606cf4136b76cf64715d17f5c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifce529878ee94fbc97ff3cdc8e49ccb4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i918170e5b2fc416bb5213a74ad72646f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6faee1c09a204c63baa2f8635ef78da4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4725be788d3c4f1f966fba475c841405_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6e2497db5f4b4eda93858dd1c188cfb5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i08889407a4ca4fa69735b8332945794b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idcc9c8d75d064da9855b8d3b37c02b10_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i42da78b36e31450dab3194041180b0ee_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id895bb14f7154486a761071e11a287ca_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4350e7d8d13e45848709eed82cdba738_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i15d6c8aebc384e4b973cac8799704239_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icb5a854388ff4957836b5593bd4f37e4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie7b73a7dc82c4055afd7242f0e94f662_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3b21fb880d134a06abed66e7d998914f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i796d55aed90341e6a68727c28ffcab70_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3bc10dff04eb494ba85791126e4db053_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i87e04afadbc24d00bf0c906ad452972e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibe63a010ec0a40ed91fe4b6b16e51a63_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic41cc6c0be824cbeb1598b4ddbddb1ed_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ied44c0afd9384c30953e94941daa0cb0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i65afee1f42ae486f84514163f3843f68_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id1742aab8c35467db6f531e481322561_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4b3b6bd9f9044238b1478ab578648204_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i18372378d12a4968ac3f82433fa9ffdd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i60e7a6142fec4b32aa305b679a0d9a87_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie4437cb5ce2e4c6cb15d052910fc825b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8aa514bfad3f4f6883b1d3d93683f530_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id12f95a53e9f4822b4ac3324b1225c13_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia6ae890426d14159b7b476af5430efdb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7fc54055a2e1411986ddfe6f5fa717bb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icfb8b583363441eba27b2030dcb092df_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7c9f187d5e3f441eacceb4c421ba47e0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i48e93ba87cab4afc961e66db38e74311_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1ae10b4b780a435b8e0e8fa9ac83e826_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i041db7ac9be74d218c0c23a960fc9a27_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i33af4ad78921440a981af5aa4715c88a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad527aecfb724bf3b4777b628fefa6b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7d1fa90756944324a7e1f45d9b688361_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i74c46eee324f4931a0808813b06bc0f2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i39397ad3a95445e39f9ab9b845a9867d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia2319d946cd342759a8f984524b58ad8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i95a7d6e4f3b642ac849cb5b1af84aca1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic8a93158890945a9aa15c60a05506723_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i31f76fe0b880480684d05d01c6f398ff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8b83eed87b2d41c1a8c610f98765bba3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6d63d8c8b08843008160820a9757c059_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5d68872fd99d4719972b30864e232d1d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iad583d8b44fc49feb98cc9caf016d5a4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ife1d684ce4c949b38894572598414983_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7af996fcfb0942ebab3aa1e8cea2e1a4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8e5c54f51e5440dd9db7d51479f49629_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i44331becfc824debbd8e96c96c590f56_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8df183ec48194fc4a2c6f8e8d986193f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iaf2b65d0efcd4588b8eaf74e00590ea7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie772b761081d4a3f88dd5b139a18cde5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id23605aa21764c15b522d6ea781638b6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8b1fe39c7ec246f0a53097e0b00b0803_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7caeaf606112447a8aa0d87b20c8f163_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if193ecf6603e436e9bc55f3e4f86a576_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4b3b69956cc9411da3f54f428aeeeb42_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4ef00ecad3374cfaa1259915898dc915_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id0d6b8513dcd4021a200090641fe0bff_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0666b87a008d48918f71fa4e40a3259d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ied5a517f75814ffdacb6613032349a19_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3bdd7b02457a4826aeec0e25dbfa4df0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i373f00d87cd7457d9b079c9415e0c4ad_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic416d710ef924adc9df8131effd1c200_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i421974800c0844798343dd8cfc3f3a20_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i26f185cbe1da4f4e89a1e2093171e27b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia7706e3163ae4d58a5f8660cb640d5ba_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaf21fc9f03d342bbbd66be0123de6225_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i943ebcf31d20440ea90b753cb238fe02_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia13e94e1a90043bcaea2ffba6d27061a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3f73d3370a5348dda651da8166f72bfc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie40a08ab45e2491eaad9788d31bc031d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:WeliregMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i98d5687c5bca4aa0ae8be180444502a5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:WeliregMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i148665041c5d4969a1b7468fc0b3306f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:WeliregMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i245f27c3d3884d16886e2a02a3bea2be_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:WeliregMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i683c95eda6cc4e83a3f200cd8c1ae979_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:WeliregMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iabc5de1d9ad9496abbed9093f2560c7e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:WeliregMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6d15bac232384d3d9b567829ed8b4e4c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0eb110c2888a401a99ce08584a59ae29_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0622fda057824fe2acccd535fdedb1c4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1317f96f8242416cb217168b296ac180_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i15590b4a502a4441b2031cb5e67c164c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0272e13e3911432484c3574c4d88dea4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie1dd61290d2e4c28bdc142b28449b630_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0676bda79d3444beb30669ea1761cefa_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i92cf8249b51045fc9f74f556cbb77945_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idd868d1665e843e8ba8e68820863660a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i85dada8cd49f441ca2211b4790538075_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9e7b43ab9aca461cbd07c3408576229d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i502537b5bd3244cba8148fdcded195c1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idd1279562a9049789bcf67e36e1345e6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if12d006ccf6947e59b7e26e27405537e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2caa7eb6734e47f694c35387f0b24c5e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iefe80ade170b452d810ea857bfb36486_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i168a16270ba04bf5bd0a98c57f6e7453_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i38f3c51ed3c142088d512d3cf86a4e85_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaxneuvanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5facb3a2afd54e37a08fcb30616f2d40_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaxneuvanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i71c307b84c814567af562b778b4c1b53_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaxneuvanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie8a9542dc59a4777a668cd31211b6c7a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaxneuvanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaa6e384e748d4e74833d7c8bd58e5051_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaxneuvanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3a9cd1b2796b45cd823635c3a4ca1ec1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaxneuvanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icc1f221331e847f78e9890ad89af8d80_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iced6646c844d4419a1591abce5241bc1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1d46a1bed5b64222a563d18e9091ab03_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iee7d83d494044d17ac974c40323b8bfa_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iaf3bf82a5181435e9e26d6dfe9ccb7a1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i83f5ca79492e42dba088722bf7ae9575_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i556f1c52ae734ae6910cf6d6b9d26d16_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie70b1f6ac9824c5c9604f2e6cda7b721_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i13c7df0a730141689941ffc740882c67_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie19b5dd8e1da4e7ca8d5114cd25d465e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8845bbae207945c29f58ed0faa7c916d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9ce84ce5bc4d4fd09f2f2edef567c63f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id3307d951777433f9183e38cea7b0eee_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie514f725ab204576a9d82e520a0747cc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic3c351d397e549f08a5550b64c7bd217_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia85cef5855f74b3aa28b80d7e773c5e5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7d745b43d42740a2a636f93305a10162_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idffa9ebb25b04dc3ab346d0e2525d0f5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i81842dbc49284aeb8c307b130fc51daf_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9ae5e82b75cb428f864e7695e7ca9c03_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5c5c36e08c35436d890e3cc5e49a26b5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i63dd5e6b38074752a8397afebca2f449_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id6a6d9596af343fe9fbfaadc1d8d3d34_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6cb822f6f0d24e56b21b1ba8cf3c5144_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie1a2a61f6cc34473ab9936b7066ad51b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie6b9400d903e47749af467e683ebf4b8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5e28d66cb4d143f5b15da4ce16a7ff80_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i83dc7aa4430a4932893b4dc1505dc632_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibd11a9dea94b46ed9112ffcc77e533a5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifa49ff54d4904fb783f4f755bf9c4739_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i16385f11510546058467040c76602eda_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i97cacd287b274b7283ca51aef88bed26_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ied566206459a4f21bda9d764fbd67597_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8c13b48a7232487dade4344d3bd6fef4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i36f1883cf7ee41de9a38e097ff1eebdc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id1f696b0a7e848ffa8cd28bc5f62be74_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i33013fc5c1544b508c1f023d7e114799_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8189ab3ff1aa4b3fac07ab4d084ef309_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0934dfe57f25400aabf7629e013bf2d9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia482068e1c6841608dd3a6fc8530cff5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i36f337569e6e4b90b6c49162eccc9245_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i370790356a1f4d0f910d0150c46829ba_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic3ad548049e7437392c37716ac4a83fb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3025f3862fa34281bb1ddc0c23288056_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iadcf254d19a94241a8a193b57dc553f7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1be1a7ec6a2548d4861b2e925582acb3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9ece7f9fc39047fbaf47a27cce6b32ab_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9c4d7a0899854fe795ccaec1a0161a84_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i01970431619244f9a83fb73990c5cf14_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i958da05d9055499a88d25a539d74f6b9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i82a61880f039405d9d8e1832fd26a2d0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i06d3dc01e4cd4880b999376bd99d6191_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7414168e369644d7a58d58414fbde705_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8d7e8ff816e241f199e0011935427e7a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iad4d2d0ea13747a1b99b669cf7ce5f36_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i01c8b28beea44e9998a1034bce51e508_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifc25085e4f3246fcbff1828176d06cb2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i42b4b84e15304e879f573aebe7198888_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1abbf56d966442aea56ac371531ef7d4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i46444b1898a945a692f90d2a907898a2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i745ba7617eb74e15ad18bf9b1bb5709e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2d35a8760f2f49e89952d761b1399baf_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i185e17abc9a24ea38c9ca4921fa60212_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i69279d4f3a814a78996b4c54c84aba07_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if658e80c557842d4a20c5570140db4b6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if0feca83d79141c7aa9f2bbb6f89ece9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id9ab213a9fd74c98afcb44eb19dbc18a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7b3ad2cd408f4af38f724dabed4a97ef_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5d330794d9a24933add16f9c3e14c0e6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i90f3bbf8132048e7a806ef1c700bcb02_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7c033c7782a84654914962664067c0b5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic44db3f3e64b400fbb66bf36b4d59948_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia0f47191ae984e44a0ea39f24de59ca8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ica88e8e09cf5471f8ec81237bf2424e8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icf3db16464a242348f5f5ec6b303e8e8_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic5dcef3812b24f21b01ed1f074b5e48e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie078fe8aa4b049019f87a49fe7163a94_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic81d4335a8564f6893a52c09eee896bb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i38f8338e607f4961b4e06e5ad59f06d1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i481c25e1dc4042e583fd9ae56af1ea83_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5ab42425f0e84d0fa9cc1faa24e50ad9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9f1f69903f024330aa3cd5f89dfe4aef_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4f18afff1f924a87aca15181db888f45_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7f2b65669412421487fc5a293c2d0226_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i252bf97a988d4ca089b4880ef38b9f6f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8ac3b496e9b7497bbd0a8568c2c05058_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0ba905ef97ef4ea2a2b74f044e828215_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i341c1828f974489ca631fd2f6fd5de33_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i91767bfb04eb4bad8b4c74cc699c4f11_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i078db72152b7433b892f65578b578811_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3d3ed97dcb1048b9b00df266e47fef85_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idf7f29b275f343aeb93a10d0bc96a43a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1c5a4e651d8048d0bb7be915788d3451_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idfe3cd40147f4e2bbdcc6daea5c4f648_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idc375c5fb83442ce960061c4c1e7d3d2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1068453fd58a43ed853c52e49d369635_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2a170523e4784bd68826594b94740470_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icd460b0376004e6c9a2f91d187784dc9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib5c0d77138754544a2110eafaf9ef1de_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie30c6b82c81544b2a213a66f88a666e6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i944297bc97294b85b64026a5234105db_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6714caf41ce2406282b4c22d36869265_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib880b79c41404a7f9ccb683284f4a657_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7242924d01844781882444c559d8edd7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0b5149a7a9724ba099430ae94f3eb7f9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3f44546bfba04d3182b566c995d1d6a5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iea28f75c29f9495d97b2490ad495e473_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1c30e990884c453a8e86bf31356441ab_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib1de53f2d14549978ff86137b26acfdf_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iea0edbdebc194dbda6f583be24a5f5be_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iff180f6730404c2fb6244e53cad88916_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="idc67e8a229ad434b9d2759887e18dcff_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3ecc10254bda49bf803e6b76575554b2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia58fab4c69fb453394fb53a0a9cb3d93_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i08f54d2fb7c74345a43dd8eb5652ccb9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia99f107296c340309c3405bc2810419c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ied991033c3cc4ae8b1774bcbdfbc6a61_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i48ac0207dbb24fba961de45411f8f863_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i83d344caa1af4fadaeddfdde40462eb2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8c73bc1480c5460787fa096cbca3e186_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4136a4c6588c473b8dbc29bd43446a8c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if77a7432ec784877b792884b4331e9ee_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id486cc4b73964a048598ee4145a36f51_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i260d3e7cbd5a4346b6de45c5013de1eb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2913a3930e88428aacc1ff729877e753_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if553fafbad26405cad25ce4550638d3f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i660405fd34d447fbac3495f01c37c868_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic90971f816384ed793878fbed1daf9b9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i904e8e179a1a49698833ce1b0110d5b4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0a26625eb0434b3aa7c78f6443da31d6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib7dcf8dd27b941e6a6224761d29aa39d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i83fa1e7afed046c4a90965eb45e55ef4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i296f4d5ae9ac48818a1c814d83edd6c5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i541f7bde3cb144d6a1a06f324c128077_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id8c4caa074434a8c891a4dbc9477a1df_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2171622cc8164fae9f90806cca105ee4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0201d118d8574b6db54cf6f7f5bb5c3e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icc177dc034fa4f9ca0cad6e36eb33f5d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icfa83b7726804a0da22e28fcde9c5ed2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i70a11b67918c44d3bfc01126c08b9fc2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icf8c3545f0134eebae2941403b2e022b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3f24746bebef41f9a462c02b830d6110_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i307318101eaf48d785d4b776c386341a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if69fe081e83e44b89e1642cb41b84015_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5e9cb136461a4e8aa85239cb391d845b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7a97503f4be84d46bdeff57349e01c23_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i809f9ceab45b4cc88ceaa644a4ed41d8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic58118074eba4189a105e403b1233b58_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i679d69340bf54bb4a090a15b7ce9076e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4067fe86262c405cb2919284c7e1f31c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib86ae90471ee4ab18226e2683b749444_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7b6b67a7073245c79ad8b17846729383_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iee1279d9656246229165b6071a908fe4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie1eaefd10a6d4f75bc5b01e6fd6e7612_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ice769ebe11cd4873b0e7fae638d4de55_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i77d9b85158ec4e37be193731477b820f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i83848e68f3b04891aad523922cca52c7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic9bae06748084a678545ae2a472fc025_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i49396c3fa3284569b4be0611825c2214_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i492a23d281624d04895b84c347c42464_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i158cbb622490428d9efea6420c58fc6b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9bc970a022044625a53b9bc92456c9d4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000310158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="interest_rate_swap">
        <measure>mrk:interest_rate_swap</measure>
    </unit>
    <unit id="case">
        <measure>mrk:case</measure>
    </unit>
    <unit id="direct_purchaser">
        <measure>mrk:direct_purchaser</measure>
    </unit>
    <unit id="claim">
        <measure>mrk:claim</measure>
    </unit>
    <unit id="state">
        <measure>mrk:state</measure>
    </unit>
    <unit id="company">
        <measure>mrk:company</measure>
    </unit>
    <unit id="patent">
        <measure>mrk:patent</measure>
    </unit>
    <unit id="segment">
        <measure>mrk:segment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180L2ZyYWc6NzkwZWFkN2ZmZjcwNGFiZmE0MDM2OTAwY2ZlZjU1ZGQvdGFibGU6MWEwNjBiM2QyNGJiNDBmNWE3YzM3NGY1ODhiNDk4MTkvdGFibGVyYW5nZToxYTA2MGIzZDI0YmI0MGY1YTdjMzc0ZjU4OGI0OTgxOV8zLTEtMS0xLTEzMTYxOA_94f05150-b88c-4ff4-8cf1-abf185b903a9">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180L2ZyYWc6NzkwZWFkN2ZmZjcwNGFiZmE0MDM2OTAwY2ZlZjU1ZGQvdGFibGU6MWEwNjBiM2QyNGJiNDBmNWE3YzM3NGY1ODhiNDk4MTkvdGFibGVyYW5nZToxYTA2MGIzZDI0YmI0MGY1YTdjMzc0ZjU4OGI0OTgxOV80LTEtMS0xLTEzMTYxOA_0cd28e01-cb5b-450b-aa36-533d28feb38d">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180L2ZyYWc6NzkwZWFkN2ZmZjcwNGFiZmE0MDM2OTAwY2ZlZjU1ZGQvdGFibGU6MWEwNjBiM2QyNGJiNDBmNWE3YzM3NGY1ODhiNDk4MTkvdGFibGVyYW5nZToxYTA2MGIzZDI0YmI0MGY1YTdjMzc0ZjU4OGI0OTgxOV81LTEtMS0xLTEzMTYxOA_c83e06f5-8eac-446a-97f6-959481ba41d2">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180L2ZyYWc6NzkwZWFkN2ZmZjcwNGFiZmE0MDM2OTAwY2ZlZjU1ZGQvdGFibGU6MWEwNjBiM2QyNGJiNDBmNWE3YzM3NGY1ODhiNDk4MTkvdGFibGVyYW5nZToxYTA2MGIzZDI0YmI0MGY1YTdjMzc0ZjU4OGI0OTgxOV82LTEtMS0xLTEzMTYxOA_f5002049-7d3b-417a-bc70-5f00636437ad">0000310158</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180L2ZyYWc6NzkwZWFkN2ZmZjcwNGFiZmE0MDM2OTAwY2ZlZjU1ZGQvdGFibGU6MWEwNjBiM2QyNGJiNDBmNWE3YzM3NGY1ODhiNDk4MTkvdGFibGVyYW5nZToxYTA2MGIzZDI0YmI0MGY1YTdjMzc0ZjU4OGI0OTgxOV83LTEtMS0xLTEzMTYxOA_1b036b4b-2009-4f50-b3d1-dee18ebbdf1d">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="ifbdf486ae9934cc9a2a5283fa0638116_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0xLTEtMS0xMzE2MTg_cdf39073-c7a9-42f3-a873-70852c2d806a">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i548bda88a4fe4bd5bffaa38757444dad_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0xLTEtMS0xMzE2MTg_eaa07838-14e0-4387-8b95-9bb43c3d8ff8">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i548bda88a4fe4bd5bffaa38757444dad_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xNDUxMzg_9df5cddc-66b1-4a33-8e29-a18d74bcc019">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="ifbdf486ae9934cc9a2a5283fa0638116_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xNDUxMzg_f3c8a52d-a48a-4e54-b19b-78f16a11f45d">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="ifaac2668425b4eb4bfaea2c9834fd061_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xMzE2MTg_408692a5-0d77-4a04-a36c-28872dc58415">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i6cd028c906f84a42bf0bf29e3a3a9fcb_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xMzE2MTg_4a4e35a6-2d31-4c12-be2f-2f5f0ad91a6c">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i03be4f41b99a4232bdc4d5da0449f285_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0xLTEtMS0xMzE2MTg_81797372-b85c-4d09-ac25-516d3f440479">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i2e8fab7c6eb24761b65cc3256e0b926b_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0xLTEtMS0xMzE2MTg_ab1b0a2e-c0bf-439c-9322-21e04e73f4f5">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i50b43bd94e56461888fca904c9a7ca24_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xLTEtMS0xMzE2MTg_3132afe6-dbe8-4b79-81d1-621892c284e2">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i143c9f2549384565bcdcfdd243771159_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xLTEtMS0xMzE2MTg_99d4d534-f137-4781-a93f-a2c418043a22">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="icdf30ba2b8b34d4e8df46f5379e5e821_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xLTEtMS0xMzE2MTg_11e2508b-56af-4ce8-a9f2-c0ca375d810e">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="ice27572fdfbf445cabdf5a62a7d76022_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xLTEtMS0xMzE2MTg_c087e16f-89b4-40c0-959b-f2b2cdd6e23c">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="iac10665025d84f23872225d16c92ffed_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMS0xLTEtMTMxNjE4_05e962d8-08ac-4061-91f8-80526dc22b48">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i45afba88d4004605825fe82844d7a4a7_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMS0xLTEtMTMxNjE4_c1218d47-d091-44ba-967a-61df1ed0b192">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i5a23903b67354e33a6fc1a8676a4b984_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMS0xLTEtMTQ1MTQy_1096f2ac-e5f3-4efe-9d17-7ead4689602e">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
      contextRef="iaf2336f30cc046a28a77fd6f2dc4b465_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMS0xLTEtMTQ1MTQy_c4114de6-2d78-4e8c-8218-b4ecfaa65a61">http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent</us-gaap:DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="i3a542fc8b3854857bda9666e66bd056e_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMS0xLTEtMTMxNjE4_8e46edaf-73d3-4fb2-a39e-a898b16444e0">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="if4fad0e8da324f249b5dc3a9f01637f7_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMS0xLTEtMTMxNjE4_a38bf2e0-7e23-4be7-a57d-412372f2f6e0">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="ie091883aa8d84ebf868769397c540276_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMS0xLTEtMTQ1MTQ3_0f134479-ab12-4419-8818-0dec3ce2d2eb">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="ib057b0780b1b420d824cb8350acd5ba2_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMS0xLTEtMTQ1MTQ3_8586bfb3-f29a-42c6-a48d-599f102341da">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <dei:DocumentType
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xODk2_a9e6369c-c0b8-4841-a5ee-7c14e8dd6782">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6MDMzMjlmNDhhYmRkNDA3NzlmNjA4MmI2NWEwZmZhN2UvdGFibGVyYW5nZTowMzMyOWY0OGFiZGQ0MDc3OWY2MDgyYjY1YTBmZmE3ZV8wLTAtMS0xLTEzMTYxOA_0ef2aa1d-3429-466e-8929-bae9e29f2bb7">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xNDA_6902a18f-1936-4fec-aebd-32023db37c09">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6N2RiYzZmMTY4MWRmNDk2ZjgyZjY1OTcxMWM4ODFlYzAvdGFibGVyYW5nZTo3ZGJjNmYxNjgxZGY0OTZmODJmNjU5NzExYzg4MWVjMF8wLTAtMS0xLTEzMTYxOA_9af3a534-f334-4a7b-b454-43742bae66d1">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xODk3_dd294642-03ce-4af2-8918-b34a07f25457">1-6571</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xODkw_dc1063ad-9eec-447d-823c-ae774448e00f">Merck&#160;&amp; Co., Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6Y2NmNGMxYjJhYzM4NDU0OWJjODQwZmM1NjljNTU0N2YvdGFibGVyYW5nZTpjY2Y0YzFiMmFjMzg0NTQ5YmM4NDBmYzU2OWM1NTQ3Zl8wLTAtMS0xLTEzMTYxOA_9bb8fa4e-1002-45db-a077-cccf42037241">NJ</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6Y2NmNGMxYjJhYzM4NDU0OWJjODQwZmM1NjljNTU0N2YvdGFibGVyYW5nZTpjY2Y0YzFiMmFjMzg0NTQ5YmM4NDBmYzU2OWM1NTQ3Zl8wLTEtMS0xLTEzMTYxOA_9f7f5728-1bb4-430c-af20-07b38d74e7af">22-1918501</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6Y2NmNGMxYjJhYzM4NDU0OWJjODQwZmM1NjljNTU0N2YvdGFibGVyYW5nZTpjY2Y0YzFiMmFjMzg0NTQ5YmM4NDBmYzU2OWM1NTQ3Zl8zLTAtMS0xLTEzMTYxOA_3f5e467f-2196-45a5-8801-7d2c70f7f450">126 East Lincoln Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6Y2NmNGMxYjJhYzM4NDU0OWJjODQwZmM1NjljNTU0N2YvdGFibGVyYW5nZTpjY2Y0YzFiMmFjMzg0NTQ5YmM4NDBmYzU2OWM1NTQ3Zl80LTAtMS0xLTEzMTYxOA_429e5483-903d-4535-b74c-4061620deaf4">Rahway</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6Y2NmNGMxYjJhYzM4NDU0OWJjODQwZmM1NjljNTU0N2YvdGFibGVyYW5nZTpjY2Y0YzFiMmFjMzg0NTQ5YmM4NDBmYzU2OWM1NTQ3Zl80LTEtMS0xLTEzMTYxOA_5aacc37d-44a6-44c1-b167-8b7d85b4d95e">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6Y2NmNGMxYjJhYzM4NDU0OWJjODQwZmM1NjljNTU0N2YvdGFibGVyYW5nZTpjY2Y0YzFiMmFjMzg0NTQ5YmM4NDBmYzU2OWM1NTQ3Zl80LTItMS0xLTEzMTYxOA_1d1bc586-43b1-40c6-8229-d3cbbab81031">07065</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xODkx_74fcea6c-72d1-4893-9a90-52788148ab69">(908)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xODky_8e211ce9-d277-4cb2-9f22-437ed660eab7">740-4000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i135ab11fbbba4bcfa384c862b2035ddd_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF8yLTAtMS0xLTEzMTYxOA_d86ab289-5682-4ffd-9727-c903224b6c36">Common Stock ($0.50&#160;par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i135ab11fbbba4bcfa384c862b2035ddd_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF8yLTEtMS0xLTEzMTYxOA_cb529e27-e822-4f40-9a67-0df5922dd889">MRK</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i135ab11fbbba4bcfa384c862b2035ddd_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF8yLTItMS0xLTEzMTYxOA_915a08cf-0363-472b-9dac-0542e7996f24">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i147620f1bebe45a09eb1c534137133ec_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF8zLTAtMS0xLTEzMTYxOA_ebbedc1f-6993-4f83-ab14-e95e629529ff">0.500% Notes due 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i147620f1bebe45a09eb1c534137133ec_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF8zLTEtMS0xLTEzMTYxOA_56bb0e3e-0444-4162-8be4-1c7109b59cf0">MRK 24</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i147620f1bebe45a09eb1c534137133ec_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF8zLTItMS0xLTEzMTYxOA_ea5e4e7d-270b-4a9b-b9a9-73deeed066f5">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="if2d8e55f082b4b91b405cb32c49e17e5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF80LTAtMS0xLTEzMTYxOA_6d86a2a0-32e6-448f-a0c3-b4fc636b4f63">1.875% Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="if2d8e55f082b4b91b405cb32c49e17e5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF80LTEtMS0xLTEzMTYxOA_beab5f44-7c3d-4a1f-a36b-0d0bd8642fce">MRK/26</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="if2d8e55f082b4b91b405cb32c49e17e5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF80LTItMS0xLTEzMTYxOA_162bc9cc-debd-4b7b-bdf1-c27dddd141f7">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i59b625119501404d81b378dc2da40e6e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF81LTAtMS0xLTEzMTYxOA_f098378b-1e96-480a-b131-48c625e0dfe4">2.500% Notes due 2034</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i59b625119501404d81b378dc2da40e6e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF81LTEtMS0xLTEzMTYxOA_92b385d4-56d2-4911-b640-8a9f1955a841">MRK/34</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i59b625119501404d81b378dc2da40e6e_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF81LTItMS0xLTEzMTYxOA_e720995f-3865-48f1-952f-28f02cc7a222">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ia0a22a157b7c4d9491fb9c5367a1371b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF82LTAtMS0xLTEzMTYxOA_a40291b0-c7b2-4a39-8a5a-b26d611d5a23">1.375% Notes due 2036</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia0a22a157b7c4d9491fb9c5367a1371b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF82LTEtMS0xLTEzMTYxOA_147790df-f046-41f1-93d7-65cb2f92f1b3">MRK 36A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia0a22a157b7c4d9491fb9c5367a1371b_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6YjUzYjFmYWQzZmY4NDdjOGE4NGM4M2VlZmRlYWQ2NmQvdGFibGVyYW5nZTpiNTNiMWZhZDNmZjg0N2M4YTg0YzgzZWVmZGVhZDY2ZF82LTItMS0xLTEzMTYxOA_83d99553-a0ce-41ea-b684-09cdc75ae00d">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xODkz_b1c24cde-b7b0-4fbc-97f0-841c8f340cb4">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xODk0_67742bb5-0278-4da9-8e98-562369793366">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6MjgzMTAwZjAyMTE0NDc2NTg4NmQxZDBkMjkwZGQyYzMvdGFibGVyYW5nZToyODMxMDBmMDIxMTQ0NzY1ODg2ZDFkMGQyOTBkZDJjM18wLTAtMS0xLTEzMTYxOA_23cc4da8-c656-4389-ab13-fa260094c00e">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6MjgzMTAwZjAyMTE0NDc2NTg4NmQxZDBkMjkwZGQyYzMvdGFibGVyYW5nZToyODMxMDBmMDIxMTQ0NzY1ODg2ZDFkMGQyOTBkZDJjM18yLTMtMS0xLTEzMTYxOA_3803a375-2884-4e3c-885f-a8d6276073ed">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGFibGU6MjgzMTAwZjAyMTE0NDc2NTg4NmQxZDBkMjkwZGQyYzMvdGFibGVyYW5nZToyODMxMDBmMDIxMTQ0NzY1ODg2ZDFkMGQyOTBkZDJjM180LTMtMS0xLTEzMTYxOA_eadaf207-a492-4b84-85ce-c008f43988a1">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xODk1_b1dd325d-1306-4e45-bead-28f343ff608e">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i6f9aa917fb244d03ab52c4fcb13190ea_I20230430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xL2ZyYWc6NzRiMWIwZDQ2MGIwNDNiZTgwMDhlY2MzNGJjYzI4M2UvdGV4dHJlZ2lvbjo3NGIxYjBkNDYwYjA0M2JlODAwOGVjYzM0YmNjMjgzZV8xODg3_be69b0d3-66c6-439c-b4a8-5f68956b99c4"
      unitRef="shares">2537435954</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMi0xLTEtMS0xMzE2MTg_22a948dc-764f-4b1e-bd35-1d8c5714fc99"
      unitRef="usd">14487000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMi0zLTEtMS0xMzE2MTg_bce1380b-87c8-407a-9c79-f8ebd0e11ede"
      unitRef="usd">15901000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfNC0xLTEtMS0xMzE2MTg_0188d0d0-f266-40a6-aa92-9c61754cf8cd"
      unitRef="usd">3926000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfNC0zLTEtMS0xMzE2MTg_2180f02d-8ce8-437f-a4ea-95b8792af6fa"
      unitRef="usd">5380000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfNS0xLTEtMS0xMzE2MTg_a4ac50f0-1dea-41f4-b71a-2a24673df9a2"
      unitRef="usd">2479000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfNS0zLTEtMS0xMzE2MTg_d408b7de-2761-4d61-ad78-59cbcefdfb94"
      unitRef="usd">2323000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfNi0xLTEtMS0xMzE2MTg_9f820cd5-8bcf-49cc-97b7-b6385fd4b003"
      unitRef="usd">4276000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfNi0zLTEtMS0xMzE2MTg_756f3780-1e8c-4b78-885d-84bda4f33475"
      unitRef="usd">2576000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:RestructuringCharges
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfNy0xLTEtMS0xMzE2MTg_44827c4c-7eba-4264-80bc-1dd8dfe84c88"
      unitRef="usd">67000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfNy0zLTEtMS0xMzE2MTg_6b97c534-fe69-4c7d-aa8f-84c89af6340e"
      unitRef="usd">53000000</us-gaap:RestructuringCharges>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfOC0xLTEtMS0xMzE2MTg_179cbe9b-cbaf-4611-ab53-9332ca253bc5"
      unitRef="usd">-89000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfOC0zLTEtMS0xMzE2MTg_1b228471-d719-454e-9351-e1fae4b738aa"
      unitRef="usd">-708000000</us-gaap:OtherNonoperatingIncomeExpense>
    <mrk:CostsExpensesAndOther
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfOS0xLTEtMS0xMzE2MTg_c5123e2e-a3c4-40cf-8372-89e9fbab2ae2"
      unitRef="usd">10837000000</mrk:CostsExpensesAndOther>
    <mrk:CostsExpensesAndOther
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfOS0zLTEtMS0xMzE2MTg_0fac0ed5-3cb8-4d9a-8ba9-8bfc51189375"
      unitRef="usd">11040000000</mrk:CostsExpensesAndOther>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTAtMS0xLTEtMTMxNjE4_c02f2f04-f0c9-4239-95ea-5a79557a3f84"
      unitRef="usd">3650000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTAtMy0xLTEtMTMxNjE4_371e37d2-281a-4235-a5a7-2f9333970a21"
      unitRef="usd">4861000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTEtMS0xLTEtMTMxNjE4_a240005f-5659-4544-bfbf-fb2bb8f88da4"
      unitRef="usd">825000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTEtMy0xLTEtMTMxNjE4_af2b2bd1-b7c0-43cd-bb39-01398ec1029f"
      unitRef="usd">554000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTItMS0xLTEtMTMxNjE4_6ca2d321-3ded-41ea-9897-2efa2c811ccb"
      unitRef="usd">2825000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTItMy0xLTEtMTMxNjE4_e0f721ab-c987-4e71-a1aa-486327058661"
      unitRef="usd">4307000000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTMtMS0xLTEtMTMxNjE4_1649114a-5201-4188-8214-62f6970413b9"
      unitRef="usd">4000000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTMtMy0xLTEtMTMxNjE4_7fad438f-474a-456b-a99b-7c86a6265a87"
      unitRef="usd">-3000000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:NetIncomeLoss
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTYtMS0xLTEtMTMxNjE4_43492766-3d70-4de9-80c0-fe2e21a3502c"
      unitRef="usd">2821000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMTYtMy0xLTEtMTMxNjE4_56c8a1aa-d900-49af-892d-b9852e0de55b"
      unitRef="usd">4310000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMjAtMS0xLTEtMTMxNjE4_e06ecac2-0828-4ce4-9b20-1e44c477d8fc"
      unitRef="usdPerShare">1.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMjAtMy0xLTEtMTMxNjE4_2fd6ca77-c5f7-4bb2-a4e8-670358fdd45e"
      unitRef="usdPerShare">1.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMjQtMS0xLTEtMTMxNjE4_0ba68e04-477d-4410-a877-9e2049b1916b"
      unitRef="usdPerShare">1.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xNi9mcmFnOjFjZjU0NGVkZTA3MzQ0OTdhNTFhNmUwMWU1M2VhMGUzL3RhYmxlOjc2NTAxOGRlYmMxNTRiMWViNDUxZGY1NmVhNWViY2QxL3RhYmxlcmFuZ2U6NzY1MDE4ZGViYzE1NGIxZWI0NTFkZjU2ZWE1ZWJjZDFfMjQtMy0xLTEtMTMxNjE4_613a5df7-687d-42a0-974e-e501b8140487"
      unitRef="usdPerShare">1.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfMi0xLTEtMS0xMzE2MTg_9d53d2c2-5134-41e9-9d8d-821d9fe93af3"
      unitRef="usd">2821000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfMi0zLTEtMS0xMzE2MTg_6e1f75f4-5afd-48c6-af9c-cbf68de94662"
      unitRef="usd">4310000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfNC0xLTEtMS0xMzE2MTg_5a7677b3-7232-48b9-a7f4-08a44a47e840"
      unitRef="usd">-133000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfNC0zLTEtMS0xMzE2MTg_9a51891c-672a-4ff0-be38-247e3c6c0521"
      unitRef="usd">63000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfNS0xLTEtMS0xMzE2MTg_8afa93a5-1374-4939-aac2-b70a3df0387a"
      unitRef="usd">50000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfNS0zLTEtMS0xMzE2MTg_2fb4cc0c-9b00-4f76-bec4-0de35149ff75"
      unitRef="usd">-32000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfNi0xLTEtMS0xMzE2MTg_68db319a-f0ba-4a40-bd7d-b928d5f6b5c1"
      unitRef="usd">68000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfNi0zLTEtMS0xMzE2MTg_cb304264-9240-44f2-90ec-ed5bec455ceb"
      unitRef="usd">-35000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfNy0xLTEtMS0xMzE2MTg_bd932dc9-79a6-48a5-8035-e1ec438564a5"
      unitRef="usd">-115000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfNy0zLTEtMS0xMzE2MTg_7861fdb2-ca43-4fc1-b735-949b79991b43"
      unitRef="usd">60000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfOC0xLTEtMS0xMzE2MTg_dc01a782-40da-4aa7-8075-ee8dfa630e14"
      unitRef="usd">2706000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18xOS9mcmFnOjdmNmZjOWU4OTU2NzQ4MzU5NjVmYWIzNjMzMDlhN2NlL3RhYmxlOjhmMGY2NTk3NGJlNDRhZmU4Y2Y5MzMzY2NjMjk2OGQyL3RhYmxlcmFuZ2U6OGYwZjY1OTc0YmU0NGFmZThjZjkzMzNjY2MyOTY4ZDJfOC0zLTEtMS0xMzE2MTg_f20970f2-647b-4a21-8e84-be3796791313"
      unitRef="usd">4370000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMy0xLTEtMS0xMzE2MTg_967daee1-ff2a-4951-bc69-ef80e6c538bc"
      unitRef="usd">9707000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMy0zLTEtMS0xMzE2MTg_cf16b07d-b043-475c-8128-383bd4d4a8d8"
      unitRef="usd">12694000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNC0xLTEtMS0xMzE2MTg_222f313d-ef29-4b3c-96cc-9f6b9a4a4310"
      unitRef="usd">680000000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNC0zLTEtMS0xMzE2MTg_6b79232d-6853-4540-a628-11657f6e55d1"
      unitRef="usd">498000000</us-gaap:ShortTermInvestments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNS0wLTEtMS0xMzE2MTgvdGV4dHJlZ2lvbjo0OGFhZGQxM2Y1YWY0YTdiOTY2NGU4M2M5MDYxODI2NF82Nw_822fc7ba-dbd7-4ca1-9492-6374e8145232"
      unitRef="usd">76000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNS0wLTEtMS0xMzE2MTgvdGV4dHJlZ2lvbjo0OGFhZGQxM2Y1YWY0YTdiOTY2NGU4M2M5MDYxODI2NF84MQ_6f908c8f-6c0a-48ea-9592-adb4ff628a9f"
      unitRef="usd">72000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNS0xLTEtMS0xMzE2MTg_1222faae-5699-4374-906d-dbbcd43c9e18"
      unitRef="usd">10415000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNS0zLTEtMS0xMzE2MTg_2632de83-4d07-44bb-b75e-8cc7340640b2"
      unitRef="usd">9450000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNi0wLTEtMS0xMzE2MTgvdGV4dHJlZ2lvbjowY2FmNDMwOTI0YzM0ZmZjOWFjMmVhMjcyNWRkNGE5M180Mg_c907277a-5910-4e63-8412-acc88ddbd2f2"
      unitRef="usd">3284000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNi0wLTEtMS0xMzE2MTgvdGV4dHJlZ2lvbjowY2FmNDMwOTI0YzM0ZmZjOWFjMmVhMjcyNWRkNGE5M181NQ_44add83a-9702-4bc1-9816-2f6bfc0a2114"
      unitRef="usd">2938000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNi0xLTEtMS0xMzE2MTg_3f76f305-e2cc-479b-8fb7-8cc02bdfac01"
      unitRef="usd">5863000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNi0zLTEtMS0xMzE2MTg_3d3b9b26-6181-4b32-9195-a9aa050fd839"
      unitRef="usd">5911000000</us-gaap:InventoryNet>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsCurrent
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNy0xLTEtMS0xMzE2MTg_68f303a5-a8cf-43f1-8d28-342523a8aead"
      unitRef="usd">6737000000</us-gaap:DeferredIncomeTaxesAndOtherAssetsCurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsCurrent
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfNy0zLTEtMS0xMzE2MTg_5b39bf45-6ea2-46c6-b9f1-3af22664561d"
      unitRef="usd">7169000000</us-gaap:DeferredIncomeTaxesAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfOC0xLTEtMS0xMzE2MTg_1ca0e339-2d4b-47fe-b39d-6d57bf6bc74b"
      unitRef="usd">33402000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfOC0zLTEtMS0xMzE2MTg_88756b45-3286-4a3b-81e1-f3a360f3d9fc"
      unitRef="usd">35722000000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfOS0xLTEtMS0xMzE2MTg_191b18c6-fc96-4880-8ded-9c835b314eb5"
      unitRef="usd">1290000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfOS0zLTEtMS0xMzE2MTg_b252f003-c2a5-48fd-87d8-75270eb6d5df"
      unitRef="usd">1015000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTAtMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NGNjNzRkM2RmNmMyNDVjMmEwOGYwODg5NmNmNjFkZWNfNzk_45b9288c-51fb-4214-8763-27e6779afff4"
      unitRef="usd">18256000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTAtMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NGNjNzRkM2RmNmMyNDVjMmEwOGYwODg5NmNmNjFkZWNfOTI_e9f6ca0c-9ee9-4abb-b0e1-9239835657f8"
      unitRef="usd">17985000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTAtMS0xLTEtMTMxNjE4_1902832c-043f-456e-9b28-17abf435c562"
      unitRef="usd">21758000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTAtMy0xLTEtMTMxNjE4_b3f2922d-1a77-495f-bd89-b28214766485"
      unitRef="usd">21422000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTEtMS0xLTEtMTMxNjE4_4562c099-5b86-4fc2-a7d5-d3f25188e55b"
      unitRef="usd">21209000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTEtMy0xLTEtMTMxNjE4_3c100ee6-afa8-4491-ae7e-905b4718a6f1"
      unitRef="usd">21204000000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTItMS0xLTEtMTMxNjE4_7787aa44-dccd-4963-95c4-6b8884765d64"
      unitRef="usd">19857000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTItMy0xLTEtMTMxNjE4_9987f72b-9b7a-46b2-b5e6-3c6844a32e71"
      unitRef="usd">20269000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTMtMS0xLTEtMTMxNjE4_e0cb0b02-4494-4513-bbb2-59c39256d635"
      unitRef="usd">10280000000</us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTMtMy0xLTEtMTMxNjE4_b41112bc-0d60-4e46-9eb8-9baefef41f5b"
      unitRef="usd">9528000000</us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTQtMS0xLTEtMTMxNjE4_0df0d197-c2c8-4ced-b066-1f734f6fd62d"
      unitRef="usd">107796000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTQtMy0xLTEtMTMxNjE4_555c1f83-c6ba-4b93-bd57-2375723dd275"
      unitRef="usd">109160000000</us-gaap:Assets>
    <us-gaap:DebtCurrent
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTctMS0xLTEtMTMxNjE4_96023f21-9b9f-4413-a412-3cf6d8317a09"
      unitRef="usd">2672000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTctMy0xLTEtMTMxNjE4_23570947-3333-4116-872a-27e71fb6fada"
      unitRef="usd">1946000000</us-gaap:DebtCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTgtMS0xLTEtMTMxNjE4_30919281-ef34-4152-86a0-6130039359d2"
      unitRef="usd">3680000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTgtMy0xLTEtMTMxNjE4_de982a18-bde9-4a2f-8703-5aa1e4467f8e"
      unitRef="usd">4264000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTktMS0xLTEtMTMxNjE4_5c75670e-171d-4642-809e-b2629b0a969e"
      unitRef="usd">13000000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMTktMy0xLTEtMTMxNjE4_941ff79c-e2eb-44b7-98cd-aabe27fb1454"
      unitRef="usd">14159000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjAtMS0xLTEtMTMxNjE4_8d3cb187-9ac4-4ea7-9401-18e573106cf0"
      unitRef="usd">1872000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjAtMy0xLTEtMTMxNjE4_83596902-72c3-4b8a-9664-ac7d0752b626"
      unitRef="usd">1986000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjEtMS0xLTEtMTMxNjE4_a730ca51-dd3b-4e99-960b-f32420625ed9"
      unitRef="usd">1907000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjEtMy0xLTEtMTMxNjE4_bb244e75-0734-4718-a367-5934625c9927"
      unitRef="usd">1884000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjItMS0xLTEtMTMxNjE4_3d9d8385-c265-4769-8757-ac8133ea94d5"
      unitRef="usd">23131000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjItMy0xLTEtMTMxNjE4_b9c1605e-67f6-4b9d-9fbe-313dce0ab1be"
      unitRef="usd">24239000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjMtMS0xLTEtMTMxNjE4_7e905a0e-7f44-487a-a3aa-fe584eacf25d"
      unitRef="usd">28074000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjMtMy0xLTEtMTMxNjE4_f846fcd2-b793-4a77-9d0f-945e2daa5251"
      unitRef="usd">28745000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjQtMS0xLTEtMTMxNjE4_e559db80-b288-453f-b0dd-14928d9eb67d"
      unitRef="usd">1442000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjQtMy0xLTEtMTMxNjE4_da5652c4-91bd-4a1b-8b13-03f6c5c5f9ef"
      unitRef="usd">1795000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjUtMS0xLTEtMTMxNjE4_759565f5-2ba5-4057-ac81-f8818f03e6d0"
      unitRef="usd">8244000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjUtMy0xLTEtMTMxNjE4_246b808e-19fc-45ce-8028-70f9bc85e926"
      unitRef="usd">8323000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjctMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NmYwYjdmMjdjZGM3NGNjMjhlMTM3YTM2YmEwNDkzY2NfMTk_128e47ea-16fc-48b1-a3d1-a39408894e0c"
      unitRef="usdPerShare">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjctMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NmYwYjdmMjdjZGM3NGNjMjhlMTM3YTM2YmEwNDkzY2NfMTk_504cabe0-2ba9-4258-9d7f-3be08ef9fb82"
      unitRef="usdPerShare">0.50</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjctMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NmYwYjdmMjdjZGM3NGNjMjhlMTM3YTM2YmEwNDkzY2NfNDU_5388a816-78d9-49f3-bcbb-4ece1514df88"
      unitRef="shares">6500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjctMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NmYwYjdmMjdjZGM3NGNjMjhlMTM3YTM2YmEwNDkzY2NfNDU_a3209d0f-d4dc-4731-b6a7-7268823b40b6"
      unitRef="shares">6500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjctMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NmYwYjdmMjdjZGM3NGNjMjhlMTM3YTM2YmEwNDkzY2NfNjQ_341472b4-707a-4453-ab41-60dfa82eaa9b"
      unitRef="shares">3577103522</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjctMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NmYwYjdmMjdjZGM3NGNjMjhlMTM3YTM2YmEwNDkzY2NfNjQ_993b83ae-b115-4843-a85c-55f40f10efe8"
      unitRef="shares">3577103522</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjctMS0xLTEtMTMxNjE4_79fb7564-56ee-4d60-986f-f2042d770186"
      unitRef="usd">1788000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjctMy0xLTEtMTMxNjE4_7b227f27-ff2b-469a-9e6d-18d2de2a2ec3"
      unitRef="usd">1788000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjgtMS0xLTEtMTMxNjE4_da6468c1-42c2-46fa-99f8-5e51d9f1c397"
      unitRef="usd">44467000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjgtMy0xLTEtMTMxNjE4_70bb3dbd-e09a-4850-88ea-f4844bd6a1d2"
      unitRef="usd">44379000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjktMS0xLTEtMTMxNjE4_cca8165e-e648-4706-bbb1-f09f38f5a380"
      unitRef="usd">62039000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMjktMy0xLTEtMTMxNjE4_3bd92cbf-1e13-437b-a6bd-77c654470344"
      unitRef="usd">61081000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzAtMS0xLTEtMTMxNjE4_b12dd89a-1d1c-47e7-ad14-8c5484cb4f6f"
      unitRef="usd">-4883000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzAtMy0xLTEtMTMxNjE4_aa72c78d-ec8d-4799-8c47-978ea8205ec5"
      unitRef="usd">-4768000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityBeforeTreasuryStock
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzEtMS0xLTEtMTMxNjE4_3d85a20a-fe4f-4877-adb6-379299a33c60"
      unitRef="usd">103411000000</us-gaap:StockholdersEquityBeforeTreasuryStock>
    <us-gaap:StockholdersEquityBeforeTreasuryStock
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzEtMy0xLTEtMTMxNjE4_66806729-0f43-42d4-9a45-d7ac807dbed8"
      unitRef="usd">102480000000</us-gaap:StockholdersEquityBeforeTreasuryStock>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzItMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NGQxMGIwNzYwNTM1NDlmMmFjZDZmNjgyMTEyODZkZTVfMzU_4156c5c2-2f3b-4715-8897-8ac783d34baf"
      unitRef="shares">1039651210</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzItMC0xLTEtMTMxNjE4L3RleHRyZWdpb246NGQxMGIwNzYwNTM1NDlmMmFjZDZmNjgyMTEyODZkZTVfNTU_b610ec30-f8ec-4c4f-9476-dbf7523bb992"
      unitRef="shares">1039269638</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzItMS0xLTEtMTMxNjE4_461a7221-c005-40d5-906e-a0ced02e8a6c"
      unitRef="usd">56577000000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzItMy0xLTEtMTMxNjE4_a783c954-4094-44da-afd5-b3063453d865"
      unitRef="usd">56489000000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:StockholdersEquity
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzMtMS0xLTEtMTMxNjE4_5d07777d-2ea2-4207-81ce-86b701e6e164"
      unitRef="usd">46834000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzMtMy0xLTEtMTMxNjE4_424582a5-e3c9-4ebf-9c9a-8325609abc41"
      unitRef="usd">45991000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzQtMS0xLTEtMTMxNjE4_f8989083-de67-4ad3-bf49-2871f5d529e2"
      unitRef="usd">71000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzQtMy0xLTEtMTMxNjE4_859d6f87-7d8d-4a30-b9e1-e33e12ca7467"
      unitRef="usd">67000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzUtMS0xLTEtMTMxNjE4_09113873-7a8f-4863-868e-d7c1db560549"
      unitRef="usd">46905000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzUtMy0xLTEtMTMxNjE4_fbdb4efa-b44f-467c-9479-6f8dc058ec69"
      unitRef="usd">46058000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzYtMS0xLTEtMTMxNjE4_986ca522-42af-495a-8d5c-73ec54bd96fe"
      unitRef="usd">107796000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yMi9mcmFnOmUxMDFiZDE5YzExOTQ5MTVhMDc1NTE4NzRiNWFkZmViL3RhYmxlOjJjNGVjNTBiZmUzOTQ1NWY5NzJhMzQ3NGI1MWE5ZTQ4L3RhYmxlcmFuZ2U6MmM0ZWM1MGJmZTM5NDU1Zjk3MmEzNDc0YjUxYTllNDhfMzYtMy0xLTEtMTMxNjE4_0dd841fe-3632-4023-8da8-907dd5c192a4"
      unitRef="usd">109160000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMy0xLTEtMS0xMzE2MTg_96df26bc-b065-421d-9b4b-f29e1526bc5e"
      unitRef="usd">2825000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMy0zLTEtMS0xMzE2MTg_d973dad5-1be3-4ae4-976a-1698ee71f3ea"
      unitRef="usd">4307000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentForAmortization
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfNS0xLTEtMS0xMzE2MTg_d90c522f-6883-4fb5-bf24-932945d33689"
      unitRef="usd">543000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfNS0zLTEtMS0xMzE2MTg_dec9ed94-267c-42fc-8d0e-ee1e62a82fc3"
      unitRef="usd">699000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:Depreciation
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfNi0xLTEtMS0xMzE2MTg_b5531913-afe0-4a79-aaea-92497ee62209"
      unitRef="usd">448000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfNi0zLTEtMS0xMzE2MTg_979a722b-8726-47dd-ae20-57e44456acf2"
      unitRef="usd">421000000</us-gaap:Depreciation>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfOC0xLTEtMS0xMzE2MTg_f770899b-d54c-4209-9c23-6d6e75dccda4"
      unitRef="usd">450000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfOC0zLTEtMS0xMzE2MTg_16542396-21c6-4733-a312-03bcbd4a33f1"
      unitRef="usd">-708000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfOS0xLTEtMS0xMzE2MTg_bc25a7bf-4cea-43c8-8289-40019cf71366"
      unitRef="usd">1192000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfOS0zLTEtMS0xMzE2MTg_263abef6-bec6-41af-9959-6ace0ce88fcc"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTAtMS0xLTEtMTMxNjE4_0de064bb-1471-4c23-b18e-ea756677c8aa"
      unitRef="usd">-277000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTAtMy0xLTEtMTMxNjE4_d5beb90c-dfa4-4c17-a15e-1cf6443250b7"
      unitRef="usd">-338000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTEtMS0xLTEtMTMxNjE4_1696e982-58c0-41ab-a25d-8c5349da8e33"
      unitRef="usd">145000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTEtMy0xLTEtMTMxNjE4_f6ba5549-ebbc-4423-bd0b-c0b78a6431eb"
      unitRef="usd">120000000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTItMS0xLTEtMTMxNjE4_6f34df55-0d21-410f-9940-256f6a21d765"
      unitRef="usd">197000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTItMy0xLTEtMTMxNjE4_124ca8e5-2693-42b6-bcdd-2688d99aedd2"
      unitRef="usd">-143000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInOperatingCapital
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTMtMS0xLTEtMTMxNjE4_bd556e0f-f8b2-4c05-95af-01089814842a"
      unitRef="usd">2890000000</us-gaap:IncreaseDecreaseInOperatingCapital>
    <us-gaap:IncreaseDecreaseInOperatingCapital
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTMtMy0xLTEtMTMxNjE4_d4095305-7596-4cc2-9835-39d54c0ed506"
      unitRef="usd">1299000000</us-gaap:IncreaseDecreaseInOperatingCapital>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTQtMS0xLTEtMTMxNjE4_d4fa6fde-1e10-4b5e-8a1f-81058bd4bc86"
      unitRef="usd">1339000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTQtMy0xLTEtMTMxNjE4_bf1fd024-50c7-49e6-a734-16e6ac7ca85d"
      unitRef="usd">4761000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTYtMS0xLTEtMTMxNjE4_d1497e77-af35-4705-a186-9a00da0399b9"
      unitRef="usd">1007000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTYtMy0xLTEtMTMxNjE4_60dd1360-f35f-417f-aeb4-8f3cdf07fdbf"
      unitRef="usd">984000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTctMS0xLTEtMTMxNjE4_485191f7-5ee4-4524-b344-fedabc168793"
      unitRef="usd">562000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTctMy0xLTEtMTMxNjE4_12420839-30b0-4a6f-885c-cfe8d9051c4f"
      unitRef="usd">372000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTgtMS0xLTEtMTMxNjE4_621f6940-d559-4c6f-9c20-b5d0d60f38f5"
      unitRef="usd">500000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTgtMy0xLTEtMTMxNjE4_92e6b1fe-156e-49da-8aac-385142f90edc"
      unitRef="usd">1000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTktMS0xLTEtMTMxNjE4_a16e09fe-9bab-4028-b7f4-62014a0f001f"
      unitRef="usd">1327000000</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMTktMy0xLTEtMTMxNjE4_457175af-1125-4f41-ae7f-ffd55d717a9a"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjEtMS0xLTEtMTMxNjE4_9fcf7baf-941d-4861-86d5-fadb2ce37601"
      unitRef="usd">-37000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjEtMy0xLTEtMTMxNjE4_042b8b62-02b2-4cab-8dac-173b990d06e5"
      unitRef="usd">-182000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjItMS0xLTEtMTMxNjE4_dde27029-013a-4f21-9d1d-da96e9b5c8e2"
      unitRef="usd">-2359000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjItMy0xLTEtMTMxNjE4_3d3e0417-06f2-4516-a14e-3d98aede7085"
      unitRef="usd">-1173000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjUtMS0xLTEtMTMxNjE4_5aad0010-ef4c-45b6-8002-7e8c4d53da42"
      unitRef="usd">1000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjUtMy0xLTEtMTMxNjE4_78e76ae4-7af1-4a54-9154-39553da4bd71"
      unitRef="usd">1250000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjctMS0xLTEtMTMxNjE4_34a99e25-8882-4dbb-99f4-0a118d022c7b"
      unitRef="usd">149000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjctMy0xLTEtMTMxNjE4_547ab818-36b8-46c6-8216-1f164b119103"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjgtMS0xLTEtMTMxNjE4_a9e81bee-bfbb-4c85-a95f-51adb653ac90"
      unitRef="usd">1853000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjgtMy0xLTEtMTMxNjE4_887f60e0-ce30-4a24-9aa1-c194599fab6f"
      unitRef="usd">1745000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjktMS0xLTEtMTMxNjE4_9fda3d61-3899-45cb-afdb-726d11db379a"
      unitRef="usd">30000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMjktMy0xLTEtMTMxNjE4_ae6beb2f-1113-4127-974b-19e7718f0947"
      unitRef="usd">12000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzAtMS0xLTEtMTMxNjE4_84a0d387-1f44-49fd-a73b-1f3774e740f0"
      unitRef="usd">-81000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzAtMy0xLTEtMTMxNjE4_6f818a21-e15d-4163-93dc-c948bf8acf5d"
      unitRef="usd">-103000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzEtMS0xLTEtMTMxNjE4_a29a9e77-4dba-4e43-808d-2537b985aa5f"
      unitRef="usd">-2054000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzEtMy0xLTEtMTMxNjE4_a5a219d0-be6a-4d13-8306-9c72bfe5372d"
      unitRef="usd">-3086000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzctMS0xLTEtMTMxNjE4_cc1d4d3f-1239-48a6-9633-85cd7548fcc8"
      unitRef="usd">87000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzctMy0xLTEtMTMxNjE4_e5fd50f1-af3c-44b9-9ac2-f6863a65efdc"
      unitRef="usd">-55000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzgtMS0xLTEtMTMxNjE4_6f769ff9-7bc0-4809-a8a1-cb9bd2cd4327"
      unitRef="usd">-2987000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzgtMy0xLTEtMTMxNjE4_b2fb9306-ccd7-4c95-8e12-84beb46b61dd"
      unitRef="usd">447000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzktMC0xLTEtMTMxNjE4L3RleHRyZWdpb246ZTQwNmNiNmMwNWZjNDI3Y2I0ODk3ZjkyMGI2ZDgxYTBfOTg_9415480a-1c90-4b11-a9f7-715a776bda3e"
      unitRef="usd">79000000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="if2cb2241175c4c8c8fd5daf0a86385e3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzktMC0xLTEtMTMxNjE4L3RleHRyZWdpb246ZTQwNmNiNmMwNWZjNDI3Y2I0ODk3ZjkyMGI2ZDgxYTBfMTA1_864b1408-ebf8-4800-a362-7266f39b0329"
      unitRef="usd">71000000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzktMS0xLTEtMTMxNjE4_c330c56f-4e92-499f-ab27-745afc28c960"
      unitRef="usd">12773000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if2cb2241175c4c8c8fd5daf0a86385e3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfMzktMy0xLTEtMTMxNjE4_e1bb938c-2e47-4577-9f92-528f4ad0ee01"
      unitRef="usd">8167000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfNDAtMC0xLTEtMTMxNjE4L3RleHRyZWdpb246ZDRjYjdjYjExZDRmNGEwYjllZWY0ZGNkNGFhZTQ3YTdfOTM_4136cb22-f5b0-48ae-9788-19eeb5a2ec2c"
      unitRef="usd">79000000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i1ff3b595ae954906bf225b8a7cc58b69_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfNDAtMC0xLTEtMTMxNjE4L3RleHRyZWdpb246ZDRjYjdjYjExZDRmNGEwYjllZWY0ZGNkNGFhZTQ3YTdfMTAx_b39ba864-55bf-43af-b36b-ee05f41e4d25"
      unitRef="usd">58000000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfNDAtMS0xLTEtMTMxNjE4_5e444c09-8ef4-47ec-a166-77e567aa8423"
      unitRef="usd">9786000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1ff3b595ae954906bf225b8a7cc58b69_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18yNS9mcmFnOjY1MWU0YTEwYjFhNDRhODQ4NmFjNjdiOTUyYzFlYTcwL3RhYmxlOmIzMzhjYTkzNTUwMzRhZTg5NTgwMGJiNDAyOTZkMTdkL3RhYmxlcmFuZ2U6YjMzOGNhOTM1NTAzNGFlODk1ODAwYmI0MDI5NmQxN2RfNDAtMy0xLTEtMTMxNjE4_2f82e097-732a-4893-bc44-d945a285b65d"
      unitRef="usd">8614000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zMS9mcmFnOmExOGMwMGVjNDM2MDQyMDU4YWFkMDBmOWM2ZDEyNjE2L3RleHRyZWdpb246YTE4YzAwZWM0MzYwNDIwNThhYWQwMGY5YzZkMTI2MTZfNTIzNA_c8ad131b-6693-448d-bbd5-b63555253a56">Basis of PresentationThe accompanying unaudited condensed consolidated financial statements of Merck&#160;&amp;amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck&#x2019;s Form 10-K filed on February&#160;24, 2023. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company&#x2019;s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zMS9mcmFnOmExOGMwMGVjNDM2MDQyMDU4YWFkMDBmOWM2ZDEyNjE2L3RleHRyZWdpb246YTE4YzAwZWM0MzYwNDIwNThhYWQwMGY5YzZkMTI2MTZfNTIzNQ_be0e9094-f28a-4ad5-bc4b-deefad9b251e">Basis of Presentation&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements of Merck&#160;&amp;amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck&#x2019;s Form 10-K filed on February&#160;24, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company&#x2019;s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. Certain reclassifications have been made to prior year amounts to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Standard&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The Company adopted the guidance effective January 1, 2023. The adoption of this guidance did not have an impact on the Company&#x2019;s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Issued Accounting Standard Not Yet Adopted&lt;/span&gt;&lt;/div&gt;In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company does not expect there to be an impact to its consolidated financial statements upon adoption</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zMS9mcmFnOmExOGMwMGVjNDM2MDQyMDU4YWFkMDBmOWM2ZDEyNjE2L3RleHRyZWdpb246YTE4YzAwZWM0MzYwNDIwNThhYWQwMGY5YzZkMTI2MTZfMjc0ODc3OTA4NDAyOA_2b498c63-3def-40b4-ba4d-64960898e05f">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zMS9mcmFnOmExOGMwMGVjNDM2MDQyMDU4YWFkMDBmOWM2ZDEyNjE2L3RleHRyZWdpb246YTE4YzAwZWM0MzYwNDIwNThhYWQwMGY5YzZkMTI2MTZfNTIzNw_c72c5834-99e5-4a52-a79f-874615827d46">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Standard&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The Company adopted the guidance effective January 1, 2023. The adoption of this guidance did not have an impact on the Company&#x2019;s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Issued Accounting Standard Not Yet Adopted&lt;/span&gt;&lt;/div&gt;In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company does not expect there to be an impact to its consolidated financial statements upon adoption</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTA0ODY_07d1381a-5073-4c20-9340-d3077ff62e74">Acquisitions, Research Collaborations and Licensing Agreements&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company&#x2019;s financial results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In April 2023, Merck announced an agreement to acquire Prometheus Biosciences, Inc. (Prometheus), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. Prometheus&#x2019; lead candidate, PRA023, is a humanized monoclonal antibody directed to tumor necrosis factor-like ligand 1A, a target associated with both intestinal inflammation and fibrosis. Prometheus is developing PRA023 for the treatment of immune-mediated diseases including ulcerative colitis, Crohn&#x2019;s disease, and other autoimmune conditions. Under the terms of the acquisition agreement, Merck, through a subsidiary, will acquire all of the outstanding shares of Prometheus for $200 per share in cash for a total equity value of approximately $10.8 billion. The acquisition is subject to Prometheus shareholder approval. The closing of the proposed transaction will be subject to certain conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. The transaction is expected to close in the third quarter of 2023. If the proposed transaction closes, the Company anticipates it will be accounted for as an asset acquisition, which would result in a charge of approximately $10.3&#160;billion in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In February 2023, Merck and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.) closed a license and collaboration agreement expanding their relationship in which Merck gained exclusive rights for the research, development, manufacture and commercialization of up to seven investigational preclinical antibody drug conjugates (ADCs) for the treatment of cancer. Kelun-Biotech retained the right to research, develop, manufacture and commercialize certain licensed and option ADCs for Chinese mainland, Hong Kong and Macau. Merck made an upfront payment of $175 million, which was recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses in the first quarter of 2023. In addition, Kelun-Biotech is eligible to receive future contingent development-related payments aggregating up to $1.0 billion, $2.8 billion in regulatory milestones, and $5.5 billion in sales-based milestones if Kelun-Biotech does not retain Chinese mainland, Hong Kong and Macau rights for the option ADCs and all candidates achieve regulatory approval. In addition, Kelun-Biotech is eligible to receive tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales for any commercialized ADC product. Also, in connection with the agreement, Merck invested $100 million in Kelun-Biotech&#x2019;s Series B preferred shares in January 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In January 2023, Merck acquired Imago BioSciences, Inc. (Imago), a clinical stage biopharmaceutical company developing new medicines for the treatment of myeloproliferative neoplasms and other bone marrow diseases, for $1.35 billion &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(including payments to settle share-based equity awards) and also incurred approximately $60&#160;million of transaction costs. Imago&#x2019;s lead candidate bomedemstat, MK-3543 (formerly IMG-7289), is an investigational orally available lysine-specific demethylase 1 inhibitor currently being evaluated in multiple Phase 2 clinical trials for the treatment of essential thrombocythemia, myelofibrosis, and polycythemia vera, in addition to other indications. The transaction was accounted for as an acquisition of an asset since bomedemstat represented substantially all of the fair value of the gross assets acquired (excluding cash and deferred income taxes). Merck recorded net assets of $219 million, as well as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses of $1.2 billion in the first quarter of 2023 related to the transaction. There are no future contingent payments associated with the acquisition.&lt;/span&gt;</mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock>
    <mrk:AssetAcquisitionSharePrice
      contextRef="i1302ee97335a4b8a864d880d15a75ffd_I20230430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfNTQ5NzU1ODM4Mzg3_d4c63538-f831-47fe-97bf-4ae60d30ba4d"
      unitRef="usdPerShare">200</mrk:AssetAcquisitionSharePrice>
    <us-gaap:AssetAcquisitionPriceOfAcquisitionExpected
      contextRef="i2c03ed79efac404d85fb217647f60f9e_D20230401-20230430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfNTQ5NzU1ODM4Mzc5_a5ddbb2e-e454-48d8-b02f-37b14b029855"
      unitRef="usd">10800000000</us-gaap:AssetAcquisitionPriceOfAcquisitionExpected>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id017497421574c008e33bacea591637e_D20230701-20230930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfNTQ5NzU1ODM5MDQz_614062ba-076a-491b-a741-beef8d298826"
      unitRef="usd">10300000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1e8e4ea1abaf40778222b2bb6dcfb639_D20230201-20230228"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTY0OTI2NzQ1NDU2OA_ce532234-2516-49a3-a45c-3e4563d6c39f"
      unitRef="usd">175000000</us-gaap:ResearchAndDevelopmentExpense>
    <mrk:CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments
      contextRef="ib9dedd741503427183ecc62df92f5085_I20230228"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTY0OTI2NzQ1NDU4NA_7c1b2c89-c79e-43d3-8e94-a6e5875046db"
      unitRef="usd">1000000000</mrk:CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments>
    <mrk:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments
      contextRef="ib9dedd741503427183ecc62df92f5085_I20230228"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTY0OTI2NzQ1NDYwMg_0f19d466-0cbe-4518-b989-72855a941e0a"
      unitRef="usd">2800000000</mrk:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments>
    <mrk:CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments
      contextRef="ib9dedd741503427183ecc62df92f5085_I20230228"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTY0OTI2NzQ1NDYxOA_6f4bc67c-fc4e-48bd-92f1-367c2868853f"
      unitRef="usd">5500000000</mrk:CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments>
    <mrk:CollaborativeArrangementPreferredStockInvestmentInCounterparty
      contextRef="i3c175c60a55e4c3eb9ac840966e13ebf_I20230131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTY0OTI2NzQ1NDYzNA_a4e29fb2-141c-487d-a9dc-93ba5790ad83"
      unitRef="usd">100000000</mrk:CollaborativeArrangementPreferredStockInvestmentInCounterparty>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="i609e1582535d4dfb834b95904e849c27_D20230101-20230131"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTY0OTI2NzQ1NDY1MQ_5cbcd9f1-00c7-4a03-9f41-13945323aab5"
      unitRef="usd">1350000000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost
      contextRef="i609e1582535d4dfb834b95904e849c27_D20230101-20230131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTY0OTI2NzQ1NDY4Nw_77edc5e1-884d-4bb6-ab2b-f1846940a192"
      unitRef="usd">60000000</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <mrk:AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i8f3adb7e1a4d42dd925db11dbf71eac5_I20230131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTY0OTI2NzQ1NDY4Mw_654d2a2e-1736-4ca5-9721-99373993720e"
      unitRef="usd">219000000</mrk:AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i609e1582535d4dfb834b95904e849c27_D20230101-20230131"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180MC9mcmFnOmEyOTU2ZjZhYTgwOTRlOTc4MmUzZDY0YWE4OTk4YTg0L3RleHRyZWdpb246YTI5NTZmNmFhODA5NGU5NzgyZTNkNjRhYTg5OThhODRfMTY0OTI2NzQ1NDY2Nw_9303e97a-c62b-475e-b1ff-9e4f0e3b2f10"
      unitRef="usd">1200000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTE2NDQ_1c37924b-3e7c-4c80-8b87-e898179b99e7">Collaborative Arrangements&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck&#x2019;s more significant collaborative arrangements are discussed below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;AstraZeneca&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca&#x2019;s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; (pembrolizumab) and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca&#x2019;s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo&#160;monotherapy and non-PD-L1/PD-1 combination therapy opportunities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Profits from Lynparza and Koselugo&#160;product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $600&#160;million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $600&#160;million liability (which remained accrued at March 31, 2023) and a corresponding increase to the intangible asset related to Lynparza. Merck also recognized $250&#160;million of cumulative amortization catch-up expense related to the recognition of this milestone in the first quarter of 2022. Also in the first quarter of 2022, Merck made a sales-based milestone payment to AstraZeneca (which had been previously accrued for) of $400&#160;million. Potential future sales-based milestone payments of $2.1 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In the first quarter of 2023, Merck made a regulatory milestone payment to AstraZeneca (which had been previously accrued for) of $105&#160;million. In 2022, Lynparza received regulatory approvals triggering capitalized milestone payments of $250&#160;million from Merck to AstraZeneca. Potential future regulatory milestone payments of $1.1 billion remain under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.5 billion at March&#160;31, 2023 and is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Intangibles, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lynparza&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Koselugo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total alliance revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Receivables from AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payables to AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payables to AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents amortization of capitalized milestone payments. Amount in the first quarter of 2022 includes $250&#160;million of cumulative amortization catch-up expense as noted above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes accrued milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Eisai&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and Lenvima.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights. In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2023, Merck determined it was probable that sales of Lenvima in the future would trigger a $125&#160;million sales-based milestone payment from Merck to Eisai. Accordingly, Merck recorded a $125&#160;million liability and a corresponding increase to the intangible asset related to Lenvima. Merck also recognized $72&#160;million of cumulative amortization catch-up expense related to the recognition of this milestone. In 2022, Merck made sales-based milestone payments to Eisai (which had been previously accrued for) aggregating $600 million (of which $300&#160;million was paid in the first quarter of 2022). Potential future sales-based milestone payments of $2.4 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In 2022, Lenvima received regulatory approvals triggering capitalized milestone payments of $50&#160;million from Merck to Eisai (of which $25&#160;million was paid in the first quarter of 2022). There are no regulatory milestone payments remaining under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $812 million at March&#160;31, 2023 and is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Intangibles, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lenvima&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Receivables from Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payables to Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents amortization of capitalized milestone payments. Amount in the first quarter of 2023 includes $72&#160;million of cumulative amortization catch-up expense as noted above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents an accrued milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Bayer AG&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer&#x2019;s Adempas (riociguat). The two companies have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer&#x2019;s Verquvo (vericiguat), which was approved in the U.S., the European Union (EU) and Japan in 2021, and has since been approved in several other markets. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck&#x2019;s share of profits from sales of Adempas and Verquvo in Bayer&#x2019;s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer&#x2019;s share of profits from sales in Merck&#x2019;s marketing territories. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. In the first quarter of 2022, Merck made the final $400 million sales-based milestone payment under this collaboration to Bayer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $613 million and $56 million, respectively, at March&#160;31, 2023 and are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Intangibles, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Adempas/Verquvo&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net sales of Adempas recorded by Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net sales of Verquvo recorded by Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Receivables from Bayer included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payables to Bayer included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes amortization of intangible assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Ridgeback Biotherapeutics LP&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, entered into a collaboration agreement to develop &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lagevrio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; (molnupiravir), an investigational orally available antiviral candidate for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lagevrio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;related molecules. Following initial authorizations in certain markets in the fourth quarter of 2021, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lagevrio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; has since received multiple additional authorizations worldwide.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit-sharing calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit-sharing amounts recorded within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback&#x2019;s share of profits) are reflected as decreases to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net sales of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Lagevrio &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;recorded by Merck&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payables to Ridgeback included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes royalty expense and amortization of capitalized milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expenses include an allocation for overhead charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes accrued royalties. Amount at December 31, 2022 also includes an accrued milestone payment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Bristol Myers Squibb&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein that is being commercialized through a global collaboration with Bristol Myers Squibb (BMS). Reblozyl is approved in the U.S., Europe and certain other markets for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and will co-promote all future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives a 20% sales royalty from BMS which could increase to a maximum of 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $80&#160;million. Merck recorded alliance revenue related to this collaboration within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; of $43 million in the first quarter of 2023 (consisting of royalties) compared with $52 million in the first quarter of 2022 (consisting of royalties of $32&#160;million and the receipt of a regulatory approval milestone payment of $20&#160;million).&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <mrk:ProbableContingentPaymentsCollaborativeArrangement
      contextRef="i58a876d3681e4986805915e1bac18ff1_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMjE3Mw_b56b74e0-0535-4054-9690-16a469ab5856"
      unitRef="usd">600000000</mrk:ProbableContingentPaymentsCollaborativeArrangement>
    <us-gaap:Liabilities
      contextRef="i3c3d2c4bb8cc45efb4e93d046dd6a753_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMjI2Mw_c9c8ddb2-95d1-46ef-9bf9-d3eda777afcb"
      unitRef="usd">600000000</us-gaap:Liabilities>
    <us-gaap:AdjustmentForAmortization
      contextRef="i6a91adde5a68413fbc1cfab655dbcbe6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMjM3Mg_dce96547-b25d-4615-b1f8-f1ac4fd3a91e"
      unitRef="usd">250000000</us-gaap:AdjustmentForAmortization>
    <mrk:MilestonePaymentsSalesBased
      contextRef="i350e44c40f67467ba477b370f98d41fc_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMjYyNw_f41fe619-0e01-4c3b-a78c-60b89ae7a08c"
      unitRef="usd">400000000</mrk:MilestonePaymentsSalesBased>
    <mrk:PotentialFutureMilestonePaymentsSalesBased
      contextRef="id6b1412b32dd45bf9b2dc2c9740d6c6f_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMjc2MA_e59d6705-d747-42e9-86fa-6bbabcc85ac5"
      unitRef="usd">2100000000</mrk:PotentialFutureMilestonePaymentsSalesBased>
    <mrk:CollaborativeArrangementRegulatoryMilestonePaymentsAccrued
      contextRef="i71ce1d5e1bd141539620a96cb8b2ec10_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMzg0ODI5MDcxNjA5Ng_f445abb1-99a6-4c1c-8e73-b288eeef069a"
      unitRef="usd">105000000</mrk:CollaborativeArrangementRegulatoryMilestonePaymentsAccrued>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="idf9cd10c9efe4059a13ad6f64f232a85_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMjk3Mg_3f2815ff-b48a-427c-86a5-7933c1e6eb84"
      unitRef="usd">250000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:PotentialFutureMilestonePaymentsRegulatory
      contextRef="id6b1412b32dd45bf9b2dc2c9740d6c6f_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMzA1Mg_864b5908-03da-4517-8564-21624333da2e"
      unitRef="usd">1100000000</mrk:PotentialFutureMilestonePaymentsRegulatory>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i654e8b5924d8442fa9eb55859bbc8647_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMzIxMQ_e0014abc-695c-4555-b300-4c43a2adb0e5"
      unitRef="usd">1500000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTE2NTc_3c242269-2707-49af-af00-29a650ff88ce">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lynparza&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Koselugo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total alliance revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Receivables from AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payables to AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payables to AstraZeneca included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents amortization of capitalized milestone payments. Amount in the first quarter of 2022 includes $250&#160;million of cumulative amortization catch-up expense as noted above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes accrued milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Lenvima&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Receivables from Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payables to Eisai included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents amortization of capitalized milestone payments. Amount in the first quarter of 2023 includes $72&#160;million of cumulative amortization catch-up expense as noted above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Represents an accrued milestone payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Alliance revenue - Adempas/Verquvo&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net sales of Adempas recorded by Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net sales of Verquvo recorded by Merck&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Receivables from Bayer included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payables to Bayer included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes amortization of intangible assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Summarized financial information related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net sales of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Lagevrio &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;recorded by Merck&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payables to Ridgeback included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes royalty expense and amortization of capitalized milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expenses include an allocation for overhead charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes accrued royalties. Amount at December 31, 2022 also includes an accrued milestone payment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="ib681c644ca864f3286e965d6d7324aa4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMi0xLTEtMS0xMzE2MTg_74799bc7-1ca0-4041-a9d1-784e79d4724a"
      unitRef="usd">275000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="ide79c33fd45c49b19bce108416c71788_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMi0zLTEtMS0xMzE2MTg_2445dbff-4eb4-46d6-b22b-4a8bf9abe3c1"
      unitRef="usd">266000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i525916f3d1464ab9b6f291401c761233_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMy0xLTEtMS0xMzE2MTg_d0a05f97-6fd7-4ee2-8d43-c2faa2305371"
      unitRef="usd">23000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i6e95ebf7c1884a0396c7c91a0e223ee6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMy0zLTEtMS0xMzE2MTg_6afd9307-c819-4227-a213-cdfe99dd151c"
      unitRef="usd">9000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i2c6d877e0a5147208fe56690fbb929b0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfNC0xLTEtMS0xMzE2MTg_b2155d73-8814-4f50-bf37-8ed20429ee2e"
      unitRef="usd">298000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i4cdf23392f5642ba818b20d852b014a9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfNC0zLTEtMS0xMzE2MTg_be895c9b-c589-47d8-914e-8187cb5166aa"
      unitRef="usd">275000000</mrk:CollaborativeArrangementProfitSharing>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i46e9161a43a44a2fa59e52960034468a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfNi0xLTEtMS0xMzE2MTg_a68e8f3c-31d9-45e0-9bdd-7df16a360b50"
      unitRef="usd">70000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i71ffa17774c44d2287fe9111206866c3_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfNi0zLTEtMS0xMzE2MTg_2f37606e-2c17-448f-820a-d0d9575d6d07"
      unitRef="usd">299000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iba6c247720a049d28349afa51cec42a7_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfNy0xLTEtMS0xMzE2MTg_510db6bc-d4e3-4767-9ad1-0f39921b337d"
      unitRef="usd">47000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id22834ff470f4f1aa7da131a94ad1d29_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfNy0zLTEtMS0xMzE2MTg_941eda5a-d0e6-4139-80a2-5e8d720047eb"
      unitRef="usd">44000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6500964c8d3f4d06b28f3f23cada56e5_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfOC0xLTEtMS0xMzE2MTg_ac61b060-8225-4634-a588-fa0168539d11"
      unitRef="usd">21000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ifc2de578164e434980f14d63a2153220_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfOC0zLTEtMS0xMzE2MTg_e788dba8-1bd1-4ec6-9893-12a63f3d4f63"
      unitRef="usd">26000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i5973fb4a5d684bcca7a62270623ac406_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMTEtMS0xLTEtMTM1MDU5_854b54f9-ca63-4780-8dfd-acdedb4a61e9"
      unitRef="usd">303000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="icb9ff33d56484784be92a715ee774c2d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMTEtMy0xLTEtMTM1MDU5_fbaf5877-e3f0-4f5a-ac6f-fc1171938592"
      unitRef="usd">303000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ife24131bdfa1419d8d2708d8b616e5b9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMTItMS0xLTEtMTM1MDU5_c5b00a61-6e39-4056-add7-365bf9702589"
      unitRef="usd">21000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="icaae108da197453bb8b3b58a2cd21d7c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMTItMy0xLTEtMTM1MDU5_6742257a-287b-4aca-92f9-3599893f8593"
      unitRef="usd">123000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i492255c072c74c9f8a70fdd6212cfe65_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMTMtMS0xLTEtMTM1MDU5_c8186b42-96de-4c6d-8a64-2e65cbc35478"
      unitRef="usd">600000000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ie92cc5b201cf42e9a6a395bf77ad597c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjM3NmY4YzNkYmZiMTQ4NGZiOGMxZGIwZTdhNzk2ZjQwL3RhYmxlcmFuZ2U6Mzc2ZjhjM2RiZmIxNDg0ZmI4YzFkYjBlN2E3OTZmNDBfMTMtMy0xLTEtMTM1MDU5_e8fdc6fd-77eb-48b2-9a4f-25a04e1cd41a"
      unitRef="usd">600000000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i46e9161a43a44a2fa59e52960034468a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMzYwNQ_37b61bd6-0fe6-42cb-b27c-7f980b54667a"
      unitRef="usd">250000000</us-gaap:AmortizationOfIntangibleAssets>
    <mrk:ProbableContingentPaymentsCollaborativeArrangement
      contextRef="i00731f51ddd64c099bf1f3a866d6e0ff_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTY0OTI2NzQ2MDA4Nw_b29673ef-c363-4cab-8a66-34060a0c9421"
      unitRef="usd">125000000</mrk:ProbableContingentPaymentsCollaborativeArrangement>
    <us-gaap:Liabilities
      contextRef="ia8a01e007c934b3285178dc642a890ea_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTY0OTI2NzQ2MDEwMQ_e986925c-8b1f-43b7-b251-90b33e20d1b3"
      unitRef="usd">125000000</us-gaap:Liabilities>
    <us-gaap:AdjustmentForAmortization
      contextRef="ibcf5abe1e04c438f81048ecae5f02ed4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTY0OTI2NzQ2MDI2MQ_00156a08-5ef2-4cba-8d1f-d66362e0fc04"
      unitRef="usd">72000000</us-gaap:AdjustmentForAmortization>
    <mrk:MilestonePaymentsSalesBased
      contextRef="i364cafd01c114c558bf6c571df9b34b1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfNTI1Ng_013770cb-4688-4be6-868d-9d2308d196ff"
      unitRef="usd">600000000</mrk:MilestonePaymentsSalesBased>
    <mrk:MilestonePaymentsSalesBased
      contextRef="i2d145059533c4960b5fc110813a1fdbf_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMzg0ODI5MDcxNjExMA_41529f8d-a1b5-4d86-850a-3113422a1d37"
      unitRef="usd">300000000</mrk:MilestonePaymentsSalesBased>
    <mrk:PotentialFutureMilestonePaymentsSalesBased
      contextRef="ief58ac433ad9415a802f0001cc903fa8_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfNTMxMQ_07a0f1e3-df84-4466-b4a2-795fe78eb01e"
      unitRef="usd">2400000000</mrk:PotentialFutureMilestonePaymentsSalesBased>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i364cafd01c114c558bf6c571df9b34b1_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfNTUyMg_24f3de46-2e58-4eca-90c0-8a6a4db624ba"
      unitRef="usd">50000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <mrk:MilestonePaymentsMadetoCollaborativePartner
      contextRef="i2d145059533c4960b5fc110813a1fdbf_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMzg0ODI5MDcxNjEyNA_1f0e6b02-7acf-4fff-aafc-0b0fe0d4499f"
      unitRef="usd">25000000</mrk:MilestonePaymentsMadetoCollaborativePartner>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ifde6e88a8c324b84b8e1ac90ed088a69_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfNTc0Nw_aadc8296-443e-45d9-abc8-4b055cf6fc05"
      unitRef="usd">812000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i4e956d6285d1456abb720e32551e7288_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfMi0xLTEtMS0xMzE2MTg_5704adaf-06bf-4c77-a032-5b6148ea4449"
      unitRef="usd">232000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i3779054dfc7a4a51b4e90d43a5ac3684_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfMi0zLTEtMS0xMzE2MTg_b4106292-b8b0-40bc-bbc4-9ca2f8ca4b31"
      unitRef="usd">227000000</mrk:CollaborativeArrangementProfitSharing>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib7eff0028e2f4952bfe2bb459510ff9f_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfNC0xLTEtMS0xMzE2MTg_4fba7867-22c0-4102-9fb4-22bb6a55f2f5"
      unitRef="usd">126000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia56fd7048ad14abf96162c372b142909_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfNC0zLTEtMS0xMzE2MTg_c1927729-3453-42d1-b7b2-1c0d658d7e49"
      unitRef="usd">53000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iace54ff30d73465189a461975d7b6b99_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfNS0xLTEtMS0xMzE2MTg_cf0131c2-2434-4c9f-b1d1-9bb902dce42f"
      unitRef="usd">51000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if1e72c11f4d449889cefb13617918cd0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfNS0zLTEtMS0xMzE2MTg_b3620da4-3001-4e38-add8-957229556c9a"
      unitRef="usd">31000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4d825d4c2aa44c79bf5a2366a7a86a9b_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfNi0xLTEtMS0xMzE2MTg_1d608a63-360d-4e67-baf3-36d2d5ac8709"
      unitRef="usd">39000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie6c9458bb97f476b867db620d779e5fb_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfNi0zLTEtMS0xMzE2MTg_8f2be031-2a7b-4b31-9087-eadee4437a0a"
      unitRef="usd">57000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ie01022120e7d4f7cb61fb037b2355db5_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfOS0xLTEtMS0xMzUwNzI_ebf8203c-9b93-4f0c-b124-e3c4d8cb08f0"
      unitRef="usd">244000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="if29e83faad31423b801afdcfcba98e44_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfOS0zLTEtMS0xMzUwNzI_efd8494d-cbee-4cb1-969e-2786013d9dc2"
      unitRef="usd">214000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8a73485be36248258f5601b826d7bfed_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfMTAtMS0xLTEtMTM1MDcy_63caf6e9-fbe8-4a2f-8936-3ed71bc08231"
      unitRef="usd">125000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6d20b318541f4dd2831d35fd11a17b0f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmU5ZWYzYmQ5NWM2ZTRmMTZhMWE1OTRiNmI0ZTZiYzIwL3RhYmxlcmFuZ2U6ZTllZjNiZDk1YzZlNGYxNmExYTU5NGI2YjRlNmJjMjBfMTAtMy0xLTEtMTM1MDcy_950c665c-6fe0-497f-a721-2429be7cbc57"
      unitRef="usd">0</us-gaap:LiabilitiesCurrent>
    <us-gaap:AdjustmentForAmortization
      contextRef="ibcf5abe1e04c438f81048ecae5f02ed4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTY0OTI2NzQ2MDUyOA_605e6f9f-ddab-4fd3-a609-fb8f81ecce5a"
      unitRef="usd">72000000</us-gaap:AdjustmentForAmortization>
    <mrk:MilestonePaymentsSalesBased
      contextRef="i3399af7b61814371b4415a2165606deb_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfNzUwMQ_86568ae3-2a89-4b8f-a220-fe9f79af8dca"
      unitRef="usd">400000000</mrk:MilestonePaymentsSalesBased>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i80a8ac9e73b64ff18bab741a42d8fdcd_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfNzg3MA_431359ce-6d67-4076-8b06-01b44e89df07"
      unitRef="usd">613000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i260c8037bbf543e0aa66e359ab18b50f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfNzg3Nw_dbb0fcf2-9914-4459-9f9e-0c340834576d"
      unitRef="usd">56000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="i9ea6ddc3ada9445c95b033d7e07dd561_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfMi0xLTEtMS0xMzE2MTg_bee6db62-be92-422b-8426-ff8cac6972d4"
      unitRef="usd">99000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementProfitSharing
      contextRef="idaa0511b79e949c7a6547505b9ae5551_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfMi0zLTEtMS0xMzE2MTg_3861b94a-aa37-4fff-b524-d2f4bb8521a0"
      unitRef="usd">72000000</mrk:CollaborativeArrangementProfitSharing>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="i8e52ba3989df4480ab8a8c4136af64aa_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfMy0xLTEtMS0xMzE2MTg_fc0d7477-fe6b-4792-8abc-07b33daafeba"
      unitRef="usd">59000000</mrk:CollaborativeArrangementSalesNet>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="i68f851c07e23480aa9ff233e42d37d7a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfMy0zLTEtMS0xMzE2MTg_ff653039-52c5-4302-8654-7717b393fbb9"
      unitRef="usd">61000000</mrk:CollaborativeArrangementSalesNet>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="i6191c4207cdc459d90d7c79d3e4e64e5_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfNC0xLTEtMS0xMzE2MTg_04da46d6-2120-41d1-b059-ca09e33c2341"
      unitRef="usd">7000000</mrk:CollaborativeArrangementSalesNet>
    <mrk:CollaborativeArrangementSalesNet
      contextRef="icbe1869e706149f48a2091f4b9534dd9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfNC0zLTEtMS0xMzE2MTg_084b60d3-b978-487a-bf1b-40c2143d9508"
      unitRef="usd">3000000</mrk:CollaborativeArrangementSalesNet>
    <us-gaap:Revenues
      contextRef="i9ea6ddc3ada9445c95b033d7e07dd561_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfNS0xLTEtMS0xMzE2MTg_cf129a58-23ac-4ee9-8614-df5b63a53506"
      unitRef="usd">165000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idaa0511b79e949c7a6547505b9ae5551_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfNS0zLTEtMS0xMzE2MTg_f9d25f4a-8836-467d-bf76-1dcf058258bb"
      unitRef="usd">136000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5ef0c87d5feb45e381dc0a07c2d16382_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfNy0xLTEtMS0xMzE2MTg_6c504c59-edb6-429f-b395-4b500f6e9560"
      unitRef="usd">57000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i63cb28ee8d6845b3bc89ee74ee01ff67_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfNy0zLTEtMS0xMzE2MTg_ae266853-f516-4de1-9bbc-b7946cdd4760"
      unitRef="usd">50000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i58e10bfa620942c4bcb811e0f171d36b_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfOC0xLTEtMS0xMzE2MTg_48b431af-91b6-46c3-8b7f-926ced1a0cad"
      unitRef="usd">33000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i7e3019b3c61c4b70a15610624c8a4983_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfOC0zLTEtMS0xMzE2MTg_6f5cd3da-684a-434e-b53f-d0f2c213d7a3"
      unitRef="usd">23000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i650127b972c04c1cbed3bec6d5fdfa9b_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfOS0xLTEtMS0xMzE2MTg_3e26c119-276d-40f4-9a44-b046efc7a254"
      unitRef="usd">25000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib2ae3db4c9364ff8843c87c364bab42b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfOS0zLTEtMS0xMzE2MTg_09db9b21-8a8b-4c8d-810e-1d2f92316943"
      unitRef="usd">17000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i9056f175eca54119943d05559433e20d_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfMTEtMS0xLTEtMTM1MDkw_565df713-1d25-4420-b05c-4af6f3a39e85"
      unitRef="usd">142000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ib66da4be09b7447ab23b1c1811b5724d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfMTEtMy0xLTEtMTM1MDkw_6de8499f-c9bf-4d75-b520-7100e5db6bba"
      unitRef="usd">143000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i36c8f57b20ce4f26a522df11b2be6320_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfMTItMS0xLTEtMTM1MDkw_5d84ed63-e6e7-4fba-b06a-66279c3afc44"
      unitRef="usd">68000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i644d973253b54d3e94a4aa3644bbe995_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOjgxMjI5MmRkMWY0NjQ5ZTc4ODZjMDM2YzdmMjc1NGNhL3RhYmxlcmFuZ2U6ODEyMjkyZGQxZjQ2NDllNzg4NmMwMzZjN2YyNzU0Y2FfMTItMy0xLTEtMTM1MDkw_e27df872-02ba-4cda-98e5-10f393e99d9c"
      unitRef="usd">80000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:Revenues
      contextRef="ie2a085dfeaeb40a083f13e8a59287e8c_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfMi0xLTEtMS0xMzE2MTg_67a5aab8-5077-4e5f-88fa-025487baace4"
      unitRef="usd">392000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5173a42466784ad9a8ffe86302cb3b87_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfMi0zLTEtMS0xMzE2MTg_9056897f-e7c4-4892-a7a1-facb86398168"
      unitRef="usd">3247000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iebdfd787169843bcaba790e915fc305b_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfNC0xLTEtMS0xMzE2MTg_2473cf88-0755-486e-9e2b-48342ce2077f"
      unitRef="usd">221000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ifd3bb7ee67904313b2975cfef294c50b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfNC0zLTEtMS0xMzE2MTg_1bec1812-312a-4d69-8255-c92dc59a04aa"
      unitRef="usd">1726000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ice904109d2ef48fd8e8ed1324f5c2c59_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfNS0xLTEtMS0xMzE2MTg_22b3e4c4-e28a-478a-9fca-aafba988135a"
      unitRef="usd">27000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic51d50d985d84a3f8f588fda28be3ce3_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfNS0zLTEtMS0xMzE2MTg_9862c8c0-3a0e-4e86-905a-e6006d1189a5"
      unitRef="usd">35000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i25207351676d4c9e9e6961bf25936afd_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfNi0xLTEtMS0xMzE2MTg_425e7ca2-e1d0-4e0f-b08b-a454303317c5"
      unitRef="usd">16000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4d5dff37e3ab4823ab8be6c8611cc6d4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfNi0zLTEtMS0xMzE2MTg_c5a0a898-96ee-4e25-a5e2-4cec541e804d"
      unitRef="usd">25000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2404a6eca015453d8c2bb0e08613ae7b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfOS0xLTEtMS0xMzUxMjE_8e2b2622-60c6-4834-8027-b1eece7661b2"
      unitRef="usd">191000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iec1c506714374a9baa8471e96e643d5b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RhYmxlOmRkOGU5MzU2N2QwNTQwNjI5Y2ZjMTc4OTVjYTZiMmYyL3RhYmxlcmFuZ2U6ZGQ4ZTkzNTY3ZDA1NDA2MjljZmMxNzg5NWNhNmIyZjJfOS0zLTEtMS0xMzUxMjE_100467b4-2fdd-4b1d-a49b-643cf66bcef9"
      unitRef="usd">348000000</us-gaap:LiabilitiesCurrent>
    <mrk:RoyaltyRatePercentage
      contextRef="idc4d047e87e6460984a1241620741fc2_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTEwMDQ_fe59036a-22cd-47d6-bd25-cbf115e3d0d3"
      unitRef="number">0.20</mrk:RoyaltyRatePercentage>
    <mrk:RoyaltyRatePercentage
      contextRef="i386e5b3e2b1d4771ae602c8544c7de85_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTEwNjc_1ca41360-8f30-4a1d-b874-e65cdef8801a"
      unitRef="number">0.24</mrk:RoyaltyRatePercentage>
    <mrk:RoyaltyRateDeductionPercentage
      contextRef="i402d58f25e9e45a68055eb38b7d1d4ab_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTExMjU_b2a05f76-a071-45be-b934-0a18a3078515"
      unitRef="number">0.50</mrk:RoyaltyRateDeductionPercentage>
    <mrk:ContingentProceedsCollaborativeArrangement
      contextRef="i0175444d0549416fb305c38749b41b24_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTEzMzM_fd6c5905-a32e-468d-a322-c8beec1f7a47"
      unitRef="usd">80000000</mrk:ContingentProceedsCollaborativeArrangement>
    <us-gaap:Revenues
      contextRef="i245cacaf455e42329f9ae587d1a10cad_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTEzNzI_5ac0347c-c6aa-4452-b4ea-1238bcadc98f"
      unitRef="usd">43000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2dba74425a51433497fa7e5529627e25_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfNTQ5NzU1ODMxOTE4_d2de489b-6e5b-416d-916d-149a5274be6e"
      unitRef="usd">52000000</us-gaap:Revenues>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="i9cff7fdd9228489e9a08ae8b3a149a6e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTE1Njk_4e146289-a74f-4594-9d6c-f3e1f5079f44"
      unitRef="usd">32000000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:ProceedsFromCollaborators
      contextRef="id17be879320f41af82dedebba088c13f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180My9mcmFnOmQ2MjIzMGNhMDI1OTQ2MGJhODAyNDk2NGIwOThmNWQ3L3RleHRyZWdpb246ZDYyMjMwY2EwMjU5NDYwYmE4MDI0OTY0YjA5OGY1ZDdfMTE2NDI_052a299e-edac-420a-a3f3-f166108216fd"
      unitRef="usd">20000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfNDg0MQ_b5a23f81-a507-423d-8706-1fcfa30e2f3b">Spin-Off of Organon &amp;amp; Co. &lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On June 2, 2021, Merck completed the spin-off of Organon through a distribution of Organon&#x2019;s publicly traded stock to Company shareholders. In connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck is providing Organon various services and, similarly, Organon is providing Merck various services. The provision of services under the TSA generally will terminate within 25 months following the spin-off; however, the provision of certain services has been extended to 35 months. Merck and Organon also entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck is continuing to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon. Under such interim operating agreements and in accordance with the separation and distribution agreement, Merck is continuing operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck is (a) manufacturing and supplying certain active pharmaceutical ingredients for Organon, (b) manufacturing and supplying certain formulated pharmaceutical products for Organon, and (c) packaging and labeling certain finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon is (a) manufacturing and supplying certain formulated pharmaceutical products for Merck, and (b) packaging and labeling certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The amounts included in the condensed consolidated statement of income for the above MSAs include sales of $94&#160;million and $99&#160;million and related cost of sales of $107&#160;million and $105&#160;million for the first quarter of 2023 and 2022, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;respectively. Amounts included in the condensed consolidated statement of income for the TSAs were immaterial for both the first quarter of 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The amounts due from Organon under all of the above agreements were $473&#160;million and $511&#160;million at March&#160;31, 2023 and December&#160;31, 2022, respectively, and are reflected in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. The amounts due to Organon under these agreements were $229&#160;million and $345&#160;million at March&#160;31, 2023 and December&#160;31, 2022, respectively, and are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal
      contextRef="ie3d1e57b1dd24ae193bd71c6385b8769_D20210602-20210602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMTUxMg_aac2e37f-a343-4c72-afc8-bb397287c7f9">P25M</us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal>
    <us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal
      contextRef="if4eb1aad4f8349af99fa7c51391e5966_D20210602-20210602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMTYwMw_5b6e89e7-82a9-411c-8518-8e624a6d6d2a">P35M</us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal>
    <us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal
      contextRef="ie7ee924f05bc48c787f3fd1d8f6303b6_D20210602-20210602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMjk1NQ_90e85114-8b2b-4494-832f-45932804432f">P4Y</us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal>
    <us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal
      contextRef="i1fd80dbdbfb341a2a9372748079c59e5_D20210602-20210602"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMjk2MQ_563a61c3-4bc3-44ac-8272-fbe62a6349d7">P10Y</us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal>
    <us-gaap:RevenueFromRelatedParties
      contextRef="iad59a4cb91a64620bac9b9c19d9f7cc5_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMzA3Mw_2a79e7ae-c051-4dc9-bca1-d38df893f1c2"
      unitRef="usd">94000000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i185eb227b4104468b3c29dc49352d43a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMzA4MA_e17d3db0-edd5-42cd-8f6b-33c990b5c880"
      unitRef="usd">99000000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RelatedPartiesAmountInCostOfSales
      contextRef="iad59a4cb91a64620bac9b9c19d9f7cc5_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMzExMg_eba6c3e0-d041-4cec-a37f-9e2acdd983c6"
      unitRef="usd">107000000</us-gaap:RelatedPartiesAmountInCostOfSales>
    <us-gaap:RelatedPartiesAmountInCostOfSales
      contextRef="i185eb227b4104468b3c29dc49352d43a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMzExOQ_163f4501-f901-4427-8ea4-8ac3494dea99"
      unitRef="usd">105000000</us-gaap:RelatedPartiesAmountInCostOfSales>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="i60b11c4ee8724493ae377bee597f7db8_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMzQ5Mg_08229b35-c1d3-42ba-a466-5d781af56091"
      unitRef="usd">473000000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="i834db89c47b44369b713641fdff58447_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMzQ5OQ_b4666865-911d-4add-a4f4-c28e32c9af6a"
      unitRef="usd">511000000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i60b11c4ee8724493ae377bee597f7db8_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMzYyOA_7467b4b9-7bd7-4b1a-8d8e-eead26f7c4a3"
      unitRef="usd">229000000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i834db89c47b44369b713641fdff58447_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY18zNC9mcmFnOjEyZmQ1ZDZiYWViNjQxN2M4ZDE1ZjY5ZGI5ZjJkYmZmL3RleHRyZWdpb246MTJmZDVkNmJhZWI2NDE3YzhkMTVmNjlkYjlmMmRiZmZfMzYzNQ_5dcf5beb-98d1-48cd-a595-cb00c82453e4"
      unitRef="usd">345000000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfMzM1MQ_1e02db7c-e14c-4516-9136-6df3038e5a2b">Restructuring&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In 2019, Merck&#160;approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on optimizing the Company&#x2019;s manufacturing and supply network, as well as reducing its global real estate footprint.&#160;The actions contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.7 billion. The Company estimates that approximately 70% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 30% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company recorded total pretax costs of $97 million and $127 million in the first quarter of 2023 and 2022, respectively, related to restructuring program activities. Since inception of the Restructuring Program through March&#160;31, 2023, Merck has recorded total pretax accumulated costs of approximately $3.4 billion. For the full year of 2023, the Company expects to record charges of approximately $400 million related to the Restructuring Program. For segment reporting, restructuring charges are unallocated expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following tables summarize the charges related to restructuring program activities by type of cost:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Separation costs are associated with actual headcount reductions, as well as involuntary headcount reductions which were probable and could be reasonably estimated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the program. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other activity in 2023 and 2022 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note&#160;10) and share-based compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges and spending relating to restructuring program activities for the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring reserves January&#160;1, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Payments) receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-cash activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring reserves March&#160;31, 2023 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)The remaining cash outlays are expected to be largely completed by the end of 2025.</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfNjE5_d1022dea-a367-4f63-a2e1-45a406210bbf"
      unitRef="usd">3700000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfNjY0_a746e296-63ef-4ebb-a029-d7bf219d8394"
      unitRef="number">0.70</mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays>
    <mrk:EstimateOfCumulativePreTaxCostsThatWillBeNoncash
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfODIw_27019124-db5f-4dec-ac7b-54c7f3a8de7d"
      unitRef="number">0.30</mrk:EstimateOfCumulativePreTaxCostsThatWillBeNoncash>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfMTAwNw_ee23e170-d0db-4e22-822b-21f8988ead88"
      unitRef="usd">97000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfMTAxNA_4f021e93-9e6d-4db2-90ee-ad854f55aa0c"
      unitRef="usd">127000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfMTMwMg_293ebde1-b892-4487-bc89-ef8ee5a5f249"
      unitRef="usd">3400000000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i7966ec436ac148489c841a585ea76477_I20231231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfMTM4Ng_4a45ee3e-51e4-4d53-925c-07198671e920"
      unitRef="usd">400000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfMzM0OQ_1c377b1c-7694-47ec-b7eb-7632e83f3320">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following tables summarize the charges related to restructuring program activities by type of cost:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i870f46cf31cd4dd99b24227fb3adf06f_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfMi0xLTEtMS0xMzE2MTg_4a251308-c167-4b29-8fe8-461fe78e61d2"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ibde26f5431b54da79586ebd96e74a36d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfMi0zLTEtMS0xMzE2MTg_2395dd4d-2ce0-4681-ab97-a60a91c5dde1"
      unitRef="usd">21000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="id6616b6afece4195a3a8c81945ca5296_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfMi01LTEtMS0xMzE2MTg_5058d124-6a72-400d-bf95-6bd11f4c00f0"
      unitRef="usd">8000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i111e37e345c242418c65ff71f8df4aa4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfMi03LTEtMS0xMzE2MTg_6a6305bb-f574-432d-9882-271d7725a466"
      unitRef="usd">29000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ia85fb7ebe86e48688eaa6cca6140b251_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfMy0xLTEtMS0xMzE2MTg_9fcfdf77-13da-4ca1-9584-5457e8cc0332"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ia7968694bdd844dcb91cdee1fa81b0c2_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfMy0zLTEtMS0xMzE2MTg_95bafa5e-a430-4fc6-a802-0aec5c5e0220"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i7c124834ee87435999488308f1f35177_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfMy01LTEtMS0xMzE2MTg_cf7ae6ce-c484-4b9e-827a-0e7cae20ab92"
      unitRef="usd">1000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ie333238530bd43c2ac7bdbedf60929b5_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfMy03LTEtMS0xMzE2MTg_b812dee7-97fb-4b7b-a2de-bf71eef6a619"
      unitRef="usd">1000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i39ffed41bf6448378d17f953bc0cc54b_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfNS0xLTEtMS0xMzE2MTg_f4d7d166-18e4-495a-91bf-55603ee2b242"
      unitRef="usd">41000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="if8831ff53ddb4e9384dd1c730f73c0d1_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfNS0zLTEtMS0xMzE2MTg_1f26925d-456a-4f98-aa2f-e6ebf1183f50"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i92816509cf8240d2ab4f3e2c2a61c6b0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfNS01LTEtMS0xMzE2MTg_cda6bde9-3780-4b1b-b0fd-e5b59e22bdb2"
      unitRef="usd">26000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="idfa73697ee0a454c9ad0fdef7eff7f65_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfNS03LTEtMS0xMzE2MTg_c65a8966-412b-4ac1-a612-a0d2ad49edf7"
      unitRef="usd">67000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i4d8c3e3d493941b186866861d3cad3af_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfNi0xLTEtMS0xMzE2MTg_d7b785a0-0061-4ad0-ab49-4f6146b6d364"
      unitRef="usd">41000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iaaa6e70cf90547429286cee866cabd66_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfNi0zLTEtMS0xMzE2MTg_09de9cbc-62dc-4b24-ab8e-f701f3170f0e"
      unitRef="usd">21000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ifef7767f302e4418af53b34093c57a9d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfNi01LTEtMS0xMzE2MTg_a76f26cb-16ee-4657-8a77-527132e0f727"
      unitRef="usd">35000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjBkNDY4ZjQ5ZTlhZjQyY2FhZWQyYzNkMGVhMzU1NDE4L3RhYmxlcmFuZ2U6MGQ0NjhmNDllOWFmNDJjYWFlZDJjM2QwZWEzNTU0MThfNi03LTEtMS0xMzE2MTg_a4187f63-7784-418f-b73b-d6c01aceee92"
      unitRef="usd">97000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i620edf85a16d4e4880ceb84b22f3cfab_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfMi0xLTEtMS0xMzE2MTg_e8b87523-455b-46f9-a71b-5290e11305b9"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i3bc8fc361d904fbeb6492f5e521452f8_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfMi0zLTEtMS0xMzE2MTg_86a9681c-7543-4563-9066-7b8d8cb54fda"
      unitRef="usd">18000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i0bf782824e144ac698d3c52441494fa9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfMi01LTEtMS0xMzE2MTg_80941371-5ecc-48c2-9ee8-8f64bb3bb234"
      unitRef="usd">28000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ie23cb3149ce14b15a9a4f74c76232a80_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfMi03LTEtMS0xMzE2MTg_2d205baf-6619-4a8e-af1f-ce78a6c45bd9"
      unitRef="usd">46000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="idb61832d74f44b15bb6f7e1e80aefe10_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfMy0xLTEtMS0xMzE2MTg_17e107e1-c573-4a67-8ae9-2f6a7c73e660"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ibd263f21d9824f4d88448a933573382e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfMy0zLTEtMS0xMzE2MTg_0f04cb32-1412-4388-b8d7-bba5c07a66f1"
      unitRef="usd">4000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i7916bd167a5949cf9496c5497260c4da_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfMy01LTEtMS0xMzE2MTg_7f77a7c6-0af0-47ba-ba71-6aa4d5af4c58"
      unitRef="usd">17000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i59bdd8e429324f6985da2aa4f9cee50f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfMy03LTEtMS0xMzE2MTg_c5d89087-b149-4fbe-abd7-5330cf2f779d"
      unitRef="usd">21000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ia26db14d5dfb4db6936c0133c122c21a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNC0xLTEtMS0xMzE2MTg_4ffb78c2-848a-4cf4-bb72-e298d67c4b5b"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ifb9eb1916f044d189f47e32c6cf11a65_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNC0zLTEtMS0xMzE2MTg_5eb49cf0-334b-4d55-9a0b-18d41ccb05fc"
      unitRef="usd">7000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i6bd41c6996df44f5ad0c156034845a9e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNC01LTEtMS0xMzE2MTg_3f35dc14-b85b-4a50-b77a-de2cf96c2640"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i45f7c7de6a3b4eb69f814c83aa49e79c_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNC03LTEtMS0xMzE2MTg_608d6eac-f46b-40b3-87dc-ab7e1e82771f"
      unitRef="usd">7000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i2f8fc3f059d944d8ad12e7fed7bcc36b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNS0xLTEtMS0xMzE2MTg_1ede5b46-b774-4818-9522-c5ced7592c03"
      unitRef="usd">26000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i53768e8ff51d41dabfcdf8423e6ee2fa_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNS0zLTEtMS0xMzE2MTg_0ed644ee-6e32-41c4-8e46-a9257c65a89e"
      unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i46e4f372c2f54684954722f000f9b4fb_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNS01LTEtMS0xMzE2MTg_7247cabc-464b-4aa8-889b-9656841bdd4b"
      unitRef="usd">27000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i72738ef779d443e9ae3f451aa08e9bd5_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNS03LTEtMS0xMzE2MTg_f499b2ed-5ee4-4cc3-8a45-7d4cd376e50f"
      unitRef="usd">53000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i1dbe9c123ccc49ce80d7ee4225c7c4d8_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNi0xLTEtMS0xMzE2MTg_5adb07b1-ca85-41e7-9ec6-5d4dcf4e1046"
      unitRef="usd">26000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i09b391351ac84dc89ccba17bcc925ec9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNi0zLTEtMS0xMzE2MTg_c8c01545-83a4-4345-9eec-e8d2c2d51064"
      unitRef="usd">29000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i80771ba562bd4e098155333659c919c8_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNi01LTEtMS0xMzE2MTg_143e66b4-e4e5-4ff0-8031-5d716e770f8c"
      unitRef="usd">72000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjc2OWFmOWM3N2E1YzRiYTM4YWY3NzdhYTYwZjAzMGZlL3RhYmxlcmFuZ2U6NzY5YWY5Yzc3YTVjNGJhMzhhZjc3N2FhNjBmMDMwZmVfNi03LTEtMS0xMzE2MTg_54b00390-2085-48c2-a043-6bffa0b72e98"
      unitRef="usd">127000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RleHRyZWdpb246MjM1ODE2MGVhZDIyNGZlZGE4OGQ3NjdjYzI0YTNmNmZfMzM0Nw_e70e3132-acf5-4b6d-b90b-d1e766b2fc0a">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges and spending relating to restructuring program activities for the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Separation&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accelerated&lt;br/&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring reserves January&#160;1, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Payments) receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-cash activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring reserves March&#160;31, 2023 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)The remaining cash outlays are expected to be largely completed by the end of 2025.</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i735d6ae1f2044389b4cd1ff056ef3646_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMS0xLTEtMS0xMzE2MTg_cb6cf49d-2d9e-4458-9517-cd2a0d9f9112"
      unitRef="usd">479000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i3cce1bf91c214333b3b50c15e3d7461c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMS0zLTEtMS0xMzE2MTg_8a0be797-80a0-43e0-ab29-a5e2e4625193"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i40da318aa247452bac9b3018762feece_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMS01LTEtMS0xMzE2MTg_aed67f0a-c975-4425-8315-95b55f90a0fd"
      unitRef="usd">34000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMS03LTEtMS0xMzE2MTg_6bba8055-6d8b-4be1-a927-501c0718a7de"
      unitRef="usd">513000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i4d8c3e3d493941b186866861d3cad3af_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMi0xLTEtMS0xMzE2MTg_75f61ce1-ef48-4355-9c4f-97acad05698a"
      unitRef="usd">41000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="iaaa6e70cf90547429286cee866cabd66_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMi0zLTEtMS0xMzE2MTg_ce85565c-61cb-4cc4-80fc-41a7a91eb2e6"
      unitRef="usd">21000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="ifef7767f302e4418af53b34093c57a9d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMi01LTEtMS0xMzE2MTg_456fd158-30b1-429d-bda9-ebc41e412fa3"
      unitRef="usd">35000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMi03LTEtMS0xMzE2MTg_beb15f2e-c1f2-4912-9b61-30d94be7957f"
      unitRef="usd">97000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:PaymentsForRestructuring
      contextRef="i4d8c3e3d493941b186866861d3cad3af_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMy0xLTEtMS0xMzE2MTg_7c7914b2-dbb7-4a5e-a3ee-c66511650972"
      unitRef="usd">47000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="iaaa6e70cf90547429286cee866cabd66_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMy0zLTEtMS0xMzE2MTg_6cd89a9c-30dc-4ee6-8511-f58b5d662548"
      unitRef="usd">0</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="ifef7767f302e4418af53b34093c57a9d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMy01LTEtMS0xMzE2MTg_dfea054e-6596-45ed-aa6b-d0f84b213ce5"
      unitRef="usd">27000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfMy03LTEtMS0xMzE2MTg_e8a98298-8bb1-4a74-8299-53cd6e086d99"
      unitRef="usd">74000000</us-gaap:PaymentsForRestructuring>
    <mrk:RestructuringReserveIncreaseDecreaseNoncashActivity
      contextRef="i4d8c3e3d493941b186866861d3cad3af_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfNC0xLTEtMS0xMzE2MTg_d389b604-ecda-4b40-a790-41625208270c"
      unitRef="usd">0</mrk:RestructuringReserveIncreaseDecreaseNoncashActivity>
    <mrk:RestructuringReserveIncreaseDecreaseNoncashActivity
      contextRef="iaaa6e70cf90547429286cee866cabd66_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfNC0zLTEtMS0xMzE2MTg_2106c809-de45-469e-aea6-d9be2af9ee2a"
      unitRef="usd">-21000000</mrk:RestructuringReserveIncreaseDecreaseNoncashActivity>
    <mrk:RestructuringReserveIncreaseDecreaseNoncashActivity
      contextRef="ifef7767f302e4418af53b34093c57a9d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfNC01LTEtMS0xMzE2MTg_b9e78c78-6d00-4744-a0cf-85258aeee6f5"
      unitRef="usd">-9000000</mrk:RestructuringReserveIncreaseDecreaseNoncashActivity>
    <mrk:RestructuringReserveIncreaseDecreaseNoncashActivity
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfNC03LTEtMS0xMzE2MTg_a9d10e8c-c90f-465f-8163-551d866b31ee"
      unitRef="usd">-30000000</mrk:RestructuringReserveIncreaseDecreaseNoncashActivity>
    <us-gaap:RestructuringReserve
      contextRef="i993831891ccf428592c3e2f850548d44_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfNS0xLTEtMS0xMzE2MTg_750a11c7-350e-4550-aa6b-db78757b1423"
      unitRef="usd">473000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ic5739c18be2b4077ac27f27ef7c6e9f6_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfNS0zLTEtMS0xMzE2MTg_2cad3c1e-f71e-4142-91db-0843db847afc"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ieb4e20bd4ba34d448a2f3a3397c0d521_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfNS01LTEtMS0xMzE2MTg_7bbf4e47-7616-47aa-a0a7-1f431d67b69f"
      unitRef="usd">33000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180Ni9mcmFnOjIzNTgxNjBlYWQyMjRmZWRhODhkNzY3Y2MyNGEzZjZmL3RhYmxlOjg2MzJjOWEyODIzNjRkMDM5NGVkZThmYTYyZDRlMTg0L3RhYmxlcmFuZ2U6ODYzMmM5YTI4MjM2NGQwMzk0ZWRlOGZhNjJkNGUxODRfNS03LTEtMS0xMzE2MTg_4f54125c-4ed5-4c8f-bc48-a02df57368fc"
      unitRef="usd">506000000</us-gaap:RestructuringReserve>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg5NTg_9664b5fd-2815-482e-ab6e-1acd36eab700">Financial Instruments&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Derivative Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A significant portion of the Company&#x2019;s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company&#x2019;s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts, and purchased collar options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCL)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and reclassified into &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; each period. The cash&#160;flows from both designated and non-designated contracts are reported as operating activities&#160;in the Condensed Consolidated Statement of&#160;Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. The Company also uses a balance sheet risk management program to mitigate the exposure of such assets and liabilities from the effects of volatility in foreign exchange. Merck principally utilizes forward exchange contracts to offset the effects of exchange in developed country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar, Australian dollar and Swiss franc. For exposures in developing country currencies, including the Chinese renminbi, the Company will enter into forward contracts to offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The forward contracts are not designated as hedges and are marked to market through &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than six months. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;and remain in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Foreign exchange risk is also managed through the use of foreign currency debt. The Company&#x2019;s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The effects of the Company&#x2019;s net investment hedges on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and the Consolidated Statement of Income are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amount of Pretax (Gain) Loss Recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; for Amounts Excluded from Effectiveness Testing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net Investment Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;No amounts were reclassified from AOCL into income related to the sale of a subsidiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Rate Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk. In March 2023, the Company entered into five forward starting swaps and in April 2023 entered into two additional forward starting swaps, each with a notional amount of $100&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair&#160;Value&#160;of&#160;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&#160;Dollar&lt;br/&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair&#160;Value&#160;of&#160;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&#160;Dollar&lt;br/&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0xLTEtMS0xMzE2MTg_cdf39073-c7a9-42f3-a873-70852c2d806a"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0xLTEtMS0xMzE2MTg_eaa07838-14e0-4387-8b95-9bb43c3d8ff8"&gt;Other Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xNDUxMzg_9df5cddc-66b1-4a33-8e29-a18d74bcc019"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xNDUxMzg_f3c8a52d-a48a-4e54-b19b-78f16a11f45d"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xMzE2MTg_408692a5-0d77-4a04-a36c-28872dc58415"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xMzE2MTg_4a4e35a6-2d31-4c12-be2f-2f5f0ad91a6c"&gt;Other current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0xLTEtMS0xMzE2MTg_81797372-b85c-4d09-ac25-516d3f440479"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0xLTEtMS0xMzE2MTg_ab1b0a2e-c0bf-439c-9322-21e04e73f4f5"&gt;Other Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xLTEtMS0xMzE2MTg_3132afe6-dbe8-4b79-81d1-621892c284e2"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xLTEtMS0xMzE2MTg_99d4d534-f137-4781-a93f-a2c418043a22"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xLTEtMS0xMzE2MTg_11e2508b-56af-4ce8-a9f2-c0ca375d810e"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xLTEtMS0xMzE2MTg_c087e16f-89b4-40c0-959b-f2b2cdd6e23c"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMS0xLTEtMTMxNjE4_05e962d8-08ac-4061-91f8-80526dc22b48"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMS0xLTEtMTMxNjE4_c1218d47-d091-44ba-967a-61df1ed0b192"&gt;Other current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMS0xLTEtMTQ1MTQy_1096f2ac-e5f3-4efe-9d17-7ead4689602e"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMS0xLTEtMTQ1MTQy_c4114de6-2d78-4e8c-8218-b4ecfaa65a61"&gt;Other Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMS0xLTEtMTMxNjE4_8e46edaf-73d3-4fb2-a39e-a898b16444e0"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMS0xLTEtMTMxNjE4_a38bf2e0-7e23-4be7-a57d-412372f2f6e0"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMS0xLTEtMTQ1MTQ3_0f134479-ab12-4419-8818-0dec3ce2d2eb"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMS0xLTEtMTQ1MTQ3_8586bfb3-f29a-42c6-a48d-599f102341da"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; below). The following table provides information on the Company&#x2019;s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross amounts recognized in the condensed consolidated balance sheet&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash collateral received/posted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net amounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Financial Statement Caption in which Effects of Fair Value or Cash Flow &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Hedges are Recorded&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(Gain) loss on fair value hedging relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impact of cash flow hedging relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amount of (loss) gain recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Increase in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; as a result of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amount of gain recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amount of loss recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest expense is a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amount of Derivative Pretax (Gain) Loss Recognized in Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income Statement Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;These derivative contracts serve as economic hedges of forecasted transactions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023, the Company estimates $71 million of pretax net unrealized losses on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. The amount ultimately reclassified to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Investments in Debt and Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Information on investments in debt and equity securities is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt and publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unrealized net gains of $338&#160;million were recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; in the first quarter of 2023 on equity securities still held at March&#160;31, 2023. Unrealized net losses of $225 million were recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; in the first quarter of 2022 on equity securities still held at March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023 and March&#160;31, 2022, the Company also had $942 million and $643 million, respectively, of equity investments without readily determinable fair values included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. During the first quarter&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;of 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; the Company recorded unrealized gains of $1 million and unrealized losses of $21&#160;million related to certain of these equity investments still held at March&#160;31, 2023. During the first quarter&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;of 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; the Company recorded unrealized gains of $14&#160;million related to certain of these investments still held at March&#160;31, 2022. Cumulative unrealized gains and cumulative unrealized losses based on observable price changes for investments in equity investments without readily determinable fair values still held at March&#160;31, 2023 were $287 million and $40 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023 and March&#160;31, 2022, the Company also had $725&#160;million and $1.2&#160;billion, respectively, recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; for equity securities held through ownership interests in investment funds. (Gains) losses recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; relating to these investment funds were $(132)&#160;million and $509&#160;million for the first quarter of 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level&#160;1 having the highest priority and Level 3 having the lowest: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Quoted prices (unadjusted) in active markets for identical assets or liabilities; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; -&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities measured at fair value on a recurring basis are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivative assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased currency options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivative liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Written currency options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#x2019;s own credit risk, the effects of which were not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023 and December&#160;31, 2022, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; included $8.8 billion and $11.3 billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value March 31 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Cost of sales, Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; expenses, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;. Includes cumulative translation adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023, $263 million of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at March&#160;31, 2023 includes $127 million recorded as a current liability for amounts expected to be paid within the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The payments of contingent consideration in both periods relate to the Sanofi Pasteur MSD liabilities described above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Some of the Company&#x2019;s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The estimated fair value of loans payable and long-term debt (including current portion) at March&#160;31, 2023, was $28.2 billion compared with a carrying value of $30.7 billion and at December&#160;31, 2022, was $26.7 billion compared with a carrying value of $30.7 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company&#x2019;s investment policy guidelines. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The majority of the Company&#x2019;s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers and retailers, hospitals and government agencies.&#160;The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.4 billion and $2.5 billion of accounts receivable as of March&#160;31, 2023 and December&#160;31, 2022, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. As of March&#160;31, 2023 and December&#160;31, 2022, the Company had collected $31&#160;million and $67&#160;million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and the related obligation to remit the cash within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. The Company remitted the cash to the financial institutions in April 2023 and January 2023, respectively. The net cash flows related to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;de minimis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company&#x2019;s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company&#x2019;s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $13 million and $66&#160;million at March&#160;31, 2023 and December&#160;31, 2022, respectively. The obligation to return such collateral is recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities&lt;/span&gt;. Cash collateral advanced by the Company to various counterparties was $19&#160;million at December&#160;31, 2022.</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:DerivativeAverageRemainingMaturity1
      contextRef="i7e6cc36740bb4d71a793d4cb817b4486_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTQ2Ng_fb4b5cd1-943b-4df2-8adc-e5a587e8e26a">P2Y</us-gaap:DerivativeAverageRemainingMaturity1>
    <us-gaap:DerivativeAverageRemainingMaturity1
      contextRef="i44fa00da50de4c2abe7a97b20631529f_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfNTA2Mg_45af942e-783a-4b0f-a194-91858dd76916">P6M</us-gaap:DerivativeAverageRemainingMaturity1>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg5NTE_4d780aad-70cf-4542-9884-2e315547e0ae">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The effects of the Company&#x2019;s net investment hedges on &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and the Consolidated Statement of Income are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amount of Pretax (Gain) Loss Recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; for Amounts Excluded from Effectiveness Testing&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net Investment Hedging Relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro-denominated notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;No amounts were reclassified from AOCL into income related to the sale of a subsidiary.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i3ade1a511bd04605a075fd4b05ec6eca_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjk2NGM0MDg0ODQ1ZjRjZjE4YWFiYzY1YzQ4NzZmN2FiL3RhYmxlcmFuZ2U6OTY0YzQwODQ4NDVmNGNmMThhYWJjNjVjNDg3NmY3YWJfNC0xLTEtMS0xMzE2MTg_cbaa9f8d-c1ed-4b35-a63c-f34c2ffc193e"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i54ec372484874e4680d7e4b7645c44f7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjk2NGM0MDg0ODQ1ZjRjZjE4YWFiYzY1YzQ4NzZmN2FiL3RhYmxlcmFuZ2U6OTY0YzQwODQ4NDVmNGNmMThhYWJjNjVjNDg3NmY3YWJfNC0zLTEtMS0xMzE2MTg_40ad9e37-c988-4b43-9d96-abfb9abcdd29"
      unitRef="usd">16000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i313438c53a3745f5a9c308e10580003d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjk2NGM0MDg0ODQ1ZjRjZjE4YWFiYzY1YzQ4NzZmN2FiL3RhYmxlcmFuZ2U6OTY0YzQwODQ4NDVmNGNmMThhYWJjNjVjNDg3NmY3YWJfNC05LTEtMS0xMzE2MTg_9ce8243e-127e-4228-87f7-58158488bd1c"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i13663e430fa9440c8b9b613386d03310_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjk2NGM0MDg0ODQ1ZjRjZjE4YWFiYzY1YzQ4NzZmN2FiL3RhYmxlcmFuZ2U6OTY0YzQwODQ4NDVmNGNmMThhYWJjNjVjNDg3NmY3YWJfNC0xMS0xLTEtMTMxNjE4_ec6b82a9-e19e-4dbd-9563-a1037ca3ae1a"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i3459fac4643e42e29a49394546d2d3b7_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjk2NGM0MDg0ODQ1ZjRjZjE4YWFiYzY1YzQ4NzZmN2FiL3RhYmxlcmFuZ2U6OTY0YzQwODQ4NDVmNGNmMThhYWJjNjVjNDg3NmY3YWJfNS0xLTEtMS0xMzE2MTg_cc87d1a8-cfb9-46d5-97f5-52ec34b8fe3f"
      unitRef="usd">-52000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ib9f85f59e99b4ea189c2a085734df397_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjk2NGM0MDg0ODQ1ZjRjZjE4YWFiYzY1YzQ4NzZmN2FiL3RhYmxlcmFuZ2U6OTY0YzQwODQ4NDVmNGNmMThhYWJjNjVjNDg3NmY3YWJfNS0zLTEtMS0xMzE2MTg_2fc0068c-85ec-47d2-8d5f-df4fe374df15"
      unitRef="usd">53000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i7c1922ae96df4166a7397fffeb3375e7_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjk2NGM0MDg0ODQ1ZjRjZjE4YWFiYzY1YzQ4NzZmN2FiL3RhYmxlcmFuZ2U6OTY0YzQwODQ4NDVmNGNmMThhYWJjNjVjNDg3NmY3YWJfNS05LTEtMS0xMzE2MTg_3517fea1-6c70-4dce-9a2a-f23ac47e017b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="i3b9f469b4df444f7b96723d7a5c8b223_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjk2NGM0MDg0ODQ1ZjRjZjE4YWFiYzY1YzQ4NzZmN2FiL3RhYmxlcmFuZ2U6OTY0YzQwODQ4NDVmNGNmMThhYWJjNjVjNDg3NmY3YWJfNS0xMS0xLTEtMTMxNjE4_64671865-e101-4ddf-b81a-0e1bf4ab1062"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfNTQ5NzU1ODM4OTQz_dde3febc-0da7-4b23-b7a6-41b04e76643b"
      unitRef="interest_rate_swap">5</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="i336c99147cdf41e191d86c13d2a751dc_I20230430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfNTQ5NzU1ODM5NDA2_34f70cf4-a002-438a-99ad-58ec8ffee05b"
      unitRef="interest_rate_swap">2</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i7029fd7c7a6f43aca68f42e012aec70b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfNTQ5NzU1ODM4OTQ3_23d8d92b-0d78-4b08-b738-32e64b745d3a"
      unitRef="usd">100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i95f9d19ca7854b0288a0454768961670_I20230430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfNTQ5NzU1ODM4OTQ3_4d8435be-b8d0-4716-812c-aaaecb689bc7"
      unitRef="usd">100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg5ODA_55be7146-6521-4eae-b448-5ea6359c9678">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.367%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair&#160;Value&#160;of&#160;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&#160;Dollar&lt;br/&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair&#160;Value&#160;of&#160;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&#160;Dollar&lt;br/&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0xLTEtMS0xMzE2MTg_cdf39073-c7a9-42f3-a873-70852c2d806a"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0xLTEtMS0xMzE2MTg_eaa07838-14e0-4387-8b95-9bb43c3d8ff8"&gt;Other Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xNDUxMzg_9df5cddc-66b1-4a33-8e29-a18d74bcc019"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xNDUxMzg_f3c8a52d-a48a-4e54-b19b-78f16a11f45d"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xMzE2MTg_408692a5-0d77-4a04-a36c-28872dc58415"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xLTEtMS0xMzE2MTg_4a4e35a6-2d31-4c12-be2f-2f5f0ad91a6c"&gt;Other current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0xLTEtMS0xMzE2MTg_81797372-b85c-4d09-ac25-516d3f440479"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0xLTEtMS0xMzE2MTg_ab1b0a2e-c0bf-439c-9322-21e04e73f4f5"&gt;Other Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xLTEtMS0xMzE2MTg_3132afe6-dbe8-4b79-81d1-621892c284e2"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xLTEtMS0xMzE2MTg_99d4d534-f137-4781-a93f-a2c418043a22"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xLTEtMS0xMzE2MTg_11e2508b-56af-4ce8-a9f2-c0ca375d810e"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xLTEtMS0xMzE2MTg_c087e16f-89b4-40c0-959b-f2b2cdd6e23c"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMS0xLTEtMTMxNjE4_05e962d8-08ac-4061-91f8-80526dc22b48"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMS0xLTEtMTMxNjE4_c1218d47-d091-44ba-967a-61df1ed0b192"&gt;Other current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMS0xLTEtMTQ1MTQy_1096f2ac-e5f3-4efe-9d17-7ead4689602e"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMS0xLTEtMTQ1MTQy_c4114de6-2d78-4e8c-8218-b4ecfaa65a61"&gt;Other Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMS0xLTEtMTMxNjE4_8e46edaf-73d3-4fb2-a39e-a898b16444e0"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMS0xLTEtMTMxNjE4_a38bf2e0-7e23-4be7-a57d-412372f2f6e0"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMS0xLTEtMTQ1MTQ3_0f134479-ab12-4419-8818-0dec3ce2d2eb"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMS0xLTEtMTQ1MTQ3_8586bfb3-f29a-42c6-a48d-599f102341da"&gt;Other Noncurrent Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeAssets
      contextRef="i548bda88a4fe4bd5bffaa38757444dad_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0yLTEtMS0xMzE2MTg_50a2c904-4c16-4a93-a288-3f287aca7d62"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i9bdddb9610a348a48e757c57cc1a2387_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC02LTEtMS0xMzE2MTg_21f0afa5-a11e-4f3a-a8ec-4a019f6f7a4a"
      unitRef="usd">300000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="ifbdf486ae9934cc9a2a5283fa0638116_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC04LTEtMS0xMzE2MTg_ed6c9da5-4ba0-433d-a263-18490c9bcb41"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic70cbdc57c9f458abe55135c7b061c1d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNC0xMi0xLTEtMTMxNjE4_f841f82a-303f-4d87-9bfa-d7225d0b9487"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i548bda88a4fe4bd5bffaa38757444dad_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS00LTEtMS0xNDMwOTA_18840083-892c-49b6-97a6-78494d07fcf1"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i425bb66138fc4a51933c6b6df28796a6_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS02LTEtMS0xNDMwOTA_a054f779-db89-4e8a-a1fb-b0d922f96892"
      unitRef="usd">200000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="ifbdf486ae9934cc9a2a5283fa0638116_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xMC0xLTEtMTQzMDkw_aecd975b-7bf3-4a61-9406-9fa9119e68a9"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i294f553218424e8cb257f3d9f97e01a5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xMi0xLTEtMTQzMDkw_2f1bf1e8-05c4-4a3b-9861-e52acced7935"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i6cd028c906f84a42bf0bf29e3a3a9fcb_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0yLTEtMS0xMzE2MTg_d2691c45-411b-4be9-beb2-e0575fe0ca39"
      unitRef="usd">104000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i6cd028c906f84a42bf0bf29e3a3a9fcb_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS02LTEtMS0xMzE2MTg_030715d4-bf1c-4933-a93c-0b3e414453cf"
      unitRef="usd">4253000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="ifaac2668425b4eb4bfaea2c9834fd061_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS04LTEtMS0xMzE2MTg_e54cbddf-083f-4d5c-80d1-029f586b1e27"
      unitRef="usd">220000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ifaac2668425b4eb4bfaea2c9834fd061_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNS0xMi0xLTEtMTMxNjE4_a3ed3c28-263d-47b9-9f44-a16216111c9b"
      unitRef="usd">4824000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i2e8fab7c6eb24761b65cc3256e0b926b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0yLTEtMS0xMzE2MTg_f313614b-040a-4301-b5ef-d66777afb721"
      unitRef="usd">32000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i2e8fab7c6eb24761b65cc3256e0b926b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi02LTEtMS0xMzE2MTg_e1124fa7-28bc-4cef-a7de-1f6c3cd58fd5"
      unitRef="usd">1756000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i03be4f41b99a4232bdc4d5da0449f285_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi04LTEtMS0xMzE2MTg_64e192d2-d430-4c23-8618-3c76ecc8443d"
      unitRef="usd">27000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i03be4f41b99a4232bdc4d5da0449f285_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNi0xMi0xLTEtMTMxNjE4_206c49a7-0bc2-4f0a-9a54-96169319ffd0"
      unitRef="usd">1609000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i50b43bd94e56461888fca904c9a7ca24_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy00LTEtMS0xMzE2MTg_a4054cbb-da6a-4acf-bf95-3fd6183ce447"
      unitRef="usd">116000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i50b43bd94e56461888fca904c9a7ca24_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy02LTEtMS0xMzE2MTg_b8d632d6-a636-4a97-96e5-e014436314c5"
      unitRef="usd">3444000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i143c9f2549384565bcdcfdd243771159_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xMC0xLTEtMTMxNjE4_381550ec-ae84-4a6b-8cfd-c04702f63f40"
      unitRef="usd">101000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i143c9f2549384565bcdcfdd243771159_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfNy0xMi0xLTEtMTMxNjE4_f7fca098-f954-48c9-825d-db0f82e20dd2"
      unitRef="usd">2691000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="icdf30ba2b8b34d4e8df46f5379e5e821_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC00LTEtMS0xMzE2MTg_89192b89-afdd-473c-b1cf-983403ceb15c"
      unitRef="usd">2000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="icdf30ba2b8b34d4e8df46f5379e5e821_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC02LTEtMS0xMzE2MTg_2e598751-aa1f-442a-b425-f16522b0c50d"
      unitRef="usd">120000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="ice27572fdfbf445cabdf5a62a7d76022_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xMC0xLTEtMTMxNjE4_9bf90ced-8fec-4c64-a19e-7a2f605efefb"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ice27572fdfbf445cabdf5a62a7d76022_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOC0xMi0xLTEtMTMxNjE4_0be777f1-a5a1-4ec6-b0e6-ff59c6feb14a"
      unitRef="usd">91000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i2a06f418da43474f9f2f260add8790b3_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOS0yLTEtMS0xMzE2MTg_3fcbf349-b567-4e91-9e0c-46dca51c752e"
      unitRef="usd">137000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i2a06f418da43474f9f2f260add8790b3_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOS00LTEtMS0xMzE2MTg_13a208cc-4199-49e3-b92a-1a853251cfc4"
      unitRef="usd">119000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i2a06f418da43474f9f2f260add8790b3_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOS02LTEtMS0xMzE2MTg_52a1ad54-6986-4218-b10f-59d3b60e3b46"
      unitRef="usd">10073000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="iaf11d32e52ad425f979acb12dcd9aaac_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOS04LTEtMS0xMzE2MTg_b1c7ea18-fbb7-409f-94b5-398c3c053779"
      unitRef="usd">247000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="iaf11d32e52ad425f979acb12dcd9aaac_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOS0xMC0xLTEtMTMxNjE4_75df709b-935a-457b-99ea-a5f3fd899fa0"
      unitRef="usd">102000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iaf11d32e52ad425f979acb12dcd9aaac_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfOS0xMi0xLTEtMTMxNjE4_57f78cee-525f-4109-937d-071952783e21"
      unitRef="usd">9215000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="iac10665025d84f23872225d16c92ffed_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMi0xLTEtMTMxNjE4_86edffdf-b6a2-486c-9ae5-f5354250882a"
      unitRef="usd">121000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iac10665025d84f23872225d16c92ffed_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtNi0xLTEtMTMxNjE4_bdb4b795-912c-47ef-8be2-7863d07933e0"
      unitRef="usd">9507000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i45afba88d4004605825fe82844d7a4a7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtOC0xLTEtMTMxNjE4_f84e4d3b-19a1-4620-bb3b-40a7a8d524e7"
      unitRef="usd">186000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i45afba88d4004605825fe82844d7a4a7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTEtMTItMS0xLTEzMTYxOA_53cdffa0-4b7f-44ba-8465-9f64f9646dd0"
      unitRef="usd">8540000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="iaf2336f30cc046a28a77fd6f2dc4b465_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMi0xLTEtMTQyNTQx_c6cc6fa1-1969-40df-8e42-6d42b9ed64f6"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iaf2336f30cc046a28a77fd6f2dc4b465_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtNi0xLTEtMTQyNTQx_4924fbff-1928-4a87-b397-2a7c30d530e8"
      unitRef="usd">65000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i5a23903b67354e33a6fc1a8676a4b984_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtOC0xLTEtMTQyNTQx_b5a47de5-1eb9-4d35-9f8b-0883412bec1d"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i5a23903b67354e33a6fc1a8676a4b984_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMTItMS0xLTE0MjU0MQ_7dedba2e-068c-4459-979a-8c3e8b365653"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="i3a542fc8b3854857bda9666e66bd056e_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItNC0xLTEtMTMxNjE4_69f37321-46fb-4389-8671-1136127008af"
      unitRef="usd">164000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i3a542fc8b3854857bda9666e66bd056e_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItNi0xLTEtMTMxNjE4_2d0806cb-1295-4aa7-afe1-c8c37686a706"
      unitRef="usd">10592000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="if4fad0e8da324f249b5dc3a9f01637f7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMTAtMS0xLTEzMTYxOA_db0536fb-8574-4554-9ed9-e5b96979e6ba"
      unitRef="usd">307000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if4fad0e8da324f249b5dc3a9f01637f7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTItMTItMS0xLTEzMTYxOA_42ac5322-fc22-404c-a467-b7c7904dd591"
      unitRef="usd">10926000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="ie091883aa8d84ebf868769397c540276_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtNC0xLTEtMTQzMTAy_3bf77e6b-3339-402e-9e91-11d304209122"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie091883aa8d84ebf868769397c540276_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtNi0xLTEtMTQzMTAy_db72235a-32cd-4983-ae11-0046a19a1efb"
      unitRef="usd">124000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeLiabilities
      contextRef="ib057b0780b1b420d824cb8350acd5ba2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMTAtMS0xLTE0MzEwMg_6046560d-992b-4a5c-b1c0-3461145925c1"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ib057b0780b1b420d824cb8350acd5ba2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTUtMTItMS0xLTE0MzEwMg_3b179ff9-c812-436d-a5f3-0207d0dc51a6"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="ibaadad87b63f48448ddf5360530646a9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMi0xLTEtMTMxNjE4_6e23a723-e2cf-4614-8922-054d5c03e151"
      unitRef="usd">122000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="ibaadad87b63f48448ddf5360530646a9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtNC0xLTEtMTMxNjE4_858d4e90-e122-45e9-96a3-ddc132677cbb"
      unitRef="usd">165000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ibaadad87b63f48448ddf5360530646a9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtNi0xLTEtMTMxNjE4_d97a9276-f9dc-4299-ae70-82b99dfdc920"
      unitRef="usd">20288000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i7161bc9f4ef34d54a1dd7e0b07640a30_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtOC0xLTEtMTMxNjE4_d4fdbe62-6fe6-441d-b156-8502179cdcab"
      unitRef="usd">186000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i7161bc9f4ef34d54a1dd7e0b07640a30_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMTAtMS0xLTEzMTYxOA_2b813906-7f95-44e1-a533-9c1abd8f82db"
      unitRef="usd">307000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i7161bc9f4ef34d54a1dd7e0b07640a30_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTMtMTItMS0xLTEzMTYxOA_ad1d41c9-5f8f-49f6-995f-714e54d2840b"
      unitRef="usd">19466000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTQtMi0xLTEtMTMxNjE4_abbde945-b8ad-48b0-96a9-7e26a2d3652a"
      unitRef="usd">259000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTQtNC0xLTEtMTMxNjE4_e1414130-a896-4356-b90b-9a7e2e94051c"
      unitRef="usd">284000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTQtNi0xLTEtMTMxNjE4_399a16b7-5043-49b0-a894-eedbc04640d0"
      unitRef="usd">30361000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTQtOC0xLTEtMTMxNjE4_439859eb-bd4a-42e8-a23b-1263f01c21ec"
      unitRef="usd">433000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTQtMTAtMS0xLTEzMTYxOA_e5fdafd1-8bd9-4b88-a121-14249c9e871b"
      unitRef="usd">409000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmM5ZWFhOGIxNTEyZTRlMDBhMGRiZTRhZDgzNzZlYWZjL3RhYmxlcmFuZ2U6YzllYWE4YjE1MTJlNGUwMGEwZGJlNGFkODM3NmVhZmNfMTQtMTItMS0xLTEzMTYxOA_8e014bfc-64c6-405b-98ea-4d2f6e4ba46b"
      unitRef="usd">28681000000</us-gaap:DerivativeNotionalAmount>
    <mrk:OffsettingAssetsAndLiabilitiesTableTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg5MDg_1489cfad-b0d8-4a6c-9617-0c63dbc04c06">The following table provides information on the Company&#x2019;s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.341%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross amounts recognized in the condensed consolidated balance sheet&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(220)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash collateral received/posted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net amounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</mrk:OffsettingAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DerivativeAssets
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfMi0xLTEtMS0xMzE2MTg_9df851ad-05b0-4cb7-a118-8dcd34af6bb4"
      unitRef="usd">259000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfMi0zLTEtMS0xMzE2MTg_cf885fb0-f77a-48e2-880a-2a3f2232ce2c"
      unitRef="usd">284000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfMi01LTEtMS0xMzE2MTg_95bfdd0c-fd01-44cc-8fcb-b7af0acbb9c5"
      unitRef="usd">433000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfMi03LTEtMS0xMzE2MTg_e20b1bd6-5591-426d-9d2b-c1668b77785f"
      unitRef="usd">409000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfMy0xLTEtMS0xMzE2MTg_7a18f736-2c52-4549-9689-4c27b80deaf8"
      unitRef="usd">148000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfMy0zLTEtMS0xMzE2MTg_968cd43a-1197-4975-b402-73bf4b0f752e"
      unitRef="usd">148000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfMy01LTEtMS0xMzE2MTg_51a1ca3b-19cb-4728-ab5e-1f686d3ff3f8"
      unitRef="usd">220000000</us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfMy03LTEtMS0xMzE2MTg_cbe65719-231a-479d-9d29-c7a436bcc183"
      unitRef="usd">220000000</us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfNC0xLTEtMS0xMzE2MTg_3d2e90e5-0268-4744-a79b-98331c0a1f59"
      unitRef="usd">13000000</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfNC0zLTEtMS0xMzE2MTg_70aa5d34-636f-47e9-9840-7ab920e6adc0"
      unitRef="usd">0</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfNC01LTEtMS0xMzE2MTg_34435864-a062-484c-a0b7-eecd4406f5be"
      unitRef="usd">66000000</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeCollateralRightToReclaimCash
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfNC03LTEtMS0xMzE2MTg_057b96d1-06dd-463a-86c5-b86d743050ce"
      unitRef="usd">19000000</us-gaap:DerivativeCollateralRightToReclaimCash>
    <us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfNS0xLTEtMS0xMzE2MTg_6ff7b00d-76fd-4681-b6d3-102be2e6e492"
      unitRef="usd">98000000</us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfNS0zLTEtMS0xMzE2MTg_1b470521-5647-4f2f-84c5-e0fe577a1026"
      unitRef="usd">136000000</us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfNS01LTEtMS0xMzE2MTg_6cd0b0ab-075c-440f-93aa-e969c056e979"
      unitRef="usd">147000000</us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmNhY2YxOWE1Mjk2NDRkN2NhNWU5MzRkN2Y4NDI2MDZjL3RhYmxlcmFuZ2U6Y2FjZjE5YTUyOTY0NGQ3Y2E1ZTkzNGQ3Zjg0MjYwNmNfNS03LTEtMS0xMzE2MTg_dcfc3945-172a-44ad-8388-083c6c353023"
      unitRef="usd">170000000</us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg5MDM_4c32dc9a-ed6a-4369-8e71-7d8b8f02e82b">&lt;div style="margin-top:4pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Financial Statement Caption in which Effects of Fair Value or Cash Flow &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Hedges are Recorded&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(Gain) loss on fair value hedging relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Hedged items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Impact of cash flow hedging relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amount of (loss) gain recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Increase in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; as a result of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; reclassifications&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Interest rate contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amount of gain recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amount of loss recognized in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;OCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; on derivatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest expense is a component of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:Revenues
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMy0xLTEtMS0xMzE2MTg_22a948dc-764f-4b1e-bd35-1d8c5714fc99"
      unitRef="usd">14487000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMy0zLTEtMS0xMzE2MTg_bce1380b-87c8-407a-9c79-f8ebd0e11ede"
      unitRef="usd">15901000000</us-gaap:Revenues>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMy01LTEtMS0xMzE2MTg_179cbe9b-cbaf-4611-ab53-9332ca253bc5"
      unitRef="usd">-89000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMy03LTEtMS0xMzE2MTg_1b228471-d719-454e-9351-e1fae4b738aa"
      unitRef="usd">-708000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMy05LTEtMS0xMzE2MTg_a155be89-531e-4713-8f68-5c9b4a90f298"
      unitRef="usd">-115000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMy0xMS0xLTEtMTMxNjE4_541f339b-0eed-442f-b7e5-fcb548e271b6"
      unitRef="usd">60000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i86b17d802f304918b52da353344f6ac4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfNi01LTEtMS0xMzE2MTg_e452a98b-c70d-41d7-a482-30f1838cc726"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="i028e5b27f0e04f339d7c2f519b8ae259_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfNi03LTEtMS0xMzE2MTg_16071167-afc5-4664-948f-741ee9249a4b"
      unitRef="usd">10000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i86b17d802f304918b52da353344f6ac4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfNy01LTEtMS0xMzE2MTg_c46d858e-ad70-4175-b211-ef3a8f53bfd4"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i028e5b27f0e04f339d7c2f519b8ae259_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfNy03LTEtMS0xMzE2MTg_d6ac96c8-7b59-42cf-a66c-7f0513662586"
      unitRef="usd">-4000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i3ade1a511bd04605a075fd4b05ec6eca_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTAtOS0xLTEtMTMxNjE4_c0b72b8a-70b7-4926-bcdb-721039df42d1"
      unitRef="usd">-66000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i54ec372484874e4680d7e4b7645c44f7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTAtMTEtMS0xLTEzMTYxOA_7f52f705-25fc-46fe-898a-a2416c811c71"
      unitRef="usd">148000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:Revenues
      contextRef="ib9ff469b241a4cd5972223863bfda226_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTEtMS0xLTEtMTMxNjE4_63ad98ab-1fb8-4feb-9763-9f0a72e303d1"
      unitRef="usd">101000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i96b677da60364882b5bc1b825a50fabe_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTEtMy0xLTEtMTMxNjE4_6d2194a2-cff0-4fee-a90b-a8f77910b7c3"
      unitRef="usd">67000000</us-gaap:Revenues>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i3ade1a511bd04605a075fd4b05ec6eca_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTEtOS0xLTEtMTMxNjE4_e526cf4a-d599-4614-981f-ed23c3e2c0d4"
      unitRef="usd">-101000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i54ec372484874e4680d7e4b7645c44f7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTEtMTEtMS0xLTEzMTYxOA_2804f17e-7256-4031-9d63-8fd5a771a8a9"
      unitRef="usd">-67000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i330867f88a774fb08f247e81d478866e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTMtNS0xLTEtMTMxNjE4_8bce689f-00d6-4a8e-96fe-978f0144a70e"
      unitRef="usd">1000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i8118cf7c392f4ea598bfcb18b7bbd4d2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTMtNy0xLTEtMTMxNjE4_229d3661-b791-403b-ace3-ae50abdbca42"
      unitRef="usd">1000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i330867f88a774fb08f247e81d478866e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTQtOS0xLTEtMTMxNjE4_44fcba0c-30ee-49d3-bb0d-76ea24a4d7f8"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="i8118cf7c392f4ea598bfcb18b7bbd4d2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjI0YWYxMmNlODBhNTQ4YTM5MDhmMDVlNWVhY2U4OTIyL3RhYmxlcmFuZ2U6MjRhZjEyY2U4MGE1NDhhMzkwOGYwNWU1ZWFjZTg5MjJfMTQtMTEtMS0xLTEzMTYxOA_8447855c-5ef4-45cb-a2d1-bc3296421787"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg5MTc_52cb4752-d5ed-47eb-9821-c6371bb02c13">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amount of Derivative Pretax (Gain) Loss Recognized in Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Income Statement Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;These derivative contracts serve as economic hedges of forecasted transactions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="if03eefb0e5be4080ba5289591b557e4d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjEyNmFmYjljZWYwZDQ3OGE5NDk5YTRkNjVmNGUzMDg3L3RhYmxlcmFuZ2U6MTI2YWZiOWNlZjBkNDc4YTk0OTlhNGQ2NWY0ZTMwODdfNC0zLTEtMS0xMzE2MTg_6d07b28c-4812-4146-81ea-f4a2fca3b9d0"
      unitRef="usd">-13000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i6b6b9e2b940749269dcc355aa0ed57d7_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjEyNmFmYjljZWYwZDQ3OGE5NDk5YTRkNjVmNGUzMDg3L3RhYmxlcmFuZ2U6MTI2YWZiOWNlZjBkNDc4YTk0OTlhNGQ2NWY0ZTMwODdfNC01LTEtMS0xMzE2MTg_34791cc4-bf9b-46f3-90f1-665d28024c67"
      unitRef="usd">-28000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ibc7fb1fb9fd543aba08f396008a05eb0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjEyNmFmYjljZWYwZDQ3OGE5NDk5YTRkNjVmNGUzMDg3L3RhYmxlcmFuZ2U6MTI2YWZiOWNlZjBkNDc4YTk0OTlhNGQ2NWY0ZTMwODdfNS0zLTEtMS0xMzE2MTg_e728eec8-5f0c-4f93-9d57-82d50a4c42d2"
      unitRef="usd">-2000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="ic3fb850e1f5f434f8e8a95228021a73d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjEyNmFmYjljZWYwZDQ3OGE5NDk5YTRkNjVmNGUzMDg3L3RhYmxlcmFuZ2U6MTI2YWZiOWNlZjBkNDc4YTk0OTlhNGQ2NWY0ZTMwODdfNS01LTEtMS0xMzE2MTg_02f54c1c-197b-43ae-91dc-30cd1f2ffb14"
      unitRef="usd">2000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfOTgyOQ_fddfd25d-1e22-47d1-bbfe-f36c4ba9f792"
      unitRef="usd">-71000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg5MTg_9432e5ed-20f3-4378-849b-4fa3d5b83c6e">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Information on investments in debt and equity securities is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.063%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gross&#160;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt and publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Unrealized net gains of $338&#160;million were recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; in the first quarter of 2023 on equity securities still held at March&#160;31, 2023. Unrealized net losses of $225 million were recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; in the first quarter of 2022 on equity securities still held at March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i776fb83d7a1241a0826d11f6ebe76e81_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0xLTEtMS0xMzU4NDQ_ebb3f79e-28e4-4edf-a924-8fdd8e33daaf"
      unitRef="usd">663000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i776fb83d7a1241a0826d11f6ebe76e81_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0zLTEtMS0xMzU4NDQ_c50bcca5-2665-47dd-9a37-7a04ba0ac298"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i776fb83d7a1241a0826d11f6ebe76e81_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy01LTEtMS0xMzU4NDQ_62978d6b-f095-4383-b06a-c328926964c7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i776fb83d7a1241a0826d11f6ebe76e81_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy03LTEtMS0xMzgyODg_95724fca-3830-4875-a860-9c1c21299590"
      unitRef="usd">663000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7a3f219a7d404a31bf65ab7515e23942_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy05LTEtMS0xMzU4NDQ_609d66b2-1f18-4a58-ad09-df256f3ea0b0"
      unitRef="usd">498000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7a3f219a7d404a31bf65ab7515e23942_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0xMS0xLTEtMTM1ODQ0_8e28da52-4455-40e0-8137-9dcfe8db9182"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7a3f219a7d404a31bf65ab7515e23942_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0xMy0xLTEtMTM1ODQ0_881c0c90-3f1f-4580-82b3-53e4fc336028"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7a3f219a7d404a31bf65ab7515e23942_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0xNS0xLTEtMTM3MDI1_1317ee72-f6a4-4f57-ab7d-7ca5768baa3b"
      unitRef="usd">498000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2e566c5f87a6490788ae30ee3d6f3b50_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0xLTEtMS0xMzE2MTg_1c0a6358-3e8d-4355-b789-ff35995fb9f9"
      unitRef="usd">92000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2e566c5f87a6490788ae30ee3d6f3b50_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0zLTEtMS0xMzE2MTg_e4f3191f-8505-4052-952e-8cce6662cc70"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2e566c5f87a6490788ae30ee3d6f3b50_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy01LTEtMS0xMzE2MTg_17046ae1-855b-4652-ad2c-490e7ede0e87"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2e566c5f87a6490788ae30ee3d6f3b50_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy03LTEtMS0xMzE2MTg_8e8bf003-394c-47c5-a608-560951f1289f"
      unitRef="usd">92000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i92a140256baa4686a25015671d14aa5b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy05LTEtMS0xMzE2MTg_440cdd91-ac34-4899-b413-5b57c68da8b7"
      unitRef="usd">68000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i92a140256baa4686a25015671d14aa5b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0xMS0xLTEtMTMxNjE4_c19d8c2a-b8db-4e5b-b64f-d78a3014c888"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i92a140256baa4686a25015671d14aa5b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0xMy0xLTEtMTMxNjE4_ec604bca-89ef-46c2-a045-52f1e2a2289e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i92a140256baa4686a25015671d14aa5b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfMy0xNS0xLTEtMTMxNjE4_da336add-720b-4c04-ba66-9de88b38852d"
      unitRef="usd">68000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i93df6ced8a7748a4abd5d6c32906498c_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNS0xLTEtMS0xMzE2MTg_9e10429e-a1f3-46b3-964e-6dfb201cf33f"
      unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i93df6ced8a7748a4abd5d6c32906498c_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNS0zLTEtMS0xMzE2MTg_a9c7cd83-64a8-4550-bba7-52f3aa32437d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i93df6ced8a7748a4abd5d6c32906498c_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNS01LTEtMS0xMzE2MTg_062e8e8c-9124-49f1-9295-1a7c0414a109"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i93df6ced8a7748a4abd5d6c32906498c_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNS03LTEtMS0xMzE2MTg_80243d15-5cbb-44a9-ab4d-3e6ab08f8e08"
      unitRef="usd">4000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5aa6408da9024f3ea458c3189fa1916d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNS05LTEtMS0xMzE2MTg_47c5d10e-de64-4295-8fab-5a7e4d1d6c15"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5aa6408da9024f3ea458c3189fa1916d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNS0xMS0xLTEtMTMxNjE4_6b5633d0-f8e7-4ba7-bac1-87b9e2ae8cfa"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5aa6408da9024f3ea458c3189fa1916d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNS0xMy0xLTEtMTMxNjE4_c0cca5ce-fb86-4548-9bde-d904cc94ac08"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5aa6408da9024f3ea458c3189fa1916d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNS0xNS0xLTEtMTMxNjE4_ac586d21-f44b-4a6d-bec1-49054b0701fa"
      unitRef="usd">3000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if1f2bc401a074570afe7c168856f7ee2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNi0xLTEtMS0xMzE2MTg_e37c5043-2f2a-4783-bb90-9fc3807a9cb8"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if1f2bc401a074570afe7c168856f7ee2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNi0zLTEtMS0xMzE2MTg_43888fd8-aa07-4f41-9d84-f953c88ffd8b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if1f2bc401a074570afe7c168856f7ee2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNi01LTEtMS0xMzE2MTg_2bdd5689-59ff-4aaa-a11a-2693b6b00d88"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if1f2bc401a074570afe7c168856f7ee2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNi03LTEtMS0xMzE2MTg_b1341752-58cc-4e67-8a83-5ea253fc5603"
      unitRef="usd">1000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i85028f8c5acd441497714b4e936b0ece_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNi05LTEtMS0xMzE2MTg_9760707e-49fb-47c5-b677-6b01c4a58a43"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i85028f8c5acd441497714b4e936b0ece_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNi0xMS0xLTEtMTMxNjE4_fdf3ea92-14e9-436e-bd39-072624ab4ab0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i85028f8c5acd441497714b4e936b0ece_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNi0xMy0xLTEtMTMxNjE4_0341e4c2-18a9-45a8-bf88-456ab3cdeb39"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i85028f8c5acd441497714b4e936b0ece_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNi0xNS0xLTEtMTMxNjE4_a92132e2-5f8b-4d47-bcc1-1f3c3beb97fc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNy0xLTEtMS0xMzE2MTg_eca26d5e-0c5d-4a81-aada-dd3182c057e4"
      unitRef="usd">760000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNy0zLTEtMS0xMzE2MTg_47dec290-97f4-41f0-87e6-0aa6e194ffa2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNy01LTEtMS0xMzE2MTg_3ff9fd31-4578-4ea8-bc11-34dee56af85c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNy03LTEtMS0xMzE2MTg_5f904d27-87dd-4ead-826e-cfcad94392d9"
      unitRef="usd">760000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNy05LTEtMS0xMzE2MTg_8f9fcbae-ebe5-4e48-b7dd-cfe150e2e2ba"
      unitRef="usd">569000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNy0xMS0xLTEtMTMxNjE4_a7e1b47f-4469-4e68-9be9-ea2934fbe819"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNy0xMy0xLTEtMTMxNjE4_efb397d7-4228-4663-b5b2-e9e01c28004a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfNy0xNS0xLTEtMTMxNjE4_4a229de1-c21a-45a5-8243-e93e7befdcb8"
      unitRef="usd">569000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfOC03LTEtMS0xMzE2MTg_cce764db-ff9e-45fa-ad78-e99c726545a1"
      unitRef="usd">1585000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfOC0xNS0xLTEtMTMxNjE4_db920bff-366b-4fc4-a49e-42206d6c385d"
      unitRef="usd">1284000000</us-gaap:EquitySecuritiesFvNi>
    <mrk:DebtSecuritiesandEquitySecuritiesFVNI
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfOS03LTEtMS0xMzE2MTg_a37b903a-f00d-4e98-a016-145a168486d5"
      unitRef="usd">2345000000</mrk:DebtSecuritiesandEquitySecuritiesFVNI>
    <mrk:DebtSecuritiesandEquitySecuritiesFVNI
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmYzYmZmNDk5NWE2NTQxODc4NjA5NTU4MWQ0Nzg0Nzg2L3RhYmxlcmFuZ2U6ZjNiZmY0OTk1YTY1NDE4Nzg2MDk1NTgxZDQ3ODQ3ODZfOS0xNS0xLTEtMTMxNjE4_23b11816-8ae4-407e-84c3-5a6ef8ee4d36"
      unitRef="usd">1853000000</mrk:DebtSecuritiesandEquitySecuritiesFVNI>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTAzNDg_e8a02200-6507-4d0c-a5d2-b7286057cebb"
      unitRef="usd">338000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTA1MzQ_a8000f2a-ccb3-4531-80e8-0b58870ce2a6"
      unitRef="usd">-225000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTA3MjI_a659a1b6-1257-4cdf-b474-b5ba6d0f1efc"
      unitRef="usd">942000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i1ff3b595ae954906bf225b8a7cc58b69_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTA3Mjk_7819aab3-e59e-4f18-8c63-036852492128"
      unitRef="usd">643000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTEyMTc_51a9dc70-2c78-4a34-9674-9808fc360cdb"
      unitRef="usd">1000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTEyNDk_d679b3be-650f-4c6e-9795-f99c84c84168"
      unitRef="usd">21000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTEzOTI_74087441-f2d2-45d0-a05a-2e00f3713822"
      unitRef="usd">14000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTE2Nzc_ccb6be9f-f29d-49e3-b207-2dd0148e3798"
      unitRef="usd">287000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTE2ODQ_896b0127-dafc-4b24-bf8e-dafc5c2e3610"
      unitRef="usd">40000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTE3Mzg_707ed689-9e7e-41d7-b4c2-1ecf26a109d1"
      unitRef="usd">725000000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="i1ff3b595ae954906bf225b8a7cc58b69_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTE3NDU_5fd15a6e-0e70-4b43-8844-730c36416d88"
      unitRef="usd">1200000000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i17a0e0f674094afda5f097dcbf70b93d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTE5NTk_d0a5bedc-df10-442d-b6f3-0be90a69b09e"
      unitRef="usd">132000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i0cda95f4db4a4d1e892c7b8b8c2bdd34_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTE5NjY_c4f6aadd-5e59-4935-a503-5822ab65e29e"
      unitRef="usd">-509000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg5ODM_093e36d5-cacb-4300-a433-140a801df272">&lt;div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Financial assets and liabilities measured at fair value on a recurring basis are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate notes and bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Publicly traded equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivative assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased currency options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Derivative liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Written currency options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest rate swap contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company&#x2019;s own credit risk, the effects of which were not significant.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i020b0ff9857f4f16af9e432e1869c1f7_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNS0xLTEtMS0xMzE2MTg_0e54fa1c-6aee-4acd-afaa-e1c5986265b1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i07c700750162434c9390aee0f12c47d9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNS0zLTEtMS0xMzE2MTg_9c68e298-88c0-43d6-a0da-ffe9c74ab8d0"
      unitRef="usd">663000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if47442341eb14e6e97a2cc3f6b5bba11_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNS01LTEtMS0xMzE2MTg_efccf205-5d4b-45a5-b28a-e6a0f9b21ce3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8bffc0a6380440728c91dc8b47e0f31e_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNS03LTEtMS0xMzE2MTg_d58408ae-0aa1-4580-8160-e3a3785039be"
      unitRef="usd">663000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4a8f3e37e4904159af4dd090e1bc5731_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNS05LTEtMS0xMzE2MTg_0e3b5efe-4ae2-4279-a9c0-3d2fcb842c76"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2a49b37db2544c739f3f57a6c315a232_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNS0xMS0xLTEtMTMxNjE4_2567dea2-5b34-4959-9afa-0aebc308d036"
      unitRef="usd">498000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i66cafb3d313644a3b3ba17dc3c1b05da_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNS0xMy0xLTEtMTMxNjE4_6a3b23e8-737e-4e94-a723-b9edab0124d4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5a99f61d5d9c4df5b63c5274b8898116_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNS0xNS0xLTEtMTMxNjE4_2daf049c-b11c-46b4-bea6-6d6092124d1c"
      unitRef="usd">498000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7f9e79091e5045c68d0f830e6ac4c990_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0xLTEtMS0xNDI4MDU_aaa59637-fab3-4866-bae2-6f1af816ed4f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2795fcc4916b4738ba959e843ff69ec3_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0zLTEtMS0xNDI4MDU_3bdea0bc-5356-4ac3-83c4-02670e8f3cfe"
      unitRef="usd">22000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i96de2214f40e4ba59e7b629d43ba4d91_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi01LTEtMS0xNDI4MDU_6e332e58-a88a-4104-91d8-b79cf7ec9891"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i451160fbee604ab990070211ebeba8de_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi03LTEtMS0xNDI4OTc_73ccbfd9-b77c-4f26-82e8-74a1dc481dad"
      unitRef="usd">22000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i46d67fffc7944fb8af71441dc67f9462_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi05LTEtMS0xNDI4MTQ_56c2e6aa-9ae5-48e3-8a38-844f5394bde4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifb8445329cbd40e38c431a9cab4cb4d6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0xMS0xLTEtMTQyODE0_d9140173-e53b-454d-8a03-30994ddf7301"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3beec2a915ab4328b794d0b11fbc0788_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0xMy0xLTEtMTQyODE0_84b9095b-f1f2-47a2-8ffd-aa1517f0b3da"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i814823701512438f9446387df4b6adcf_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0xNS0xLTEtMTQyODk3_ebaa5901-0aaa-4ca8-ad5a-741b7e77e61e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0d93e6ac796f4cc0a31cd2625e3240a0_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0xLTEtMS0xMzE2MTg_884af47b-a529-4cc6-9685-b638d5df485d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idef3c5cc57074bf7bab4f63f14c711d4_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0zLTEtMS0xMzE2MTg_1fccf83e-484b-4e05-bba2-62d03e5eb4d1"
      unitRef="usd">1000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia38b8466a7354dcfb672c615593eeffb_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi01LTEtMS0xMzE2MTg_2f535a18-44ac-455f-a8db-c795d14bd486"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i743f68c0230549c8bfbd0ad0a8901f37_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi03LTEtMS0xMzE2MTg_78cf2b88-306a-4f88-b54f-d383655d2f69"
      unitRef="usd">1000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4d3fb0c5d5a24db099308a75d6d48348_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi05LTEtMS0xMzE2MTg_ae698376-872f-46fc-b710-53b2468985f7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic4232e5688d9417880fdb23acd1671dc_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0xMS0xLTEtMTMxNjE4_4475b2b7-02c6-46c5-aae9-97b6fac707cc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4c5ea1c804e54b9da2cfa1e35191be79_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0xMy0xLTEtMTMxNjE4_fe1f1e39-6c59-4492-a54d-f6057804f23c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i31c000934f3b49b4a1049b7c5825c3d0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNi0xNS0xLTEtMTMxNjE4_e55660ab-f3d2-48b4-a76a-b60223b51e11"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i012d7bd208a247b4b543d54583a218ef_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNy0xLTEtMS0xMzE2MTg_b26b196d-d28e-4b44-80d1-ae7a4000970f"
      unitRef="usd">1284000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i07338fb5662b49d5bc2528a3307c626b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNy0zLTEtMS0xMzE2MTg_767b5fb1-432c-4252-8b7f-b5a1c59bdbce"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic115d2d37fd44d80b15e651843a0417f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNy01LTEtMS0xMzE2MTg_19ae8582-9021-47e0-ae04-3bf16d691cb0"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id8d827d1b17a45afbc3e288430a5dc82_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNy03LTEtMS0xMzE2MTg_035fdb1c-cf4d-41d1-b7c4-e3c11a1af9d2"
      unitRef="usd">1284000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6bb17c88faa0435c933b88267089cb0f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNy05LTEtMS0xMzE2MTg_fcd82b47-bbc0-4c85-a37b-631874a80b4a"
      unitRef="usd">1015000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib04f9b00c03c4e4ea6423dcfad58d6b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNy0xMS0xLTEtMTMxNjE4_7efdc7f9-72d3-4b34-9816-0d9d31a1e50b"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie908803a7baf418983f47014731e40ea_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNy0xMy0xLTEtMTMxNjE4_1f84d769-2780-471a-89c0-f9076e0a54b1"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i1db38063fdeb45aaa60b2e97a4474133_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfNy0xNS0xLTEtMTMxNjE4_21988a98-02bb-41b5-a30d-e1dc03b4c60f"
      unitRef="usd">1015000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:TradingSecurities
      contextRef="idebf467c560c4d1d9245b765b6e590d9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfOC0xLTEtMS0xMzE2MTg_4e4e971f-a4b0-41c0-890c-e274b7e2923d"
      unitRef="usd">1284000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i89142ce181ae48e3a2d77a9f72861963_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfOC0zLTEtMS0xMzE2MTg_f6e2f1a6-d2b2-4586-8abe-6e4bde4e8b74"
      unitRef="usd">686000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i57ae55075eed47cdb14839b87c57acd5_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfOC01LTEtMS0xMzE2MTg_a8f16158-84ce-4260-bf3e-1a2b77537f23"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i6f4032436bb84e00a3478c08a4a4bac8_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfOC03LTEtMS0xMzE2MTg_4c724860-a9a6-401b-b051-7756ecc7b7c6"
      unitRef="usd">1970000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i4bd81adc1667472a96ce3692b39fdda2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfOC05LTEtMS0xMzE2MTg_2e52ab60-a4d3-4acc-9d80-ead68654c649"
      unitRef="usd">1015000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i871a358ebbbd48f496202064b0918f47_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfOC0xMS0xLTEtMTMxNjE4_b0794eec-ed80-419b-b140-9eb616a79d80"
      unitRef="usd">498000000</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i6e90f41ec72b4d99ab066bfbad83afec_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfOC0xMy0xLTEtMTMxNjE4_80c26481-74a1-4d11-83d1-231c47605b71"
      unitRef="usd">0</us-gaap:TradingSecurities>
    <us-gaap:TradingSecurities
      contextRef="i1a48a4589b004511be5ec5ad70c7e2da_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfOC0xNS0xLTEtMTMxNjE4_0e575ddb-093d-4dce-a701-a729e92740f4"
      unitRef="usd">1513000000</us-gaap:TradingSecurities>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7f9e79091e5045c68d0f830e6ac4c990_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTAtMS0xLTEtMTMxNjE4_b7c1774b-3226-4605-88f3-ffd02dbb5576"
      unitRef="usd">70000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2795fcc4916b4738ba959e843ff69ec3_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTAtMy0xLTEtMTMxNjE4_d80dfe03-f2c8-46d3-8d9d-ae292b277c45"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i96de2214f40e4ba59e7b629d43ba4d91_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTAtNS0xLTEtMTMxNjE4_5696dfda-858a-44f8-aa3f-0f1de3e51b31"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i451160fbee604ab990070211ebeba8de_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTAtNy0xLTEtMTMxNjE4_96f45da5-f6a7-428b-9c26-420e3f43d14e"
      unitRef="usd">70000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i46d67fffc7944fb8af71441dc67f9462_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTAtOS0xLTEtMTMxNjE4_c4c7ec95-902b-44e1-9a72-0cc089655c01"
      unitRef="usd">68000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ifb8445329cbd40e38c431a9cab4cb4d6_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTAtMTEtMS0xLTEzMTYxOA_8e6882df-69cc-43b6-92c5-6b02032038bc"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i3beec2a915ab4328b794d0b11fbc0788_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTAtMTMtMS0xLTEzMTYxOA_f478da74-6cfe-494e-9c7c-d312ae56e06b"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i814823701512438f9446387df4b6adcf_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTAtMTUtMS0xLTEzMTYxOA_e0dbc358-8f5c-4477-adb7-e1f332799b80"
      unitRef="usd">68000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0c30409b333846a0b003f5261f708353_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTEtMS0xLTEtMTMxNjE4_5f566187-2eb1-48c2-97f7-2c159c59ea87"
      unitRef="usd">4000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i4d1c02180ad34f3e83fbb3df043ae3f5_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTEtMy0xLTEtMTMxNjE4_7c5c3aa8-c0b3-4a1f-8d99-d5b536f050c8"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6288684e9335426a899ee4586882280c_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTEtNS0xLTEtMTMxNjE4_26355afe-92f3-46f1-ba80-d9110584de78"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i305ac9c4908a4bffa1b9ce0a56239183_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTEtNy0xLTEtMTMxNjE4_b4bd97eb-c6c3-4491-b71f-d23814cf4375"
      unitRef="usd">4000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i3eaafa1e0ba64836a551188797cd7c7c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTEtOS0xLTEtMTMxNjE4_5a24c76e-6057-4665-8584-a8e8f721fc56"
      unitRef="usd">3000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic36ef238f34c4ab180d3b3a52624eb9d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTEtMTEtMS0xLTEzMTYxOA_3a8192b4-d20e-4fa4-88ad-fe6c85e7ed87"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib784c86ce67446f7940a517458674fd1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTEtMTMtMS0xLTEzMTYxOA_ca1d9860-b54f-460d-9830-bf60df710d8b"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i004682e5e94d4b12b9f2913eefd3a7fb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTEtMTUtMS0xLTEzMTYxOA_c53c81dd-ecab-4af7-accf-670d4d759793"
      unitRef="usd">3000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i012d7bd208a247b4b543d54583a218ef_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTItMS0xLTEtMTMxNjE4_0c5b3078-6b13-4fa4-867c-93f3112b530f"
      unitRef="usd">301000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i07338fb5662b49d5bc2528a3307c626b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTItMy0xLTEtMTMxNjE4_dd65fcb2-a6bd-4fb6-bc1d-10911ad2ef40"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic115d2d37fd44d80b15e651843a0417f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTItNS0xLTEtMTMxNjE4_84b98074-1b42-42c2-823d-5feee64de00e"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id8d827d1b17a45afbc3e288430a5dc82_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTItNy0xLTEtMTMxNjE4_01172adc-e976-43c7-b190-2dc1de853e05"
      unitRef="usd">301000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6bb17c88faa0435c933b88267089cb0f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTItOS0xLTEtMTMxNjE4_d8e922eb-e03c-4a4b-a32b-c7854d522014"
      unitRef="usd">269000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib04f9b00c03c4e4ea6423dcfad58d6b3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTItMTEtMS0xLTEzMTYxOA_cc97dd16-0871-4d57-ac48-cac4203bccfb"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie908803a7baf418983f47014731e40ea_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTItMTMtMS0xLTEzMTYxOA_de47a288-b36d-44b8-97d1-b01f8b3b73bd"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1db38063fdeb45aaa60b2e97a4474133_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTItMTUtMS0xLTEzMTYxOA_7b34bd22-cd04-4cbd-91e1-7a917f7e7eaf"
      unitRef="usd">269000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="idebf467c560c4d1d9245b765b6e590d9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTMtMS0xLTEtMTMxNjE4_292d338b-e4a7-46ab-b976-e6e4607c57f3"
      unitRef="usd">375000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i89142ce181ae48e3a2d77a9f72861963_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTMtMy0xLTEtMTMxNjE4_4825e079-11ba-4dea-80d4-9e0817058aec"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i57ae55075eed47cdb14839b87c57acd5_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTMtNS0xLTEtMTMxNjE4_0ab20310-6b48-4e18-9499-a4d6eea90eb3"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6f4032436bb84e00a3478c08a4a4bac8_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTMtNy0xLTEtMTMxNjE4_9783e758-1216-4218-b674-8ab5f9ee62c1"
      unitRef="usd">375000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i4bd81adc1667472a96ce3692b39fdda2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTMtOS0xLTEtMTMxNjE4_fcd41c03-7b67-4fce-8ca4-3317b93b11e5"
      unitRef="usd">340000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i871a358ebbbd48f496202064b0918f47_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTMtMTEtMS0xLTEzMTYxOA_5d8904c2-de85-4a36-809a-a1c1f6ae4b82"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6e90f41ec72b4d99ab066bfbad83afec_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTMtMTMtMS0xLTEzMTYxOA_d3fe0a7c-5618-490a-95b7-9982c5fe7220"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1a48a4589b004511be5ec5ad70c7e2da_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTMtMTUtMS0xLTEzMTYxOA_29f75233-134b-465e-b19b-49dfb159de7c"
      unitRef="usd">340000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:DerivativeAssets
      contextRef="i34260a2a17d947768f68d2798eb0f8c1_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTYtMS0xLTEtMTMxNjE4_ca36872b-5bfe-42b2-93b4-a0b8b968576a"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i0b068359fb3948a182327c67ab308fb4_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTYtMy0xLTEtMTMxNjE4_b0cd73d8-2b57-4754-be46-a5fd56f17be3"
      unitRef="usd">139000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ia8f7806f9be14762977b7e08e79e4daf_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTYtNS0xLTEtMTMxNjE4_3546d76f-fdfb-41cb-903a-68bb4d765c65"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i8a2e484401b24c479443887a01bf805c_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTYtNy0xLTEtMTMxNjE4_dfa00044-779f-41b4-a83f-12d03be91fe4"
      unitRef="usd">139000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i2b1b40aabc7a4eedbc4ba7ac12424d0c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTYtOS0xLTEtMTMxNjE4_df1f3877-2282-48e1-b140-7768875f1dbf"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i5265c6f93c7f46d1ab829156c30fdf74_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTYtMTEtMS0xLTEzMTYxOA_2fe12f6d-57a4-4776-a315-8d550fb49a97"
      unitRef="usd">215000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ic497e29b39d04693be035586e02049ba_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTYtMTMtMS0xLTEzMTYxOA_3bc604fd-c461-4663-af44-8be75b1e76c3"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i970e6180f53c4baeb53fdd14d90061da_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTYtMTUtMS0xLTEzMTYxOA_b28c6326-6031-44db-9fdd-bd862903f773"
      unitRef="usd">215000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i075080b8fa0045b6adf42ad9d680a586_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTctMS0xLTEtMTQyNzM5_0c24c1b0-0975-465c-9422-c5059618e9ba"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="if826811b47d7448eb6e1f3d6c36b5841_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTctMy0xLTEtMTQyNzM5_b9066cb5-337e-4246-9d51-c2408a0ea254"
      unitRef="usd">119000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i96e781b662154001934e50bb59beb7cd_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTctNS0xLTEtMTQyNzM5_d24738f0-8879-4bac-84e6-699c957684ae"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ibffb1c0f1856491795524f9ede8241fc_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTctNy0xLTEtMTQyNzM5_f9ceb638-bc1a-49ae-8c1a-31e382cdddb8"
      unitRef="usd">119000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i5ba1c7342bdd4e82a5d14645ae050399_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTctOS0xLTEtMTQyNzM5_bfd9b65a-26e5-49bd-ad0b-8392d0378711"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i294603384e1e48b1b1962054c70f8781_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTctMTEtMS0xLTE0MjczOQ_0d7ae1eb-e839-4658-bdd8-3a60b50c9151"
      unitRef="usd">218000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ie2707a83a0684b81b3f82c21c1a7d1e9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTctMTMtMS0xLTE0MjczOQ_95ea9c4a-7172-4401-b15d-5eb65d8b05f2"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ia524db85b9fb4e5faaed403cdac7f778_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTctMTUtMS0xLTE0MjczOQ_749b4f51-5f97-4cf5-9ff1-8d9b6ce4f5f4"
      unitRef="usd">218000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="id4b65ea8a7a94fb5acbe089d34abecfd_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMS0xLTEtMTQyNjM5_359fe91c-b543-42a8-846f-a49881989970"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="iefe9381ed615477a8d395b385d4bfc96_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMy0xLTEtMTQyNjM5_add84cbf-83a4-4e47-9505-f779aa30b8ba"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="iec2a2a2cde214dcf9145e7fed863dfaf_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtNS0xLTEtMTQyNjM5_a98df310-7cd0-4565-9a0a-dd4677e59b62"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ie0fdebb01cd44ff4b7dd90a3757e19a8_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtNy0xLTEtMTQyOTAw_1935a71d-f60f-42c0-b621-d68401600e44"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i92b2724f66144388bc9d877014d99971_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtOS0xLTEtMTQyNjM5_4a9e2ed3-83ef-49ec-a881-f2d27ce14dba"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i402e5d3ff33d4949b0046490210e38a1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMTEtMS0xLTE0MjYzOQ_17f6df11-b755-4b6f-8c28-622c23fe9c63"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ia4a496ea51974c41968d7d7ece436a35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMTMtMS0xLTE0MjYzOQ_4e142787-e72f-4516-8e1a-15d8679c2fc1"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i04e31d8852884bf89e5bcb8b4f124896_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMTUtMS0xLTE0MjkwMA_410446bf-d1af-4dcf-906a-f57c822644ec"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="idebf467c560c4d1d9245b765b6e590d9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMS0xLTEtMTMxNjE4_9b24cb78-a48f-4a20-91f2-b2cc52391c8d"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i89142ce181ae48e3a2d77a9f72861963_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMy0xLTEtMTMxNjE4_53abf6f3-62df-4e76-9697-be441d83fb49"
      unitRef="usd">259000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i57ae55075eed47cdb14839b87c57acd5_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtNS0xLTEtMTMxNjE4_4e7d2486-4293-46dc-8206-1f6d8d93321d"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i6f4032436bb84e00a3478c08a4a4bac8_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtNy0xLTEtMTMxNjE4_8ed6e4b1-9fbf-44d5-b2ad-4671b6263c58"
      unitRef="usd">259000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i4bd81adc1667472a96ce3692b39fdda2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtOS0xLTEtMTMxNjE4_5d074d82-04a0-4fe5-b072-81bf95f40d1c"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i871a358ebbbd48f496202064b0918f47_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMTEtMS0xLTEzMTYxOA_cc2a570a-97b1-44ce-af07-5f0c1a640cb7"
      unitRef="usd">433000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i6e90f41ec72b4d99ab066bfbad83afec_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMTMtMS0xLTEzMTYxOA_8ae18f96-6d3b-43ed-ba57-67240c0dfd12"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i1a48a4589b004511be5ec5ad70c7e2da_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTgtMTUtMS0xLTEzMTYxOA_284f4954-e0c9-43b7-9bf0-10fa07c5e1b1"
      unitRef="usd">433000000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idebf467c560c4d1d9245b765b6e590d9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTktMS0xLTEtMTMxNjE4_58916fb2-9d1b-40e8-9f85-0d1c3c679c51"
      unitRef="usd">1659000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i89142ce181ae48e3a2d77a9f72861963_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTktMy0xLTEtMTMxNjE4_5f3bf00a-64cc-4917-a293-bfdbcef934c9"
      unitRef="usd">945000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i57ae55075eed47cdb14839b87c57acd5_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTktNS0xLTEtMTMxNjE4_b655d779-28b5-4cd1-8d8b-5fc9761830d8"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6f4032436bb84e00a3478c08a4a4bac8_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTktNy0xLTEtMTMxNjE4_6b4d4136-85e1-4f14-b3b9-9e3fa023da9f"
      unitRef="usd">2604000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4bd81adc1667472a96ce3692b39fdda2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTktOS0xLTEtMTMxNjE4_f2cf04e7-a236-4643-bcb8-2eed165c7855"
      unitRef="usd">1355000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i871a358ebbbd48f496202064b0918f47_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTktMTEtMS0xLTEzMTYxOA_76cedcc4-4a6b-4536-8477-c41e9d972482"
      unitRef="usd">931000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6e90f41ec72b4d99ab066bfbad83afec_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTktMTMtMS0xLTEzMTYxOA_4960d5cd-0675-4292-b1f8-eafce8616e9b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1a48a4589b004511be5ec5ad70c7e2da_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMTktMTUtMS0xLTEzMTYxOA_a8330c04-4d6c-417b-b9c7-123fa114b6db"
      unitRef="usd">2286000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="idebf467c560c4d1d9245b765b6e590d9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjItMS0xLTEtMTMxNjE4_483e8c09-8fd3-4704-b97d-002e40b38d10"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i89142ce181ae48e3a2d77a9f72861963_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjItMy0xLTEtMTMxNjE4_8d1fbb4d-d276-4025-80cb-7537cc352a36"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i57ae55075eed47cdb14839b87c57acd5_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjItNS0xLTEtMTMxNjE4_9a72a642-8e82-4e99-b714-adb309aa9824"
      unitRef="usd">353000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6f4032436bb84e00a3478c08a4a4bac8_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjItNy0xLTEtMTMxNjE4_d25bf528-9231-4ba8-9aec-b1bbc9947029"
      unitRef="usd">353000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4bd81adc1667472a96ce3692b39fdda2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjItOS0xLTEtMTMxNjE4_88da0802-966b-4747-a7d3-89fc8d1761f4"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i871a358ebbbd48f496202064b0918f47_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjItMTEtMS0xLTEzMTYxOA_67dc2411-5000-4474-b67a-7c69401f7c52"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6e90f41ec72b4d99ab066bfbad83afec_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjItMTMtMS0xLTEzMTYxOA_19d25332-f73b-4c80-ac60-db5e4d1d038b"
      unitRef="usd">456000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1a48a4589b004511be5ec5ad70c7e2da_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjItMTUtMS0xLTEzMTYxOA_84bfb37e-b89d-48e0-a3f3-08164eb33d77"
      unitRef="usd">456000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DerivativeLiabilities
      contextRef="i075080b8fa0045b6adf42ad9d680a586_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjQtMS0xLTEtMTMxNjE4_7fb4b891-f36b-4b58-93ee-1865502b2ff1"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="if826811b47d7448eb6e1f3d6c36b5841_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjQtMy0xLTEtMTMxNjE4_849178a0-9960-4c32-bbdf-897b019c2a76"
      unitRef="usd">276000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i96e781b662154001934e50bb59beb7cd_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjQtNS0xLTEtMTMxNjE4_30447676-6124-476e-84e4-6e98b6c6496e"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ibffb1c0f1856491795524f9ede8241fc_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjQtNy0xLTEtMTMxNjE4_db589160-61c7-41fd-94b5-e1b0c9c35dfa"
      unitRef="usd">276000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i5ba1c7342bdd4e82a5d14645ae050399_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjQtOS0xLTEtMTMxNjE4_2cecf214-d3fe-4d3b-b75d-dbf3dbb49a68"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i294603384e1e48b1b1962054c70f8781_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjQtMTEtMS0xLTEzMTYxOA_2c5212ca-19aa-4b55-acd7-24f2d0b1691e"
      unitRef="usd">402000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ie2707a83a0684b81b3f82c21c1a7d1e9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjQtMTMtMS0xLTEzMTYxOA_97006aaa-a6f2-4c7c-a096-bfd142a55687"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ia524db85b9fb4e5faaed403cdac7f778_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjQtMTUtMS0xLTEzMTYxOA_9b23a4de-9f1f-4733-893a-f2c6bd10d8f6"
      unitRef="usd">402000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i34260a2a17d947768f68d2798eb0f8c1_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjUtMS0xLTEtMTMxNjE4_eba8a516-d7d5-413d-8f4c-2538153b6e7e"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i0b068359fb3948a182327c67ab308fb4_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjUtMy0xLTEtMTMxNjE4_0cfb45d0-81a5-425b-9a07-f2b8b369f752"
      unitRef="usd">7000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ia8f7806f9be14762977b7e08e79e4daf_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjUtNS0xLTEtMTMxNjE4_b533cf8b-13ee-4517-ace8-a52379956989"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i8a2e484401b24c479443887a01bf805c_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjUtNy0xLTEtMTMxNjE4_3dd0ac8c-acb4-4e00-ac7a-10d0f9a6c305"
      unitRef="usd">7000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i2b1b40aabc7a4eedbc4ba7ac12424d0c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjUtOS0xLTEtMTMxNjE4_05325343-7ff4-4597-b6a5-a8b6dc33f8a5"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i5265c6f93c7f46d1ab829156c30fdf74_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjUtMTEtMS0xLTEzMTYxOA_762439c4-93ca-4fc0-91c3-1854b6061e9a"
      unitRef="usd">7000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ic497e29b39d04693be035586e02049ba_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjUtMTMtMS0xLTEzMTYxOA_4f213633-9202-409e-8c29-923e8db35773"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i970e6180f53c4baeb53fdd14d90061da_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjUtMTUtMS0xLTEzMTYxOA_6a1cb643-070f-4b60-a5e0-0f20fbe6eae3"
      unitRef="usd">7000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="id4b65ea8a7a94fb5acbe089d34abecfd_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMS0xLTEtMTQyNjYy_024ffe50-d376-4c95-bce6-99e121e627fb"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="iefe9381ed615477a8d395b385d4bfc96_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMy0xLTEtMTQyNjYy_fca214be-cfa6-4cef-84fe-cc43d44ab8d0"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="iec2a2a2cde214dcf9145e7fed863dfaf_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctNS0xLTEtMTQyNjYy_51aa7166-3ebe-4ee0-87ba-fbbb12541b7e"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ie0fdebb01cd44ff4b7dd90a3757e19a8_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctNy0xLTEtMTQyOTA1_d40c5be6-44a8-41c9-bd2f-aa6dd24efd34"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i92b2724f66144388bc9d877014d99971_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctOS0xLTEtMTQyNjYy_495c74db-3a49-4c66-8949-318bc67356bf"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i402e5d3ff33d4949b0046490210e38a1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMTEtMS0xLTE0MjY2Mg_269bf6d4-76e1-47dd-be52-efb7022fefea"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ia4a496ea51974c41968d7d7ece436a35_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMTMtMS0xLTE0MjY2Mg_6df333ce-8880-4bd8-a301-c400065f1764"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i04e31d8852884bf89e5bcb8b4f124896_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMTUtMS0xLTE0MjkwNQ_4d7d9ef9-ca6c-4d6f-8128-1a8750b46d18"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="idebf467c560c4d1d9245b765b6e590d9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjYtMS0xLTEtMTMxNjE4_b857af57-9d2e-4eb5-9dd5-1f34bf374b7f"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i89142ce181ae48e3a2d77a9f72861963_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjYtMy0xLTEtMTMxNjE4_5535b5e1-3f27-403e-a8ef-1bc6a00ccd1a"
      unitRef="usd">284000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i57ae55075eed47cdb14839b87c57acd5_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjYtNS0xLTEtMTMxNjE4_bcca3703-a77d-4d28-9c9f-ef89a99462b2"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i6f4032436bb84e00a3478c08a4a4bac8_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjYtNy0xLTEtMTMxNjE4_fd46a7fd-f447-45bf-8841-88f4e7c8d3dd"
      unitRef="usd">284000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i4bd81adc1667472a96ce3692b39fdda2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjYtOS0xLTEtMTMxNjE4_dee273a3-9619-4474-96b8-49885d93ac42"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i871a358ebbbd48f496202064b0918f47_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjYtMTEtMS0xLTEzMTYxOA_ecaddc40-f9eb-4e29-9dfa-e2cec2451f9e"
      unitRef="usd">409000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i6e90f41ec72b4d99ab066bfbad83afec_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjYtMTMtMS0xLTEzMTYxOA_d0af7ed3-95ce-4a5d-9629-e463ec23d3e4"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i1a48a4589b004511be5ec5ad70c7e2da_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjYtMTUtMS0xLTEzMTYxOA_473cf8ad-74c1-4db0-9ec0-5b2db273d472"
      unitRef="usd">409000000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="idebf467c560c4d1d9245b765b6e590d9_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMS0xLTEtMTMxNjE4_0c86ec9e-e6fd-42b1-82ce-8d4cbc61cb18"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i89142ce181ae48e3a2d77a9f72861963_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMy0xLTEtMTMxNjE4_820c292d-a492-40f2-ae40-217bfcf5d286"
      unitRef="usd">284000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i57ae55075eed47cdb14839b87c57acd5_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctNS0xLTEtMTMxNjE4_229c5749-4671-4364-985a-21d5f134e1d7"
      unitRef="usd">353000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6f4032436bb84e00a3478c08a4a4bac8_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctNy0xLTEtMTMxNjE4_9152b670-9b27-4261-be56-a76cbb6c1ad0"
      unitRef="usd">637000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i4bd81adc1667472a96ce3692b39fdda2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctOS0xLTEtMTMxNjE4_3cef6eb2-da16-40ac-a2d3-c8696cf3e143"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i871a358ebbbd48f496202064b0918f47_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMTEtMS0xLTEzMTYxOA_5979c81c-86d2-4e6c-8da4-ad307b8cc0b9"
      unitRef="usd">409000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6e90f41ec72b4d99ab066bfbad83afec_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMTMtMS0xLTEzMTYxOA_4843c7b6-5dde-4aa6-a5c3-005f3e625252"
      unitRef="usd">456000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i1a48a4589b004511be5ec5ad70c7e2da_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOmVlZTk1YjM1YWVkZjRhNzA4NjhmOGYxOGQwODg2ZjVlL3RhYmxlcmFuZ2U6ZWVlOTViMzVhZWRmNGE3MDg2OGY4ZjE4ZDA4ODZmNWVfMjctMTUtMS0xLTEzMTYxOA_6853952c-b498-47a2-b79c-07d82b45501c"
      unitRef="usd">865000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i8dcc8586471c42e6a0ee92dda4a6bd01_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTQyMzE_756d628a-d2cf-4408-96d7-4b7016dc49da"
      unitRef="usd">8800000000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i8f39864d8e8e466da61d331c664f14db_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTQyMzg_569481a9-ffb8-4b27-bad8-0e5c06ddb3a7"
      unitRef="usd">11300000000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg5Nzk_77d6f099-347e-4ded-9d4d-8c753d5a96ab">&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value January 1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value March 31 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Cost of sales, Research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; expenses, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;. Includes cumulative translation adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;At March&#160;31, 2023, $263 million of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at March&#160;31, 2023 includes $127 million recorded as a current liability for amounts expected to be paid within the next 12 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfMS0xLTEtMS0xMzE2MTg_144665d5-ea1c-43c1-9aef-5f5684399d89"
      unitRef="usd">456000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if2cb2241175c4c8c8fd5daf0a86385e3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfMS0zLTEtMS0xMzE2MTg_f44b2f37-b77f-411d-977f-63b293cb5d5a"
      unitRef="usd">777000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfMi0xLTEtMS0xMzE2MTg_3eebe763-44f1-4be7-85bd-478614d9db0c"
      unitRef="usd">14000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfMi0zLTEtMS0xMzE2MTg_a2cfc153-5828-4ebf-97fb-c3ee10feb3b6"
      unitRef="usd">-84000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfMy0xLTEtMS0xMzE2MTg_4d12b177-9678-4d70-b824-edfc1a591885"
      unitRef="usd">117000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfMy0zLTEtMS0xMzE2MTg_446bc6f6-c8ff-442d-b484-b2d78e5f4d91"
      unitRef="usd">119000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfNC0xLTEtMS0xMzE2MTg_f34d6fff-2ba0-47a0-9b9d-b7014565b79a"
      unitRef="usd">0</mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther>
    <mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfNC0zLTEtMS0xMzE2MTg_9e60961c-a4d4-4846-bf26-70f7a060b5a9"
      unitRef="usd">2000000</mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfNS0xLTEtMS0xMzE2MTg_937a569b-3c02-4cb3-b545-8f46e95255c6"
      unitRef="usd">353000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1ff3b595ae954906bf225b8a7cc58b69_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RhYmxlOjZiZjYxYTEzNjMwYTQ4ZGQ4YmY2ZjA5N2ZlMzViYzU1L3RhYmxlcmFuZ2U6NmJmNjFhMTM2MzBhNDhkZDhiZjZmMDk3ZmUzNWJjNTVfNS0zLTEtMS0xMzE2MTg_f5c083dd-45d4-43c3-8187-91a5c8278e76"
      unitRef="usd">572000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8ae2044462124fec8e736b9c160ff048_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTQ2ODE_f0029f4c-363a-4329-b0ee-b08014ee1ee9"
      unitRef="usd">263000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i8ae2044462124fec8e736b9c160ff048_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTQ4NzI_84ce529a-09f8-40ac-bd31-4ab974671ecd"
      unitRef="number">0.115</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTUxODk_e22e0c6e-3065-42f2-9080-127c8d38a9af"
      unitRef="usd">127000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTU3NDc_dd08989f-2216-4edb-b796-c503fe479885"
      unitRef="usd">28200000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTU3ODQ_4bddb375-cd4d-4b80-8747-ec3b4e5fd365"
      unitRef="usd">30700000000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTU4MDI_fb050a51-0b39-4b7b-aefb-34671fcd6d62"
      unitRef="usd">26700000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTU4Mzk_ca6ef105-6c3d-4d8a-a844-b11cccd7a0b6"
      unitRef="usd">30700000000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:AccountsReceivableSale
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTcxNzI_3b64962b-ba67-4dfa-8d8c-68996b3eee4a"
      unitRef="usd">2400000000</us-gaap:AccountsReceivableSale>
    <us-gaap:AccountsReceivableSale
      contextRef="i8fbdfdee6afe4e74be18dd0c62050372_D20220101-20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTcxNzk_3508a104-7358-486a-84b3-3fd5843cf9e9"
      unitRef="usd">2500000000</us-gaap:AccountsReceivableSale>
    <us-gaap:RestrictedCashCurrent
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTc3MTE_29b14408-9971-40df-802b-4c63e56ae094"
      unitRef="usd">31000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTc3MTg_ab0d93d2-301c-48bb-abea-677752a41a12"
      unitRef="usd">67000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg3Njg_d0033a4b-116f-4d9e-afb2-d46a836a0099"
      unitRef="usd">13000000</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeCollateralObligationToReturnCash
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfMTg3NzU_3583c354-e49f-4b24-8233-399cd07c5518"
      unitRef="usd">66000000</us-gaap:DerivativeCollateralObligationToReturnCash>
    <us-gaap:DerivativeCollateralRightToReclaimSecurities
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY180OS9mcmFnOjE1ODhjZjM4ZjI3OTRjMmY5NWFkOGFkYWNiZWM0NzllL3RleHRyZWdpb246MTU4OGNmMzhmMjc5NGMyZjk1YWQ4YWRhY2JlYzQ3OWVfNTQ5NzU1ODQyNDM0_3a44d50f-65f2-4ace-ae90-ba4fdee12ef2"
      unitRef="usd">19000000</us-gaap:DerivativeCollateralRightToReclaimSecurities>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RleHRyZWdpb246ZjlkNGE0ODA3MmViNDkyZTlkMGQ0ODIxNzlkNjBlMjZfNDE1_4c332579-e324-41dd-9b03-06a4608d6fe6">Inventories&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventories consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total (approximates current cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decrease to LIFO cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amounts recognized as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; are comprised almost entirely of raw materials and work in process inventories. At March&#160;31, 2023 and December&#160;31, 2022, these amounts included $2.7 billion and $2.4 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $590 million and $516 million at March&#160;31, 2023 and December&#160;31, 2022, respectively, of inventories produced in preparation for product launches.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RleHRyZWdpb246ZjlkNGE0ODA3MmViNDkyZTlkMGQ0ODIxNzlkNjBlMjZfNDA5_5283fbab-b21a-4cc0-a45c-e64bf59e84a6">&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inventories consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials and work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total (approximates current cost)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Decrease to LIFO cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfMS0xLTEtMS0xMzE2MTg_e1f6b193-23f4-45f6-a0ff-65afe27b34ec"
      unitRef="usd">1883000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfMS0zLTEtMS0xMzE2MTg_dfd8aeb2-f296-41b7-b8be-0329788b9701"
      unitRef="usd">1841000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryWorkInProcessAndRawMaterials
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfMi0xLTEtMS0xMzE2MTg_a1fc6eec-983f-49e3-a65d-e8dd0b1f9b93"
      unitRef="usd">7348000000</us-gaap:InventoryWorkInProcessAndRawMaterials>
    <us-gaap:InventoryWorkInProcessAndRawMaterials
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfMi0zLTEtMS0xMzE2MTg_63aa8994-a633-4972-934d-ce15a670318a"
      unitRef="usd">7063000000</us-gaap:InventoryWorkInProcessAndRawMaterials>
    <us-gaap:OtherInventorySupplies
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfMy0xLTEtMS0xMzE2MTg_8af8aeca-6237-43ab-877f-433e3133ea01"
      unitRef="usd">266000000</us-gaap:OtherInventorySupplies>
    <us-gaap:OtherInventorySupplies
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfMy0zLTEtMS0xMzE2MTg_5c3f5a84-2d10-46d4-915e-43ab902e6726"
      unitRef="usd">238000000</us-gaap:OtherInventorySupplies>
    <us-gaap:InventoryGross
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfNC0xLTEtMS0xMzE2MTg_a885691e-a5f3-49e1-a1ec-dbb2526192e0"
      unitRef="usd">9497000000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfNC0zLTEtMS0xMzE2MTg_8dc1d0d1-7d74-490c-9e5a-1bcab747bc63"
      unitRef="usd">9142000000</us-gaap:InventoryGross>
    <us-gaap:InventoryLIFOReserve
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfNS0xLTEtMS0xMzE2MTg_11a9a970-489b-405e-8b07-ac844e2ad6e9"
      unitRef="usd">350000000</us-gaap:InventoryLIFOReserve>
    <us-gaap:InventoryLIFOReserve
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfNS0zLTEtMS0xMzE2MTg_b959ab9b-2ed9-4237-8288-871c069d11d6"
      unitRef="usd">293000000</us-gaap:InventoryLIFOReserve>
    <mrk:InventoryNetAndInventoryNoncurrent
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfNi0xLTEtMS0xMzE2MTg_0f4ba765-458d-4eff-8f69-7ca34c91bf12"
      unitRef="usd">9147000000</mrk:InventoryNetAndInventoryNoncurrent>
    <mrk:InventoryNetAndInventoryNoncurrent
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfNi0zLTEtMS0xMzE2MTg_1b4eba78-0003-4fee-9a6a-cb4475c2773d"
      unitRef="usd">8849000000</mrk:InventoryNetAndInventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfOC0xLTEtMS0xMzE2MTg_59a83081-cdc6-481b-a41d-a5fa08b70c85"
      unitRef="usd">5863000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfOC0zLTEtMS0xMzE2MTg_8381d8f5-0cb0-4788-bdf7-520cc25f1f91"
      unitRef="usd">5911000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfOS0xLTEtMS0xMzE2MTg_2f636f35-37e8-4a37-9a84-f3e6e0032938"
      unitRef="usd">3284000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RhYmxlOjRjM2FiMmNhNmIxNTRhNWViNjU0OWQwYTVkZjA5ODM4L3RhYmxlcmFuZ2U6NGMzYWIyY2E2YjE1NGE1ZWI2NTQ5ZDBhNWRmMDk4MzhfOS0zLTEtMS0xMzE2MTg_9a179ab2-4d38-4998-99b4-6e89a5f22c91"
      unitRef="usd">2938000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="idf5ff6cbdf22489b9efa70ffb318b8aa_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RleHRyZWdpb246ZjlkNGE0ODA3MmViNDkyZTlkMGQ0ODIxNzlkNjBlMjZfMTky_99619c2c-e46e-4e78-84fe-2645edfe4d6d"
      unitRef="usd">2700000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ie2fc780817394ba39db27d26c677ae95_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RleHRyZWdpb246ZjlkNGE0ODA3MmViNDkyZTlkMGQ0ODIxNzlkNjBlMjZfMTk5_bc507a30-3a03-4bd0-ad9d-68d00864527a"
      unitRef="usd">2400000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i49dd486feefe4b749fbe2cca62e80318_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RleHRyZWdpb246ZjlkNGE0ODA3MmViNDkyZTlkMGQ0ODIxNzlkNjBlMjZfMzA5_aca92398-3c98-4b83-a9ed-0ee0fac2032e"
      unitRef="usd">590000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="i3e717c1f26e14e87978e3de102e7c698_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181Mi9mcmFnOmY5ZDRhNDgwNzJlYjQ5MmU5ZDBkNDgyMTc5ZDYwZTI2L3RleHRyZWdpb246ZjlkNGE0ODA3MmViNDkyZTlkMGQ0ODIxNzlkNjBlMjZfMzE2_b00c67e1-0554-464d-8b73-541b7e4fada9"
      unitRef="usd">516000000</us-gaap:InventoryNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfMjM4Njk_a2d92dec-e1f1-4934-9a15-0b554c1df578">Contingencies&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company&#x2019;s financial condition, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i)&#160;what claims, if any, will survive dispositive motion practice, (ii)&#160;the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii)&#160;how the discovery process will affect the litigation, (iv)&#160;the settlement posture of the other parties to the litigation and (v)&#160;any other factors that may have a material effect on the litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Product Liability Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gardasil/Gardasil 9&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Merck is a defendant in product liability lawsuits in the U.S. involving &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gardasil &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gardasil&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). As of March&#160;31, 2023, approximately 95 cases were filed and pending against Merck in either federal or state court. In these actions, plaintiffs allege, among other things, that they suffered various personal injuries after vaccination with &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gardasil &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gardasil&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; 9, with postural orthostatic tachycardia syndrome as a predominate alleged injury. In August 2022, the Judicial Panel on Multidistrict Litigation ordered that &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gardasil/Gardasil&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; 9 product liability cases pending in federal courts nationwide be transferred to Judge Robert J. Conrad in the Western District of North Carolina for coordinated pre-trial proceedings. There are fewer than 15 product liability cases pending outside the U.S., including one purported class action in Colombia.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Governmental Proceedings&lt;/span&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As previously disclosed, from time to time, the Company&#x2019;s subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company&#x2019;s policy is to cooperate with these authorities and to provide responses as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Commercial and Other Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Zetia&lt;/span&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As previously disclosed, Merck, Merck Sharp &amp;amp; Dohme, LLC. (MSD), Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in a number of lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases were consolidated in a federal multidistrict litigation (the Zetia MDL) before Judge Rebecca Beach Smith in the Eastern District of Virginia.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. In August 2020, the district court granted in part the direct purchasers&#x2019; motion for class certification and certified a class of 35 direct purchasers. In August 2021, the Fourth Circuit vacated the district court&#x2019;s class certification order and remanded for further proceedings consistent with the court&#x2019;s ruling. In September 2021, the direct purchaser plaintiffs filed a renewed motion for class certification. In April 2022, the district court denied the direct purchaser plaintiffs&#x2019; renewed motion for class certification. In August 2021, the district court granted certification of a class of indirect purchasers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In 2020 and 2021, United Healthcare Services, Inc., Humana Inc., Centene Corporation and others, and Kaiser Foundation Health Plan, Inc. (collectively, the Insurer Plaintiffs), each filed a lawsuit in a jurisdiction outside of the Eastern District of Virginia against the Merck Defendants and others, making similar allegations as those made in the Zetia MDL, as well as additional allegations about Vytorin. These cases have been transferred to the Eastern District of Virginia to proceed with the Zetia MDL and remain pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In February 2022, the Insurer Plaintiffs filed amended complaints. In March 2022, the Merck Defendants, jointly with other defendants, moved to dismiss certain aspects of the Insurer Plaintiffs&#x2019; complaints, including any claims for Vytorin damages. That motion to dismiss the Vytorin-related claims is still pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In April 2022, the direct purchaser plaintiffs moved for an order setting a deadline for direct purchasers of Zetia not currently parties to the case to file cases against defendants in order for those cases to be coordinated for trial with the existing direct purchaser plaintiffs and other MDL plaintiff groups. The court granted that motion, setting a deadline of June 30, 2022 for unnamed direct purchasers to file claims. On June 30, 2022, 23 new entities, many related, brought new complaints against defendants or otherwise sought to intervene. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On February 10, 2023, the district court denied the Merck Defendants&#x2019; and Glenmark Defendants&#x2019; motions for summary judgment. In April 2023, the Merck Defendants reached settlements with the direct purchaser and retailer plaintiffs and a proposed settlement, subject to court approval, with the indirect purchaser class. Under these agreements, Merck will pay $572.5 million to resolve the direct purchaser, retailer, and indirect purchaser plaintiffs&#x2019; claims, which was recorded as an expense in the Company&#x2019;s first quarter 2023 financial results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;RotaTeq Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;On March 3, 2023, the Mayor and City Council of Baltimore filed a putative class action against MSD in the Eastern District of Pennsylvania on behalf of all third-party payors in 35 states that indirectly purchased, paid, and/or provided reimbursement for some or all of the purchase price of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;RotaTeq &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(Rotavirus Vaccine, Live Oral, Pentavalent), other than for resale, from March 3, 2019 to the present. Plaintiff alleges that MSD violated federal and state antitrust laws and state consumer protection laws. Plaintiff alleges that MSD has implemented an anticompetitive vaccine bundling scheme whereby MSD leverages its alleged monopoly power in certain pediatric vaccine markets to maintain its alleged monopoly power in the U.S. market for rotavirus vaccines in order to charge supracompetitive prices for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;RotaTeq&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. Plaintiff seeks permanent injunctive relief and unspecified monetary damages on purchases of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;RotaTeq&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, trebled, and fees and costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bravecto Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As previously disclosed, in January 2020, the Company was served with a complaint in the U.S. District Court for the District of New Jersey. Following motion practice, the plaintiffs filed a second amended complaint on July 1, 2021, seeking to certify a nationwide class action of purchasers or users of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bravecto&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; (fluralaner) products in the U.S. or its territories between May 1, 2014 and July 1, 2021. Plaintiffs contend &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bravecto&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; causes neurological events in dogs and cats and alleges violations of the New Jersey Consumer Fraud Act, Breach of Warranty, Product Liability, and related theories. The Company moved to dismiss or, alternatively, to strike the class allegations from the second amended complaint, and that motion is pending. A similar case was filed in Quebec, Canada in May 2019. The Superior Court certified a class of dog owners in Quebec who gave &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bravecto&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Chew to their dogs between February 16, 2017 and November 2, 2018 whose dogs experienced one of the conditions in the post-marketing adverse reactions section of the labeling approved on November 2, 2018. The Company and plaintiffs each appealed the class certification decision. The Court of Appeal of Quebec heard the appeal in February 2022 and issued a decision in April 2022 allowing both parties&#x2019; appeals in part. The Court of Appeal amended the class period to start on July 2, 2014, allowed a second plaintiff to serve as a class representative, and modified the list of conditions in the class definition by adding &#x201c;death&#x201d; and removing &#x201c;lack of efficacy.&#x201d; The Court of Appeal also added to the list of questions to be considered by the trial court the questions of whether the Consumer Protection Act of Quebec applies to the sale of a veterinary product and, if so, whether it was breached. The Company sought leave to appeal to the Supreme Court of Canada, which was denied. The case is proceeding in the Superior Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company&#x2019;s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company&#x2019;s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bridion &lt;/span&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bridion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; (sugammadex) Injection.&#160;In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies.&#160;All actions in the District of New Jersey have been consolidated. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;may occur earlier. The West Virginia case was jointly dismissed with prejudice on August 8, 2022 in favor of proceeding in New Jersey. The remaining defendants in the New Jersey action have stipulated to infringement of the asserted claims and have stated they are withdrawing all remaining claims and defenses other than a defense seeking to shorten the patent term extension of the sugammadex patent to December 2022. The U.S. District Court for the District of New Jersey held a one-day trial on December 19, 2022 on this remaining patent term extension calculation defense. The court ordered post-trial briefing on this defense and held closing arguments on February 3, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has settled with five generic companies providing that these generic companies can bring their generic versions of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bridion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company has agreed to stay the lawsuit filed against two generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bridion &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;to the market before January 2026 or later, depending on any applicable pediatric exclusivity, unless the Company receives an adverse court decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia, Janumet, Janumet XR&lt;/span&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; As previously disclosed, the FDA granted pediatric exclusivity with respect to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(sitagliptin), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(sitagliptin/metformin HCI), and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; (sitagliptin and metformin HCl extended-release), which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA&#x2019;s Orange Book. Adding this exclusivity to the term of the key patent protection extended exclusivity on these products to January 2023. However, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin that expires in May 2027, including pediatric exclusivity (2027 salt/polymorph patent). In 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; following expiration of key patent protection, but prior to the expiration of the 2027 salt/polymorph patent, and a later granted patent owned by the Company covering the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; formulation where its term plus the pediatric exclusivity ends in 2029. The Company also filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel on Multidistrict Litigation entered an order transferring the Company&#x2019;s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Prior to the beginning of the scheduled October 2021 trial in the U.S. District Court for the District of Delaware on invalidity issues, the Company settled with all defendants scheduled to participate in that trial. In the Company&#x2019;s case against Mylan, a bench trial was held in December 2021 in the U.S. District Court for the Northern District of West Virginia, and the closing arguments were held in April 2022. In September 2022, the District Court for the Northern District of West Virginia issued a decision in the Company&#x2019;s favor, upholding all asserted patent claims. Mylan (now Viatris) appealed to the U.S. Court of Appeals for the Federal Circuit. The parties have now settled the matter, and Mylan has agreed to voluntarily dismiss the appeal following entry of an amended final judgment by the district court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Additionally, in 2019, Mylan filed a petition for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;inter partes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; review (IPR) at the U.S. Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2027 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial was held in February 2021 and a final decision was rendered in May 2021, holding that all of the challenged claims were not invalid. Mylan appealed the USPTO&#x2019;s decision to the U.S. Court of Appeals for the Federal Circuit, and a hearing was held in August 2022. In September 2022, the U.S. Court of Appeals for the Federal Circuit ruled in the Company&#x2019;s favor, upholding the USPTO&#x2019;s decision. Mylan submitted a combined petition for panel rehearing and rehearing en banc, for which the Company was invited by the court to provide a response. On February 3, 2023, the court issued a per curiam decision denying both rehearing requests.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In total, the Company has settled with 25 generic companies providing that these generic companies can bring their generic versions of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;to the market in May 2026 or earlier under certain circumstances, and their generic versions of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet XR &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;to the market in July 2026 or earlier under certain circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus&#x2019;s NDA seeking approval of its sitagliptin tablets. In December 2022, the parties reached settlement that included dismissal of the case without prejudice enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In January 2023, the Company received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying the Company that Zydus has filed a NDA seeking approval of sitagliptin/metformin HCl tablets and certifying that no valid or enforceable claim of any of the patents listed in FDA&#x2019;s Orange Book for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; will be infringed by the proposed Zydus product. In March 2023, the parties reached settlement enabling Zydus to seek final approval of a non-automatically substitutable product containing a different form of sitagliptin than that used in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;As a result of these favorable court rulings and settlement agreements related to the later expiring patent directed to the specific sitagliptin salt form of the products, the Company expects that &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Januvia &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; will not lose market exclusivity in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;the U.S. until May 2026 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet XR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; will not lose market exclusivity in the U.S. until July 2026&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;, although another non-automatically substitutable form of sitagliptin is likely to be available prior to 2026&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Supplementary Protection Certificates (SPCs) for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; expired between April 7 and 10, 2023, for the majority of European countries. Prior to expiration, generic companies sought revocation of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; SPCs in a number of European countries. In February 2022, a Finnish court referred certain questions to the Court of Justice of the European Union (CJEU) that could determine the validity of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;SPCs in Europe, for which an oral hearing was held on March 8, 2023, and an Advocate General Opinion is expected on July 13, 2023. If the CJEU renders a decision that negatively impacts the validity of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; SPCs throughout Europe, generic companies that were prevented from launching products during the SPC period in certain European countries may have an action for damages. Those countries include Belgium, Czech Republic, Ireland, Finland, France, Slovakia and Switzerland. If the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;SPCs are ultimately upheld, the Company has reserved its rights related to the pursuit of damages for those countries where a generic launched prior to expiry of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Janumet &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;SPC.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company filed a complaint against The Johns Hopkins University (JHU) on November 29, 2022, in the District Court of Maryland. This action concerns patents emerging from a joint research collaboration between Merck and JHU regarding the use of pembrolizumab, which Merck sells under the trade name &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. Merck and JHU partnered to design and conduct a clinical study administering &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Keytruda&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; to cancer patients having tumors that had the genetic biomarker known as microsatellite instability-high (MSI-H). After the conclusion of the study, JHU secured U.S. patents citing the joint research study. Merck alleges that JHU has breached the collaboration agreement by filing and obtaining these patents without informing or involving Merck and then licensing the patents to others. Merck therefore brought this action for breach of contract; declaratory judgment of noninfringement; and promissory estoppel. JHU answered the complaint on April 13, 2023, denying Merck&#x2019;s claims, and counterclaiming for willful infringement of five issued U.S. patents, including a demand for damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lynparza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; In December 2022, AstraZeneca Pharmaceuticals LP received a Paragraph IV Certification Letter under the Hatch-Waxman Act notifying AstraZeneca that Natco Pharma Limited (Natco) has filed an application to the FDA seeking pre-patent expiry approval to sell generic versions of Lynparza (olaparib) tablet. In February 2023, AstraZeneca and the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Natco. This lawsuit, which asserts one or more patents covering olaparib, automatically stays FDA approval of the generic application until June 2025 or until an adverse court decision, if any, whichever may occur earlier.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Other Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company&#x2019;s financial condition, results of operations or cash flows either individually or in the aggregate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#00857c;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Legal Defense Reserves&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company&#x2019;s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of March&#160;31, 2023 and December&#160;31, 2022 of approximately $225 million and $230 million, respectively, represents the Company&#x2019;s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LegalCostsPolicyTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfMjM4ODI_742de232-8515-4d34-814a-a249c63924e4">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.</us-gaap:LegalCostsPolicyTextBlock>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ie81327a316a94b36974954a7e8642bc5_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfNjM4Mg_077e1822-fc37-45b9-a87e-2b9a60f0b7fb"
      unitRef="case">95</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ide0712a78628418ab61bbe9bb313aae7_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfNjk5MQ_66d877f2-2855-4d20-a17d-2356ffed2073"
      unitRef="case">15</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i7358a61460544d15a70b0957807efa73_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfNzA1NA_7d77d8a9-f37b-4c13-845a-debef74650e7"
      unitRef="case">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i674ee2f2e244467391945b56813ef740_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfOTE3MQ_27bedc13-deb8-4aff-a0a0-29ea498e6a54"
      unitRef="direct_purchaser">35</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i486acde0965b4e4fa567b783874fdd1b_D20220630-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfMTExNTU_67e7e2c1-fcb5-42eb-8851-48b975b16c89"
      unitRef="claim">23</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i07e39fac74fc4d08a501e1e14a991816_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfNTQ5NzU1OTAwNzMx_80c4d5be-3421-4a0a-b221-69ca44c1f0e1"
      unitRef="usd">-572500000</us-gaap:GainLossRelatedToLitigationSettlement>
    <mrk:LossContingencyNumberOfStatesInWhichPlaintiffsReside
      contextRef="i88f1868d275a4b89ac8e4f956b24ddc5_I20230303"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfMjc0ODc3OTE1NjQwNA_7d9cd40d-964c-4f9f-9203-61ffda2d796a"
      unitRef="state">35</mrk:LossContingencyNumberOfStatesInWhichPlaintiffsReside>
    <mrk:LossContingencyTrialPeriod
      contextRef="i4305661e65274f559b5b59766d3c5cc3_D20221219-20221219"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfMjc0ODc3OTE1NjQwNw_9663f7fe-ce41-4262-9103-cfb75f192549">P1D</mrk:LossContingencyTrialPeriod>
    <us-gaap:LossContingencyClaimsSettledNumber
      contextRef="i4bd3fe27e3bf4036897cd39ae0448f14_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfMTU2NDc_e41291d9-fbdc-4ace-adb5-d485d6a1750a"
      unitRef="company">5</us-gaap:LossContingencyClaimsSettledNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i79aeb0bcc641443b80308ef30bbad1d3_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfMTU5NDE_97198d3d-5fdf-4063-9c7a-e7ddd8204303"
      unitRef="company">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyClaimsSettledNumber
      contextRef="id8407355ea334e558a58d39cf813e848_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfNTQ5NzU1ODUzOTg3_58fcfea1-9958-4bb9-8d6b-bc828abcfaed"
      unitRef="company">25</us-gaap:LossContingencyClaimsSettledNumber>
    <us-gaap:LossContingencyPatentsAllegedlyInfringedNumber
      contextRef="i270837c6ca8b41c49574b8b379172454_D20230413-20230413"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfNTQ5NzU1ODU0MDIz_db06a4e7-66fd-4e4a-afcb-a46d2bbdd18b"
      unitRef="patent">5</us-gaap:LossContingencyPatentsAllegedlyInfringedNumber>
    <us-gaap:LitigationReserve
      contextRef="i5913ce6cd24f4f45a393b8a13ce74d4d_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfMjMyNjg_3cea9046-e2cc-4593-8c4b-44b32a39b73f"
      unitRef="usd">225000000</us-gaap:LitigationReserve>
    <us-gaap:LitigationReserve
      contextRef="ica1e472338aa4a5298e4b867322ded49_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY181OC9mcmFnOjc5OGI2NTAyMDFkYjRmMjU4ZmQ1NWRmYmYzNGU3NmZhL3RleHRyZWdpb246Nzk4YjY1MDIwMWRiNGYyNThmZDU1ZGZiZjM0ZTc2ZmFfNTQ5NzU1ODU0MjMy_7de2f884-2dc4-4988-9930-4051c329a43b"
      unitRef="usd">230000000</us-gaap:LitigationReserve>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RleHRyZWdpb246YjZhODViNTUxOGFlNDk3OWEzZTZlYWM5YmY3ZmNkMTlfMjA_a3624188-3689-4101-958b-3de4cf30928e">Equity&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;br/&gt;Paid-In&lt;br/&gt;Capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Retained&lt;br/&gt;Earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Non-&lt;br/&gt;controlling&lt;br/&gt;Interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ and shares in millions except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Par&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(57,109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash dividends declared on common stock ($0.69 per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,754)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,754)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation plans and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(57,063)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56,489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash dividends declared on common stock ($0.73 per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,863)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,863)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Treasury stock shares purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation plans and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,883)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56,577)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityTableTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RleHRyZWdpb246YjZhODViNTUxOGFlNDk3OWEzZTZlYWM5YmY3ZmNkMTlfMzA_69ef70d4-a187-4028-b94e-703e168d085e">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.378%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other&lt;br/&gt;Paid-In&lt;br/&gt;Capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Retained&lt;br/&gt;Earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Non-&lt;br/&gt;controlling&lt;br/&gt;Interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ and shares in millions except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Par&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(57,109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash dividends declared on common stock ($0.69 per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,754)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,754)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation plans and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net loss attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(57,063)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56,489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash dividends declared on common stock ($0.73 per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,863)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,863)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Treasury stock shares purchased&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation plans and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,883)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56,577)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia75c3b66a14446a7b7855544f19742bf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMy0xLTEtMS0xMzE2MTg_00e39d87-4530-4b70-af6d-4051e5b842b3"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia75c3b66a14446a7b7855544f19742bf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMy0yLTEtMS0xMzE2MTg_4ddc6db0-4b61-43ec-b275-702ca36a6335"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ice6bdceaee0c415785e978b1546e824f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMy0zLTEtMS0xMzE2MTg_2bff4825-46c6-4871-8a42-dfdda7ef581f"
      unitRef="usd">44238000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4f9c7cab12f84742bc529ca888140834_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMy00LTEtMS0xMzE2MTg_7af0b20a-1f5d-4b8c-8931-e73c20ffc589"
      unitRef="usd">53696000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0c01235f9a47471bbfd246c179b8ec70_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMy01LTEtMS0xMzE2MTg_f5edb140-e0b3-4b62-b7f4-dbd1f5ffd6ef"
      unitRef="usd">-4429000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ifa0666b9b0854af18214a4de1da949d6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMy02LTEtMS0xMzE2MTg_193ab8bd-5208-430b-b226-2f784e403788"
      unitRef="shares">1049000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifa0666b9b0854af18214a4de1da949d6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMy03LTEtMS0xMzE2MTg_49b4d697-57b2-4a04-b3b7-d90db55b09fc"
      unitRef="usd">-57109000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i957a5e7283804544961eeffd229d90ef_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMy04LTEtMS0xMzE2MTg_efc21552-1da4-413f-9ca5-fa493bef71c8"
      unitRef="usd">73000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if2cb2241175c4c8c8fd5daf0a86385e3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMy05LTEtMS0xMzE2MTg_479c921e-7b99-4e2a-b26e-3dd32b9624ae"
      unitRef="usd">38257000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ieba2932606cf4136b76cf64715d17f5c_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfNC00LTEtMS0xMzE2MTg_7ee6c7b2-ac48-495f-b230-f84f45694b37"
      unitRef="usd">4310000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfNC05LTEtMS0xMzE2MTg_6829220b-b062-4f31-a045-b1a7c53f88e7"
      unitRef="usd">4310000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ifce529878ee94fbc97ff3cdc8e49ccb4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfNS01LTEtMS0xMzE2MTg_0039b2f6-f0ee-43ca-9820-36979d9df1e7"
      unitRef="usd">60000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfNS05LTEtMS0xMzE2MTg_903c0510-1faa-445d-baf6-e24595d17b18"
      unitRef="usd">60000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfNi0wLTEtMS0xMzE2MTgvdGV4dHJlZ2lvbjo4NjIzMzlmYTg1Mjg0YjA5YjU1ZWQwMjNmNDMxYzljNl80NQ_c8eaff0d-d63b-42c3-8300-eea32f0c3040"
      unitRef="usdPerShare">0.69</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="ieba2932606cf4136b76cf64715d17f5c_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfNi00LTEtMS0xMzE2MTg_eef64ab9-ceac-4d12-a773-31a0349ced8a"
      unitRef="usd">1754000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfNi05LTEtMS0xMzE2MTg_83146dbb-86de-4d39-a50e-febd3580a5ef"
      unitRef="usd">1754000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockholdersEquityOther
      contextRef="i918170e5b2fc416bb5213a74ad72646f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfOC0zLTEtMS0xMzE2MTg_6ec3c77d-efae-4b88-a41b-118c6d8adb57"
      unitRef="usd">-37000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i6faee1c09a204c63baa2f8635ef78da4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfOC03LTEtMS0xMzE2MTg_bf3018f8-1928-4e6d-8489-c663bc3cd424"
      unitRef="usd">-46000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfOC05LTEtMS0xMzE2MTg_434ef5ac-1204-4ce4-a6ac-e84e9e547ee6"
      unitRef="usd">-83000000</us-gaap:StockholdersEquityOther>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i4725be788d3c4f1f966fba475c841405_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfOS04LTEtMS0xMzE2MTg_db25c73b-064f-4387-997b-18b202361271"
      unitRef="usd">3000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfOS05LTEtMS0xMzE2MTg_1c3da830-c2b5-42ab-b273-eb255e45a8df"
      unitRef="usd">3000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6e2497db5f4b4eda93858dd1c188cfb5_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTEtMS0xLTEtMTMxNjE4_64786792-553d-4c53-925d-d075e2799de7"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6e2497db5f4b4eda93858dd1c188cfb5_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTEtMi0xLTEtMTMxNjE4_1cbf0e51-20e5-4105-9a31-09794fe159b7"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i08889407a4ca4fa69735b8332945794b_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTEtMy0xLTEtMTMxNjE4_a79cd451-8411-4f1a-a131-bb354873202b"
      unitRef="usd">44275000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idcc9c8d75d064da9855b8d3b37c02b10_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTEtNC0xLTEtMTMxNjE4_6f2b82bd-1d18-4c4f-af22-1e5116bb94ff"
      unitRef="usd">56252000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i42da78b36e31450dab3194041180b0ee_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTEtNS0xLTEtMTMxNjE4_557a9836-7ad8-46a3-935a-00932fd70e16"
      unitRef="usd">-4369000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="id895bb14f7154486a761071e11a287ca_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTEtNi0xLTEtMTMxNjE4_e8ef6fb9-4bfc-4800-b351-5e04b6d58a25"
      unitRef="shares">1049000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id895bb14f7154486a761071e11a287ca_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTEtNy0xLTEtMTMxNjE4_9006f905-2967-4620-869f-6b10a7badd5f"
      unitRef="usd">-57063000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4350e7d8d13e45848709eed82cdba738_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTEtOC0xLTEtMTMxNjE4_1809f653-65d3-4a1e-b698-943e127d3e2c"
      unitRef="usd">70000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1ff3b595ae954906bf225b8a7cc58b69_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTEtOS0xLTEtMTMxNjE4_271ac0f6-c83c-4eb0-8ff9-5f89970b1acd"
      unitRef="usd">40953000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i15d6c8aebc384e4b973cac8799704239_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTItMS0xLTEtMTMxNjE4_009c386e-688d-4ce3-830e-210049a2807c"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i15d6c8aebc384e4b973cac8799704239_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTItMi0xLTEtMTMxNjE4_f2bbb453-e234-4bac-8248-772151c439f5"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icb5a854388ff4957836b5593bd4f37e4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTItMy0xLTEtMTMxNjE4_8b67cc09-b6eb-4d1e-9398-0fc5705d094d"
      unitRef="usd">44379000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie7b73a7dc82c4055afd7242f0e94f662_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTItNC0xLTEtMTMxNjE4_4f2ccda2-ed8b-4189-856c-5e26cfd31fa0"
      unitRef="usd">61081000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3b21fb880d134a06abed66e7d998914f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTItNS0xLTEtMTMxNjE4_35542f8a-cf77-4c65-a246-c6addc3425d4"
      unitRef="usd">-4768000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i796d55aed90341e6a68727c28ffcab70_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTItNi0xLTEtMTMxNjE4_93597b8b-97b0-4928-a347-b7260c51e041"
      unitRef="shares">1039000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i796d55aed90341e6a68727c28ffcab70_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTItNy0xLTEtMTMxNjE4_81a6fee2-ed67-4c4f-bee6-cb46c6262f1e"
      unitRef="usd">-56489000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3bc10dff04eb494ba85791126e4db053_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTItOC0xLTEtMTMxNjE4_ca799a99-a538-4b54-af0e-7338ccfc3e3b"
      unitRef="usd">67000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTItOS0xLTEtMTMxNjE4_7cb7a964-11ac-4a10-872b-984fba4248b5"
      unitRef="usd">46058000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i87e04afadbc24d00bf0c906ad452972e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTMtNC0xLTEtMTMxNjE4_77490c9b-2824-4712-b2dc-a5598ef4cec5"
      unitRef="usd">2821000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTMtOS0xLTEtMTMxNjE4_6b1597ce-de1d-45ae-a2fb-dce203385551"
      unitRef="usd">2821000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibe63a010ec0a40ed91fe4b6b16e51a63_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTQtNS0xLTEtMTMxNjE4_211c4cd3-8f60-4393-bee7-5f1b5240aa14"
      unitRef="usd">-115000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTQtOS0xLTEtMTMxNjE4_158da7f7-bc51-4522-a2d2-ef6c9564860a"
      unitRef="usd">-115000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTUtMC0xLTEtMTMxNjE4L3RleHRyZWdpb246MDIwZjA5OGQxNDVlNDFlMzkyYjViM2VmNDY0MDQzZDZfNDU_93a1a064-af7d-43b4-b1e4-ba0cc5ecd5e2"
      unitRef="usdPerShare">0.73</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="i87e04afadbc24d00bf0c906ad452972e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTUtNC0xLTEtMTMxNjE4_d097457b-ecdf-45ea-b8d7-fa6140ea494b"
      unitRef="usd">1863000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTUtOS0xLTEtMTMxNjE4_aac68bce-43bc-4ea2-bc21-4d8637534e8a"
      unitRef="usd">1863000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ic41cc6c0be824cbeb1598b4ddbddb1ed_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTYtNi0xLTEtMTM3ODE5_1b9678c8-10a3-47d3-be0b-b983b0909850"
      unitRef="shares">1000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ic41cc6c0be824cbeb1598b4ddbddb1ed_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTYtNy0xLTEtMTM3ODE5_1654c72c-4652-4fd7-bce0-6eb4976632d9"
      unitRef="usd">149000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTYtOS0xLTEtMTM3ODE5_60570ec4-daf6-43d7-948f-b4696c83b26e"
      unitRef="usd">149000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockholdersEquityOther
      contextRef="ied44c0afd9384c30953e94941daa0cb0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTYtMy0xLTEtMTMxNjE4_bfb140c9-53be-488c-ae2b-be5a2f37f9c0"
      unitRef="usd">-88000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ic41cc6c0be824cbeb1598b4ddbddb1ed_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTYtNy0xLTEtMTMxNjE4_a6149862-b2f5-4ff8-a2cf-4b83052e1aff"
      unitRef="usd">-61000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTYtOS0xLTEtMTMxNjE4_b1f25aab-cbf7-4b89-9e81-c5d02327e2c1"
      unitRef="usd">-149000000</us-gaap:StockholdersEquityOther>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i65afee1f42ae486f84514163f3843f68_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTctOC0xLTEtMTMxNjE4_548eff4e-54fc-4857-ac1c-28935f703c7b"
      unitRef="usd">-4000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTctOS0xLTEtMTMxNjE4_9ca324f8-7231-43ee-ab3e-53121d69602f"
      unitRef="usd">-4000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="id1742aab8c35467db6f531e481322561_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTktMS0xLTEtMTMxNjE4_5e8636c3-f860-4177-8d79-69d9e020965c"
      unitRef="shares">3577000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id1742aab8c35467db6f531e481322561_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTktMi0xLTEtMTMxNjE4_3a6cfe71-aa08-4117-b5b6-70c8c954676d"
      unitRef="usd">1788000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b3b6bd9f9044238b1478ab578648204_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTktMy0xLTEtMTMxNjE4_835da5bc-b1ed-412c-99b8-6e363da3232f"
      unitRef="usd">44467000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i18372378d12a4968ac3f82433fa9ffdd_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTktNC0xLTEtMTMxNjE4_0cee5ce6-7fa5-4bf0-a945-bd94cbdda1b4"
      unitRef="usd">62039000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i60e7a6142fec4b32aa305b679a0d9a87_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTktNS0xLTEtMTMxNjE4_0f900243-0722-4d81-8828-c9462d27c4ba"
      unitRef="usd">-4883000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ie4437cb5ce2e4c6cb15d052910fc825b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTktNi0xLTEtMTMxNjE4_96f2ad4c-fd9c-45b4-b596-106d27e47a1c"
      unitRef="shares">1040000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie4437cb5ce2e4c6cb15d052910fc825b_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTktNy0xLTEtMTMxNjE4_b397eb37-0a27-4cd2-84f8-9d320d35eebc"
      unitRef="usd">-56577000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8aa514bfad3f4f6883b1d3d93683f530_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTktOC0xLTEtMTMxNjE4_d7db5414-8597-4614-b692-73f44d934a00"
      unitRef="usd">71000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5c3c68968d5a49b98049b259f527466f_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182MS9mcmFnOmI2YTg1YjU1MThhZTQ5NzlhM2U2ZWFjOWJmN2ZjZDE5L3RhYmxlOjdkOTNkOGQ4MjM3YzRjMjg4ZTY4NzFhZTc0YzBkMjc5L3RhYmxlcmFuZ2U6N2Q5M2Q4ZDgyMzdjNGMyODhlNjg3MWFlNzRjMGQyNzlfMTktOS0xLTEtMTMxNjE4_60259264-e5ec-44d1-aa27-82518ff19967"
      unitRef="usd">46905000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RleHRyZWdpb246YzRiMjQ5MmIzMjMxNGRhNmJhMzhkMTgyMTFmOTUwZDlfOQ_0f12f849-f5a4-4846-863e-6737f43a2e6f">Pension and Other Postretirement Benefit Plans&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost (credit) of such plans consisted of the following components:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of unrecognized prior service credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (gain) loss amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of unrecognized prior service credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net gain amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;In connection with restructuring actions (see Note&#160;5), termination charges were recorded on pension plans related to expanded eligibility for certain employees e&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;x&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;iting Merck. Also, in connection with these restructuring activities, curtailments were recorded on certain pension plans. In addition, lump sum payments to U.S. pension plan participants triggered a partial settlement resulting in a charge of $21&#160;million in the first quarter of 2023. This partial settlement triggered a remeasurement of some of the Company&#x2019;s U.S. pension plans. The remeasurement, which was calculated using discount rates and asset values as of March&#160;31, 2023, resulted in a net increase of $44&#160;million to net pension liabilities and also resulted in a related adjustment to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The components of net periodic benefit cost (credit) other than the service cost component are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other (income) expense, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; (see Note&#160;11), with the exception of certain amounts for termination benefits and curtailments which are recorded in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; if the event giving rise to the termination benefits or curtailment is related to restructuring actions.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="id12f95a53e9f4822b4ac3324b1225c13_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RleHRyZWdpb246YzRiMjQ5MmIzMjMxNGRhNmJhMzhkMTgyMTFmOTUwZDlfMjM3NA_27e92262-4dcb-446c-83d7-b3bf5dd3bc32">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost (credit) of such plans consisted of the following components:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.677%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of unrecognized prior service credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net (gain) loss amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Curtailments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ia6ae890426d14159b7b476af5430efdb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMy0xLTEtMS0xMzE2MTg_bc50d610-0f0e-4ec7-972a-239d01f1578b"
      unitRef="usd">76000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i7fc54055a2e1411986ddfe6f5fa717bb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMy0zLTEtMS0xMzE2MTg_e925becf-d54a-4a3e-9f71-d06d95ef6b0b"
      unitRef="usd">49000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="icfb8b583363441eba27b2030dcb092df_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMy01LTEtMS0xMzE2MTg_bce15ca3-af33-4069-b8ae-cf90a91668a9"
      unitRef="usd">99000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i7c9f187d5e3f441eacceb4c421ba47e0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMy03LTEtMS0xMzE2MTg_360fe79a-ce15-4b0d-9ddf-a36b730563da"
      unitRef="usd">75000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ia6ae890426d14159b7b476af5430efdb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNC0xLTEtMS0xMzE2MTg_ce68275b-2586-4ad3-98a5-e060e1147a83"
      unitRef="usd">133000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i7fc54055a2e1411986ddfe6f5fa717bb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNC0zLTEtMS0xMzE2MTg_eaefb7de-0edd-454b-a7c9-42dab90ee439"
      unitRef="usd">74000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="icfb8b583363441eba27b2030dcb092df_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNC01LTEtMS0xMzE2MTg_46f55eaa-ff9e-4c24-a5cf-ce02b3dd74f6"
      unitRef="usd">103000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i7c9f187d5e3f441eacceb4c421ba47e0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNC03LTEtMS0xMzE2MTg_85c474bc-135d-4e46-bc7f-220fdbc2acf1"
      unitRef="usd">38000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ia6ae890426d14159b7b476af5430efdb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNS0xLTEtMS0xMzE2MTg_7f0a9699-e219-4ab9-8d41-929217a8c069"
      unitRef="usd">187000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i7fc54055a2e1411986ddfe6f5fa717bb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNS0zLTEtMS0xMzE2MTg_1bec951e-9ef8-4389-a54f-ac365441058e"
      unitRef="usd">128000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="icfb8b583363441eba27b2030dcb092df_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNS01LTEtMS0xMzE2MTg_f178e151-3c0e-4b7f-8d49-44457f298800"
      unitRef="usd">196000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i7c9f187d5e3f441eacceb4c421ba47e0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNS03LTEtMS0xMzE2MTg_2d032457-09d4-402a-875f-8a2dd780f0d3"
      unitRef="usd">101000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ia6ae890426d14159b7b476af5430efdb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNi0xLTEtMS0xMzE2MTg_0d92a81f-84cd-411d-a033-71d5121cb9b9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i7fc54055a2e1411986ddfe6f5fa717bb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNi0zLTEtMS0xMzE2MTg_0bdda1e1-1499-4eb3-b56d-8e4f9bf0fcd5"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="icfb8b583363441eba27b2030dcb092df_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNi01LTEtMS0xMzE2MTg_83365e9f-dfc1-407a-ac75-37d8c7011f50"
      unitRef="usd">-8000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i7c9f187d5e3f441eacceb4c421ba47e0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNi03LTEtMS0xMzE2MTg_50eec8d2-c0b7-479b-96ab-77ccc96224aa"
      unitRef="usd">-4000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ia6ae890426d14159b7b476af5430efdb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNy0xLTEtMS0xMzE2MTg_9c541295-0226-4cb9-86e7-5c2193ac6913"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i7fc54055a2e1411986ddfe6f5fa717bb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNy0zLTEtMS0xMzE2MTg_041f3f1f-9aae-4e00-99eb-5d47589d6706"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="icfb8b583363441eba27b2030dcb092df_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNy01LTEtMS0xMzE2MTg_40f055d0-feaa-482a-b292-414119447d2a"
      unitRef="usd">-56000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i7c9f187d5e3f441eacceb4c421ba47e0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfNy03LTEtMS0xMzE2MTg_291f4111-2046-45e1-afdf-a65cf991e4c6"
      unitRef="usd">-25000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="ia6ae890426d14159b7b476af5430efdb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfOS0xLTEtMS0xMzE2MTg_5a9d163e-2113-4feb-9c1a-6a70693bdade"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i7fc54055a2e1411986ddfe6f5fa717bb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfOS0zLTEtMS0xMzE2MTg_88d0d1de-80d6-401d-a96c-8b24230aef7e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="icfb8b583363441eba27b2030dcb092df_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfOS01LTEtMS0xMzE2MTg_3a61c696-8c48-4940-bc29-306a9f1e7d4f"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="i7c9f187d5e3f441eacceb4c421ba47e0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfOS03LTEtMS0xMzE2MTg_c4d51d50-96f0-4fdf-8267-35a0eb0f8227"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="ia6ae890426d14159b7b476af5430efdb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMTAtMS0xLTEtMTMxNjE4_bb68c941-c06c-44a0-97b7-d1311bfb71be"
      unitRef="usd">-21000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i7fc54055a2e1411986ddfe6f5fa717bb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMTAtMy0xLTEtMTMxNjE4_5af1743a-1dbe-4e1c-b8a3-9895e6eb73e2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="icfb8b583363441eba27b2030dcb092df_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMTAtNS0xLTEtMTMxNjE4_83756ca4-5ec6-4c1d-96fb-cf1d82aa3d9e"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i7c9f187d5e3f441eacceb4c421ba47e0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMTAtNy0xLTEtMTMxNjE4_b6f9fee0-967e-4741-a199-e7b1f4da27ff"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ia6ae890426d14159b7b476af5430efdb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMTEtMS0xLTEtMTMxNjE4_d02a4bee-a295-4c96-9430-48656b02422e"
      unitRef="usd">45000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i7fc54055a2e1411986ddfe6f5fa717bb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMTEtMy0xLTEtMTMxNjE4_9a6d5834-5eab-45f7-ae3a-343937984d65"
      unitRef="usd">-9000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="icfb8b583363441eba27b2030dcb092df_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMTEtNS0xLTEtMTMxNjE4_89e75757-00de-4678-8b9a-6d5a91652ef4"
      unitRef="usd">58000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i7c9f187d5e3f441eacceb4c421ba47e0_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmQxOTFiZmRjNmIzNTRlZjFhNGYxNTM4MDM0NjRjNWQ4L3RhYmxlcmFuZ2U6ZDE5MWJmZGM2YjM1NGVmMWE0ZjE1MzgwMzQ2NGM1ZDhfMTEtNy0xLTEtMTMxNjE4_3579012d-8762-40f2-9a32-d6765d80f3d3"
      unitRef="usd">33000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i48e93ba87cab4afc961e66db38e74311_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RleHRyZWdpb246YzRiMjQ5MmIzMjMxNGRhNmJhMzhkMTgyMTFmOTUwZDlfMjM3Ng_d22f16e8-c377-4bb7-9a6d-ffb833ba1a39">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of unrecognized prior service credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net gain amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i48e93ba87cab4afc961e66db38e74311_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfMi0xLTEtMS0xMzE2MTg_29f68b7d-a0e6-4222-b8db-c03b4dbc62e4"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i1ae10b4b780a435b8e0e8fa9ac83e826_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfMi0zLTEtMS0xMzE2MTg_73d10c4f-c0d9-43d0-85c2-b3bc9d15aa44"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i48e93ba87cab4afc961e66db38e74311_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfMy0xLTEtMS0xMzE2MTg_674b1119-47ff-4351-8d19-21a0f55b9b85"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i1ae10b4b780a435b8e0e8fa9ac83e826_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfMy0zLTEtMS0xMzE2MTg_1c0ff7b5-0ab1-4bd8-ad72-fd338c79a089"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i48e93ba87cab4afc961e66db38e74311_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfNC0xLTEtMS0xMzE2MTg_d12fa7c3-e5c6-4a47-baa2-cb65d0132be4"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i1ae10b4b780a435b8e0e8fa9ac83e826_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfNC0zLTEtMS0xMzE2MTg_a2d31808-20ba-4d3c-a083-2566a4668cd7"
      unitRef="usd">21000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i48e93ba87cab4afc961e66db38e74311_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfNS0xLTEtMS0xMzE2MTg_4b486b63-924c-4404-9650-39c984ee3c28"
      unitRef="usd">-12000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i1ae10b4b780a435b8e0e8fa9ac83e826_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfNS0zLTEtMS0xMzE2MTg_1e432350-0b2c-47a3-afee-290511ee84c1"
      unitRef="usd">-14000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i48e93ba87cab4afc961e66db38e74311_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfNi0xLTEtMS0xMzE2MTg_9b783ab4-019e-4537-8a64-ee3f17e999ea"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i1ae10b4b780a435b8e0e8fa9ac83e826_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfNi0zLTEtMS0xMzE2MTg_abb38f13-6628-4b0f-b3f6-c614699880fd"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i48e93ba87cab4afc961e66db38e74311_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfOS0xLTEtMS0xMzE2MTg_afb053dd-c992-46c5-931f-3bd631f868db"
      unitRef="usd">-15000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i1ae10b4b780a435b8e0e8fa9ac83e826_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RhYmxlOmI1NWMyN2U1M2YyZTQ1MmNiNzVjMmVjMGYzZDc3NjVjL3RhYmxlcmFuZ2U6YjU1YzI3ZTUzZjJlNDUyY2I3NWMyZWMwZjNkNzc2NWNfOS0zLTEtMS0xMzE2MTg_e6da31f9-161f-4433-9748-f9b5db3a3923"
      unitRef="usd">-23000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RleHRyZWdpb246YzRiMjQ5MmIzMjMxNGRhNmJhMzhkMTgyMTFmOTUwZDlfNTQ5NzU1ODIwNDQz_fec62dca-f4d5-4970-a61a-e106e8a55058"
      unitRef="usd">21000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182NC9mcmFnOmM0YjI0OTJiMzIzMTRkYTZiYTM4ZDE4MjExZjk1MGQ5L3RleHRyZWdpb246YzRiMjQ5MmIzMjMxNGRhNmJhMzhkMTgyMTFmOTUwZDlfMTU0OQ_8511f4af-951b-4e83-9a3c-07c449cb9124"
      unitRef="usd">-44000000</us-gaap:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RleHRyZWdpb246NjE1MGViYjZiZjJkNDdjYjhhOWEzMDkzYWYxOGI2MmFfNTQz_77d6322f-495b-49a8-abe5-645edbc9682b">Other (Income) Expense, Net&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net, consisted of:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exchange losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Income) loss from investments in equity securities, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(450)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net periodic defined benefit plan (credit) cost other than service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other, net (as reflected in the table above) in the first quarter of 2023 includes a $572.5&#160;million charge related to settlements with certain plaintiffs in the Zetia antitrust litigation (see Note&#160;8).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Interest paid for the three months ended March&#160;31, 2023 and 2022 was $208 million and $211 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RleHRyZWdpb246NjE1MGViYjZiZjJkNDdjYjhhOWEzMDkzYWYxOGI2MmFfNTMy_b340d380-d644-4b04-86a2-e75946091343">&lt;div style="margin-top:5pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other (income) expense, net, consisted of:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exchange losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(Income) loss from investments in equity securities, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(450)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net periodic defined benefit plan (credit) cost other than service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)&#160;&#160;&#160;&#160;Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag.</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfMi0xLTEtMS0xMzE2MTg_417fcad4-7b2b-41f6-8340-2c6e3a29e34e"
      unitRef="usd">112000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfMi0zLTEtMS0xMzE2MTg_dd8f0efd-258b-47ee-a5e6-d7c668c3fbf5"
      unitRef="usd">7000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfMy0xLTEtMS0xMzE2MTg_0f7948f9-55b1-4158-93d3-4eb7ae5a810a"
      unitRef="usd">242000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfMy0zLTEtMS0xMzE2MTg_a440762d-f421-41a8-9e57-736957bf4a0f"
      unitRef="usd">243000000</us-gaap:InterestExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfNC0xLTEtMS0xMzE2MTg_fe389e9d-6841-45c0-aaff-5db521a10efa"
      unitRef="usd">-61000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfNC0zLTEtMS0xMzE2MTg_7d48caf1-fdc9-4581-80b8-ef7cf2932001"
      unitRef="usd">-39000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfNS0xLTEtMS0xMzE2MTg_a6e95474-b090-4279-82a8-4ca384d387cb"
      unitRef="usd">450000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfNS0zLTEtMS0xMzE2MTg_f65933b2-02ac-461e-ae1c-d94d55becdf0"
      unitRef="usd">-708000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfNi0xLTEtMS0xMzE2MTg_19d0878c-2c26-4d71-bfdf-e13e344c1061"
      unitRef="usd">-115000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfNi0zLTEtMS0xMzE2MTg_a83031d2-9eaa-4ded-bb72-ebfd78c4321b"
      unitRef="usd">-121000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <mrk:OtherNonoperatingIncomeExpenseOther
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfNy0xLTEtMS0xMzE2MTg_a270fae4-fab0-4298-a8c7-791e19be4d4b"
      unitRef="usd">-463000000</mrk:OtherNonoperatingIncomeExpenseOther>
    <mrk:OtherNonoperatingIncomeExpenseOther
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfNy0zLTEtMS0xMzE2MTg_318ff1a0-1f99-4c29-84e6-f8d6582406c9"
      unitRef="usd">154000000</mrk:OtherNonoperatingIncomeExpenseOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfOC0xLTEtMS0xMzE2MTg_a42a836e-c95a-4390-a982-934bb9261b30"
      unitRef="usd">-89000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RhYmxlOmQ1MTE1ZDc2YTgwNDQ3Njk5MTY5ZmRhMjhmNzhlYzRiL3RhYmxlcmFuZ2U6ZDUxMTVkNzZhODA0NDc2OTkxNjlmZGEyOGY3OGVjNGJfOC0zLTEtMS0xMzE2MTg_40411eb7-290c-4a99-a4ed-b3c1efe6db04"
      unitRef="usd">-708000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i07e39fac74fc4d08a501e1e14a991816_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RleHRyZWdpb246NjE1MGViYjZiZjJkNDdjYjhhOWEzMDkzYWYxOGI2MmFfNTQ5NzU1ODE1MzA2_80c4d5be-3421-4a0a-b221-69ca44c1f0e1"
      unitRef="usd">-572500000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:InterestPaid
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RleHRyZWdpb246NjE1MGViYjZiZjJkNDdjYjhhOWEzMDkzYWYxOGI2MmFfNTA5_3f9fe702-c913-446d-aac7-906079c5f2a9"
      unitRef="usd">208000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY182Ny9mcmFnOjYxNTBlYmI2YmYyZDQ3Y2I4YTlhMzA5M2FmMThiNjJhL3RleHRyZWdpb246NjE1MGViYjZiZjJkNDdjYjhhOWEzMDkzYWYxOGI2MmFfNTE2_073f6b7d-7d2b-4bad-9e07-a8cd40c69667"
      unitRef="usd">211000000</us-gaap:InterestPaid>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183MC9mcmFnOmZjYjk5MjQxZTI4YjQ4MzViYTY0Y2FmNmVjZjUyNmQ1L3RleHRyZWdpb246ZmNiOTkyNDFlMjhiNDgzNWJhNjRjYWY2ZWNmNTI2ZDVfMTcyNA_b561dd59-fd06-4f46-abf2-b8bae80c0c1e">Taxes on IncomeThe effective income tax rates were 22.6% and 11.4% for the first quarter of 2023 and 2022, respectively. The effective income tax rate for the first quarter of 2023 reflects the unfavorable discrete impact of a charge for the acquisition of Imago for which no tax benefit was recognized, as well as higher foreign taxes, the impact of the R&amp;amp;D capitalization provision of the Tax Cuts and Jobs Act of 2017 on the Company&#x2019;s U.S. global intangible low-taxed income inclusion, and net unrealized gains from investments in equity securities, which were taxed at the U.S. tax rate, partially offset by higher foreign tax credits. The effective income tax rate in the first quarter of 2022 includes the favorable impact of net unrealized losses from investments in equity securities, which were taxed at the U.S. tax rate.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183MC9mcmFnOmZjYjk5MjQxZTI4YjQ4MzViYTY0Y2FmNmVjZjUyNmQ1L3RleHRyZWdpb246ZmNiOTkyNDFlMjhiNDgzNWJhNjRjYWY2ZWNmNTI2ZDVfNzY_4f83916f-7825-4290-9b6e-3241daa35023"
      unitRef="number">0.226</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183MC9mcmFnOmZjYjk5MjQxZTI4YjQ4MzViYTY0Y2FmNmVjZjUyNmQ1L3RleHRyZWdpb246ZmNiOTkyNDFlMjhiNDgzNWJhNjRjYWY2ZWNmNTI2ZDVfODM_8e518908-0a2f-4b5d-9662-4c93fb2d26fc"
      unitRef="number">0.114</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <mrk:TaxBenefitResultingFromAcquisitionCharge
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183MC9mcmFnOmZjYjk5MjQxZTI4YjQ4MzViYTY0Y2FmNmVjZjUyNmQ1L3RleHRyZWdpb246ZmNiOTkyNDFlMjhiNDgzNWJhNjRjYWY2ZWNmNTI2ZDVfMjc0ODc3OTA3NTc0OA_d609f97d-72fd-428b-a143-99ff04b22871"
      unitRef="usd">0</mrk:TaxBenefitResultingFromAcquisitionCharge>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RleHRyZWdpb246NjUxNWU3ZDMyOTZjNGQ1YmI2Zjc5MDM4ZDA1MjMxMTJfNDQ5_15ab1976-79a2-4368-a526-5e8b16739d87">Earnings Per Share&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The calculations of earnings per share are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.236%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ and shares in millions except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Income Attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common shares issuable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Average common shares outstanding assuming dilution &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic Earnings per Common Share Attributable to Merck &amp;amp; Co., Inc. Common Shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per Common Share Assuming Dilution Attributable to Merck &amp;amp; Co., Inc. Common Shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Issuable primarily under share-based compensation plans.&lt;/span&gt;&lt;/div&gt;For the first quarter of 2023 and 2022, 1 million and 7 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RleHRyZWdpb246NjUxNWU3ZDMyOTZjNGQ1YmI2Zjc5MDM4ZDA1MjMxMTJfNDYx_78002e68-a337-4efc-967c-d79086e29177">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The calculations of earnings per share are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.236%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ and shares in millions except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net Income Attributable to Merck&#160;&amp;amp; Co., Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common shares issuable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Average common shares outstanding assuming dilution &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic Earnings per Common Share Attributable to Merck &amp;amp; Co., Inc. Common Shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earnings per Common Share Assuming Dilution Attributable to Merck &amp;amp; Co., Inc. Common Shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Issuable primarily under share-based compensation plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNC0xLTEtMS0xMzE2MTg_83d23b6a-af3a-441b-a01d-dc74e3c73fd3"
      unitRef="usd">2821000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNC0xLTEtMS0xMzE2MTg_bf7181b2-d549-480f-8afb-653e35103a42"
      unitRef="usd">2821000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNC0zLTEtMS0xMzE2MTg_648701dc-ed48-46bf-8e67-e2c62d4ed953"
      unitRef="usd">4310000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNC0zLTEtMS0xMzE2MTg_7e7c14f8-226a-4f08-bd98-2e83b3a39731"
      unitRef="usd">4310000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNS0xLTEtMS0xMzE2MTg_615ef519-aa4a-49c3-a94f-efebfc5aafce"
      unitRef="shares">2538000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNS0zLTEtMS0xMzE2MTg_d076aaf5-53ab-4897-b20b-e76cf27118de"
      unitRef="shares">2528000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNi0xLTEtMS0xMzE2MTg_40b45c6c-53d6-485e-a9c9-ac5d349900d8"
      unitRef="shares">13000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNi0zLTEtMS0xMzE2MTg_a5404a0a-54c8-4549-bf26-9631509c4344"
      unitRef="shares">9000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNy0xLTEtMS0xMzE2MTg_af551db3-0e9a-4d33-8b9f-c988c9ae2b7b"
      unitRef="shares">2551000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfNy0zLTEtMS0xMzE2MTg_7db26e1d-bd26-4f41-b587-f8ab48a0c996"
      unitRef="shares">2537000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfMTEtMS0xLTEtMTMxNjE4_f16f05ec-d3f7-4a8d-895b-fba44d7e42bb"
      unitRef="usdPerShare">1.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfMTEtMy0xLTEtMTMxNjE4_2dfe0dfd-0e6a-455d-92ee-ca8926c301c4"
      unitRef="usdPerShare">1.70</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfMTUtMS0xLTEtMTMxNjE4_16f50926-d120-46fc-bc50-68cd6f7b308a"
      unitRef="usdPerShare">1.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RhYmxlOmZjYzBlNTljZmNmMzRjZmY5NDM2MTYwMTU5NDNlYzY3L3RhYmxlcmFuZ2U6ZmNjMGU1OWNmY2YzNGNmZjk0MzYxNjAxNTk0M2VjNjdfMTUtMy0xLTEtMTMxNjE4_cfab628f-6e32-4deb-8ae3-a2f9342604bc"
      unitRef="usdPerShare">1.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RleHRyZWdpb246NjUxNWU3ZDMyOTZjNGQ1YmI2Zjc5MDM4ZDA1MjMxMTJfMTYw_c557fab6-60e1-44aa-9ae4-80a542395262"
      unitRef="shares">1000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183My9mcmFnOjY1MTVlN2QzMjk2YzRkNWJiNmY3OTAzOGQwNTIzMTEyL3RleHRyZWdpb246NjUxNWU3ZDMyOTZjNGQ1YmI2Zjc5MDM4ZDA1MjMxMTJfMTY3_4ff01dad-53bb-492d-9c5e-5f0bf55ce9c4"
      unitRef="shares">7000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RleHRyZWdpb246Njc5OWNmZTk5MmM4NDc1MWFmMDZhMTU3OGNjZjM4MDRfMzMz_b15db8b0-2371-4e6f-a81d-7feb1e9577cc">Other Comprehensive Income (Loss)&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Changes in each component of other comprehensive income (loss) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Employee&lt;br/&gt;Benefit&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Foreign Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance January 1, 2022, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance March 31, 2022, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance January 1, 2023, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance March 31, 2023, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,458)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,365)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,883)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Primarily relates to foreign currency cash flow hedges that were reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note&#160;10).&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.339%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RleHRyZWdpb246Njc5OWNmZTk5MmM4NDc1MWFmMDZhMTU3OGNjZjM4MDRfMzQ2_d99aa86d-93d7-40a8-b05d-693303caf62b">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Changes in each component of other comprehensive income (loss) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.531%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.577%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Employee&lt;br/&gt;Benefit&lt;br/&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Foreign Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance January 1, 2022, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance March 31, 2022, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,369)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance January 1, 2023, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reclassification adjustments, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance March 31, 2023, net of taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,458)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,365)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,883)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Primarily relates to foreign currency cash flow hedges that were reclassified from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;AOCL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt; to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Sales&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Includes net amortization of prior service cost, actuarial gains and losses, settlements and curtailments included in net periodic benefit cost (see Note&#160;10).&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.339%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:98.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i041db7ac9be74d218c0c23a960fc9a27_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMi0xLTEtMS0xMzE2MTg_44810d6b-12bb-4ebb-8780-dffbe96bc17e"
      unitRef="usd">144000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i33af4ad78921440a981af5aa4715c88a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMi0zLTEtMS0xMzE2MTg_fde501ed-d121-4679-b37c-d87cf6ff2b15"
      unitRef="usd">-2743000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iad527aecfb724bf3b4777b628fefa6b2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMi01LTEtMS0xMzE2MTg_5602d1b7-f946-476a-8997-6eb898f303a7"
      unitRef="usd">-1830000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0c01235f9a47471bbfd246c179b8ec70_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMi03LTEtMS0xMzE2MTg_86f111b7-a84a-4ec2-8fa0-8d4c7aecc3d7"
      unitRef="usd">-4429000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i7d1fa90756944324a7e1f45d9b688361_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMy0xLTEtMS0xMzE2MTg_f2fc2a50-705d-4181-8e01-d40afc780aab"
      unitRef="usd">148000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i74c46eee324f4931a0808813b06bc0f2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMy0zLTEtMS0xMzE2MTg_3807828e-c921-43fb-a2e4-420df6bc9e02"
      unitRef="usd">1000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i39397ad3a95445e39f9ab9b845a9867d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMy01LTEtMS0xMzE2MTg_49165ab9-5dc3-491c-93b5-6c6dca697ead"
      unitRef="usd">-18000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMy03LTEtMS0xMzE2MTg_c753905e-3607-400f-ab2b-98429325ca82"
      unitRef="usd">131000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i7d1fa90756944324a7e1f45d9b688361_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNC0xLTEtMS0xMzE2MTg_04ff338a-2b90-4ed6-bd79-ff2bdb702b7b"
      unitRef="usd">31000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i74c46eee324f4931a0808813b06bc0f2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNC0zLTEtMS0xMzE2MTg_25df2b21-d481-4186-9aba-138314bfc60e"
      unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i39397ad3a95445e39f9ab9b845a9867d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNC01LTEtMS0xMzE2MTg_44893c5d-f0cd-4c9f-b3ae-7391902ee51e"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNC03LTEtMS0xMzE2MTg_57c55961-6700-4334-a0a0-ccc8a40d8554"
      unitRef="usd">50000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i7d1fa90756944324a7e1f45d9b688361_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNS0xLTEtMS0xMzE2MTg_67a46a52-066d-4c51-a37c-449d8572b4a9"
      unitRef="usd">117000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i74c46eee324f4931a0808813b06bc0f2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNS0zLTEtMS0xMzE2MTg_20bb398a-30a0-4cc7-957b-ca1b82e0250f"
      unitRef="usd">-1000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i39397ad3a95445e39f9ab9b845a9867d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNS01LTEtMS0xMzE2MTg_0385cb5f-45ba-48d6-a250-801c15473624"
      unitRef="usd">-35000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNS03LTEtMS0xMzE2MTg_d0370e0b-025a-4978-a6cd-57946ac7a4ae"
      unitRef="usd">81000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i7d1fa90756944324a7e1f45d9b688361_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNi0xLTEtMS0xMzE2MTg_f1d504c7-965c-498c-ad7a-6b46731d82f7"
      unitRef="usd">68000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i74c46eee324f4931a0808813b06bc0f2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNi0zLTEtMS0xMzE2MTg_66e937a9-6b49-46e9-b62a-f533e2db84a3"
      unitRef="usd">-45000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i39397ad3a95445e39f9ab9b845a9867d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNi01LTEtMS0xMzE2MTg_ef33b7e4-9433-46b9-838b-e5ea08fa1518"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNi03LTEtMS0xMzE2MTg_cbba4b1b-94c1-4c62-8d93-af7c5579c4bd"
      unitRef="usd">23000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i7d1fa90756944324a7e1f45d9b688361_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNy0xLTEtMS0xMzE2MTg_c25c89a8-5c00-459e-b1ff-6f88ec6b5e90"
      unitRef="usd">14000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i74c46eee324f4931a0808813b06bc0f2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNy0zLTEtMS0xMzE2MTg_a4f92724-44d0-4daf-8b05-4729e90d9fc7"
      unitRef="usd">-12000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i39397ad3a95445e39f9ab9b845a9867d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNy01LTEtMS0xMzE2MTg_9c4c0598-222b-437f-8ea6-25de9ddb3994"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfNy03LTEtMS0xMzE2MTg_33ec11d8-bc14-4b4c-bc6d-85e941a4568c"
      unitRef="usd">2000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i7d1fa90756944324a7e1f45d9b688361_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfOC0xLTEtMS0xMzE2MTg_c3dfe168-cd5a-4f39-9c20-eb02a0955b31"
      unitRef="usd">54000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i74c46eee324f4931a0808813b06bc0f2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfOC0zLTEtMS0xMzE2MTg_c44ae61e-5e89-4caf-bee2-ffbd9054338f"
      unitRef="usd">-33000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i39397ad3a95445e39f9ab9b845a9867d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfOC01LTEtMS0xMzE2MTg_6c6779ea-a1ab-485a-aed7-a460e5b997a2"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfOC03LTEtMS0xMzE2MTg_51d07f75-ab80-4ccc-9d39-4c6e3b953679"
      unitRef="usd">21000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7d1fa90756944324a7e1f45d9b688361_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfOS0xLTEtMS0xMzE2MTg_cc363569-8c98-4432-a380-783b8897dd6e"
      unitRef="usd">63000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i74c46eee324f4931a0808813b06bc0f2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfOS0zLTEtMS0xMzE2MTg_76bc7884-3d22-4bfd-86e4-8eea8b88704b"
      unitRef="usd">32000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i39397ad3a95445e39f9ab9b845a9867d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfOS01LTEtMS0xMzE2MTg_5c4d85cf-db10-4870-bb0a-baeac0608b62"
      unitRef="usd">-35000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfOS03LTEtMS0xMzE2MTg_1333dd8e-1dd4-4fd0-aa63-aaee814d686f"
      unitRef="usd">60000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia2319d946cd342759a8f984524b58ad8_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTAtMS0xLTEtMTMxNjE4_c2753a79-c7f8-4191-b5bf-b15be4baa965"
      unitRef="usd">207000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i95a7d6e4f3b642ac849cb5b1af84aca1_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTAtMy0xLTEtMTMxNjE4_c706ce6c-c0f4-4619-8b4e-68a78f04c417"
      unitRef="usd">-2711000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic8a93158890945a9aa15c60a05506723_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTAtNS0xLTEtMTMxNjE4_b9c63d63-f143-4dd5-bff7-18bb4a37200e"
      unitRef="usd">-1865000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i42da78b36e31450dab3194041180b0ee_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTAtNy0xLTEtMTMxNjE4_54b20997-795c-4b88-8a83-b4e674de0736"
      unitRef="usd">-4369000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i31f76fe0b880480684d05d01c6f398ff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTEtMS0xLTEtMTMxNjE4_0c887a02-21c7-4164-8bf5-2436f00cf930"
      unitRef="usd">73000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8b83eed87b2d41c1a8c610f98765bba3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTEtMy0xLTEtMTMxNjE4_8cc9cd45-d572-480f-9303-8093278de5d6"
      unitRef="usd">-2408000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6d63d8c8b08843008160820a9757c059_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTEtNS0xLTEtMTMxNjE4_abac9ac0-2b80-4356-955e-c4ff9861b4b1"
      unitRef="usd">-2433000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3b21fb880d134a06abed66e7d998914f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTEtNy0xLTEtMTMxNjE4_65f6608a-8bb6-4134-ba6d-0fd93184f36a"
      unitRef="usd">-4768000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i5d68872fd99d4719972b30864e232d1d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTItMS0xLTEtMTMxNjE4_dd84de2f-d242-43bb-bfc8-d3bfc2b1f317"
      unitRef="usd">-66000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="iad583d8b44fc49feb98cc9caf016d5a4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTItMy0xLTEtMTMxNjE4_ba64b2ae-e33b-4ac2-9008-af2eab88bf17"
      unitRef="usd">-47000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="ife1d684ce4c949b38894572598414983_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTItNS0xLTEtMTMxNjE4_49703699-5a0b-4652-b159-d9582b6e1bd4"
      unitRef="usd">79000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTItNy0xLTEtMTMxNjE4_04560a5c-3dfc-4d30-a247-8f4b359633b2"
      unitRef="usd">-34000000</us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i5d68872fd99d4719972b30864e232d1d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTMtMS0xLTEtMTMxNjE4_50ed424b-af09-43d9-8c57-614acbe8fc3c"
      unitRef="usd">-14000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="iad583d8b44fc49feb98cc9caf016d5a4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTMtMy0xLTEtMTMxNjE4_e7ed1079-0111-47da-b167-d28477d37c03"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="ife1d684ce4c949b38894572598414983_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTMtNS0xLTEtMTMxNjE4_d80d2519-6c46-40d3-aa2c-6a8694a40e6f"
      unitRef="usd">20000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTMtNy0xLTEtMTMxNjE4_46b07516-ed3d-4dab-8bb0-d8c42dff25d3"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i5d68872fd99d4719972b30864e232d1d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTQtMS0xLTEtMTMxNjE4_022d8ce9-b8e4-4661-8a14-9303534f5856"
      unitRef="usd">-52000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="iad583d8b44fc49feb98cc9caf016d5a4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTQtMy0xLTEtMTMxNjE4_bfbb089e-3f91-402d-b77f-5adb5e3ea779"
      unitRef="usd">-45000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ife1d684ce4c949b38894572598414983_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTQtNS0xLTEtMTMxNjE4_1a5f7e54-b3e8-41ee-967d-d1c54eaf2691"
      unitRef="usd">59000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTQtNy0xLTEtMTMxNjE4_62892b5a-89a4-4b87-96f6-9a5f03c5d2ad"
      unitRef="usd">-38000000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i5d68872fd99d4719972b30864e232d1d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTUtMS0xLTEtMTMxNjE4_293f7994-d602-466b-935c-f543c7e00401"
      unitRef="usd">102000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="iad583d8b44fc49feb98cc9caf016d5a4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTUtMy0xLTEtMTMxNjE4_95bc1f2f-6e9d-47ed-a883-b9253a1e702e"
      unitRef="usd">7000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="ife1d684ce4c949b38894572598414983_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTUtNS0xLTEtMTMxNjE4_74113e62-de86-43ee-9b17-91a562957a47"
      unitRef="usd">-9000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTUtNy0xLTEtMTMxNjE4_cc32a334-3561-4a30-8ebb-aff6c9524b91"
      unitRef="usd">100000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i5d68872fd99d4719972b30864e232d1d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTYtMS0xLTEtMTMxNjE4_86bbacad-7c71-4512-b74c-b4ba1c7ada8a"
      unitRef="usd">21000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="iad583d8b44fc49feb98cc9caf016d5a4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTYtMy0xLTEtMTMxNjE4_592cef05-3b2d-4d8f-adb8-efd416df6083"
      unitRef="usd">2000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="ife1d684ce4c949b38894572598414983_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTYtNS0xLTEtMTMxNjE4_6575f2c5-b139-4798-a59e-f0e68418f78e"
      unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTYtNy0xLTEtMTMxNjE4_0f37f855-e7ed-48b0-a551-4e9c3a0dd067"
      unitRef="usd">23000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i5d68872fd99d4719972b30864e232d1d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTctMS0xLTEtMTMxNjE4_c5281d00-1799-4705-8807-e57fe3d60973"
      unitRef="usd">81000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="iad583d8b44fc49feb98cc9caf016d5a4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTctMy0xLTEtMTMxNjE4_c003d93a-807f-4383-a9fc-338e9c7f152a"
      unitRef="usd">5000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="ife1d684ce4c949b38894572598414983_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTctNS0xLTEtMTMxNjE4_44e31216-07b2-4f62-8efc-09d529966ff3"
      unitRef="usd">-9000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTctNy0xLTEtMTMxNjE4_df0d3458-7957-4239-a78a-85082040b024"
      unitRef="usd">77000000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5d68872fd99d4719972b30864e232d1d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTgtMS0xLTEtMTMxNjE4_36bdebc4-d9a8-4f3a-bdfc-df10e562783b"
      unitRef="usd">-133000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iad583d8b44fc49feb98cc9caf016d5a4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTgtMy0xLTEtMTMxNjE4_a83f2f5e-7ff0-4639-86b7-f9a9bc1f22aa"
      unitRef="usd">-50000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ife1d684ce4c949b38894572598414983_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTgtNS0xLTEtMTMxNjE4_66b67526-37cc-452f-92c5-8ba4ee1fc1cc"
      unitRef="usd">68000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTgtNy0xLTEtMTMxNjE4_3c343a9e-abab-4fc7-8b65-6d2ffa3d911f"
      unitRef="usd">-115000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7af996fcfb0942ebab3aa1e8cea2e1a4_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTktMS0xLTEtMTMxNjE4_775755c5-b1e3-42c5-987c-45e712d0bc7c"
      unitRef="usd">-60000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8e5c54f51e5440dd9db7d51479f49629_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTktMy0xLTEtMTMxNjE4_e7a84c46-8fc0-498f-84eb-0dd64cdde26a"
      unitRef="usd">-2458000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i44331becfc824debbd8e96c96c590f56_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTktNS0xLTEtMTMxNjE4_5a930cdf-1510-45e2-bae6-314e19b2f150"
      unitRef="usd">-2365000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i60e7a6142fec4b32aa305b679a0d9a87_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183Ni9mcmFnOjY3OTljZmU5OTJjODQ3NTFhZjA2YTE1NzhjY2YzODA0L3RhYmxlOmM4M2UzMGQwODBhOTQxNzY5NmVjZTBiZTM4MDM1NTgxL3RhYmxlcmFuZ2U6YzgzZTMwZDA4MGE5NDE3Njk2ZWNlMGJlMzgwMzU1ODFfMTktNy0xLTEtMTMxNjE4_58b4c4dd-a9fc-4a7b-b764-001bc601d98b"
      unitRef="usd">-4883000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfNTQ3Mw_8877f9a1-419b-4a94-a407-cc796264c2c3">Segment Reporting&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s operations are principally managed on a product basis and include two operating segments, Pharmaceutical and Animal Health, both of which are reportable segments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S.&#160;Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors, animal producers, farmers and pet owners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sales of the Company&#x2019;s products were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pharmaceutical:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Keytruda&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue-Lynparza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue-Lenvima&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue-Reblozyl&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Welireg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Gardasil/Gardasil &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;ProQuad/M-M-R &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;II&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;/Varivax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;RotaTeq&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Vaxneuvance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Pneumovax &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Vaqta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Hospital Acute Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Bridion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Prevymis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Primaxin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Dificid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Noxafil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zerbaxa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue-Adempas/Verquvo &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Adempas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Virology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Lagevrio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Isentress/Isentress&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;HD&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Belsomra&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Simponi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Remicade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Januvia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Janumet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other pharmaceutical &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total Pharmaceutical segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Animal Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Livestock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Companion Animals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total Animal Health segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. plus international may not equal total due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Alliance revenue for Lynparza and Lenvima represents Merck&#x2019;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note&#160;3).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Alliance revenue for Reblozyl represents royalties and, for 2022, also includes the receipt of a regulatory approval milestone payment (see Note&#160;3).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Alliance revenue for Adempas/Verquvo represents Merck&#x2019;s share of profits from sales in Bayer&#x2019;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note&#160;3).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(4)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(5)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased sales by $99&#160;million and $69&#160;million for the three months ended March&#160;31, 2023 and 2022, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the three months ended March&#160;31, 2023 and 2022 also includes $51&#160;million and $114&#160;million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by $3.1 billion and $2.9 billion for the three months ended March&#160;31, 2023 and 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Consolidated sales by geographic area where derived are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asia Pacific (other than China and Japan)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A reconciliation of segment profits to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Before Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Animal Health segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total segment profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unallocated:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(543)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Charge for Zetia antitrust litigation settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(573)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other unallocated, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,607)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company&#x2019;s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and purchase accounting adjustments are not allocated to segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfOTM_92d0a8f5-7ea6-4292-a1d9-a4cf9e489335"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfNTUwNQ_05fdad2b-f964-4b65-a6aa-55463b2bfa68">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Sales of the Company&#x2019;s products were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.888%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Int&#x2019;l&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Pharmaceutical:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Keytruda&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue-Lynparza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue-Lenvima&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue-Reblozyl&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Welireg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Vaccines&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Gardasil/Gardasil &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;ProQuad/M-M-R &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;II&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;/Varivax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;RotaTeq&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Vaxneuvance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Pneumovax &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Vaqta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Hospital Acute Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Bridion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Prevymis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Primaxin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Dificid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Noxafil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Zerbaxa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Cardiovascular&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Alliance revenue-Adempas/Verquvo &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Adempas&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Virology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Lagevrio&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;3,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Isentress/Isentress&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;HD&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Belsomra&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Simponi&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Remicade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Diabetes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Januvia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;Janumet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other pharmaceutical &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total Pharmaceutical segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;12,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Animal Health:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Livestock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Companion Animals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total Animal Health segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Total segment sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;6,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;14,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;7,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;8,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;15,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. plus international may not equal total due to rounding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Alliance revenue for Lynparza and Lenvima represents Merck&#x2019;s share of profits, which are product sales net of cost of sales and commercialization costs (see Note&#160;3).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(2)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Alliance revenue for Reblozyl represents royalties and, for 2022, also includes the receipt of a regulatory approval milestone payment (see Note&#160;3).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Alliance revenue for Adempas/Verquvo represents Merck&#x2019;s share of profits from sales in Bayer&#x2019;s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note&#160;3).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(4)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(5)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased sales by $99&#160;million and $69&#160;million for the three months ended March&#160;31, 2023 and 2022, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the three months ended March&#160;31, 2023 and 2022 also includes $51&#160;million and $114&#160;million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:Revenues
      contextRef="i8df183ec48194fc4a2c6f8e8d986193f_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNS0xLTEtMS0xMzE2MTg_ef2b120d-82cf-425c-bf17-0d8b4328bf97"
      unitRef="usd">3485000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf2b65d0efcd4588b8eaf74e00590ea7_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNS0zLTEtMS0xMzE2MTg_15002e29-bc96-473e-b310-574b29a87c4d"
      unitRef="usd">2310000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie772b761081d4a3f88dd5b139a18cde5_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNS01LTEtMS0xMzE2MTg_91234f17-3414-4369-8991-7bb8006a9ad8"
      unitRef="usd">5795000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id23605aa21764c15b522d6ea781638b6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNS03LTEtMS0xMzE2MTg_044f057b-9ed0-4726-8254-cc91383def5f"
      unitRef="usd">2779000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8b1fe39c7ec246f0a53097e0b00b0803_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNS05LTEtMS0xMzE2MTg_e64bb3b1-06cb-4484-aeb3-b34f27343f26"
      unitRef="usd">2030000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7caeaf606112447a8aa0d87b20c8f163_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNS0xMS0xLTEtMTMxNjE4_2e409739-686b-48f2-8fab-a534ed940485"
      unitRef="usd">4809000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if193ecf6603e436e9bc55f3e4f86a576_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNi0xLTEtMS0xMzE2MTg_94ed05c5-b448-447e-a261-e3ae0e338382"
      unitRef="usd">142000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4b3b69956cc9411da3f54f428aeeeb42_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNi0zLTEtMS0xMzE2MTg_3890109d-7d86-4663-ab06-325348a981e7"
      unitRef="usd">133000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4ef00ecad3374cfaa1259915898dc915_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNi01LTEtMS0xMzE2MTg_81acfbca-54ce-459b-a4a9-7a228af04df4"
      unitRef="usd">275000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id0d6b8513dcd4021a200090641fe0bff_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNi03LTEtMS0xMzE2MTg_2d4fdf33-6355-4938-81b0-59a862f9decd"
      unitRef="usd">141000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0666b87a008d48918f71fa4e40a3259d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNi05LTEtMS0xMzE2MTg_6a4dfb95-4059-4e70-bac1-52736254fad7"
      unitRef="usd">125000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ied5a517f75814ffdacb6613032349a19_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNi0xMS0xLTEtMTMxNjE4_ce2b4fb0-4458-4df5-b9f9-262c161c6911"
      unitRef="usd">266000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3bdd7b02457a4826aeec0e25dbfa4df0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNy0xLTEtMS0xMzE2MTg_790133c1-4058-4f19-b508-bc9bc557581f"
      unitRef="usd">153000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i373f00d87cd7457d9b079c9415e0c4ad_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNy0zLTEtMS0xMzE2MTg_9f347d7a-9176-4027-9b86-4f7b621ad47a"
      unitRef="usd">79000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic416d710ef924adc9df8131effd1c200_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNy01LTEtMS0xMzE2MTg_5eecc9b5-6917-4325-bbef-8d586cf33296"
      unitRef="usd">232000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i421974800c0844798343dd8cfc3f3a20_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNy03LTEtMS0xMzE2MTg_0e5c0569-f11f-47c5-b2c1-bd7635281d6c"
      unitRef="usd">156000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i26f185cbe1da4f4e89a1e2093171e27b_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNy05LTEtMS0xMzE2MTg_2c60a0aa-f6b9-488c-8055-0108620030f1"
      unitRef="usd">71000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia7706e3163ae4d58a5f8660cb640d5ba_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNy0xMS0xLTEtMTMxNjE4_aa3611ea-2e5f-44d0-94e4-2e9cb44b77f4"
      unitRef="usd">227000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf21fc9f03d342bbbd66be0123de6225_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOC0xLTEtMS0xMzE2MTg_ba66b2ec-a0bf-45fe-afb1-9dc52dcb8eb7"
      unitRef="usd">30000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i943ebcf31d20440ea90b753cb238fe02_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOC0zLTEtMS0xMzE2MTg_34b8ac87-3d93-491d-bc80-5e62ced6a1f9"
      unitRef="usd">12000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i245cacaf455e42329f9ae587d1a10cad_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOC01LTEtMS0xMzE2MTg_5ac0347c-c6aa-4452-b4ea-1238bcadc98f"
      unitRef="usd">43000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia13e94e1a90043bcaea2ffba6d27061a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOC03LTEtMS0xMzE2MTg_d6fa372a-29db-4d93-95ec-373ad653729e"
      unitRef="usd">27000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3f73d3370a5348dda651da8166f72bfc_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOC05LTEtMS0xMzE2MTg_254485a1-b420-4ddb-9070-730a8d7af23d"
      unitRef="usd">25000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2dba74425a51433497fa7e5529627e25_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOC0xMS0xLTEtMTMxNjE4_d2de489b-6e5b-416d-916d-149a5274be6e"
      unitRef="usd">52000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie40a08ab45e2491eaad9788d31bc031d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOS0xLTEtMS0xMzc0NDA_1adb609a-9bce-4383-888e-7e300a6c7e79"
      unitRef="usd">41000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i98d5687c5bca4aa0ae8be180444502a5_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOS0zLTEtMS0xMzc0NDA_ec4c6f90-c108-4860-81c2-091efdc43173"
      unitRef="usd">1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i148665041c5d4969a1b7468fc0b3306f_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOS01LTEtMS0xMzc0NDA_93b9bbaa-586a-49b0-8a26-b18af9af0238"
      unitRef="usd">42000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i245f27c3d3884d16886e2a02a3bea2be_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOS03LTEtMS0xMzc0NDA_9eca8a7a-0ddb-4fe0-8ff9-0956abb9f30c"
      unitRef="usd">18000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i683c95eda6cc4e83a3f200cd8c1ae979_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOS05LTEtMS0xMzc0NDA_a4b6e895-f779-4b5d-bf36-1df737ecc25c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iabc5de1d9ad9496abbed9093f2560c7e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfOS0xMS0xLTEtMTM3NDQw_6254b731-d2a1-4cdd-aeaa-054c8deeb219"
      unitRef="usd">18000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6d15bac232384d3d9b567829ed8b4e4c_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTAtMS0xLTEtMTMxNjE4_f9bed54c-4a2f-4ae3-afa7-37e2080b714e"
      unitRef="usd">416000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0eb110c2888a401a99ce08584a59ae29_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTAtMy0xLTEtMTMxNjE4_6d44ab5a-ef76-43cf-96e2-f5cb3e63075b"
      unitRef="usd">1556000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0622fda057824fe2acccd535fdedb1c4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTAtNS0xLTEtMTMxNjE4_752bbfd3-712e-4866-a1ec-3c2c19d4af3a"
      unitRef="usd">1972000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1317f96f8242416cb217168b296ac180_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTAtNy0xLTEtMTMxNjE4_d5569185-a478-4ce6-9edd-eebb5f7b0ed5"
      unitRef="usd">418000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i15590b4a502a4441b2031cb5e67c164c_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTAtOS0xLTEtMTMxNjE4_0176a57a-43a0-417f-82c1-6ef19d14c304"
      unitRef="usd">1042000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0272e13e3911432484c3574c4d88dea4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTAtMTEtMS0xLTEzMTYxOA_27e46f8e-652a-4297-b949-a2c714973d97"
      unitRef="usd">1460000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie1dd61290d2e4c28bdc142b28449b630_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTEtMS0xLTEtMTMxNjE4_df881402-b4dd-42bc-bdb9-ca896f30bb73"
      unitRef="usd">421000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0676bda79d3444beb30669ea1761cefa_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTEtMy0xLTEtMTMxNjE4_771f5bf0-476b-4f0b-a74d-eb96033d23c6"
      unitRef="usd">107000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i92cf8249b51045fc9f74f556cbb77945_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTEtNS0xLTEtMTMxNjE4_7525428d-e657-4a74-9c6b-ce730da27cd1"
      unitRef="usd">528000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idd868d1665e843e8ba8e68820863660a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTEtNy0xLTEtMTMxNjE4_340fe18e-f036-43be-a7cd-607a0c021571"
      unitRef="usd">371000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i85dada8cd49f441ca2211b4790538075_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTEtOS0xLTEtMTMxNjE4_9fb82f91-48f4-40c2-8966-74fb8360589b"
      unitRef="usd">99000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9e7b43ab9aca461cbd07c3408576229d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTEtMTEtMS0xLTEzMTYxOA_1e49a012-3af6-49c5-84d2-c2517239dff5"
      unitRef="usd">470000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i502537b5bd3244cba8148fdcded195c1_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTItMS0xLTEtMTMxNjE4_9e2ced00-99ed-4dfc-8db1-e55a286f0405"
      unitRef="usd">180000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idd1279562a9049789bcf67e36e1345e6_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTItMy0xLTEtMTMxNjE4_46cacb43-eb46-476d-ac6e-22f3a4566e80"
      unitRef="usd">117000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if12d006ccf6947e59b7e26e27405537e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTItNS0xLTEtMTMxNjE4_392ae0ce-1b6c-487a-b804-9d84727fe8b5"
      unitRef="usd">297000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2caa7eb6734e47f694c35387f0b24c5e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTItNy0xLTEtMTMxNjE4_9a44aaaa-f945-43cc-b00d-e80c2f15b178"
      unitRef="usd">175000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iefe80ade170b452d810ea857bfb36486_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTItOS0xLTEtMTMxNjE4_042a94b0-50cd-43f1-a354-450f88805877"
      unitRef="usd">41000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i168a16270ba04bf5bd0a98c57f6e7453_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTItMTEtMS0xLTEzMTYxOA_b7b7d7d7-8539-4fe0-ac52-89f511647ca5"
      unitRef="usd">216000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i38f3c51ed3c142088d512d3cf86a4e85_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtMS0xLTEtMTQwNzkz_fc2a3e1a-08d8-49b5-afe3-55dc744da2ae"
      unitRef="usd">94000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5facb3a2afd54e37a08fcb30616f2d40_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtMy0xLTEtMTQwNzkz_8781e8e5-aa49-4852-a335-1835e13b37ed"
      unitRef="usd">13000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i71c307b84c814567af562b778b4c1b53_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtNS0xLTEtMTQwNzkz_b62c2169-ae8e-45f4-829f-f7fbdccaeb49"
      unitRef="usd">106000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie8a9542dc59a4777a668cd31211b6c7a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtNy0xLTEtMTQwNzkz_fa20673d-0873-435f-a672-e41474cdc1c3"
      unitRef="usd">5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaa6e384e748d4e74833d7c8bd58e5051_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtOS0xLTEtMTQwNzkz_8d2ad58d-1417-45e4-9671-0cfc84a0d7ed"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a9cd1b2796b45cd823635c3a4ca1ec1_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtMTEtMS0xLTE0MDc5Mw_636c85f0-b166-4bf3-ab44-efdc270ecfa3"
      unitRef="usd">5000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icc1f221331e847f78e9890ad89af8d80_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTMtMS0xLTEtMTMxNjE4_624b7c58-4c09-42ba-9447-131afd4d1d2c"
      unitRef="usd">40000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iced6646c844d4419a1591abce5241bc1_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTMtMy0xLTEtMTMxNjE4_4fbabf03-716b-4068-8111-4078d3877b7a"
      unitRef="usd">56000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1d46a1bed5b64222a563d18e9091ab03_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTMtNS0xLTEtMTMxNjE4_32f352ba-63ba-44a6-96f7-a420dc4101d7"
      unitRef="usd">96000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iee7d83d494044d17ac974c40323b8bfa_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTMtNy0xLTEtMTMxNjE4_b6a38190-85ca-435a-aa28-090efeb5cf60"
      unitRef="usd">118000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf3bf82a5181435e9e26d6dfe9ccb7a1_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTMtOS0xLTEtMTMxNjE4_5452738d-004d-4b75-bd3b-7b66f362051e"
      unitRef="usd">55000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i83f5ca79492e42dba088722bf7ae9575_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTMtMTEtMS0xLTEzMTYxOA_c77eb623-e028-4786-bf10-3dde2d6851fc"
      unitRef="usd">173000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i556f1c52ae734ae6910cf6d6b9d26d16_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtMS0xLTEtMTMxNjE4_a39766a8-ac1e-4069-8f30-14db5ac60474"
      unitRef="usd">30000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie70b1f6ac9824c5c9604f2e6cda7b721_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtMy0xLTEtMTMxNjE4_a07d1e82-aa60-406d-96a2-a927daf3aede"
      unitRef="usd">10000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i13c7df0a730141689941ffc740882c67_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtNS0xLTEtMTMxNjE4_b2136ab7-b707-40b2-8c01-c9840620503f"
      unitRef="usd">40000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie19b5dd8e1da4e7ca8d5114cd25d465e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtNy0xLTEtMTMxNjE4_725ba813-1e18-4fa5-bc5a-b79c6aa50921"
      unitRef="usd">29000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8845bbae207945c29f58ed0faa7c916d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtOS0xLTEtMTMxNjE4_c7648a55-100c-43ae-85e7-44e046e71261"
      unitRef="usd">7000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9ce84ce5bc4d4fd09f2f2edef567c63f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTQtMTEtMS0xLTEzMTYxOA_2879c2b0-801a-41d2-98b6-ae9386bd854b"
      unitRef="usd">36000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id3307d951777433f9183e38cea7b0eee_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTYtMS0xLTEtMTMxNjE4_69b43d5d-2874-4f77-b3df-8d67ccb08c83"
      unitRef="usd">276000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie514f725ab204576a9d82e520a0747cc_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTYtMy0xLTEtMTMxNjE4_3dc80213-b2be-4a0f-8a14-060d68004459"
      unitRef="usd">210000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic3c351d397e549f08a5550b64c7bd217_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTYtNS0xLTEtMTMxNjE4_165198a2-3775-4392-a7fd-6eb73797b0cf"
      unitRef="usd">487000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia85cef5855f74b3aa28b80d7e773c5e5_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTYtNy0xLTEtMTMxNjE4_4008ef98-0426-480a-9ffa-f5529d725532"
      unitRef="usd">195000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7d745b43d42740a2a636f93305a10162_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTYtOS0xLTEtMTMxNjE4_e370ffbd-5012-4819-8941-96cb8a65a5c7"
      unitRef="usd">199000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idffa9ebb25b04dc3ab346d0e2525d0f5_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTYtMTEtMS0xLTEzMTYxOA_ca912eb9-d99e-45fc-93fb-1b421f68dc9c"
      unitRef="usd">395000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i81842dbc49284aeb8c307b130fc51daf_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTctMS0xLTEtMTMxNjE4_cde0af28-b4bb-4b65-8ac5-e34587a7e814"
      unitRef="usd">54000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9ae5e82b75cb428f864e7695e7ca9c03_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTctMy0xLTEtMTMxNjE4_34051f84-3cdc-403f-85ce-cb9aaa6d3f3f"
      unitRef="usd">75000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5c5c36e08c35436d890e3cc5e49a26b5_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTctNS0xLTEtMTMxNjE4_2052c7b7-1767-4ac3-9bd0-83b9c61560e8"
      unitRef="usd">129000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i63dd5e6b38074752a8397afebca2f449_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTctNy0xLTEtMTMxNjE4_c3c1de80-0c8b-4c8f-beb3-94c3a07d008b"
      unitRef="usd">40000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id6a6d9596af343fe9fbfaadc1d8d3d34_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTctOS0xLTEtMTMxNjE4_e67d7ccd-e0af-4148-a301-b0c15a434335"
      unitRef="usd">54000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6cb822f6f0d24e56b21b1ba8cf3c5144_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTctMTEtMS0xLTEzMTYxOA_17c8f864-f3e0-430e-a0e3-fa97a9934af7"
      unitRef="usd">94000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie1a2a61f6cc34473ab9936b7066ad51b_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtMS0xLTEtMTQwNzgw_e2db4b26-2581-47a5-8c63-4455c67ca5b6"
      unitRef="usd">4000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie6b9400d903e47749af467e683ebf4b8_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtMy0xLTEtMTQwNzgw_82bedd10-76e6-4d7d-bf2a-cdc4ced4bb8d"
      unitRef="usd">76000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5e28d66cb4d143f5b15da4ce16a7ff80_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtNS0xLTEtMTQwNzgw_460a5fb3-cfd5-4122-a8f0-3eaa52f20421"
      unitRef="usd">80000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i83dc7aa4430a4932893b4dc1505dc632_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtNy0xLTEtMTQwNzgw_131401d6-6a0e-4418-ae95-b1f812dcfaa5"
      unitRef="usd">1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibd11a9dea94b46ed9112ffcc77e533a5_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtOS0xLTEtMTQwNzgw_307d7b22-1799-402a-8b68-cf1e17fd113d"
      unitRef="usd">58000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifa49ff54d4904fb783f4f755bf9c4739_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtMTEtMS0xLTE0MDc4MA_a68309f8-de33-4763-8109-cc42f11af76b"
      unitRef="usd">58000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i16385f11510546058467040c76602eda_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTgtMS0xLTEtMTMxNjE4_f6048126-f496-4593-8a4f-23f8a614720d"
      unitRef="usd">62000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i97cacd287b274b7283ca51aef88bed26_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTgtMy0xLTEtMTMxNjE4_00af82de-c4cf-4e2a-9289-bafcf93b0132"
      unitRef="usd">3000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ied566206459a4f21bda9d764fbd67597_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTgtNS0xLTEtMTMxNjE4_940cb2d9-3fe8-4cc7-9fb4-b581c42f6421"
      unitRef="usd">65000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8c13b48a7232487dade4344d3bd6fef4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTgtNy0xLTEtMTMxNjE4_43d7bb5c-962f-4e34-baf6-7d986541fbf4"
      unitRef="usd">49000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i36f1883cf7ee41de9a38e097ff1eebdc_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTgtOS0xLTEtMTMxNjE4_2f141819-9699-4a22-99b6-892e9f2623aa"
      unitRef="usd">3000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id1f696b0a7e848ffa8cd28bc5f62be74_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMTgtMTEtMS0xLTEzMTYxOA_eb9b2e43-4811-4a67-a118-35d137ecfe7a"
      unitRef="usd">52000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i33013fc5c1544b508c1f023d7e114799_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtMS0xLTEtMTMxNjE4_a655c2cd-de64-49f3-8391-fc00e85d4f43"
      unitRef="usd">14000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8189ab3ff1aa4b3fac07ab4d084ef309_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtMy0xLTEtMTMxNjE4_b91ed4a7-918b-4d10-9ea5-8c6c09eeec57"
      unitRef="usd">46000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0934dfe57f25400aabf7629e013bf2d9_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtNS0xLTEtMTMxNjE4_82d8444d-4060-4c3a-80ab-6a3dd1b0e618"
      unitRef="usd">60000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia482068e1c6841608dd3a6fc8530cff5_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtNy0xLTEtMTMxNjE4_4764bde1-b2f7-4ff4-816f-d5b4ddfcc733"
      unitRef="usd">10000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i36f337569e6e4b90b6c49162eccc9245_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtOS0xLTEtMTMxNjE4_0b46e29e-a5cf-4454-b391-96b7caa9011a"
      unitRef="usd">48000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i370790356a1f4d0f910d0150c46829ba_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjAtMTEtMS0xLTEzMTYxOA_292325fc-1429-4db9-936f-1d5917f6ff71"
      unitRef="usd">57000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic3ad548049e7437392c37716ac4a83fb_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjMtMS0xLTEtMTMxNjE4_e0c48a8f-2572-4686-ba40-7085bc440f90"
      unitRef="usd">27000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3025f3862fa34281bb1ddc0c23288056_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjMtMy0xLTEtMTMxNjE4_fc6e5ef3-d88c-4071-8f8e-81e20bd96439"
      unitRef="usd">23000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iadcf254d19a94241a8a193b57dc553f7_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjMtNS0xLTEtMTMxNjE4_b5873064-3610-414f-a44e-06e93d18ac4f"
      unitRef="usd">50000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1be1a7ec6a2548d4861b2e925582acb3_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjMtNy0xLTEtMTMxNjE4_8adaf06a-1d02-44d4-a2f7-68457466bff4"
      unitRef="usd">18000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9ece7f9fc39047fbaf47a27cce6b32ab_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjMtOS0xLTEtMTMxNjE4_7eb9b714-2767-4c28-9362-8fa73debc790"
      unitRef="usd">12000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9c4d7a0899854fe795ccaec1a0161a84_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjMtMTEtMS0xLTEzMTYxOA_3709754b-3cbf-463d-ba03-8137f05831a3"
      unitRef="usd">30000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i01970431619244f9a83fb73990c5cf14_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjUtMS0xLTEtMTMxNjE4_8362f82e-1c98-49c0-a1e4-13b640813631"
      unitRef="usd">83000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i958da05d9055499a88d25a539d74f6b9_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjUtMy0xLTEtMTMxNjE4_0e5c4fa6-ed5c-4b86-9379-14336022f583"
      unitRef="usd">16000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i82a61880f039405d9d8e1832fd26a2d0_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjUtNS0xLTEtMTMxNjE4_7702f13b-b60f-41ec-8bbb-9b36eba7021e"
      unitRef="usd">99000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i06d3dc01e4cd4880b999376bd99d6191_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjUtNy0xLTEtMTMxNjE4_7d306b7f-4787-4bf0-9467-a33f85c6ee55"
      unitRef="usd">71000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7414168e369644d7a58d58414fbde705_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjUtOS0xLTEtMTMxNjE4_ff53446a-30e3-4375-b4ec-cf72de9b587a"
      unitRef="usd">1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8d7e8ff816e241f199e0011935427e7a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjUtMTEtMS0xLTEzMTYxOA_b1b33d9e-cd4d-4c8a-9e05-96f96049c279"
      unitRef="usd">72000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iad4d2d0ea13747a1b99b669cf7ce5f36_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjYtMS0xLTEtMTMxNjE4_009088eb-775e-4a93-83e0-7a0dba8d40a2"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i01c8b28beea44e9998a1034bce51e508_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjYtMy0xLTEtMTMxNjE4_f93d0d7a-77a7-4d32-ac0d-1bd53ffb54b4"
      unitRef="usd">59000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifc25085e4f3246fcbff1828176d06cb2_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjYtNS0xLTEtMTMxNjE4_b42464fc-f701-469a-a8e1-cf7dbccff949"
      unitRef="usd">59000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i42b4b84e15304e879f573aebe7198888_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjYtNy0xLTEtMTMxNjE4_d44cc367-4687-4822-83ad-dfef01970e0f"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1abbf56d966442aea56ac371531ef7d4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjYtOS0xLTEtMTMxNjE4_26ad746c-5c90-4465-81df-ba7138dab08f"
      unitRef="usd">61000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i46444b1898a945a692f90d2a907898a2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjYtMTEtMS0xLTEzMTYxOA_8a605ae1-6bdc-4d94-880c-ac5663de8009"
      unitRef="usd">61000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i745ba7617eb74e15ad18bf9b1bb5709e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjgtMS0xLTEtMTMxNjE4_d2e02649-10c3-4966-94b2-8a5438a5b354"
      unitRef="usd">-2000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2d35a8760f2f49e89952d761b1399baf_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjgtMy0xLTEtMTMxNjE4_c3078931-c03e-4b6b-be9e-1fdb050615d1"
      unitRef="usd">394000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i185e17abc9a24ea38c9ca4921fa60212_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjgtNS0xLTEtMTMxNjE4_c45526d4-afc9-4353-9af9-e2372ab0ab98"
      unitRef="usd">392000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i69279d4f3a814a78996b4c54c84aba07_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjgtNy0xLTEtMTMxNjE4_272525b6-f820-45e5-ab38-eae0f0127194"
      unitRef="usd">1523000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if658e80c557842d4a20c5570140db4b6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjgtOS0xLTEtMTMxNjE4_b9724a28-b5ad-461f-a863-3d5234b58db9"
      unitRef="usd">1723000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if0feca83d79141c7aa9f2bbb6f89ece9_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjgtMTEtMS0xLTEzMTYxOA_59e90e64-dd82-4bb7-9f1d-e938906902bf"
      unitRef="usd">3247000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id9ab213a9fd74c98afcb44eb19dbc18a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjktMS0xLTEtMTMxNjE4_ebbc4ea9-5fd8-485b-b3ff-8a2383782f29"
      unitRef="usd">52000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7b3ad2cd408f4af38f724dabed4a97ef_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjktMy0xLTEtMTMxNjE4_cd5ae235-c1eb-46c3-a30b-34c6eb8de73a"
      unitRef="usd">71000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5d330794d9a24933add16f9c3e14c0e6_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjktNS0xLTEtMTMxNjE4_0434947b-2e95-4df9-a1a0-2d22279ae247"
      unitRef="usd">123000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i90f3bbf8132048e7a806ef1c700bcb02_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjktNy0xLTEtMTMxNjE4_5c844838-6108-4091-ad9a-852e9fd0d85d"
      unitRef="usd">61000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7c033c7782a84654914962664067c0b5_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjktOS0xLTEtMTMxNjE4_4d36f132-0cf7-4f4c-9c52-6ab9c1a3841c"
      unitRef="usd">97000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic44db3f3e64b400fbb66bf36b4d59948_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMjktMTEtMS0xLTEzMTYxOA_df855e64-6908-494b-b24d-89bb704193df"
      unitRef="usd">158000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia0f47191ae984e44a0ea39f24de59ca8_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzEtMS0xLTEtMTMxNjE4_ed3dc208-fdef-436e-ab28-b29584635cab"
      unitRef="usd">16000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ica88e8e09cf5471f8ec81237bf2424e8_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzEtMy0xLTEtMTMxNjE4_901d919a-c006-419f-981f-a9a04c94fc8a"
      unitRef="usd">40000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icf3db16464a242348f5f5ec6b303e8e8_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzEtNS0xLTEtMTMxNjE4_f1b96916-cd2f-476b-b304-3f0431533b6c"
      unitRef="usd">56000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic5dcef3812b24f21b01ed1f074b5e48e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzEtNy0xLTEtMTMxNjE4_c58ebf9a-c33e-453d-bf47-b0d1a528cabc"
      unitRef="usd">20000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie078fe8aa4b049019f87a49fe7163a94_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzEtOS0xLTEtMTMxNjE4_6f5f230c-e941-434c-849c-f530228ecacb"
      unitRef="usd">48000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic81d4335a8564f6893a52c09eee896bb_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzEtMTEtMS0xLTEzMTYxOA_fcc29d89-cf9e-4f7d-a2a2-c686323c34bb"
      unitRef="usd">69000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i38f8338e607f4961b4e06e5ad59f06d1_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzMtMS0xLTEtMTMxNjE4_06586f62-37aa-4215-a57c-bc3b32fbf8db"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i481c25e1dc4042e583fd9ae56af1ea83_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzMtMy0xLTEtMTMxNjE4_a43a37bf-cae2-4b71-a63a-064ec2f0ba6e"
      unitRef="usd">180000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5ab42425f0e84d0fa9cc1faa24e50ad9_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzMtNS0xLTEtMTMxNjE4_d39446ea-dae2-4f8a-9c46-7c0895ffcb9f"
      unitRef="usd">180000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9f1f69903f024330aa3cd5f89dfe4aef_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzMtNy0xLTEtMTMxNjE4_a44eb7cb-344e-47fd-bf4d-41a9d3faa265"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4f18afff1f924a87aca15181db888f45_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzMtOS0xLTEtMTMxNjE4_71baa138-34ee-4828-9898-5e30552159cb"
      unitRef="usd">186000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7f2b65669412421487fc5a293c2d0226_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzMtMTEtMS0xLTEzMTYxOA_21e54091-77a9-4e76-ac29-67c14dd4e092"
      unitRef="usd">186000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i252bf97a988d4ca089b4880ef38b9f6f_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzQtMS0xLTEtMTMxNjE4_2dce8da4-7855-4324-9b0b-ef2a881bf53a"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8ac3b496e9b7497bbd0a8568c2c05058_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzQtMy0xLTEtMTMxNjE4_b35356f6-7be8-4495-82ef-69c3b0e3f9db"
      unitRef="usd">51000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0ba905ef97ef4ea2a2b74f044e828215_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzQtNS0xLTEtMTMxNjE4_323184cb-6ee3-4bb3-999b-22fb850bd3ba"
      unitRef="usd">51000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i341c1828f974489ca631fd2f6fd5de33_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzQtNy0xLTEtMTMxNjE4_2d64884c-59bc-4cde-a8fb-e6294649db9e"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i91767bfb04eb4bad8b4c74cc699c4f11_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzQtOS0xLTEtMTMxNjE4_6df05aec-8419-4a1b-a946-7149a51584dc"
      unitRef="usd">61000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i078db72152b7433b892f65578b578811_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzQtMTEtMS0xLTEzMTYxOA_dec801b9-74bc-47a9-89c8-fb0995af45b0"
      unitRef="usd">61000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3d3ed97dcb1048b9b00df266e47fef85_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzYtMS0xLTEtMTMxNjE4_42abdd8d-d8a7-46eb-878b-f611b122ae16"
      unitRef="usd">271000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idf7f29b275f343aeb93a10d0bc96a43a_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzYtMy0xLTEtMTMxNjE4_efa28396-43f0-4f4e-a554-dd19047b69cb"
      unitRef="usd">280000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1c5a4e651d8048d0bb7be915788d3451_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzYtNS0xLTEtMTMxNjE4_7bfa03f7-8536-4454-9aa0-75d5b9978061"
      unitRef="usd">551000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idfe3cd40147f4e2bbdcc6daea5c4f648_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzYtNy0xLTEtMTMxNjE4_93f7770b-9c4f-4460-abda-cee60e110b9a"
      unitRef="usd">325000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idc375c5fb83442ce960061c4c1e7d3d2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzYtOS0xLTEtMTMxNjE4_eda8d58e-a5b4-4bed-9fe5-a754b0e43797"
      unitRef="usd">454000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1068453fd58a43ed853c52e49d369635_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzYtMTEtMS0xLTEzMTYxOA_85db9919-9c69-4015-9a49-43423005b538"
      unitRef="usd">779000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2a170523e4784bd68826594b94740470_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzctMS0xLTEtMTMxNjE4_9a8f0c4f-f5e9-4d59-8500-869cc42f442a"
      unitRef="usd">56000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icd460b0376004e6c9a2f91d187784dc9_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzctMy0xLTEtMTMxNjE4_796f7198-0fe6-4f0c-9a95-6bf417495824"
      unitRef="usd">272000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib5c0d77138754544a2110eafaf9ef1de_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzctNS0xLTEtMTMxNjE4_1c6001ef-90d8-404e-8e2f-529c0f165852"
      unitRef="usd">329000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie30c6b82c81544b2a213a66f88a666e6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzctNy0xLTEtMTMxNjE4_fa47f488-9d24-47b5-91a1-916fdd657552"
      unitRef="usd">63000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i944297bc97294b85b64026a5234105db_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzctOS0xLTEtMTMxNjE4_39b78dcc-d7f3-4ffa-9641-18af1df42b3a"
      unitRef="usd">391000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6714caf41ce2406282b4c22d36869265_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzctMTEtMS0xLTEzMTYxOA_06efb935-6747-493c-aed9-a854a591d8c0"
      unitRef="usd">454000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib880b79c41404a7f9ccb683284f4a657_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzgtMS0xLTEtMTMxNjE4_c90feffd-32e6-4616-b76a-a71541b516ed"
      unitRef="usd">172000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7242924d01844781882444c559d8edd7_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzgtMy0xLTEtMTMxNjE4_b54c44ca-13db-41b8-b587-e4d6cd1205e3"
      unitRef="usd">414000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0b5149a7a9724ba099430ae94f3eb7f9_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzgtNS0xLTEtMTMxNjE4_243f0539-7b6a-4534-b610-52a29988e70d"
      unitRef="usd">584000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3f44546bfba04d3182b566c995d1d6a5_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzgtNy0xLTEtMTMxNjE4_4b5acf86-2bdf-4361-ab00-713955542104"
      unitRef="usd">160000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iea28f75c29f9495d97b2490ad495e473_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzgtOS0xLTEtMTMxNjE4_98e25f04-1ba2-4e87-bb96-468b98dda3f2"
      unitRef="usd">443000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1c30e990884c453a8e86bf31356441ab_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzgtMTEtMS0xLTEzMTYxOA_5eecc931-c9fe-4033-a930-f31aabe63709"
      unitRef="usd">602000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib1de53f2d14549978ff86137b26acfdf_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzktMS0xLTEtMTMxNjE4_464bca47-180b-4995-ae73-5430c55e334a"
      unitRef="usd">6117000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iea0edbdebc194dbda6f583be24a5f5be_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzktMy0xLTEtMTMxNjE4_a1642759-028f-4ab1-b5e0-b83e9a525c7a"
      unitRef="usd">6604000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iff180f6730404c2fb6244e53cad88916_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzktNS0xLTEtMTMxNjE4_49ed9b4e-a36f-44ed-8ada-c3f29974cc8f"
      unitRef="usd">12721000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idc67e8a229ad434b9d2759887e18dcff_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzktNy0xLTEtMTMxNjE4_50228069-c141-4870-8dea-ec78d994cde3"
      unitRef="usd">6773000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3ecc10254bda49bf803e6b76575554b2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzktOS0xLTEtMTMxNjE4_e9848f28-e5a8-4f0a-9bce-565597bed367"
      unitRef="usd">7334000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia58fab4c69fb453394fb53a0a9cb3d93_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfMzktMTEtMS0xLTEzMTYxOA_819143ad-b68a-4e33-833a-826bc508a5ca"
      unitRef="usd">14107000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i08f54d2fb7c74345a43dd8eb5652ccb9_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDEtMS0xLTEtMTMxNjE4_43d124bd-db25-4181-8e18-8bf953c34b32"
      unitRef="usd">174000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia99f107296c340309c3405bc2810419c_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDEtMy0xLTEtMTMxNjE4_2dd1f72f-3611-4256-ae55-0cbb477ce99f"
      unitRef="usd">676000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ied991033c3cc4ae8b1774bcbdfbc6a61_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDEtNS0xLTEtMTMxNjE4_c3ca8c54-26b5-4b9e-9105-4bd209bcb0a3"
      unitRef="usd">849000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i48ac0207dbb24fba961de45411f8f863_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDEtNy0xLTEtMTMxNjE4_43d77804-b7e3-4a3e-8501-a4a3248a094b"
      unitRef="usd">171000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i83d344caa1af4fadaeddfdde40462eb2_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDEtOS0xLTEtMTMxNjE4_45770cb1-fe8f-4ddd-926e-ac9acf8b58b9"
      unitRef="usd">661000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8c73bc1480c5460787fa096cbca3e186_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDEtMTEtMS0xLTEzMTYxOA_18e494e8-8760-40ef-a709-0ec4834fb2b0"
      unitRef="usd">832000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4136a4c6588c473b8dbc29bd43446a8c_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDItMS0xLTEtMTMxNjE4_8f160c29-8390-4d1f-8c10-48edc7fe4fc0"
      unitRef="usd">308000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if77a7432ec784877b792884b4331e9ee_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDItMy0xLTEtMTMxNjE4_9551723d-4994-42b3-b696-31c42fe8280e"
      unitRef="usd">334000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id486cc4b73964a048598ee4145a36f51_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDItNS0xLTEtMTMxNjE4_2f231c72-adca-4969-9d92-dc2512e75e9d"
      unitRef="usd">642000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i260d3e7cbd5a4346b6de45c5013de1eb_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDItNy0xLTEtMTMxNjE4_9d295a3c-76b9-4c1c-b1d0-f4f41aca9362"
      unitRef="usd">302000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2913a3930e88428aacc1ff729877e753_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDItOS0xLTEtMTMxNjE4_103c718c-a7ed-48ff-bb15-8a1c71265ddf"
      unitRef="usd">348000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if553fafbad26405cad25ce4550638d3f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDItMTEtMS0xLTEzMTYxOA_22fcbfa2-f551-423a-a4f1-505f6939cc41"
      unitRef="usd">650000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i660405fd34d447fbac3495f01c37c868_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDMtMS0xLTEtMTMxNjE4_c9a2c592-3dd8-4252-a381-4877e061c9b3"
      unitRef="usd">482000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic90971f816384ed793878fbed1daf9b9_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDMtMy0xLTEtMTMxNjE4_63bee262-7be2-4492-8ebb-928b3fc2a1e4"
      unitRef="usd">1010000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i904e8e179a1a49698833ce1b0110d5b4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDMtNS0xLTEtMTMxNjE4_787cdef4-0937-4cd8-9959-d62cbc8ece21"
      unitRef="usd">1491000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0a26625eb0434b3aa7c78f6443da31d6_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDMtNy0xLTEtMTMxNjE4_92ccec34-9d1f-4be5-9427-06903dd8c13a"
      unitRef="usd">473000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib7dcf8dd27b941e6a6224761d29aa39d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDMtOS0xLTEtMTMxNjE4_b889ca21-8e1f-4102-9a6f-42eb9b83d401"
      unitRef="usd">1009000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i83fa1e7afed046c4a90965eb45e55ef4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDMtMTEtMS0xLTEzMTYxOA_2ef2246b-6c21-471d-a5d9-5058c75f6b4a"
      unitRef="usd">1482000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i296f4d5ae9ac48818a1c814d83edd6c5_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDQtMS0xLTEtMTMxNjE4_5feb8fa3-515c-44b8-a057-7beb9b1aa868"
      unitRef="usd">6599000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i541f7bde3cb144d6a1a06f324c128077_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDQtMy0xLTEtMTMxNjE4_84ac04c5-039c-4583-aa02-a6b0077cd1c5"
      unitRef="usd">7614000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id8c4caa074434a8c891a4dbc9477a1df_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDQtNS0xLTEtMTMxNjE4_ae37c227-14ed-4741-a155-a31b659ec67c"
      unitRef="usd">14212000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2171622cc8164fae9f90806cca105ee4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDQtNy0xLTEtMTMxNjE4_d672ec05-7276-450b-9914-34d058f42b75"
      unitRef="usd">7246000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0201d118d8574b6db54cf6f7f5bb5c3e_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDQtOS0xLTEtMTMxNjE4_a63e5363-8419-459c-a2fb-39864fd958ca"
      unitRef="usd">8343000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icc177dc034fa4f9ca0cad6e36eb33f5d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDQtMTEtMS0xLTEzMTYxOA_ec4af8fa-e539-4a8e-abe3-fb15cb243fb9"
      unitRef="usd">15589000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icfa83b7726804a0da22e28fcde9c5ed2_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDUtMS0xLTEtMTMxNjE4_64b6e335-bef7-4f7a-bd55-506876f02edd"
      unitRef="usd">60000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i70a11b67918c44d3bfc01126c08b9fc2_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDUtMy0xLTEtMTMxNjE4_9deb4a1a-ad98-43e0-96c3-604cafb07109"
      unitRef="usd">214000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icf8c3545f0134eebae2941403b2e022b_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDUtNS0xLTEtMTMxNjE4_f1712555-79c6-4dc2-b6f3-1aa090f88bc1"
      unitRef="usd">275000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3f24746bebef41f9a462c02b830d6110_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDUtNy0xLTEtMTMxNjE4_a3b98f10-18b0-43e1-878f-f51f7cc352c3"
      unitRef="usd">93000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i307318101eaf48d785d4b776c386341a_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDUtOS0xLTEtMTMxNjE4_d2c21f26-4598-4b74-a022-6a0acaae81cc"
      unitRef="usd">220000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if69fe081e83e44b89e1642cb41b84015_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDUtMTEtMS0xLTEzMTYxOA_ecfa1695-f3e6-4910-bb2a-a7b31d8b1404"
      unitRef="usd">312000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5e9cb136461a4e8aa85239cb391d845b_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDYtMS0xLTEtMTMxNjE4_32d6a6fa-9829-49dc-ae00-7544dae524f8"
      unitRef="usd">6659000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7a97503f4be84d46bdeff57349e01c23_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDYtMy0xLTEtMTMxNjE4_0ebaf935-cd67-4312-afd6-c22068f8f875"
      unitRef="usd">7828000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDYtNS0xLTEtMTMxNjE4_caa70205-c25a-4785-b056-9ed26b521571"
      unitRef="usd">14487000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i809f9ceab45b4cc88ceaa644a4ed41d8_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDYtNy0xLTEtMTMxNjE4_a3d3fc3f-e336-4c7e-8ce8-58f6034c877c"
      unitRef="usd">7339000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic58118074eba4189a105e403b1233b58_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDYtOS0xLTEtMTMxNjE4_b31c0435-9612-4186-a2cf-2f2b4cd99a36"
      unitRef="usd">8563000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjI2OWZhZWQyMzBhMjRhYWM5MWU5NDI4ODA5NjliODVlL3RhYmxlcmFuZ2U6MjY5ZmFlZDIzMGEyNGFhYzkxZTk0Mjg4MDk2OWI4NWVfNDYtMTEtMS0xLTEzMTYxOA_f82df2d4-7ac0-4665-899e-343f53d34937"
      unitRef="usd">15901000000</us-gaap:Revenues>
    <mrk:IncreaseDecreaseInHedgeRevenue
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfNTQ5NzU1ODIwNzc5_627192b8-5092-4f99-b82d-e675cc6c2a03"
      unitRef="usd">99000000</mrk:IncreaseDecreaseInHedgeRevenue>
    <mrk:IncreaseDecreaseInHedgeRevenue
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfNTQ5NzU1ODIwNzg3_6e7eca59-4393-451f-9bff-d822ae6b6c49"
      unitRef="usd">69000000</mrk:IncreaseDecreaseInHedgeRevenue>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfMjgxMA_c41639be-76e7-4717-b6ce-90797ecc2923"
      unitRef="usd">51000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfMjgxNw_06d0af1b-4675-4859-ba6e-576293ec3c38"
      unitRef="usd">114000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <mrk:SalesDiscounts
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfMzQ2MQ_1b0585f9-763e-42aa-80ad-e4740e0504b5"
      unitRef="usd">3100000000</mrk:SalesDiscounts>
    <mrk:SalesDiscounts
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfMzQ2OA_a8953536-8d80-4270-8c7f-08a18bbbcaef"
      unitRef="usd">2900000000</mrk:SalesDiscounts>
    <us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfNTQ4NA_024fa4e0-421d-4f84-b58b-b8dd4c7c6dc7">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Consolidated sales by geographic area where derived are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.674%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Europe, Middle East and Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asia Pacific (other than China and Japan)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
    <us-gaap:Revenues
      contextRef="i5e9cb136461a4e8aa85239cb391d845b_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfMi0xLTEtMS0xMzE2MTg_8acfbe8a-4750-4cde-a751-509b9b1eb504"
      unitRef="usd">6659000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i809f9ceab45b4cc88ceaa644a4ed41d8_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfMi0zLTEtMS0xMzE2MTg_db062b2a-335b-4968-b37a-b2150da16643"
      unitRef="usd">7339000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i679d69340bf54bb4a090a15b7ce9076e_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfMy0xLTEtMS0xMzE2MTg_420ef679-9547-4710-9c21-f01436be7491"
      unitRef="usd">3303000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4067fe86262c405cb2919284c7e1f31c_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfMy0zLTEtMS0xMzE2MTg_75c92b69-79d2-499a-a8ac-856ae32e665b"
      unitRef="usd">4359000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib86ae90471ee4ab18226e2683b749444_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfNC0xLTEtMS0xMzE2MTg_f7f0799b-6755-4818-b812-430b4d78156c"
      unitRef="usd">1715000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7b6b67a7073245c79ad8b17846729383_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfNC0zLTEtMS0xMzE2MTg_0678dfe1-7865-4389-bbb4-a3509289d339"
      unitRef="usd">1143000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iee1279d9656246229165b6071a908fe4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfNS0xLTEtMS0xNDQ0OTM_bd13176d-2d50-423b-a924-c122f38f11db"
      unitRef="usd">846000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie1eaefd10a6d4f75bc5b01e6fd6e7612_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfNS0zLTEtMS0xNDQ0OTM_419bff35-b60d-426b-967f-6d40bf428195"
      unitRef="usd">930000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ice769ebe11cd4873b0e7fae638d4de55_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfNS0xLTEtMS0xMzE2MTg_af0989cb-f3b3-4a2b-b90e-596cae6763e3"
      unitRef="usd">758000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i77d9b85158ec4e37be193731477b820f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfNS0zLTEtMS0xMzE2MTg_212e8a97-0d62-4365-a0c5-008ea6205e0f"
      unitRef="usd">989000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i83848e68f3b04891aad523922cca52c7_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfNy0xLTEtMS0xMzE2MTg_16895df7-1630-48a7-bbb7-6051b41df14b"
      unitRef="usd">661000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic9bae06748084a678545ae2a472fc025_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfNy0zLTEtMS0xMzE2MTg_69feecdc-cfde-4be8-8467-f14c6d88b417"
      unitRef="usd">607000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i49396c3fa3284569b4be0611825c2214_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfOC0xLTEtMS0xMzE2MTg_0c43bbc3-ad75-4e76-a4b1-d88a82af73e2"
      unitRef="usd">545000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i492a23d281624d04895b84c347c42464_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfOC0zLTEtMS0xMzE2MTg_14d13378-92e4-4e44-b0e2-abf3ba81de9b"
      unitRef="usd">534000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfOS0xLTEtMS0xMzE2MTg_9a32c585-90c8-4774-8e80-2891c0f92fe4"
      unitRef="usd">14487000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjU5OGE4ODBkOTM4YTQ5Y2Q4NjNlNjMxMmIxYWNhZDE0L3RhYmxlcmFuZ2U6NTk4YTg4MGQ5MzhhNDljZDg2M2U2MzEyYjFhY2FkMTRfOS0zLTEtMS0xMzE2MTg_58dcbd93-aa7c-442f-8864-d21733a8306c"
      unitRef="usd">15901000000</us-gaap:Revenues>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RleHRyZWdpb246YTIxZmFiYjcyNDE1NDRjNzg4MWRhZjhkMzJhN2ZiMTlfNTQ3Nw_271793ba-f9b9-491b-bb6c-038502f74f6f">&lt;div style="margin-top:6pt;text-align:justify;text-indent:45pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;A reconciliation of segment profits to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Before Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;($ in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Segment profits:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Animal Health segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total segment profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other profits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unallocated:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(543)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,147)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restructuring costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Charge for Zetia antitrust litigation settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(573)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other unallocated, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,607)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iff180f6730404c2fb6244e53cad88916_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMy0xLTEtMS0xMzE2MTg_db560a57-eb51-4c7c-8620-c1e229fc8122"
      unitRef="usd">9140000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia58fab4c69fb453394fb53a0a9cb3d93_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMy0zLTEtMS0xMzE2MTg_4563d745-d4b6-4773-914b-99b8875bb0a7"
      unitRef="usd">9501000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i904e8e179a1a49698833ce1b0110d5b4_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfNC0xLTEtMS0xMzE2MTg_25406fb4-7cb7-42f5-87dd-0de77af4d93c"
      unitRef="usd">566000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i83fa1e7afed046c4a90965eb45e55ef4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfNC0zLTEtMS0xMzE2MTg_7aa88ea1-e238-4033-b889-1b0ab25b8897"
      unitRef="usd">585000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id8c4caa074434a8c891a4dbc9477a1df_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfNS0xLTEtMS0xMzE2MTg_2128dfa3-e31a-46e6-bd91-7748d93123f5"
      unitRef="usd">9706000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icc177dc034fa4f9ca0cad6e36eb33f5d_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfNS0zLTEtMS0xMzE2MTg_93d39df7-ee23-45bc-a1b7-dc2f71ca2e32"
      unitRef="usd">10086000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icf8c3545f0134eebae2941403b2e022b_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfNi0xLTEtMS0xMzE2MTg_fd5b5857-916f-4978-b7c1-626225946bfa"
      unitRef="usd">164000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if69fe081e83e44b89e1642cb41b84015_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfNi0zLTEtMS0xMzE2MTg_7a6bf9c1-77d4-4df5-b32e-3bbd30d79cf7"
      unitRef="usd">194000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i158cbb622490428d9efea6420c58fc6b_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfOC0xLTEtMS0xMzE2MTg_55627434-dec2-4436-a779-6573f08f0ec0"
      unitRef="usd">112000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i9bc970a022044625a53b9bc92456c9d4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfOC0zLTEtMS0xMzE2MTg_eb0d237c-8981-4b04-8370-95c4ed45f849"
      unitRef="usd">7000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i158cbb622490428d9efea6420c58fc6b_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfOS0xLTEtMS0xMzE2MTg_f99e5cd7-ab3b-4ddb-a1f4-f42f80028599"
      unitRef="usd">242000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i9bc970a022044625a53b9bc92456c9d4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfOS0zLTEtMS0xMzE2MTg_cfe94af6-c88b-4446-956c-258a0eb24f5d"
      unitRef="usd">243000000</us-gaap:InterestExpense>
    <us-gaap:AdjustmentForAmortization
      contextRef="i158cbb622490428d9efea6420c58fc6b_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTAtMS0xLTEtMTMxNjE4_c1e92fd2-fbe5-43cd-864a-430d251cdee1"
      unitRef="usd">543000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i9bc970a022044625a53b9bc92456c9d4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTAtMy0xLTEtMTMxNjE4_6a62b77f-d8fb-4884-b6d6-b562bcf8961e"
      unitRef="usd">699000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:Depreciation
      contextRef="i158cbb622490428d9efea6420c58fc6b_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTEtMS0xLTEtMTMxNjE4_33f222f5-9e60-4f0b-a385-a98bf01fc58e"
      unitRef="usd">398000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i9bc970a022044625a53b9bc92456c9d4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTEtMy0xLTEtMTMxNjE4_86811367-cac3-44d1-9e87-2b9614469684"
      unitRef="usd">378000000</us-gaap:Depreciation>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i158cbb622490428d9efea6420c58fc6b_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTItMS0xLTEtMTMxNjE4_da141c0a-bf31-44ee-be5f-8677d0402bea"
      unitRef="usd">4147000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9bc970a022044625a53b9bc92456c9d4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTItMy0xLTEtMTMxNjE4_46891065-8529-4e23-b938-853fee2538b7"
      unitRef="usd">2446000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:RestructuringCharges
      contextRef="i158cbb622490428d9efea6420c58fc6b_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTMtMS0xLTEtMTMxNjE4_d580a05c-b9a3-46b3-9f33-e43ee7694fce"
      unitRef="usd">67000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i9bc970a022044625a53b9bc92456c9d4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTMtMy0xLTEtMTMxNjE4_67754d23-a072-4bb8-bbd7-f729d89f6637"
      unitRef="usd">53000000</us-gaap:RestructuringCharges>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i158cbb622490428d9efea6420c58fc6b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTQtMS0xLTEtMTQ0MTUw_4626e948-711d-48d0-8395-d4398490d415"
      unitRef="usd">-573000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i9bc970a022044625a53b9bc92456c9d4_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTQtMy0xLTEtMTQ0MTUw_a90df1b5-4a33-4f81-87ee-b6711bbefeec"
      unitRef="usd">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <mrk:SegmentReportingUnallocatedOtherExpensesNet
      contextRef="i158cbb622490428d9efea6420c58fc6b_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTQtMS0xLTEtMTMxNjE4_9e832d62-b9eb-46a8-9804-da7ad83ecf3b"
      unitRef="usd">362000000</mrk:SegmentReportingUnallocatedOtherExpensesNet>
    <mrk:SegmentReportingUnallocatedOtherExpensesNet
      contextRef="i9bc970a022044625a53b9bc92456c9d4_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTQtMy0xLTEtMTMxNjE4_6bafc467-d4f6-4298-a10a-cc89692c24d4"
      unitRef="usd">1607000000</mrk:SegmentReportingUnallocatedOtherExpensesNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9898fd351c244a31961383ac8941ad7d_D20230101-20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTUtMS0xLTEtMTMxNjE4_b3c84d4c-c521-4439-9afb-f564a0d7abd1"
      unitRef="usd">3650000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if9338a0a8c8f45b6a4eb9cfb13b6e334_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjNjY2NjZjM3Njc3ZDQzZjg4MDAyZjhkOTk1ZTJmZDNjL3NlYzozY2NjY2YzNzY3N2Q0M2Y4ODAwMmY4ZDk5NWUyZmQzY183OS9mcmFnOmEyMWZhYmI3MjQxNTQ0Yzc4ODFkYWY4ZDMyYTdmYjE5L3RhYmxlOjZmZGE4MzIzNzU3ZDQ5MTBiMzMyNDJmZWVlMzcxOTNlL3RhYmxlcmFuZ2U6NmZkYTgzMjM3NTdkNDkxMGIzMzI0MmZlZWUzNzE5M2VfMTUtMy0xLTEtMTMxNjE4_7eedbb30-3c6e-4dc9-8db5-844f77725fd7"
      unitRef="usd">4861000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>77
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" #R/*56]E0KGE4'  !J,P  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;+6;[W.;-AR'_Q6=M_7:NS@&"9RD37SGN,F6M4G3.-NNV^V% G+,!9 GY/SX
M[R>!8]FI^$(HO$F,[>_'>M /'K Y?.#B+ILS)M%C$J?946\NY>+]8) %<Y;0
M;)<O6*I>F7&14*DVQ>T@6PA&P[PHB0?8<8:#A$9I;W28/W<I1H=\*>,H99<"
M9<LDH>+IF,7\X:CG]IZ?N(INYU(_,1@=+N@MFS+YQ^)2J*W!.B6,$I9F$4^1
M8+.CWMA]/_$]79"_X\^(/60;CY%&N>'\3F^<A4<]1[>(Q2R0.H*J?_=LPN)8
M)ZEV_+<*[:T_4Q=N/GY./\WA%<P-S=B$QW]%H9P?]?9[*&0SNHSE%7_XC:V
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M;Z,X$/XK%K=:M5(WO">DFR U:597J4FKIGOWX70?'' "*N"<[32]?W]CH(2
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MIJ4R,$CCK/C';Z4C:@J HU:P2@6KJ>!T*-BE@IT;6C#+S;K% OL31H^(26E
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M$2K:G*8I7.MUA-D'K3I3B6@2$L9E840AQ [#>@^P7+Z\5#J@H#BJ5Y&!V7*
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M(N_8(N+$-'HU"B4Y4RI;9SRM+WW3&RX1:](-JHKB'-T*S=LH#XT>"$:V^5%
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M9@IW("J- 7Q?"J%?.N:8;6Y5T1]02P,$%     @ \CRE5KD=.ZNP!@  9!L
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M#]13(Z(8 /<RP")\S1L14CIJ54NB%YTC'WE%'P4>J)P'9'1;*D!?\1WM>E#
MM;)P\8'KAK!QMBE*AL$S&Z75Y!%KPHS<I;-KZ\+&:F6CX]['-,,BA32-YJ.[
M.::%#ST>,4CD^M99%F<AVZ _&*% "V72=*2V@$^)LP[196T[@?/*,V/I'%#%
M4.0J@5<J)- I 3.#02S"5!D [NQAIT*.*:]DS*O"J WV(H!M";X1;SDMW*I0
MQJUM!K[]YOUJ^>Y[__49<W9MV+IV2L<>.F4WTHE[ &=L TKD^#04!R6F=8:
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M1BM!K@B]$:SLU8_DCR*N21.(, 1SRSRU,NHLP8[5<O+CV7G#(26!*B4#,38
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MJIPH'%^U[J5N'O!N[X?MJS^^O-_79>3XK&GK]^Z^#\ W%, ;2U29Z^PU=+V
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MF^$<7UBZ9E4W1LD91[J#(I(G$B1$B/VI+]8L3.[ <>I+J??DFEG56=UDV.8
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M AM?X"@))D""WWIXPP%HRAL,"+Q;,Z2%:^<VS2"@ .R(O1,:9L*.A0?Z;:P
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MUHG0ZKK-XW"ILWW<;,[K4XC4$(4' AKX3&]!L>'WJ<)Z[ET%RPUF]^Y%EZD
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MRI%W9XC!X.DPG$F&TSB<28:S,)KIY>QGA%1Q999#3ZY[!B@'NQ6L5>1]M*F
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M,!X&H+O&T&VL:GPQ7BM+I=TO*^JEJ)T"G6^4LL>-NZ#OSLM_ 5!+ P04
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MLC9N+=2J[=+4Q:;UI;45+1(*ORA,T9@.)"L]Z69E6WJ]@8;41><+1X2>]X&
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M&S/Q4_C#!%(HN%LLT1[!GL]"=CR>H,. C<<T7YQ?TGF[ON.1/45$YD;%#\U
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M!IHTK%:0K6OY'@"6)2,3%DQ,UAP$MV8>3_*F@7@^1L6&_L7/XRM?X"1YU((
MQ;4YO_=K,X\-+7D/PT+Y(%.' D>!,WH#]8YV]D!TT%@]YUI9S'#%HJB,BU(T
M0RJ,6G[H^FJ;[@J1 G9:EV?R00(0P#$%2.@9]GZ=+O-;&<GU(0&X'FGN/#NN
MEN];Q*G38NW*U@>(9.VX DDICDS9WU^1\.$:B9?W7^#V*;ZC2?O([/6RX0N
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;*U7[V_;-A#]5PBW*&S
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M9:&D+PU04 18PQ)DO2NW#WK;,E>*=$U;,%P2IJ1U";1U'>K_\*W[UJ.VJ'9
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MML!?%EE>@/<+@V2T#VR@^V\[_P=02P,$%     @ \CRE5B;^ZT'K P  [0@
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M;]5"TRC<HN2\1&FXDJ!Q-0EF\?E\X.R]P7>.&[/3!Y?)4JD'-[C))T'D"*'
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MY(F/)[5JN2EIZUCR6FDK_FR#1Y376BB:L^A/2)!?A3)VZ*8=*FC!):QH,C/
MFQ)<A)!";-!:B3[>_IQH6BYD>R!:2Z5KT,[8FEJS*D5!U=3@4EB/#Z&A!OV3
ML@AQ-#@Y]I<WVIM):M0K/WD9TMXTMAU/^M-^N#MO9YK/XNUD2)E:.1\D+DDU
M.IED >AVVFHW5JW]A'.K+,U+?EG1@(K:"=#]4A'3;N,,]"/O_"]02P,$%
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M"Z4)H.=;(70[,0VZ\]SB'U!+ P04    " #R/*56.<0]:Y\-  #2+@  &0
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MVD88&;SH<(3_G,^E$DB"?_?%:"'B_1"Z,4YE2W(Z=9#YDHH'ZLR./P2I?W;
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MZ'P12X6N.^M[VIPA^EFST66]4?+"1BE\,MH7#C[H'/-]_SZ1;IDGC\PODZ.
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MS%,.*_RSR1%H \8' AY!3&?L_A"QBH1G4Q0<""'*'=:SC9:/U<HX_((\\CK
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MB<W[#)L#Q?/R@?TC5XIGY<<EP0D1Y@+]_9QS]7)@$M1OE4S_!U!+ P04
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M\:L9OOW5>,@B?20L ,%:.EF#9DYP8!3J-J;+M!@ID'EKJ- Y<V=$'6H4E.9
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M,;I@HKA GW]*4_6Z4Q2P634_^Q=02P,$%     @ \CRE5ME&&6G\"0  <&0
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MM.XTC^MTEE;!Y;!N6:= &U^AC0_/\]SSQ3IA,A<O!H\(F\W$VGA/Y#6L:]W
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M@2#86@R\XO:,QC$SWLHZPNO!BJP'HT\RV\IZ</)69D_I.C$.1UBQOO<[J)I
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MT)V,L1U?[P>@W&0H<G:B%R 8<G@8ZM$+#.4"O@:]FR(4K%!JJO>)P)QX](X
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MG-P9TNA+]OFJ#36=T,;CT8;"?M#4'J_>NU%!Z0>EIGJ6,,D;?6F?!X4HJ)I
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M<U;J6+5 4K-K86#' QGB-'NREO48;]JS/>:,]MC3$(D'(TFY5!IM<Q')[LC
M^8.7!DG-SM90C<>=VA05>;#4[%H8Z/% ECC-I@%TA:S2:H_Q>[[O/4,F'HPF
MEDW)O^08/H4E!Z\6DII= $,\WM2I<U$Q"$O-KH4!(0_DB].<>]YRY:1I7&B(
M_6^X014*HTK3MT/(%98>NF98:G8A# 91SZ5_*2HL8:G9M3"P1$$ .<F_E23(
MKQUCO&F/@PW-4)AFF@[NY5E89_ 2N=BGH0:+J._4KJC0A*5FU\) $X7W@DZR
M*V]9<=IT:WL([7.K@1H*0\V]C/2A]7NREHF^S$;EJHE5'":ACEL4>^:=X:+N
MX6"IV34PK$3/G'H7%9NPU.Q:&&RB\$[12=Z=MB^C3>^VAQQ<C>U8#=90&&N.
M\.Z1Y N?:/ 2NMCM80:AV,1I\P"5HK#4[%H8BF+P9M(I=JXD(?(%A]BA&LAA
M,.0<Y^8A/ R?</!*NM@D8@<=,;<M,=R>F O88@:V&'Y;K)($7=T>XO>XVK 0
M^[^^V#&N[F5D6'WPLKG80&*&M9C3MAE#92XL-;L6AKD8?NN,M1MC3<[H&M+3
MV66&B1C,1,4"B6RY*5=K)9]DE&YCF:C.&%'WC;#4[,0-8#&G'32&2E58:O:-
M"(:J?/P>&BPYM !^N]O68VW?\)$/\U&?M8_D9EA]<((N=IE\ V"^TY:<CTI;
M6&IV+0QM^?@M.5AR< ':S;L>Q/8/[B:"N0EP^Q"NAL\R.%$7FU6^ 33?:8?/
M1P4T+#6[%@;0?/P.'RPYN #M7F#?-=Z@E@^C%N#Z7NZ&)0=GY6)/RS?\YCMM
M!?JH2(>E9M?"()V/WPJ$)0<7X.BN(3=PQF$XNSLN$5AE\!V8+K:VN$$W[K1!
MR%'1#4O-KH5!-X[?(.3MYE_0O%&X8PQG/68U;,5AMNHPZY&X#0L/7C,7FUC<
MP!AWVC'DJ!"&I6;7XN#F<?R.(6^W UMW$G>,Z;N5F!M*XC E=?MW"$##)QB\
M=BYVLKC!*^ZT>\A120M+S:Z%(2V.WSWD[=9@<V,:'&*':D"(PR#4[>)>((;5
M!B^3B[VLP.!2X+1#&*!B%)::70N#40%^A["2#+HOJU5:'6.:_\J-#Y[#BV6V
M+A]/S/5Y=XG:/[M6'ZT?@;PJ'_QK'+_V+A;[!QF-S/ZYREN1K<,D)Y%\U)*3
M#V?Z0Y3M'U7<OU'IMGS:[R%5*HW+EQLI5C(K!NB_/Z:I>GU3G*!^8'3^'U!+
M P04    " #R/*56*\36F9<$  "#&@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970T,"YX;6RU65UOXC@4_2M6=K3J2*6)'2"E"T@MG='N0W=0JYE]6.V#26XA
MFB1F;5/:?[_.1V-(4B]8\ ))\#WWGIOD^&"/MXS_%"L B5[3)!,39R7E^L9U
M1;B"E(HKMH9,_?+,>$JE.N5+5ZPYT*@(2A.7>-[036F<.=-Q<6W.IV.VD4F<
MP9PCL4E3RM_N(&';B8.=]PN/\7(E\PON=+RF2W@"^7T]Y^K,K5&B.(5,Q"Q#
M')XGSBV^F9%1'E",^!'#5NP<HYS*@K&?^<D?T<3Q\HH@@5#F$%1]O< ,DB1'
M4G7\6X$Z=<X\</?X'?UK05Z165 !,Y;\%4=R-7&N'13!,]TD\I%M?X>*T"#'
M"UDBBD^T+<<&Q$'A1DB65L&J@C3.RF_Z6C5B)T#A= >0*H T _H?!/A5@%\0
M+2LK:-U32:=CSK:(YZ,56GY0]*:(5FSB++^-3Y*K7V,5)Z>/("3?A'+#XVR)
M>N@V;VLL8Q!H\8;FG"TY3='%/4@:)^*S&O']Z1Y=?/J,/J$X0P]QDJB[(<:N
M5,7DD&Y8);XK$Y,/$OOH@65R)="7+()H/]Y5)&HFY)W)'3$"/E!^A7Q\B8A'
M_(YZ9H>'$T,Y?MU8O\#S#VJL.@/^ NCO1Y8D2#V 6\JC?[JZ5J+VNU'SE_I&
MK&D($T>]M06F,_WU%SST?NNB?"*PO0;TZP;T3>B-!E3XEV@!RSC+\DL+FM L
MA*XFE,C# CD7HI?I *M[^K++S9C=DMN@YC8P<OORJF140.=C7T8.=FH?!8W2
M!RUZF.@Q>Q4-ZXJ&QHHNYO1-J:M4KRB'$.*U%)<H ]E5X;!582_H-THT9K/L
M;E!S"8Q<_F19+Z1B56I\+-^Z2 1M$K[7(&%,8TGBNB9Q;?/X0Q;]S[-_W2(V
M\(8-8L;4EL1&-;&1D=@3K"FGQ1P\8T)VO@-&A&-%[$1@>V2QI^='[RPZ7L&>
MJ >G0MMOPHY)P&?3\@IZ]X'N!Z/& VW.;\N/:'[$6L^KT+WZ<;/\]A@R[!9T
MK T$-D[/1TEZ!;4GA_WFM&/.9]MD[0>PV1 <).L5QBZ1IJJ;T]C2T%,_-L_]
MUL*.V\Z@'S1=C3FY+3GM(K#91MR&H?J'I>0=(G0/*D48%U+?R>=$'J$B?@['
M@;7EP,%Y9/Y$'J-JPCD<"]:6!5MYEL-DONU;6B_N.6P+UKX%FXV+4>1';0%O
MB7S'F%&WR!-M+XAQYCY*Y"LH4XO-V2Q;3+1/(&:?<)#$D[8AZ+6:;4YD2T0;
M F(V!-8B3]I.H'6/C*EMJ6E;0<RVXIM< >\L_:1+#Z="VV>IS0;IGT7/R8G,
M1=6$<U@5HJT*L;(J!^DY:;L5O[E(8$YO2T^;%6(V*R9!)^U%#G_0+'_86H<)
MR >"KHT$,2]>'"7H'8L8I.G:S?ELFZP] 3%[@L,DO3WY]YI_\<QY;'GHV9^8
M9W][11^UGA*_Z=K-N8_EYNXLYZ? E\4NAT AVV2R7 ^OK]8[*;?%_D'C^AV^
MF97[(1JFW)YYH%QI@$ )/"M([RI0MXZ7.Q[EB63K8M-@P:1D:7&X AH!SP>H
MWY\9D^\G>8)ZWVGZ'U!+ P04    " #R/*56C!IC;F()  "\50  &0   'AL
M+W=O<FMS:&5E=',O<VAE970T,2YX;6R]G/UOV[@=QO\5PCL,+=#6%B6_I$L"
M-):(RW#M%>VZ_3 ,!T9F;.'TXJ-DIQGZQQ\I*98IR8S5/=TOB26+'U)\R*_(
MQQ0O'S+Y>[X1HB!?DSC-KT:;HMB^'8_S<",2GK_)MB)5W]QG,N&%.I3K<;Z5
M@J_*1$D\II/);)SP*!U=7Y;G/LKKRVQ7Q%$J/DJ2[Y*$R\<;$6</5R-G]'3B
M4[3>%/K$^/IRR]?BLRB^;#]*=30^4%91(M(\RE(BQ?W5Z)WSEGDSG:"\XI^1
M>,B//A-]*W=9]KL^N%U=C2:Z1"(68:$17/W;BZ6(8TU2Y?BCAHX.>>J$QY^?
MZ*R\>74S=SP7RRS^5[0J-E>CQ8BLQ#W?Q<6G[.%G4=_05//"+,[+O^2AOG8R
M(N$N+[*D3JQ*D$1I]9]_K2OB*('GG$A ZP2TE8#2$PG<.H%[;@*O3N"=6Z1I
MG6!Z;@ZS.D$IYKBJK+*F?5[PZTN9/1"IKU8T_:&4JTRM*CA*=<OZ7$CU;:32
M%=<L2GD:1CPFMVE>R)UJ-$5.7I,/7$JN12<O?%'P*,Y?DI](E)+W41RK)I%?
MC@N5O8:,PSJKFRHK>B(KE[S/TF*3DR!=B55/>M^>?F9)/U:W?;AW^G3O-]0*
M?,_E&^(ZKPB=4)=\^>R3%S^]5/=8""GRXC=U_^*W_(%O>XJZ/)],G\A]=VS'
M_'V7*LSD64Q@Q[S;R@-FX'TR.]D7X7/W:2CC'EJE6W+=DUP9[:OF]^]?U'?D
MMA!)_I^^-E>!O'Z0CLMO\RT/Q=5(!=Y<R+T87?_U+\YL\K<^59$P'PD+D# &
M@AG2>@=I/1O]^L,NN1.29/>'!DAT R2Z >9D(^(5>:'"3,^7+\FW\QKM356"
M:5D"_6C=7T\OQ_MCH:UE'"HT$A8@80P$,X2>'H2>6H7^1U:HIXJ6B*29'D6H
M(YYDN[3HDZQBS8XD<R?NS&G)9LUQJ&Q(6("$L6YET,5LT52&H<?LH,?,JL='
MJ9[C7TFJ1JN[5 U"X^B_8D7B+,]%3M08;W6(N;D:8!0[&:5K-1@I-JHWIN)K
M01Q*DNH!K#I@I"Y1R8N,W DUP@QCGN?1?:1.W<LL(>]^7=[J+W,>B]ZAPJS3
M1>=ML:VW,U1L)"Q PA@(9K2)^:%-S*UM(OAC%Q6/*JHJT8MJZ*<55S,0HJ<I
M4?RHFH6*N&K@R>]B0>YY),F>Q[M^4><=42\\VE)UWFG;,\\UK_&MA1XJ%A+&
M0#!#K,5!K(55K"]-KUVK*6.NNUVV3LL366J(J+JLJ*3-1:AZ<A&)LY7M$W;1
M$;;=67NN\%JJ6N]NJ*I(& /!#%4O#JI>G*MJ'8M_C*R]'?:BHQIM"VLM_= H
MC(0%2!@#P8PFX$R:2?C$V@B6NV075_.=7;N7FVV@=]H]Z<JXF+=TM)=@J)!0
M6@"E,13-U/+(4'&^0\MFG/6<F$Y'3&_2UM):@L%:(FD!E,90-%-+VFA)SQD?
M-='VE9K+I.I BOYI3,TSQK6T/?GLN<BADY;(OKUH@V5!TAB*9LK2N$..U:&X
M?G&;AEDB7I:]JIIP//>8?*4G/KV*N1TQ7GO33H_K7C6?+-J*01T?*(VA:*9B
MC>GCV%T?=AB':.<GSKAZL&WY8SE&X:D.C^GZM1ZWJ.'+7?%*21C&NY6>@=:=
MC6PSJ4V$7@F[?@]==#K4TE[$P5$3ZOI ::RO0F;SHPHQ56P<'<=NZ?BE-B&7
M\E%+<]K-J3G'!7 G\ZXB4#\'2@N@-/9LA9B*-)Z.8S=U& ^+3*KQ!0]#+48Y
M>Q#17G>L7F&ZO@OUNKI K9>:9MA9TW:> 31/AJ*9LC2VBF/W53ZI9Y&,0NV0
MA3S?]"K1-4O<]MS+GLM@':"V"I3&>FIC-C_1.1J_Q+$;)DM5]23,8C4:%Y+'
M===XLBC+_B+DEDL]/NB5J,?4<-L2(8T('TH+H#364QNSV0F)&O/#L;L?;8GX
M:L_3L#*6SQ (:0$LH30?2@N@-.9T?1_GHE]*VG@8U.YA?-[=Y6K8K<=JP?[$
M],B.&"H8E.9#:0&4QE T4]K&TJ .ZN=XBIS^+Z$T'TH+H#2&HID*-T8'M1L=
M_X]?Y>U%&-PTD#0?2@MHU^!I_0S&4!F:>C<."K4[*+6QQ7;IJO?):D\^6"OH
MNAHH+8#2&(IFRMK8+-2#!6JDX["$TGPH+8#2&(IF*MQ8,-1NP2"M3]HU)5X[
M;OL'>]I=C3*=7+2L3WNI!RL&]5Y0-%.QQJ*A=HOF%[$7,:&] B ]CR64YD-I
M 93&4#13T<;=H7-8E$6Z)$LHS8?2 BB-H6BFPHUS1,]PCG0@W?/XU ^UM.N'
M+!8=*]6>T6#)H/X0E,9ZZL-QW%,6-VTL(FJWB&X[<PX29FDA>7A"%Z@I!*7Y
M4%H I3$4S5SPW]A'[@055%VHBP2E^5!: *4Q%,U4N'&17/O"F&$+PMWN.ABG
M$UWM.0[6#NH/06D,13.U:_PAU^X/V8(P^4;.\7[M.0SNM5#[!TH+H#2&HIG*
M'[V)A7L5"_LN%O9E+.S;6-C7L7Z$:>0VII%K7YLS,"Y#?2,HS8?2@IHVLSV!
M&"I+4[O&#G*?6Y'3O+3CBSQ:I^5K.3PG/XO56B_2.7JMMU=.I-6RA-)\*"V
MTAB*9NK>F$KN#!:5H283E.9#:0&4QE T4^'&9'+M2X@&1N7N^AD5J^;MU2KV
M/ >K!S60H#364R$7U)GVFQ%N8PRY=F/H.-Y^R(KOC+E(WV4)I?E06@"E,13-
MU+XQHMP+6,R%>E!0F@^E!5 :0]',G0D:#\JS+V$:%G-KF+&N=4(7K;<"EO8\
MAZH'I050&NNI$.?".[5(T&N,(\]N'+WG7Z-DEY!OY'\>[MIS&MHQH30?2@N@
M-(:BF2V@L9\\B@J]'M1F@M)\*"V TAB*9BK<V$R>?4'24Q_G>R'Y6I"M4CQ;
MZ05IU5X4Y:O.ZJAQ':.4/ HN<_(B%GE.B@U/^_9&NGDF8UI1>L6'.E!06@"E
M,13-%/]H2R"[ ]4?X+][?&W/;7 (@%I44%H I3$4S6P%C9?E36%!'NI:06D^
ME!9 :0Q%,Q5N7"O/OA3J!P9Y>\:S>N>B7O6ACA:4%D!I#$6KU!\?;3J9"+DN
MMP?-J[=VJCT8#V</6Y"^*S?>;)V_<=XNJXU$&TRUK^E[+M=Z"XQ8W"ODY,U<
M-5]9;15:'139MMS:\BXKBBPI/VX$7PFI+U#?WV=9\72@,SALV'K])U!+ P04
M    " #R/*56S]MZZ+0#   ;$   &0   'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6S-6-MNXS80_96!NB@<((XNOB2;V@9RVVZ 31LDW?:AZ ,CC2UB)=)+
MTI<N]N,[I!39RBI"LU#0OL2B-',XYW"&Y&2RD>J33A$-;/-,Z*F7&K,\]7T=
MIY@S?227*.C+7*J<&1JJA:^7"EGBG/+,CX)@[.>,"V\V<>]NU6PB5R;C F\5
MZ%6>,_7W.69R,_5"[_'%'5^DQK[P9Y,E6^ ]FH_+6T4COT))>(Y"<RE X7SJ
MG86G%^'0.CB+WSEN]-XS6"H/4GZR@^MDZ@4V(LPP-A:"T<\:+S#++!+%\;D$
M]:HYK>/^\R/Z.T>>R#PPC1<R^X,G)IUZ)QXD.&>KS-S)S7LL"8TL7BPS[?["
MIK0-/(A7VLB\=*8(<BZ*7[8MA=AS()QFAZATB)XZ#)]Q&)0. T>TB,S1NF2&
MS29*;D!9:T*S#TX;YTULN+#+>&\4?>7D9V;ON& BYBR#:Z&-6M$*&0U]N)K/
M26B0<_B%<NE:K%$;^PW>8[) #;U+-(QG^H!L/]Y?0N_- ;P!+N"&9QFMCY[X
MAL*SD_AQ&<IY$4KT3"@#N)'"I!JN1())W=\G6A6WZ)';>=0*>,/4$0S"0XB"
M:- 0S\6_=X]:PAE44@\<WO YJ:6BI!* VSAE8H$0$UU%>=RH52N6+>Y3O60Q
M3CVJ7HUJC=[LQQ_"<?!3$]&.P&JTAQ7MH4,?/$/[$A5?,UNL^REV"#_3'@.]
M#U)3#OWY@9S@VF"N_VH28]BE&!V!U<0856*,6G/@+)<KX<KJ5E$!;:%G93@
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M.^TC1U6V9>7$R%71V<RDP3ZI&"ZQE05E#?#]7$KS.+'-4MT<)S\!4$L#!!0
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MN! T2O%\$K'L/S@6SPXLX.\9)W$1+%H0ATG^BGX4B:@$")SN %@$P&; L"?
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MG<+F;#7JESL8QSV3%4J[#-5V^:S*!-N6N;D\JVEUI2L)Z\JE6X9JMWQ>92I
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M5T?37./#$)0UP/&EE.;0L4^/[JF9_P)02P,$%     @ \CRE5BO C!G2 @
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M\&7>ZN03+=*L6U@*C;U'-HRP.P1I#'!_)81^G)@&I.PW_7]02P,$%     @
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MYRRK'N>4B#4G!<3O=XSQYR^R@]5MZNG_4$L#!!0    ( /(\I59O -O#S@0
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M90WP^TI*L^O8"=KZ-_D%4$L#!!0    ( /(\I58C@)QS40(  +4%   9
M>&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;*U446_3,!#^*U:0T"9!DR9=!R6-
MU'9#\%!4K0(>$ ]N<FVL.7:PW6;\>\YV&KJ157O@);;/]WV^[W)W:2/5O2X!
M#'FHN-#3H#2FGH2ASDNHJ![(&@3>;*6JJ,&CVH6Z5D +!ZIX&$?1.*PH$T&6
M.MM*9:G<&\X$K!31^ZJBZO<<N&RFP3 X&N[8KC36$&9I37>P!O.U7BD\A1U+
MP2H0FDE!%&RGP6PX68RLOW/XQJ#1)WMBE6RDO+>'S\4TB&Q P"$WEH'B<H %
M<&Z),(Q?+6?0/6F!I_LC^T>G';5LJ(:%Y-]98<II\"X@!6SIGIL[V7R"5L^5
MY<LEU^Y+&N\[?A^0?*^-K%HP1E QX5?ZT.;A!( \_8"X!<1/ :-G $D+2)Q0
M'YF3=4,-S5(E&Z*L-[+9C<N-0Z,:)NQ?7!N%MPQQ)KNE2C"QTV0%BJQ+JH"\
M)5^H4M2FEUS<@*&,ZTNT:GNKCPL39,DXQU^AT]!@))8OS-M7Y_[5^)E7$[*4
MPI2:W(H"BL?X$!5T,N*CC'E\EG!)U8 DPS<DCN*D)Y[%R^'QF7"2+JN)XTM>
MGM4?LXTV"JOV9U^Z/-VHG\YV\D37-(=I@*VJ01T@R%Z_&HZC#WU:_Q/9(^6C
M3OGH''LV$X85C.]=];2E<H&UXK>7?=H]X94CM$/GD W3\' JZ%^/Z\[#1QF>
M=$ %:N<&@R:YW OCJZBS=K-GYEKNB7V.,\F/D+\T?J!AC>R8T(3#%BFCP37&
MH_R0\ <C:]=G&VFP:]VVQ+D*RCK@_59*<SS8![I)G?T!4$L#!!0    ( /(\
MI5:2 &Z+= 8  "@H   9    >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;+V:
M6V_;-A3'OPKA%4,+U+5XD6QGCH'$Z; ""Q:D[?8P[$&Q:5NK+JXDQ\VW'W6)
M:)&'=!QK?DE\.3S\GZ,C_@YE3G9)^BU;<YZC'U$89Y>]=9YO+@:#;+[FD9]]
M2#8\%M\LDS3R<_$V70VR3<K]13DH"@?$<;Q!Y =Q;SHI/[M+IY-DFX=!S.]2
ME&VCR$^?KGF8["Y[N/?\P7VP6N?%!X/I9..O^&>>?]W<I>+=H/&R""(>9T$2
MHY0O+WM7^&+&QL6 TN+/@.^RO=>H".4A2;X5;SXM+GM.H8B'?)X7+GSQ[Y'/
M>!@6GH2.[[737C-G,7#_];/W7\O@13 /?L9G2?A7L,C7E[U1#RWXTM^&^7VR
M^XW7 ;F%OWD29N5?M*MMG1Z:;[,\B>K!0D$4Q-5__T>=B+T!P@\\@-0#B#J
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MV,[IH_H)K -UJ"YF@ UFS%"ODKK8CMW_O9W  )X]3XU--\)L9(A-0AS;*6X
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M1!$=LRK5 ).^89]*)(B)'<1G:C4(0&2F[K4@(T.^J:0V/64C;BX0"FW!%<&
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M6'L";";@FWT<A/_6?VLOEQ[0\HZ&N-)9%0%,JA)5VGA=N]G26>4 -(IVPZ9
MZVIHI3-Q0((*WWTZP$);!3RTHV!+\09ZG?AVB0R(@).WJD35-EX';[9TTW(
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M4'GQ<D!<+B3;Z!GK*Y-JD_5ABE&">1&@KJ\8D^^+X@;UF'[Z'U!+ P04
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ \CRE5DPW0=D9!0  ]2H
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M;[Y3R@\J,WUK^&K_UN;^C=.K?P!02P,$%     @ \CRE5K5Q8'P6 @  JB8
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M[01Z.^KM!'H[ZNT$>OMDLYM ;T>]G4!O1[V=0&]'O9U ;T>]G4!O1[V=0.]
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M              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ \CRE5O94*YY5!P  :C,  !@              ("!#@@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( /(\I5:K.6*@>@0  . /   8
M              " @9D/  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    " #R/*56ADY[>*\#  #7"@  &               @(%)%   >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ \CRE5JV#&1LH!P
M=1P  !@              ("!+A@  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( /(\I5;E0*5030,  &$)   8              " @8P?
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #R/*56N1T[
MJ[ &  !D&P  &               @($/(P  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ \CRE5JX+5G=R @  V@8  !@
M ("!]2D  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( /(\
MI58%:S+#XP0  $H+   8              " @9TL  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    " #R/*56B#KJ+%L&   7$0  &
M        @(&V,0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ \CRE5E.F6!3H"0  *1@  !D              ("!1S@  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #R/*56I<U83]$0  !".P
M&0              @(%F0@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( /(\I59BEQA1L <  !<4   9              " @6Y3  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ \CRE5H3PW$*/
M'   16,  !D              ("!55L  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    " #R/*56B=/ORV8#  "I!P  &0
M@($;>   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( /(\
MI59700@-DR$  )%E   9              " @;A[  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ \CRE5M%B2&L4!   B@L  !D
M         ("!@IT  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    " #R/*56/U44FY4%  ###0  &0              @('-H0  >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( /(\I58F_NM!ZP,  .T(
M   9              " @9FG  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ \CRE5@O4^!MD P  V0<  !D              ("!NZL
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #R/*56^A8[
MW^P"   1!P  &0              @(%6KP  >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( /(\I58HEDY"1@0  /X*   9
M  " @7FR  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
M\CRE5@<Y;$V!#@  D",  !D              ("!]K8  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    " #R/*56085'MW$%  "^#0  &0
M            @(&NQ0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( /(\I5::D\%"\00  *8/   9              " @5;+  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ \CRE5KAC;I6S P
MVPD  !D              ("!?M   'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    " #R/*56.<0]:Y\-  #2+@  &0              @(%H
MU   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( /(\I58N
MX"A3S0(  .X%   9              " @3[B  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ \CRE5B&COM<B!   F L  !D
M     ("!0N4  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M" #R/*565\Q_#"\$  "W"P  &0              @(&;Z0  >&PO=V]R:W-H
M965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( /(\I5:J'F"YS (  "8&   9
M              " @0'N  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L!
M A0#%     @ \CRE5N:OJ>[Y @  %P<  !D              ("!!/$  'AL
M+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #R/*56\"Z/:U4$
M  #@"@  &0              @($T]   >&PO=V]R:W-H965T<R]S:&5E=#,R
M+GAM;%!+ 0(4 Q0    ( /(\I5: 1Q'!3@D  /T4   9              "
M@<#X  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ \CRE
M5F+28$3[!   82(  !D              ("!10(! 'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    " #R/*56RF2D7!H'  !!/P  &0
M        @(%W!P$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( /(\I5;91AEI_ D  '!D   9              " @<@. 0!X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ \CRE5O_%G)78"P  5G\
M !D              ("!^Q@! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    " #R/*56O8]11X$#  !5#P  &0              @($*)0$
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( /(\I5:D?5_H
MF 8  #PZ   9              " @<(H 0!X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ \CRE5BO$UIF7!   @QH  !D
M ("!D2\! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " #R
M/*56C!IC;F()  "\50  &0              @(%?- $ >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( /(\I5;/VWKHM ,  !L0   9
M          " @?@] 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#
M%     @ \CRE5D0\O?:G!P  2T$  !D              ("!XT$! 'AL+W=O
M<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " #R/*56X'C9 '<#   H
M"P  &0              @('!20$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM
M;%!+ 0(4 Q0    ( /(\I59DNZ=0N@0  !45   9              " @6]-
M 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ \CRE5NW#
MDMPA P  _PD  !D              ("!8%(! 'AL+W=O<FMS:&5E=',O<VAE
M970T-BYX;6Q02P$"% ,4    " #R/*56YV<@.K8%   >)P  &0
M    @(&X50$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (
M /(\I5;K3@.J%A0  *80 0 9              " @:5; 0!X;"]W;W)K<VAE
M971S+W-H965T-#@N>&UL4$L! A0#%     @ \CRE5K@X^GCJ P   P\  !D
M             ("!\F\! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"
M% ,4    " #R/*56Z;59A44#  !V"@  &0              @($3= $ >&PO
M=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( /(\I58KP(P9T@(
M 'L*   9              " @8]W 0!X;"]W;W)K<VAE971S+W-H965T-3$N
M>&UL4$L! A0#%     @ \CRE5AOG*24T"   "UT  !D              ("!
MF'H! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " #R/*56
M@VYJM'\'  !9+0  &0              @($#@P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4S+GAM;%!+ 0(4 Q0    ( /(\I59O -O#S@0  &(8   9
M      " @;F* 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%
M  @ \CRE5H6)?<9K @  :@4  !D              ("!OH\! 'AL+W=O<FMS
M:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " #R/*56"_E5I58#  #>"0
M&0              @(%@D@$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+
M 0(4 Q0    ( /(\I59+*0;$Q@(  'T(   9              " @>V5 0!X
M;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ \CRE5IQVXAZ"
M @  >@8  !D              ("!ZI@! 'AL+W=O<FMS:&5E=',O<VAE970U
M."YX;6Q02P$"% ,4    " #R/*565:\*G6<#   +"P  &0
M@(&CFP$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( /(\
MI58C@)QS40(  +4%   9              " @4&? 0!X;"]W;W)K<VAE971S
M+W-H965T-C N>&UL4$L! A0#%     @ \CRE5I( ;HMT!@  *"@  !D
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M=#8U+GAM;%!+ 0(4 Q0    ( /(\I5;;[\L*/ ,  ,P3   -
M  "  ?#- 0!X;"]S='EL97,N>&UL4$L! A0#%     @ \CRE5I>*NQS
M$P(   L              ( !5]$! %]R96QS+RYR96QS4$L! A0#%     @
M\CRE5DPW0=D9!0  ]2H   \              ( !0-(! 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( /(\I5:U<6!\%@(  *HF   :              "
M 8;7 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( /(\
MI5;2-&04[ $   <F   3              "  =39 0!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@    !) $D ]A,  /'; 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>577</ContextCount>
  <ElementCount>298</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>134</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONDENSED CONSOLIDATED STATEMENT OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEET</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/BasisofPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Spin-Off of Organon &amp; Co.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SpinOffofOrganonCo</Role>
      <ShortName>Spin-Off of Organon &amp; Co.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Acquisitions, Research Collaborations and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements</Role>
      <ShortName>Acquisitions, Research Collaborations and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Collaborative Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CollaborativeArrangements</Role>
      <ShortName>Collaborative Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Pension and Other Postretirement Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Other (Income) Expense, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIncomeExpenseNet</Role>
      <ShortName>Other (Income) Expense, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Taxes on Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncome</Role>
      <ShortName>Taxes on Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherComprehensiveIncomeLoss</Role>
      <ShortName>Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/BasisofPresentationPolicies</Role>
      <ShortName>Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Collaborative Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CollaborativeArrangementsTables</Role>
      <ShortName>Collaborative Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/CollaborativeArrangements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/RestructuringTables</Role>
      <ShortName>Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/Restructuring</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/FinancialInstruments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/Inventories</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/Equity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Other (Income) Expense, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIncomeExpenseNetTables</Role>
      <ShortName>Other (Income) Expense, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherIncomeExpenseNet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/EarningsPerShare</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherComprehensiveIncomeLossTables</Role>
      <ShortName>Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherComprehensiveIncomeLoss</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.merck.com/role/SegmentReporting</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Spin-Off of Organon &amp; Co. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SpinOffofOrganonCoDetails</Role>
      <ShortName>Spin-Off of Organon &amp; Co. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/SpinOffofOrganonCo</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Acquisitions, Research Collaborations and License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails</Role>
      <ShortName>Acquisitions, Research Collaborations and License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Collaborative Arrangements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails</Role>
      <ShortName>Collaborative Arrangements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Collaborative Arrangements - Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails</Role>
      <ShortName>Collaborative Arrangements - Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Restructuring - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/RestructuringNarrativeDetails</Role>
      <ShortName>Restructuring - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails</Role>
      <ShortName>Restructuring - Charges Activities by Type of Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Restructuring - Activities by Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/RestructuringActivitiesbyProgramDetails</Role>
      <ShortName>Restructuring - Activities by Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Financial Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails</Role>
      <ShortName>Financial Instruments - Effect of Net Investment Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails</Role>
      <ShortName>Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails</Role>
      <ShortName>Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails</Role>
      <ShortName>Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails</Role>
      <ShortName>Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Financial Instruments - Information on Available-for-sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails</Role>
      <ShortName>Financial Instruments - Information on Available-for-sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails</Role>
      <ShortName>Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Inventories - Schedule of Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/InventoriesScheduleofInventoriesDetails</Role>
      <ShortName>Inventories - Schedule of Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Inventories - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/InventoriesNarrativeDetails</Role>
      <ShortName>Inventories - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/ContingenciesDetails</Role>
      <ShortName>Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/Contingencies</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/EquityTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails</Role>
      <ShortName>Pension and Other Postretirement Benefit Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails</Role>
      <ShortName>Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherIncomeExpenseNetTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Other (Income) Expense, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails</Role>
      <ShortName>Other (Income) Expense, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherIncomeExpenseNetTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Taxes on Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/TaxesonIncomeDetails</Role>
      <ShortName>Taxes on Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/TaxesonIncome</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share - Calculations of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Earnings Per Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/EarningsPerShareNarrativeDetails</Role>
      <ShortName>Earnings Per Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/OtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.merck.com/role/OtherComprehensiveIncomeLossTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Segment Reporting - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingNarrativeDetails</Role>
      <ShortName>Segment Reporting - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Segment Reporting - Sales from Products (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingSalesfromProductsDetails</Role>
      <ShortName>Segment Reporting - Sales from Products (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Segment Reporting - Consolidated Sales by Geographic Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails</Role>
      <ShortName>Segment Reporting - Consolidated Sales by Geographic Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="mrk-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails</Role>
      <ShortName>Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept RevenueFromRelatedParties in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. mrk-20230331.htm 4</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueFromRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. mrk-20230331.htm 4</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. mrk-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="mrk-20230331.htm">mrk-20230331.htm</File>
    <File>exhibit311-rule13ax14a15dx.htm</File>
    <File>exhibit312-rule13ax14a15dx.htm</File>
    <File>exhibit321-section1350cert.htm</File>
    <File>exhibit322-section1350cert.htm</File>
    <File>mrk-20230331.xsd</File>
    <File>mrk-20230331_cal.xml</File>
    <File>mrk-20230331_def.xml</File>
    <File>mrk-20230331_lab.xml</File>
    <File>mrk-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1204">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>83
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mrk-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 31,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 1204,
    "http://xbrl.sec.gov/dei/2022": 41
   },
   "contextCount": 577,
   "dts": {
    "calculationLink": {
     "local": [
      "mrk-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mrk-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mrk-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mrk-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mrk-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mrk-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 565,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 20,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 25
   },
   "keyCustom": 33,
   "keyStandard": 265,
   "memberCustom": 65,
   "memberStandard": 66,
   "nsprefix": "mrk",
   "nsuri": "http://www.merck.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.merck.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Acquisitions, Research Collaborations and License Agreements",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements",
     "shortName": "Acquisitions, Research Collaborations and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Collaborative Arrangements",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.merck.com/role/CollaborativeArrangements",
     "shortName": "Collaborative Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Restructuring",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.merck.com/role/Restructuring",
     "shortName": "Restructuring",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Financial Instruments",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.merck.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Inventories",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.merck.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Contingencies",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.merck.com/role/Contingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Equity",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.merck.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Pension and Other Postretirement Benefit Plans",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans",
     "shortName": "Pension and Other Postretirement Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Other (Income) Expense, Net",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.merck.com/role/OtherIncomeExpenseNet",
     "shortName": "Other (Income) Expense, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Taxes on Income",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.merck.com/role/TaxesonIncome",
     "shortName": "Taxes on Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONDENSED CONSOLIDATED STATEMENT OF INCOME",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
     "shortName": "CONDENSED CONSOLIDATED STATEMENT OF INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "mrk:CostsExpensesAndOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Earnings Per Share",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.merck.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Other Comprehensive Income (Loss)",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.merck.com/role/OtherComprehensiveIncomeLoss",
     "shortName": "Other Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Segment Reporting",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.merck.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Basis of Presentation (Policies)",
     "menuCat": "Policies",
     "order": "23",
     "role": "http://www.merck.com/role/BasisofPresentationPolicies",
     "shortName": "Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Collaborative Arrangements (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.merck.com/role/CollaborativeArrangementsTables",
     "shortName": "Collaborative Arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Restructuring (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.merck.com/role/RestructuringTables",
     "shortName": "Restructuring (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.merck.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Inventories (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.merck.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Equity (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.merck.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "id12f95a53e9f4822b4ac3324b1225c13_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables",
     "shortName": "Pension and Other Postretirement Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "id12f95a53e9f4822b4ac3324b1225c13_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME",
     "shortName": "CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Other (Income) Expense, Net (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.merck.com/role/OtherIncomeExpenseNetTables",
     "shortName": "Other (Income) Expense, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Earnings Per Share (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.merck.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Other Comprehensive Income (Loss) (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.merck.com/role/OtherComprehensiveIncomeLossTables",
     "shortName": "Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Segment Reporting (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.merck.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "iad59a4cb91a64620bac9b9c19d9f7cc5_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Spin-Off of Organon & Co. (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.merck.com/role/SpinOffofOrganonCoDetails",
     "shortName": "Spin-Off of Organon & Co. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "iad59a4cb91a64620bac9b9c19d9f7cc5_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Acquisitions, Research Collaborations and License Agreements (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
     "shortName": "Acquisitions, Research Collaborations and License Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i1302ee97335a4b8a864d880d15a75ffd_I20230430",
      "decimals": "2",
      "lang": "en-US",
      "name": "mrk:AssetAcquisitionSharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentForAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Collaborative Arrangements - Narrative (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
     "shortName": "Collaborative Arrangements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i6a91adde5a68413fbc1cfab655dbcbe6_D20220101-20220331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentForAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Collaborative Arrangements - Financial Information (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
     "shortName": "Collaborative Arrangements - Financial Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i5973fb4a5d684bcca7a62270623ac406_I20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Restructuring - Narrative (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.merck.com/role/RestructuringNarrativeDetails",
     "shortName": "Restructuring - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails",
     "shortName": "Restructuring - Charges Activities by Type of Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i111e37e345c242418c65ff71f8df4aa4_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Restructuring - Activities by Program (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
     "shortName": "Restructuring - Activities by Program (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfInterestRateDerivativesHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "interest_rate_swap",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Financial Instruments - Narrative (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfInterestRateDerivativesHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "interest_rate_swap",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i3ade1a511bd04605a075fd4b05ec6eca_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
     "shortName": "Financial Instruments - Effect of Net Investment Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i3ade1a511bd04605a075fd4b05ec6eca_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
     "shortName": "Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i2a06f418da43474f9f2f260add8790b3_I20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails",
     "shortName": "Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
     "shortName": "Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i330867f88a774fb08f247e81d478866e_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "if03eefb0e5be4080ba5289591b557e4d_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
     "shortName": "Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "if03eefb0e5be4080ba5289591b557e4d_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Financial Instruments - Information on Available-for-sale Investments (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails",
     "shortName": "Financial Instruments - Information on Available-for-sale Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i6f4032436bb84e00a3478c08a4a4bac8_I20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:TradingSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails",
     "shortName": "Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Inventories - Schedule of Inventories (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails",
     "shortName": "Inventories - Schedule of Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Inventories - Narrative (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.merck.com/role/InventoriesNarrativeDetails",
     "shortName": "Inventories - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "idf5ff6cbdf22489b9efa70ffb318b8aa_I20230331",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:InventoryNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i5913ce6cd24f4f45a393b8a13ce74d4d_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Contingencies (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.merck.com/role/ContingenciesDetails",
     "shortName": "Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i5913ce6cd24f4f45a393b8a13ce74d4d_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Equity (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.merck.com/role/EquityDetails",
     "shortName": "Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i48e93ba87cab4afc961e66db38e74311_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i48e93ba87cab4afc961e66db38e74311_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanSettlementsPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails",
     "shortName": "Pension and Other Postretirement Benefit Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanSettlementsPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails",
     "shortName": "Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Other (Income) Expense, Net - Narrative (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails",
     "shortName": "Other (Income) Expense, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Taxes on Income (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.merck.com/role/TaxesonIncomeDetails",
     "shortName": "Taxes on Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails",
     "shortName": "Earnings Per Share - Calculations of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Earnings Per Share - Narrative (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.merck.com/role/EarningsPerShareNarrativeDetails",
     "shortName": "Earnings Per Share - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i3a0fcc70ef544d5ca3bcf9ba3b0a0ae8_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Other Comprehensive Income (Loss) (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails",
     "shortName": "Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Segment Reporting - Narrative (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.merck.com/role/SegmentReportingNarrativeDetails",
     "shortName": "Segment Reporting - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Segment Reporting - Sales from Products (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails",
     "shortName": "Segment Reporting - Sales from Products (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Segment Reporting - Consolidated Sales by Geographic Area (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails",
     "shortName": "Segment Reporting - Consolidated Sales by Geographic Area (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i679d69340bf54bb4a090a15b7ce9076e_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails",
     "shortName": "Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "id8c4caa074434a8c891a4dbc9477a1df_D20230101-20230331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i5c3c68968d5a49b98049b259f527466f_I20230331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Basis of Presentation",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.merck.com/role/BasisofPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Spin-Off of Organon & Co.",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.merck.com/role/SpinOffofOrganonCo",
     "shortName": "Spin-Off of Organon & Co.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mrk-20230331.htm",
      "contextRef": "i9898fd351c244a31961383ac8941ad7d_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 134,
   "tag": {
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CO": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COLOMBIA",
        "terseLabel": "COLOMBIA"
       }
      }
     },
     "localname": "CO",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S.",
        "verboseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails",
      "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mrk_A0.500Notesdue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.500% Notes due 2024 [Member]",
        "label": "0.500% Notes due 2024 [Member]",
        "terseLabel": "0.500% Notes due 2024"
       }
      }
     },
     "localname": "A0.500Notesdue2024Member",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A1.375Notesdue2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.375% Notes due 2036 [Member]",
        "label": "1.375% Notes due 2036 [Member]",
        "terseLabel": "1.375% Notes due 2036"
       }
      }
     },
     "localname": "A1.375Notesdue2036Member",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A1.875Notesdue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.875% Notes due 2026 [Member]",
        "label": "1.875% Notes due 2026 [Member]",
        "terseLabel": "1.875% Notes due 2026"
       }
      }
     },
     "localname": "A1.875Notesdue2026Member",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_A2.500Notesdue2034Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.500% Notes due 2034 [Member]",
        "label": "2.500% Notes due 2034 [Member]",
        "terseLabel": "2.500% Notes due 2034"
       }
      }
     },
     "localname": "A2.500Notesdue2034Member",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AcceleratedDepreciationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated Depreciation [Member]",
        "label": "Accelerated Depreciation [Member]",
        "terseLabel": "Accelerated Depreciation"
       }
      }
     },
     "localname": "AcceleratedDepreciationMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to acquisitions, divestitures, research collaborations and license agreements.",
        "label": "Acquisitions Research Collaborations And License Agreements [Text Block]",
        "terseLabel": "Acquisitions, Research Collaborations and License Agreements"
       }
      }
     },
     "localname": "AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrk_AdempasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adempas",
        "label": "Adempas [Member]",
        "terseLabel": "Adempas"
       }
      }
     },
     "localname": "AdempasMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AllianceRevenueAdempasVerquvoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alliance revenue - Adempas/Verquvo",
        "label": "Alliance revenue - Adempas/Verquvo [Member]",
        "terseLabel": "Alliance revenue - Adempas/Verquvo"
       }
      }
     },
     "localname": "AllianceRevenueAdempasVerquvoMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AllianceRevenueKoselugoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alliance revenue - Koselugo",
        "label": "Alliance revenue - Koselugo [Member]",
        "terseLabel": "Alliance revenue - Koselugo"
       }
      }
     },
     "localname": "AllianceRevenueKoselugoMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AllianceRevenueReblozylMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alliance Revenue - Reblozyl",
        "label": "Alliance Revenue - Reblozyl [Member]",
        "terseLabel": "Alliance Revenue - Reblozyl"
       }
      }
     },
     "localname": "AllianceRevenueReblozylMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AlliancerevenueLynparzaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alliance revenue - Lynparza [Member]",
        "label": "Alliance revenue - Lynparza [Member]",
        "terseLabel": "Alliance revenue - Lynparza"
       }
      }
     },
     "localname": "AlliancerevenueLynparzaMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AnimalHealthsegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Animal Health segment [Member]",
        "label": "Animal Health segment [Member]",
        "terseLabel": "Animal Health",
        "verboseLabel": "Animal Health segment"
       }
      }
     },
     "localname": "AnimalHealthsegmentMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Assets Acquired And Liabilities Assumed, Net",
        "label": "Asset Acquisition, Assets Acquired And Liabilities Assumed, Net",
        "terseLabel": "Net assets acquired"
       }
      }
     },
     "localname": "AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_AssetAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in an asset acquisition.",
        "label": "Asset Acquisition Share Price",
        "terseLabel": "Asset acquisition, share price (in dollars per share)"
       }
      }
     },
     "localname": "AssetAcquisitionSharePrice",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mrk_AstraZenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AstraZeneca [Member]",
        "label": "AstraZeneca [Member]",
        "terseLabel": "AstraZeneca"
       }
      }
     },
     "localname": "AstraZenecaMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_BayerAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer AG [Member]",
        "label": "Bayer AG [Member]",
        "terseLabel": "Bayer AG"
       }
      }
     },
     "localname": "BayerAGMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_BelsomraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Belsomra [Member]",
        "label": "Belsomra [Member]",
        "terseLabel": "Belsomra"
       }
      }
     },
     "localname": "BelsomraMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_BridionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bridion [Member].",
        "label": "Bridion [Member]",
        "terseLabel": "Bridion"
       }
      }
     },
     "localname": "BridionMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_BristolMyersSquibbMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol Myers Squibb",
        "label": "Bristol Myers Squibb [Member]",
        "terseLabel": "Bristol Myers Squibb"
       }
      }
     },
     "localname": "BristolMyersSquibbMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_CollaborativeArrangementPreferredStockInvestmentInCounterparty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Preferred Stock Investment In Counterparty",
        "label": "Collaborative Arrangement, Preferred Stock Investment In Counterparty",
        "terseLabel": "Preferred stock investment in counterparty"
       }
      }
     },
     "localname": "CollaborativeArrangementPreferredStockInvestmentInCounterparty",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementProfitSharing": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Profit Sharing",
        "label": "Collaborative Arrangement, Profit Sharing",
        "terseLabel": "Alliance revenue - profit sharing"
       }
      }
     },
     "localname": "CollaborativeArrangementProfitSharing",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementRegulatoryMilestonePaymentsAccrued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Regulatory Milestone Payments Accrued",
        "label": "Collaborative Arrangement, Regulatory Milestone Payments Accrued",
        "terseLabel": "Regulatory milestone payments accrued"
       }
      }
     },
     "localname": "CollaborativeArrangementRegulatoryMilestonePaymentsAccrued",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Contingent Development-Related Payments",
        "terseLabel": "Eligible future contingent development-related payments (up to)"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateContingentDevelopmentRelatedPayments",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments",
        "terseLabel": "Regulatory milestones payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Sales-Based Milestone Payments",
        "terseLabel": "Sales milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateSalesBasedMilestonePayments",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementSalesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Sales, Net",
        "label": "Collaborative Arrangement, Sales, Net",
        "terseLabel": "Net sales by Merck"
       }
      }
     },
     "localname": "CollaborativeArrangementSalesNet",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CollaborativeArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements [Abstract]",
        "label": "Collaborative Arrangements [Abstract]",
        "terseLabel": "Collaborative Arrangements [Abstract]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAbstract",
     "nsuri": "http://www.merck.com/20230331",
     "xbrltype": "stringItemType"
    },
    "mrk_CompanionAnimalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Companion Animals [Member]",
        "label": "Companion Animals [Member]",
        "terseLabel": "Companion Animals"
       }
      }
     },
     "localname": "CompanionAnimalsMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ComplaintAgainstTheJohnsHopkinsUniversityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Complaint Against The Johns Hopkins University",
        "label": "Complaint Against The Johns Hopkins University [Member]",
        "terseLabel": "Complaint Against The Johns Hopkins University"
       }
      }
     },
     "localname": "ComplaintAgainstTheJohnsHopkinsUniversityMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ContingentProceedsCollaborativeArrangement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents proceeds that may be received in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement.",
        "label": "Contingent Proceeds Collaborative Arrangement",
        "terseLabel": "Contingent proceeds collaborative arrangement"
       }
      }
     },
     "localname": "ContingentProceedsCollaborativeArrangement",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_CostsExpensesAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of cost of sales, operating expenses and nonoperating income or expense.",
        "label": "Costs Expenses And Other",
        "totalLabel": "Total Costs, Expenses and Other"
       }
      }
     },
     "localname": "CostsExpensesAndOther",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DebtSecuritiesandEquitySecuritiesFVNI": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities and Equity Securities, FV-NI",
        "label": "Debt Securities and Equity Securities, FV-NI",
        "totalLabel": "Total debt and publicly traded equity securities, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesandEquitySecuritiesFVNI",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Income Taxes and Other Assets, Current",
        "label": "Deferred Income Taxes and Other Assets, Current [Member]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndOtherAssetsCurrentMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Income Taxes And Other Assets, Noncurrent",
        "label": "Deferred Income Taxes And Other Assets, Noncurrent [Member]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrentMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_DificidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dificid",
        "label": "Dificid [Member]",
        "terseLabel": "Dificid"
       }
      }
     },
     "localname": "DificidMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_EisaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eisai [Member]",
        "label": "Eisai [Member]",
        "terseLabel": "Eisai"
       }
      }
     },
     "localname": "EisaiMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimate of cumulative pre tax costs that will be noncash.",
        "label": "Estimate Of Cumulative Pre Tax Costs That Will Be Noncash",
        "terseLabel": "Estimate of cumulative pre tax costs that will be noncash"
       }
      }
     },
     "localname": "EstimateOfCumulativePreTaxCostsThatWillBeNoncash",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense).",
        "label": "Estimate Of Cumulative Pre Tax Costs That Will Result In Cash Outlays",
        "terseLabel": "Estimate of cumulative pre tax costs that will result in cash outlays"
       }
      }
     },
     "localname": "EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_EurodominatedNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Euro-dominated Notes [Member]",
        "label": "Euro-dominated Notes [Member]",
        "terseLabel": "Euro-denominated notes"
       }
      }
     },
     "localname": "EurodominatedNotesMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_GardasilGardasil9Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gardasil/Gardasil 9 [Member].",
        "label": "Gardasil/Gardasil 9 [Member]",
        "terseLabel": "Gardasil/Gardasil 9"
       }
      }
     },
     "localname": "GardasilGardasil9Member",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ImagoBioSciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Imago Bio Sciences, Inc.",
        "label": "Imago Bio Sciences, Inc. [Member]",
        "terseLabel": "Imago Bio Sciences, Inc."
       }
      }
     },
     "localname": "ImagoBioSciencesIncMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_IncreaseDecreaseInHedgeRevenue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Hedge Revenue",
        "label": "Increase (Decrease) In Hedge Revenue",
        "terseLabel": "Increase (Decrease) In Hedge Revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInHedgeRevenue",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_InternationalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International [Member]",
        "label": "International [Member]",
        "terseLabel": "Int\u2019l"
       }
      }
     },
     "localname": "InternationalMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InventoriesProducedinPreparationforProductLaunchesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories Produced in Preparation for Product Launches [Member]",
        "label": "Inventories Produced in Preparation for Product Launches [Member]",
        "terseLabel": "Inventories Produced in Preparation for Product Launches"
       }
      }
     },
     "localname": "InventoriesProducedinPreparationforProductLaunchesMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InventoryNetAndInventoryNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of current and noncurrent inventories.",
        "label": "Inventory Net And Inventory Noncurrent",
        "totalLabel": "Total current and noncurrent inventories"
       }
      }
     },
     "localname": "InventoryNetAndInventoryNoncurrent",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_InventoryNotExpectedtobeSoldWithinOneYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory Not Expected to be Sold Within One Year [Member]",
        "label": "Inventory Not Expected to be Sold Within One Year [Member]",
        "terseLabel": "Inventories Not Expected to be Sold Within One Year"
       }
      }
     },
     "localname": "InventoryNotExpectedtobeSoldWithinOneYearMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_InventoryTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory [Table]",
        "label": "Inventory [Table]",
        "terseLabel": "Inventory [Table]"
       }
      }
     },
     "localname": "InventoryTable",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_IsentressIsentressHDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Isentress/Isentress HD [Member].",
        "label": "Isentress/Isentress HD [Member]",
        "terseLabel": "Isentress/Isentress HD"
       }
      }
     },
     "localname": "IsentressIsentressHDMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_JanumetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janumet [Member].",
        "label": "Janumet [Member]",
        "terseLabel": "Janumet"
       }
      }
     },
     "localname": "JanumetMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_JanuviaAndJanumetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Januvia and Janumet",
        "label": "Januvia and Janumet [Member]",
        "terseLabel": "Januvia and Janumet"
       }
      }
     },
     "localname": "JanuviaAndJanumetMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_JanuviaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Januvia [Member] .",
        "label": "Januvia [Member]",
        "terseLabel": "Januvia"
       }
      }
     },
     "localname": "JanuviaMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_KeytrudaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Keytruda [Member]",
        "label": "Keytruda [Member]",
        "terseLabel": "Keytruda"
       }
      }
     },
     "localname": "KeytrudaMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LagevrioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lagevrio",
        "label": "Lagevrio [Member]",
        "terseLabel": "Lagevrio"
       }
      }
     },
     "localname": "LagevrioMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LegalDefenseCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Defense Costs [Member]",
        "label": "Legal Defense Costs [Member]",
        "terseLabel": "Legal Defense Costs"
       }
      }
     },
     "localname": "LegalDefenseCostsMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LenvimaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lenvima [Member]",
        "label": "Lenvima [Member]",
        "terseLabel": "Alliance revenue - Lenvima",
        "verboseLabel": "Lenvima"
       }
      }
     },
     "localname": "LenvimaMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LivestockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Livestock [Member]",
        "label": "Livestock [Member]",
        "terseLabel": "Livestock"
       }
      }
     },
     "localname": "LivestockMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_LossContingencyNumberOfStatesInWhichPlaintiffsReside": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of States In Which Plaintiffs Reside",
        "label": "Loss Contingency, Number Of States In Which Plaintiffs Reside",
        "terseLabel": "Loss Contingency, number of states in which plaintiffs reside"
       }
      }
     },
     "localname": "LossContingencyNumberOfStatesInWhichPlaintiffsReside",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mrk_LossContingencyTrialPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Trial Period",
        "label": "Loss Contingency, Trial Period",
        "terseLabel": "Loss contingency, trial period"
       }
      }
     },
     "localname": "LossContingencyTrialPeriod",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mrk_LynparzaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lynparza [Member]",
        "label": "Lynparza [Member]",
        "terseLabel": "Lynparza"
       }
      }
     },
     "localname": "LynparzaMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ManufacturingAndSupplyAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing and supply agreements",
        "label": "Manufacturing and supply agreements [Member]",
        "terseLabel": "Manufacturing and supply agreements"
       }
      }
     },
     "localname": "ManufacturingAndSupplyAgreementsMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_MilestonePaymentsMadetoCollaborativePartner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments Made to Collaborative Partner",
        "label": "Milestone Payments Made to Collaborative Partner",
        "terseLabel": "Capitalized milestone payment"
       }
      }
     },
     "localname": "MilestonePaymentsMadetoCollaborativePartner",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_MilestonePaymentsSalesBased": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payments Sales-Based",
        "label": "Milestone Payments Sales-Based",
        "terseLabel": "Sales-based milestone payments"
       }
      }
     },
     "localname": "MilestonePaymentsSalesBased",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_NoxafilMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noxafil [Member].",
        "label": "Noxafil [Member]",
        "terseLabel": "Noxafil"
       }
      }
     },
     "localname": "NoxafilMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OffsettingAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis.",
        "label": "Offsetting Assets And Liabilities [Table Text Block]",
        "terseLabel": "Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis"
       }
      }
     },
     "localname": "OffsettingAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mrk_OrganonCoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organon &amp; Co.",
        "label": "Organon &amp; Co. [Member]",
        "terseLabel": "Organon &amp; Co."
       }
      }
     },
     "localname": "OrganonCoMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OtherCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Countries [Member]",
        "label": "Other Countries [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCountriesMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_OtherNonoperatingIncomeExpenseOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other nonoperating income and expense items not separately disclosed.",
        "label": "Other Nonoperating Income Expense, Other",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseOther",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_OtherPharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other pharmaceutical.",
        "label": "Other Pharmaceutical [Member]",
        "terseLabel": "Other pharmaceutical"
       }
      }
     },
     "localname": "OtherPharmaceuticalMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PharmaceuticalsegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical segment.",
        "label": "Pharmaceutical segment [Member]",
        "terseLabel": "Pharmaceutical",
        "verboseLabel": "Pharmaceutical segment"
       }
      }
     },
     "localname": "PharmaceuticalsegmentMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_Pneumovax23Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pneumovax 23[Member].",
        "label": "Pneumovax 23 [Member]",
        "terseLabel": "Pneumovax 23"
       }
      }
     },
     "localname": "Pneumovax23Member",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PotentialFutureMilestonePaymentsRegulatory": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Future Milestone Payments Regulatory",
        "label": "Potential Future Milestone Payments Regulatory",
        "terseLabel": "Potential future regulatory milestone payments"
       }
      }
     },
     "localname": "PotentialFutureMilestonePaymentsRegulatory",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_PotentialFutureMilestonePaymentsSalesBased": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Future Milestone Payments Sales-Based",
        "label": "Potential Future Milestone Payments Sales-Based",
        "terseLabel": "Potential future sales-based milestone payments"
       }
      }
     },
     "localname": "PotentialFutureMilestonePaymentsSalesBased",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_PrevymisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prevymis [Member]",
        "label": "Prevymis [Member]",
        "terseLabel": "Prevymis"
       }
      }
     },
     "localname": "PrevymisMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_PrimaxinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primaxin [Member].",
        "label": "Primaxin [Member]",
        "terseLabel": "Primaxin"
       }
      }
     },
     "localname": "PrimaxinMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ProQuadMMRIIVarivaxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ProQuad/M-M-R II/Varivax [Member].",
        "label": "ProQuad MMR II Varivax [Member]",
        "terseLabel": "ProQuad/M-M-R II/Varivax"
       }
      }
     },
     "localname": "ProQuadMMRIIVarivaxMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ProbableContingentPaymentsCollaborativeArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Probable Contingent Payments Collaborative Arrangement",
        "label": "Probable Contingent Payments Collaborative Arrangement",
        "terseLabel": "Probable contingent payments"
       }
      }
     },
     "localname": "ProbableContingentPaymentsCollaborativeArrangement",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_PrometheusBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prometheus Biosciences, Inc.",
        "label": "Prometheus Biosciences, Inc. [Member]",
        "terseLabel": "Prometheus Biosciences, Inc."
       }
      }
     },
     "localname": "PrometheusBiosciencesIncMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_RecognizedAsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recognized as.",
        "label": "Recognized As [Abstract]",
        "terseLabel": "Recognized as:"
       }
      }
     },
     "localname": "RecognizedAsAbstract",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory Milestones [Member]",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestones"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_RemicadeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remicade [Member].",
        "label": "Remicade [Member]",
        "terseLabel": "Remicade"
       }
      }
     },
     "localname": "RemicadeMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_RestructuringReserveIncreaseDecreaseNoncashActivity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash activity affecting the restructuring reserve, including accelerated depreciation.",
        "label": "Restructuring Reserve, Increase (Decrease) Noncash Activity",
        "terseLabel": "Non-cash activity"
       }
      }
     },
     "localname": "RestructuringReserveIncreaseDecreaseNoncashActivity",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_RidgebackBiotherapeuticsLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ridgeback Biotherapeutics LP",
        "label": "Ridgeback Biotherapeutics LP [Member]",
        "terseLabel": "Ridgeback Biotherapeutics LP"
       }
      }
     },
     "localname": "RidgebackBiotherapeuticsLPMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_RotaTeqAntitrustLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RotaTeq Antitrust Litigation",
        "label": "RotaTeq Antitrust Litigation [Member]",
        "terseLabel": "RotaTeq Antitrust Litigation"
       }
      }
     },
     "localname": "RotaTeqAntitrustLitigationMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_RotateqMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RotaTeq [Member]",
        "label": "Rotateq [Member]",
        "terseLabel": "RotaTeq"
       }
      }
     },
     "localname": "RotateqMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_RoyaltyRateDeductionPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Rate, Deduction, Percentage",
        "label": "Royalty Rate, Deduction, Percentage",
        "terseLabel": "Royalty rate, deduction"
       }
      }
     },
     "localname": "RoyaltyRateDeductionPercentage",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "mrk_RoyaltyRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Rate, Percentage",
        "label": "Royalty Rate, Percentage",
        "terseLabel": "Royalty rate"
       }
      }
     },
     "localname": "RoyaltyRatePercentage",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mrk_SalesBasedMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-Based Milestones [Member]",
        "label": "Sales-Based Milestones [Member]",
        "terseLabel": "Sales-Based Milestones"
       }
      }
     },
     "localname": "SalesBasedMilestonesMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SalesDiscounts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Discounts",
        "label": "Sales Discounts",
        "terseLabel": "Sales discounts"
       }
      }
     },
     "localname": "SalesDiscounts",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_SanofiPasteurMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi Pasteur [Member]",
        "label": "Sanofi Pasteur [Member]",
        "terseLabel": "Sanofi Pasteur"
       }
      }
     },
     "localname": "SanofiPasteurMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SegmentReportingUnallocatedOtherExpensesNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other net expenses not allocated to segments.",
        "label": "Segment Reporting Unallocated Other Expenses Net",
        "negatedLabel": "Other unallocated, net"
       }
      }
     },
     "localname": "SegmentReportingUnallocatedOtherExpensesNet",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.",
        "label": "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. [Member]",
        "terseLabel": "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd."
       }
      }
     },
     "localname": "SichuanKelunBiotechBiopharmaceuticalCoLtdMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_SimponiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Simponi [Member].",
        "label": "Simponi [Member]",
        "terseLabel": "Simponi"
       }
      }
     },
     "localname": "SimponiMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_StockholdersEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Stockholders Equity [Table]",
        "label": "Stockholders Equity [Line Items]",
        "terseLabel": "Stockholders Equity [Line Items]"
       }
      }
     },
     "localname": "StockholdersEquityLineItems",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_StockholdersEquityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders Equity [Table]",
        "label": "Stockholders Equity [Table]",
        "terseLabel": "Stockholders Equity [Table]"
       }
      }
     },
     "localname": "StockholdersEquityTable",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mrk_TaxBenefitResultingFromAcquisitionCharge": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Benefit Resulting From Acquisition Charge",
        "label": "Tax Benefit Resulting From Acquisition Charge",
        "terseLabel": "Tax benefit resulting from acquisition charge"
       }
      }
     },
     "localname": "TaxBenefitResultingFromAcquisitionCharge",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mrk_TransitionServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transition services agreement",
        "label": "Transition services agreement [Member]",
        "terseLabel": "Transition services agreement"
       }
      }
     },
     "localname": "TransitionServicesAgreementMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_VaqtaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vaqta [Member]",
        "label": "Vaqta [Member]",
        "terseLabel": "Vaqta"
       }
      }
     },
     "localname": "VaqtaMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_VaxneuvanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vaxneuvance",
        "label": "Vaxneuvance [Member]",
        "terseLabel": "Vaxneuvance"
       }
      }
     },
     "localname": "VaxneuvanceMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_VerquvoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Verquvo",
        "label": "Verquvo [Member]",
        "terseLabel": "Verquvo"
       }
      }
     },
     "localname": "VerquvoMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_WeliregMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Welireg",
        "label": "Welireg [Member]",
        "terseLabel": "Welireg"
       }
      }
     },
     "localname": "WeliregMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ZerbaxaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zerbaxa [Member]",
        "label": "Zerbaxa [Member]",
        "terseLabel": "Zerbaxa"
       }
      }
     },
     "localname": "ZerbaxaMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mrk_ZetiaantitrustlitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zetia antitrust litigation [Member]",
        "label": "Zetia antitrust litigation [Member]",
        "terseLabel": "Zetia antitrust litigation"
       }
      }
     },
     "localname": "ZetiaantitrustlitigationMember",
     "nsuri": "http://www.merck.com/20230331",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_AsiaPacificMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asia Pacific [Member]",
        "terseLabel": "Asia Pacific (other than China and Japan)"
       }
      }
     },
     "localname": "AsiaPacificMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r263",
      "r309",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r331",
      "r397",
      "r398",
      "r399",
      "r400",
      "r402",
      "r403",
      "r405",
      "r407",
      "r408",
      "r776",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r263",
      "r309",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r331",
      "r397",
      "r398",
      "r399",
      "r400",
      "r402",
      "r403",
      "r405",
      "r407",
      "r408",
      "r776",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r261",
      "r262",
      "r410",
      "r415",
      "r677",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LatinAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Latin America [Member]",
        "terseLabel": "Latin America"
       }
      }
     },
     "localname": "LatinAmericaMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r392",
      "r393",
      "r394",
      "r395",
      "r506",
      "r621",
      "r637",
      "r670",
      "r671",
      "r694",
      "r707",
      "r716",
      "r778",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r392",
      "r393",
      "r394",
      "r395",
      "r506",
      "r621",
      "r637",
      "r670",
      "r671",
      "r694",
      "r707",
      "r716",
      "r778",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r333",
      "r622",
      "r695",
      "r714",
      "r773",
      "r774",
      "r779",
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/ContingenciesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r333",
      "r622",
      "r695",
      "r714",
      "r773",
      "r774",
      "r779",
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/ContingenciesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r392",
      "r393",
      "r394",
      "r395",
      "r454",
      "r506",
      "r510",
      "r511",
      "r512",
      "r597",
      "r621",
      "r637",
      "r670",
      "r671",
      "r694",
      "r707",
      "r716",
      "r768",
      "r778",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r392",
      "r393",
      "r394",
      "r395",
      "r454",
      "r506",
      "r510",
      "r511",
      "r512",
      "r597",
      "r621",
      "r637",
      "r670",
      "r671",
      "r694",
      "r707",
      "r716",
      "r768",
      "r778",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r261",
      "r262",
      "r410",
      "r415",
      "r679",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SpinOffofOrganonCoDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r507",
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r282",
      "r507",
      "r727",
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r334",
      "r335",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r696",
      "r715",
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails",
      "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r334",
      "r335",
      "r659",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r696",
      "r715",
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails",
      "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r282",
      "r507",
      "r727",
      "r728",
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction.",
        "label": "Legal Entity of Counterparty, Type [Axis]",
        "terseLabel": "Legal Entity of Counterparty, Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.",
        "label": "Accounts Payable and Accrued Liabilities [Member]",
        "terseLabel": "Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r29",
      "r713"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r339",
      "r340"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable (net of allowance for doubtful accounts of $76 in 2023 and $72 in 2022)"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableSale": {
     "auth_ref": [
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease from sale of accounts receivable.",
        "label": "Accounts Receivable, Sale",
        "terseLabel": "Factored accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableSale",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r17",
      "r185",
      "r197"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r43",
      "r49",
      "r151",
      "r738",
      "r739",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r103",
      "r217"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": {
     "auth_ref": [
      "r238",
      "r246",
      "r547",
      "r739",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest"
       }
      }
     },
     "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r238",
      "r247",
      "r248",
      "r547",
      "r681",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r46",
      "r48",
      "r49",
      "r228",
      "r631",
      "r642",
      "r643"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r246",
      "r247",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r45",
      "r49",
      "r151",
      "r587",
      "r638",
      "r639",
      "r738",
      "r739",
      "r740",
      "r753",
      "r754",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "verboseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityDetails",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r42",
      "r49",
      "r151",
      "r247",
      "r248",
      "r579",
      "r580",
      "r581",
      "r582",
      "r584",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation Adjustment"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Other paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r513",
      "r514",
      "r515",
      "r753",
      "r754",
      "r755",
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Other Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r73",
      "r101"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "negatedLabel": "Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r229",
      "r341",
      "r352"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r73",
      "r97",
      "r101"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "auth_ref": [
      "r708",
      "r786",
      "r787",
      "r788"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.",
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Consideration transferred, asset acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": {
     "auth_ref": [
      "r708",
      "r786",
      "r787",
      "r788"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Transaction Cost",
        "terseLabel": "Asset acquisition costs"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredTransactionCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionPriceOfAcquisitionExpected": {
     "auth_ref": [
      "r785"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of expected asset acquisition prior to consideration being transferred. Excludes business acquisition.",
        "label": "Asset Acquisition, Price of Acquisition, Expected",
        "terseLabel": "Asset acquisition, price of acquisition, expected"
       }
      }
     },
     "localname": "AssetAcquisitionPriceOfAcquisitionExpected",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r184",
      "r196",
      "r220",
      "r258",
      "r317",
      "r323",
      "r329",
      "r350",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r404",
      "r406",
      "r408",
      "r409",
      "r543",
      "r548",
      "r572",
      "r713",
      "r776",
      "r777",
      "r800"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r214",
      "r231",
      "r258",
      "r350",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r404",
      "r406",
      "r408",
      "r409",
      "r543",
      "r548",
      "r572",
      "r713",
      "r776",
      "r777",
      "r800"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Debt securities, unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Debt securities, unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r343",
      "r359"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Debt securities, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r91",
      "r342",
      "r359",
      "r625"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_TradingSecurities",
       "weight": 1.0
      },
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Debt securities, fair value",
        "verboseLabel": "Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r161",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r537",
      "r746"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Changes in estimated fair value"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r141",
      "r142",
      "r536"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Fair value, ending balance",
        "periodStartLabel": "Fair value, beginning balance",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r141",
      "r143"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Current liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Contingent consideration, measurement input, discount rate"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r75",
      "r216",
      "r673"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r69",
      "r75",
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $79 and $58 at March\u00a031, 2023 and 2022, respectively, included in Other current assets)",
        "periodStartLabel": "Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $79 and $71 at January 1, 2023 and 2022, respectively, included in Other current assets)"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r69",
      "r180"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r730"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r174"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "negatedTerseLabel": "Derivatives designated as hedging instruments"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": {
     "auth_ref": [
      "r174"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge",
        "negatedTerseLabel": "Hedged items"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r258",
      "r286",
      "r287",
      "r294",
      "r296",
      "r303",
      "r304",
      "r350",
      "r397",
      "r400",
      "r401",
      "r402",
      "r408",
      "r409",
      "r413",
      "r414",
      "r417",
      "r421",
      "r428",
      "r572",
      "r672",
      "r726",
      "r749",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r538",
      "r539",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "auth_ref": [
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r115",
      "r389",
      "r390",
      "r660",
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/Contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividends declared on common stock (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r753",
      "r754",
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock ($0.50\u00a0par value)",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage",
      "http://www.merck.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Common stock, ending balance (in shares)",
        "periodStartLabel": "Common stock, beginning balance (in shares)",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical",
      "http://www.merck.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r20",
      "r713"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2023 and 2022"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r50",
      "r243",
      "r245",
      "r252",
      "r627",
      "r633"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive Income Attributable to Merck\u00a0&amp; Co., Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r63",
      "r251",
      "r626",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r697",
      "r699",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate notes and bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r85",
      "r322",
      "r323",
      "r324",
      "r325",
      "r331",
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate, Non-Segment",
        "verboseLabel": "Corporate, Non-Segment"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r58",
      "r622"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 1.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of sales",
        "verboseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs, Expenses and Other"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrencySwapMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.",
        "label": "Currency Swap [Member]",
        "terseLabel": "Currency Swap"
       }
      }
     },
     "localname": "CurrencySwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r222"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt and lease obligation, classified as current.",
        "label": "Debt, Current",
        "terseLabel": "Loans payable and current portion of long-term debt"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r411",
      "r571",
      "r692",
      "r693"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of loans payable and long-term debt, including current portion"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.",
        "label": "Debt, Long-Term and Short-Term, Combined Amount",
        "terseLabel": "Debt, carrying amount"
       }
      }
     },
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r73",
      "r136",
      "r523",
      "r528",
      "r529",
      "r751"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r516",
      "r517"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred Income Taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed within one year or normal operating cycle, if longer.",
        "label": "Deferred Income Taxes and Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.",
        "label": "Deferred Income Taxes and Other Assets, Noncurrent",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r431",
      "r470",
      "r495",
      "r699",
      "r700"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedLabel": "Net (gain) loss amortization"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r431",
      "r471",
      "r496",
      "r699",
      "r700"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of unrecognized prior service credit"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement": {
     "auth_ref": [
      "r780"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from remeasurement due to settlement. Excludes decrease to benefit obligation for settlement payment.",
        "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Remeasurement due to Settlement",
        "negatedTerseLabel": "Increase to pension liabilities due to remeasurement"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r431",
      "r469",
      "r494",
      "r699",
      "r700"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r431",
      "r436",
      "r468",
      "r493",
      "r699",
      "r700"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r466",
      "r491",
      "r699",
      "r700"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": {
     "auth_ref": [
      "r432",
      "r473",
      "r498"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment",
        "negatedLabel": "Curtailments"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": {
     "auth_ref": [
      "r432",
      "r473",
      "r498"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r434",
      "r467",
      "r492",
      "r699",
      "r700"
     ],
     "calculation": {
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": {
     "auth_ref": [
      "r452"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.",
        "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement",
        "terseLabel": "Partial settlement charge"
       }
      }
     },
     "localname": "DefinedBenefitPlanSettlementsPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r73",
      "r102"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "negatedLabel": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": {
     "auth_ref": [
      "r40",
      "r41"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.",
        "label": "Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election",
        "totalLabel": "Net amounts, asset"
       }
      }
     },
     "localname": "DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": {
     "auth_ref": [
      "r39",
      "r41",
      "r233"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative asset.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset",
        "negatedTerseLabel": "Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset"
       }
      }
     },
     "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes derivative asset.",
        "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r232",
      "r235",
      "r571",
      "r680"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "netLabel": "Gross amounts recognized in the consolidated balance sheet, asset",
        "terseLabel": "Derivative assets",
        "verboseLabel": "Fair Value of Derivative, Asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAverageRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average remaining period until maturity of the derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Average Remaining Maturity",
        "terseLabel": "Maximum average period of maturities of contracts in years (less than)"
       }
      }
     },
     "localname": "DerivativeAverageRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativeCollateralObligationToReturnCash": {
     "auth_ref": [
      "r41",
      "r171",
      "r234",
      "r678"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset",
        "negatedLabel": "Cash collateral received, asset",
        "terseLabel": "Cash collateral received from counterparties"
       }
      }
     },
     "localname": "DerivativeCollateralObligationToReturnCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeCollateralRightToReclaimCash": {
     "auth_ref": [
      "r41",
      "r171",
      "r234",
      "r678"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset",
        "negatedLabel": "Cash collateral received, liability"
       }
      }
     },
     "localname": "DerivativeCollateralRightToReclaimCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeCollateralRightToReclaimSecurities": {
     "auth_ref": [
      "r41",
      "r234",
      "r678"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of right to receive securities collateral under master netting arrangements that have not been offset against derivative liabilities.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Security Not Offset",
        "terseLabel": "Cash collateral advanced to counterparties"
       }
      }
     },
     "localname": "DerivativeCollateralRightToReclaimSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r792"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedTerseLabel": "Amount of gain recognized in Other (income) expense, net on derivatives"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r162",
      "r163",
      "r167",
      "r169",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r159",
      "r162",
      "r167",
      "r169",
      "r173",
      "r175",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": {
     "auth_ref": [
      "r557"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.",
        "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred",
        "negatedLabel": "Pretax net unrealized losses on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r166",
      "r793"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "negatedTerseLabel": "Amount of Derivative Pretax (Gain) Loss Recognized in Income"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r232",
      "r235",
      "r571",
      "r680"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "netLabel": "Gross amounts recognized in the consolidated balance sheet, liability",
        "terseLabel": "Derivative liabilities",
        "verboseLabel": "Fair Value of Derivative, Liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": {
     "auth_ref": [
      "r40",
      "r41"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.",
        "label": "Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election",
        "totalLabel": "Net amounts, liability"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": {
     "auth_ref": [
      "r39",
      "r41",
      "r233"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative liability.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset",
        "negatedTerseLabel": "Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability"
       }
      }
     },
     "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes derivative liability.",
        "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r790",
      "r791"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Total swap notional amount",
        "verboseLabel": "U.S Dollar Notional Amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r155",
      "r157",
      "r158",
      "r159",
      "r160",
      "r165",
      "r167",
      "r170",
      "r172",
      "r175",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives Designated as Hedging Instruments"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of expected continuing involvement with a discontinued operation after the disposal date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Discontinued Operation, Period of Continuing Involvement after Disposal",
        "terseLabel": "Period of continuing involvement after disposal"
       }
      }
     },
     "localname": "DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]",
        "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r12",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Spin-Off of Organon &amp; Co."
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCo"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedLabel": "Cash dividends declared on common stock"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r782",
      "r783",
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r227",
      "r399",
      "r400",
      "r401",
      "r407",
      "r408",
      "r409",
      "r589",
      "r675",
      "r752"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due from Related Parties, Current",
        "terseLabel": "Due from related parties, current"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r29",
      "r399",
      "r400",
      "r401",
      "r407",
      "r408",
      "r409",
      "r589",
      "r752"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Due to related parties, current"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EMEAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regions of Europe, Middle East and Africa.",
        "label": "EMEA [Member]",
        "terseLabel": "Europe, Middle East and Africa"
       }
      }
     },
     "localname": "EMEAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r253",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r283",
      "r286",
      "r294",
      "r295",
      "r296",
      "r300",
      "r561",
      "r562",
      "r628",
      "r634",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic Earnings Per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r253",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r286",
      "r294",
      "r295",
      "r296",
      "r300",
      "r561",
      "r562",
      "r628",
      "r634",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r297",
      "r298",
      "r299",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r577"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r119",
      "r210",
      "r246",
      "r247",
      "r248",
      "r269",
      "r270",
      "r271",
      "r273",
      "r279",
      "r281",
      "r302",
      "r351",
      "r429",
      "r513",
      "r514",
      "r515",
      "r524",
      "r525",
      "r560",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r584",
      "r587",
      "r638",
      "r639",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityFundsMember": {
     "auth_ref": [
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An investment that pools funds from many investors to invest in a combination of underlying investments, primarily equity investments.",
        "label": "Equity Funds [Member]",
        "terseLabel": "Equity Funds"
       }
      }
     },
     "localname": "EquityFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFVNINoncurrent": {
     "auth_ref": [
      "r570"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.",
        "label": "Equity Securities, FV-NI, Noncurrent",
        "terseLabel": "Equity securities, noncurrent"
       }
      }
     },
     "localname": "EquitySecuritiesFVNINoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r221",
      "r570",
      "r676"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_TradingSecurities",
       "weight": 1.0
      },
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "mrk_DebtSecuritiesandEquitySecuritiesFVNI",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Publicly traded equity securities, fair value",
        "verboseLabel": "Publicly traded equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r764"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "negatedLabel": "Loss (income) from investments in equity securities, net",
        "negatedTerseLabel": "(Income) loss from investments in equity securities, net"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r635",
      "r764"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedTerseLabel": "Unrealized net (gains) losses"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r94",
      "r194",
      "r717",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Publicly traded equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r347"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity investments without readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount": {
     "auth_ref": [
      "r348"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount",
        "terseLabel": "Unrealized losses recognized on investments in equity securities without readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount": {
     "auth_ref": [
      "r348"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative loss from downward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount",
        "terseLabel": "Cumulative unrealized losses on investments"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount": {
     "auth_ref": [
      "r349"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount",
        "terseLabel": "Unrealized gains recognized on investments in equity securities without readily determinable fair value"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount": {
     "auth_ref": [
      "r349"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount",
        "terseLabel": "Cumulative unrealized gains on investments"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on Recurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r563",
      "r564",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r411",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r564",
      "r594",
      "r595",
      "r596",
      "r692",
      "r693",
      "r697",
      "r698",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r563",
      "r564",
      "r565",
      "r566",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r411",
      "r457",
      "r462",
      "r564",
      "r594",
      "r697",
      "r698",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r411",
      "r457",
      "r462",
      "r564",
      "r595",
      "r692",
      "r693",
      "r697",
      "r698",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r411",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r564",
      "r596",
      "r692",
      "r693",
      "r697",
      "r698",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r177",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Information About the Changes in Liabilities for Contingent Consideration"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r178"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r411",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r594",
      "r595",
      "r596",
      "r692",
      "r693",
      "r697",
      "r698",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r567",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r161",
      "r165",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r344",
      "r345",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r361",
      "r362",
      "r412",
      "r426",
      "r558",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r686",
      "r761",
      "r762",
      "r763",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r100",
      "r623"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Finite-lived intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r573",
      "r574",
      "r575",
      "r576"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedLabel": "Exchange losses"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r680",
      "r697",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign exchange contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignExchangeFutureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A standardized contract, traded on a futures exchange, to buy or sell a certain currency, at a specified future date, at a fixed exercise rate (expressed as an exchange).",
        "label": "Foreign Exchange Future [Member]",
        "terseLabel": "Foreign Exchange Future"
       }
      }
     },
     "localname": "ForeignExchangeFutureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignExchangeOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An option that allows the holder to buy (if call) or sell (if put) an underlying currency at a fixed exercise rate, expressed as an exchange, during a specified period (an American option) or at a specified date (a European option).",
        "label": "Foreign Exchange Option [Member]",
        "terseLabel": "Currency options"
       }
      }
     },
     "localname": "ForeignExchangeOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r781",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Debt Security, Government, Non-US [Member]",
        "terseLabel": "Foreign government bonds"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r782",
      "r783",
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r770"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedTerseLabel": "Loss related to litigation settlement",
        "terseLabel": "Charge for Zetia antitrust litigation settlements"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r218",
      "r364",
      "r624",
      "r687",
      "r713",
      "r766",
      "r767"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r159",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": {
     "auth_ref": [
      "r145",
      "r147"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Net Income (Loss) Attributable to Noncontrolling Interests"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r53",
      "r182",
      "r191",
      "r205",
      "r317",
      "r322",
      "r328",
      "r331",
      "r629",
      "r685"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Profits",
        "totalLabel": "Income Before Taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r147",
      "r258",
      "r272",
      "r317",
      "r322",
      "r328",
      "r331",
      "r350",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r404",
      "r406",
      "r408",
      "r409",
      "r562",
      "r572",
      "r685",
      "r776"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r105",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r374",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r259",
      "r520",
      "r521",
      "r522",
      "r526",
      "r530",
      "r532",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Taxes on Income"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/TaxesonIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r260",
      "r280",
      "r281",
      "r315",
      "r518",
      "r527",
      "r531",
      "r636"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Taxes on Income"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapital": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.",
        "label": "Increase (Decrease) in Operating Capital",
        "negatedLabel": "Net changes in assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r96",
      "r99"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Other Intangibles, Net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r181",
      "r193",
      "r249",
      "r311",
      "r586"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaid": {
     "auth_ref": [
      "r747"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.",
        "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r680",
      "r697",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest Rate Contract"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest rate swap contracts"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r732"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r736"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails_1": {
       "order": 1.0,
       "parentTag": "mrk_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total (approximates current cost)"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLIFOReserve": {
     "auth_ref": [
      "r735"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails_1": {
       "order": 2.0,
       "parentTag": "mrk_InventoryNetAndInventoryNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.",
        "label": "Inventory, LIFO Reserve",
        "negatedLabel": "Decrease to LIFO cost"
       }
      }
     },
     "localname": "InventoryLIFOReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r230",
      "r674",
      "r713"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 1.0,
       "parentTag": "mrk_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "verboseLabel": "Inventories (excludes inventories of $3,284 in 2023 and $2,938 in 2022 classified in Other assets - see Note\u00a07)"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET",
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r731"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "mrk_InventoryNetAndInventoryNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Inventories classified in Other assets",
        "verboseLabel": "Other Assets"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical",
      "http://www.merck.com/role/InventoriesNarrativeDetails",
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessAndRawMaterials": {
     "auth_ref": [
      "r736"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.",
        "label": "Inventory, Work in Process and Raw Materials",
        "terseLabel": "Raw materials and work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessAndRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r60",
      "r310"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest income",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LegalCostsPolicyTextBlock": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.",
        "label": "Legal Costs, Policy [Policy Text Block]",
        "terseLabel": "Legal Costs"
       }
      }
     },
     "localname": "LegalCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LegalEntityTypeOfCounterpartyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of the other party participating in a financial transaction.",
        "label": "Legal Entity Type of Counterparty [Domain]",
        "terseLabel": "Legal Entity Type of Counterparty [Domain]"
       }
      }
     },
     "localname": "LegalEntityTypeOfCounterpartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r30",
      "r258",
      "r350",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r404",
      "r406",
      "r408",
      "r409",
      "r544",
      "r548",
      "r549",
      "r572",
      "r684",
      "r776",
      "r800",
      "r801"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r187",
      "r201",
      "r713",
      "r750",
      "r765",
      "r796"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r32",
      "r215",
      "r258",
      "r350",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r404",
      "r406",
      "r408",
      "r409",
      "r544",
      "r548",
      "r549",
      "r572",
      "r713",
      "r776",
      "r800",
      "r801"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "verboseLabel": "Payables included in Accrued and other liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r18",
      "r19",
      "r258",
      "r350",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r404",
      "r406",
      "r408",
      "r409",
      "r544",
      "r548",
      "r549",
      "r572",
      "r776",
      "r800",
      "r801"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "terseLabel": "Payables included in Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationReserve": {
     "auth_ref": [
      "r34",
      "r770"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.",
        "label": "Estimated Litigation Liability",
        "terseLabel": "Legal defense costs reserve"
       }
      }
     },
     "localname": "LitigationReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r223"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r116",
      "r117",
      "r391",
      "r392",
      "r393",
      "r771",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyClaimsSettledNumber": {
     "auth_ref": [
      "r771",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims settled.",
        "label": "Loss Contingency, Claims Settled, Number",
        "terseLabel": "Loss contingency, claims settled"
       }
      }
     },
     "localname": "LossContingencyClaimsSettledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r771",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Loss contingency, new claims filed"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPatentsAllegedlyInfringedNumber": {
     "auth_ref": [
      "r771",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of another entity's patents that the entity has allegedly infringed.",
        "label": "Loss Contingency, Patents Allegedly Infringed, Number",
        "terseLabel": "Loss contingency, number of patents allegedly infringed"
       }
      }
     },
     "localname": "LossContingencyPatentsAllegedlyInfringedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r771",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Loss contingency, pending claims"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "terseLabel": "Segment Reconciling Items"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r38",
      "r186",
      "r200",
      "r258",
      "r350",
      "r397",
      "r400",
      "r401",
      "r402",
      "r408",
      "r409",
      "r572"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r256"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash Used in Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r256"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net Cash Used in Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r69",
      "r71",
      "r74"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net Cash Provided by Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r55",
      "r74",
      "r192",
      "r204",
      "r213",
      "r241",
      "r244",
      "r248",
      "r258",
      "r272",
      "r274",
      "r275",
      "r276",
      "r277",
      "r280",
      "r281",
      "r292",
      "r317",
      "r322",
      "r328",
      "r331",
      "r350",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r404",
      "r406",
      "r408",
      "r409",
      "r562",
      "r572",
      "r685",
      "r776"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net Income Attributable to Merck\u00a0&amp; Co., Inc.",
        "totalLabel": "Net Income Attributable to Merck &amp; Co., Inc.",
        "verboseLabel": "Net income attributable to Merck\u00a0&amp; Co., Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME",
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r149",
      "r153",
      "r241",
      "r244",
      "r280",
      "r281",
      "r740"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net income (loss) attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r277",
      "r283",
      "r284",
      "r293",
      "r296",
      "r317",
      "r322",
      "r328",
      "r331",
      "r685"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net income attributable to Merck &amp; Co., Inc., basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r285",
      "r288",
      "r289",
      "r290",
      "r291",
      "r293",
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net income attributable to Merck &amp; Co., Inc., diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": {
     "auth_ref": [
      "r431"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.",
        "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component",
        "terseLabel": "Net periodic defined benefit plan (credit) cost other than service cost"
       }
      }
     },
     "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Standards and Recently Issued Accounting Standards Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r145",
      "r429",
      "r753",
      "r754",
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- controlling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "verboseLabel": "Derivatives Not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfInterestRateDerivativesHeld": {
     "auth_ref": [
      "r156",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date.",
        "label": "Number of Interest Rate Derivatives Held",
        "verboseLabel": "Number of interest rate swaps held (in interest rate swaps)"
       }
      }
     },
     "localname": "NumberOfInterestRateDerivativesHeld",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "OCI, before Reclassifications, before Tax, Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss) before reclassification adjustments, pretax"
       }
      }
     },
     "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": {
     "auth_ref": [
      "r49",
      "r51"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.",
        "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent",
        "totalLabel": "Other comprehensive income (loss) before reclassification adjustments, net of taxes"
       }
      }
     },
     "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OneTimeTerminationBenefitsMember": {
     "auth_ref": [
      "r688",
      "r689",
      "r690",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities.",
        "label": "One-time Termination Benefits [Member]",
        "terseLabel": "Separation Costs"
       }
      }
     },
     "localname": "OneTimeTerminationBenefitsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments",
        "verboseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r77",
      "r78",
      "r79",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/BasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r219"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r44",
      "r46",
      "r147",
      "r150"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent",
        "negatedLabel": "Benefit plan net (loss) gain and prior service (cost) credit, net of amortization"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r147",
      "r148",
      "r150"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Cumulative translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": {
     "auth_ref": [
      "r47",
      "r246"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax",
        "negatedTerseLabel": "Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent",
        "verboseLabel": "Net unrealized (loss) gain on derivatives, net of reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r236",
      "r237",
      "r551",
      "r552",
      "r556"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Amount of gain (loss) recognized in OCI on derivatives"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r237",
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "terseLabel": "Increase in Sales as a result of AOCL reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r553"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "negatedLabel": "Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r554"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax",
        "negatedLabel": "Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r51",
      "r119",
      "r242",
      "r245",
      "r251",
      "r578",
      "r583",
      "r584",
      "r626",
      "r632",
      "r738",
      "r739"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other Comprehensive (Loss) Income Net of Taxes:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r147",
      "r148",
      "r150",
      "r242",
      "r245"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss)",
        "totalLabel": "Other comprehensive income (loss), net of taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r161",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r124",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "Other (Income) Expense, Net"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other Intangible Assets"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInventorySupplies": {
     "auth_ref": [
      "r733"
     ],
     "calculation": {
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.",
        "label": "Other Inventory, Supplies, Gross",
        "terseLabel": "Supplies"
       }
      }
     },
     "localname": "OtherInventorySupplies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r31",
      "r713"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Noncurrent Assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 5.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": -1.0
      },
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income) expense, net",
        "negatedTotalLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r126",
      "r430",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r481",
      "r484",
      "r487",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r503",
      "r504",
      "r505",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Other Postretirement Benefit Plans"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [
      "r688",
      "r689",
      "r690",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r741",
      "r742"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchases of treasury stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r378",
      "r745"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedLabel": "(Payments) receipts, net"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedLabel": "Dividends paid to stockholders"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired": {
     "auth_ref": [
      "r742"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Business Two, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of Imago BioSciences, Inc., net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessTwoNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of securities and other investments"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r254",
      "r786",
      "r787",
      "r788"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r454",
      "r456",
      "r462",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r501",
      "r502",
      "r503",
      "r509",
      "r699"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Pension and Other Postretirement Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r125",
      "r430",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r481",
      "r484",
      "r487",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r503",
      "r504",
      "r508",
      "r699",
      "r700",
      "r704",
      "r705",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension Plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r729"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/BasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "terseLabel": "Proceeds from Collaborators"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r743",
      "r744"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from sales of securities and other investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Proceeds from Sale of Intangible Assets",
        "terseLabel": "Revenue related to the sale of the marketing rights"
       }
      }
     },
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r66",
      "r133"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r213",
      "r241",
      "r244",
      "r255",
      "r258",
      "r272",
      "r280",
      "r281",
      "r317",
      "r322",
      "r328",
      "r331",
      "r350",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r404",
      "r406",
      "r408",
      "r409",
      "r542",
      "r545",
      "r546",
      "r562",
      "r572",
      "r629",
      "r685",
      "r709",
      "r710",
      "r740",
      "r776"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net Income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r104",
      "r203",
      "r630",
      "r713"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,256 in 2023 and $17,985 in 2022"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]",
        "terseLabel": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]",
        "terseLabel": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r202",
      "r206",
      "r713"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "verboseLabel": "Receivables included in Other current assets"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent",
        "negatedLabel": "Reclassification adjustments, pretax"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": {
     "auth_ref": [
      "r49",
      "r51"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent",
        "negatedTotalLabel": "Reclassification adjustments, net of taxes"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodTax": {
     "auth_ref": [
      "r47",
      "r240",
      "r246"
     ],
     "calculation": {
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).",
        "label": "Reclassification from AOCI, Current Period, Tax",
        "terseLabel": "Tax"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r82",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Segment Profits to Income before Taxes"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartiesAmountInCostOfSales": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount included in cost of sales related to transactions with related parties incurred and recorded in the statement of operations for the period.",
        "label": "Related Parties Amount in Cost of Sales",
        "terseLabel": "Related party amount in cost of sales"
       }
      }
     },
     "localname": "RelatedPartiesAmountInCostOfSales",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r209",
      "r588",
      "r589",
      "r799"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Payments on debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off",
        "terseLabel": "Charge for the acquisition of Imago BioSciences, Inc."
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r135",
      "r208",
      "r808"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 3.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedLabel": "Research and development",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r75",
      "r76",
      "r183",
      "r198",
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r730",
      "r748"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r376",
      "r378",
      "r381",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/Restructuring"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "auth_ref": [
      "r377",
      "r380",
      "r384",
      "r386"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs incurred to date for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "terseLabel": "Cumulative costs since program inception"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r377",
      "r380",
      "r384",
      "r386"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Expected restructuring and related cost"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "auth_ref": [
      "r377",
      "r380",
      "r384",
      "r386"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "terseLabel": "Total pretax restructuring costs",
        "verboseLabel": "Expenses"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r73",
      "r382",
      "r384",
      "r769"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 4.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "negatedLabel": "Restructuring costs",
        "terseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesMember": {
     "auth_ref": [
      "r111",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included.",
        "label": "Restructuring Charges [Member]",
        "terseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "RestructuringChargesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r377",
      "r378",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r378",
      "r383"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Restructuring reserve, ending balance",
        "periodStartLabel": "Restructuring reserve, beginning balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r120",
      "r199",
      "r641",
      "r643",
      "r713"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r210",
      "r269",
      "r270",
      "r271",
      "r273",
      "r279",
      "r281",
      "r351",
      "r513",
      "r514",
      "r515",
      "r524",
      "r525",
      "r560",
      "r638",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r481",
      "r484",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r782",
      "r783",
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r481",
      "r484",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r782",
      "r783",
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r125",
      "r126",
      "r430",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r481",
      "r484",
      "r487",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r503",
      "r504",
      "r505",
      "r508",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r125",
      "r126",
      "r430",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r478",
      "r479",
      "r481",
      "r484",
      "r487",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r503",
      "r504",
      "r505",
      "r508",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r56",
      "r207",
      "r399",
      "r400",
      "r401",
      "r407",
      "r408",
      "r409"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Revenue from related party"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SpinOffofOrganonCoDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r250",
      "r258",
      "r308",
      "r309",
      "r321",
      "r326",
      "r327",
      "r333",
      "r334",
      "r337",
      "r350",
      "r397",
      "r398",
      "r400",
      "r401",
      "r402",
      "r404",
      "r406",
      "r408",
      "r409",
      "r572",
      "r629",
      "r776"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Sales",
        "totalLabel": "Sales"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyIncomeNonoperating": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.",
        "label": "Royalty Income, Nonoperating",
        "terseLabel": "Royalties"
       }
      }
     },
     "localname": "RoyaltyIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Sales",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r49",
      "r797",
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Changes in AOCI by Component"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Information on Investments in Debt and Equity Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r137",
      "r138",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Collaboration Arrangements"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r131",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails",
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r162",
      "r167",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Location and Amount of Pretax Gains and Losses of Derivatives"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Fair Value of Derivatives on a Gross Basis Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Calculations of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Sales from Products"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r13",
      "r26",
      "r27",
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Net Benefit Costs"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r794"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Effect of Net Investment Hedges on OCI and the Consolidated Statement of Income"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r166",
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.",
        "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]",
        "terseLabel": "Income Statement Effects of Derivatives Not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Other (Income) Expense, Net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/OtherIncomeExpenseNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r377",
      "r378",
      "r379",
      "r380",
      "r384",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails",
      "http://www.merck.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r109",
      "r110",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Charges Related to Restructuring Program Activities by Type of Cost"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r108",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Charges and Spending Relating to Restructuring Activities by Program"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": {
     "auth_ref": [
      "r57",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]",
        "terseLabel": "Consolidated Sales by Geographic Area"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r52",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r80",
      "r81",
      "r83",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.",
        "label": "Schedule of Stockholders Equity [Table Text Block]",
        "terseLabel": "Schedule of Equity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r305",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r337",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r380",
      "r386",
      "r687",
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r317",
      "r320",
      "r325",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r336",
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": {
       "order": 2.0,
       "parentTag": "mrk_CostsExpensesAndOther",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r188",
      "r189",
      "r195",
      "r737"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r212",
      "r305",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r337",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r375",
      "r380",
      "r386",
      "r687",
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails",
      "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails",
      "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r258",
      "r286",
      "r287",
      "r294",
      "r296",
      "r303",
      "r304",
      "r350",
      "r397",
      "r400",
      "r401",
      "r402",
      "r408",
      "r409",
      "r413",
      "r414",
      "r417",
      "r421",
      "r428",
      "r572",
      "r672",
      "r726",
      "r749",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r35",
      "r119",
      "r210",
      "r246",
      "r247",
      "r248",
      "r269",
      "r270",
      "r271",
      "r273",
      "r279",
      "r281",
      "r302",
      "r351",
      "r429",
      "r513",
      "r514",
      "r515",
      "r524",
      "r525",
      "r560",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r584",
      "r587",
      "r638",
      "r639",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityDetails",
      "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r20",
      "r23",
      "r24",
      "r89",
      "r713",
      "r750",
      "r765",
      "r796"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Merck\u00a0&amp; Co., Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Merck\u00a0&amp; Co., Inc. Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityBeforeTreasuryStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.",
        "label": "Stockholders' Equity before Treasury Stock",
        "totalLabel": "Stockholders' equity before deduction for treasury stock"
       }
      }
     },
     "localname": "StockholdersEquityBeforeTreasuryStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r145",
      "r146",
      "r152",
      "r210",
      "r211",
      "r247",
      "r269",
      "r270",
      "r271",
      "r273",
      "r279",
      "r351",
      "r429",
      "r513",
      "r514",
      "r515",
      "r524",
      "r525",
      "r560",
      "r578",
      "r579",
      "r584",
      "r587",
      "r639",
      "r640",
      "r750",
      "r765",
      "r796"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Equity, ending balance",
        "periodStartLabel": "Equity, beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET",
      "http://www.merck.com/role/EquityDetails",
      "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r123",
      "r257",
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r427",
      "r429",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Share-based compensation plans and other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r585",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/ContingenciesDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r585",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/ContingenciesDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r585",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/ContingenciesDetails",
      "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradingSecurities": {
     "auth_ref": [
      "r190",
      "r221",
      "r676"
     ],
     "calculation": {
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI",
        "totalLabel": "Investments"
       }
      }
     },
     "localname": "TradingSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r344",
      "r345",
      "r412",
      "r426",
      "r558",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r761",
      "r762",
      "r763",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "periodEndLabel": "Treasury stock, ending balance (in shares)",
        "periodStartLabel": "Treasury stock, beginning balance (in shares)",
        "terseLabel": "Treasury stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical",
      "http://www.merck.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r37",
      "r121",
      "r122"
     ],
     "calculation": {
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Value",
        "terseLabel": "Less treasury stock, at cost: 1,039,651,210 shares in 2023 and 1,039,269,638 shares in 2022"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r20",
      "r119",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Treasury stock shares purchased (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r119",
      "r120",
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Treasury stock shares purchased"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails",
      "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails",
      "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r377",
      "r378",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails",
      "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r682",
      "r697",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government and agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r758"
     ],
     "calculation": {
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "terseLabel": "Common shares issuable (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r285",
      "r296"
     ],
     "calculation": {
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Average common shares outstanding assuming dilution (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r283",
      "r296"
     ],
     "calculation": {
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(c))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "https://asc.fasb.org/topic&trid=49130413",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "https://asc.fasb.org/topic&trid=2122503",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(21))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)(ii)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)(i)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80845-113994",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "https://asc.fasb.org/topic&trid=2134417",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226038-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r721": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r722": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r723": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r724": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r725": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r814": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r815": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r816": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r817": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r818": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0001628280-23-015990-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-015990-xbrl.zip
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M_;\SZFDE/%?98O3]1.72L@]RSFYUSHOOFQ9A:5EI5!(&6O5O"36QB'^<UR9
M3J8*N32I=T1VW-RG*E*.]7OMWF,C]E8_AO^E^:_K?[)5_ZN;V\GXA_'5Y63\
M\<.O-.!?E74J680F50C8,^J=EE\K).,FI$32./:^S:[Y3-DFB_$(%9E+N7MU
M,#P]>QFF]MJO#GK'W;/-SS%+^4PR(V=*SL$/+E66_5QQ ZAE"[27&@[2!?M!
MFYSUNJV_,)VP]]+$=TLQ_=,S,$B[R<9%C'6&;UZ(TXYV.NT=MW 5G)(OV%VA
MYYD44]D,OJL])C04*32(%^MP53!>+%A5.%-)V $J]JP,5W*6X\DHGK&$QV@R
M3.<@"J?#N(T!A8REM=PL:$C.[R3679-IT2:@#);,/*5C#1H0*P,*Q[ "TZ&)
MD(;-4Q6GS%;TL9H_ET;60LB 7-D,7$]I8ZY<"@-M*6.O(,DMH9H6,'.&:8)%
MBW4WO" T])^/!LD25<#?%+J5?YN  H:CVZSUJR+!!N.4]/$]SBH!F8CAFC.;
MB+^B35DB!(0>0E66K>!11\8^61H(%+Z::-*(*L, 8$(C<'XYZ_6)N4U9DNFY
M70+&R*FR#J6(8YP:@][0LKD6=[M49D/;%Q3ZP<[03Q[YZ=7!Z5'OY,S6P:US
M"6T<G20*CX?VM7?BF'$C?;C@?A5EDMS*)# 29<JF-(.&Y> -X@YZ%LK&F;85
MYA&C&)V%N)5&QU*@V;)#A$E(Q#W$XN8^3GDQE>P2F_6VRC"BU^>MWO!0!BUZ
M0Q&>PJ.BZJ((>"'YC';T&HQ"6$F7O1=*'BV48"&R\RFX,()RT+/3;<D%L5(K
MDTF QS<,(?YZ%X2NI86^\*2GX5\.<Y,R1,PKN_\4HNI((F3U2H'\=64@ -L8
MA8\G!XR2A9=#U<^*5M:IR<B,>PS4[+^*8[.F+>I4H!CH8G6FA#]UV"JR2BAN
M%!F@0H[R9%F0I,I2WO"[QOHDXZD$QQHHA/.&GU2B)%%QE7%B0)CEE5CE'\P(
MV6P]">-;)&D@2 KSI7@V*?V1,!;MB;&]-_H&U/:GB+T1!Y3.E" @<8OS+G$A
MMP AE2F$+F[$,M+ GN*1RI1;4([:MBSAWH/"QSM ]M'0M3+'4^Y];5!9F1)X
MLSZGQK$VPBO@"YZI+) J,\ ./;(D/-,0%',!6L"]*L%Z+QI<\4YPW<QX5OE=
M3IZ728(21,W@,[NEE'A(D7NP5GC<7EUX+&$B&,>&&B;2E=NMP3Z\RA]&2RK0
MDE\N;UFT+/W\]I#!$]#'0X$6>*EP$+NY)GAZ,V)T *H+!=^S%1;/8!C*43J.
M*T-Q64L(6Z3FVCJTTPL4R+(Q!-5'7':X8TH"@&'O/QE=*XYB6?JS&QWKBNI!
MK]=!JY3;A^Q)K.$!*86G4^^/FNH6.*'=R:P^R#T9W_S-+OI5(/QV(3?\_:MP
M_^I#+ ';7&UG8I=UT*QV-H7]&0ETHTQZT(ZC5'+:V(><Y1L@,L?IWTGY!>Z,
M-+(B]0L%_;R00T +5&6)"O&7"K;E?I _5PKJ>^Q71>R/?*__3XOM2QR7J211
M  *=/>@4$RN)L-7YYJ'HG4M^1PDDE 0^A?ABQK^?61Z=GP6&NCX-)[\M#, %
M)EKY0  [@5.70)B"Z*-2:88L9I'";)4C=G"5-Z8FWJTO&5Y\AMI=#5\B$24&
MVZV)D$A/$@BJ?]551[\9>%P5,YW-))%YP:?U&SM3\XK,RTPO)'KGJ0Y,PA]A
M"UCX73)=^[?1]U=R_S5<Z4F&O>>+X/=A,UPO?6/V#/>R)YCP'-7K)J?+T7"7
M)<X?>&H9$?:R-"U8E/'2RM'RRQDR5)GQQ4@57B\_Z>SQBK3"C#(=JI5Z%;]@
MZ*YOU ;#]G%O0)=JSN"_6"Y<W[>U_7U;QXG-OC?MP<GQSMYNN[>S[TM23T_;
M_:/!7F([7N.@-?QB2UZ\;?0;RPDU,8V.RGO6>^QLXJH-U^CR?[\M_'7FNX7?
M%+NHZ0G*:J_\D0U^=3  V_G/I[=MC\S<,\!=LK;Q1=?4VXCV'<8R_Q**+0U]
MIM_"]OE*KKO]^.[F=N+==?GW\5_I^OLJY0H)O&BRJU3)A-W<R[BBLR[[&&I;
MG_<_X3BKA+^M?^KACB>/+02V?O]>ZO#K@U%XVS>3&S?R*U][]NFNIO (#J_<
M[BF[+K1W7N_7G^&7!OXW#Q?_ 5!+ P04    " #R/*564"LR;\4'  "I(
M'@   &5X:&EB:70S,3(M<G5L93$S87@Q-&$Q-61X+FAT;>5::6_C.!+]OK^"
MXV![TH!O.XG;20=(.VF,@?0Q@6<;^VE!BY3%C2QJ2,J.]]?O*U(^$MO=SLSL
M'-D 4221+-;Q^*HHYN*[ZT^#T3\_W[#$35/V^:=WM\,!J]0:C2^=0:-Q/;IF
M/XP^W+)NO=EB(\,SJYS2&4\;C9N/%59)G,O[C<9\/J_/.W5M)HW178-$=1NI
MUE;6A1.5RPMZ@ZODXO)O%]_5:NQ:1\549HY%1G(G!2NLRB;LBY#VGM5J9:^!
MSA=&31+'VLUVAWW1YE[->&AWRJ7R<BGGHA&>+QI^DHNQ%HO+"Z%F3(FW%27;
MLMDZZT8]WCOM]GK=WAGO1*<=\:8;Q[$XC?[5@I(-= ]CK%ND\FUEJK):(FG^
M?K==/SO)W?E<"9?T6\WFWRN^Z^5%K#.'^0S&A]L@9EL8-Q/(&VOG]+3?:D.8
MDP^NQE,UR?K>RDJ0MAP1Z52;_E'3_YQ32RWF4Y4N^M^/U%1:]E'.V9V>\NS[
MJD5D:E8:%8>.5OU'0DU,XA_GI160DZI,+JUJM<F.FX=$C95CG5:]_=B(@]6/
M$ )IPAN5"3SU.Z?Y_]Z@LYT&#6[N1L/WP\'5:/CIXR^TZ-^%=2I>/#*IU?L=
M3-H=HV&5#;C1U,!NE8N26,E45%DD#:G)7,+=JZ.3WOG+,+=5?W74.FV>;U^'
M+.$SR8R<*3D';[A$6?9SP0WPER[P/M?&,9VQ]]I,6:M9^Y'IF'V0)KI?BNGT
MSL$L]2H;9A'F.7GS0IS6WNNT=]S"57#*=,'N,SU/I9C(:O!=Z3&AH4BF0<B8
MAZN,\6S!BLR90L(.4+1G:[B2LRF>C.(IBWF$5X;I*=C#Z=!OJT,F(VDM-POJ
M,N7W$O-NR+1X)Z ,IDP]U6,.ZA I VI'MPS#H8F0ALT3%27,%G19CY]+(TLA
M9,!4V10Y@-+)7+D$!MI<1EY!DIM#-2U@Y@S#!!LO-MWP@M#0>3X:)(M5!G]3
MZ-;^K0(*Z(YFL]&NLA@+C%,Q@/LH+01D(H8;SJPB_HH698X0$'H(56FZAD<9
M&?MD:B!0^"JC2CV*%!V "8W ^>FLUR?B-F%QJN=V"1@C)\HZE"B.<7H9](:6
MU8VXVZ4R6]J^H-!W]X9^],A/KXYZ[=;9N2V#6^826C@ZCA4>C^UK[\0AXT;Z
M<,']:IQ*<BN3P,@X53:A$=1M"MX@[J!GH6R4:EM@'#$*4E>(6VYT) 5>6W:,
M, F)N(=8W#Q$"<\FDEUAL=X5*7JT.KS6.CF608O6B0A/X5%1R9$%O)!\1BMZ
M T8AK*3+P1/%CR:*,1'9^11<Z$$YZ-GI-N>"6*F6RCC XT\,(?YZ'X2NI86^
M\*2GX6^'N4H9(N*%/7P(4?58(F3E3('\=6$@ ,MXIJPG!_22F9=#U<^:5C:I
MR<B4>PR4[+^.8[6D+6I4H!CH8E%?";\;L<78*J&X462 "CG*DV5&D@I+><.O
M&NN3C*<2;'>@$/8A?E".DD1%1<J) 6&65V*=?S B9+/-)(R[L:2.("F,E^+9
MI/17PMCX0(P=O-"WH'8X11R,.*!TI@0!B5OL@XD+N04(J4PA='$CEI$&]A0?
MJU2Y!>6H7=,2[CTH?+P#9!]UW2AS/.4^E ;EA<F!-^MS:A1I([P"ON"9R RI
M,@7LT")SPC-U03$7H 7<JQRL]Z+!%>T%U\V,IX5?Y>1Y&<<H0=0,/K,[2HE5
MBCR M<+C[NK"8PD#P3@VU#!C7;C]&AS"JWS56U*!%G^[O&7C9>GGEX<,GH ^
M'@HTP4N%@]C/-<'3VQ&C#5!9*/B6G;!X!L-0CM)15!B*RT9"V"%UJJW#>_JJ
M EDV@J!RB\N.]PR) 3"L_2>]2\51+$N_=Z-M75:L]'H=M$JX765/8@T/2"D\
MG7I_E%2WP [M7J;E1NY)_^JO=M$O N&?%W(GOWT5[C]]B"5@J^OE3.RR"9KU
MRJ:P/R.!;I5)*^TX2B6GC5WE+/\"(J?8_3LIO\*=8XVL2.U"03\OY!C0 E59
MHD+\I8)MN1[DSX6"^A[[11;Y+=_K_]-B^PK;92I)%(! >P_:Q41*(FQEOED5
MO7/)[RF!A)+ IQ!?S/CO,\NM\[/ 4-:G8>>W@P&XP$ K5P2P%SAE"80AB#XJ
ME6K(8A8IS!93Q ZN\L:4Q+OS(\.+SU#[J^$K)*+88+E5$1+I20)!]9^ZRNA7
M X^K;*;3F20RS_BD_&)G2EZ1TSS5"XG6>:(#D_!'V (6?I-,5_]U]/T'N?\:
MKO0DL^W_#WP1;DZJX1SJ6P8ZG?=//)"<WR"4K6-@7YH:+$IY;F5_>7,.1L]3
MONBKS.OE!YT_=A:=/<TH,R"[E_[RK@O-Y;%4][3>Z9[0R90S^!7+B<M#J[H_
MM&HXL=WVIMYI[6]MUEM[V[XFM=>K=]\<)K;A-0Y:PR\VY]G;2J>R'% NY'X[
M?V"MQ["AM;WE&IW__C#R9X+O%GM M'U=H:CTS5_9[%='77"$O^XZIWIDZH&A
M;I+%E:^ZIUQ0M-S0E_G/-VQI[#-]%Q;2'^2^P=7=I]OAQQMV.QP-?G@_O+F]
MIA/EFP<9%;0S9/] '<@^8]>G*$U5V2!1,F;O5^3[*52*VWYN>#+9055/SK5S
M'0[V^^&#V4QNG72OG>X)J;D>PL?P?.'V#]DZ**Y\X]B\O(9#?/_O!)?_!5!+
M P04    " #R/*56*0E,7&0$  !@#P  '@   &5X:&EB:70S,C$M<V5C=&EO
M;C$S-3!C97)T+FAT;>U76V_;-A1^WZ\XM;%< %L72TYLV3'0VBX6H+DT<1?L
M:: ERN(BB2I%Q?%^_0Y)*<GBI$F!%MV&^4&P=&[?N9/C-[.SZ>*W\SDD,DOA
M_-.[#\=3:'5M^\J;VO9L,8-?%B<?P+<<%Q:"Y"63C.<DM>WY:0M:B91%8-OK
M]=I:>Q87*WMQ82M5OIUR7E(KDE%K,E9?\$E)-/EI_*;;A1D/JXSF$D)!B:01
M5"7+5W 5T?(:NMV::\J+C6"K1$+/Z7EPQ<4UNR&&+IE,Z:31,[;-^]C61L9+
M'FTFXXC= (N.6BST_.&!UQNZ-"0^[??)<GBP[+D#9TE#;]CW?W<1I(WL1J:4
MFY0>M3*6=Q.J[ =^SSKL%W*T9I%, M=Q?FYIULDXYKE$>P+ES5^C9DN9I+>R
M2U*VR@/M4LN(-N20IUP$;4?_1HK2C4G&TDVPNV 9+>&4KN&"9R3?[928AFY)
M!8L-8\G^I(@)X>G7=0T9]:0LIXT+;D^!GM\F;,DD>#W+A;]#?N@Y$2MT7O(B
M<)7;#\"'&&TJOCOZPR?17])0E=].VSUP1J[7=YYWX9\">4J%9#$+B0(./(9I
MPF@,\UL:5I+=4#B+D4K%MB??&._AJ^K#A/9_+*_$\D2U_5&5F/"-Z1F61UA\
M@7=0_*B&/Z]$61&T*SFX _AD75I3"[8:J0,RH5 A7%&B%SB1>5V76+(G5(37
MAG>G[0U&.)BM#ASGH05[2FRG/>CUG-&49P7)-_K-'>UW(*&"+C<0FA9 GV1"
MI#94L^Z6\+$B KLSW< %+;B0@%WRGHL,7*?[$6(N-/]GPP44 49P0D28&#R>
MVS'+X2$0HZG! 7&5HOH03:8*Q)K)1"L5]'/%!%7[HU1N/@K*'MD'-._V]Z)]
M158BR%()7(&H9GX;)B1?47@;2D5VAYX/)(_NG60YPL],XX>8*,)47%FNB;6W
M,6'*]T+04L'H*#))4T QS#=)$619(*[2)"AF.<E#]1T51GH7:YO(5:7&"UY0
MH6V6#>@ZV-:KYOVC<5]7,Q:O),N4-@)++K!2NEC$*2E*&C1_1A$KBY1L I;K
M4M1"HUK]DDO),VWA1I5$2-+:BC9HR/6*'0XLU^VK+2MQM<JH,5PO8$LO8%M&
MV[2^8PV&_K-DQW*?I7U1K>4-A]]<J^]8OG/X*K6V#H1H&.HF[_EZLJ @IJ#$
M-!^UO%;#4Y HPF-5X("KN1H;=ZP'7V:M3;ZDOE?<*JF'99/2>"O))K^M[S'#
M7YZ%^L0VPZ;::?=Q@)V0C6GSOAD?CPYO+\?I:WW^$>[NM/W#4:F?J&Z)R.#$
M@AFY8>6=OU^1YF>KZ)ZU'@OZW%B@OSQE$32._IM"=THR4RGJ9+]05POS]C!L
M__$07)R]FU\L=,6\_?7X4@5BFN"V0L4=<X@U'71WDC6OS7%6;:5S7$LLTM>S
MQ^5FZ\VP=:I[XB;U NW1/&PN:@4W-]5 T)0H=%M7M_N$Z:WDW(N0)6:MDMLB
M+]SVZJ>Y>^I;\.0O4$L#!!0    ( /(\I5;N:"198P0  * .   >    97AH
M:6)I=#,R,BUS96-T:6]N,3,U,&-E<G0N:'1MW5=9;]M&$'[OKYA(J ] XB'J
ML"E90"K)B 'YB*/4Z%.Q(I?BUA2762XM*[^^L[NDK5I6' =-4M0/A.BYOF]G
M=F8X>#.^',W^N)I +)<)7'W\;7HV@EK3MF^\D6V/9V-X-SN?0MMR7)@)DN9,
M,IZ2Q+8G%S6HQ5)FOFVO5BMKY5E<+.S9M:U<M>V$\YQ:H0QKPX'Z#SXI"8>_
M#-XTFS#F0;&DJ81 4")I"$7.T@7<A#2_A6:SU!KQ;"W8(I;0<EH>W'!QR^Z(
MD4LF$SJL_ QL\SZP=9#!G(?KX2!D=\#"DQH[[A$O:G>/>G/':W=IFX0N)=U>
MV"$HZ=#6GRZ"M%'=V.1RG="3VI*ES9BJ^'Z[9?4ZF>RO6"ACWW6<7VM:=3B(
M>"HQGD![\].XV7(FZ;ULDH0M4E]3JAG32ASPA N_[NB_OI(T([)DR=K?G[$E
MS>&"KN":+TFZW\@Q#<V<"A89Q9Q]IH@)X>G750D9_20LI14%MZ5 3^YC-F<2
MO);5@G]"WF1.Q +)2Y[YKJ*] 3[ TZ;BNZ/O/8O^ PU4^>W5W:[3=[V.LYO"
M?P7RB K)(A80!1QX!*.8T0A.64K2@)$$+B.44O$"$Y:&R,+WNEE5.<\4W;]B
M9,[LKR)'V.O^=_;SH\O_JA!Y03"NY. >P4?K@S6R8*NL&B!C"@7"%3FRP/[$
MRRQA L^I"&Z-[E[=.^ICF[(:<)8&%APHL[WZ4:OE]$=\F9%TK=_<_F$#8BKH
M? V!*0CD)&,B=:!2=3^']P416*O)&JYIQH4$K)E3+I;@.LWW$'&A]3\9+: (
M,(1S(H+8X/'<AFF5FT",IPH'1$6"[@,,F2@0*R9C[5303P435'737-%\<B@'
MY! PO-LY" ^56)F@2B%P(*";R7T0DW1!X6T@E=@]]MI TO"1)$L1_M)<@P 3
M19@Z5Y9J8<DV(DQQSP3-%8R&$I,D 33#?.-E04&&N'*3H.CA$J'#4$\F'1.U
MBL2PX!D5.F9>@2X/V_JJ[O>D^975C,4KR3RAE<&<"ZR4)A9Q0K*<^M6/?LCR
M+"%KGZ6Z%+51OW0_YU+RI8YPITHB($D910<TXG+@'!];/:>G9H[$:R?#*G Y
MCBP]CFP9;LLZCN5UNSO%CN7NE'W1K>5U=EM^J]>V8QT?>5_EUM8'(2J%\I*W
MVKJSH"&F(,<TG]2\6J63D3#$)<-WP-5:58P'U>Z75<N0+[EO9??*:K-L$AIM
M)=GD=W.+^(&]4.\O8[5X[=4[V,&PAZS-1>^8!O)DF7GYI%[+^F<0WJNW>_U<
M/V%$!%<:,&4RB+$=)^$#YU<D>V<M/:J6S4'O4AERQK A5&1?>7SHY">=W059
M4ETK:O#/U*YMWC;/[/_,?_3V^G)Z=C&!Z=EL].[T;#(=JY.8W.,(E.R.PN^X
M'L 53AZF=IS&KC5ON\AL/15>L<$^OWM]J^Q)!ZT^=#)NOO1\01.B"&Y]^CSF
M5\\QY]&$S#')A=PV>>%KJ7R:;S?]%3G\&U!+ P04    " #R/*56*BMPET$(
M P"T)"8 $    &UR:RTR,#(S,#,S,2YH=&WLO6N7'$6N+OS]_ I>WJ^GAK@H
M(A2L&<XRMF&SMR^,;89C?V%)(85=T%WMJ>HV-K_^*/OB&QXP4-V569W@9=<E
M*[,J]4AZI) 4?_\_+P\//GFAZ\WR:/6/3_W?W*>?_)\O_O[_+1;_]\L'=SZY
M==1.#G5U_,G-M=*QRB<_+X^???*]Z.:G3_KZZ/"3[X_6/RU?T&)Q^IF;1\]?
MK9=/GQU_$ER([[VY_KS[TGT->>')^04PT8+ Y85+T!22*[6'__WT\Y;9M]1T
M4<". ."\J"GSHCH-$,4'9/W?\GEL]E^/)9<B$#NB<Z&CU)HT=(EMN.RS8_MU
M]@M7F\]%E__X]-GQ\?///_OL):\/_K;1]K>G1R\^LS<^LZ\;/CT_</GR>&'O
MO3[XYY]_?GWL<G6P7.EP:SX[7M-JTX_6AW1LM\[.X-/"X2+ZU^?9'$'PY9WS
MG%[X:/W4#G?QL_,C+CY@I_[I-XX>WF;:Z,7A[>AD=;Q^]>$?=?[F.S]L.&#Y
M6U]GM3FF57M]@9>_^D(_Q].C?:WUL]-WW]RS_W1>']^Z:6]_$WE/'.=?(W]V
M]N;%H8?K=[_"H:[;3W]K1X?#3XLNOKG?F_7QZR,[;?CTC/;BN_=@L_S0+[(+
M^\_^[]T[#]LS/:3%>W?B/]^# 5\7IS[9+)X2/?_U=SA_XWV0??B._1;"@ENX
ML/!G)_G\@%9/__&IKA;?/?S4D*XD7_S]4(_ID^&T"_WWR?+%/SZ]>;0Z-OU=
M/'KUW'Y-.WOVCT^/]>7Q9Z=?_K,O_M?_^E]_/UX>'^@7=J\7%W?U[Y^=O?;W
MS\[.S$?RZHN_R_+%)YOC5P?ZCT]EN7E^0*\^7QVMU*Z_?/GY<*"NSQXN171U
M^M#>OV<V9+UL9Y=_>?Q ^S\^75:L:&J:? L %'W-/F*DAA4\29$?;IU^%6^6
MXHVD5W0X7%J7G]\PLR2#:?KJ@)Y^^LG9;;+3OCS^O"]?JBPZ'0RZLA1[4>*_
M7O&MHQ=WPH,7C^/=$_GQ]HLG7]<?[_]X[\?'X=Z/3WZ\&^_]V.*36__\Y<F/
M3^'NK1NOGOSX[*?[CW[R3Q[]]^&36_=^O!/O'3S^Y>B7X?C'X?$O]WYY'.^%
M?[J[X3'<OW7CY[N'C^')K9_2O>^_>_7D\)^_//;H[H0GKQY_W_*]7W[Z^<GW
M7_UT+SPY?/)C^_G>UU\MGQS>=G=OW0WW']WX^7%X<O#DQ^_\DZ__^4+L/?[Z
MNWSW^]L_W_OQR^7=\,]7][[^[^6]6U\>WOO^=GS\BWW7KQ_[^[>>V6L_P=U'
M/YU_YE]VK;1Z\NCHY>-'-\+=K[_YY<FM;]SCPV_<73O^\2/Y\>XOS=EUX/[7
MW[C[CYZ^O/\O_.7.H]O'=Q^ZE_;O+W<?/7YY_\8/%;I+/KD%([8%] X+;-TO
MB+O'Q-5%JI]^\=6-.P]O__VS=T1\F1*_\$5?+3>-#AXKK;^R5S:SB']/Q.X#
M(G9- JK=Z<:)%^9[>4$4\R+%:&]TY8CRZ1>#&'8FX6_M_$<RR_BC9.P_(..&
M45WN:8%*IL:0:5%+'\A4!?1,X"5\^L4__15*^/;*O,JKFR;C-1U\LQ)]^3_Z
M:I;N[TDW?$"Z/1G?=5 71:)IL"^TX%;<(G4C43%#+&0:[.R_:-)(>(52OGFR
M7K]CJ&^OY):%#^^Z:;%7%H=VV6<+H1D$OPN"^ $0>'8Q,[")P57SU(//M@AI
M(:H>E5FZ-Q#X\%G\0UK>[8. F;36"*U5"I0"QDZ&+/0^__#-P&5]>"/V<X[[
M^2T[V0OCJR_TQF:CQP^/3<B#2;_?OUJNC%(OS:X?;98#H;W]TKCH9LD'>GLU
M?(E3EKMC&-Q_6 _;X5>K^S_>'L0V7 >>_/A-O/_HP8]VO!W[U4_WO_[JI\??
MWUL^^?ZNN_?+P<&=^.#9X\.7!_</[R:#SC,3V<M[CVZ_>O+HP<'=6U\^N_OU
M@Z4]?O;DUE/[#D\.'G__Y,>+S]BU3IZ$[_)C.\_C[V_#8[ONW4?_?7#OZ^]^
MOOOU[9^??#T\MFO>LM][^*]G3P[O]7LW3R%P"H6[O]P.=Q\]_:%)C]65N&B%
M# >AQP6A/2T.4VA!T&7Z](O?"DS^_UO:U=16OEE9<*6/Z*5N;JSD_O$S79^*
M<G.NU7\$1PF0A1 )N@)+XMZ-96!)!0"$Y!1'[YB/&4<[Q9$2N8(1%Q[4+<!$
MM4"N:5&9(;8HV#M.%$=WEL3+ V,?,Y8N 4L/WV#IWJWO#$]/?ZC24Q-IBYS9
M+XQ&1".BH2[(HQ3@UIROOX.E4]1<"&ZIFWM'J_;'T;,-;S:CYXK1TV-#$Y,L
M") 6H D6["LO"G:?R?L.2:X&/40MY(P0$H,:U^JD%%K%"%U<]C,7&@ER+GP8
M.,S55'SAI!2S.PX6%'-;!,02I"4$GW;@PW(3%[!5B\@1" )WQSU4C12I]L8S
M%QH;C@@T)LJ+(-'\5_-AP1KZ(G0+L4FJI]QV@",76:&#YUH-13&P-) D!G.H
M/6":[=$N<;3\-8[0EUIB,?1@:@L0"]3-HZ1%\EEB!W!0?H\'_2Z._IQK"XJ=
MN+2L'*!DSSFU%D/*ZKB&/)NDL4&)V+.CH(MFOL/"L]H6-8:P"%X=:#$T];_L
MVOX<E)*S )&E&E'+D#TB]D;5@;'MTBC '*'M&DZO?@VGZ&.@KGDAK+@ +G6!
M7OPB!X\UM("@X0]R[#_AT#S$9IXK08T(*2=NTKI(@%B*]ZG.X=D(H5.K&.N(
ML.@^&LDNZ!=48U]89 3VLR!2N +H#&E/QQ08.8* H@7ZN:=8JB;%X&>KLV/H
MW/] CM%[#<DA+U(F<V+-3(\%0,%\6J-8DJ!W>B61?=-04@E=.AL-2XU8NO']
M0$5*MLO,AF>$Z&D.B_K<%U@9%N":&]:S>=$#AR:2-<3?B\JV@QYJWN6<7##$
M0@\12PCVV.=60^\ZKVWL$CEWWRR5'M]]=/?EO1]OPP\N:<U!<.%PJ(=PV2^J
M[[A ET*6%@+#+A8W(%%G0A1P#K)+&%(WYX4 4@BHS ']V(#4O!%D@;*P6-X/
M!<JTJ+G0(GOI7L6QK[]'?BYEE8Q"K"YR+C&!QDBY-T^82R;@BC #::= NOL6
MD/YIQ__SU0_>U=R#&2--/2[ ,+&HXLNB* EDK,9"?H\*75(\3^;18C9VW9H9
M)0I(I72Q+RL-&'*:O=O8L&1QEP?1(5U=+)A7; N+@'#!H*T396.V?C=8BI0@
M]&8Q&B; 5%BHYIPU9Q:7LLY1VL[Q],VOG1PJ9!6+T$H4LTV=PX)BU05A1?89
M -1=?H3?H9,X"^PI!F/94#E)&Q;,G,^Q](\B1S-VKAH[%)%[4&>.+!AV6,N"
M4I$%F* LX X]7P5VU-@98B1"B]"4.V8LN<9:6@(72I[MSLZQ\]W[?BS^X+J/
M *4NB'TP<NWK M'\F!-ML6F0H'PE 3X[<U6NH-%YAN $ S3&F!PU24QS>FB4
M\,&$F3O'10^5%A!:'BJ(9)%J[=[4';S\7B7L'X#/9^_VNJT' J6KIIL/=.@-
M_9*?;TX;# U@GYSV3WY^_.JY 6>S/'Q^,'0;GK[V;#W@[^UFO+^]W(B=X;-W
M3W%V^3?7//\*FZ.3]>FSTW[/S\\Q?0:G/U/8?W$B/>W=N'BVE.%Y7^KZD],O
MI!_LE[WYS?^\VX/P_H>_N'CIW;,_/^W]N7BV.:;U\=! <-J0M+ OY_S%Y]Z\
M]_IKREN'QD7T;RYQ]L[%\XN+?/;.C?K@??,QF3GRG9DMEC8^'1$:YL#!Q22R
MB_MV_O/UZ6!5SIZ*7>SE\X-E6Q[?U4.V2\CR<# M0VOWA7%Z;8EN'M!F<[\_
M/#YJ/]UXN=Q\^L7%(3>/#@^/5J=OG)WG[Y]]\/2O;]WK;S$-84+)P=P,*RLD
M<E6'?G.S#+'X&+7MAS#-?GQ^P_TM.7?OZ%@W<J+V8V ?Y=F#H*;4'08&KN:M
M76H<0X.JOFC:(WGZOV%);\DS[Z,\4^4<DO<U.0\.!#W'@M*"$#C-ND?R#._J
M9]Q+_21'(9 W-ET:2(5J?K2:P<V%!I/+>R1/_[?XMG[&O=3/W"M1]:6SD4AQ
MD3B9K>V-O1%*IW0>5T-T(^".9Z,\CL_O "RB>WVB\W<^[@Z<K)9G/W_SC(QC
MO_YEATJ;D[5^<2Z TS<O3G'QWL7SX1R_.M_)*;5_]P/G@V$^_^[AK8\YU[O>
ML,:(IG+8L$/B3*"F;=V$PUECA%-M"Q?:%L9(\</'HSK\%52_+8-O=?UP$-[K
M>R'+%_8;WC[TWEEP?K3^D^+ZU>>'%V_IZNAPN?K0:3\64N^<XK-WO_WOH26U
MV(:%)I1$4+FBL[]#JCV% CGWMW)DNP?)N[K\MMS_F"Z_<P<BN=Y:<=J36;/4
M*%I\5]G^<:9%BF^E>49U!X9!0-NY STT#@&\+ZE95&MV8^@GZ&9"<L2D\?0.
M^/'= ;^U.^![CYQJ(JT)JLO<0TB,5%I+R/F\!'5\6A"VI@4^NJ!:2XQF!^R7
M8S;>C4Y\HI)ZEZOSZ7^6FIVN4-YH_SY9GF55W["R;]='AWK\3$\V7RZ/-FUY
MFBS[9M5^AYM]/"D\X8W^^\2^[NT7]M<P:NO=?,I[!VR?$VZ+Y+P#B=!<5"E5
M.[73,"P9X?,E0^G9]7H1AL$%;9^Q,4ILO!\OP,?'"V\#Z2_$"^)\@5J,(J4"
MS3DT&LK4E%(=%G$O@%0N@%1G($T!2.7C@52W R2OJ*#DB:F#*P5#"!R8LUA\
MDV,]!U*X %((.#8@;=;'G]\<9G/J^KG=LE?WZ%#?@.CALCT[H=7_Z,')RF!T
MK.V9_?/<(H!#TY>3XV6C@YM'=XYE6Z@:8'2_WUBO:?7T-*_Q_D+ P0'QT?JL
MG.O-48^&R934!@WX?GG\[-OAESPZ^D]'7SX4P\=#,2P";@&*7$5%"OCD(H3B
M,6IK.4BOH2>'%_5Q,P+W%('O,JZW0?570M$VA&#944H*+2I7:@BNYJS>GET$
MXWY\^=$95-L'E=].9)==53\T%<0D()TQ M=4'2A";:&\GWT?(;I^GWU]<TA/
MCPQ3#S^:>%UMYMUO)_../9)P44\@$$1J2,+>"_?BE5H:KX$8B0@O1<,2$I8L
M,:-7J)C166"3U%N,X[%WOX.,^Y^QWQ;!R$D[OK]^J.L7R_:6_;[S:F56_1?Z
MJ^;YM[W$C<WQFI[H2MM?OM#O^(%3GT0'NOF2-BIWE_;H^&BEFTLV&5>UK/$>
MIX@2&C!C:Y"T,VB-XB"+9"HI7EUJ<\;D.#!Y*?GC3-63B";*"#YV;KYUXIS,
M0376?%ULX#1M1'(*T,#U7" 7)BB%8W&]HH#O[;H(;S+&8NR!S.XA+9D]^,#1
M6#(D[I6#M-!J 2>Y7>6Z]HSD*2/Y4DH.BF_J98@0Q$":8LW!4<V-D8,V[ZZN
MY& &YYZ <WO5(-)K$^]:U:Y@D2SY2))['F:<!,+T'AF843JC]++(P#N0_BL%
MJPD4.=4 @@"A4U5."5-E;IBA7'<R<(&@+^E@V/7NX3/5XSM'C=XDZ"Z..&V-
M>],/=S858")>ES/ZEBW.&8J;>@R8M>8D64H,0 03*$/_;3C<.#A8#O);ZPM=
MG>BVT7$V%>)U!?R' 7*:PK@NEG542PS;"IRTU!9CMZBI01U&[AM7=0@^M^(+
MXN1S ;.6[)>6["2]D,)0N]:CQ6\9B"OG'JH'YUO)QHCCWOB2!V=:\C]'&STX
M>7HT:\E$M60WC6):DW(OS2,"N5C-A[3JR6D(4?=@46#6DOW2DIWXDM"R8"GJ
M*'DHP6'7E'-UG;F&RFX"OF0&['4RZ]!DF XY5+IF"$SHD8?Y2"FP\T!U F9]
M!NQULK!@1,1G3Q )@$*G5#6%F@U1 !EI A9V3^"S7<6\>;0YOM\_1CTG:6>+
M[YU\*04:@(2 I1N.O0\N8\XM3L#.SK#=*6QW8FV9<@M0C,F2@RH!(U0RF^N;
M-@CTJX+S$<+VC]$#M2AP]?1KP_&:#FZLY(8<+E?+ =L#RFZ_?&ZGG0G$E"WQ
M8'PC] [%=>B>J CYZ*D"B9>P?XQWAO2^<^*<G*L9&@Y[4(K+'+!'"^L:":4\
MJ:%Y'P7I![I16K=G!N9;^D(/CIX/QYXC>0;R=&US;T$T%?09%(QJH.L>)$<*
M/D6SQ?MFFV<@[ZE%3K7$SD!),@*W1H5R",7E$(<!+'F\54I_L'[HYA\H'IH1
M>[5%4HUK[S%*RH!0#(=:+63S275(0P09;VGR#,(=@W"+ ^DT@(57+)T\^"HH
M9@91D+,W9LIU'RSAC=8&P&R^I5?$!SK$6*VM3U3>VGA@AN6X;"/14 IGH7\M
MD"(/NPYS0@I-@I?2]L$VSK"<G+6$&D)*S970S$77CE1<%\F&Q-;UG:WZ)@O+
M]^K.9S".U48:76PML<7;K4/02IEB3=Q+(;$ 9R]LY S&B5A&YTKT/7DQ:PC-
MU<K=]TB8LV1UO4\@Q_G;B+B]W-!R&Z#[C1XC7;U8'N[/](O=)RP)R7DU;+8:
M@6/ Y(?=33($PK>V3YC!N/]@O)P^M]83L1K$H$'$CMX!FL_0U%U0F7Z?V\>A
M8)*V(9J?HB[&GKR'EA)RSRT5+[VR&8OW1XF-D4==$R,Q=UW_'I:#>$@NU11C
M@YH=IVZH=N@C^2[<)[ P-V-YXEC>EEW6GI#,FT:2"CX1NM -:;ZUZF(GG#G;
M#.&K9WI=-"LB88L!&.V/>C)$JCA[-8]XG>1*(;/?8RU :\J2+8P<_&TFYA*<
MQI"2UQ+.&_;'3_<OV49=?<//Z%)L(XAN2JDN@?16""CY81:M$XB4J,6,N]B:
M<(;JZ*&ZFR:&HMT87D -'6H*W#4P@T4SWO5>Y]3QW'4S+MM**7<I#I",!A#W
MFGT.+9; 'D)U4VA1F %[G=K$J&F"WJ.3$B$GCY4@^UJ2%,Y<ZVQAQ]JV,VZZ
ML)LFA"'6:MYW$("*6)L..VYG7ZK')E-H0IC!/$(P[V9<@F!( BT0 ;12N2<*
M,6<JA)DJ3\ R3Z6C9@*D9I+V6'.KD)"YE@XE,^8BG(-QC5(U=9Z /9XA/!H(
M[V;)R= YK/ [+0*]-,Z^LXN%0QPVU1EQ6>\5XF47S3ZCP^KEK"V%JA@[D40/
M(3(Z3UU:;TP5%6"\A;PS_/:@=!>I1,#$&G, HZ/84W:>,60IW%5FZS>:=IXQ
M W)[]C!+<!P])AB"_&&JD9>8NGA/OK#KLSV< 7FE%C+&6JD7HX7H(1;/,!0F
M!9_-4&;1*80XOXW,+^F5KF]\?<T+AW8?B* CI%:U1,[0NT<F+N )@J QPA&[
MXC](T[Y9F2X^70YF:6M3 7YC=KCHX7.:2I51R*[A$'UR3Q#5$>6L,55BPT-R
MD]U/\5^Z_O?)BZU-;+\<I(T%!%4IB[1(0A4@M9K8)"Y%71%)V4\@,7RE+F>N
MX-GES$8BE[SG4K5";85R@I)<XDJ:4GJ_E68&ZPS6'7(L38$I5JS2 8QQ\5#5
M#3YFZAEH^A/*9[!.BD/NWGQG[)A\<T5#'!2":A\VG5"+.F*10K/YGC5B9QJQ
MFXF]OOH&P94F#5*5ZJ2T4L5T0C-,8F+OE6C$E09\^Z)VD_01C=5CKEI<]E [
M( 57?0>N*8+(]&N>9XV8KD;L9H:P=M>P2.K*D#2BE^;(7$80GR.&V4>,@L.,
MM ]@-T0_-@ZHBL/8Z\21&U;5 JK.]Y[+;,1GR([-RJ)ZQYVRT0T(#;@Q>J^N
M^^(EYBD42(\P-IWK_7>USYP:5BO'EBV^Y.+(I^Q=#M"0H.+T]YF;X7R=.'!.
MSH?"M83FH'D+$B6RMFRD6/K<OK+-VO])4)M)VF0.I%$86HU#T0TB1(OKFCUA
M8@A3J.Z:03PB$._$$E>7LG'BI(T2>%\K1'$I)?LW:G CKAR[4L3,700'ES4*
M-V<A8'65"T A#I%]\Q:L<2H!1KR;T0S _2C2S@U[*AQ<4^@A4PI!NL$OL.88
MW&P!Y[Z!JVYD 9!:8DB1$TC4"@1$1BR!66M-LTV<(7G%5E(#.4S2E93!V>/8
M?52D5 ,6Q3:!B/VWL?E@*4^5J?WTY?)H\*3T7$^.EVUSY]MYU76K:]EWZ*F^
M,-SM8TH@^1() N1<$$@J8>^*.;K0.#).?Z%LUI+]TI+=C,U@Z5*P^%P1(C=B
M*M5I]:FWZ-(4LK^[UI)YA7GGMKY+9"ZJV; +T4<.M:36M8<*+;DII']G%(\)
MQ3NQQ4T-O=Y5"=H!NZ"BBH\!>FJAI>F/^!P+8YG7FG=5@9R\)"?5HE?CY+%C
M3VA IX"LL>GT2R=FA(\'X3NQX2$%5V+RN62!5K5JKMES#ZD.S8DRV_ )+("/
M&]<[L=P@27J/12,Q8+"_S63GAMG[UK),?R^2&=>[QO5N[#4XH*R-#&60HF +
MS$Z= 3N2%I[JBN/EPWE>\;FZ14AMOB67RS"Y#*@R$4+Q6K-FB))XJHN0,TIW
MC]+MK4M* W%0%(O!,KMJ(9X/X+,Q8O"][4$WW=I"J*.#NZ]TO7GX[Y,E\Q4!
MX\ZR#9]8/;WQ=*VG[V]EVMJ#X6IG5QJ>WK40\?#D<$_HZ\EJ>8;+U<GPQ5\C
M[5!I<[+6+\[/80\O3G#QSL7SX0P?!'K$K(FC!O8"I7C2[$+#-&S_((I[,%I@
MSX%.+_<(Z._&:2Y(PAZ25H5$&5U*RA&YB&&5IK^>-R%H3A) SA>S8^;($U3S
MW9VC2RUB@<K@.< ,H!'9MC?$T6Z6771U;(\V=N_6IT3WRU?#5WKSTT]7SKZD
MC<K=I3TZ/EKMYW)P@-2H40>S?1!BJ'T88HAF LF[1E-)PO[&V*:#@^40UCS0
M%[HZL7_XX.B75P?;<)4#@(X.EG(*H&^.]7#S7FG[\U-PK9X^//LM6\/PZ\38
MER>F)+K97%S@S<_^]AFM#ZF=QHAT<'XS]Q+ PE0 0J)D(7^$6CH532G4'(J&
M-)%LZPS@$0!X-ZULK??216H("%BUDD-2Y$@>*F6="(#W@D5,$D#B"RN6&H/K
MX*EC$!5E-AQA\['/ )HN#7V@3T\.Z/AH_>K*:.AN:FNC>$V%O4@ 4E\C2_$M
M1TR,)9_5<WF775A</!@;AM\L2YK 5,ZV\WBSQ<<;F9Z^N!Q>._?UF]?PFFRF
MTA"3%RY\#&C>._2OE+*"LB<2Z&B\CWJM1OU:\K$:EFK.,VC&G?7;"6BTJ-8
MW25N@*U@Z;&+%^S9HEO>*]#<I=5)MQ=/UH,/6\G#D^?/#U[MP<+(3I#CNZ 3
M%NX<C6<%JK&$ NA*;:F>3TF>D3/;G%\AAR15@L;54X8<'%.K7)NO4GMI;?J+
M8/?73VEUM+JYE]V1'I-R"(7!.X!LD7D+51K4F() G/Y^ 5<EO=W,;'/L?0.U
M"#F R8PT%HN7C2"67H1QJE5KERBT2ZG+,HIN=[LV,#V"F"L7'S.83^T](4"9
M:EW6U<AA>Y5'Q0(C;28!:AZ&A&-#(S/);!R5#.5,#G&L<GB=.'[8=$7VH]_P
MAXM7OCI::Z/-9=<K;FT[ZN(ZY-:C;S+L+% Y@#D;XY@DW>4^ 6[P5D'V\?KD
MG#0.#8A&'(<B[?4+?6]=8:6/[../='VX7)WEO72E?;F]]-K(>B1W,^A1-.1A
M3TT_C..A4A-F9:E9"U#,4UC:_6ADG2Z4M:8'0QY5Y98^-R.P/)7Y#*DM[GR8
ML\^<J6M3\#51)&SHZU!$,*RX[A.DWAE0]\[1,Z*V&%QYKT.KE"'(_!YX;#GU
M7GQ'Z4 TA1JJ69QO93HP=2[*:JX&,",J46Z-L@?'(4UA']^ILIGM-#)/$W46
MU&"NP"(62LJ0:&NBZCNA9S>);HK),9UK#+?2? ",ISDEB*G6"HC18?<])E_*
M/L%M)"SH&J--8XPA8HJ.!6(+U H+J_3L:J@\A<6#6=0?.=.Y]JX"GGL&,S %
MQ9=>4^3F6DLPA8Z4/]K!_Y;U>4;KI]OK'[U\^C9)B'7S5+[W%$48M$8$$=]*
M=+W$YF2O"/I8J-*?@/DDL54#^IQ<;1T#. G$T*,&<UG9M\QN0MB:D/GZH\1L
MDM"23B7F6E0=08)625P7[46'XOF\=R3HNI@,$&Q1HT"-U7B/1XOC[8^7V$@B
MS:M?DY<P$64MKO7J$A0(YB1RL\@YYT8L>:^6#/X\X9BD:+O9WY)+CRXH@$<R
M6LD17(TM%:I[M<!XO=QM#DZE8R*?!10075-&X!!Z;)VF,"1ZJFG\/1_</&S"
MWELT#U\==%;.4$-/FH*'%#KN$[+&$G_N.:0<]X+!0D[U -1R16./*9A'@@J=
MZCY!:B3I^#U'E(;8.!I\FD&*?:)*T NTDD,,A&Y"B)K%^>E2.'N,00IT&,3)
MG'M1K^A(N_HIB7-J;&8<BSD[01U+R+$'(SKFFCH((@!2C3&5&#%,8:[#Y)C.
M-89;J3ZS^%PH57-<W?[*+4$M(;L&,H4NI:FQH&N,ME2'6BN%4(<]=_*P2PD%
M,I9DE$F3F\+,D5G4'YG #5G8GVYJP&!4JL;<G(^Q^1!:\%,R+./95F#\BP4[
MP5KGJNS-DW4'(!YKAZ(QM-RZ]Y2G,,QM@EC;W;+%;CJ"6<"W7&L6BP=[(G'-
MI^PB(%BH/R5B/B&0[6P!92<8@]3+,. \4V10<YH=/32,1I&JEMIFC$U<P*$/
MRQC=I2K57!62^*"EJQ1N+>8IK9!-J-;I6I&A%$M&Q=Z3-X<EQ+U)1PA1LVKH
M4R+>DTD@[:#N:C?^*2OT6"R ZPDR0DU00N@F_%X9^FR^9NKSIQ.1H40<*H.J
M $2MI+%#\D0.M;+L8PQW+4R&%];:?(BMM6%E%)T450@AM=*, 4U(KC/A^*"$
M7>58?31=;0C2L+;&Y ="6T/2ME>%%-<LYX&N%,^4<F !=15]2C'&G&JKOK;]
M5-[KX6YCDDSJ>W#F;M'86Q/?+3#-VF.&/-ZY:J.VQI<R>\U<IWKNU;<P[%42
M.7(:<H\:I4#V;0]D=:5V]5*$!$XH>B0*4""%TUFMT7DL.735IGL@I*NTD)<B
MHUHCFHQ,D5J'@*F&%C5T3"X!6M@QWJ&>4S%ZVQO\V5*)%C<@:V P&D(ME!Z*
M18@M:^UY#V2U*Z.WQ5VS&30, R:8(LA0J!9ZI!AK:4Y2\'L@I!T9O>W)J&@>
MEA8*.&:0XJG4*- 8_3!2%Z?02?>GQ[Y_- S^2^6IB?26;I9/5Q_(UER\H7)C
M<W[L-ZL!"\,OV,=6+H!.SBA-<J+0 K$6JH6#R]&G4*?48?M[LKUWM)+7XOVK
M@+I>>R%'$O64O&=QD%TB5U(W;^"2FI=N-"&4W+)?_>*T*N^-8C]8;GYZ%RO#
ME&A#RNV7[=D@Y&$[KC6UO;0 ";3%$H9AWP44\FGB%KAD2,VL0YE0[F?,LMU-
M.Z6/$+$EXVH6K/9$M46'ZEW"00!3:L'^J,664_)F=O[H8F?2LT]MN9AIS##;
MS93>F'-4B*Y3!7 -N7+V,6*6 5)3ZJ":839B:P:I=FJ0P< 6-%0ZG0N3($N0
MR%,:K/G;LAT2!K=/UD=R=)K44;EW=+R? WZX=C2_5+56!B6/U6(0AZE$D![K
M_I"/G8AT-RM.S=<02$_KIWW.5$R.O7?E&$O2*6GI9)S!]3$8T2P&9#,60W&^
M12=<<PE1"B5C'2'$"1F,&5UCL%TGJ^4YM(8=O'1S_,.0I/]A\S,]?PV<0Z7-
MR5I/;\2O#[LX\<51%\^',W\8PS&W6CV4-EA(]=4+YN:C!"K)2SO/IAN?'BMT
M'Y[P1O]]8A^Z_<+^>K,I^7\XX+)3Z+"(;ALI=!=JE](*Y0Z1&F7L1C2=-W?6
MBN/Q+W-\7,SPS3F&'QB$'QJ")[+"45.OXFNC@@G8!41RQOY+QII]+F[\>G,I
MXKGN6MO9S"AF8YPU0FN5 J6 L9/+$;V?0(G3'X?%1X;Y'_T-1K8N=BE5(0F0
MA<QH0%=@2=P[4<22BC%)(=E'ZWY]<+)%-\,B8G&%=Q3!T()J$&GVIWD*AI<9
M)[O%R4=_B2_I@%9-'SY3?2^Z&HC\+>VZ7JN<!52/Z*5N;JSD--ZZL=GH\<:B
MKG9B1TP&N$91&\N 5(N1$Q)K2CZF5MAEW[S,CG &[B@],X1AZ%[V$7L#2K[&
MV#)GZ0%+S32!&L#_++'W$SGGDKFS)%X>+(^7VVLTW&_E&8N1#15Z2C%XA "*
MC4,J/4KMM:CSE,9O9&>LCANKV[.K%M^TD#,.]A64@3LIA58Q0A?C!./'ZBC<
M\64NQ%\5)[@Y*4*0F[B K;K<$0@"=\<]5(T4J?8V@43L#-P) 7=[[,!%5NC@
MN5:#;0P6C@VC$<D!5&.S$V ',W"O:Q06%#OQT';% 4KVG%-K,:2LCFO(L]&=
ML3M:NYL<0V2IH"E#]HC8&U4W[ 18&H4)='Q^9%1V\])"LKU7GK%@U4-L1@82
M#-OKIIRX2>LB 6(IWJ<Z?HXP8W7<6-T>)VC2HV,*C#PT_BI*A]Q3+%63XA0:
M?\>0[9KA>E4K8!I**J%+YPZ0ABU$>Z(<J$C)IA=[8UIGN.Z#=0WD<@>/0A"A
M0#=6T$-V)(*E.H[CMZ[CS:)OSZA0]UYBT!1((*1>2Z7&/DB32D03&,LT7BEM
M3Y>H>9=S<B$)0A_J=$*PQSZW&GK7"51W7>G\@GW*5DPK10R).A.B@#N=I8!F
M4HQ*(X 4 BK3-R<S4/=B$2Y1B-5%SB4FT!@I]^8)<\D$7!%FH.XM4">W=D'F
M\6/NT;5F1I4"4BE=<C>2!@PYS=Y_QNI8"$"D!*$WY(@),!46JCEGS9EEF,L[
M?JR./O\[.649"S8[=!*G*#1LW!F@<I(VU-PXGV/I$R"G,S;'A<WM^7AUU>.P
M1QI:A*_<,6/)=9A!FL"%,E>)S_#<I>ED9Z[<%73L&8(3#,/PU9@<-4E,\]K#
M#,]=6D\F$A(LG&,'!$"1GF)V*;IL$5,=O_7<)C3&8C2*SYZ'=CWM$20!>9&B
MSNQ(!D?1C=]HC$<JV],5S.R+H L].C#2P2D8(4XQ O1,#28TPFJW$R<N?\31
MGX#,[H=8N8":.)3NU$&/L4H9=EKTE9$TI"GMI#7CZ[?QM9,1?%S[Z9"T )[
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M#^"HHK=8EFB8<M 0:1\%]ZXZGFKH#?GQ9'-\.!VYD:102(WNEP#<(T,IA7/
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MF07MJ\*0'[8[5F^*XB#R4 P=>F?*$HP>^>FSH-FI[)..[&81K9<XU,4-W3.
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MAG&#&CV?E<Z'7M2JT1?GXLO#&DN(T4SGKRN!54*.9HVME]]C"]U7PC1GOB+
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MJEJ &,^&R+?=D0WQ:Z'64QU7JKK?:<7 ?Z:]7&AGYK3S[J+0X<10PS2M8N*
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M9MD[9=G9<)-RE*I$%4J)@L$JC44FRH"(#C1$:FGT;/U8]HDW?JL29$YL,R"
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MM;??D(62\<II&O>V,_]ZN$UYW&IB53AS:G345B?4CON[5 "'\PC2:.FMH#F
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M<EP_!V>H9-;%))&+&<X0FY QPB!I?<0^:IV\S]41FA+ZYQKQ_=-WA6S'%'O
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M7GNON=?>/=W[Y_/7O>T==DAW,%R3??[Z[6SWW0[]O'WTX_#@5=H_./H"F%H
M=K*(> ,HRA$P4TU22!%AE9(N6!:?O53SU=6%4Y8AJ42]HY03HH3G/NO9(()-
MH'(ETR*R0E*D)JE'35*[!UODB\YEO1QK%%W2&9EC9)FD.5]>)F8<9M0 3<UG
MQF5)^]^V,[2]LP;9:&3KKI!9EC4;6<Z>Q#)MNG6VT1B)WY(7,A:WJQ2EY3)_
M- >@R_QULUT;?MCK 0TV;!F'?1?+NG(1+R[JG94Z8Y\BZ%^5EKNE@[5V$ZQ0
MF,U%;QC#7LB$>#04<6,2LHZ"@N/")D^U-S+7_-(-M: SYHHC.&L5OKG;V,U3
M%!>K0C"UN%@?<3$7K"'.&:8]HI$KQ(52R"00'(+JQ&W ,>;1('J#R#N/]ZY#
MQ*:Z&*Q@UD-1>PD6> G>Y''/J5%Y[Z[V$"QC.0G/O-1&ZB L-\YH##^I,$E0
MQ0%2%[ESK3ZFM>6T,ND!U_FUY;3]X>OAUP#_?_,#?F_OO<O/T6I]_N<0?WZW
M]PVN#VO[FQT>!##&=[]PPF16,2B)/-5=VXB,TCK7+D8G+(V>^L7&^%HZG);U
M$)"4F!-&V&@$-UBZ1*EPVBKOA7;25'"\IO-'3>>[!UL_OC@&5I:6' GA )DS
MFY!CTB'0KB)Q$GF@>5JX7N@AV+4]?USI6E9["5;F);@?1+#0%%B$"^[?$OC7
M#4,XM]V1QVT4K0J<U$;1^HC[N3;MD7/NL4$Z)HZXBAY9(B52*@JIK-6<LF<O
MS89:4"%PJ^CH[<V/>TS&N,5B9UTPM2RN9?$-9/&J '0MB]='%L\ZJ&C2-&*C
MD&+4@HUH&'*><Q0,!PM1"R=SV;K>D&2^OO,QRN+BP/KWP+I67&#>MFWOJ-DI
M]U87Y9@'6HR]>V)4FAGUX#@VK/?=-MSP+*>*=+J#V&_8'KS< 0-D$(]ZMM4X
ML;U2JS4X;O8S^X;8R>7M\%O9.9N]1*DJ@H1/]P?P0FX&L7FIB3]:!*>;2L!"
M3[K]9C[M/WJQ9;,=].=I,PR.Q])DZHNC$\7G7[$.UC <7/Z5J?V6#[W?J"$:
M:,:6F?J95UU$#//P7V)**A4X2SI/F$DZ&",B38'Y+U0_&W_IN'?N.#F*R/6B
M_89L@B?[P[9.[5G_V;\O[@=LQLS^+[]U7X?]03.=W=_>53<'D=SMV7+NP/2Q
MES_U[.5>(=I!M_%Z0IJOITGS[80T/XY)L]]X/NS886C"^[/&Y2RQ7OK8+_^O
MZ\'>SA'Y]8X0--K5TH$4UIAVAA&]\!0NNIOSARX[%RV47^$4N$+39+,!_XU4
M_MZP#1?Q*\B.OZC>7]E^L[^?MD!6#3MY2N-[.%U_5OT\@#N]:I4NM@^IH'_N
MCA5T^\V/_7>[H%C_Y^O>]B[=W?[[;'?[$S_\Y^VWW>U7[?U_=NGG[3=GH!SI
MK%\*E#H__+EU^OF?7;S[\_!T;WOG=._@^/CPG[_A>H?B\&=6TCMT]^!SVCO8
M^;FW]<5K&P@C#DD)FI5S'9!S02 GF1"""F:%K%!7LS.,82O#',JC3IQ)S"/C
M#BOG7.XT'2T-(<(WGC4BH)Z33/V]89P@NKLZWOW>D>TT?Q;./F==^&-T[N][
ML0_$7;TT[ ,-]OO;L,)>LS0C!&PW0QG-V/^MJ>+O+R[B:+#A*%$-H,MF@O#<
M@0B-R8;L[R!QEBI(9-@3QX7 G,<HK%&1!2E (%,L19JEBG(Z)7PT=3YC"#>B
ME9?S?T_+2WAOM(;RY>JH?KV.B^L6EEC' G8\22X9-4P$(GS@&/X.42ZIU2[(
M4R[N+0)!Q[;3_([\FE\O[@CH'FR54@8GRTVBQF@O6#+.N^SXL@N@WT0?+H'P
MRN'OQI[_5N'T_V/;)W^"\MW<R%5GFXWGY;U&MP?0,<+KY68O&L?V>VRX&#N-
MDUX$< D7/QGV^D/;&60UGC_;&[9B%;3LQ:-AJVQ%/YMI\/=)MU>FL</FO 6[
MK4$P^GNSD25 +^O*[$3W@,]M,T/8RK++&YDO%II]W^KVA[T2X@0+,-_;G96=
MJ,0'+*D)3WF2;W\4.Q'P;ZN\'T\&E5,^+^]3I^Q4P1. )3YM?MQ\T7C^;FOK
M_8NRR+ROK3B(U]C!#+8!=I_[_8]C+S8[FPTXH5*T!TBNV9[^1O^X.VS!LF&7
MHBU+@KM\'78J8_NT.3@N:QP?Y^*[PF948#_[]R/L^G3<872DFA+U9W^RR?^!
M2[7@ WG?H^OEG,?JV"FO8AJ;C<+LT^2[ !X]8C:\'EL!<0U;%6]T3V)O1+OP
M%Q#_Y#Q/JHC[^/0[T8-.LSU8/GPD@&V9[:#*Z+KLBFG$5VG8:C7.HNUM M=-
M<]KD!+LGS0Y\9:,!Q-RP(6]P10;CVYZ5B]E&LLW>.9F,;K^8"L^9>$(YF:CR
M ^5'A:<"QFN-6#C'CXI]:0? >YOS9'+7 /(][':ORG+X$'W+]OO-5#89T,-D
M/Z8@Q6\&&G:_>KR_[=G^P18OOJ"M+]1QH&[)$ LQ(0[*%3G+ Y+<2 P'DN.>
MLX#@]4CL]F:V>)I:VC;$+.5/\HD4LFW8=A:^Q82#<\\2>ZP&QG''\K&3*92Q
M^4M8<8?$M!=/I_!FK]N!7WW%%K5=,D*@IU^\HEYHQI$Q4>1IFQ1991+2BDLB
M- 6[>,XN20$+0[WE"E,>,#,^&2NUTI%S[*V;LTM6X:VXH55\_4!ZT2@@=H!
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M/_&O%WCQ@7+C0^ZXL%Q*+G0R0*I)8Y\]Y3KJ9>V)!U6]TY)P_)1%^A9/:KR
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M0#_TT7<' _2A"Q?H-K8RBNH!AFGLM/-J1X![*WN%)Q+<P_O==G:!3POP@Z)
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MY@&%<#3>>2:XTL]>RDMG3]_0^W%=27R/'MU?+NDV"6._(>-'0ST8*!03G_*
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M($UP1"309"@CTG P5\CZQT?7UER9V;<4]^U;CO=[GT #]?J?L[9S_%.7;]J
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M;(?8!E@2Q0KU$H!'IZE8RMR^ANW&ANWU.IE/)(;&=;-_W@#Q']A6XSS:X$'
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M%5&K[[JI[PI\\%I]?X3ZSOGHSD2EO=)(!@RKK^(<68!EI 45VL8890(???[
M9:V]FZN]*W#1:^W]$=H[Y\(#U!(<M4?>X 2+KP#%)9(A(4@ 6\HQ$N/6+L/K
MH;X_E AQV2,R:U'48D&9L,8*"PF*'2V>5&QH06',//J([9 %]<-RJ<^RB.(;
M,EN*L":6J(DEGIW:96#Y(MH0[Q.G6ACJ6:1)"_ M=>"\.$NU;$97?9;J"4O4
M@IH>2F!+B%>("1P1%P)7FT!.:264(YRRG&.QXK-4ZT8>4?/TU'"Z(7 *+CPS
MGF@7J>-8*>NI2E2!R^]E-$D^#T[K>/HJ8'8^#)?W0SR)*"GXP0%5D2'!(:PY
M"TYS9=/JXNDUU-906T/M"J V.AXI=H$[RSA8JMK2Q"QC1GD<!"6UY?IRD#H7
M&E7.)1ZY0DH2B0!!+;+8*D029R1(Y:1)6[NL-EQK-*W1=!W05'CFI392!V&Y
M<49C^$F%28(J+F6JT?3ET'0N5,V3X(2*G+ =!.)>)^0\UP"I-"3P.*3.!JK
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M=&9.YB'JS#ZE;-TC7@.Z6;*49\KS3,C>JPS95/"CHQ';>;<#UM$0?D"@>TW
M$I!+& LP-SLI@25;6#J%X00#!. QQ,+"XIJRID<+S9#;W7>Z93P-GKQ=F;FQ
M:$)NRA!,)VW6QB)+OEE8T_VF;UZ5X- %>*^BZL.&94QKYPNRVI:<[X,N-"Z/
M OCDT)L1SEP-X/575:-@"*]M-Q3:G..V53O'-_L2?JL;=A8$7S9F69OQ4V N
M -XGG(?1&!2 V<ULXJ$4VMC,W(5#S^9--BP:PY I@"S@\*2G\P9$NS?Y/5Q=
M+A +"<A_JXR>S]GHV8%U9[18]J<:G=O\<&LC+%$-<+&:G;QJ#%M>3GY_[")
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M+U45W_;^Z@T2OO^W%$]KSVWWQOSU%NGK;>^L>&/SC^QQ-_5;DB-ZJSN=8)5
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M[IK$3722$P")9BQ-E!@F-+$QY&2BM\SP:L960JR$^-"$6-UZ]T*()U<)T;!
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M_N_8#48X6D10V>H=G,#I'!^DMX.#SGXZB!TWZFRZ0=@?S[E@SYNOK7>NP/(
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M%X9_.OKMWME8FZ'N%(&\@P/Z]: ?/CTYI^&>W'Z]N4MQQPH5)0DN> *"4N)
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M',W6<Q:2J)I/I:+V4I'Q.0?JE# 4@&IN@F4Q& \:M1_!4M5\'I9RQ%7*B=(
M-2X1ZAQ#RC&4&*01DH03VD@JK$]5\ZETTTZZ 6>R2$(GL!28M"Y#C-32Q'R0
M6K ?-5"OFL_#T)"<]OD(+U,N[I[$"7!MB;-HBHG(<_ &>-"J:CZ5BMI+1;Q4
MUQ8Z>BX!@A8VBRRU4T$PZ;C@BZ>B2CDSN9DW3UW-.YM?M_#S72Z5CLEQ(KT
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MQEQ;F4, RU X:6&\0P,]&1 Y*YN"J)&DAX7KMZMP%3XF1WT@4DA5TO8$,2(
MH5QIFDP6(:>U#7Y3GZN*U%5%JE4QH78/&6@J55!1_'K%;03A'41;TT]:BF!V
M%<&EGS5/TA!GC"/ *!#+HB%>VY!U"M;8Q27>5ABW#,8@T5*GV:>D*#B/FC+5
ME#.6?/+.Q)JZ\<!P%1?ANKT3=K4(P>=H$9\:;?C,%3&\N!'!L1C L.AB%;B/
M$:DJ*HWO%K0%R-ZXK!D KCG^JP5U#Z'&*G 7@6!Y2>#NO-N5*O"DG"/6)4E*
MXW1BG##$X+)*80$UZL5Y_BN,6P9C1"Z %-P&'U%U%B: 8,X&YR%XB/?@-:\P
M7HBCZCR3X-W)]NLW=!>-'*!,"Y*D*'G;$!''5!!!K848LQ:T*LZ/%L<"5>;
MG642D2NX07,)(O6,91^H-J;BN*TX/KF"8P/>4BL]R2QS MIQ8G*.Q#DFF<[4
MB^@JCA\KC@T#PX6FN-8<A$%5&I0P.F;PRL60*XY;BN.M2_+XD]A-OH2.*"N'
M&AR!X QQ43JTC)G72>ND6&HCCA]]&0Y$!/[:NQC2]OU>G"^$?=O\H-5C(AJM
M*/%J;56&$*@3+$2NN$R" W4UA-U6)KIZK,$8<!FT)TYRBT04%+'*2.)1L$2)
MDL7(^(A3^YXXC&/*(L@0I*8:?-8>[8.L1&80-&,1JD>])2'L4[BR<O[:B$3
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MLFF9]M$RK:#*1Q>EPQXJH13/@HO8V%=SX9AM ?#=,N>J1@TR)&=R(%%'@2.
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MVYR:EMFOR>QKP7GNBE%<",*$#$1JE3%]''YSJ02F7,HF/AS(?]/Z[2M-C][
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M4!:3E*7(8%)RU NC3&;.7WDL1:M!;\N72QKTY>NG9V^8$\H;EDC1M "RC90
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M<KGW1*AMM7UH14\K>G:OE*05/7<@>E:13^(J%,4M<5PP N<%O_D<26 A1.?
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M /,2;'AE:WZ<8BQDE:/RR=!H,F]+NN^:V==*NJ7!9H ^$2,C(S(%2ER.E*C
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M"NA#(C2K2'5*07BS]X2Q@_6TK_FYH]I9$3S["'1.076 RNF==[Z9*H_!I)<
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M&34)&(V=T&";):=K7,[RKD\\6\3)!<_24@[2-[A[S7,</O_E6WC\@ML]=8:
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M_-0+*C S7DCIB*4!!<5Y,)H*9B5%%+(?H[(I;.FK=@??+K*E.X.9%<0 R&D
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M  ;+!&0.*NIR\B41/WRR6 "L -A# )@71A MG)784LB8#DY@B@-,S>,YQP7
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M" >0,QV\1X%B[:GD05*&*.(D$$E)X/+N#N ,EW3I6+ARU] N=BQD5$:/C7K
M:+" 2B: ML@"+!5A04!BA=G:I25A<XT$\/XB,$4 [UT YV,SRFJ":9! 8((
M)=X#;4B41X(P<EQQB,-Z">!W(C.N,SSKZO,T6+],9LN5#WGE79/6ZLZ,U<HO
M:<XXU;D1S7RXYK3]O^NN[MD48VNU]< >MPC:;B64_)$LMM5,UD9JIZ4U.PZ)
M:!QJ(RUAE MG>(AP%HU%1#!F'.6VL3=(PYVJ>:\*=5X/A^-4IE-JWU>ED3Z/
MVO,:B7G)";<$!)DXJ)$00#JA %=.>8BAXLQN[9)M)GZXC_6JP6;E3:[O7\ W
MK0/V:F=DDZ!NT1!?%<Z5]MAK"(N=.5@DFMO@!0):0QEA$0E@F.% 0"NM2NO/
M7:($$2O+NRRP^-A84&#Q+K!(#3'<.!44I!03:1 54ALF)*<20UI@<8-A<3XW
M3A+F-#,V\22["(O8 J6,!-P33IPFF.3X!=V. %EPL>#B3XR+2!*!B9 .84T5
ME]J2(#$E)&@5@G,%%S<7%Q?8<6'<^,SZ:!\&S0 U 0*M* -1+U)KG-/(T*U=
MCK<A657:7<'%QP:#@HMWJM_GT(N48X^#M]%XC"XU@=&U$DI#I[045P/CC3.)
M"T(^.D+.QQEA] ]@5'\ "HP3LR8"4F()K*(<.RSB5M#1<MR6<@4<FX^.C>4\
MX>[G"9Y2(JR)ZA1[:KDUB#G(L$(P6(F9N:GA-$/K41\NU,\KDKY"29\/G2D>
ML';4@N"4!92EKCI,<8 @CW+NJ=#(IM 9I+"80L44^IE-H;M#73&%-@<@%P@=
MB!+>$ &@Q@)0ZS"0*2=(.8*A(\Q[$P&2\:5GKIMG"Q5P+.!XA_B9U)HA:H)V
M)-# HU]@D"-.$2Y)8 0^=/RLH-ZM4&\A]]@)9QA%%$BF(NKQ^)/A"@,1EY?&
M9:4:PJU=L:JR^@)[CRWK!?;N GO,$LNEXM(Q3951$L9_8Z8"PX)R'LJQP09C
MXGQ0C,.XLIA3X)F/KC)U*=\DVH31]D<R!*04%UN[E&\KN-B)>A-Q,2<H_SMO
MN=WFA?;'IU&H;/5[VH.=WCA33S8M=:<:4I_JP5&GET?'9S'O9#P<=<)Y?%!5
M2=_,0_4Z<0ZZ^FSH?VU^^*U)G^[TLKCF+_U6W[Z>'+:$)B ]L/KXMZ\=-SK^
M-74'SB)>IUW7SZT^1#OYH[FUJ3Y3<D?!JS^&.^A_E@44USG]_.E=^9V$^D8D
M8!*(E=]]_:9C4ZY\PA/[A%_MZ5U9%FN#KBR+M4%7EL7:H"O+8FW0E66Q-NC*
MLE@;=&59K VZLBS6!EU9%FN#KBR+M4%7EL7:H"O+8FW0E66Q-NC*LE@;=&59
MK VZLBS6!EU9%FN#KIS-M9EDTN1,+6+C/X$(+H2C)$@)(0[2*<4\#H[83YQN
M[7XW_:9.?P IW_!7))<FY,QVWD@7;5V1>">9L'?OURWF$^]PRJU!<*=*DUK\
M]__.9!^U?IQS=3;_[B_?&Z8DNY[+;6W^Z@]' S_J#/QIG(C??<^'SFBXUQG:
M;G\X'OC#^.S?NWW[^9%3Z?9?-*ET;?CAY#4\./RST[YX?=$^?//YP^''SH?#
M=OS.2]H^>?GMX\EGU'[U=TJ+Z_K_O#G_^-Z=&4SYAXLWG?;)WZQ]&K]WTOZV
M_^K-\?[IG\?MB^//[<.C\_;A'Z<'A^^^?MSKAH._/\& XMZC"@2F*:"2<B Y
M\8 +(@(E&GL>JB3)3F_LW?.4C(@QPU83KQTT-&BL:? F2.Y=0-I[MM7R0ZO/
MXGJ,!N,H$?5JY#;&>3U:LPO2JE>D]5?J=KR8F98V;",/<UEJU7I]?T"S+Q <
M@Y9)2 W&U DK,4ZMXIB71ANMS=;N=?O3Q1E33*?>K8'&KQJJ+2&8&A3'81&Y
MP?Y\:X^]&W?]0=CWS7Y,[<Z'ASD?]"?=CBD#=/_Y)RR\PIBG.F5K *7< ID:
MEAMB G..&$OP_!:[59KB#"I2=C4HWBX;>1X4%[*1,R@>'OO6B_YI?-QYZU@/
M6RZN?<^[EJEEX*P6EK/<^=OVO\2G](Y:/KY )Z56^M.S;O_<^V&KTVM%86J]
MVWF[DT4K_F[]8*3C?_NA%0&N:E_4RX*BNZWAV P[KJ,''3_<::5Q]'QZWJ#3
M=W&/-P.P<1^V?K$#[SJC9^E.P[$]G@PG#FXXBL.-?T\/#_UNM_\U#3"U+8_Z
MKS<:_CJ7&WN-'F/KD4:*(-R!\$Z)I!SO<(JO_'@ND?3&MQ4[F) [W?7ZSQBY
M<=+K+<;*,-N8L6[2O$8#\:9WW0BC>%.NO&'B\2,4_X@;=FZ9LK2O)-M&DQ>:
M+4M "V4)U[RP]4G'//XK'QX/O&^UXW7'P];+J-K=_YK!OW<GQ.-73L,#[YDK
MD]75_&HL%H%LR%)<2_%.;O>:/\=TX7O?G3\I2N;;_-H9Q4?8F[!'_"L9T?'^
MW6@Q#Q>*_>^ZB==X\R7GX=YE]<>G:SW4ZNMI=^H&L_8 $U/VT4^PC]8/^C?E
MRA]LR;.2_;6RKCO?C2_ES?76#[YTK,]AG#N6)W__M1^%^.!F[W]7XH,;O/2#
M<AO<[&UOP6V@N?9208JY0Q0Q982A@NO *($^.'.#5G:S0>R]*G)9AZ]3[+[>
M>RF2O;4N] 1W#&)7] 2G?W\[./RC\_'TS<G^Z>N+_<,WW8\G?QSOO_KP;3]^
MK[W7AOLG\;/W?]-Y>H)$<]!^'\?]*H[NI(WV7_USVG[_$GX\>8G:%T=?VQ=_
MX_U7;?1Q[SA,F-[?PF_MBY>X?7CTR5@&'4<0P  ]H-X*H 36 !/E( J("6FV
M=@5?+3/!C1#OAWDY5X7 \Y9"P;>?&-]$L(Q"QC3V$=^0DMRYX'E@00LD3,&W
M1\6WBWE\\PHSXVT CE$-J"8>J" 0<) [Q7S@!J9NN"LF;"_X5O!M0_'-!B,-
MDX1P0BGR1F-A,"3060,5=B'C&V[P#1=\>U!\0XOVFT?,:@)T( 10R!4P4GM@
M@X):(<ZE5EN[JN!;P;>";]E^LRH@*1SSB9,2>1W?WU!+,3*:"@\+OCTFOI%Y
M?",<!B^4!@GG #70 14-;J )-X) ECJ21?]TQ<QY#XUOZQ?2W)0K;QUZ#?F?
M-8^N-M2<2\.KEZD5MWO-Q^D>LHD!QF;Z"X+?$L$G/=.F$-QZ+K%@!F F>?3
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M'V=JJ+L'H?[#RV^I_#3.\'3+BZ9 M4#N;2!W28(54@Y*(2W %G- G4# !!>
M1\032BV"/'6]^"$VQ!++6C?YOC_[J,CWH\KWXBF>C.B,' ;*Z]39SSM@C,#
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M!7*&-6I$XY(.*>MJ!X2G">$%]Y9#'=&BJ$S=O>5J4FP%%%A=:CM+$GUIU<X
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ML,N!.U<8'_Y[FI?-IQ@"00_Y EW?"L0T7(8O'$\U2-G9)\=GL$"C<NN_J_^
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M/]S"&#[(=3[()Y<^$V18@/8O?+HJ+L%C?/'@AH-J3-2X7936!;,M 1WX T[
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MO*A,[N!R,"Q>CLQ)<+SX]@EH_,# :WT,!B!Y[@*= Q),?P3;.J_M3O#"@C$
MT;G:- R\#U*[F,[FX B!T3,&\U*!=Y8UOI(%20%N87G96R: VL* APYA)P"<
M)4=@!%</O&NBQC[\,+L4WH^7V%R=C\ ,@R_@519\C6K^L@G(_<G,VLF'PRG
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M$G 0#M^P, Q Y=17H*0QJJHI%%#A1U\[>#)(H]IJAB=X,O[H#6IPNKZAX8D
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MA.ND!N2<KE;=1=@$ ,,-,0(!&/@7B6(>!<<8=' EO.+EV4\D94(^J?W)=54
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M*\Q-4DO1F V2KA_<E_^L SWKI!L<%^">JC+73YI<.0#"P,_E#HY/G[\&MM$
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M(%DD\N_]';.<834"@LX1W%4G?180K69)Y%4-QUDZ-?:9<+Y6MZM?V&YI?QV
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M@8W/VH'C-55P7#D7O"HFKI95OL$UIG6: @D#:V'@-R]_E)\MB#,F\2D 9OC
MSQ1\LJ_)[(WS$QR7>6'R\ZEJAF<VAU;!\04.%9I]@;!6I0>K6IIBZO,Q0637
M0/V03_HU!H/3GX)C_]L3A&E3?5)/'[IP@V*,4GV*B9[P_-'E )-AS:498$[N
M<?73LR?!$! +'Q?EEK T.Y3#G%LUQKH8O+2IEIJ43DWP0D\^5^=>CJ>#83'"
M%&V?&HY/[L-W\/NHFF6KFWY98.+YXMKE2T[F4%U^.VRC=$"^KJ[8PN1B?/U*
M*BW 2P%0_1 YAPC(5#Z8 C;Z31/S&4$O6NVK:[XKK]P-'XQ< X!B.AG#=?5
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M5D<C;*@12H^)7B&NC#!V*YB&J-$P)S9_I#_94TX7O@F[RQ8U A(H%NA62=2
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M8KRA@Q_-L <DPX:,-!T\C1-I"(.-*M]KN]BMDHY!X\C!? $)[Z/23:$5?D+
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MB!-OSGD]B_<@0I,79&/DAX;MB%? .T,I>W#IJE/Y<J=R?5VG\A+V'%^[V%&
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M6EM?/VJJ4'A^!9)RW95]7H9(.M10[^?XHD>GF1L>!+^QKTD7$>IX>[[4G17
MA+V'?<]Q,$V7NMSP(-RVKK-X-\H'N!0KV@WR*[CG/T!Z8JM R8FO0,3MI2#V
M$GZG-Q.7I!ZU>Q1L3@U<V:77J&';S,;+*-A74>.[VXD+*$+07MY5N+\.>[FB
MXM=#Q>@-5+D<IXTR+X^1*GR@F3HU!D$TI6DSMA-1$N_!N[>LA\RKD" ['[J
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M@]C<2R= *AF.H@*#J;F(IGQ=%\LF1.0L[_OPS"@"R70F'!G_//Y3@9E[?8E
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MY %6C/,.M(N:"(%D*""7-^) 38&ESX9T^SA\5!DQ*V.ZF,9+H3F1&?R8%E5
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MG/J-1.L9//L./UGA28O<@ 4]B^YQ;=$]COM[I.,?MW??9MQ1MM,'8"#VZ(F
MM:;A>36I\G&GPR#$8BOJE@=K?!M\O%291_ BBORK>^<T!,@R5L?8>(^9=Z "
MV%P?[BX'1Z?,^C0*23R<O54(3,\%-0ME;<8,B42:,CCHT@4,4L<2S<]L,UQB
MQ"P9"G$<%*((^C20%8"-.:V61- HRY^:9(4)1P_YW*- ,E8#B.^PF3>31I[
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MVX0?_1]<9@W$:-KRG,7"4U]K+=HT)4+3)]L/0LD\5W<Z^\K'9 @MX^^[Z_,
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M#W[;1!+'/\%^4DX_B)0[3=R$4,)>)'BS]I4?.*"36?R1.]X,+!?;90:C1D+
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M%I1L05*D^Y3KM5S^1J\]MA5 T3=:G;\Q*N=F0&.1+TMY05O[%D5=R)Z!E6S
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MW(!CJQAL&',$J29?V)%3!%:)LZ/Q"CN. #W<H[FR5L_EZ.T#V<<6LUI#6QO
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M5A\N,4R;LV068)K+DM] %PF:<ODCR 1)-RN%92,9MF(XA%/T)"MA6$[/4%F
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M5MA>7GPP,E)I:XTC0I4#0XAT$F(N/22!4FU FNJ#DN\EZBELG?0.HITTU1^
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MG5U*59:K#8'*XRFD2V_'ER^N)1C'2T2,DC1&,DS9:2RC'5C*Q&H%&&MP'C'
ME$'6/V>Z&6V[[RQ=?\_ACU,HMQTLSEL>3<MGJ\FS7'AM (C1N52\4[?ECZ:5
M\S*'@N&:JGT&Y"'T#>H$0R_@NKDEU9/V*N[27Z=PV9+<R? H?T2!-)_1-H\C
M%'&\:B"-YR,5.0L\1V*L*.-M52(N2R"6V<B5XR+DVIM5VU$ZI+S[D2!77:$]
M@N_M= X-M LQ:*T=+S-*:3*X(,JJ"+&<):><68OYJ8K]@^PR14-*V1\)3%LK
MJ$?07$+SB%-CM2BM3DEB.A&+$05N"<4TPVAIA:[>>'TG04.Z#NJ1(+.M>GI$
MS">(LR_3<NX&)5"."9:#5Z_/X'CV&>;SR6+^*1OEE'V45!$(Y2BQEQ33&\Q&
M6'99"9:YJ-Z2L2VM@YJ8_TA ZT&K>XNS"KEMH1?:4?2!JER*HV60L]16$6LL
M6ED5LA0Z0XK]V[!;R=L$:?HOCK0ZNGL4 _?JK"D9^^+B) W*!..1/"27R.R0
M;J"!Q, AHG5&8UU_A-AVM&X"._,7AUT/6NVOB+;<",*?H22]TQ:0Z(OMBK6_
MWKZ MLO;=BZ>56.U4N&L>^&'V72VNLWXRLM'T4B>&!<D!>6(M"P1&RDC*9M,
M#8O60.U5?S=%-<KYB^E5B\>NDI21\@$S$ZJ)IV7CV6+,Z92T)&B5LLQ1B.J#
M$VZC90B[.SW@8UU5?V=55-SG6;Q]Q5G6/GBO.9&==P8TS.B=(]*DE8.0M'&U
M"Z372!C$[LY><+"]Y*NI_\VL03E.7W6[5?'\N/'3UG>3$%?.\V+8AE7:8F+
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MZM^PK+C\O/P1? O_^-O_ U!+ P04    " #R/*564&L+M:J!  !UA@4 %
M &UR:RTR,#(S,#,S,5]D968N>&UL[+U9=UM'DB[ZWK_"U^?U1CGGH597GR7)
M=K56JRQ=R=5];K]@Y1 IH0T"*@"4K?KU)Q(D. +@!G9N<))KE4R1-/:7\<7.
MC(B,X5__]Q\GD^^^X'PQGDW_\CW_$_O^.YRF61Y//_[E^[__^C.X[__WO_W+
MO_SK_P/P?UZ^?_/=C[-T>H+3Y7>OYAB6F+_[?;S\]-U_95S\]EV9STZ^^Z_9
M_+?QEP#P;ZO_Z-7L\]?Y^..GY7>""7GSI_,_%VX+]\( #XR#BB% 4,P TRJA
MTLSZ(O[?CW].)O*D$X)5]!M*10->FPB>H5 R<^$BKCYT,I[^]N?Z1PP+_(X6
M-UVL_OJ7[S\MEY___,,/O__^^Y_^B//)GV;SCS\(QN0/Z]_^_OS7_[CU^[_+
MU6]S[_T/JY]>_.IBO.D7Z6/Y#__G;V\^I$]X$F \72S#-%T^@!Z?EQ?_X54T
M^H>S']*O+L9_7JS^^S>S%)8K>NY<PG=;?Z/^#=:_!O5;P 5(_J<_%OG[?_N7
M[[X[DUR8I_EL@N^Q?'?^Y=_?O[Z-=#Q=_I#')S^<_\X/83(AQ*M/6'[]C'_Y
M?C$^^3S!]?<^S;%L1;]><@6E*YS_53_MA]Z8/A&0>3HEO:#OXK0J>$.,FSZ]
M/^:+SX*,)9Q.E@T1W_[LIGAG)V'<4L"W/KH!VM4'P0F>1)RWA'KM<Z_@7(.\
MB;!^Y FISV]_2K.3'U;87LUH$WX7/N+=N$[FOT'=3)D\>WW_U^5_>^791/)X
M.J[[QAOZZ_D'U$<=@ +_6.(T8_[^NW'^R_=CYT0I&!%3DHIV;X>9.:D]EZBD
M47QT^3$5SQK19):N?>JD[FNS"R(F(>)D]=U1QO'HI^ERO/SZ>EIF\Y-PO@Q\
MO<23Q4CYY))G!40($E01$5R*#B0K3'B,)4=^F\K%6C46F/[T<?;E!WH*\2E$
M_:(*5)R1N?/99Q(^;$7KH_-7^MV1#<%H+!J$+@54* 8<*P&01QLL%UD%U6L-
M5Y]V'?6E9KR8K_&?OR('OD/UX&_.W'+60'1GO!#X[[^;S3/.__(]:T'A_W<:
MYDN<3[Z^Q\^S^7+D!3(7K85@8P3E4H98C :5$DLAL\1+;L+FC0<_&6+["/0V
MQ[P%Q^]P/I[EGZ;Y1[)S1S)8C4DKP*P(!F,*?"@$+8J<=&2"Q0W'QP$,7WOL
MD^'W<&'>9E<TV83G@:R+NLASC2/70VEE!%E'7($2.D'@!D%)E$SH'(VR;3;D
M&T]^,ASW$NEMFF4?FL^6^?-X@K^<5F&,LLWD.F8$;HP!97T QYT&(YT.W$8O
MF&Y@,UP^\='3VDN$M^E4_>E\CQ_'BR5IV?*7<((CH:5,A=%R5";U"H)## $)
M5&32>5N<[[<E;WKJ$Z&UARAO4ZO[4_MZFF9SVC16B_RPI$/BU>QTNIQ_?37+
M./*Q"!^8@>@=!Y4MP3-T?&B9G4F:8\XMF-X)XHD0WT[0M_7 ]->#7\,?KS.=
M)>,R/@MZG>\])M%OQ\@A&Y5!Z4Q[C^$)$BW6T_(C"M=  [8\_HEPWT*XMUFW
M_5E_D?,<%XOS?]7E\I'7#D5"!U$3,N5IO9[%#&0V<HL:LS3][+&MCWXB;/<5
MZFVF73.F7]&7;^>_SGZ?CI#69I#< &<U^0*N,/+YA %+IB)+T@EE63N>+Q_\
MM%@^4*"W.?;-.%X=+F_G[^:S+^-IPA'+-JC )6#RA5P]1[N,5[3.F(.3R .J
MV([H&T]_6FSW$>V&:$FOD-@U8.]FBV68_/?X\\J:$$[+D&F%.CJ"Y4D=@Q.!
M[(K(/ O>6=LO*K;]V4^+[\/%NH'M7L&QNL^\F&-8 <%DO+6)W 3CR&M 2=:B
MUP8"6BQ1!Q-+/[/\ZM,>/:,'BVX#A[U"8/4^>?+NTVRZ=NQI=^ L,@L\>P=*
M> 4A(0?:0E"FH$C/1"\>;S[QT7/92X0;^.P5Z_J Z71.*^0B_CI>3LB+RUHF
M1]HD5"(KCQL!WI@,+CM6O#"FY'[[[LTG/GH^>XEP Y^]@EV_SD--O_GP]23.
M)B,98W$Q"2!?S)-FY0).9PF&^8B9:5U\/S*O/>[1,WFX\#;0V"NPM=:IG_Y(
MG\+T(ZX";8GQ*'A&8*P:Y\R1F1YM :0#7(CHF7-M7LVK3WWTI/86Y09N&P2K
M7IW.YSA=GMUV5*4CL_QT,7(B%JG)$,>L:S"5CH$H702,.J%"(Y(P#<S>S4]_
M]%PW$^T&SAN$JEY/ES@/:3G^@C^&93C'.:*M17*C/%GB2.>_R[3:8A!2X1QM
MXL65-BDIFY[^1#AO(-H-G#<(6M4[L/DK<KD_SN9?1SHKHXM-0#9?K-'2!%&A
MA<!J]+QH+*Y%8/+:0Y\(PX<+<@.Q#2)5'T["9/+R=$'+6RQ&F; +,M0AH2";
MC\QY\!X%6!DTX9*N8+^4K T/?2+$'B[(#>D=#<)1/YW@_",=&W^=SWY??GHU
M._D<IE]'CE:2>20UR[RNT20(5D?@)B=NG2Z&M]BD-S[\B1#=7[ ;".\5D3I7
MP$\XF:SA:,\#V0*T1(:9X&1-5H*RD%GTREKGN6S!\]5G/A%Z#Q;C!E9[Q:C.
MK<#9R4F]I9ZEWSY\"G-<O#U=UE**ZN&-BLI>,S+^E J";$$9P-,. UAL#IHS
MM"RT,+-W8'@BK#<3\P8MZ!79>G&"TUQ3RWZ>A(\C,OVS8DF#%%@OMCCI(ROD
M 3AA@G#TK^Q[$7[M<8^>V\.%MX'&7@&M=8+@S^-%"I/_'\/\9_K.8A2]13+R
M:GZ@9J"PT+&A48+D6O-B&1;?SU'>\N!'3VT+@6X@N5>XZSJFLWS?,U0VJ^)K
M1!R+IE4FK<$SQ8!GEVUAO&1>&M)\Y=%/C.A#A;J!ZA;1+\(U#Y/7TXQ__ =^
M'1GRYK2H19R65(YVF BQ)N^7)&5RW@>20(OS^/IC'SW%_86Y@=Y>@:[SP,OE
MYK).VU<%@Y L *F8H25&^BJZFB)(2\_!!1'[)>%M>_*C)[F)2#?PW#^X-<;%
MKR%.<*1-E"84!9[G ,I7;PZ9!:55\L61X2\;I.>L']>0T2NUQ\=Y60\2V:8B
MI>_."DG_G":S!>:_?+^<G^+E-V?3)?ZQ_&F"]0#XR_<+_'AR*];;G?#3!7P,
MX?-HE3I4/^C5)"P6;\O*ZG_QQW@QXCI*C\J!,9F,AQJ)BYPLB$S_)._H:]SU
M=I>PB"M^SI]TI@4X62[6W[E4ASO!-%2/'67@&]3E,&YG0\BX85G;&MA5/#^N
M-L).B$8WBM$;L7\;3<M]?ELE_27IC>F:#2+KXVB!Y-RQ:$/-5ZEWJ44">8@!
M=$!)!F74PNRZEG[([%_K2W"/Y.\CXB%(OXSQ_&UE^XRTUZQ8Y" S(]/#A00^
M"0G"6!\U6H-Z5T7<09S?!'$\PZX5,S>)[B76AM7I)_/?1B_8GS1CO\R6N,BG
M2-)7YYC(VE&%'$9PZ!,=849 4,:!-YQ[;Y!G):]3?:O'Q*[/?[0L-A-:PQ=V
MA8G_R5E]!9,YQU2TYG7K <9JFJ&CW<F':""91&@P,Q%\%R*W?/[C)K*%T!I6
MFZ\PB>O*)2^4BY0JERQ DY-'RI7( :$=8I6QKS/W"D7N0N26SW_<1+806L-Z
M\G/EDE>52ZZ52W/.,1*<R 6"XI[3!H$(O*B094"=TUWM>W9]_N,FLH70ME:2
M_^L/-V1"[OUO!_5>>G=F*X9I?KO\A/-:;3''Y7B^L@M?XI2>L'PW"=,SUW!Q
M'5FG#DW[/J%O'Z=>*[K1[8EI'FQ&:5.D\T]JQZ2U/IC$+6VK/H[V?5@_0_;'
M*@_,5S[WQ_&B1E!.YW@9X/%*6>&,A&)X[1I3:OJ85\ E\SJJG*/9=;5TB'';
M"5CO\$WZA/ET@F_++[B6[2L2^)EL?R7J7M*O_U8S,J2O57_T2GE000MP028(
MWC!&NV@RN*NDXZ!@3C=HQ]_1VFO,K8#/ *PT] UNP[PMDL6E3,XC8(X5VNF#
M!%L;MRBO.>$,$8)$;57QBH==^17]5*@#P*%#R/>A/JUY>2A1Y_<7YT%=4^WB
MM@JQD#7'><0",C$%2I)AX36]&3:E8!46+\6NF^%#5&PSDF/'FX_ _*PY P-$
MI6ZC.C<YN^ :*"R]#=/]!*=;\':G*O00^C&50N2HG*F>.Q,,5*FW,RPPR"E;
M*37]I+0^D8ZK#'?$JH^I"_O(>@ =./<ISO;!:UOCN0O)G,J,_!!@,55\R1 ^
MGX#KI,A=#=')U%@7[L)T?,NV#7NS 44_@!5[AY.Y$;(64DO+ T@Z.D%Q>D\"
M,QI\0?H^_3#(7;E)AVC+ 3"?B (-3=#6[:9=1.C#Y_'T;2FS\G;^,4QGTU>S
M'W$9QI-#8C_;/ZMOE*<CRAOQG."4<3P843Q7#'DTC(OD(V><)ZWU:/O']GMQ
M:^NY$[RX<'T9)G4HPH=/B,L7T_PBY]7ZP^2*W?OR*_WE\VP1)G^=STX_+^@C
M)J<U+;W^#KDJX^DIYK=D<*_R>Q:7[IA0P7BG&(C"2)^$8W5>! <CN+&6Z8AN
M5RW7(2_\$9?7=PO=^/%GV:5ORZNSGQ"*U],OL\F7U6I>E"7.UV!'3 ;TQKG:
MCMF"LMR!1RM!!6MJ]I3:W7GSH.A:/\C'WUH?JK;?W*V/J0L#6 /O\0L2])])
M_N]Q4B?2O OSFL8U*I$%D1U"*1X)6.UEZ6OW6HLR^X!:L5V-Y0[S%K: ^:9^
MVQV0%OP-XH5>1?/BI'9)?3VM4=VWY4.8$$"_&C7 +:20#2AMR5RA-X%,)F4B
MSQA#:ITT=2>H;XJV7=%:\MDP3^!B(][T%EPT0?".<6W) "^UTYM-"J(@QZNX
M@M[;)%B1K4_<'7B^J=G6X[05BPT3&*Y@^W6V&1D/P@@F/=BLZ.R.Y-T'9/0'
M5R(H1_^DUI'X[6B^:=<.[6K!8,/N_,>3X-D="'>%>YD3O4*U<:))FJR"J*%P
M%X,.F>OF<;\C+>U8]YF/1=<?HD;=]WWJ8KX<O:\=T%:!?XV%*2\\&%D#__3B
MUZD-$80J,B49L]W9M_/B7:!/O?(>T-\NWX%K#[RO6]('J0FSOHPT]%DN0*RC
MJ1U@['-[VD5!VH>P[[XD[2'\F_3UD-R 1+H4R<_UM4.PJ55H2H'+*H&6PD<>
M8TQN5U'F@R%PR\5F>_[V$5ACWOY&DCHY/3D'HGA :XL%Y6P!)24"V?Z^MN)7
M1G(>R?AOP-RUAQ[/;NXE]ED+F34,):Z A#^N #%,95Z4 *ED'8@2/423#9AB
M99%&AJ0[>=MWD7?UH8^0O(-E-FRX[NMJ$%UM)$G2JQN+9%KIE"/86$)5KDRN
M$2<OW--N(XVSR;4.GNR \\V*NFU%M69Q@/#<%FCK$HD.X ;+5]L![+Z2UAK1
MV$T]>G!PO)UH#=(+$6MF@]!8VZD5 =&9 L4:;FC799[MZA[[2!3DSD2V>]&/
M/43?N*#S<C3J!YQ_&2=<O/@XQ]4^?'Y\BF)=4B$ =YK 6543;D0]B7.(+I%
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MJ$V7@,) \+[I8S/R;NOCP5."=BWI'>D(SN>85WTG7T^_$.3Z_5JA=1GC&?'
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M>>J0I-HP(5D%7O("T:22@A*68?-2JX>@4'=<7]V_/NU#S"!S1C;OS>N.N'3
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MUI04 V,^&33&6Y93X*/=']V[\N[RLVMY*2E7K0.;?\$W%YU8<E&N).X@Q*Q
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M;*0-M20D UU'2#RGQ+EA/'7JS=53,>Y9&_J2U4$1]I+T,"'U3LE0BH?L>2R
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M:5ZWL/:%N4('%G KZ6245M1>!AIT85KIZ*T7PU347@%Q?#NB-5,;JVH/%?,
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M_Z:GS:B]K:.]Y^U=RNKR#+A2DXO+D3/UG8D!,BMD9<B0P0=!5@:W@M=QYGK
MQNY;0#U)G6I+Q6U=L8]H8@:S,N=L!1CZBG9NK<!K@>3=EZ)9J,4*P_7O?F83
M,]KH[(-2B4=13)VY=MPS#=K4,;M%"WJ;/:.OLH[2R>A*ZU*EAUA,_5!5:)_B
MZGVH/'[5[-W8OA57[\WB?N6S^U-P;#5!G1TKB8'F0I!'KR3$4A!\#O23;)3*
MSWMBQF#:L8_D!RZN_O![^+RNY\0@&7DB8%10]4(E0PUB0_:E-B346JO6X9'-
M2!Y8!>U>;.THJCY0U$<OJ-;%&&E#[4I9VRYK N>9LO1'M-X6ARA:]U5[3 75
M?=2AG> 'V!9N!BS>GB[?EA<IG9Z<3FH!SK8(R&JO3.0S^.(L<)\B&5J"-+HV
M->4BY,!3%$FV/DSZX/UF^NXT?8^F"@-<B1Z*_?SU[H)^(..Y'_+[,:^/IRF-
M5+0'S0]HSUV[&8E%M#8!#W7V#J^C3V6,X(HI@DGMZ(5_!DIZAY'_6'5T'W8?
MD&ZNFP:M1N_6I)B<$IDT$B$:LI@2]R$9D6TP#\4BN"\[\YCZT4@U#R!W  ?F
MPACZZ1^GX^77BG,VK:;4ZI6UP28AN(%L/;VR.2>(C&=(*:*.S+,@6L]\W GH
MF[&YT]AL1^8 *4\W,)V_>5U #60D;@1T/[9?0^)F0TE]@'-Q,[CJ_J.ES5"7
MFA^EO8/@= #:BI47Y-5;U;ITZHBJ<(>%=6Q-V$?8 VC E7-RO9U>2P&A371R
MFFEOK;6A-<8SFTQ6F75GP<#S,]216:FJ49G)E*R=^30=W\%#-CH$IBUCIK7Q
MW@3X\>VD!DHPNV\&![""=@U8+(JIPNM+)ARC YE0Q2(=L,0$,UQ+X5I?-3_O
M@;A]+*!61 Z0@;M[0F,7<-\&XNY-XUX#3P_AX/@#<8.U.A0&F3G:JT5DX*+@
M]%?+O(F^%&P]+^]Q#<0=3C_V$?U]#<3%S&1R18'V!6M3-PXNDZUH3+$NHQ.Q
M^>W1HQR(NP^5APS$W8>'>QJ(>T-"/]&:TW(QNY(WNSCR(-N6B(9H5S"8Q&YT
M,& B!]JJ(AH;5&#)N:2%LEQ)5HHQ>F,'@Y;@CM+4 !F*[.GU(_.^=B(T!GP@
M%R $X77208C4.DOF.$T--C[EFNPW-&*]@%&3U=$SELDK ^-< &4E@B\\ G?<
MNN)T]LW+XGN#?K!U!?OH6:<<[<&H''0\[>!^FS%D6@FC0=;33A5I(/!(SIO-
MPO,0;?'#C9AY9G4'S77Z_E7B4=0=(!/("PK@49M:NTMFG?4"4DPY!%.RQ=9M
M:IYYW<%>*K1/W<$^5!X]H;P#MF]U!WNSN%=F^0$4'+T\106=#4^@6>TI8'R
MZ&P"(Y!Q*7,6J?W8A,=4=S"8=NPC^0&TXJS_8?IZ)1'><A9"+ )D$#7O69F:
M765!ZU2\*+IHU3HN>!O% TLPWXNEFXT^^HEX^%J#GT^7I_-UN,E:[KU+%M!)
M <IY _5&&$P)='QRIYUOW19F!YPGI :MA'Z\>X+5QL>\RNAS FFQEE94@TE@
MA)2-]*2T+#4?-OR\+RW[F*FMB!R@!&!W%+T+N&^7EGO3N->EU"$<'/W2DMC+
MTGH&(=%YJ5A <$'1#ES0,*FB#+RUV_RX+BT'U(\]1']?EY;9,Q=022BEE@?;
MZ,A,UQI8$,X8%,SX0=J)/;)+R[VH/.32<A\>ALA%#Y.+1NX2561&,3"VMG8R
MF,!'61,?69%2!XZ^]8YQY?%/B?E#I;IU,QCZ5KK,YB>KQ9.\OX3QI-I7]+T%
MK>/U] LNEH/</._WU&%NEWNL_,8-<N;61N0B9\=5R=Y[]#%PJ7WA-CBUY09Y
M/P ]W_;T"?/I!-^6BT>1LU6U]0.FT_EJJL/EA8=3P3A4%H(0]<)#*'"B,' ,
M$QG>3DK6.@MS+X"]$Z%O/.)'C,O+Q[PXJ8V3_XGYU6RQ?!D69#'0AAP+>1S
MO7*UGVB$H*,'02Q+6Y!\WM9]A_?%>/Q==#B=NI7V/"1? YRM=^"]DL0])]_X
M>G?;LSZAM>$BG1W:2R'!L]HI7F<.WO ,,3B>11"QQ-;U8$V /V--'(#9(>I
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M'?>3>M!$068/C-V'KK'H63+57G21%J;(4 3G-0(&M$ZS1 YEZUOKAZ^I=^1
M/'A%W8?4(1)[9R?UII"@O0MT *T3#8.SMJ0(L2@$10X).$X6)F:'67A44;6.
M:VX$<GP[__ZXO9D.W)N8 2YU_O[AK[,O.)^N7J./2,N^&?!:W_L[;4SF!;*)
MEE;N5(WN.XB"B\P2ZM*\GK0KMF>L4X/0-\BF-/\\FX<E;@3GE;8Q94U6"N%2
M%A5$SA "+P5Y-%SGUC/.=@)ZQ@K5CJ@![E#.,^DO57XC2&-U,K7W6)(Q@#*1
M0?358>(^ZJ!-SJEUWE<G8,]8J]H3M_5F9=C4LHOOO5@L<%F#P6_&(8XGY\L(
MB],YYK"\&.,[F[ZOJYR3W%<Y'&U3SEJA&2(5;1!)W6QRDH/F"E$SG95&[I,P
M-BM2T$)O:+(;4]1: >NYE:T__@S%BXTHWEX^FG[AE]ET?@W)9:PQ%K1*6CK8
M4YU,6;(%+UT!D4,(HO9>;-ZRJ>D">E^NKS!<0/IQO*A134+P(BY6I5PC)XL/
MCH13<C"TMR1-NQ?^W_:^;,N-',GR??X%W=B7ESE'J<RJ4HTJI9&RNL_T2QP#
M8)#8'2*5)$.5JJ\? Y?8N(23#B<CJ'I1AJ24^X5=<\#,8 NPVJ@IH%<<>.LY
M.D^".OV!<#ZMV[AN;\K8";+==N8#\ 3 "WELM.'4M"<GZ804@?D"PBFD$RS^
M./D:C6D]-D?C$$X&:TK]*%? !1V*THJ9"(;LIZB8!Z^8%24FFUQ4IG5][?/(
MT1A6)WK+>@ _A>SNVJ[XGD*2F4+O](Y)O4@4T8&%[#2CI:+-OI@T1*#W(8A+
M8[Z?E =(S5H42"W77#M5+ZK_YU<N@O,B(@LQ)Z8E)P^J@O*H"!)$54KKK@I;
M@5P:_?VE/4"'YKL*[R6R*W*+$8O*+ E%7C-7@D6,GH&*3@!M2L4.-V5ZB>'2
MB.\EXP%2KW:N]BH)F:55EI'-0<IH>&*02#>=!*NB "7$R9R.2]."-E(?((_J
MGD>U;^UDH*!RTC! 6].#<F#1 GE0.8>L$IJD6J?L=D/V(WNE W W@'OQT\V,
M5CN;O9Y\B:/QHMBRMJPA4= )2#_-1GE1H5UC>,OU?+\2'#%!4DPZ7L?9IL2B
M(MS5&N9D*9?4? 3%$3!/KWM#,#XY+5V#MHR[)Y^KI.C+0C*JHS.+/K2U]+NV
MF3#:2M3TIWJX[JSW@%RDEO07^0".[/YU7Z5(_T0:STHRG.D@) L<%(LQ&,<#
M %G=)SW#+E(S&I(P@-/;XO!>IK<6E-(7QTFYD0YN:\F"1PG,*)5=MB6B;7YO
MVPK\J5+0GX^I=![>GTTB^WKU/WU?K;4^]4]3_/VF=GQ<=@ZE$]OQ+)C@M#@-
MQ; H4+/,C<7BDRS-1\IU@'6N!/<SZ<LNK6W$VP"VURW$;0#7N1@=( Z4Z=X!
MWID2V%M3NTMU&O-R)A6R&+2!F)B,')GFR3*OZ;<Y)ZN=S%+DP5(&3JTZ3V64
M/P/-.82.$VG,['8O7N5GI22]==Z3:8DD YD<B\D+QHU/Z$U15@YFH.W!=<:
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M5K$$)V>8'26TLCEYLT_CU[_VO: R]IJW!,2IRU.OTA?T>SH^[F2=GWK5ZO:
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M+Y 9(;FI%P)?!2".SC%MX8<^-0\*/O1>/+Q%PHTL\T*\7XEW="T7DC"<J(P
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MR!A3+$H@2(G47*(WDWIC2:"V'@F5448E5%:U?J<0=FZ,]%YKDYL 1/6X-KT
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M\%IXAV0ZVV=PWFLR!K(C<X0!=1-$NQ4Z^*DN;=L!]>U8H#HD*HX [E3YBEY
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M5O+QOGBBW^)D\]&E:9)!2 ".38^<&') (AR!%$G!>!K')+2JMGIT]-G1VD;
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MJ[.@^&K(='*>:?LPG5/WH/W2V1O<B*$JUXM?\E5^_WB_,4+BB$8(:=-#Q@C
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MI/=0_X.R(Z&+X1^9>_8PKR6\"FH9/08E]D'@*_[PZ!S3AAKVJ7D05=A[\<
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M]( =.TC_MK.!W.::A#P&J;_AE6$W#]O9';8<7\"$L3@E*8 JS#2_D PP'B>
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MEDH6ZUWL$?MF5?YW!P^SWKX)-_I[U7%^O<C2-_=UGE<;-3@!M;9@^RU8?2>
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M99/GW>1@&[VNRC8W>YW;Z&836I=/T\KGY>)[(95\^_+WE9+W\[H6FMEQ"B-
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MAZ5G#FUJ<G% [LX."/C=Y78B^.BX&]4#CM) 5G<S"]JR#@\WRQP[F%:RL!<
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MP:_;L9';7G+P7(L.1%-VP/;"^SA!.X_#]9/^?M#M_:1L!^Q6:G @=K,\72_
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M=)^7<9R0P4_JFUH\._II3N$E5,:1+9&7L1(9&XY+0" S&\DTDYP2B:5?4?]
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M2UY*G(.R9 1@+@M $&, EQ1++4N!L?+JFGQNI*F9KUW9/'L>GP63&"I73&-
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MT!DT&R<)2\#SC "1%D01B@AS[YVS]^2IT5 CG'LXUCY._11SE?8#DT<C5T!
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M"'@062@28Q'7A5?!CYY.*=M'1WO7CT<_I\3<HYN3%T3SNFSW!CK3-"<(V6B
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M&EV^(XPLWJN-K5WV<;6T;9/DJQ]_K)5\N_AUMF +85.EMW4'MGL(2#%&.11
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M<]S>?9_>F9_^UW]K?V/^8Q-?_M=_^_\ 4$L#!!0    ( /(\I59%VE!U:*X
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MBVSYC47W*Q![7EG0PZ4Z"%!\.@N3R8OS!4ECL1AE8E50_ 0)!;G3%&6!]RC
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MGTGZH5"LB(*!]-P(*3/CL8-GA#OI&8*_W 1"S80^  #5UEU_C">342Z8,H8
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M7/W^SLX?HR!,\IQ8+@7)^^ N0?0IT9Z):'0)"G,'O0F;T-[W9537MJ\/%0\
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M@2]PBF6\''G+90S20?8I@E*U214S$8R(L13$Q+'S%CPW2>IY-L70 -Q2@0/
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M6XO95)0(T2 "RXGK%$,JLOEURN-('&3FY2GPV%I] T#G_M(<\6AU]B:#%TJ
M"N1:A#J=TXKH;' A,]%?@#O(O$M7F.Q(:0/(N[PN!=/R?7G])SFXTU/\2$?_
M^VEEMOY_?3WT+4QPU?N4Y#A.Y!BLDO/3?/,W-O[F2%GTR04%F=-F5-HR$D:.
M0!Y&$%)*]+8U;CM@8S"M]=IF;OI6^ !,\%',?L#Y>);OEH1>]'G8%.M:U".4
MI(Y0;P5JMWV5M0:?72;E%5\$22O+UK7F3\OA8!H%MMTI X;)  Z.XRQ&9(JD
M[QD09Q*J_:##6$J05OOB/#*4K9.HW1\&3]&_<$ 0?Y02#T;LU]5&(@G,ET/
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MMO[MR\DZ 5W*3G)(P0E0PLHZC[Q ?8"(KD3,N74[GEVT#&4RQ" N,ILH;*#
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M:A$U]S%E$L5>I4T/*7YST1Y?%+50_,'R&X"3>=V;]$8/E!??K\8")I711+*
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MNC;#53QK:Y5J#JI=Q.R'LA__7J"-M@8 NP_S64+,BU](UM?2G<U)/#(HGXP
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MQ0\TO^H8E!VIGJ%![/H![ZAXZ2(C@60A0JWSD^"%<H \"YZ25:+YN.6MA/Q
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M::)S^+[LNJ)J0G^Y^Z^N9N!ZEHPBY\1%$H#"G,%YC8 !K=,L>=4\DFI)_[B
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MR_\HK,\A0-0F@0E!:Y?JI-K![MV'Y'3RSC(*N([12*?@DEM6&+,E,I()Y\&
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M!_R34/%K'H27VZ9"P[PL/#JP41:2--UL(8D$LGBE3.918.M!W,=3NQ?LW?_
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MM:PGH$DE4#Q#4HF@ @4ZP5D!TJ6@M3+D5K3.2#]/U;A&J!T"]H36D>H8>4[
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MW!'*&?F.7*\J^IV^=[;$E_/E]36?K(FI#FHM/M 5X$($AU% -LJF&+0I]VO
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M/S\O*.XCD9!>KI)-OV&A?U,GU[*"06IR+:01!8@9A% P0?+6JJCIPYLO*SF
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M,I4=,EVT)R6(ZUO"M@BIM XO77[:R9O8=;%3Z;[W:C&NUQ7O!'A\G[\/17.
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M%?%[ON_4^"E'L:EYE?N#L^F0P#?481M?-MS]H/XGP@K_^S_^'U!+ 0(4 Q0
M   ( /(\I596LE]OP <  $XA   >              "  0    !E>&AI8FET
M,S$Q+7)U;&4Q,V%X,31A,35D>"YH=&U02P$"% ,4    " #R/*564"LR;\4'
M  "I(   '@              @ '\!P  97AH:6)I=#,Q,BUR=6QE,3-A>#$T
M83$U9'@N:'1M4$L! A0#%     @ \CRE5BD)3%QD!   8 \  !X
M     ( !_0\  &5X:&EB:70S,C$M<V5C=&EO;C$S-3!C97)T+FAT;5!+ 0(4
M Q0    ( /(\I5;N:"198P0  * .   >              "  9T4  !E>&AI
M8FET,S(R+7-E8W1I;VXQ,S4P8V5R="YH=&U02P$"% ,4    " #R/*56*BMP
MET$( P"T)"8 $               @ $\&0  ;7)K+3(P,C,P,S,Q+FAT;5!+
M 0(4 Q0    ( /(\I58$6N'2PQ,  ";9   0              "  :LA P!M
M<FLM,C R,S S,S$N>'-D4$L! A0#%     @ \CRE5BY_"VIO(0  E4$! !0
M             ( !G#4# &UR:RTR,#(S,#,S,5]C86PN>&UL4$L! A0#%
M  @ \CRE5E!K"[6J@0  =88% !0              ( !/5<# &UR:RTR,#(S
M,#,S,5]D968N>&UL4$L! A0#%     @ \CRE5G&EIH@#"@$ 1, * !0
M         ( !&=D# &UR:RTR,#(S,#,S,5]L86(N>&UL4$L! A0#%     @
M\CRE5D7:4'5HK@  :*D' !0              ( !3N,$ &UR:RTR,#(S,#,S
?,5]P<F4N>&UL4$L%!@     *  H M (  .B1!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
